[{"id": 67001, "ingredient1": "Citalopram", "ingredient2": "Paraldehyde", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67088/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67002, "ingredient1": "Citalopram", "ingredient2": "Paramethadione", "severity": "Moderate", "effect": "The efficacy of anticonvulsants may be diminished during coadministration with selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitor (SNRIs). Antidepressants including SSRIs and SNRIs can reduce seizure threshold.Coadministration of SSRIs or SNRIs with some anticonvulsants, particularly carbamazepine, eslicarbazepine, oxcarbazepine and valproic acid, may increase the risk of hyponatremia. The risk appears to be dose-related, and elderly patients and patients who are volume depleted (e.g., diuretic use) may be at greater risk.", "source": "DDInter", "management_text": "SSRIs and SNRIs should be avoided in patients with unstable epilepsy, and used cautiously in patients with epilepsy controlled with anticonvulsant medications. Treatment with SSRIs and SNRIs should be discontinued if seizures develop or seizure frequency increases. Patients receiving SSRIs or SNRIs with anticonvulsants, particularly carbamazepine, eslicarbazepine, oxcarbazepine and/or valproic acid, should also have serum sodium levels measured regularly and monitored for development of hyponatremia, particularly when higher dosages of these medications are used. Signs and symptoms of hyponatremia include nausea, vomiting, headache, difficulty concentrating, memory impairment, confusion, malaise, lethargy, muscle weakness or spasms, and unsteadiness. In more severe and/or acute cases, hallucination, syncope, seizure, coma, respiratory arrest, and death may occur.", "mechanism_text": "Antagonism", "recommendation": "SSRIs and SNRIs should be avoided in patients with unstable epilepsy, and used cautiously in patients with epilepsy controlled with anticonvulsant medications.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67089/", "reference_text": "[1] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[2] Belcastro V, Costa C, Striano P \"Levetiracetam-associated hyponatremia.\" Seizure 17 (2008): 389-90[3] Gandhi S, McArthur E, Mamdani MM, et.al \"Antiepileptic drugs and hyponatremia in older adults: Two population-based cohort studies.\" Epilepsia 57 (2016): 2067-79[4] \"Product Information. Aptiom (eslicarbazepine).\" Sunovion Pharmaceuticals Inc, Marlborough, MA.[5] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[6] \"Product Information. Tegretol (carbamazepine).\" Novartis Pharmaceuticals, East Hanover, NJ.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[9] Falhammar H, Lindh JD, Calissendorff J, et.al \"Differences in associations of antiepileptic drugs and hospitalization due to hyponatremia: A population-based case-control study.\" Seizure 59 (2018): 28-33[10] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[11] Bavbek N, Alkan R, Uz E, Kaftan O, Akcay A \"Hyponatremia associated with sodium valproate in a 22-year-old male.\" Nephrol Dial Transplant 23 (2008): epub[12] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[13] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[14] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[15] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[16] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[17] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[18] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[19] Patel KR, Meesala A, Stanilla JK \"Sodium valproate-induced hyponatremia: a case report.\" Prim Care Companion J Clin Psychiatry 12 (2010): epub[20] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[21] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[22] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[23] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[24] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[25] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[26] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[27] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[28] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Oxitriptan, Bupropion, Viloxazine, Tryptophan", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67003, "ingredient1": "Citalopram", "ingredient2": "Pasireotide", "severity": "Major", "effect": "Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.", "mechanism_text": "Synergism", "recommendation": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67090/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm.\" ([2011 Aug 24]):[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm.\" ([2012 Mar 28]):[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[9] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[12] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Kaletra (lopinavir-ritonavir)\" Abbott Pharmaceutical, Abbott Park, IL.[15] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Phenelzine, Duloxetine, Tranylcypromine, Vilazodone, Paroxetine, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, More", "alternatives_b": "Nafarelin, Elagolix, Cetrorelix, Ganirelix, Lanreotide, Gonadorelin", "updated_at": 1767369485}, {"id": 67004, "ingredient1": "Citalopram", "ingredient2": "Pazopanib", "severity": "Major", "effect": "Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.", "mechanism_text": "Synergism", "recommendation": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67091/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm.\" ([2011 Aug 24]):[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm.\" ([2012 Mar 28]):[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[9] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[12] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Kaletra (lopinavir-ritonavir)\" Abbott Pharmaceutical, Abbott Park, IL.[15] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Phenelzine, Duloxetine, Tranylcypromine, Vilazodone, Desvenlafaxine, Isocarboxazid, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, More", "alternatives_b": "Dacomitinib, Tepotinib, Selumetinib, Cobimetinib, Capmatinib, Afatinib, Tivozanib, Brigatinib, Axitinib, Ripretinib, Alpelisib, More", "updated_at": 1767369485}, {"id": 67005, "ingredient1": "Citalopram", "ingredient2": "Pentamidine", "severity": "Major", "effect": "Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.", "mechanism_text": "Synergism", "recommendation": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67092/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm.\" ([2011 Aug 24]):[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm.\" ([2012 Mar 28]):[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[9] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[12] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Kaletra (lopinavir-ritonavir)\" Abbott Pharmaceutical, Abbott Park, IL.[15] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Phenelzine, Duloxetine, Tranylcypromine, Vilazodone, Paroxetine, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, More", "alternatives_b": "Miltefosine, Nifurtimox, Benznidazole", "updated_at": 1767369485}, {"id": 67006, "ingredient1": "Citalopram", "ingredient2": "Pentazocine", "severity": "Major", "effect": "Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John's wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucination, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.", "source": "DDInter", "management_text": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk. Patients should be closely monitored for symptoms of the serotonin syndrome during treatment. Particular caution is advised when increasing the dosages of these agents. The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.", "mechanism_text": "Synergism", "recommendation": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67093/", "reference_text": "[1] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S \"Rare case of serotonin syndrome with therapeutic doses of paroxetine.\" Am J Ther 13 (2006): 550-552[2] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics.\" J Clin Psychopharmacol 10 (1990): 48-50[3] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[4] George TP, Godleski LS \"Possible serotonin syndrome with trazodone addition to fluoxetine.\" Biol Psychiatry 39 (1996): 384-5[5] Fugh-Berman A \"Herb-drug interactions.\" Lancet 355 (2000): 134-8[6] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[7] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[8] Ruiz F \"Fluoxetine and the serotonin syndrome.\" Ann Emerg Med 24 (1994): 983-5[9] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[10] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[11] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[12] Bergeron L, Boule M, Perreault S \"Serotonin toxicity associated with concomitant use of linezolid.\" Ann Pharmacother 39 (2005): 956-61[13] Wigen CL, Goetz MB \"Serotonin syndrome and linezolid.\" Clin Infect Dis 34 (2002): 1651-2[14] Metz A \"Interaction between fluoxetine and buspirone.\" Can J Psychiatry 35 (1990): 722-3[15] Tahir N \"Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram.\" J Am Med Dir Assoc 5 (2004): 111-3[16] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[17] Lane R, Baldwin D \"Selective serotonin reuptake inhibitor--induced serotonin syndrome: review.\" J Clin Psychopharmacol 17 (1997): 208-21[18] \"Product Information. Maxalt (rizatriptan).\" Merck & Co, Inc, West Point, PA.[19] Hammerness P, Parada H, Abrams A \"Linezolid: MAOI Activity and Potential Drug Interactions.\" Psychosomatics 43 (2002): 248-9[20] Morales N, Vermette H \"Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine.\" Psychosomatics 46 (2005): 274-5[21] Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM \"The serotonin syndrome associated wtih paroxetine, an over-the-counter cold remedy, and vascular disease.\" Am J Emerg Med 12 (1994): 642-4[22] Manos GH \"Possible serotonin syndrome associated with buspirone added to fluoxetine.\" Ann Pharmacother 34 (2000): 871-4[23] Gordon JB \"SSRI's and St. John's Wort: possible toxicity?\" Am Fam Physician 57 (1998): 950,953[24] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[25] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997): 175-7[26] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993): 84-8[27] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[28] Gillman PK \"Linezolid and serotonin toxicity.\" Clin Infect Dis 37 (2003): 1274-5[29] Taylor JJ, Wilson JW, Estes LL \"Linezolid and serotonergic drug interactions: a retrospective survey.\" Clin Infect Dis 43 (2006): 180-7[30] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003): 32-5[31] Nijhawan PK, Katz G, Winter S \"Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission.\" Crit Care Med 24 (1996): 1086-9[32] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals, Raritan, NJ.[33] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[34] Mackay FJ, Dunn NR, Mann RD \"Antidepressants and the serotonin syndrome in general practice.\" Br J Gen Pract 49 (1999): 871-4[35] Perry NK \"Venlafaxine-induced serotonin syndrome with relapse following amitriptyline.\" Postgrad Med J 76 (2000): 254-6[36] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995): 440-2[37] Margolese HC, Chouinard G \"Serotonin syndrome from addition of low-dose trazodone to nefazodone.\" Am J Psychiatry 157 (2000): 1022[38] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006): 1589[39] Boyer EW, Shannon M \"The serotonin syndrome.\" N Engl J Med 352 (2005): 1112-20[40] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995): 481-2[41] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[42] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[43] Dannawi M \"Possible serotonin syndrome after combination of buspirone and St John's Wort.\" J Psychopharmacol 16 (2002): 401[44] Lee J, Franz L, Goforth HW \"Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine.\" Psychosomatics 50 (2009): 638-9[45] Bhatara VS, Magnus RD, Paul KL, Preskorn SH \"Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms.\" Ann Pharmacother 32 (1998): 432-6[46] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992): 1061-6[47] Strouse TB, Kerrihard TN, Forscher CA, Zakowski P \"Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine.\" J Clin Psychopharmacol 26 (2006): 681-683[48] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990): 949-50[49] Packer S, Berman SA \"Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid.\" Am J Psychiatry 164 (2007): 346-7[50] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[51] John L, Perreault MM, Tao T, Blew PG \"Serotonin syndrome associated with nefazodone and paroxetine.\" Ann Emerg Med 29 (1997): 287-9[52] \"Product Information. Imitrex (sumatriptan).\" Glaxo Wellcome, Research Triangle Park, NC.[53] \"Product Information. Oleptro (traZODone).\" Labopharm Inc, Laval, AL.[54] Reeves RR, Bullen JA \"Serotonin syndrome produced by paroxetine and low-dose trazodone.\" Psychosomatics 36 (1995): 159-60[55] Weiner AL \"Meperidine as a potential cause of serotonin syndrome in the emergency department.\" Acad Emerg Med 6 (1999): 156-8[56] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997): 181-2[57] Mathew NT, Tietjen GE, Lucker C \"Serotonin syndrome complicating migraine pharmacotherapy.\" Cephalalgia 16 (1996): 323-7[58] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002): 1647-1648[59] Gardner DM, Lynd LD \"Sumatriptan contraindications and the serotonin syndrome.\" Ann Pharmacother 32 (1998): 33-8[60] Baetz M, Malcolm D \"Serotonin syndrome from fluvoxamine and buspirone.\" Can J Psychiatry 40 (1995): 428-9[61] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007): 199-202[62] Mugele J, Nanagas KA, Tormoehlen LM \"Serotonin Syndrome Associated With MDPV Use: A Case Report.\" Ann Emerg Med (2012):[63] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[64] Thomas CR, Rosenberg M, Blythe V, Meyer WJ 3rd \"Serotonin syndrome and linezolid.\" J Am Acad Child Adolesc Psychiatry 43 (2004): 790[65] Turkel SB, Nadala JG, Wincor MZ \"Possible serotonin syndrome in association with 5-HT3 antagonist agents.\" Psychosomatics 42 (2001): 258-60[66] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008): 521-5[67] Shapiro RE, Tepper SJ \"The serotonin syndrome, triptans, and the potential for drug-drug interactions.\" Headache 47 (2007): 266-9[68] Goldberg RJ, Huk M \"Serotonin syndrome from trazodone and buspirone.\" Psychosomatics 33 (1992): 235-6[69] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990): 213-7[70] Lantz MS, Buchalter E, Giambanco V \"St. John's wort and antidepressant drug interactions in the elderly.\" J Geriatr Psychiatr Neurol 12 (1999): 7-10[71] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[72] Harvey AT, Preskorn SH \"Interactions of serotonin reuptake inhibitors with tricyclic antidepressants.\" Arch Gen Psychiatry 52 (1995): 783-4[73] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[74] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994): 593-7[75] Laird LK \"Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder.\" Psychopharmacol Bull 32 (1996): 569-78[76] Insel TR, Roy BF, Cohen RM, Murphy DL \"Possible development of the serotonin syndrome in man.\" Am J Psychiatry 139 (1982): 954-5[77] Smith DL, Wenegrat BG \"A case report of serotonin syndrome associated with combined nefazodone and fluoxetine.\" J Clin Psychiatry 61 (2000): 146[78] Bernard L, Stern R, Lew D, Hoffmeyer P \"Serotonin syndrome after concomitant treatment with linezolid and citalopram.\" Clin Infect Dis 36 (2003): 1197[79] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001): 2163-75[80] \"Product Information. Zomig (zolmitriptan).\" Zeneca Pharmaceuticals, Wilmington, DE.[81] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[82] \"Product Information. Flexeril (cyclobenzaprine).\" Merck & Co, Inc, West Point, PA.[83] Giese SY, Neborsky R \"Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl.\" Plast Reconstr Surg 107 (2001): 293-4[84] Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Grau S \"Linezolid-associated serotonin syndrome: what we can learn from cases reported so far.\" J Antimicrob Chemother 56 (2005): 1176-8[85] Duggal HS, Fetchko J \"Serotonin syndrome and atypical antipsychotics.\" Am J Psychiatry 159 (2002): 672-3[86] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001): 224-7[87] DeBellis RJ, Schaefer OP, Liquori M, Volturo GA \"Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient.\" J Intensive Care Med 20 (2005): 351-3[88] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[89] Jones SL, Athan E, O'Brien D \"Serotonin syndrome due to co-administration of linezolid and venlafaxine.\" J Antimicrob Chemother 54 (2004): 289-90[90] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[91] Steinberg M, Morin AK \"Mild serotonin syndrome associated with concurrent linezolid and fluoxetine.\" Am J Health Syst Pharm 64 (2007): 59-62[92] Lavery S, Ravi H, McDaniel WW, Pushkin YR \"Linezolid and serotonin syndrome.\" Psychosomatics 42 (2001): 432-4[93] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[94] Hachem RY, Hicks K, Huen A, Raad I \"Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients.\" Clin Infect Dis 37 (2003): E8-E11[95] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[96] Keegan MT, Brown DR, Rabinstein AA \"Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs.\" Anesth Analg 103 (2006): 1466-8[97] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[98] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003): 1511-1512[99] Achamallah NS \"Visual hallucinations after combining fluoxetine and dextromethorphan .\" Am J Psychiatry 149 (1992): 1406[100] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8", "alternatives_a": "Viloxazine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67007, "ingredient1": "Citalopram", "ingredient2": "Pentobarbital", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67094/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Levomilnacipran, Oxitriptan, Viloxazine, Milnacipran, Tryptophan", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67008, "ingredient1": "Citalopram", "ingredient2": "Perampanel", "severity": "Moderate", "effect": "The efficacy of anticonvulsants may be diminished during coadministration with selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitor (SNRIs). Antidepressants including SSRIs and SNRIs can reduce seizure threshold.Coadministration of SSRIs or SNRIs with some anticonvulsants, particularly carbamazepine, eslicarbazepine, oxcarbazepine and valproic acid, may increase the risk of hyponatremia. The risk appears to be dose-related, and elderly patients and patients who are volume depleted (e.g., diuretic use) may be at greater risk.", "source": "DDInter", "management_text": "SSRIs and SNRIs should be avoided in patients with unstable epilepsy, and used cautiously in patients with epilepsy controlled with anticonvulsant medications. Treatment with SSRIs and SNRIs should be discontinued if seizures develop or seizure frequency increases. Patients receiving SSRIs or SNRIs with anticonvulsants, particularly carbamazepine, eslicarbazepine, oxcarbazepine and/or valproic acid, should also have serum sodium levels measured regularly and monitored for development of hyponatremia, particularly when higher dosages of these medications are used. Signs and symptoms of hyponatremia include nausea, vomiting, headache, difficulty concentrating, memory impairment, confusion, malaise, lethargy, muscle weakness or spasms, and unsteadiness. In more severe and/or acute cases, hallucination, syncope, seizure, coma, respiratory arrest, and death may occur.", "mechanism_text": "Antagonism", "recommendation": "SSRIs and SNRIs should be avoided in patients with unstable epilepsy, and used cautiously in patients with epilepsy controlled with anticonvulsant medications.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67095/", "reference_text": "[1] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[2] Belcastro V, Costa C, Striano P \"Levetiracetam-associated hyponatremia.\" Seizure 17 (2008): 389-90[3] Gandhi S, McArthur E, Mamdani MM, et.al \"Antiepileptic drugs and hyponatremia in older adults: Two population-based cohort studies.\" Epilepsia 57 (2016): 2067-79[4] \"Product Information. Aptiom (eslicarbazepine).\" Sunovion Pharmaceuticals Inc, Marlborough, MA.[5] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[6] \"Product Information. Tegretol (carbamazepine).\" Novartis Pharmaceuticals, East Hanover, NJ.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[9] Falhammar H, Lindh JD, Calissendorff J, et.al \"Differences in associations of antiepileptic drugs and hospitalization due to hyponatremia: A population-based case-control study.\" Seizure 59 (2018): 28-33[10] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[11] Bavbek N, Alkan R, Uz E, Kaftan O, Akcay A \"Hyponatremia associated with sodium valproate in a 22-year-old male.\" Nephrol Dial Transplant 23 (2008): epub[12] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[13] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[14] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[15] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[16] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[17] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[18] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[19] Patel KR, Meesala A, Stanilla JK \"Sodium valproate-induced hyponatremia: a case report.\" Prim Care Companion J Clin Psychiatry 12 (2010): epub[20] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[21] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[22] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[23] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[24] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[25] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[26] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[27] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[28] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Oxitriptan, Bupropion, Viloxazine, Tryptophan", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67009, "ingredient1": "Citalopram", "ingredient2": "Perflutren", "severity": "Major", "effect": "Perflutren lipid microsphere suspension (Definity)has been reported to cause prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Concomitant use of perflutren lipid microsphere suspension with other agents that can prolong the QT interval should be avoided in some cases. Please refer to the prescribing information for these drugs for more information. No data are available regarding the effect of perflutren protein-type A microsphere suspension (Optison) on the QT interval of the electrocardiogram.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of perflutren lipid microsphere suspension with other agents that can prolong the QT interval should be avoided in some cases.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67096/", "reference_text": "[1] \"Product Information. Optison (perflutren).\" Mallinckrodt Medical Inc, St. Louis, MO.[2] \"Product Information. Definity (perflutren).\" Lantheus Medical Imaging Inc, North Billerica, MA.", "alternatives_a": "Phenelzine, Duloxetine, Tranylcypromine, Vilazodone, Paroxetine, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67010, "ingredient1": "Citalopram", "ingredient2": "Pergolide", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67097/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67011, "ingredient1": "Citalopram", "ingredient2": "Perphenazine", "severity": "Major", "effect": "Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.", "mechanism_text": "Synergism", "recommendation": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67098/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm.\" ([2011 Aug 24]):[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm.\" ([2012 Mar 28]):[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[9] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[12] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Kaletra (lopinavir-ritonavir)\" Abbott Pharmaceutical, Abbott Park, IL.[15] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Oxitriptan, Vilazodone, Vortioxetine, Tryptophan", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67012, "ingredient1": "Citalopram", "ingredient2": "Pexidartinib", "severity": "Major", "effect": "Coadministration with CYP450 2C19 inhibitors may increase the plasma concentrations of citalopram, which is partially metabolized by the isoenzyme. Cases of QT interval prolongation and torsade de pointes have been reported during postmarketing use. In general, the risk of ventricular arrhythmia in association with QT prolongation is largely unpredictable, but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances (e.g., hypokalemia, hypomagnesemia).", "source": "DDInter", "management_text": "Given the risk of dose-dependent QT prolongation, citalopram dosage should not exceed 20 mg/day when prescribed in combination with CYP450 2C19 inhibitors such as cimetidine, esomeprazole, etravirine, felbamate, fluconazole, lansoprazole, letrozole, modafinil, omeprazole, oxcarbazepine, ticlopidine, and voriconazole. Alternatives should be considered when possible, and hypokalemia or hypomagnesemia should be corrected prior to initiation of citalopram treatment and periodically monitored. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, irregular heartbeat, shortness of breath, or syncope.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of dose-dependent QT prolongation, citalopram dosage should not exceed 20 mg/day when prescribed in combination with CYP450 2C19 inhibitors such as cimetidine, esomeprazole, etravirine, felbamate, fluconazole, lansoprazole, letrozole, modafinil, omeprazole, oxcarbazepine, ticlopidine, and voriconazole.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67099/", "reference_text": "[1] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[2] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm.\" ([2011 Aug 24]):[3] Priskorn M, Larsen F, Segonzac A, Moulin M \"Pharmacokinetic interaction study of citalopram and cimetidine in healhy subjects.\" Eur J Clin Pharmacol 52 (1997): 241-2[4] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[6] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[7] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Sertraline, Maprotiline, Fluoxetine, Levomilnacipran, Doxepin, Isocarboxazid, Amoxapine, Imipramine, Esketamine, Phenelzine, Desipramine, More", "alternatives_b": "Dacomitinib, Tepotinib, Selumetinib, Cobimetinib, Capmatinib, Afatinib, Tivozanib, Brigatinib, Axitinib, Ripretinib, Alpelisib, More", "updated_at": 1767369485}, {"id": 67013, "ingredient1": "Citalopram", "ingredient2": "Phenacemide", "severity": "Moderate", "effect": "The efficacy of anticonvulsants may be diminished during coadministration with selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitor (SNRIs). Antidepressants including SSRIs and SNRIs can reduce seizure threshold.Coadministration of SSRIs or SNRIs with some anticonvulsants, particularly carbamazepine, eslicarbazepine, oxcarbazepine and valproic acid, may increase the risk of hyponatremia. The risk appears to be dose-related, and elderly patients and patients who are volume depleted (e.g., diuretic use) may be at greater risk.", "source": "DDInter", "management_text": "SSRIs and SNRIs should be avoided in patients with unstable epilepsy, and used cautiously in patients with epilepsy controlled with anticonvulsant medications. Treatment with SSRIs and SNRIs should be discontinued if seizures develop or seizure frequency increases. Patients receiving SSRIs or SNRIs with anticonvulsants, particularly carbamazepine, eslicarbazepine, oxcarbazepine and/or valproic acid, should also have serum sodium levels measured regularly and monitored for development of hyponatremia, particularly when higher dosages of these medications are used. Signs and symptoms of hyponatremia include nausea, vomiting, headache, difficulty concentrating, memory impairment, confusion, malaise, lethargy, muscle weakness or spasms, and unsteadiness. In more severe and/or acute cases, hallucination, syncope, seizure, coma, respiratory arrest, and death may occur.", "mechanism_text": "Antagonism", "recommendation": "SSRIs and SNRIs should be avoided in patients with unstable epilepsy, and used cautiously in patients with epilepsy controlled with anticonvulsant medications.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67100/", "reference_text": "[1] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[2] Belcastro V, Costa C, Striano P \"Levetiracetam-associated hyponatremia.\" Seizure 17 (2008): 389-90[3] Gandhi S, McArthur E, Mamdani MM, et.al \"Antiepileptic drugs and hyponatremia in older adults: Two population-based cohort studies.\" Epilepsia 57 (2016): 2067-79[4] \"Product Information. Aptiom (eslicarbazepine).\" Sunovion Pharmaceuticals Inc, Marlborough, MA.[5] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[6] \"Product Information. Tegretol (carbamazepine).\" Novartis Pharmaceuticals, East Hanover, NJ.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[9] Falhammar H, Lindh JD, Calissendorff J, et.al \"Differences in associations of antiepileptic drugs and hospitalization due to hyponatremia: A population-based case-control study.\" Seizure 59 (2018): 28-33[10] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[11] Bavbek N, Alkan R, Uz E, Kaftan O, Akcay A \"Hyponatremia associated with sodium valproate in a 22-year-old male.\" Nephrol Dial Transplant 23 (2008): epub[12] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[13] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[14] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[15] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[16] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[17] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[18] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[19] Patel KR, Meesala A, Stanilla JK \"Sodium valproate-induced hyponatremia: a case report.\" Prim Care Companion J Clin Psychiatry 12 (2010): epub[20] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[21] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[22] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[23] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[24] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[25] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[26] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[27] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[28] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Oxitriptan, Bupropion, Viloxazine, Tryptophan", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67014, "ingredient1": "Citalopram", "ingredient2": "Phendimetrazine", "severity": "Major", "effect": "Serotonin reuptake inhibitors may potentiate the pharmacologic response to sympathomimetic agents.", "source": "DDInter", "management_text": "In general, amphetamines and other sympathomimetic appetite suppressants should not be combined with selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs). Close monitoring for enhanced sympathomimetic effects and possible serotonin syndrome is recommended if these agents must be used together.", "mechanism_text": "Synergism", "recommendation": "In general, amphetamines and other sympathomimetic appetite suppressants should not be combined with selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs).", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67101/", "reference_text": "[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[2] Barrett J, Meehan O, Fahy T \"SSRI and sympathomimetic interaction.\" Br J Psychiatry 168 (1996): 253[3] Prior FH, Isbister GK, Dawson AH, Whyte IM \"Serotonin toxicity with therapeutic doses of dexamphetamine and venlafaxine.\" Med J Aust 176 (2002): 240-1[4] Walters AM \"Sympathomimetic-fluoxetine interaction.\" J Am Acad Child Adolesc Psychiatry 31 (1992): 565-6[5] Bostwick JM, Brown TM \"A toxic reaction from combining fluoxetine and phentermine.\" J Clin Psychopharmacol 16 (1996): 189-90[6] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[7] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[8] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[9] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[12] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Maprotiline, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Trazodone, Tryptophan", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67015, "ingredient1": "Citalopram", "ingredient2": "Phenelzine", "severity": "Major", "effect": "By inhibiting serotonin metabolism, monoamine oxidase inhibitors (MAOIs) may potentiate the pharmacologic activity of selective serotonin reuptake inhibitors (SSRIs) and increase the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.", "source": "DDInter", "management_text": "In general, SSRIs should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with SSRIs, and vice versa.", "mechanism_text": "Metabolism", "recommendation": "In general, SSRIs should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67102/", "reference_text": "[1] Beasley CM Jr, Masica DN, Heiligenstein JH, Wheadon DE, Zerbe RL \"Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings.\" J Clin Psychopharmacol 13 (1993): 312-20[2] Kline SS, Mauro LS, Scala-Bennett DM, Zick D \"Serotonin syndrome versus neuroleptic malignant death syndrome as a cause of death.\" Clin Pharm 8 (1989): 510-4[3] Bhatara VS, Bandettini FC \"Possible interaction between sertraline and tranylcypromine.\" Clin Pharm 12 (1993): 222-5[4] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[5] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[6] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[7] Suchowersky O, deVries JD \"Interaction of fluoxetine and selegiline.\" Can J Psychiatry 35 (1990): 571-2[8] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[9] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995): 440-2[10] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[11] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth (2005):[12] Suchowersky O, deVries J \"Possible interactions between deprenyl and prozac.\" Can J Neurol Sci 17 (1990): 352-3[13] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990): 213-7[14] Sternbach H \"Danger of MAOI therapy after fluoxetine withdrawal.\" Lancet 2 (1988): 850-1[15] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995): 481-2[16] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[17] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[18] Phillips SD, Ringo P \"Phenelzine and venlafaxine interaction.\" Am J Psychiatry 152 (1995): 1400-1[19] Feighner JP, Boyer WF, Tyler DL, Neborsky RJ \"Adverse consequences of fluoxetine-MAOI combination therapy.\" J Clin Psychiatry 51 (1990): 222-5[20] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[21] Jimenez-Genchi A \"Immediate switching from moclobemide to duloxetine may induce serotonin syndrome.\" J Clin Psychiatry 67 (2006): 1821-1822[22] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[23] Graber MA, Hoehns TB, Perry PJ \"Sertraline-phenelzine drug interaction: a serotonin syndrome reaction.\" Ann Pharmacother 28 (1994): 732-5[24] Ruiz F \"Fluoxetine and the serotonin syndrome.\" Ann Emerg Med 24 (1994): 983-5[25] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[26] Graham PM, Ilett KF \"Danger of MAOI therapy after fluoxetine withdrawal.\" Lancet 2 (1988): 1255-6[27] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[28] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics.\" J Clin Psychopharmacol 10 (1990): 48-50[29] Brannan SK, Talley BJ, Bowden CL \"Sertraline and isocarboxazid cause a serotonin syndrome.\" J Clin Psychopharmacol 14 (1994): 144-5[30] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[31] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[32] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[33] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993): 84-8[34] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[35] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S \"Rare case of serotonin syndrome with therapeutic doses of paroxetine.\" Am J Ther 13 (2006): 550-552[36] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[37] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[38] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[39] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[40] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[41] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[42] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[43] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[44] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[45] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[46] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[47] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[48] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[49] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[50] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[51] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[52] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[53] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[54] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80[55] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[56] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[57] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[58] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Phenelzine", "alternatives_b": "Citalopram, Esketamine", "updated_at": 1767369485}, {"id": 67016, "ingredient1": "Citalopram", "ingredient2": "Phenindamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67103/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Vilazodone, Sertraline, Paroxetine, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Milnacipran, Vortioxetine, Tryptophan, More", "alternatives_b": "Azelastine, Ketotifen", "updated_at": 1767369485}, {"id": 67017, "ingredient1": "Citalopram", "ingredient2": "Phenobarbital", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67104/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Levomilnacipran, Oxitriptan, Viloxazine, Milnacipran, Tryptophan", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67018, "ingredient1": "Citalopram", "ingredient2": "Phenolphthalein", "severity": "Moderate", "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67105/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Schaefer DC, Cheskin LJ \"Constipation in the elderly.\" Am Fam Physician 58 (1998): 907-14[4] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993): 138-45[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998): 517-8", "alternatives_a": "Maprotiline, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 67019, "ingredient1": "Citalopram", "ingredient2": "Phensuximide", "severity": "Moderate", "effect": "The efficacy of anticonvulsants may be diminished during coadministration with selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitor (SNRIs). Antidepressants including SSRIs and SNRIs can reduce seizure threshold.Coadministration of SSRIs or SNRIs with some anticonvulsants, particularly carbamazepine, eslicarbazepine, oxcarbazepine and valproic acid, may increase the risk of hyponatremia. The risk appears to be dose-related, and elderly patients and patients who are volume depleted (e.g., diuretic use) may be at greater risk.", "source": "DDInter", "management_text": "SSRIs and SNRIs should be avoided in patients with unstable epilepsy, and used cautiously in patients with epilepsy controlled with anticonvulsant medications. Treatment with SSRIs and SNRIs should be discontinued if seizures develop or seizure frequency increases. Patients receiving SSRIs or SNRIs with anticonvulsants, particularly carbamazepine, eslicarbazepine, oxcarbazepine and/or valproic acid, should also have serum sodium levels measured regularly and monitored for development of hyponatremia, particularly when higher dosages of these medications are used. Signs and symptoms of hyponatremia include nausea, vomiting, headache, difficulty concentrating, memory impairment, confusion, malaise, lethargy, muscle weakness or spasms, and unsteadiness. In more severe and/or acute cases, hallucination, syncope, seizure, coma, respiratory arrest, and death may occur.", "mechanism_text": "Antagonism", "recommendation": "SSRIs and SNRIs should be avoided in patients with unstable epilepsy, and used cautiously in patients with epilepsy controlled with anticonvulsant medications.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67106/", "reference_text": "[1] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[2] Belcastro V, Costa C, Striano P \"Levetiracetam-associated hyponatremia.\" Seizure 17 (2008): 389-90[3] Gandhi S, McArthur E, Mamdani MM, et.al \"Antiepileptic drugs and hyponatremia in older adults: Two population-based cohort studies.\" Epilepsia 57 (2016): 2067-79[4] \"Product Information. Aptiom (eslicarbazepine).\" Sunovion Pharmaceuticals Inc, Marlborough, MA.[5] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[6] \"Product Information. Tegretol (carbamazepine).\" Novartis Pharmaceuticals, East Hanover, NJ.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[9] Falhammar H, Lindh JD, Calissendorff J, et.al \"Differences in associations of antiepileptic drugs and hospitalization due to hyponatremia: A population-based case-control study.\" Seizure 59 (2018): 28-33[10] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[11] Bavbek N, Alkan R, Uz E, Kaftan O, Akcay A \"Hyponatremia associated with sodium valproate in a 22-year-old male.\" Nephrol Dial Transplant 23 (2008): epub[12] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[13] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[14] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[15] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[16] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[17] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[18] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[19] Patel KR, Meesala A, Stanilla JK \"Sodium valproate-induced hyponatremia: a case report.\" Prim Care Companion J Clin Psychiatry 12 (2010): epub[20] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[21] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[22] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[23] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[24] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[25] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[26] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[27] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[28] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Oxitriptan, Bupropion, Viloxazine, Tryptophan", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67020, "ingredient1": "Citalopram", "ingredient2": "Phentermine", "severity": "Major", "effect": "Serotonin reuptake inhibitors may potentiate the pharmacologic response to sympathomimetic agents.", "source": "DDInter", "management_text": "In general, amphetamines and other sympathomimetic appetite suppressants should not be combined with selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs). Close monitoring for enhanced sympathomimetic effects and possible serotonin syndrome is recommended if these agents must be used together.", "mechanism_text": "Synergism", "recommendation": "In general, amphetamines and other sympathomimetic appetite suppressants should not be combined with selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs).", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67107/", "reference_text": "[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[2] Barrett J, Meehan O, Fahy T \"SSRI and sympathomimetic interaction.\" Br J Psychiatry 168 (1996): 253[3] Prior FH, Isbister GK, Dawson AH, Whyte IM \"Serotonin toxicity with therapeutic doses of dexamphetamine and venlafaxine.\" Med J Aust 176 (2002): 240-1[4] Walters AM \"Sympathomimetic-fluoxetine interaction.\" J Am Acad Child Adolesc Psychiatry 31 (1992): 565-6[5] Bostwick JM, Brown TM \"A toxic reaction from combining fluoxetine and phentermine.\" J Clin Psychopharmacol 16 (1996): 189-90[6] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[7] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[8] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[9] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[12] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Ephedrine", "alternatives_b": "Maprotiline, St. John's Wort, Oxitriptan, Mirtazapine, Viloxazine, Trazodone, Tryptophan", "updated_at": 1767369485}, {"id": 67021, "ingredient1": "Citalopram", "ingredient2": "Phenylbutazone", "severity": "Moderate", "effect": "Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.", "source": "DDInter", "management_text": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67108/", "reference_text": "[1] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG \"Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin.\" Acta Psychiatr Scand Suppl 350 (1989): 102-6[2] Skop BP, Brown TM \"Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors.\" Psychosomatics 37 (1996): 12-6[3] Settle EC \"Antidepressant drugs: disturbing and potentially dangerous adverse effects.\" J Clin Psychiatry 59 Suppl 16 (1998): 25-30[4] Layton D, Clark DWJ, Pearce GL, Shakir SAW \"Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England.\" Eur J Clin Pharmacol 57 (2001): 167-76[5] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[6] Leung M, Shore R \"Fluvoxamine-associated bleeding.\" Can J Psychiatry 41 (1996): 604-5[7] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[8] Tata LJ, Fortun PJ, Hubbard RB, et al. \"Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?\" Aliment Pharmacol Ther 22 (2005): 175-81[9] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[10] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B \"Paroxetine decreases platelet serotonin storage and platelet function in human beings.\" Clin Pharmacol Ther 68 (2000): 435-42[11] de Abajo FJ, Rodriguez LA, Montero D \"Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study.\" BMJ 319 (1999): 1106-9[12] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[13] Alderman CP, Moritz CK, Ben-Tovim DI \"Abnormal platelet aggregation associated with fluoxetine therapy.\" Ann Pharmacother 26 (1992): 1517-9[14] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[15] Krivy J, Wiener J \"Sertraline and platelet counts in idiopathic thrombocytopenia purpura.\" Lancet 345 (1995): 132[16] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[17] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[18] Pai VB, Kelly MW \"Bruising associated with the use of fluoxetine.\" Ann Pharmacother 30 (1996): 786-8[19] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990): 213-7[20] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ \"Fluoxetine and bleeding in obsessive-compulsive disorder.\" Am J Psychiatry 148 (1991): 949[21] Alderman CP, Seshadri P, Ben-Tovim DI \"Effects of serotonin reuptake inhibitors on hemostasis.\" Ann Pharmacother 30 (1996): 1232-4[22] Humphries JE, Wheby MS, VandenBerg SR \"Fluoxetine and the bleeding time.\" Arch Pathol Lab Med 114 (1990): 727-8[23] Woolfrey S, Gammack NS, Dewar MS, Brown PJ \"Fluoxetine-warfarin interaction.\" BMJ 307 (1993): 241[24] Messiha FS \"Fluoxetine - adverse effects and drug-drug interactions.\" J Toxicol Clin Toxicol 31 (1993): 603-30[25] Ford MA, Anderson ML, Rindone JP, Jaskar DW \"Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin.\" J Clin Psychopharmacol 17 (1997): 110-2[26] Ottervanger JP, Stricker BH, Huls J, Weeda JN \"Bleeding attributed to the intake of paroxetine.\" Am J Psychiatry 151 (1994): 781-2[27] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[28] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH \"Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study.\" Arch Intern Med 163 (2003): 59-64[29] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[30] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[31] Aranth J, Lindberg C \"Bleeding, a side effect of fluoxetine.\" Am J Psychiatry 149 (1992): 412[32] Cerner Multum, Inc. \"Australian Product Information.\" O 0[33] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S \"Intracranial haemorrhage and use of selective serotonin reuptake inhibitors.\" Br J Clin Pharmacol 50 (2000): 43-7[34] de Maistre E, Allart C, Lecompte T, Bollaert PE \"Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors.\" Am J Med 113 (2002): 530-2[35] Claire RJ, Servis ME, Cram DL Jr \"Potential interaction between warfarin sodium and fluoxetine.\" Am J Psychiatry 148 (1991): 1604[36] Dent LA, Orrock MW \"Warfarin-fluoxetine and diazepam-fluoxetine interaction.\" Pharmacotherapy 17 (1997): 170-2[37] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[38] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[39] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[40] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[41] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[42] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Maprotiline, St. John's Wort, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, More", "alternatives_b": "Chondroitin sulfate, Glucosamine, Tolazoline, Dimethyl sulfoxide", "updated_at": 1767369485}, {"id": 67022, "ingredient1": "Citalopram", "ingredient2": "Phenylpropanolamine", "severity": "Major", "effect": "Serotonin reuptake inhibitors may potentiate the pharmacologic response to sympathomimetic agents.", "source": "DDInter", "management_text": "In general, amphetamines and other sympathomimetic appetite suppressants should not be combined with selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs). Close monitoring for enhanced sympathomimetic effects and possible serotonin syndrome is recommended if these agents must be used together.", "mechanism_text": "Synergism", "recommendation": "In general, amphetamines and other sympathomimetic appetite suppressants should not be combined with selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs).", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67109/", "reference_text": "[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[2] Barrett J, Meehan O, Fahy T \"SSRI and sympathomimetic interaction.\" Br J Psychiatry 168 (1996): 253[3] Prior FH, Isbister GK, Dawson AH, Whyte IM \"Serotonin toxicity with therapeutic doses of dexamphetamine and venlafaxine.\" Med J Aust 176 (2002): 240-1[4] Walters AM \"Sympathomimetic-fluoxetine interaction.\" J Am Acad Child Adolesc Psychiatry 31 (1992): 565-6[5] Bostwick JM, Brown TM \"A toxic reaction from combining fluoxetine and phentermine.\" J Clin Psychopharmacol 16 (1996): 189-90[6] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[7] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[8] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[9] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[12] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Maprotiline, Nefazodone, St. John's Wort, Oxitriptan, Mirtazapine, Viloxazine, Trazodone, Tryptophan, Esketamine", "alternatives_b": "Pseudoephedrine, Phenylephrine", "updated_at": 1767369485}, {"id": 67023, "ingredient1": "Citalopram", "ingredient2": "Phenytoin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67110/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Nefazodone, Oxitriptan, Viloxazine, Milnacipran, Tryptophan, Levomilnacipran", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67024, "ingredient1": "Citalopram", "ingredient2": "Pimavanserin", "severity": "Major", "effect": "Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.", "mechanism_text": "Synergism", "recommendation": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67111/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm.\" ([2011 Aug 24]):[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm.\" ([2012 Mar 28]):[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[9] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[12] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Kaletra (lopinavir-ritonavir)\" Abbott Pharmaceutical, Abbott Park, IL.[15] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Phenelzine, Duloxetine, Tranylcypromine, Vilazodone, Desvenlafaxine, Isocarboxazid, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67025, "ingredient1": "Citalopram", "ingredient2": "Pimozide", "severity": "Major", "effect": "Coadministration with citalopram has been shown to potentiate the effects of pimozide on the QT interval. The mechanism of interaction is unknown.", "source": "DDInter", "management_text": "The use of pimozide in combination with citalopram or escitalopram is considered contraindicated.", "mechanism_text": "Synergism", "recommendation": "The use of pimozide in combination with citalopram or escitalopram is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67112/", "reference_text": "[1] \"Product Information. Orap Tablets (pimozide).\" Gate Pharmaceuticals, Sellersville, PA.[2] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp.\" ([2006]):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[6] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[7] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[8] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[9] \"Product Information. Orap Tablets (pimozide).\" Gate Pharmaceuticals, Sellersville, PA.[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[12] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Oxitriptan, Vilazodone, Vortioxetine, Tryptophan", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67026, "ingredient1": "Citalopram", "ingredient2": "Pirbuterol", "severity": "Moderate", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.", "source": "DDInter", "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67113/", "reference_text": "[1] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990): 575-9[6] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003): 1817-24[8] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998): 145-7[11] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990): 1396-9[16] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.[17] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006): 582-90[19] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[20] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[21] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001): 45-51[26] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986): 619-20", "alternatives_a": "St. John's Wort, Nefazodone, Oxitriptan, Viloxazine, Vortioxetine, Tryptophan, Vilazodone, Esketamine, Fluvoxamine", "alternatives_b": "Ephedrine, Mometasone furoate, Umeclidinium, Aclidinium, Mometasone, Glycopyrronium, Ipratropium, Beclomethasone dipropionate", "updated_at": 1767369485}, {"id": 67027, "ingredient1": "Citalopram", "ingredient2": "Piroxicam", "severity": "Moderate", "effect": "Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.", "source": "DDInter", "management_text": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67114/", "reference_text": "[1] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG \"Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin.\" Acta Psychiatr Scand Suppl 350 (1989): 102-6[2] Skop BP, Brown TM \"Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors.\" Psychosomatics 37 (1996): 12-6[3] Settle EC \"Antidepressant drugs: disturbing and potentially dangerous adverse effects.\" J Clin Psychiatry 59 Suppl 16 (1998): 25-30[4] Layton D, Clark DWJ, Pearce GL, Shakir SAW \"Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England.\" Eur J Clin Pharmacol 57 (2001): 167-76[5] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[6] Leung M, Shore R \"Fluvoxamine-associated bleeding.\" Can J Psychiatry 41 (1996): 604-5[7] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[8] Tata LJ, Fortun PJ, Hubbard RB, et al. \"Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?\" Aliment Pharmacol Ther 22 (2005): 175-81[9] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[10] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B \"Paroxetine decreases platelet serotonin storage and platelet function in human beings.\" Clin Pharmacol Ther 68 (2000): 435-42[11] de Abajo FJ, Rodriguez LA, Montero D \"Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study.\" BMJ 319 (1999): 1106-9[12] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[13] Alderman CP, Moritz CK, Ben-Tovim DI \"Abnormal platelet aggregation associated with fluoxetine therapy.\" Ann Pharmacother 26 (1992): 1517-9[14] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[15] Krivy J, Wiener J \"Sertraline and platelet counts in idiopathic thrombocytopenia purpura.\" Lancet 345 (1995): 132[16] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[17] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[18] Pai VB, Kelly MW \"Bruising associated with the use of fluoxetine.\" Ann Pharmacother 30 (1996): 786-8[19] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990): 213-7[20] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ \"Fluoxetine and bleeding in obsessive-compulsive disorder.\" Am J Psychiatry 148 (1991): 949[21] Alderman CP, Seshadri P, Ben-Tovim DI \"Effects of serotonin reuptake inhibitors on hemostasis.\" Ann Pharmacother 30 (1996): 1232-4[22] Humphries JE, Wheby MS, VandenBerg SR \"Fluoxetine and the bleeding time.\" Arch Pathol Lab Med 114 (1990): 727-8[23] Woolfrey S, Gammack NS, Dewar MS, Brown PJ \"Fluoxetine-warfarin interaction.\" BMJ 307 (1993): 241[24] Messiha FS \"Fluoxetine - adverse effects and drug-drug interactions.\" J Toxicol Clin Toxicol 31 (1993): 603-30[25] Ford MA, Anderson ML, Rindone JP, Jaskar DW \"Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin.\" J Clin Psychopharmacol 17 (1997): 110-2[26] Ottervanger JP, Stricker BH, Huls J, Weeda JN \"Bleeding attributed to the intake of paroxetine.\" Am J Psychiatry 151 (1994): 781-2[27] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[28] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH \"Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study.\" Arch Intern Med 163 (2003): 59-64[29] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[30] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[31] Aranth J, Lindberg C \"Bleeding, a side effect of fluoxetine.\" Am J Psychiatry 149 (1992): 412[32] Cerner Multum, Inc. \"Australian Product Information.\" O 0[33] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S \"Intracranial haemorrhage and use of selective serotonin reuptake inhibitors.\" Br J Clin Pharmacol 50 (2000): 43-7[34] de Maistre E, Allart C, Lecompte T, Bollaert PE \"Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors.\" Am J Med 113 (2002): 530-2[35] Claire RJ, Servis ME, Cram DL Jr \"Potential interaction between warfarin sodium and fluoxetine.\" Am J Psychiatry 148 (1991): 1604[36] Dent LA, Orrock MW \"Warfarin-fluoxetine and diazepam-fluoxetine interaction.\" Pharmacotherapy 17 (1997): 170-2[37] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[38] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[39] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[40] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[41] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[42] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Phenelzine, Desipramine, Tranylcypromine, Trimipramine, Maprotiline, St. John's Wort, Isocarboxazid, Oxitriptan, Viloxazine, Tryptophan, Amoxapine, More", "alternatives_b": "Chondroitin sulfate, Glucosamine, Tolazoline, Dimethyl sulfoxide, Cortisone, Betamethasone, Fluorometholone", "updated_at": 1767369485}, {"id": 67028, "ingredient1": "Citalopram", "ingredient2": "Pitolisant", "severity": "Major", "effect": "Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.", "mechanism_text": "Synergism", "recommendation": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67115/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm.\" ([2011 Aug 24]):[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm.\" ([2012 Mar 28]):[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[9] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[12] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Kaletra (lopinavir-ritonavir)\" Abbott Pharmaceutical, Abbott Park, IL.[15] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Phenelzine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Vilazodone, Esketamine", "alternatives_b": "Dalfampridine, Tafamidis", "updated_at": 1767369485}, {"id": 67029, "ingredient1": "Citalopram", "ingredient2": "Plicamycin", "severity": "Moderate", "effect": "Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.", "source": "DDInter", "management_text": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67116/", "reference_text": "[1] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG \"Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin.\" Acta Psychiatr Scand Suppl 350 (1989): 102-6[2] Skop BP, Brown TM \"Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors.\" Psychosomatics 37 (1996): 12-6[3] Settle EC \"Antidepressant drugs: disturbing and potentially dangerous adverse effects.\" J Clin Psychiatry 59 Suppl 16 (1998): 25-30[4] Layton D, Clark DWJ, Pearce GL, Shakir SAW \"Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England.\" Eur J Clin Pharmacol 57 (2001): 167-76[5] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[6] Leung M, Shore R \"Fluvoxamine-associated bleeding.\" Can J Psychiatry 41 (1996): 604-5[7] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[8] Tata LJ, Fortun PJ, Hubbard RB, et al. \"Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?\" Aliment Pharmacol Ther 22 (2005): 175-81[9] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[10] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B \"Paroxetine decreases platelet serotonin storage and platelet function in human beings.\" Clin Pharmacol Ther 68 (2000): 435-42[11] de Abajo FJ, Rodriguez LA, Montero D \"Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study.\" BMJ 319 (1999): 1106-9[12] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[13] Alderman CP, Moritz CK, Ben-Tovim DI \"Abnormal platelet aggregation associated with fluoxetine therapy.\" Ann Pharmacother 26 (1992): 1517-9[14] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[15] Krivy J, Wiener J \"Sertraline and platelet counts in idiopathic thrombocytopenia purpura.\" Lancet 345 (1995): 132[16] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[17] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[18] Pai VB, Kelly MW \"Bruising associated with the use of fluoxetine.\" Ann Pharmacother 30 (1996): 786-8[19] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990): 213-7[20] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ \"Fluoxetine and bleeding in obsessive-compulsive disorder.\" Am J Psychiatry 148 (1991): 949[21] Alderman CP, Seshadri P, Ben-Tovim DI \"Effects of serotonin reuptake inhibitors on hemostasis.\" Ann Pharmacother 30 (1996): 1232-4[22] Humphries JE, Wheby MS, VandenBerg SR \"Fluoxetine and the bleeding time.\" Arch Pathol Lab Med 114 (1990): 727-8[23] Woolfrey S, Gammack NS, Dewar MS, Brown PJ \"Fluoxetine-warfarin interaction.\" BMJ 307 (1993): 241[24] Messiha FS \"Fluoxetine - adverse effects and drug-drug interactions.\" J Toxicol Clin Toxicol 31 (1993): 603-30[25] Ford MA, Anderson ML, Rindone JP, Jaskar DW \"Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin.\" J Clin Psychopharmacol 17 (1997): 110-2[26] Ottervanger JP, Stricker BH, Huls J, Weeda JN \"Bleeding attributed to the intake of paroxetine.\" Am J Psychiatry 151 (1994): 781-2[27] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[28] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH \"Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study.\" Arch Intern Med 163 (2003): 59-64[29] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[30] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[31] Aranth J, Lindberg C \"Bleeding, a side effect of fluoxetine.\" Am J Psychiatry 149 (1992): 412[32] Cerner Multum, Inc. \"Australian Product Information.\" O 0[33] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S \"Intracranial haemorrhage and use of selective serotonin reuptake inhibitors.\" Br J Clin Pharmacol 50 (2000): 43-7[34] de Maistre E, Allart C, Lecompte T, Bollaert PE \"Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors.\" Am J Med 113 (2002): 530-2[35] Claire RJ, Servis ME, Cram DL Jr \"Potential interaction between warfarin sodium and fluoxetine.\" Am J Psychiatry 148 (1991): 1604[36] Dent LA, Orrock MW \"Warfarin-fluoxetine and diazepam-fluoxetine interaction.\" Pharmacotherapy 17 (1997): 170-2[37] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[38] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[39] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[40] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[41] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[42] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Maprotiline, St. John's Wort, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, More", "alternatives_b": "Valrubicin, Ixabepilone, Bleomycin, Mitomycin, Dactinomycin", "updated_at": 1767369485}, {"id": 67030, "ingredient1": "Citalopram", "ingredient2": "Polyethylene glycol (3350)", "severity": "Moderate", "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67117/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Schaefer DC, Cheskin LJ \"Constipation in the elderly.\" Am Fam Physician 58 (1998): 907-14[4] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993): 138-45[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998): 517-8", "alternatives_a": "Maprotiline, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67031, "ingredient1": "Citalopram", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics. The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that can prolong the QT interval, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; mefloquine; halofantrine; lumefantrine), and some narcotic analgesics (methadone; propoxyphene).", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67118/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[6] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[9] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[14] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[15] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67032, "ingredient1": "Citalopram", "ingredient2": "Polythiazide", "severity": "Moderate", "effect": "Coadministration with diuretics may potentiate the risk of hyponatremia associated with the use of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). Elderly patients and patients taking diuretics or who are otherwise volume-depleted may be at greater risk of developing hyponatremia with SSRIs and SNRIs. Antihypertensive agents such as diuretics may potentiate the orthostatic effect that is occasionally observed upon the initiation of SSRI or SNRI therapy. Syncope and orthostatic hypotension tend to occur within the first week of SNRI/SSRI therapy but can occur at any time during treatment, particularly after a dosage increase. The use of SSRIs or SNRIs may also cause sustained increases in blood pressure and heart rate, which may antagonize the therapeutic effects of antihypertensive medications.", "source": "DDInter", "management_text": "Caution is recommended if SSRIs or SNRIs are prescribed in combination with diuretics, particularly in the elderly. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hyponatremia such as nausea, vomiting, headache, malaise, lethargy, irritability, difficulty concentrating, memory impairment, confusion, weakness, muscle spasm, and unsteadiness (which may lead to falls). More severe and/or acute cases may include hallucination, syncope, seizure, coma, respiratory arrest, and death. Discontinuation of SSRI/SNRI therapy should be considered in patients who develop symptomatic hyponatremia, and appropriate medical intervention instituted as necessary. Patients should also have their blood pressure and pulse monitored before and during SSRI/SNRI therapy, especially during the first few weeks and following a dosage increase. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if SSRIs or SNRIs are prescribed in combination with diuretics, particularly in the elderly.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67119/", "reference_text": "[1] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[2] Jackson C, Carson W, Markowitz J, Mintzer J \"SIADH associated with fluoxetine and sertraline therapy.\" Am J Psychiatry 152 (1995): 809-10[3] Robinson D, Brooks J, Mahler E, Sheikh JI \"SIADH--compulsive drinking or SSRI influence?\" Ann Pharmacother 30 (1996): 885[4] Odeh M, Beny A, Oliven A \"Severe symptomatic hyponatremia during citalopram therapy.\" Am J Med Sci 321 (2001): 159-60[5] Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA \"Fluoxetine as a cause of SIADH.\" Am J Psychiatry 148 (1991): 542-3[6] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[7] Jacob S, Spinler SA \"Hyponatremia associated with selective serotonin-reuptake inhibitors in older adults.\" Ann Pharmacother 40 (2006): 1618-22[8] Fitzgerald MA \"Hyponatremia associated with SSRI use in a 65-year-old woman.\" Nurse Pract 33 (2008): 11-2[9] van Campen JP, Voets AJ \"SIADH caused by paroxetine.\" Ann Pharmacother 30 (1996): 1499[10] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[11] Kessler J, Samuels SC \"Sertraline and hyponatremia.\" N Engl J Med 335 (1996): 524[12] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[13] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[14] Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J \"Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine.\" J Toxicol Clin Toxicol 35 (1997): 93-5[15] Crews JR, Potts NL, Schreiber J, Lipper S \"Hyponatremia in a patient treated with sertraline.\" Am J Psychiatry 150 (1993): 1564[16] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[17] Bradley ME, Foote EF, Lee EN, Merkle L \"Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature.\" Pharmacotherapy 16 (1996): 680-3[18] Odeh M, Seligmann H, Oliven A \"Severe life-threatening hyponatremia during paroxetine therapy.\" J Clin Pharmacol 39 (1999): 1290-1[19] Thornton SL, Resch DS \"SIADH associated with sertraline therapy.\" Am J Psychiatry 152 (1995): 809[20] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[21] \"Selective serotonin reuptake inhibitors and SIADH.\" Med J Aust 164 (1996): 562[22] Bouman WP, Johnson H, TrescoliSerrano C, Jones RG \"Recurrent hyponatremia associated with sertraline and lofepramine.\" Am J Psychiatry 154 (1997): 580[23] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[24] Goddard C, Paton C \"Hyponatraemia associated with paroxetine.\" BMJ 305 (1992): 1332[25] Barclay TS, Lee AJ \"Citalopram-associated SIADH.\" Ann Pharmacother 36 (2002): 1558-63[26] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[27] Covyeou JA, Jackson CW \"Hyponatremia associated with escitalopram.\" N Engl J Med 356 (2007): 94-5[28] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[29] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[30] Schattner A, Skurnik Y \"Fluoxetine-induced SIADH.\" J Am Geriatr Soc 44 (1996): 1413[31] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[32] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[33] Spigset O, hedenmalm K \"Hyponatremia in relation to treatment with antidepressants: a survey of reports in the World Health Organization data base for spontaneous reporting of adverse drug reactions.\" Pharmacotherapy 17 (1997): 348-52[34] Staab JP, Yerkes SA, Cheney EM, Clayton AH \"Transient SIADH associated with fluoxetine.\" Am J Psychiatry 147 (1990): 1569-70[35] Blacksten JV, Birt JA \"Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine.\" Ann Pharmacother 27 (1993): 723-4[36] Llorente MD, Gorelick M, Silverman MA \"Sertraline as the cause of inappropriate antidiuretic hormone secretion.\" J Clin Psychiatry 55 (1994): 543-4[37] Baliga RR, McHardy KC \"Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119].\" Br J Clin Pract 47 (1993): 62-3[38] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[39] Hwang AS, Magraw RM \"Syndrome of inappropriate secretion of antidiuretic hormone due to fluoxetine.\" Am J Psychiatry 146 (1989): 399[40] Cohen BJ, Mahelsky M, Adler L \"More cases of SIADH with fluoxetine.\" Am J Psychiatry 147 (1990): 948-9[41] Ayonrinde OT, Sanfilippo FM \"SSRI antidepressants and SIADH.\" Aust N Z J Psychiatry 31 (1997): 306-7[42] Kazal LA, Jr Hall DL, Miller LG, Noel ML \"Fluoxetine-induced SIADH: a geriatric occurrence?\" J Fam Pract 36 (1993): 341-3[43] Ayonrinde OT, Reutens SG, Sanfilippo FM \"Paroxetine-induced SIADH.\" Med J Aust 163 (1995): 390[44] Chua TP, Vong SK \"Hyponatraemia associated with paroxetine.\" BMJ 306 (1993): 143[45] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Woo MH, Smythe MA \"Association of SIADH with selective serotonin reuptake inhibitors.\" Ann Pharmacother 31 (1997): 108-10[47] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[48] Rosner MH \"Severe hyponatremia associated with the combined use of thiazide diuretics and selective serotonin reuptake inhibitors.\" Am J Med Sci 327 (2004): 109-11[49] Doshi D, Borison R \"Association of transient SIADH with sertraline.\" Am J Psychiatry 151 (1994): 779-80[50] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[51] Madhusoodanan S, Brenner R, Brafman I, Bogunovic O \"Hyponatremia associated with paroxetine use.\" South Med J 92 (1999): 843[52] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[53] Esposito P, Rampino T, Gregorini M, et al. \"Severe symptomatic hyponatremia during sibutramine therapy: a case report.\" Am J Kidney Dis 52 (2008): 137-9[54] Spier SA, Frontera MA \"Unexpected deaths in depressed medical inpatients treated with fluoxetine.\" J Clin Psychiatry 52 (1991): 377-82[55] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[56] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[57] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Desipramine, St. John's Wort, Oxitriptan, Viloxazine, Nortriptyline, Tryptophan, Protriptyline, Esketamine", "alternatives_b": "Tinidazole, Mitapivat, Ascorbic acid, Oxytetracycline, Ciclopirox, Sulfamethizole, Simeprevir, Diazoxide, Econazole, Povidone-iodine, Sulfisoxazole, More", "updated_at": 1767369485}, {"id": 67033, "ingredient1": "Citalopram", "ingredient2": "Ponatinib", "severity": "Moderate", "effect": "Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.", "source": "DDInter", "management_text": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67120/", "reference_text": "[1] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG \"Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin.\" Acta Psychiatr Scand Suppl 350 (1989): 102-6[2] Skop BP, Brown TM \"Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors.\" Psychosomatics 37 (1996): 12-6[3] Settle EC \"Antidepressant drugs: disturbing and potentially dangerous adverse effects.\" J Clin Psychiatry 59 Suppl 16 (1998): 25-30[4] Layton D, Clark DWJ, Pearce GL, Shakir SAW \"Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England.\" Eur J Clin Pharmacol 57 (2001): 167-76[5] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[6] Leung M, Shore R \"Fluvoxamine-associated bleeding.\" Can J Psychiatry 41 (1996): 604-5[7] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[8] Tata LJ, Fortun PJ, Hubbard RB, et al. \"Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?\" Aliment Pharmacol Ther 22 (2005): 175-81[9] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[10] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B \"Paroxetine decreases platelet serotonin storage and platelet function in human beings.\" Clin Pharmacol Ther 68 (2000): 435-42[11] de Abajo FJ, Rodriguez LA, Montero D \"Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study.\" BMJ 319 (1999): 1106-9[12] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[13] Alderman CP, Moritz CK, Ben-Tovim DI \"Abnormal platelet aggregation associated with fluoxetine therapy.\" Ann Pharmacother 26 (1992): 1517-9[14] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[15] Krivy J, Wiener J \"Sertraline and platelet counts in idiopathic thrombocytopenia purpura.\" Lancet 345 (1995): 132[16] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[17] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[18] Pai VB, Kelly MW \"Bruising associated with the use of fluoxetine.\" Ann Pharmacother 30 (1996): 786-8[19] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990): 213-7[20] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ \"Fluoxetine and bleeding in obsessive-compulsive disorder.\" Am J Psychiatry 148 (1991): 949[21] Alderman CP, Seshadri P, Ben-Tovim DI \"Effects of serotonin reuptake inhibitors on hemostasis.\" Ann Pharmacother 30 (1996): 1232-4[22] Humphries JE, Wheby MS, VandenBerg SR \"Fluoxetine and the bleeding time.\" Arch Pathol Lab Med 114 (1990): 727-8[23] Woolfrey S, Gammack NS, Dewar MS, Brown PJ \"Fluoxetine-warfarin interaction.\" BMJ 307 (1993): 241[24] Messiha FS \"Fluoxetine - adverse effects and drug-drug interactions.\" J Toxicol Clin Toxicol 31 (1993): 603-30[25] Ford MA, Anderson ML, Rindone JP, Jaskar DW \"Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin.\" J Clin Psychopharmacol 17 (1997): 110-2[26] Ottervanger JP, Stricker BH, Huls J, Weeda JN \"Bleeding attributed to the intake of paroxetine.\" Am J Psychiatry 151 (1994): 781-2[27] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[28] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH \"Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study.\" Arch Intern Med 163 (2003): 59-64[29] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[30] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[31] Aranth J, Lindberg C \"Bleeding, a side effect of fluoxetine.\" Am J Psychiatry 149 (1992): 412[32] Cerner Multum, Inc. \"Australian Product Information.\" O 0[33] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S \"Intracranial haemorrhage and use of selective serotonin reuptake inhibitors.\" Br J Clin Pharmacol 50 (2000): 43-7[34] de Maistre E, Allart C, Lecompte T, Bollaert PE \"Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors.\" Am J Med 113 (2002): 530-2[35] Claire RJ, Servis ME, Cram DL Jr \"Potential interaction between warfarin sodium and fluoxetine.\" Am J Psychiatry 148 (1991): 1604[36] Dent LA, Orrock MW \"Warfarin-fluoxetine and diazepam-fluoxetine interaction.\" Pharmacotherapy 17 (1997): 170-2[37] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[38] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[39] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[40] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[41] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[42] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Maprotiline, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, Trimipramine, More", "alternatives_b": "Dacomitinib, Tepotinib, Selumetinib, Cobimetinib, Capmatinib, Afatinib, Tivozanib, Brigatinib, Axitinib, Ripretinib, Alpelisib, More", "updated_at": 1767369485}, {"id": 67034, "ingredient1": "Citalopram", "ingredient2": "Porfimer sodium", "severity": "Moderate", "effect": "Concomitant use of porfimer with drugs known to cause photosensitivity may increase the risk of a photosensitivity reaction. Photosensitivity with porfimer is due to residual drug being present in the skin. Patients treated with porfimer will be photosensitive for at least 30 days.", "source": "DDInter", "management_text": "Concomitant use of photosensitizing agents with porfimer should be avoided for at least 30 days and maybe up to 90 days or longer depending on patient's hepatic and/or renal function.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of photosensitizing agents with porfimer should be avoided for at least 30 days and maybe up to 90 days or longer depending on patient's hepatic and/or renal function.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67121/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Photofrin (porfimer).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[3] Blakely KM, Drucker AM, Rosen CF \"Drug-induced photosensitivityan update: Culprit drugs, prevention and management.\" Drug Saf 42 (2019): 827-47[4] Hoffman GA, Gradl G, Schulz M, Haidinger G, Tanew A, Weber B \"The frequency of photosensitizing drug dispensings in Austria and Germany: A correlation with their photosensitizing potential based on published literature.\" J Eur Acad Dermatol Venereol 34 (2020): 589-600[5] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[6] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Duloxetine, Tranylcypromine, Vilazodone, Desvenlafaxine, Maprotiline, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, More", "alternatives_b": "Pertuzumab, Olaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, Enasidenib, More", "updated_at": 1767369485}, {"id": 67035, "ingredient1": "Citalopram", "ingredient2": "Posaconazole", "severity": "Major", "effect": "Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.", "mechanism_text": "Synergism", "recommendation": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67122/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm.\" ([2011 Aug 24]):[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm.\" ([2012 Mar 28]):[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[9] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[12] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Kaletra (lopinavir-ritonavir)\" Abbott Pharmaceutical, Abbott Park, IL.[15] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "St. John's Wort, Vortioxetine, Milnacipran, Isocarboxazid, Viloxazine, Imipramine, Esketamine, Fluvoxamine, Phenelzine, Tranylcypromine, Trimipramine, More", "alternatives_b": "Flucytosine, Anidulafungin, Micafungin, Oteseconazole", "updated_at": 1767369485}, {"id": 67036, "ingredient1": "Citalopram", "ingredient2": "Pramipexole", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67123/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67037, "ingredient1": "Citalopram", "ingredient2": "Prasugrel", "severity": "Moderate", "effect": "Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.", "source": "DDInter", "management_text": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67124/", "reference_text": "[1] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG \"Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin.\" Acta Psychiatr Scand Suppl 350 (1989): 102-6[2] Skop BP, Brown TM \"Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors.\" Psychosomatics 37 (1996): 12-6[3] Settle EC \"Antidepressant drugs: disturbing and potentially dangerous adverse effects.\" J Clin Psychiatry 59 Suppl 16 (1998): 25-30[4] Layton D, Clark DWJ, Pearce GL, Shakir SAW \"Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England.\" Eur J Clin Pharmacol 57 (2001): 167-76[5] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[6] Leung M, Shore R \"Fluvoxamine-associated bleeding.\" Can J Psychiatry 41 (1996): 604-5[7] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[8] Tata LJ, Fortun PJ, Hubbard RB, et al. \"Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?\" Aliment Pharmacol Ther 22 (2005): 175-81[9] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[10] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B \"Paroxetine decreases platelet serotonin storage and platelet function in human beings.\" Clin Pharmacol Ther 68 (2000): 435-42[11] de Abajo FJ, Rodriguez LA, Montero D \"Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study.\" BMJ 319 (1999): 1106-9[12] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[13] Alderman CP, Moritz CK, Ben-Tovim DI \"Abnormal platelet aggregation associated with fluoxetine therapy.\" Ann Pharmacother 26 (1992): 1517-9[14] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[15] Krivy J, Wiener J \"Sertraline and platelet counts in idiopathic thrombocytopenia purpura.\" Lancet 345 (1995): 132[16] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[17] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[18] Pai VB, Kelly MW \"Bruising associated with the use of fluoxetine.\" Ann Pharmacother 30 (1996): 786-8[19] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990): 213-7[20] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ \"Fluoxetine and bleeding in obsessive-compulsive disorder.\" Am J Psychiatry 148 (1991): 949[21] Alderman CP, Seshadri P, Ben-Tovim DI \"Effects of serotonin reuptake inhibitors on hemostasis.\" Ann Pharmacother 30 (1996): 1232-4[22] Humphries JE, Wheby MS, VandenBerg SR \"Fluoxetine and the bleeding time.\" Arch Pathol Lab Med 114 (1990): 727-8[23] Woolfrey S, Gammack NS, Dewar MS, Brown PJ \"Fluoxetine-warfarin interaction.\" BMJ 307 (1993): 241[24] Messiha FS \"Fluoxetine - adverse effects and drug-drug interactions.\" J Toxicol Clin Toxicol 31 (1993): 603-30[25] Ford MA, Anderson ML, Rindone JP, Jaskar DW \"Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin.\" J Clin Psychopharmacol 17 (1997): 110-2[26] Ottervanger JP, Stricker BH, Huls J, Weeda JN \"Bleeding attributed to the intake of paroxetine.\" Am J Psychiatry 151 (1994): 781-2[27] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[28] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH \"Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study.\" Arch Intern Med 163 (2003): 59-64[29] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[30] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[31] Aranth J, Lindberg C \"Bleeding, a side effect of fluoxetine.\" Am J Psychiatry 149 (1992): 412[32] Cerner Multum, Inc. \"Australian Product Information.\" O 0[33] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S \"Intracranial haemorrhage and use of selective serotonin reuptake inhibitors.\" Br J Clin Pharmacol 50 (2000): 43-7[34] de Maistre E, Allart C, Lecompte T, Bollaert PE \"Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors.\" Am J Med 113 (2002): 530-2[35] Claire RJ, Servis ME, Cram DL Jr \"Potential interaction between warfarin sodium and fluoxetine.\" Am J Psychiatry 148 (1991): 1604[36] Dent LA, Orrock MW \"Warfarin-fluoxetine and diazepam-fluoxetine interaction.\" Pharmacotherapy 17 (1997): 170-2[37] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[38] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[39] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[40] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[41] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[42] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Maprotiline, St. John's Wort, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, More", "alternatives_b": "Protein C, Selexipag", "updated_at": 1767369485}, {"id": 67038, "ingredient1": "Citalopram", "ingredient2": "Pregabalin", "severity": "Moderate", "effect": "The efficacy of anticonvulsants may be diminished during coadministration with selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitor (SNRIs). Antidepressants including SSRIs and SNRIs can reduce seizure threshold.Coadministration of SSRIs or SNRIs with some anticonvulsants, particularly carbamazepine, eslicarbazepine, oxcarbazepine and valproic acid, may increase the risk of hyponatremia. The risk appears to be dose-related, and elderly patients and patients who are volume depleted (e.g., diuretic use) may be at greater risk.", "source": "DDInter", "management_text": "SSRIs and SNRIs should be avoided in patients with unstable epilepsy, and used cautiously in patients with epilepsy controlled with anticonvulsant medications. Treatment with SSRIs and SNRIs should be discontinued if seizures develop or seizure frequency increases. Patients receiving SSRIs or SNRIs with anticonvulsants, particularly carbamazepine, eslicarbazepine, oxcarbazepine and/or valproic acid, should also have serum sodium levels measured regularly and monitored for development of hyponatremia, particularly when higher dosages of these medications are used. Signs and symptoms of hyponatremia include nausea, vomiting, headache, difficulty concentrating, memory impairment, confusion, malaise, lethargy, muscle weakness or spasms, and unsteadiness. In more severe and/or acute cases, hallucination, syncope, seizure, coma, respiratory arrest, and death may occur.", "mechanism_text": "Antagonism", "recommendation": "SSRIs and SNRIs should be avoided in patients with unstable epilepsy, and used cautiously in patients with epilepsy controlled with anticonvulsant medications.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67125/", "reference_text": "[1] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[2] Belcastro V, Costa C, Striano P \"Levetiracetam-associated hyponatremia.\" Seizure 17 (2008): 389-90[3] Gandhi S, McArthur E, Mamdani MM, et.al \"Antiepileptic drugs and hyponatremia in older adults: Two population-based cohort studies.\" Epilepsia 57 (2016): 2067-79[4] \"Product Information. Aptiom (eslicarbazepine).\" Sunovion Pharmaceuticals Inc, Marlborough, MA.[5] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[6] \"Product Information. Tegretol (carbamazepine).\" Novartis Pharmaceuticals, East Hanover, NJ.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[9] Falhammar H, Lindh JD, Calissendorff J, et.al \"Differences in associations of antiepileptic drugs and hospitalization due to hyponatremia: A population-based case-control study.\" Seizure 59 (2018): 28-33[10] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[11] Bavbek N, Alkan R, Uz E, Kaftan O, Akcay A \"Hyponatremia associated with sodium valproate in a 22-year-old male.\" Nephrol Dial Transplant 23 (2008): epub[12] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[13] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[14] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[15] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[16] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[17] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[18] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[19] Patel KR, Meesala A, Stanilla JK \"Sodium valproate-induced hyponatremia: a case report.\" Prim Care Companion J Clin Psychiatry 12 (2010): epub[20] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[21] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[22] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[23] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[24] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[25] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[26] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[27] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[28] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Oxitriptan, Viloxazine, Tryptophan", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67039, "ingredient1": "Citalopram", "ingredient2": "Primaquine", "severity": "Major", "effect": "Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.", "mechanism_text": "Synergism", "recommendation": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67126/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm.\" ([2011 Aug 24]):[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm.\" ([2012 Mar 28]):[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[9] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[12] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Kaletra (lopinavir-ritonavir)\" Abbott Pharmaceutical, Abbott Park, IL.[15] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Phenelzine, Tranylcypromine, Vilazodone, Paroxetine, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, More", "alternatives_b": "Artesunate, Artemether, Pyrimethamine, Tafenoquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 67040, "ingredient1": "Citalopram", "ingredient2": "Primidone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67127/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Levomilnacipran, Oxitriptan, Viloxazine, Milnacipran, Tryptophan", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67041, "ingredient1": "Citalopram", "ingredient2": "Probucol", "severity": "Major", "effect": "Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.", "mechanism_text": "Synergism", "recommendation": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67128/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm.\" ([2011 Aug 24]):[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm.\" ([2012 Mar 28]):[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[9] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[12] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Kaletra (lopinavir-ritonavir)\" Abbott Pharmaceutical, Abbott Park, IL.[15] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Phenelzine, Duloxetine, Tranylcypromine, Vilazodone, Paroxetine, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, More", "alternatives_b": "Fenofibric acid, Mipomersen, Pitavastatin, Evinacumab, Evolocumab, Dextrothyroxine, Cholestyramine, Clofibrate, Cerivastatin, Colestipol, Bempedoic acid, More", "updated_at": 1767369485}, {"id": 67042, "ingredient1": "Citalopram", "ingredient2": "Procainamide", "severity": "Major", "effect": "Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.", "mechanism_text": "Synergism", "recommendation": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67129/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm.\" ([2011 Aug 24]):[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm.\" ([2012 Mar 28]):[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[9] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[12] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Kaletra (lopinavir-ritonavir)\" Abbott Pharmaceutical, Abbott Park, IL.[15] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Duloxetine, Vilazodone, Paroxetine, Desvenlafaxine, St. John's Wort, Nefazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, More", "alternatives_b": "Moricizine, Tocainide, Bretylium, Mexiletine", "updated_at": 1767369485}, {"id": 67043, "ingredient1": "Citalopram", "ingredient2": "Procarbazine", "severity": "Major", "effect": "By inhibiting serotonin metabolism, monoamine oxidase inhibitors (MAOIs) may potentiate the pharmacologic activity of selective serotonin reuptake inhibitors (SSRIs) and increase the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.", "source": "DDInter", "management_text": "In general, SSRIs should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with SSRIs, and vice versa.", "mechanism_text": "Metabolism", "recommendation": "In general, SSRIs should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67130/", "reference_text": "[1] Beasley CM Jr, Masica DN, Heiligenstein JH, Wheadon DE, Zerbe RL \"Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings.\" J Clin Psychopharmacol 13 (1993): 312-20[2] Kline SS, Mauro LS, Scala-Bennett DM, Zick D \"Serotonin syndrome versus neuroleptic malignant death syndrome as a cause of death.\" Clin Pharm 8 (1989): 510-4[3] Bhatara VS, Bandettini FC \"Possible interaction between sertraline and tranylcypromine.\" Clin Pharm 12 (1993): 222-5[4] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[5] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[6] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[7] Suchowersky O, deVries JD \"Interaction of fluoxetine and selegiline.\" Can J Psychiatry 35 (1990): 571-2[8] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[9] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995): 440-2[10] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[11] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth (2005):[12] Suchowersky O, deVries J \"Possible interactions between deprenyl and prozac.\" Can J Neurol Sci 17 (1990): 352-3[13] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990): 213-7[14] Sternbach H \"Danger of MAOI therapy after fluoxetine withdrawal.\" Lancet 2 (1988): 850-1[15] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995): 481-2[16] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[17] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[18] Phillips SD, Ringo P \"Phenelzine and venlafaxine interaction.\" Am J Psychiatry 152 (1995): 1400-1[19] Feighner JP, Boyer WF, Tyler DL, Neborsky RJ \"Adverse consequences of fluoxetine-MAOI combination therapy.\" J Clin Psychiatry 51 (1990): 222-5[20] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[21] Jimenez-Genchi A \"Immediate switching from moclobemide to duloxetine may induce serotonin syndrome.\" J Clin Psychiatry 67 (2006): 1821-1822[22] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[23] Graber MA, Hoehns TB, Perry PJ \"Sertraline-phenelzine drug interaction: a serotonin syndrome reaction.\" Ann Pharmacother 28 (1994): 732-5[24] Ruiz F \"Fluoxetine and the serotonin syndrome.\" Ann Emerg Med 24 (1994): 983-5[25] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[26] Graham PM, Ilett KF \"Danger of MAOI therapy after fluoxetine withdrawal.\" Lancet 2 (1988): 1255-6[27] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[28] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics.\" J Clin Psychopharmacol 10 (1990): 48-50[29] Brannan SK, Talley BJ, Bowden CL \"Sertraline and isocarboxazid cause a serotonin syndrome.\" J Clin Psychopharmacol 14 (1994): 144-5[30] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[31] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[32] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[33] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993): 84-8[34] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[35] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S \"Rare case of serotonin syndrome with therapeutic doses of paroxetine.\" Am J Ther 13 (2006): 550-552[36] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[37] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[38] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[39] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[40] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[41] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[42] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[43] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[44] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[45] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[46] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[47] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[48] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[49] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[50] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[51] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[52] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[53] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[54] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80[55] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[56] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[57] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[58] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Esketamine", "alternatives_b": "Pertuzumab, Olaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, Enasidenib, More", "updated_at": 1767369485}, {"id": 67044, "ingredient1": "Citalopram", "ingredient2": "Prochlorperazine", "severity": "Major", "effect": "Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.", "mechanism_text": "Synergism", "recommendation": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67131/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm.\" ([2011 Aug 24]):[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm.\" ([2012 Mar 28]):[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[9] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[12] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Kaletra (lopinavir-ritonavir)\" Abbott Pharmaceutical, Abbott Park, IL.[15] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Oxitriptan, Viloxazine, Vortioxetine, Tryptophan, Vilazodone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67045, "ingredient1": "Citalopram", "ingredient2": "Procyclidine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67132/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Vilazodone, St. John's Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67046, "ingredient1": "Citalopram", "ingredient2": "Promazine", "severity": "Major", "effect": "Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.", "mechanism_text": "Synergism", "recommendation": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67133/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm.\" ([2011 Aug 24]):[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm.\" ([2012 Mar 28]):[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[9] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[12] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Kaletra (lopinavir-ritonavir)\" Abbott Pharmaceutical, Abbott Park, IL.[15] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Oxitriptan, Viloxazine, Vortioxetine, Tryptophan, Vilazodone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67047, "ingredient1": "Citalopram", "ingredient2": "Promethazine", "severity": "Major", "effect": "Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.", "mechanism_text": "Synergism", "recommendation": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67134/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm.\" ([2011 Aug 24]):[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm.\" ([2012 Mar 28]):[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[9] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[12] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Kaletra (lopinavir-ritonavir)\" Abbott Pharmaceutical, Abbott Park, IL.[15] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "alternatives_b": "Azelastine, Ketotifen, Tetracaine, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Deferoxamine, Levoleucovorin, More", "updated_at": 1767369485}, {"id": 67048, "ingredient1": "Citalopram", "ingredient2": "Propafenone", "severity": "Major", "effect": "Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.", "mechanism_text": "Synergism", "recommendation": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67135/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm.\" ([2011 Aug 24]):[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm.\" ([2012 Mar 28]):[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[9] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[12] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Kaletra (lopinavir-ritonavir)\" Abbott Pharmaceutical, Abbott Park, IL.[15] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Phenelzine, Tranylcypromine, Desvenlafaxine, St. John's Wort, Isocarboxazid, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Vilazodone, Esketamine", "alternatives_b": "Moricizine, Tocainide, Bretylium, Mexiletine", "updated_at": 1767369485}, {"id": 67049, "ingredient1": "Citalopram", "ingredient2": "Propiomazine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67136/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67050, "ingredient1": "Dextropropoxyphene", "ingredient2": "Citalopram", "severity": "Major", "effect": "Sedatives, tranquilizers, muscle relaxants, antidepressants, and other central nervous system (CNS) depressants may have additive CNS- and/or respiratory-depressant effects with propoxyphene. Misuse of propoxyphene, either alone or in combination with other CNS depressants, has been a major cause of drug-related deaths, particularly in patients with a history of emotional disturbances, suicidal ideation, or alcohol and drug abuse. Pharmacokinetically, propoxyphene is an inhibitor of CYP450 2D6 and may increase the plasma concentrations of many psychotropic agents that are metabolized by the isoenzyme such as phenothiazines, haloperidol, risperidone, phenobarbital, and some tricyclic antidepressants and serotonin reuptake inhibitors.", "source": "DDInter", "management_text": "Caution is advised if propoxyphene is used with sedatives, tranquilizers, muscle relaxants, antidepressants, and other CNS depressants, particularly in the elderly and in patients with a history of emotional disturbances, suicidal ideation, or alcohol and drug abuse. Dosage reductions may be appropriate. Patients should be monitored for potentially excessive or prolonged CNS and respiratory depression and other CNS adverse effects. Patients should be warned not to exceed recommended dosages, to avoid alcohol, and to avoid activities requiring mental alertness until they know how these agents affect them.", "mechanism_text": "Metabolism, Synergism", "recommendation": "Caution is advised if propoxyphene is used with sedatives, tranquilizers, muscle relaxants, antidepressants, and other CNS depressants, particularly in the elderly and in patients with a history of emotional disturbances, suicidal ideation, or alcohol and drug abuse.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67137/", "reference_text": "[1] Hansen BS, Dam M, Brandt J, et al \"Influence of dextropropoxyphene on steady state serum levels and protein binding of three anti-epileptic drugs in man.\" Acta Neurol Scand 61 (1980): 357-67[2] Peterson GR, Covault HP, Hostetler RM \"Acute inhibition of microsomal drug metabolism by propoxphene in narcotic tolerant/dependent mice.\" Life Sci 22 (1978): 2087-96[3] Abernethy DR, Greenblatt DJ, Morse DS, Shader RI \"Interaction of propoxyphene with diazepam, alprazolam and lorazepam.\" Br J Clin Pharmacol 19 (1985): 51-7[4] Abernethy DR, Greenblatt DJ, Steel K, Shader RI \"Impairment of hepatic drug oxidation by propoxyphene.\" Ann Intern Med 97 (1982): 223-4[5] Puckett WH Jr, Visconti JA \"Orphenadrine and propoxyphene.\" N Engl J Med 283 (1970): 544[6] Pearson RE, Salter FJ \"Drug interaction? Orphenadrine with propoxyphene.\" N Engl J Med 282 (1970): 1215[7] Shorr RI, Griffin MR, Daugherty JR, Ray WA \"Opioid analgesics and the risk of hip fracture in the elderly: codeine and propoxyphene.\" J Gerontol 47 (1992): m111-5[8] \"Product Information. Darvon (propoxyphene).\" Lilly, Eli and Company, Indianapolis, IN.[9] \"Product Information. Darvon (propoxyphene).\" Lilly, Eli and Company, Indianapolis, IN.[10] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Viloxazine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67051, "ingredient1": "Citalopram", "ingredient2": "Propranolol", "severity": "Moderate", "effect": "Limited clinical data suggest that selective serotonin reuptake inhibitors (SSRIs) may potentiate the pharmacologic effects of some beta-blockers. The proposed mechanism is SSRI inhibition (competitive and/or noncompetitive) of CYP450 2D6, the isoenzyme responsible for the metabolic clearance of beta-blockers such as carvedilol, labetalol, metoprolol, nebivolol, propranolol, and timolol. Paroxetine and norfluoxetine (the active metabolite of fluoxetine), in particular, are potent inhibitors of CYP450 2D6 and may be more likely than other SSRIs to cause the interaction. On the other hand, fluvoxamine is a potent inhibitor of CYP450 1A2 and may significantly interact with propranolol, which is a substrate of both CYP450 2D6 and 1A2.", "source": "DDInter", "management_text": "During concomitant therapy with SSRIs, a lower initial dosage and more cautious titration of the beta-blocker may be appropriate. Cardiac function should be closely monitored and the beta-blocker dosage adjusted accordingly, particularly following initiation, discontinuation or change of dosage of SSRI in patients who are stabilized on their beta-blocker regimen. Due to the long half-life of fluoxetine and its active metabolite, norfluoxetine, the risk of an interaction may exist for an extended period (up to several weeks) after discontinuation of fluoxetine. To avoid the interaction, use of beta-blockers that are primarily eliminated by the kidney such as atenolol, acebutolol, betaxolol, carteolol, and nadolol may be considered.", "mechanism_text": "Metabolism", "recommendation": "During concomitant therapy with SSRIs, a lower initial dosage and more cautious titration of the beta-blocker may be appropriate.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67138/", "reference_text": "[1] Walley T, Pirmohamed M, Proudlove C, Maxwell D \"Interaction of metoprolol and fluoxetine.\" Lancet 341 (1993): 967-8[2] Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE \"The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes.\" Br J Clin Pharmacol 34 (1992): 262-5[3] Kashuba ADM, Nafziger AN, Kearns GL, Leeder JS, Gotschall R, Rocci ML, Kulawy RW, Beck DJ, Bertino JS \"Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping.\" Clin Pharmacol Ther 64 (1998): 257-68[4] Riesenman C \"Antidepressant drug interactions and the cytochrome p450 system: a critical appraisal.\" Pharmacotherapy 15 (1995): s84-99[5] Ereshefsky L \"Treating depression: potential drug-drug interactions: commentary.\" J Clin Psychopharmacol 16 (suppl (1996): s50-3[6] Hemeryck A, Lefebvre RA, DeVriendt C, Belpaire FM \"Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers.\" Clin Pharmacol Ther 67 (2000): 283-91[7] Perucca E, Gatti G, Spina E \"Clinical pharmacokinetics of fluvoxamine.\" Clin Pharmacokinet 27 (1994): 175-90[8] Amchin J, Ereshefsky L, Zarycranski W, Taylor K, Albano D, Klockowski PM \"Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe.\" J Clin Pharmacol 41 (2001): 443-51[9] Nemeroff CB, Devane CL, Pollock BG \"Newer antidepressants and the cytochrome p450 system.\" Am J Psychiatry 153 (1996): 311-20[10] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Otton SV, Wu D, Joffe RT, Cheung SW, Sellers EM \"Inhibition by fluoxetine of cytochrome P450 2D6 activity.\" Clin Pharmacol Ther 53 (1993): 401-9[13] Brosen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S \"Fluvoxamine is a potent inhibitor of cytochrome P4501A2.\" Biochem Pharmacol 45 (1993): 1211-4[14] Drake WM, Gordon GD \"Heart block in a patient on propranolol and fluoxetine.\" Lancet 343 (1994): 425-6[15] Hemeryck A, DeVriendt CA, Belpaire FM \"Metoprolol-paroxetine interaction in human liver microsomes: Stereoselective aspects and prediction of the in vivo interaction.\" Drug Metab Disposition 29 (2001): 656-63[16] Richelson E \"Pharmacokinetic interactions of antidepressants.\" J Clin Psychiatry 59 (1998): 22-6[17] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[20] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "St. John's Wort, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Vilazodone, Esketamine, Escitalopram", "alternatives_b": "Esmolol, Betaxolol, Carteolol, Penbutolol", "updated_at": 1767369485}, {"id": 67052, "ingredient1": "Citalopram", "ingredient2": "Protriptyline", "severity": "Major", "effect": "Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval including tricyclic antidepressants and other antidepressants (e.g., trazodone) may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death. Concomitant use of agents with serotonergic activity including selective serotonin reuptake inhibitors, tricyclic antidepressants, and other antidepressants may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.", "source": "DDInter", "management_text": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure. However, if treatment with citalopram is required in these patients, the labeling recommends that the dosage not exceed 40 mg/day, as higher dosages may have an excessive effect on the QT interval and confer no additional benefit in the treatment of depression. In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk. Patients should be closely monitored for symptoms of the serotonin syndrome during treatment. Particular caution is advised when increasing the dosages of these agents. If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary. Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).", "mechanism_text": "Synergism", "recommendation": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67139/", "reference_text": "[1] Lane R, Baldwin D \"Selective serotonin reuptake inhibitor--induced serotonin syndrome: review.\" J Clin Psychopharmacol 17 (1997): 208-21[2] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993): 84-8[3] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995): 481-2[4] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[5] Insel TR, Roy BF, Cohen RM, Murphy DL \"Possible development of the serotonin syndrome in man.\" Am J Psychiatry 139 (1982): 954-5[6] Laird LK \"Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder.\" Psychopharmacol Bull 32 (1996): 569-78[7] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm.\" ([2011 Aug 24]):[8] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[9] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995): 440-2[10] Nijhawan PK, Katz G, Winter S \"Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission.\" Crit Care Med 24 (1996): 1086-9[11] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[12] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[13] Harvey AT, Preskorn SH \"Interactions of serotonin reuptake inhibitors with tricyclic antidepressants.\" Arch Gen Psychiatry 52 (1995): 783-4[14] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[15] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[16] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[17] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[18] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[20] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[21] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[22] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Protriptyline, Viloxazine", "alternatives_b": "Citalopram, Esketamine", "updated_at": 1767369485}, {"id": 67053, "ingredient1": "Citalopram", "ingredient2": "Mepyramine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67140/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "alternatives_b": "Tetracaine, Azelastine, Ketotifen", "updated_at": 1767369485}, {"id": 67054, "ingredient1": "Citalopram", "ingredient2": "Quazepam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67141/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67055, "ingredient1": "Citalopram", "ingredient2": "Quetiapine", "severity": "Major", "effect": "Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.", "mechanism_text": "Synergism", "recommendation": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67142/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm.\" ([2011 Aug 24]):[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm.\" ([2012 Mar 28]):[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[9] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[12] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Kaletra (lopinavir-ritonavir)\" Abbott Pharmaceutical, Abbott Park, IL.[15] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Oxitriptan, Vilazodone, Vortioxetine, Tryptophan", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67056, "ingredient1": "Citalopram", "ingredient2": "Quinidine", "severity": "Major", "effect": "Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.", "mechanism_text": "Synergism", "recommendation": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67143/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm.\" ([2011 Aug 24]):[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm.\" ([2012 Mar 28]):[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[9] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[12] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Kaletra (lopinavir-ritonavir)\" Abbott Pharmaceutical, Abbott Park, IL.[15] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Desvenlafaxine, St. John's Wort, Oxitriptan, Tryptophan, Milnacipran, Levomilnacipran, Vilazodone, Esketamine", "alternatives_b": "Moricizine, Tocainide, Bretylium, Mexiletine", "updated_at": 1767369485}, {"id": 67057, "ingredient1": "Citalopram", "ingredient2": "Quinine", "severity": "Major", "effect": "Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.", "mechanism_text": "Synergism", "recommendation": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67144/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm.\" ([2011 Aug 24]):[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm.\" ([2012 Mar 28]):[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[9] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[12] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Kaletra (lopinavir-ritonavir)\" Abbott Pharmaceutical, Abbott Park, IL.[15] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Phenelzine, Tranylcypromine, Vilazodone, Desvenlafaxine, Isocarboxazid, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Bupropion, More", "alternatives_b": "Risdiplam, Collagenase clostridium histolyticum, Onasemnogene abeparvovec, Hyaluronic acid, Artesunate, Artemether, Pyrimethamine, Tafenoquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 67058, "ingredient1": "Citalopram", "ingredient2": "Ramelteon", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67145/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Vilazodone, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Bupropion", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67059, "ingredient1": "Citalopram", "ingredient2": "Ramucirumab", "severity": "Moderate", "effect": "Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.", "source": "DDInter", "management_text": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67146/", "reference_text": "[1] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG \"Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin.\" Acta Psychiatr Scand Suppl 350 (1989): 102-6[2] Skop BP, Brown TM \"Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors.\" Psychosomatics 37 (1996): 12-6[3] Settle EC \"Antidepressant drugs: disturbing and potentially dangerous adverse effects.\" J Clin Psychiatry 59 Suppl 16 (1998): 25-30[4] Layton D, Clark DWJ, Pearce GL, Shakir SAW \"Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England.\" Eur J Clin Pharmacol 57 (2001): 167-76[5] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[6] Leung M, Shore R \"Fluvoxamine-associated bleeding.\" Can J Psychiatry 41 (1996): 604-5[7] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[8] Tata LJ, Fortun PJ, Hubbard RB, et al. \"Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?\" Aliment Pharmacol Ther 22 (2005): 175-81[9] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[10] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B \"Paroxetine decreases platelet serotonin storage and platelet function in human beings.\" Clin Pharmacol Ther 68 (2000): 435-42[11] de Abajo FJ, Rodriguez LA, Montero D \"Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study.\" BMJ 319 (1999): 1106-9[12] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[13] Alderman CP, Moritz CK, Ben-Tovim DI \"Abnormal platelet aggregation associated with fluoxetine therapy.\" Ann Pharmacother 26 (1992): 1517-9[14] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[15] Krivy J, Wiener J \"Sertraline and platelet counts in idiopathic thrombocytopenia purpura.\" Lancet 345 (1995): 132[16] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[17] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[18] Pai VB, Kelly MW \"Bruising associated with the use of fluoxetine.\" Ann Pharmacother 30 (1996): 786-8[19] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990): 213-7[20] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ \"Fluoxetine and bleeding in obsessive-compulsive disorder.\" Am J Psychiatry 148 (1991): 949[21] Alderman CP, Seshadri P, Ben-Tovim DI \"Effects of serotonin reuptake inhibitors on hemostasis.\" Ann Pharmacother 30 (1996): 1232-4[22] Humphries JE, Wheby MS, VandenBerg SR \"Fluoxetine and the bleeding time.\" Arch Pathol Lab Med 114 (1990): 727-8[23] Woolfrey S, Gammack NS, Dewar MS, Brown PJ \"Fluoxetine-warfarin interaction.\" BMJ 307 (1993): 241[24] Messiha FS \"Fluoxetine - adverse effects and drug-drug interactions.\" J Toxicol Clin Toxicol 31 (1993): 603-30[25] Ford MA, Anderson ML, Rindone JP, Jaskar DW \"Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin.\" J Clin Psychopharmacol 17 (1997): 110-2[26] Ottervanger JP, Stricker BH, Huls J, Weeda JN \"Bleeding attributed to the intake of paroxetine.\" Am J Psychiatry 151 (1994): 781-2[27] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[28] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH \"Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study.\" Arch Intern Med 163 (2003): 59-64[29] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[30] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[31] Aranth J, Lindberg C \"Bleeding, a side effect of fluoxetine.\" Am J Psychiatry 149 (1992): 412[32] Cerner Multum, Inc. \"Australian Product Information.\" O 0[33] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S \"Intracranial haemorrhage and use of selective serotonin reuptake inhibitors.\" Br J Clin Pharmacol 50 (2000): 43-7[34] de Maistre E, Allart C, Lecompte T, Bollaert PE \"Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors.\" Am J Med 113 (2002): 530-2[35] Claire RJ, Servis ME, Cram DL Jr \"Potential interaction between warfarin sodium and fluoxetine.\" Am J Psychiatry 148 (1991): 1604[36] Dent LA, Orrock MW \"Warfarin-fluoxetine and diazepam-fluoxetine interaction.\" Pharmacotherapy 17 (1997): 170-2[37] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[38] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[39] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[40] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[41] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[42] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Maprotiline, St. John's Wort, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Amivantamab, Atezolizumab, Pembrolizumab, More", "updated_at": 1767369485}, {"id": 67060, "ingredient1": "Citalopram", "ingredient2": "Ranolazine", "severity": "Major", "effect": "Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.", "mechanism_text": "Synergism", "recommendation": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67147/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm.\" ([2011 Aug 24]):[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm.\" ([2012 Mar 28]):[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[9] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[12] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Kaletra (lopinavir-ritonavir)\" Abbott Pharmaceutical, Abbott Park, IL.[15] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Phenelzine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone, Esketamine", "alternatives_b": "Regadenoson, Ubidecarenone", "updated_at": 1767369485}, {"id": 67061, "ingredient1": "Citalopram", "ingredient2": "Rasagiline", "severity": "Major", "effect": "By inhibiting serotonin metabolism, monoamine oxidase inhibitors (MAOIs) may potentiate the pharmacologic activity of selective serotonin reuptake inhibitors (SSRIs) and increase the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucinations, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea. The extent to which rasagiline, a selective MAO-B inhibitor, may interact with SSRIs is unknown.", "source": "DDInter", "management_text": "In general, SSRIs should not be used concurrently with MAOIs or other agents that possess MAOI activity. At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with SSRIs, and vice versa. Due to the long half-life of fluoxetine and its active metabolite, norfluoxetine, a washout period of 5 weeks minimum is recommended when switching from fluoxetine to an MAOI. Similarly, a washout period of 3 weeks is recommended when switching from vortioxetine to an MAOI.", "mechanism_text": "Synergism", "recommendation": "In general, SSRIs should not be used concurrently with MAOIs or other agents that possess MAOI activity.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67148/", "reference_text": "[1] Suchowersky O, deVries J \"Possible interactions between deprenyl and prozac.\" Can J Neurol Sci 17 (1990): 352-3[2] Suchowersky O, deVries JD \"Interaction of fluoxetine and selegiline.\" Can J Psychiatry 35 (1990): 571-2[3] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995): 481-2[4] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990): 213-7[5] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[6] Graham PM, Ilett KF \"Danger of MAOI therapy after fluoxetine withdrawal.\" Lancet 2 (1988): 1255-6[7] \"Product Information. Azilect (rasagiline).\" Teva Pharmaceuticals USA, North Wales, PA.[8] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[9] Sternbach H \"Danger of MAOI therapy after fluoxetine withdrawal.\" Lancet 2 (1988): 850-1[10] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics.\" J Clin Psychopharmacol 10 (1990): 48-50[11] Feighner JP, Boyer WF, Tyler DL, Neborsky RJ \"Adverse consequences of fluoxetine-MAOI combination therapy.\" J Clin Psychiatry 51 (1990): 222-5[12] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993): 84-8[13] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[14] Beasley CM Jr, Masica DN, Heiligenstein JH, Wheadon DE, Zerbe RL \"Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings.\" J Clin Psychopharmacol 13 (1993): 312-20[15] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[16] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[17] Ruiz F \"Fluoxetine and the serotonin syndrome.\" Ann Emerg Med 24 (1994): 983-5[18] McGrath PJ, Stewart JW, Quitkin FM \"A possible L-deprenyl induced hypertensive reaction.\" J Clin Psychopharmacol 9 (1989): 310-1[19] \"Product Information. Azilect (rasagiline).\" Teva Pharmaceuticals USA, North Wales, PA.[20] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[21] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[22] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[23] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[24] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[25] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[26] Ito D, Amano T, Sato H, Fukuuchi Y \"Paroxysmal hypertensive crises induced by selegiline in a patient with Parkinson's disease.\" J Neurol 248 (2001): 533-4[27] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[28] Lefebvre H, Noblet C, Morre N, Wolf LM \"Pseudo-phaeochromocytoma after multiple drug interactions involving the selective monoamine oxidase inhibitor selegiline.\" Clin Endocrinol (Oxf) 42 (1995): 95-8[29] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[30] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[31] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[32] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67062, "ingredient1": "Citalopram", "ingredient2": "Regorafenib", "severity": "Moderate", "effect": "Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.", "source": "DDInter", "management_text": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67149/", "reference_text": "[1] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG \"Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin.\" Acta Psychiatr Scand Suppl 350 (1989): 102-6[2] Skop BP, Brown TM \"Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors.\" Psychosomatics 37 (1996): 12-6[3] Settle EC \"Antidepressant drugs: disturbing and potentially dangerous adverse effects.\" J Clin Psychiatry 59 Suppl 16 (1998): 25-30[4] Layton D, Clark DWJ, Pearce GL, Shakir SAW \"Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England.\" Eur J Clin Pharmacol 57 (2001): 167-76[5] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[6] Leung M, Shore R \"Fluvoxamine-associated bleeding.\" Can J Psychiatry 41 (1996): 604-5[7] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[8] Tata LJ, Fortun PJ, Hubbard RB, et al. \"Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?\" Aliment Pharmacol Ther 22 (2005): 175-81[9] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[10] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B \"Paroxetine decreases platelet serotonin storage and platelet function in human beings.\" Clin Pharmacol Ther 68 (2000): 435-42[11] de Abajo FJ, Rodriguez LA, Montero D \"Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study.\" BMJ 319 (1999): 1106-9[12] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[13] Alderman CP, Moritz CK, Ben-Tovim DI \"Abnormal platelet aggregation associated with fluoxetine therapy.\" Ann Pharmacother 26 (1992): 1517-9[14] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[15] Krivy J, Wiener J \"Sertraline and platelet counts in idiopathic thrombocytopenia purpura.\" Lancet 345 (1995): 132[16] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[17] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[18] Pai VB, Kelly MW \"Bruising associated with the use of fluoxetine.\" Ann Pharmacother 30 (1996): 786-8[19] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990): 213-7[20] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ \"Fluoxetine and bleeding in obsessive-compulsive disorder.\" Am J Psychiatry 148 (1991): 949[21] Alderman CP, Seshadri P, Ben-Tovim DI \"Effects of serotonin reuptake inhibitors on hemostasis.\" Ann Pharmacother 30 (1996): 1232-4[22] Humphries JE, Wheby MS, VandenBerg SR \"Fluoxetine and the bleeding time.\" Arch Pathol Lab Med 114 (1990): 727-8[23] Woolfrey S, Gammack NS, Dewar MS, Brown PJ \"Fluoxetine-warfarin interaction.\" BMJ 307 (1993): 241[24] Messiha FS \"Fluoxetine - adverse effects and drug-drug interactions.\" J Toxicol Clin Toxicol 31 (1993): 603-30[25] Ford MA, Anderson ML, Rindone JP, Jaskar DW \"Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin.\" J Clin Psychopharmacol 17 (1997): 110-2[26] Ottervanger JP, Stricker BH, Huls J, Weeda JN \"Bleeding attributed to the intake of paroxetine.\" Am J Psychiatry 151 (1994): 781-2[27] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[28] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH \"Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study.\" Arch Intern Med 163 (2003): 59-64[29] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[30] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[31] Aranth J, Lindberg C \"Bleeding, a side effect of fluoxetine.\" Am J Psychiatry 149 (1992): 412[32] Cerner Multum, Inc. \"Australian Product Information.\" O 0[33] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S \"Intracranial haemorrhage and use of selective serotonin reuptake inhibitors.\" Br J Clin Pharmacol 50 (2000): 43-7[34] de Maistre E, Allart C, Lecompte T, Bollaert PE \"Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors.\" Am J Med 113 (2002): 530-2[35] Claire RJ, Servis ME, Cram DL Jr \"Potential interaction between warfarin sodium and fluoxetine.\" Am J Psychiatry 148 (1991): 1604[36] Dent LA, Orrock MW \"Warfarin-fluoxetine and diazepam-fluoxetine interaction.\" Pharmacotherapy 17 (1997): 170-2[37] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[38] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[39] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[40] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[41] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[42] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Maprotiline, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, Trimipramine, More", "alternatives_b": "Dacomitinib, Tepotinib, Selumetinib, Cobimetinib, Capmatinib, Afatinib, Tivozanib, Brigatinib, Axitinib, Ripretinib, Alpelisib, More", "updated_at": 1767369485}, {"id": 67063, "ingredient1": "Citalopram", "ingredient2": "Relugolix", "severity": "Major", "effect": "Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.", "mechanism_text": "Synergism", "recommendation": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67150/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm.\" ([2011 Aug 24]):[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm.\" ([2012 Mar 28]):[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[9] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[12] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Kaletra (lopinavir-ritonavir)\" Abbott Pharmaceutical, Abbott Park, IL.[15] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Phenelzine, Duloxetine, Tranylcypromine, Vilazodone, Paroxetine, Desvenlafaxine, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, More", "alternatives_b": "Nafarelin, Elagolix, Cetrorelix, Ganirelix, Lanreotide, Gonadorelin, Darolutamide, Aminoglutethimide", "updated_at": 1767369485}, {"id": 67064, "ingredient1": "Citalopram", "ingredient2": "Remifentanil", "severity": "Major", "effect": "Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John's wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucination, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.", "source": "DDInter", "management_text": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk. Patients should be closely monitored for symptoms of the serotonin syndrome during treatment. Particular caution is advised when increasing the dosages of these agents. The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.", "mechanism_text": "Synergism", "recommendation": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67151/", "reference_text": "[1] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S \"Rare case of serotonin syndrome with therapeutic doses of paroxetine.\" Am J Ther 13 (2006): 550-552[2] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics.\" J Clin Psychopharmacol 10 (1990): 48-50[3] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[4] George TP, Godleski LS \"Possible serotonin syndrome with trazodone addition to fluoxetine.\" Biol Psychiatry 39 (1996): 384-5[5] Fugh-Berman A \"Herb-drug interactions.\" Lancet 355 (2000): 134-8[6] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[7] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[8] Ruiz F \"Fluoxetine and the serotonin syndrome.\" Ann Emerg Med 24 (1994): 983-5[9] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[10] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[11] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[12] Bergeron L, Boule M, Perreault S \"Serotonin toxicity associated with concomitant use of linezolid.\" Ann Pharmacother 39 (2005): 956-61[13] Wigen CL, Goetz MB \"Serotonin syndrome and linezolid.\" Clin Infect Dis 34 (2002): 1651-2[14] Metz A \"Interaction between fluoxetine and buspirone.\" Can J Psychiatry 35 (1990): 722-3[15] Tahir N \"Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram.\" J Am Med Dir Assoc 5 (2004): 111-3[16] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[17] Lane R, Baldwin D \"Selective serotonin reuptake inhibitor--induced serotonin syndrome: review.\" J Clin Psychopharmacol 17 (1997): 208-21[18] \"Product Information. Maxalt (rizatriptan).\" Merck & Co, Inc, West Point, PA.[19] Hammerness P, Parada H, Abrams A \"Linezolid: MAOI Activity and Potential Drug Interactions.\" Psychosomatics 43 (2002): 248-9[20] Morales N, Vermette H \"Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine.\" Psychosomatics 46 (2005): 274-5[21] Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM \"The serotonin syndrome associated wtih paroxetine, an over-the-counter cold remedy, and vascular disease.\" Am J Emerg Med 12 (1994): 642-4[22] Manos GH \"Possible serotonin syndrome associated with buspirone added to fluoxetine.\" Ann Pharmacother 34 (2000): 871-4[23] Gordon JB \"SSRI's and St. John's Wort: possible toxicity?\" Am Fam Physician 57 (1998): 950,953[24] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[25] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997): 175-7[26] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993): 84-8[27] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[28] Gillman PK \"Linezolid and serotonin toxicity.\" Clin Infect Dis 37 (2003): 1274-5[29] Taylor JJ, Wilson JW, Estes LL \"Linezolid and serotonergic drug interactions: a retrospective survey.\" Clin Infect Dis 43 (2006): 180-7[30] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003): 32-5[31] Nijhawan PK, Katz G, Winter S \"Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission.\" Crit Care Med 24 (1996): 1086-9[32] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals, Raritan, NJ.[33] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[34] Mackay FJ, Dunn NR, Mann RD \"Antidepressants and the serotonin syndrome in general practice.\" Br J Gen Pract 49 (1999): 871-4[35] Perry NK \"Venlafaxine-induced serotonin syndrome with relapse following amitriptyline.\" Postgrad Med J 76 (2000): 254-6[36] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995): 440-2[37] Margolese HC, Chouinard G \"Serotonin syndrome from addition of low-dose trazodone to nefazodone.\" Am J Psychiatry 157 (2000): 1022[38] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006): 1589[39] Boyer EW, Shannon M \"The serotonin syndrome.\" N Engl J Med 352 (2005): 1112-20[40] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995): 481-2[41] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[42] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[43] Dannawi M \"Possible serotonin syndrome after combination of buspirone and St John's Wort.\" J Psychopharmacol 16 (2002): 401[44] Lee J, Franz L, Goforth HW \"Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine.\" Psychosomatics 50 (2009): 638-9[45] Bhatara VS, Magnus RD, Paul KL, Preskorn SH \"Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms.\" Ann Pharmacother 32 (1998): 432-6[46] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992): 1061-6[47] Strouse TB, Kerrihard TN, Forscher CA, Zakowski P \"Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine.\" J Clin Psychopharmacol 26 (2006): 681-683[48] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990): 949-50[49] Packer S, Berman SA \"Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid.\" Am J Psychiatry 164 (2007): 346-7[50] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[51] John L, Perreault MM, Tao T, Blew PG \"Serotonin syndrome associated with nefazodone and paroxetine.\" Ann Emerg Med 29 (1997): 287-9[52] \"Product Information. Imitrex (sumatriptan).\" Glaxo Wellcome, Research Triangle Park, NC.[53] \"Product Information. Oleptro (traZODone).\" Labopharm Inc, Laval, AL.[54] Reeves RR, Bullen JA \"Serotonin syndrome produced by paroxetine and low-dose trazodone.\" Psychosomatics 36 (1995): 159-60[55] Weiner AL \"Meperidine as a potential cause of serotonin syndrome in the emergency department.\" Acad Emerg Med 6 (1999): 156-8[56] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997): 181-2[57] Mathew NT, Tietjen GE, Lucker C \"Serotonin syndrome complicating migraine pharmacotherapy.\" Cephalalgia 16 (1996): 323-7[58] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002): 1647-1648[59] Gardner DM, Lynd LD \"Sumatriptan contraindications and the serotonin syndrome.\" Ann Pharmacother 32 (1998): 33-8[60] Baetz M, Malcolm D \"Serotonin syndrome from fluvoxamine and buspirone.\" Can J Psychiatry 40 (1995): 428-9[61] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007): 199-202[62] Mugele J, Nanagas KA, Tormoehlen LM \"Serotonin Syndrome Associated With MDPV Use: A Case Report.\" Ann Emerg Med (2012):[63] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[64] Thomas CR, Rosenberg M, Blythe V, Meyer WJ 3rd \"Serotonin syndrome and linezolid.\" J Am Acad Child Adolesc Psychiatry 43 (2004): 790[65] Turkel SB, Nadala JG, Wincor MZ \"Possible serotonin syndrome in association with 5-HT3 antagonist agents.\" Psychosomatics 42 (2001): 258-60[66] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008): 521-5[67] Shapiro RE, Tepper SJ \"The serotonin syndrome, triptans, and the potential for drug-drug interactions.\" Headache 47 (2007): 266-9[68] Goldberg RJ, Huk M \"Serotonin syndrome from trazodone and buspirone.\" Psychosomatics 33 (1992): 235-6[69] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990): 213-7[70] Lantz MS, Buchalter E, Giambanco V \"St. John's wort and antidepressant drug interactions in the elderly.\" J Geriatr Psychiatr Neurol 12 (1999): 7-10[71] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[72] Harvey AT, Preskorn SH \"Interactions of serotonin reuptake inhibitors with tricyclic antidepressants.\" Arch Gen Psychiatry 52 (1995): 783-4[73] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[74] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994): 593-7[75] Laird LK \"Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder.\" Psychopharmacol Bull 32 (1996): 569-78[76] Insel TR, Roy BF, Cohen RM, Murphy DL \"Possible development of the serotonin syndrome in man.\" Am J Psychiatry 139 (1982): 954-5[77] Smith DL, Wenegrat BG \"A case report of serotonin syndrome associated with combined nefazodone and fluoxetine.\" J Clin Psychiatry 61 (2000): 146[78] Bernard L, Stern R, Lew D, Hoffmeyer P \"Serotonin syndrome after concomitant treatment with linezolid and citalopram.\" Clin Infect Dis 36 (2003): 1197[79] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001): 2163-75[80] \"Product Information. Zomig (zolmitriptan).\" Zeneca Pharmaceuticals, Wilmington, DE.[81] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[82] \"Product Information. Flexeril (cyclobenzaprine).\" Merck & Co, Inc, West Point, PA.[83] Giese SY, Neborsky R \"Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl.\" Plast Reconstr Surg 107 (2001): 293-4[84] Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Grau S \"Linezolid-associated serotonin syndrome: what we can learn from cases reported so far.\" J Antimicrob Chemother 56 (2005): 1176-8[85] Duggal HS, Fetchko J \"Serotonin syndrome and atypical antipsychotics.\" Am J Psychiatry 159 (2002): 672-3[86] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001): 224-7[87] DeBellis RJ, Schaefer OP, Liquori M, Volturo GA \"Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient.\" J Intensive Care Med 20 (2005): 351-3[88] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[89] Jones SL, Athan E, O'Brien D \"Serotonin syndrome due to co-administration of linezolid and venlafaxine.\" J Antimicrob Chemother 54 (2004): 289-90[90] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[91] Steinberg M, Morin AK \"Mild serotonin syndrome associated with concurrent linezolid and fluoxetine.\" Am J Health Syst Pharm 64 (2007): 59-62[92] Lavery S, Ravi H, McDaniel WW, Pushkin YR \"Linezolid and serotonin syndrome.\" Psychosomatics 42 (2001): 432-4[93] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[94] Hachem RY, Hicks K, Huen A, Raad I \"Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients.\" Clin Infect Dis 37 (2003): E8-E11[95] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[96] Keegan MT, Brown DR, Rabinstein AA \"Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs.\" Anesth Analg 103 (2006): 1466-8[97] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[98] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003): 1511-1512[99] Achamallah NS \"Visual hallucinations after combining fluoxetine and dextromethorphan .\" Am J Psychiatry 149 (1992): 1406[100] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8", "alternatives_a": "Viloxazine", "alternatives_b": "Desflurane, Enflurane, Esketamine, Nitrous oxide", "updated_at": 1767369485}, {"id": 67065, "ingredient1": "Citalopram", "ingredient2": "Remimazolam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67152/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67066, "ingredient1": "Citalopram", "ingredient2": "Repaglinide", "severity": "Moderate", "effect": "The hypoglycemic effect of insulin secretagogues (e.g., sulfonylureas, meglitinides) may be potentiated by certain drugs, including ACE inhibitors, 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinine, quinidine, and ginseng. These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, fibrates, ginseng); stimulating insulin secretion (salicylates, NSAIDs, disopyramide, quinine, quinidine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs). Or, they may increase plasma concentration of insulin secretagogues by displacing them from plasma protein binding sites and/or inhibiting their metabolism (fibrates, NSAIDs, salicylates, sulfonamides).", "source": "DDInter", "management_text": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment. The oral antidiabetic dosage(s) may require adjustment if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their doctor if it occurs. Patients should be observed for loss of glycemic control when these drugs are withdrawn.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67153/", "reference_text": "[1] Christensen LK, Hansen JM, Kristensen M \"Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics.\" Lancet 2 (1963): 1298-301[2] Turtle JR, Burgess JA \"Hypoglycemic action of fenfluramine in diabetes mellitus.\" Diabetes 22 (1973): 858-67[3] Field JB, Ohta M, Boyle C, Remer A \"Potentiation of acetohexamide hypoglycemia by phenylbutazone.\" N Engl J Med 277 (1967): 889-94[4] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V \"Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia.\" Eur J Clin Nutr 57 (2003): 243-8[5] Deeg MA, Lipkin EW \"Hypoglycemia associated with the use of fluoxetine.\" West J Med 164 (1996): 262-3[6] Sjoberg S, Wiholm BE, Gunnarsson R, Emilsson H, Thunberg E, Christenson I, Ostman J \"Lack of pharmacokinetic interaction between glibenclamide and trimethoprim-sulphamethoxazole.\" Diabet Med 4 (1987): 245-7[7] World Health Organization \"WHO Public Assessment Reports (WHOPARs) Available from: URL: https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars.\" ([2020]):[8] Niemi M, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ, Kivisto KT \"Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride.\" Clin Pharmacol Ther 69 (2001): 194-200[9] Ravic M, Johnston A, Turner P \"Clinical pharmacological studies of some possible interactions of lornoxicam with other drugs.\" Postgrad Med J 66 (1990): s30-4[10] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J \"Captopril and insulin sensitivity.\" Ann Intern Med 102 (1985): 134-5[11] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[12] Tran PO, Gleason CE, Robertson RP \"Inhibition of interleukin-1beta-induced COX-2 and EP3 gene expression by sodium salicylate enhances pancreatic islet beta-cell function.\" Diabetes 51 (2002): 1772-8[13] Ahmad S \"Drug interaction induces hypoglycemia.\" J Fam Pract 40 (1995): 540-1[14] Baron SH \"Salicylates as hypoglycemic agents.\" Diabetes Care 5 (1982): 64-71[15] Slade IH, and Iosefa RN \"Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases.\" J Am Geriatr Soc 15 (1967): 948-50[16] \"Product Information. Increlex (mecasermin).\" Tercica Inc, Brisbane, CA.[17] Feher MD, Amiel S \"ACE inhibitors and hypoglycaemia.\" Lancet 346 (1995): 125-6[18] Vuksan V, Sievenpiper JL, Koo VY, et al \"American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus.\" Arch Intern Med 160 (2000): 1009-13[19] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K \"The effect of gemfibrozil on serum lipids in diabetic patients.\" Ann Clin Res 11 (1979): 240-5[20] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[21] Morrison PJ, Rogers HJ, Spector RG, Bradbrook ID, John VA \"Effect of pirprofen on glibenclamide kinetics and response.\" Br J Clin Pharmacol 14 (1982): 123-6[22] Wu B, Sato T, Kiyosue T, Arita M \"Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs.\" Cardiovasc Res 26 (1992): 1095-101[23] Barbato M \"Another problem with Kinidin.\" Med J Aust 141 (1984): 685[24] Phillips RE, Looareesuwan S, White NJ, et al \"Hypoglycaemia and antimalarial drugs: quinidine and release of insulin.\" Br Med J 292 (1986): 1319-21[25] Ahmad S \"Gemfibrozil: interaction with glyburide.\" South Med J 84 (1991): 102[26] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T \"Hypoglycemia induced by interaction between clarithromycin and disopyramide.\" Jpn Heart J 40 (1999): 91-6[27] Strathman I, Schubert EN, Cohen A, Nitzberg DM \"Hypoglycemia in patients receiving disopyramide phosphate.\" Drug Intell Clin Pharm 17 (1983): 635-8[28] Sawka AM, Burgart V, Zimmerman D \"Loss of awareness of hypoglycemia temporally associated with selective serotonin reuptake inhibitors.\" Diabetes Care 24 (2001): 1845-6[29] Wing LM, Miners JO \"Cotrimoxazole as an inhibitor of oxidative drug metabolism: effects of trimethoprim and sulphamethoxazole separately and combined on tolbutamide disposition.\" Br J Clin Pharmacol 20 (1985): 482-5[30] Tremaine LM, Wilner KD, Preskorn SH \"A study of the potential effect of sertraline on the pharmacokinetics and protein binding of tolbutamide.\" Clin Pharmacokinet 32(Suppl 1) (1997): 31-36[31] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[32] Tannenbaum H, Anderson LG, Soeldner JS \"Phenylbutazone-tolbutamide drug interaction.\" N Engl J Med 290 (1974): 344[33] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y \"Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus.\" Br J Clin Pharmacol 17 (1984): 89-91[34] Salmela PI, Sotaniemi EA, Viikari J, et al \"Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism.\" Diabetes Care 4 (1981): 535-40[35] David DS, Steere AC Jr, Pi-Sunyer XF, Sakai S, Clark SB \"Aspirin-induced hypoglycaemia in a patient on haemodialysis.\" Lancet 2 (1971): 1092-3[36] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD \"Fenfluramine increases insulin action in patients with NIDDM.\" Diabetes Care 12 (1989): 252-8[37] Morris AD, Newton RW, Boyle DI, et al. \"ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes.\" Diabetes Care 20 (1997): 1363-7[38] Kradjan WA, Witt DM, Opheim KE, Wood FC \"Lack of interaction between glipizide and co-trimoxazole.\" J Clin Pharmacol 34 (1994): 997-1002[39] Johnson J, Dobmeier M \"Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction.\" DICP 24 (1990): 250-1[40] Pollak PT, Mukherjee SD, Fraser AD \"Sertraline-induced hypoglycemia.\" Ann Pharmacother 35 (2001): 1371-4[41] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[42] Feldman JM, Chapman B \"Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion.\" Diabetologia 11 (1975): 487-94[43] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R \"Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas.\" Metabolism 38 (1989): 179-83[44] Daubresse JC, Luyckx AS, Lefebvre PJ \"Potentiation of hypoglycemic effect of sulfonylureas by clofibrate.\" N Engl J Med 294 (1976): 613[45] Cooper AJ, Ashcroft G \"Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs.\" Lancet 1 (1966): 407-9[46] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[47] Quevedo SF, Krauss DS, Chazan JA, et al \"Fasting hypoglycemia secondary to disopyramide therapy.\" JAMA 245 (1981): 2424[48] Lozada A, Dujovne CA \"Drug interactions with fibric acids.\" Pharmacol Ther 63 (1994): 163-76[49] Shah SJ, Bhandarkar SD, Satoskar RS \"Drug interaction between chlorpropamide and non-steroidal anti-flammatory drugs, ibuprofen and phenylbutazone.\" Int J Clin Pharmacol Ther Toxicol 22 (1984): 470-2[50] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[51] Nikkila EA, Ylikahri R, Huttunen JK \"Gemfibrozil: effect on serum lipids, lipoproteins, postheparin plasma lipase activities and glucose tolerance in primary hypertriglyceridaemia.\" Proc R Soc Med 69 (1976): 58-63[52] Davis TM, Karbwang J, Looareesuwan S, et al \"Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers.\" Br J Clin Pharmacol 30 (1990): 397-403[53] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M \"Lisinopril administration improves insulin action in aged patients with hypertension.\" J Hum Hypertens 9 (1995): 541-6[54] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[55] Hundal RS, Petersen KF, Mayerson AB, et al \"Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes.\" J Clin Invest 109 (2002): 1321-6[56] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[57] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P \"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.\" Am J Med 89 (1990): 811-3[58] de Salcedo I, Gorringe AL, Silva JL, Santos JA \"Gemfibrozil in a group of diabetics.\" Proc R Soc Med 69 (1976): 64-70[59] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[60] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P \"Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension.\" Br J Clin Pharmacol 46 (1998): 467-71[61] Prince RL, Larkins RG, Alford FP \"The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects.\" Metabolism 30 (1981): 293-8[62] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C \"Severe hypoglycemia associated with disopyramide.\" West J Med 138 (1983): 95-7[63] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[64] Ferrari C, Fressati S, Romussi M, et al. \"Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia.\" Metabolism 26 (1977): 129-39[65] Asplund K, Wiholm BE, Lithner F \"Glibenclamide-associated hypoglycaemia: a report on 57 cases.\" Diabetologia 24 (1983): 412-7[66] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A \"Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme.\" Lancet 345 (1995): 1195-8[67] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K \"Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection.\" Eur J Endocrinol 136 (1997): 3046[68] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ \"Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents.\" Br J Clin Pharmacol 7 (1979): 599-603[69] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL \"Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect.\" Int J Obes 7 (1983): 289-97[70] Whitcroft IA, Thomas JM, Rawsthorne A, et al \"Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics.\" Horm Metab Res Suppl 22 (1990): 42-6[71] Rubin M, Zakheim B, Pitchumoni C \"Disopyramide-induced profound hypoglycemia.\" N Y State J Med July,Aug,S (1983): 1057-8[72] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S \"Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release.\" Am J Physiol 265 (1993): c337-42[73] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW \"Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats.\" Diabetes 38 (1989): 499-503[74] \"Product Information. Micronase (glyburide).\" Pharmacia and Upjohn, Kalamazoo, MI.[75] Harrison LC, King-Roach A, Martin FI, Melick RA \"The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue.\" Postgrad Med J 51 Suppl 1 (1975): 110-4[76] Petitpierre B, Perrin L, Rudhardt M, et al \"Behaviour of chlorpropamide in renal insufficiency and under the effect of associated drug therapy.\" Int J Clin Pharmacol 6 (1972): 120-4[77] Pond SM, Birkett DJ, Wade DN \"Mechanisms of inhibition of tolbutamide metabolism: phenylbutazone, oxyphenbutazone, sulfaphenazole.\" Clin Pharmacol Ther 22 (1977): 573-9[78] Sone H, Takahashi A, Yamada N \"Ibuprofen-related hypoglycemia in a patient receiving sulfonylurea.\" Ann Intern Med 134 (2001): 344[79] Giugliano D, Ceriello A, Saccomanno F, et al \"Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus.\" J Clin Endocrinol Metab 61 (1985): 160-6[80] Goldberg IJ, Brown LK, Rayfield EJ \"Disopyramide (norpace)-induced hypoglycemia.\" Am J Med 69 (1980): 463-6[81] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C \"Disopyramide-induced hypoglycemia: case report and review of the literature.\" Fundam Clin Pharmacol 3 (1989): 527-35[82] Aleyassine H, Gardiner RJ \"Dual action of antidepressant drugs (MAO inhibitors) on insulin release.\" Endocrinology 96 (1975): 702-10[83] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL \"Disopyramide-induced hypoglycaemia and increased serum insulin.\" N Z Med J July (1987): 407-8[84] Baciewicz AM, Swafford WB Jr \"Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole.\" Drug Intell Clin Pharm 18 (1984): 309-10[85] Kubacka RT, Antla EJ, Juhl RP, Welshman IR \"Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects.\" Ann Pharmacother 30 (1996): 20-6[86] Johnson JA, Kappel JE, Sharif MN \"Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient.\" Ann Pharmacother 27 (1993): 304-6[87] Aleyassine H, Lee SH \"Inhibition of insulin release by substrates and inhibitors of monoamine oxidase.\" Am J Physiol 222 (1972): 565-9[88] Cattaneo AG, Caviezel F, Pozza G \"Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man.\" Int J Clin Pharmacol Ther Toxicol 28 (1990): 229-34[89] Almirall J, Montoliu J, Torras A, Revert L \"Propoxyphene-induced hypoglycemia in a patient with chronic renal failure.\" Nephron 53 (1989): 273-5[90] Phillips AF, Matty PJ, Porte PJ, Raye JR \"Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb.\" Am J Obstet Gynecol 148 (1984): 481-7[91] Vuksan V, Stavro MP, Sievenpiper JL, et al \"Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes.\" Diabetes Care 23 (2000): 1221-6[92] Richardson T, Foster J, Mawer GE \"Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects.\" Br J Clin Pharmacol 22 (1986): 43-8[93] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P \"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.\" Am J Med 89 (1990): 811-3[94] Lumholtz B, Siersbaek-Nielsen K, Skovsted L, Kampmann J, Hansen JM \"Sulfamethizole-induced inhibition of diphenylhydantoin, tolbutamide, and warfarin metabolism.\" Clin Pharmacol Ther 17 (1975): 731-4[95] Diwan PV, Sastry MS, Satyanarayana NV \"Potentiation of hypoglycemic response of glibenclamide by piroxicam in rats and humans.\" Indian J Exp Biol 30 (1992): 317-9[96] Semel JD, Wortham E, Karl DM \"Fasting hypoglycemia associated with disopyramide.\" Am Heart J 106 (1983): 1160-1[97] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D \"Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia.\" Br J Clin Pharmacol 52 (2001): 456-7[98] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[99] Wiederholt IC, Genco M, Foley JM \"Recurrent episodes of hypoglycemia induced by propoxyphene.\" Neurology 17 (1967): 703-6[100] Hellman B \"Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells.\" Metabolism 23 (1974): 839-46[101] Harris EL \"Adverse reactions to oral antidiabetic agents.\" Br Med J 3 (1971): 29-30[102] Hartmann D, Korn A, Komjati M, Heinz G, Haefelfinger P, Defoin R, Waldhausl WK \"Lack of effect of tenoxicam on dynamic responses to concurrent oral doses of glucose and glibenclamide.\" Br J Clin Pharmacol 30 (1990): 245-52[103] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[104] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[105] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[106] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[107] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[108] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[109] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[110] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[111] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[112] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Desipramine, Trimipramine, Desvenlafaxine, Maprotiline, Clomipramine, Oxitriptan, Trazodone, Milnacipran, Tryptophan, Amitriptyline, Levomilnacipran, More", "alternatives_b": "Lixisenatide, Albiglutide, Guar gum, Canagliflozin, Pramlintide, Sitagliptin, Alogliptin, Liraglutide, Troglitazone, Ertugliflozin, Semaglutide, More", "updated_at": 1767369485}, {"id": 67067, "ingredient1": "Citalopram", "ingredient2": "Reteplase", "severity": "Moderate", "effect": "Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.", "source": "DDInter", "management_text": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67154/", "reference_text": "[1] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG \"Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin.\" Acta Psychiatr Scand Suppl 350 (1989): 102-6[2] Skop BP, Brown TM \"Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors.\" Psychosomatics 37 (1996): 12-6[3] Settle EC \"Antidepressant drugs: disturbing and potentially dangerous adverse effects.\" J Clin Psychiatry 59 Suppl 16 (1998): 25-30[4] Layton D, Clark DWJ, Pearce GL, Shakir SAW \"Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England.\" Eur J Clin Pharmacol 57 (2001): 167-76[5] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[6] Leung M, Shore R \"Fluvoxamine-associated bleeding.\" Can J Psychiatry 41 (1996): 604-5[7] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[8] Tata LJ, Fortun PJ, Hubbard RB, et al. \"Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?\" Aliment Pharmacol Ther 22 (2005): 175-81[9] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[10] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B \"Paroxetine decreases platelet serotonin storage and platelet function in human beings.\" Clin Pharmacol Ther 68 (2000): 435-42[11] de Abajo FJ, Rodriguez LA, Montero D \"Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study.\" BMJ 319 (1999): 1106-9[12] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[13] Alderman CP, Moritz CK, Ben-Tovim DI \"Abnormal platelet aggregation associated with fluoxetine therapy.\" Ann Pharmacother 26 (1992): 1517-9[14] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[15] Krivy J, Wiener J \"Sertraline and platelet counts in idiopathic thrombocytopenia purpura.\" Lancet 345 (1995): 132[16] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[17] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[18] Pai VB, Kelly MW \"Bruising associated with the use of fluoxetine.\" Ann Pharmacother 30 (1996): 786-8[19] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990): 213-7[20] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ \"Fluoxetine and bleeding in obsessive-compulsive disorder.\" Am J Psychiatry 148 (1991): 949[21] Alderman CP, Seshadri P, Ben-Tovim DI \"Effects of serotonin reuptake inhibitors on hemostasis.\" Ann Pharmacother 30 (1996): 1232-4[22] Humphries JE, Wheby MS, VandenBerg SR \"Fluoxetine and the bleeding time.\" Arch Pathol Lab Med 114 (1990): 727-8[23] Woolfrey S, Gammack NS, Dewar MS, Brown PJ \"Fluoxetine-warfarin interaction.\" BMJ 307 (1993): 241[24] Messiha FS \"Fluoxetine - adverse effects and drug-drug interactions.\" J Toxicol Clin Toxicol 31 (1993): 603-30[25] Ford MA, Anderson ML, Rindone JP, Jaskar DW \"Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin.\" J Clin Psychopharmacol 17 (1997): 110-2[26] Ottervanger JP, Stricker BH, Huls J, Weeda JN \"Bleeding attributed to the intake of paroxetine.\" Am J Psychiatry 151 (1994): 781-2[27] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[28] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH \"Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study.\" Arch Intern Med 163 (2003): 59-64[29] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[30] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[31] Aranth J, Lindberg C \"Bleeding, a side effect of fluoxetine.\" Am J Psychiatry 149 (1992): 412[32] Cerner Multum, Inc. \"Australian Product Information.\" O 0[33] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S \"Intracranial haemorrhage and use of selective serotonin reuptake inhibitors.\" Br J Clin Pharmacol 50 (2000): 43-7[34] de Maistre E, Allart C, Lecompte T, Bollaert PE \"Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors.\" Am J Med 113 (2002): 530-2[35] Claire RJ, Servis ME, Cram DL Jr \"Potential interaction between warfarin sodium and fluoxetine.\" Am J Psychiatry 148 (1991): 1604[36] Dent LA, Orrock MW \"Warfarin-fluoxetine and diazepam-fluoxetine interaction.\" Pharmacotherapy 17 (1997): 170-2[37] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[38] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[39] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[40] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[41] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[42] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Protein C, Selexipag", "alternatives_b": "Maprotiline, St. John's Wort, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, More", "updated_at": 1767369485}, {"id": 67068, "ingredient1": "Citalopram", "ingredient2": "Ribociclib", "severity": "Major", "effect": "Ribociclib can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Coadministration with ribociclib may increase the plasma concentrations and pharmacologic effects of drugs that are substrates of CYP450 3A4. The proposed mechanism is decreased clearance due to ribociclib-mediated inhibition of CYP450 3A4 metabolism.", "source": "DDInter", "management_text": "Coadministration of ribociclib with other drugs that can prolong the QT interval and are substrates of CYP450 3A4, particularly those with a narrow therapeutic range, should generally be avoided. Since the magnitude of QT prolongation may increase with increasing plasma concentrations of these drugs, caution and close clinical monitoring are recommended if concomitant use with these drugs is unavoidable. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ribociclib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism, Synergism", "recommendation": "Coadministration of ribociclib with other drugs that can prolong the QT interval and are substrates of CYP450 3A4, particularly those with a narrow therapeutic range, should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67155/", "reference_text": "[1] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[4] Abbas R, Hug BA, Leister C, Sonnichsen D \"A randomized, crossover, placebo- and moxifloxacin-controlled study to evaluate the effects of bosutinib (SKI-606), a dual Src/Abl tyrosine kinase inhibitor, on cardiac repolarization in healthy adult subjects.\" Int J Cancer 131 (2012): Epub[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Uroxatral (alfuzosin).\" sanofi-aventis , Bridgewater, NJ.[7] \"Product Information. Kisqali (ribociclib).\" Novartis Pharmaceuticals, East Hanover, NJ.[8] \"Product Information. Fareston (toremifene).\" Schering Laboratories, Kenilworth, NJ.[9] Therapeutic Research Faculty \"Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com.\" ([1995-2008...]):[10] \"Product Information. Kisqali (ribociclib).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Phenelzine, Duloxetine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Bupropion, More", "alternatives_b": "Dacomitinib, Tepotinib, Selumetinib, Cobimetinib, Capmatinib, Afatinib, Tivozanib, Brigatinib, Axitinib, Ripretinib, Alpelisib, More", "updated_at": 1767369485}, {"id": 67069, "ingredient1": "Citalopram", "ingredient2": "Rifampicin", "severity": "Moderate", "effect": "Coadministration with potent inducers of CYP450 2C19 and/or 3A4, such as rifampin and St. John's wort, may significantly decrease the plasma concentrations of drugs which are primarily metabolized by these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when potent inducers of CYP450 2C19 and/or 3A4 are used concomitantly with medications that are substrates of these CYP450 isoenzymes. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever St. John's wort or rifampin is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when potent inducers of CYP450 2C19 and/or 3A4 are used concomitantly with medications that are substrates of these CYP450 isoenzymes.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67156/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Rifadin (rifampin).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[3] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[4] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[6] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Phenelzine, Tranylcypromine, Desvenlafaxine, Maprotiline, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, Milnacipran, Tryptophan, More", "alternatives_b": "Capreomycin, Rifamycin, Rifapentine, Streptomycin, Cycloserine, Rifabutin, Pyridoxine, Ethionamide, Pretomanid, Aminosalicylic acid", "updated_at": 1767369485}, {"id": 67070, "ingredient1": "Citalopram", "ingredient2": "Rilpivirine", "severity": "Major", "effect": "Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.", "mechanism_text": "Synergism", "recommendation": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67157/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm.\" ([2011 Aug 24]):[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm.\" ([2012 Mar 28]):[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[9] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[12] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Kaletra (lopinavir-ritonavir)\" Abbott Pharmaceutical, Abbott Park, IL.[15] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Phenelzine, Duloxetine, Tranylcypromine, Vilazodone, Desvenlafaxine, Isocarboxazid, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, More", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Zanamivir, Velpatasvir, Dolutegravir, Brincidofovir, Remdesivir, More", "updated_at": 1767369485}, {"id": 67071, "ingredient1": "Citalopram", "ingredient2": "Risperidone", "severity": "Major", "effect": "Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.", "mechanism_text": "Synergism", "recommendation": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67158/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm.\" ([2011 Aug 24]):[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm.\" ([2012 Mar 28]):[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[9] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[12] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Kaletra (lopinavir-ritonavir)\" Abbott Pharmaceutical, Abbott Park, IL.[15] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Oxitriptan, Vilazodone, Vortioxetine, Tryptophan", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67072, "ingredient1": "Citalopram", "ingredient2": "Ritodrine", "severity": "Major", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride. It may be appropriate to monitor ECG and serum electrolytes during chronic systemic use or high-dose therapy. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67159/", "reference_text": "[1] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990): 259-61[2] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998): 145-7[3] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982): 726-32[4] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997): 1867-75[5] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986): 619-20[6] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994): 729-33[7] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977): 861-9[8] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981): 723-5[9] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994): 1654-9[10] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[11] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[12] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980): 1225-6[13] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001): 45-51[14] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988): 763-6[15] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998): 1400-5[16] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[17] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987): 65-71[18] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.[19] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[20] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978): 767-9[21] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[22] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006): 582-90[23] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990): 1396-9[24] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977): 174-9[25] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990): 575-9[26] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981): 500-1[27] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003): 1817-24", "alternatives_a": "Paroxetine, St. John's Wort, Nefazodone, Oxitriptan, Viloxazine, Vortioxetine, Tryptophan, Vilazodone, Esketamine, Fluvoxamine", "alternatives_b": "Bremelanotide, Black cohosh", "updated_at": 1767369485}, {"id": 67073, "ingredient1": "Citalopram", "ingredient2": "Ritonavir", "severity": "Minor", "effect": "Coadministration with inhibitors of CYP450 3A4 is not expected to significantly affect the pharmacokinetics of citalopram or escitalopram, both of which are partially metabolized by the isoenzyme. Administration of racemic citalopram (40 mg) in combination with the potent CYP450 3A4 inhibitor ketoconazole (200 mg) decreased the ketoconazole peak plasma concentration (Cmax) by 21% and systemic exposure (AUC) by 10%, but did not significantly affect the pharmacokinetics of citalopram.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67160/", "reference_text": "[1] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[2] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[3] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[4] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[6] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Phenelzine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Viloxazine, Milnacipran, Tryptophan, Esketamine", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Zanamivir, Velpatasvir, Dolutegravir, Brincidofovir, Remdesivir, More", "updated_at": 1767369485}, {"id": 67074, "ingredient1": "Citalopram", "ingredient2": "Rivaroxaban", "severity": "Moderate", "effect": "Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.", "source": "DDInter", "management_text": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67161/", "reference_text": "[1] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG \"Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin.\" Acta Psychiatr Scand Suppl 350 (1989): 102-6[2] Skop BP, Brown TM \"Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors.\" Psychosomatics 37 (1996): 12-6[3] Settle EC \"Antidepressant drugs: disturbing and potentially dangerous adverse effects.\" J Clin Psychiatry 59 Suppl 16 (1998): 25-30[4] Layton D, Clark DWJ, Pearce GL, Shakir SAW \"Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England.\" Eur J Clin Pharmacol 57 (2001): 167-76[5] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[6] Leung M, Shore R \"Fluvoxamine-associated bleeding.\" Can J Psychiatry 41 (1996): 604-5[7] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[8] Tata LJ, Fortun PJ, Hubbard RB, et al. \"Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?\" Aliment Pharmacol Ther 22 (2005): 175-81[9] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[10] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B \"Paroxetine decreases platelet serotonin storage and platelet function in human beings.\" Clin Pharmacol Ther 68 (2000): 435-42[11] de Abajo FJ, Rodriguez LA, Montero D \"Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study.\" BMJ 319 (1999): 1106-9[12] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[13] Alderman CP, Moritz CK, Ben-Tovim DI \"Abnormal platelet aggregation associated with fluoxetine therapy.\" Ann Pharmacother 26 (1992): 1517-9[14] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[15] Krivy J, Wiener J \"Sertraline and platelet counts in idiopathic thrombocytopenia purpura.\" Lancet 345 (1995): 132[16] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[17] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[18] Pai VB, Kelly MW \"Bruising associated with the use of fluoxetine.\" Ann Pharmacother 30 (1996): 786-8[19] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990): 213-7[20] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ \"Fluoxetine and bleeding in obsessive-compulsive disorder.\" Am J Psychiatry 148 (1991): 949[21] Alderman CP, Seshadri P, Ben-Tovim DI \"Effects of serotonin reuptake inhibitors on hemostasis.\" Ann Pharmacother 30 (1996): 1232-4[22] Humphries JE, Wheby MS, VandenBerg SR \"Fluoxetine and the bleeding time.\" Arch Pathol Lab Med 114 (1990): 727-8[23] Woolfrey S, Gammack NS, Dewar MS, Brown PJ \"Fluoxetine-warfarin interaction.\" BMJ 307 (1993): 241[24] Messiha FS \"Fluoxetine - adverse effects and drug-drug interactions.\" J Toxicol Clin Toxicol 31 (1993): 603-30[25] Ford MA, Anderson ML, Rindone JP, Jaskar DW \"Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin.\" J Clin Psychopharmacol 17 (1997): 110-2[26] Ottervanger JP, Stricker BH, Huls J, Weeda JN \"Bleeding attributed to the intake of paroxetine.\" Am J Psychiatry 151 (1994): 781-2[27] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[28] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH \"Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study.\" Arch Intern Med 163 (2003): 59-64[29] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[30] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[31] Aranth J, Lindberg C \"Bleeding, a side effect of fluoxetine.\" Am J Psychiatry 149 (1992): 412[32] Cerner Multum, Inc. \"Australian Product Information.\" O 0[33] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S \"Intracranial haemorrhage and use of selective serotonin reuptake inhibitors.\" Br J Clin Pharmacol 50 (2000): 43-7[34] de Maistre E, Allart C, Lecompte T, Bollaert PE \"Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors.\" Am J Med 113 (2002): 530-2[35] Claire RJ, Servis ME, Cram DL Jr \"Potential interaction between warfarin sodium and fluoxetine.\" Am J Psychiatry 148 (1991): 1604[36] Dent LA, Orrock MW \"Warfarin-fluoxetine and diazepam-fluoxetine interaction.\" Pharmacotherapy 17 (1997): 170-2[37] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[38] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[39] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[40] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[41] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[42] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Maprotiline, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, Trimipramine, More", "alternatives_b": "Protein C, Selexipag", "updated_at": 1767369485}, {"id": 67075, "ingredient1": "Citalopram", "ingredient2": "Rivastigmine", "severity": "Moderate", "effect": "Acetylcholinesterase inhibitors may have vagotonic effects on the sinoatrial and atrioventricular nodes, which occasionally manifest as bradycardia or heart block (<2%). Because bradycardia is a risk factor for torsade de pointes, a theoretical risk exists when combined with agents that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when acetylcholinesterase inhibitors are used with drugs that can prolong the QT interval. Patients should be monitored for bradycardia, atrioventricular block and syncope, and advised to seek medical attention if they experience dizziness, lightheadedness, fainting, shortness of breath, or slow or irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when acetylcholinesterase inhibitors are used with drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67162/", "reference_text": "[1] \"Product Information. Razadyne (galantamine).\" Johnson and Johnson Medical Inc, Arlington, TX.[2] \"Product Information. Exelon (rivastigmine)\" Novartis Pharmaceuticals, East Hanover, NJ.[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Aricept (donepezil).\" Pfizer US Pharmaceuticals, New York, NY.[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"", "alternatives_a": "Phenelzine, Tranylcypromine, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, More", "alternatives_b": "Aducanumab", "updated_at": 1767369485}, {"id": 67076, "ingredient1": "Citalopram", "ingredient2": "Rizatriptan", "severity": "Major", "effect": "Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John's wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucination, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.", "source": "DDInter", "management_text": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk. Patients should be closely monitored for symptoms of the serotonin syndrome during treatment. Particular caution is advised when increasing the dosages of these agents. The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.", "mechanism_text": "Synergism", "recommendation": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67163/", "reference_text": "[1] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S \"Rare case of serotonin syndrome with therapeutic doses of paroxetine.\" Am J Ther 13 (2006): 550-552[2] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics.\" J Clin Psychopharmacol 10 (1990): 48-50[3] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[4] George TP, Godleski LS \"Possible serotonin syndrome with trazodone addition to fluoxetine.\" Biol Psychiatry 39 (1996): 384-5[5] Fugh-Berman A \"Herb-drug interactions.\" Lancet 355 (2000): 134-8[6] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[7] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[8] Ruiz F \"Fluoxetine and the serotonin syndrome.\" Ann Emerg Med 24 (1994): 983-5[9] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[10] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[11] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[12] Bergeron L, Boule M, Perreault S \"Serotonin toxicity associated with concomitant use of linezolid.\" Ann Pharmacother 39 (2005): 956-61[13] Wigen CL, Goetz MB \"Serotonin syndrome and linezolid.\" Clin Infect Dis 34 (2002): 1651-2[14] Metz A \"Interaction between fluoxetine and buspirone.\" Can J Psychiatry 35 (1990): 722-3[15] Tahir N \"Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram.\" J Am Med Dir Assoc 5 (2004): 111-3[16] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[17] Lane R, Baldwin D \"Selective serotonin reuptake inhibitor--induced serotonin syndrome: review.\" J Clin Psychopharmacol 17 (1997): 208-21[18] \"Product Information. Maxalt (rizatriptan).\" Merck & Co, Inc, West Point, PA.[19] Hammerness P, Parada H, Abrams A \"Linezolid: MAOI Activity and Potential Drug Interactions.\" Psychosomatics 43 (2002): 248-9[20] Morales N, Vermette H \"Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine.\" Psychosomatics 46 (2005): 274-5[21] Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM \"The serotonin syndrome associated wtih paroxetine, an over-the-counter cold remedy, and vascular disease.\" Am J Emerg Med 12 (1994): 642-4[22] Manos GH \"Possible serotonin syndrome associated with buspirone added to fluoxetine.\" Ann Pharmacother 34 (2000): 871-4[23] Gordon JB \"SSRI's and St. John's Wort: possible toxicity?\" Am Fam Physician 57 (1998): 950,953[24] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[25] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997): 175-7[26] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993): 84-8[27] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[28] Gillman PK \"Linezolid and serotonin toxicity.\" Clin Infect Dis 37 (2003): 1274-5[29] Taylor JJ, Wilson JW, Estes LL \"Linezolid and serotonergic drug interactions: a retrospective survey.\" Clin Infect Dis 43 (2006): 180-7[30] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003): 32-5[31] Nijhawan PK, Katz G, Winter S \"Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission.\" Crit Care Med 24 (1996): 1086-9[32] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals, Raritan, NJ.[33] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[34] Mackay FJ, Dunn NR, Mann RD \"Antidepressants and the serotonin syndrome in general practice.\" Br J Gen Pract 49 (1999): 871-4[35] Perry NK \"Venlafaxine-induced serotonin syndrome with relapse following amitriptyline.\" Postgrad Med J 76 (2000): 254-6[36] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995): 440-2[37] Margolese HC, Chouinard G \"Serotonin syndrome from addition of low-dose trazodone to nefazodone.\" Am J Psychiatry 157 (2000): 1022[38] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006): 1589[39] Boyer EW, Shannon M \"The serotonin syndrome.\" N Engl J Med 352 (2005): 1112-20[40] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995): 481-2[41] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[42] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[43] Dannawi M \"Possible serotonin syndrome after combination of buspirone and St John's Wort.\" J Psychopharmacol 16 (2002): 401[44] Lee J, Franz L, Goforth HW \"Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine.\" Psychosomatics 50 (2009): 638-9[45] Bhatara VS, Magnus RD, Paul KL, Preskorn SH \"Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms.\" Ann Pharmacother 32 (1998): 432-6[46] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992): 1061-6[47] Strouse TB, Kerrihard TN, Forscher CA, Zakowski P \"Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine.\" J Clin Psychopharmacol 26 (2006): 681-683[48] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990): 949-50[49] Packer S, Berman SA \"Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid.\" Am J Psychiatry 164 (2007): 346-7[50] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[51] John L, Perreault MM, Tao T, Blew PG \"Serotonin syndrome associated with nefazodone and paroxetine.\" Ann Emerg Med 29 (1997): 287-9[52] \"Product Information. Imitrex (sumatriptan).\" Glaxo Wellcome, Research Triangle Park, NC.[53] \"Product Information. Oleptro (traZODone).\" Labopharm Inc, Laval, AL.[54] Reeves RR, Bullen JA \"Serotonin syndrome produced by paroxetine and low-dose trazodone.\" Psychosomatics 36 (1995): 159-60[55] Weiner AL \"Meperidine as a potential cause of serotonin syndrome in the emergency department.\" Acad Emerg Med 6 (1999): 156-8[56] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997): 181-2[57] Mathew NT, Tietjen GE, Lucker C \"Serotonin syndrome complicating migraine pharmacotherapy.\" Cephalalgia 16 (1996): 323-7[58] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002): 1647-1648[59] Gardner DM, Lynd LD \"Sumatriptan contraindications and the serotonin syndrome.\" Ann Pharmacother 32 (1998): 33-8[60] Baetz M, Malcolm D \"Serotonin syndrome from fluvoxamine and buspirone.\" Can J Psychiatry 40 (1995): 428-9[61] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007): 199-202[62] Mugele J, Nanagas KA, Tormoehlen LM \"Serotonin Syndrome Associated With MDPV Use: A Case Report.\" Ann Emerg Med (2012):[63] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[64] Thomas CR, Rosenberg M, Blythe V, Meyer WJ 3rd \"Serotonin syndrome and linezolid.\" J Am Acad Child Adolesc Psychiatry 43 (2004): 790[65] Turkel SB, Nadala JG, Wincor MZ \"Possible serotonin syndrome in association with 5-HT3 antagonist agents.\" Psychosomatics 42 (2001): 258-60[66] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008): 521-5[67] Shapiro RE, Tepper SJ \"The serotonin syndrome, triptans, and the potential for drug-drug interactions.\" Headache 47 (2007): 266-9[68] Goldberg RJ, Huk M \"Serotonin syndrome from trazodone and buspirone.\" Psychosomatics 33 (1992): 235-6[69] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990): 213-7[70] Lantz MS, Buchalter E, Giambanco V \"St. John's wort and antidepressant drug interactions in the elderly.\" J Geriatr Psychiatr Neurol 12 (1999): 7-10[71] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[72] Harvey AT, Preskorn SH \"Interactions of serotonin reuptake inhibitors with tricyclic antidepressants.\" Arch Gen Psychiatry 52 (1995): 783-4[73] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[74] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994): 593-7[75] Laird LK \"Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder.\" Psychopharmacol Bull 32 (1996): 569-78[76] Insel TR, Roy BF, Cohen RM, Murphy DL \"Possible development of the serotonin syndrome in man.\" Am J Psychiatry 139 (1982): 954-5[77] Smith DL, Wenegrat BG \"A case report of serotonin syndrome associated with combined nefazodone and fluoxetine.\" J Clin Psychiatry 61 (2000): 146[78] Bernard L, Stern R, Lew D, Hoffmeyer P \"Serotonin syndrome after concomitant treatment with linezolid and citalopram.\" Clin Infect Dis 36 (2003): 1197[79] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001): 2163-75[80] \"Product Information. Zomig (zolmitriptan).\" Zeneca Pharmaceuticals, Wilmington, DE.[81] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[82] \"Product Information. Flexeril (cyclobenzaprine).\" Merck & Co, Inc, West Point, PA.[83] Giese SY, Neborsky R \"Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl.\" Plast Reconstr Surg 107 (2001): 293-4[84] Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Grau S \"Linezolid-associated serotonin syndrome: what we can learn from cases reported so far.\" J Antimicrob Chemother 56 (2005): 1176-8[85] Duggal HS, Fetchko J \"Serotonin syndrome and atypical antipsychotics.\" Am J Psychiatry 159 (2002): 672-3[86] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001): 224-7[87] DeBellis RJ, Schaefer OP, Liquori M, Volturo GA \"Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient.\" J Intensive Care Med 20 (2005): 351-3[88] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[89] Jones SL, Athan E, O'Brien D \"Serotonin syndrome due to co-administration of linezolid and venlafaxine.\" J Antimicrob Chemother 54 (2004): 289-90[90] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[91] Steinberg M, Morin AK \"Mild serotonin syndrome associated with concurrent linezolid and fluoxetine.\" Am J Health Syst Pharm 64 (2007): 59-62[92] Lavery S, Ravi H, McDaniel WW, Pushkin YR \"Linezolid and serotonin syndrome.\" Psychosomatics 42 (2001): 432-4[93] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[94] Hachem RY, Hicks K, Huen A, Raad I \"Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients.\" Clin Infect Dis 37 (2003): E8-E11[95] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[96] Keegan MT, Brown DR, Rabinstein AA \"Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs.\" Anesth Analg 103 (2006): 1466-8[97] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[98] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003): 1511-1512[99] Achamallah NS \"Visual hallucinations after combining fluoxetine and dextromethorphan .\" Am J Psychiatry 149 (1992): 1406[100] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8", "alternatives_a": "Viloxazine, Esketamine", "alternatives_b": "Rimegepant, Eptinezumab, Ubrogepant, Galcanezumab, Atogepant, Erenumab, Fremanezumab", "updated_at": 1767369485}, {"id": 67077, "ingredient1": "Citalopram", "ingredient2": "Romidepsin", "severity": "Major", "effect": "Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.", "mechanism_text": "Synergism", "recommendation": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67164/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm.\" ([2011 Aug 24]):[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm.\" ([2012 Mar 28]):[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[9] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[12] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Kaletra (lopinavir-ritonavir)\" Abbott Pharmaceutical, Abbott Park, IL.[15] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Phenelzine, Duloxetine, Tranylcypromine, Vilazodone, Paroxetine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, More", "alternatives_b": "Pertuzumab, Olaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, Enasidenib, More", "updated_at": 1767369485}, {"id": 67078, "ingredient1": "Citalopram", "ingredient2": "Ropinirole", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67165/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Levomilnacipran, Oxitriptan, Vortioxetine, Milnacipran, Tryptophan, Vilazodone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67079, "ingredient1": "Citalopram", "ingredient2": "Rotigotine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67166/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67080, "ingredient1": "Citalopram", "ingredient2": "Rucaparib", "severity": "Major", "effect": "Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.", "mechanism_text": "Synergism", "recommendation": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67167/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm.\" ([2011 Aug 24]):[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm.\" ([2012 Mar 28]):[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[9] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[12] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Kaletra (lopinavir-ritonavir)\" Abbott Pharmaceutical, Abbott Park, IL.[15] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Phenelzine, Tranylcypromine, Paroxetine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, More", "alternatives_b": "Pertuzumab, Olaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, Enasidenib, More", "updated_at": 1767369485}, {"id": 67081, "ingredient1": "Citalopram", "ingredient2": "Rufinamide", "severity": "Moderate", "effect": "The efficacy of anticonvulsants may be diminished during coadministration with selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitor (SNRIs). Antidepressants including SSRIs and SNRIs can reduce seizure threshold.Coadministration of SSRIs or SNRIs with some anticonvulsants, particularly carbamazepine, eslicarbazepine, oxcarbazepine and valproic acid, may increase the risk of hyponatremia. The risk appears to be dose-related, and elderly patients and patients who are volume depleted (e.g., diuretic use) may be at greater risk.", "source": "DDInter", "management_text": "SSRIs and SNRIs should be avoided in patients with unstable epilepsy, and used cautiously in patients with epilepsy controlled with anticonvulsant medications. Treatment with SSRIs and SNRIs should be discontinued if seizures develop or seizure frequency increases. Patients receiving SSRIs or SNRIs with anticonvulsants, particularly carbamazepine, eslicarbazepine, oxcarbazepine and/or valproic acid, should also have serum sodium levels measured regularly and monitored for development of hyponatremia, particularly when higher dosages of these medications are used. Signs and symptoms of hyponatremia include nausea, vomiting, headache, difficulty concentrating, memory impairment, confusion, malaise, lethargy, muscle weakness or spasms, and unsteadiness. In more severe and/or acute cases, hallucination, syncope, seizure, coma, respiratory arrest, and death may occur.", "mechanism_text": "Antagonism", "recommendation": "SSRIs and SNRIs should be avoided in patients with unstable epilepsy, and used cautiously in patients with epilepsy controlled with anticonvulsant medications.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67168/", "reference_text": "[1] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[2] Belcastro V, Costa C, Striano P \"Levetiracetam-associated hyponatremia.\" Seizure 17 (2008): 389-90[3] Gandhi S, McArthur E, Mamdani MM, et.al \"Antiepileptic drugs and hyponatremia in older adults: Two population-based cohort studies.\" Epilepsia 57 (2016): 2067-79[4] \"Product Information. Aptiom (eslicarbazepine).\" Sunovion Pharmaceuticals Inc, Marlborough, MA.[5] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[6] \"Product Information. Tegretol (carbamazepine).\" Novartis Pharmaceuticals, East Hanover, NJ.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[9] Falhammar H, Lindh JD, Calissendorff J, et.al \"Differences in associations of antiepileptic drugs and hospitalization due to hyponatremia: A population-based case-control study.\" Seizure 59 (2018): 28-33[10] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[11] Bavbek N, Alkan R, Uz E, Kaftan O, Akcay A \"Hyponatremia associated with sodium valproate in a 22-year-old male.\" Nephrol Dial Transplant 23 (2008): epub[12] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[13] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[14] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[15] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[16] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[17] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[18] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[19] Patel KR, Meesala A, Stanilla JK \"Sodium valproate-induced hyponatremia: a case report.\" Prim Care Companion J Clin Psychiatry 12 (2010): epub[20] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[21] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[22] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[23] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[24] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[25] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[26] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[27] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[28] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Oxitriptan, Viloxazine, Tryptophan", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67082, "ingredient1": "Citalopram", "ingredient2": "Ruxolitinib", "severity": "Moderate", "effect": "Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.", "source": "DDInter", "management_text": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67169/", "reference_text": "[1] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG \"Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin.\" Acta Psychiatr Scand Suppl 350 (1989): 102-6[2] Skop BP, Brown TM \"Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors.\" Psychosomatics 37 (1996): 12-6[3] Settle EC \"Antidepressant drugs: disturbing and potentially dangerous adverse effects.\" J Clin Psychiatry 59 Suppl 16 (1998): 25-30[4] Layton D, Clark DWJ, Pearce GL, Shakir SAW \"Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England.\" Eur J Clin Pharmacol 57 (2001): 167-76[5] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[6] Leung M, Shore R \"Fluvoxamine-associated bleeding.\" Can J Psychiatry 41 (1996): 604-5[7] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[8] Tata LJ, Fortun PJ, Hubbard RB, et al. \"Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?\" Aliment Pharmacol Ther 22 (2005): 175-81[9] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[10] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B \"Paroxetine decreases platelet serotonin storage and platelet function in human beings.\" Clin Pharmacol Ther 68 (2000): 435-42[11] de Abajo FJ, Rodriguez LA, Montero D \"Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study.\" BMJ 319 (1999): 1106-9[12] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[13] Alderman CP, Moritz CK, Ben-Tovim DI \"Abnormal platelet aggregation associated with fluoxetine therapy.\" Ann Pharmacother 26 (1992): 1517-9[14] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[15] Krivy J, Wiener J \"Sertraline and platelet counts in idiopathic thrombocytopenia purpura.\" Lancet 345 (1995): 132[16] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[17] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[18] Pai VB, Kelly MW \"Bruising associated with the use of fluoxetine.\" Ann Pharmacother 30 (1996): 786-8[19] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990): 213-7[20] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ \"Fluoxetine and bleeding in obsessive-compulsive disorder.\" Am J Psychiatry 148 (1991): 949[21] Alderman CP, Seshadri P, Ben-Tovim DI \"Effects of serotonin reuptake inhibitors on hemostasis.\" Ann Pharmacother 30 (1996): 1232-4[22] Humphries JE, Wheby MS, VandenBerg SR \"Fluoxetine and the bleeding time.\" Arch Pathol Lab Med 114 (1990): 727-8[23] Woolfrey S, Gammack NS, Dewar MS, Brown PJ \"Fluoxetine-warfarin interaction.\" BMJ 307 (1993): 241[24] Messiha FS \"Fluoxetine - adverse effects and drug-drug interactions.\" J Toxicol Clin Toxicol 31 (1993): 603-30[25] Ford MA, Anderson ML, Rindone JP, Jaskar DW \"Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin.\" J Clin Psychopharmacol 17 (1997): 110-2[26] Ottervanger JP, Stricker BH, Huls J, Weeda JN \"Bleeding attributed to the intake of paroxetine.\" Am J Psychiatry 151 (1994): 781-2[27] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[28] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH \"Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study.\" Arch Intern Med 163 (2003): 59-64[29] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[30] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[31] Aranth J, Lindberg C \"Bleeding, a side effect of fluoxetine.\" Am J Psychiatry 149 (1992): 412[32] Cerner Multum, Inc. \"Australian Product Information.\" O 0[33] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S \"Intracranial haemorrhage and use of selective serotonin reuptake inhibitors.\" Br J Clin Pharmacol 50 (2000): 43-7[34] de Maistre E, Allart C, Lecompte T, Bollaert PE \"Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors.\" Am J Med 113 (2002): 530-2[35] Claire RJ, Servis ME, Cram DL Jr \"Potential interaction between warfarin sodium and fluoxetine.\" Am J Psychiatry 148 (1991): 1604[36] Dent LA, Orrock MW \"Warfarin-fluoxetine and diazepam-fluoxetine interaction.\" Pharmacotherapy 17 (1997): 170-2[37] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[38] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[39] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[40] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[41] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[42] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Phenelzine, Desipramine, Tranylcypromine, Trimipramine, Maprotiline, Isocarboxazid, Oxitriptan, Mirtazapine, Bupropion, Trazodone, Tryptophan, More", "alternatives_b": "Dacomitinib, Tepotinib, Selumetinib, Cobimetinib, Capmatinib, Afatinib, Tivozanib, Brigatinib, Axitinib, Ripretinib, Alpelisib, More", "updated_at": 1767369485}, {"id": 67083, "ingredient1": "Citalopram", "ingredient2": "Safinamide", "severity": "Moderate", "effect": "By inhibiting serotonin metabolism, monoamine oxidase inhibitors (MAOIs), including the selective MAO-B inhibitor safinamide, may potentiate the pharmacologic activity of serotonergic agents such as the serotonin reuptake inhibitors (SSRIs). The result may be an increased risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucinations, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.", "source": "DDInter", "management_text": "Caution is advised if safinamide is used concomitantly with SSRIs and the SSRI should be administered at the lowest effective dose. Clinical and laboratory monitoring should be considered when these drugs are used concomitantly.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if safinamide is used concomitantly with SSRIs and the SSRI should be administered at the lowest effective dose.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67170/", "reference_text": "[1] Weiner LA, Smythe M, Cisek J \"Serotonin syndrome secondary to phenelzine-venlafaxine interaction.\" Pharmacotherapy 18 (1998): 399-403[2] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995): 481-2[3] Diamond S \"The use of sumatriptan in patients on monoamine oxidase inhibitors.\" Neurology 45 (1995): 1039-40[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth (2005):[6] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[9] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[10] Graham PM, Ilett KF \"Danger of MAOI therapy after fluoxetine withdrawal.\" Lancet 2 (1988): 1255-6[11] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[12] Jimenez-Genchi A \"Immediate switching from moclobemide to duloxetine may induce serotonin syndrome.\" J Clin Psychiatry 67 (2006): 1821-1822[13] Klysner R, Larsen JK, Sorensen P, Hyllested M, Pedersen BD \"Toxic interaction of venlafaxine and isocarboxazide.\" Lancet 346 (1995): 1298-9[14] Brubacher JR, Hoffman RS, Lurin MJ \"Serotonin syndrome from venlafaxine-tranylcypromine interaction.\" Vet Hum Toxicol 38 (1996): 358-61[15] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[16] White K, Simpson G \"Combined MAOI-tricyclic antidepressant treatment: a reevaluation.\" J Clin Psychopharmacol 1 (1981): 264-82[17] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993): 84-8[18] \"Product Information. Xadago (safinamide).\" US WorldMeds LLC, Louisville , KY.[19] Feighner JP, Boyer WF, Tyler DL, Neborsky RJ \"Adverse consequences of fluoxetine-MAOI combination therapy.\" J Clin Psychiatry 51 (1990): 222-5[20] Phillips SD, Ringo P \"Phenelzine and venlafaxine interaction.\" Am J Psychiatry 152 (1995): 1400-1[21] Sternbach H \"Danger of MAOI therapy after fluoxetine withdrawal.\" Lancet 2 (1988): 850-1[22] Spiker DG, Pugh DD \"Combining tricyclic and monoamine oxidase inhibitor antidepressants.\" Arch Gen Psychiatry 33 (1976): 828-30[23] Graber MA, Hoehns TB, Perry PJ \"Sertraline-phenelzine drug interaction: a serotonin syndrome reaction.\" Ann Pharmacother 28 (1994): 732-5[24] Bem JL, Peck R \"Dextromethorphan. An overview of safety issues.\" Drug Saf 7 (1992): 190-9[25] Sovner R, Wolfe J \"Interaction between dextromethorphan and monoamine oxidase inhibitor therapy with isocarboxazid .\" N Engl J Med 319 (1988): 1671[26] Beasley CM Jr, Masica DN, Heiligenstein JH, Wheadon DE, Zerbe RL \"Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings.\" J Clin Psychopharmacol 13 (1993): 312-20[27] Diamond S, Pepper BJ, Diamond ML, Freitag FG, Urban GJ, Erdemoglu AK \"Serotonin syndrome induced by transitioning from phenelzine to venlafaxine: four patient reports.\" Neurology 51 (1998): 274-6[28] Jacob JE, Wagner ML, Sage JI \"Safety of selegiline with cold medications.\" Ann Pharmacother 37 (2003): 438-41[29] Staufenberg EF, Tantam D \"Malignant hyperpyrexia syndrome in combined treatment.\" Br J Psychiatry 154 (1989): 577-8[30] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[31] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[32] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[33] Bhatara VS, Bandettini FC \"Possible interaction between sertraline and tranylcypromine.\" Clin Pharm 12 (1993): 222-5[34] Heisler MA, Guidry JR, Arnecke B \"Serotonin syndrome induced by administration of venlafaxine and phenelzine.\" Ann Pharmacother 30 (1996): 84[35] Pope HG Jr, Jonas JM, Hudson JI, Kafka MP \"Toxic reactions to the combination of monoamine oxidase inhibitors and tryptophan.\" Am J Psychiatry 142 (1985): 491-2[36] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[37] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995): 440-2[38] Bodner RA, Lynch T, Lewis L, Kahn D \"Serotonin syndrome.\" Neurology 45 (1995): 219-23[39] Mathew NT, Tietjen GE, Lucker C \"Serotonin syndrome complicating migraine pharmacotherapy.\" Cephalalgia 16 (1996): 323-7[40] \"Product Information. Manerix (moclobemide).\" Hoffmann-La Roche Limited, Mississauga, IA.[41] Suchowersky O, deVries JD \"Interaction of fluoxetine and selegiline.\" Can J Psychiatry 35 (1990): 571-2[42] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[43] Brannan SK, Talley BJ, Bowden CL \"Sertraline and isocarboxazid cause a serotonin syndrome.\" J Clin Psychopharmacol 14 (1994): 144-5[44] Thomas JM, Rubin EH \"Case report of a toxic reaction from a combination of tryptophan and phenelzine.\" Am J Psychiatry 141 (1984): 281-3[45] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[46] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[47] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[48] Gardner DM, Lynd LD \"Sumatriptan contraindications and the serotonin syndrome.\" Ann Pharmacother 32 (1998): 33-8[49] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[50] Levy AB, Bucher P, Votolato N \"Myoclonus, hyperreflexia and diaphoresis in patients on phenelzine- tryptophan combination treatment.\" Can J Psychiatry 30 (1985): 434-6[51] Alvine G, Black DW, Tsuang D \"Case of delirium secondary to phenelzine/L-tryptophan combination.\" J Clin Psychiatry 51 (1990): 311[52] Graham PM, Potter JM, Paterson J \"Combination monoamine oxidase inhibitor/tricyclic antidepressants interaction.\" Lancet 2 (1982): 440[53] Rivers N, Horner B \"Possible lethal reaction between nardil and dextromethorphan.\" Can Med Assoc J 103 (1970): 85[54] White K, Pistole T, Boyd JL \"Combined monoamine oxidase inhibitor-tricyclic antidepressant treatment: a pilot study.\" Am J Psychiatry 137 (1980): 1422-5[55] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[56] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[57] Cetaruk EW, Aaron CK \"Hazards of nonprescription medications.\" Emerg Med Clin North Am 12 (1994): 483-510[58] \"Product Information. Xadago (safinamide).\" US WorldMeds LLC, Louisville , KY.[59] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[60] Ueda N, Yoshimura R, Umene-Nakano W, et al. \"Grapefruit juice alters plasma sertraline levels after single ingestion of sertraline in healthy volunteers.\" World J Biol Psychiatry 10(4 Pt 3) (2009): 832-5[61] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[62] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67084, "ingredient1": "Citalopram", "ingredient2": "Salmeterol", "severity": "Moderate", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.", "source": "DDInter", "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67171/", "reference_text": "[1] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990): 575-9[6] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003): 1817-24[8] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998): 145-7[11] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990): 1396-9[16] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.[17] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006): 582-90[19] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[20] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[21] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001): 45-51[26] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986): 619-20", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Vortioxetine, Tryptophan, Vilazodone, Esketamine, Fluvoxamine", "alternatives_b": "Mometasone furoate, Umeclidinium, Aclidinium, Mometasone, Glycopyrronium, Ipratropium, Beclomethasone dipropionate", "updated_at": 1767369485}, {"id": 67085, "ingredient1": "Citalopram", "ingredient2": "Saquinavir", "severity": "Major", "effect": "Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.", "mechanism_text": "Synergism", "recommendation": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67172/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm.\" ([2011 Aug 24]):[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm.\" ([2012 Mar 28]):[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[9] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[12] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Kaletra (lopinavir-ritonavir)\" Abbott Pharmaceutical, Abbott Park, IL.[15] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Phenelzine, Duloxetine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Vortioxetine, Milnacipran, Tryptophan, Esketamine", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Zanamivir, Velpatasvir, Dolutegravir, Brincidofovir, Remdesivir, More", "updated_at": 1767369485}, {"id": 67086, "ingredient1": "Citalopram", "ingredient2": "Secobarbital", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67173/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Levomilnacipran, Oxitriptan, Viloxazine, Milnacipran, Tryptophan", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67087, "ingredient1": "Citalopram", "ingredient2": "Selegiline", "severity": "Major", "effect": "By inhibiting serotonin metabolism, monoamine oxidase inhibitors (MAOIs) may potentiate the pharmacologic activity of selective serotonin reuptake inhibitors (SSRIs) and increase the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.", "source": "DDInter", "management_text": "In general, SSRIs should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with SSRIs, and vice versa.", "mechanism_text": "Metabolism", "recommendation": "In general, SSRIs should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67174/", "reference_text": "[1] Beasley CM Jr, Masica DN, Heiligenstein JH, Wheadon DE, Zerbe RL \"Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings.\" J Clin Psychopharmacol 13 (1993): 312-20[2] Kline SS, Mauro LS, Scala-Bennett DM, Zick D \"Serotonin syndrome versus neuroleptic malignant death syndrome as a cause of death.\" Clin Pharm 8 (1989): 510-4[3] Bhatara VS, Bandettini FC \"Possible interaction between sertraline and tranylcypromine.\" Clin Pharm 12 (1993): 222-5[4] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[5] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[6] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[7] Suchowersky O, deVries JD \"Interaction of fluoxetine and selegiline.\" Can J Psychiatry 35 (1990): 571-2[8] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[9] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995): 440-2[10] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[11] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth (2005):[12] Suchowersky O, deVries J \"Possible interactions between deprenyl and prozac.\" Can J Neurol Sci 17 (1990): 352-3[13] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990): 213-7[14] Sternbach H \"Danger of MAOI therapy after fluoxetine withdrawal.\" Lancet 2 (1988): 850-1[15] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995): 481-2[16] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[17] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[18] Phillips SD, Ringo P \"Phenelzine and venlafaxine interaction.\" Am J Psychiatry 152 (1995): 1400-1[19] Feighner JP, Boyer WF, Tyler DL, Neborsky RJ \"Adverse consequences of fluoxetine-MAOI combination therapy.\" J Clin Psychiatry 51 (1990): 222-5[20] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[21] Jimenez-Genchi A \"Immediate switching from moclobemide to duloxetine may induce serotonin syndrome.\" J Clin Psychiatry 67 (2006): 1821-1822[22] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[23] Graber MA, Hoehns TB, Perry PJ \"Sertraline-phenelzine drug interaction: a serotonin syndrome reaction.\" Ann Pharmacother 28 (1994): 732-5[24] Ruiz F \"Fluoxetine and the serotonin syndrome.\" Ann Emerg Med 24 (1994): 983-5[25] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[26] Graham PM, Ilett KF \"Danger of MAOI therapy after fluoxetine withdrawal.\" Lancet 2 (1988): 1255-6[27] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[28] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics.\" J Clin Psychopharmacol 10 (1990): 48-50[29] Brannan SK, Talley BJ, Bowden CL \"Sertraline and isocarboxazid cause a serotonin syndrome.\" J Clin Psychopharmacol 14 (1994): 144-5[30] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[31] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[32] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[33] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993): 84-8[34] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[35] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S \"Rare case of serotonin syndrome with therapeutic doses of paroxetine.\" Am J Ther 13 (2006): 550-552[36] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[37] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[38] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[39] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[40] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[41] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[42] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[43] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[44] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[45] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[46] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[47] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[48] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[49] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[50] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[51] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[52] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[53] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[54] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80[55] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[56] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[57] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[58] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67088, "ingredient1": "Citalopram", "ingredient2": "Selpercatinib", "severity": "Major", "effect": "Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.", "mechanism_text": "Synergism", "recommendation": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67175/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm.\" ([2011 Aug 24]):[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm.\" ([2012 Mar 28]):[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[9] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[12] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Kaletra (lopinavir-ritonavir)\" Abbott Pharmaceutical, Abbott Park, IL.[15] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Phenelzine, Duloxetine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Bupropion, More", "alternatives_b": "Dacomitinib, Tepotinib, Selumetinib, Cobimetinib, Capmatinib, Afatinib, Tivozanib, Brigatinib, Axitinib, Ripretinib, Alpelisib, More", "updated_at": 1767369485}, {"id": 67089, "ingredient1": "Citalopram", "ingredient2": "Sertraline", "severity": "Major", "effect": "Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval including tricyclic antidepressants and other antidepressants (e.g., trazodone) may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death. Concomitant use of agents with serotonergic activity including selective serotonin reuptake inhibitors, tricyclic antidepressants, and other antidepressants may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.", "source": "DDInter", "management_text": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure. However, if treatment with citalopram is required in these patients, the labeling recommends that the dosage not exceed 40 mg/day, as higher dosages may have an excessive effect on the QT interval and confer no additional benefit in the treatment of depression. In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk. Patients should be closely monitored for symptoms of the serotonin syndrome during treatment. Particular caution is advised when increasing the dosages of these agents. If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary. Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).", "mechanism_text": "Synergism", "recommendation": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67176/", "reference_text": "[1] Lane R, Baldwin D \"Selective serotonin reuptake inhibitor--induced serotonin syndrome: review.\" J Clin Psychopharmacol 17 (1997): 208-21[2] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993): 84-8[3] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995): 481-2[4] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[5] Insel TR, Roy BF, Cohen RM, Murphy DL \"Possible development of the serotonin syndrome in man.\" Am J Psychiatry 139 (1982): 954-5[6] Laird LK \"Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder.\" Psychopharmacol Bull 32 (1996): 569-78[7] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm.\" ([2011 Aug 24]):[8] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[9] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995): 440-2[10] Nijhawan PK, Katz G, Winter S \"Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission.\" Crit Care Med 24 (1996): 1086-9[11] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[12] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[13] Harvey AT, Preskorn SH \"Interactions of serotonin reuptake inhibitors with tricyclic antidepressants.\" Arch Gen Psychiatry 52 (1995): 783-4[14] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[15] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[16] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[17] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[18] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[20] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[21] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[22] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Viloxazine, Sertraline, Esketamine", "alternatives_b": "Citalopram, Esketamine", "updated_at": 1767369485}, {"id": 67090, "ingredient1": "Citalopram", "ingredient2": "Sevoflurane", "severity": "Major", "effect": "Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.", "mechanism_text": "Synergism", "recommendation": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67177/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm.\" ([2011 Aug 24]):[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm.\" ([2012 Mar 28]):[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[9] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[12] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Kaletra (lopinavir-ritonavir)\" Abbott Pharmaceutical, Abbott Park, IL.[15] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Duloxetine, Vilazodone, Desvenlafaxine, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion, Fluvoxamine", "alternatives_b": "Desflurane, Enflurane, Esketamine, Nitrous oxide", "updated_at": 1767369485}, {"id": 67091, "ingredient1": "Citalopram", "ingredient2": "Sibutramine", "severity": "Major", "effect": "Concomitant use of sibutramine with other serotonin reuptake inhibitors or other agents that possess or enhance serotonergic activity such as monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, phenylpiperidine opioids, bupropion, dextromethorphan, linezolid, lithium, St. John's wort, tramadol, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.", "source": "DDInter", "management_text": "In general, the concomitant use of sibutramine with other agents that affect the serotonergic neurotransmitter system should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk. Patients should be closely monitored for symptoms of the serotonin syndrome during treatment. Particular caution is advised when initiating or increasing the dosages of these agents. The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life. For example, a 5-week washout period is recommended following use of fluoxetine and 3 weeks following use of vortioxetine before administering another serotonergic agent such as sibutramine. At least 14 days should elapse between discontinuation of other serotonergic agents and initiation of treatment with sibutramine. If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary. Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine). Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.", "mechanism_text": "Synergism", "recommendation": "In general, the concomitant use of sibutramine with other agents that affect the serotonergic neurotransmitter system should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67178/", "reference_text": "[1] Giese SY, Neborsky R \"Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl.\" Plast Reconstr Surg 107 (2001): 293-4[2] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[3] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993): 84-8[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] Insel TR, Roy BF, Cohen RM, Murphy DL \"Possible development of the serotonin syndrome in man.\" Am J Psychiatry 139 (1982): 954-5[6] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[7] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[8] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[9] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[10] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[11] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[12] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Esketamine", "alternatives_b": "Ephedrine", "updated_at": 1767369485}, {"id": 67092, "ingredient1": "Citalopram", "ingredient2": "Siponimod", "severity": "Major", "effect": "Due to its significant bradycardic effects, the risk of QT prolongation and torsade de pointes arrhythmia may be increased during initiation of siponimod treatment in patients receiving drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Siponimod has not been studied in patients receiving drugs that can prolong the QT interval. Because bradycardia and AV block are recognized risk factors for QT prolongation and torsade de pointes arrhythmia, treatment with siponimod should generally not be initiated in patients who are concurrently treated with QT prolonging drugs with known arrhythmogenic properties.", "mechanism_text": "Synergism", "recommendation": "Siponimod has not been studied in patients receiving drugs that can prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67179/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Mayzent (siponimod).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[4] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[6] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Phenelzine, Duloxetine, Tranylcypromine, Vilazodone, Desvenlafaxine, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, More", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, More", "updated_at": 1767369485}, {"id": 67093, "ingredient1": "Citalopram", "ingredient2": "Sirolimus", "severity": "Moderate", "effect": "Coadministration of sirolimus or tacrolimus with other drugs that are also metabolized by CYP450 3A4 may result in elevated plasma concentrations of the macrolide immunosuppressant and/or the coadministered drug(s). The mechanism is decreased drug clearance due to competitive inhibition of CYP450 3A4 activity.", "source": "DDInter", "management_text": "Pharmacologic responses and/or plasma drug levels should be monitored more closely whenever a macrolide immunosuppressant or another substrate of CYP450 3A4 is added to or withdrawn from therapy, and the dosage(s) adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic responses and/or plasma drug levels should be monitored more closely whenever a macrolide immunosuppressant or another substrate of CYP450 3A4 is added to or withdrawn from therapy, and the dosage(s) adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67180/", "reference_text": "[1] \"Product Information. Prograf (tacrolimus).\" Fujisawa, Deerfield, IL.[2] \"Product Information. Rapamune (sirolimus)\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[3] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[4] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[6] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[7] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.", "alternatives_a": "Maprotiline, Vortioxetine, Milnacipran, Levomilnacipran, Doxepin, Isocarboxazid, Amoxapine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, More", "alternatives_b": "Vitamin A, Ascorbic acid, Nandrolone, Potassium Iodide, Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, More", "updated_at": 1767369485}, {"id": 67094, "ingredient1": "Citalopram", "ingredient2": "Sodium oxybate", "severity": "Major", "effect": "The central nervous system and respiratory depressant effects of sodium oxybate, which is the sodium salt of gamma hydroxybutyrate (GHB), may be potentiated by concomitant use of other agents with CNS depressant effects. An increased risk of serious adverse reactions such as respiratory depression, hypotension, profound sedation, syncope, coma, and even death should be considered.", "source": "DDInter", "management_text": "Concomitant use of sodium oxybate with other CNS depressants should be avoided whenever possible. Otherwise, close monitoring and/or dosage reductions should be considered. If short-term use of a CNS depressant is required (e.g., post- or perioperative opioid), a temporary interruption of sodium oxybate therapy may be appropriate.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of sodium oxybate with other CNS depressants should be avoided whenever possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67181/", "reference_text": "[1] \"Product Information. Xyrem (sodium oxybate).\" Orphan Medical, Minnetonka, MN.[2] \"Product Information. Xywav (calcium/magnesium/potass/sodium oxybates).\" Jazz Pharmaceuticals, Palo Alto, CA.[3] \"Product Information. Xyrem (sodium oxybate).\" Orphan Medical, Minnetonka, MN.[4] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[6] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[7] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Duloxetine, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran", "alternatives_b": "Desflurane, Enflurane, Esketamine, Nitrous oxide, Dalfampridine, Tafamidis", "updated_at": 1767369485}, {"id": 67095, "ingredient1": "Citalopram", "ingredient2": "Salicylic acid (sodium)", "severity": "Moderate", "effect": "Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.", "source": "DDInter", "management_text": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67182/", "reference_text": "[1] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG \"Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin.\" Acta Psychiatr Scand Suppl 350 (1989): 102-6[2] Skop BP, Brown TM \"Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors.\" Psychosomatics 37 (1996): 12-6[3] Settle EC \"Antidepressant drugs: disturbing and potentially dangerous adverse effects.\" J Clin Psychiatry 59 Suppl 16 (1998): 25-30[4] Layton D, Clark DWJ, Pearce GL, Shakir SAW \"Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England.\" Eur J Clin Pharmacol 57 (2001): 167-76[5] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[6] Leung M, Shore R \"Fluvoxamine-associated bleeding.\" Can J Psychiatry 41 (1996): 604-5[7] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[8] Tata LJ, Fortun PJ, Hubbard RB, et al. \"Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?\" Aliment Pharmacol Ther 22 (2005): 175-81[9] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[10] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B \"Paroxetine decreases platelet serotonin storage and platelet function in human beings.\" Clin Pharmacol Ther 68 (2000): 435-42[11] de Abajo FJ, Rodriguez LA, Montero D \"Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study.\" BMJ 319 (1999): 1106-9[12] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[13] Alderman CP, Moritz CK, Ben-Tovim DI \"Abnormal platelet aggregation associated with fluoxetine therapy.\" Ann Pharmacother 26 (1992): 1517-9[14] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[15] Krivy J, Wiener J \"Sertraline and platelet counts in idiopathic thrombocytopenia purpura.\" Lancet 345 (1995): 132[16] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[17] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[18] Pai VB, Kelly MW \"Bruising associated with the use of fluoxetine.\" Ann Pharmacother 30 (1996): 786-8[19] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990): 213-7[20] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ \"Fluoxetine and bleeding in obsessive-compulsive disorder.\" Am J Psychiatry 148 (1991): 949[21] Alderman CP, Seshadri P, Ben-Tovim DI \"Effects of serotonin reuptake inhibitors on hemostasis.\" Ann Pharmacother 30 (1996): 1232-4[22] Humphries JE, Wheby MS, VandenBerg SR \"Fluoxetine and the bleeding time.\" Arch Pathol Lab Med 114 (1990): 727-8[23] Woolfrey S, Gammack NS, Dewar MS, Brown PJ \"Fluoxetine-warfarin interaction.\" BMJ 307 (1993): 241[24] Messiha FS \"Fluoxetine - adverse effects and drug-drug interactions.\" J Toxicol Clin Toxicol 31 (1993): 603-30[25] Ford MA, Anderson ML, Rindone JP, Jaskar DW \"Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin.\" J Clin Psychopharmacol 17 (1997): 110-2[26] Ottervanger JP, Stricker BH, Huls J, Weeda JN \"Bleeding attributed to the intake of paroxetine.\" Am J Psychiatry 151 (1994): 781-2[27] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[28] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH \"Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study.\" Arch Intern Med 163 (2003): 59-64[29] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[30] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[31] Aranth J, Lindberg C \"Bleeding, a side effect of fluoxetine.\" Am J Psychiatry 149 (1992): 412[32] Cerner Multum, Inc. \"Australian Product Information.\" O 0[33] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S \"Intracranial haemorrhage and use of selective serotonin reuptake inhibitors.\" Br J Clin Pharmacol 50 (2000): 43-7[34] de Maistre E, Allart C, Lecompte T, Bollaert PE \"Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors.\" Am J Med 113 (2002): 530-2[35] Claire RJ, Servis ME, Cram DL Jr \"Potential interaction between warfarin sodium and fluoxetine.\" Am J Psychiatry 148 (1991): 1604[36] Dent LA, Orrock MW \"Warfarin-fluoxetine and diazepam-fluoxetine interaction.\" Pharmacotherapy 17 (1997): 170-2[37] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[38] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[39] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[40] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[41] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[42] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Maprotiline, St. John's Wort, Vortioxetine, Levomilnacipran, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Esketamine, Phenelzine, Desipramine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67096, "ingredient1": "Citalopram", "ingredient2": "Solifenacin", "severity": "Major", "effect": "Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.", "mechanism_text": "Synergism", "recommendation": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67183/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm.\" ([2011 Aug 24]):[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm.\" ([2012 Mar 28]):[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[9] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[12] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Kaletra (lopinavir-ritonavir)\" Abbott Pharmaceutical, Abbott Park, IL.[15] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Duloxetine, Vilazodone, Desvenlafaxine, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Bupropion, Esketamine, Paroxetine", "alternatives_b": "Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Trospium, Mirabegron, Yohimbine, Avanafil, Ammonium chloride, Dimethyl sulfoxide, Silodosin", "updated_at": 1767369485}, {"id": 67097, "ingredient1": "Citalopram", "ingredient2": "Sorafenib", "severity": "Major", "effect": "Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.", "mechanism_text": "Synergism", "recommendation": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67184/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm.\" ([2011 Aug 24]):[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm.\" ([2012 Mar 28]):[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[9] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[12] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Kaletra (lopinavir-ritonavir)\" Abbott Pharmaceutical, Abbott Park, IL.[15] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Phenelzine, Tranylcypromine, Desvenlafaxine, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, More", "alternatives_b": "Dacomitinib, Tepotinib, Selumetinib, Cobimetinib, Capmatinib, Afatinib, Tivozanib, Brigatinib, Axitinib, Ripretinib, Alpelisib, More", "updated_at": 1767369485}, {"id": 67098, "ingredient1": "Citalopram", "ingredient2": "Sotalol", "severity": "Major", "effect": "Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.", "mechanism_text": "Synergism", "recommendation": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67185/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm.\" ([2011 Aug 24]):[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm.\" ([2012 Mar 28]):[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[9] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[12] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Kaletra (lopinavir-ritonavir)\" Abbott Pharmaceutical, Abbott Park, IL.[15] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Desvenlafaxine, St. John's Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone, Esketamine, Fluvoxamine", "alternatives_b": "Esmolol, Betaxolol, Carteolol, Penbutolol", "updated_at": 1767369485}, {"id": 67099, "ingredient1": "Citalopram", "ingredient2": "Sparfloxacin", "severity": "Major", "effect": "Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.", "mechanism_text": "Synergism", "recommendation": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67186/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm.\" ([2011 Aug 24]):[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm.\" ([2012 Mar 28]):[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[9] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[12] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Kaletra (lopinavir-ritonavir)\" Abbott Pharmaceutical, Abbott Park, IL.[15] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Phenelzine, Duloxetine, Tranylcypromine, Paroxetine, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, More", "alternatives_b": "Enoxacin, Nalidixic acid, Cinoxacin, Trovafloxacin, Delafloxacin", "updated_at": 1767369485}, {"id": 67100, "ingredient1": "Citalopram", "ingredient2": "St. John's Wort", "severity": "Major", "effect": "Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John's wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucination, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.", "source": "DDInter", "management_text": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk. Patients should be closely monitored for symptoms of the serotonin syndrome during treatment. Particular caution is advised when increasing the dosages of these agents. The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.", "mechanism_text": "Synergism", "recommendation": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67187/", "reference_text": "[1] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S \"Rare case of serotonin syndrome with therapeutic doses of paroxetine.\" Am J Ther 13 (2006): 550-552[2] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics.\" J Clin Psychopharmacol 10 (1990): 48-50[3] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[4] George TP, Godleski LS \"Possible serotonin syndrome with trazodone addition to fluoxetine.\" Biol Psychiatry 39 (1996): 384-5[5] Fugh-Berman A \"Herb-drug interactions.\" Lancet 355 (2000): 134-8[6] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[7] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[8] Ruiz F \"Fluoxetine and the serotonin syndrome.\" Ann Emerg Med 24 (1994): 983-5[9] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[10] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[11] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[12] Bergeron L, Boule M, Perreault S \"Serotonin toxicity associated with concomitant use of linezolid.\" Ann Pharmacother 39 (2005): 956-61[13] Wigen CL, Goetz MB \"Serotonin syndrome and linezolid.\" Clin Infect Dis 34 (2002): 1651-2[14] Metz A \"Interaction between fluoxetine and buspirone.\" Can J Psychiatry 35 (1990): 722-3[15] Tahir N \"Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram.\" J Am Med Dir Assoc 5 (2004): 111-3[16] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[17] Lane R, Baldwin D \"Selective serotonin reuptake inhibitor--induced serotonin syndrome: review.\" J Clin Psychopharmacol 17 (1997): 208-21[18] \"Product Information. Maxalt (rizatriptan).\" Merck & Co, Inc, West Point, PA.[19] Hammerness P, Parada H, Abrams A \"Linezolid: MAOI Activity and Potential Drug Interactions.\" Psychosomatics 43 (2002): 248-9[20] Morales N, Vermette H \"Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine.\" Psychosomatics 46 (2005): 274-5[21] Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM \"The serotonin syndrome associated wtih paroxetine, an over-the-counter cold remedy, and vascular disease.\" Am J Emerg Med 12 (1994): 642-4[22] Manos GH \"Possible serotonin syndrome associated with buspirone added to fluoxetine.\" Ann Pharmacother 34 (2000): 871-4[23] Gordon JB \"SSRI's and St. John's Wort: possible toxicity?\" Am Fam Physician 57 (1998): 950,953[24] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[25] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997): 175-7[26] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993): 84-8[27] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[28] Gillman PK \"Linezolid and serotonin toxicity.\" Clin Infect Dis 37 (2003): 1274-5[29] Taylor JJ, Wilson JW, Estes LL \"Linezolid and serotonergic drug interactions: a retrospective survey.\" Clin Infect Dis 43 (2006): 180-7[30] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003): 32-5[31] Nijhawan PK, Katz G, Winter S \"Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission.\" Crit Care Med 24 (1996): 1086-9[32] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals, Raritan, NJ.[33] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[34] Mackay FJ, Dunn NR, Mann RD \"Antidepressants and the serotonin syndrome in general practice.\" Br J Gen Pract 49 (1999): 871-4[35] Perry NK \"Venlafaxine-induced serotonin syndrome with relapse following amitriptyline.\" Postgrad Med J 76 (2000): 254-6[36] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995): 440-2[37] Margolese HC, Chouinard G \"Serotonin syndrome from addition of low-dose trazodone to nefazodone.\" Am J Psychiatry 157 (2000): 1022[38] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006): 1589[39] Boyer EW, Shannon M \"The serotonin syndrome.\" N Engl J Med 352 (2005): 1112-20[40] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995): 481-2[41] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[42] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[43] Dannawi M \"Possible serotonin syndrome after combination of buspirone and St John's Wort.\" J Psychopharmacol 16 (2002): 401[44] Lee J, Franz L, Goforth HW \"Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine.\" Psychosomatics 50 (2009): 638-9[45] Bhatara VS, Magnus RD, Paul KL, Preskorn SH \"Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms.\" Ann Pharmacother 32 (1998): 432-6[46] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992): 1061-6[47] Strouse TB, Kerrihard TN, Forscher CA, Zakowski P \"Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine.\" J Clin Psychopharmacol 26 (2006): 681-683[48] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990): 949-50[49] Packer S, Berman SA \"Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid.\" Am J Psychiatry 164 (2007): 346-7[50] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[51] John L, Perreault MM, Tao T, Blew PG \"Serotonin syndrome associated with nefazodone and paroxetine.\" Ann Emerg Med 29 (1997): 287-9[52] \"Product Information. Imitrex (sumatriptan).\" Glaxo Wellcome, Research Triangle Park, NC.[53] \"Product Information. Oleptro (traZODone).\" Labopharm Inc, Laval, AL.[54] Reeves RR, Bullen JA \"Serotonin syndrome produced by paroxetine and low-dose trazodone.\" Psychosomatics 36 (1995): 159-60[55] Weiner AL \"Meperidine as a potential cause of serotonin syndrome in the emergency department.\" Acad Emerg Med 6 (1999): 156-8[56] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997): 181-2[57] Mathew NT, Tietjen GE, Lucker C \"Serotonin syndrome complicating migraine pharmacotherapy.\" Cephalalgia 16 (1996): 323-7[58] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002): 1647-1648[59] Gardner DM, Lynd LD \"Sumatriptan contraindications and the serotonin syndrome.\" Ann Pharmacother 32 (1998): 33-8[60] Baetz M, Malcolm D \"Serotonin syndrome from fluvoxamine and buspirone.\" Can J Psychiatry 40 (1995): 428-9[61] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007): 199-202[62] Mugele J, Nanagas KA, Tormoehlen LM \"Serotonin Syndrome Associated With MDPV Use: A Case Report.\" Ann Emerg Med (2012):[63] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[64] Thomas CR, Rosenberg M, Blythe V, Meyer WJ 3rd \"Serotonin syndrome and linezolid.\" J Am Acad Child Adolesc Psychiatry 43 (2004): 790[65] Turkel SB, Nadala JG, Wincor MZ \"Possible serotonin syndrome in association with 5-HT3 antagonist agents.\" Psychosomatics 42 (2001): 258-60[66] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008): 521-5[67] Shapiro RE, Tepper SJ \"The serotonin syndrome, triptans, and the potential for drug-drug interactions.\" Headache 47 (2007): 266-9[68] Goldberg RJ, Huk M \"Serotonin syndrome from trazodone and buspirone.\" Psychosomatics 33 (1992): 235-6[69] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990): 213-7[70] Lantz MS, Buchalter E, Giambanco V \"St. John's wort and antidepressant drug interactions in the elderly.\" J Geriatr Psychiatr Neurol 12 (1999): 7-10[71] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[72] Harvey AT, Preskorn SH \"Interactions of serotonin reuptake inhibitors with tricyclic antidepressants.\" Arch Gen Psychiatry 52 (1995): 783-4[73] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[74] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994): 593-7[75] Laird LK \"Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder.\" Psychopharmacol Bull 32 (1996): 569-78[76] Insel TR, Roy BF, Cohen RM, Murphy DL \"Possible development of the serotonin syndrome in man.\" Am J Psychiatry 139 (1982): 954-5[77] Smith DL, Wenegrat BG \"A case report of serotonin syndrome associated with combined nefazodone and fluoxetine.\" J Clin Psychiatry 61 (2000): 146[78] Bernard L, Stern R, Lew D, Hoffmeyer P \"Serotonin syndrome after concomitant treatment with linezolid and citalopram.\" Clin Infect Dis 36 (2003): 1197[79] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001): 2163-75[80] \"Product Information. Zomig (zolmitriptan).\" Zeneca Pharmaceuticals, Wilmington, DE.[81] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[82] \"Product Information. Flexeril (cyclobenzaprine).\" Merck & Co, Inc, West Point, PA.[83] Giese SY, Neborsky R \"Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl.\" Plast Reconstr Surg 107 (2001): 293-4[84] Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Grau S \"Linezolid-associated serotonin syndrome: what we can learn from cases reported so far.\" J Antimicrob Chemother 56 (2005): 1176-8[85] Duggal HS, Fetchko J \"Serotonin syndrome and atypical antipsychotics.\" Am J Psychiatry 159 (2002): 672-3[86] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001): 224-7[87] DeBellis RJ, Schaefer OP, Liquori M, Volturo GA \"Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient.\" J Intensive Care Med 20 (2005): 351-3[88] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[89] Jones SL, Athan E, O'Brien D \"Serotonin syndrome due to co-administration of linezolid and venlafaxine.\" J Antimicrob Chemother 54 (2004): 289-90[90] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[91] Steinberg M, Morin AK \"Mild serotonin syndrome associated with concurrent linezolid and fluoxetine.\" Am J Health Syst Pharm 64 (2007): 59-62[92] Lavery S, Ravi H, McDaniel WW, Pushkin YR \"Linezolid and serotonin syndrome.\" Psychosomatics 42 (2001): 432-4[93] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[94] Hachem RY, Hicks K, Huen A, Raad I \"Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients.\" Clin Infect Dis 37 (2003): E8-E11[95] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[96] Keegan MT, Brown DR, Rabinstein AA \"Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs.\" Anesth Analg 103 (2006): 1466-8[97] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[98] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003): 1511-1512[99] Achamallah NS \"Visual hallucinations after combining fluoxetine and dextromethorphan .\" Am J Psychiatry 149 (1992): 1406[100] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8", "alternatives_a": "Viloxazine, Bupropion, St. John's Wort, Esketamine", "alternatives_b": "Citalopram, Esketamine", "updated_at": 1767369485}, {"id": 67101, "ingredient1": "Citalopram", "ingredient2": "Stiripentol", "severity": "Moderate", "effect": "The concomitant administration of stiripentol may significantly increase plasma concentrations, pharmacologic effects, and toxicities of drugs that are substrates of CYP450 2C19, 3A4, and/or 2D6. The mechanism is inhibition of cytochrome P-450 metabolism by stiripentol.", "source": "DDInter", "management_text": "Clinical and laboratory monitoring for altered efficacy and safety is recommended during concomitant use. Dosage adjustments may be required if increased plasma levels or effects are observed.", "mechanism_text": "Metabolism", "recommendation": "Clinical and laboratory monitoring for altered efficacy and safety is recommended during concomitant use.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67188/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[3] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[4] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[5] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[6] \"Product Information. Diacomit (stiripentol).\" Biocodex Inc, Creswell, OR.", "alternatives_a": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67102, "ingredient1": "Citalopram", "ingredient2": "Streptokinase", "severity": "Moderate", "effect": "Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.", "source": "DDInter", "management_text": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67189/", "reference_text": "[1] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG \"Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin.\" Acta Psychiatr Scand Suppl 350 (1989): 102-6[2] Skop BP, Brown TM \"Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors.\" Psychosomatics 37 (1996): 12-6[3] Settle EC \"Antidepressant drugs: disturbing and potentially dangerous adverse effects.\" J Clin Psychiatry 59 Suppl 16 (1998): 25-30[4] Layton D, Clark DWJ, Pearce GL, Shakir SAW \"Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England.\" Eur J Clin Pharmacol 57 (2001): 167-76[5] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[6] Leung M, Shore R \"Fluvoxamine-associated bleeding.\" Can J Psychiatry 41 (1996): 604-5[7] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[8] Tata LJ, Fortun PJ, Hubbard RB, et al. \"Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?\" Aliment Pharmacol Ther 22 (2005): 175-81[9] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[10] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B \"Paroxetine decreases platelet serotonin storage and platelet function in human beings.\" Clin Pharmacol Ther 68 (2000): 435-42[11] de Abajo FJ, Rodriguez LA, Montero D \"Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study.\" BMJ 319 (1999): 1106-9[12] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[13] Alderman CP, Moritz CK, Ben-Tovim DI \"Abnormal platelet aggregation associated with fluoxetine therapy.\" Ann Pharmacother 26 (1992): 1517-9[14] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[15] Krivy J, Wiener J \"Sertraline and platelet counts in idiopathic thrombocytopenia purpura.\" Lancet 345 (1995): 132[16] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[17] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[18] Pai VB, Kelly MW \"Bruising associated with the use of fluoxetine.\" Ann Pharmacother 30 (1996): 786-8[19] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990): 213-7[20] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ \"Fluoxetine and bleeding in obsessive-compulsive disorder.\" Am J Psychiatry 148 (1991): 949[21] Alderman CP, Seshadri P, Ben-Tovim DI \"Effects of serotonin reuptake inhibitors on hemostasis.\" Ann Pharmacother 30 (1996): 1232-4[22] Humphries JE, Wheby MS, VandenBerg SR \"Fluoxetine and the bleeding time.\" Arch Pathol Lab Med 114 (1990): 727-8[23] Woolfrey S, Gammack NS, Dewar MS, Brown PJ \"Fluoxetine-warfarin interaction.\" BMJ 307 (1993): 241[24] Messiha FS \"Fluoxetine - adverse effects and drug-drug interactions.\" J Toxicol Clin Toxicol 31 (1993): 603-30[25] Ford MA, Anderson ML, Rindone JP, Jaskar DW \"Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin.\" J Clin Psychopharmacol 17 (1997): 110-2[26] Ottervanger JP, Stricker BH, Huls J, Weeda JN \"Bleeding attributed to the intake of paroxetine.\" Am J Psychiatry 151 (1994): 781-2[27] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[28] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH \"Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study.\" Arch Intern Med 163 (2003): 59-64[29] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[30] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[31] Aranth J, Lindberg C \"Bleeding, a side effect of fluoxetine.\" Am J Psychiatry 149 (1992): 412[32] Cerner Multum, Inc. \"Australian Product Information.\" O 0[33] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S \"Intracranial haemorrhage and use of selective serotonin reuptake inhibitors.\" Br J Clin Pharmacol 50 (2000): 43-7[34] de Maistre E, Allart C, Lecompte T, Bollaert PE \"Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors.\" Am J Med 113 (2002): 530-2[35] Claire RJ, Servis ME, Cram DL Jr \"Potential interaction between warfarin sodium and fluoxetine.\" Am J Psychiatry 148 (1991): 1604[36] Dent LA, Orrock MW \"Warfarin-fluoxetine and diazepam-fluoxetine interaction.\" Pharmacotherapy 17 (1997): 170-2[37] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[38] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[39] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[40] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[41] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[42] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Protein C, Selexipag, Hemin, Conestat alfa, Betibeglogene autotemcel, Hyaluronidase, Human C1-esterase inhibitor, Crizanlizumab, Lanadelumab, Icatibant", "alternatives_b": "Maprotiline, St. John's Wort, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, More", "updated_at": 1767369485}, {"id": 67103, "ingredient1": "Citalopram", "ingredient2": "Sufentanil", "severity": "Major", "effect": "Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John's wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucination, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.", "source": "DDInter", "management_text": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk. Patients should be closely monitored for symptoms of the serotonin syndrome during treatment. Particular caution is advised when increasing the dosages of these agents. The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.", "mechanism_text": "Synergism", "recommendation": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67190/", "reference_text": "[1] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S \"Rare case of serotonin syndrome with therapeutic doses of paroxetine.\" Am J Ther 13 (2006): 550-552[2] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics.\" J Clin Psychopharmacol 10 (1990): 48-50[3] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[4] George TP, Godleski LS \"Possible serotonin syndrome with trazodone addition to fluoxetine.\" Biol Psychiatry 39 (1996): 384-5[5] Fugh-Berman A \"Herb-drug interactions.\" Lancet 355 (2000): 134-8[6] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[7] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[8] Ruiz F \"Fluoxetine and the serotonin syndrome.\" Ann Emerg Med 24 (1994): 983-5[9] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[10] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[11] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[12] Bergeron L, Boule M, Perreault S \"Serotonin toxicity associated with concomitant use of linezolid.\" Ann Pharmacother 39 (2005): 956-61[13] Wigen CL, Goetz MB \"Serotonin syndrome and linezolid.\" Clin Infect Dis 34 (2002): 1651-2[14] Metz A \"Interaction between fluoxetine and buspirone.\" Can J Psychiatry 35 (1990): 722-3[15] Tahir N \"Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram.\" J Am Med Dir Assoc 5 (2004): 111-3[16] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[17] Lane R, Baldwin D \"Selective serotonin reuptake inhibitor--induced serotonin syndrome: review.\" J Clin Psychopharmacol 17 (1997): 208-21[18] \"Product Information. Maxalt (rizatriptan).\" Merck & Co, Inc, West Point, PA.[19] Hammerness P, Parada H, Abrams A \"Linezolid: MAOI Activity and Potential Drug Interactions.\" Psychosomatics 43 (2002): 248-9[20] Morales N, Vermette H \"Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine.\" Psychosomatics 46 (2005): 274-5[21] Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM \"The serotonin syndrome associated wtih paroxetine, an over-the-counter cold remedy, and vascular disease.\" Am J Emerg Med 12 (1994): 642-4[22] Manos GH \"Possible serotonin syndrome associated with buspirone added to fluoxetine.\" Ann Pharmacother 34 (2000): 871-4[23] Gordon JB \"SSRI's and St. John's Wort: possible toxicity?\" Am Fam Physician 57 (1998): 950,953[24] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[25] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997): 175-7[26] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993): 84-8[27] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[28] Gillman PK \"Linezolid and serotonin toxicity.\" Clin Infect Dis 37 (2003): 1274-5[29] Taylor JJ, Wilson JW, Estes LL \"Linezolid and serotonergic drug interactions: a retrospective survey.\" Clin Infect Dis 43 (2006): 180-7[30] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003): 32-5[31] Nijhawan PK, Katz G, Winter S \"Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission.\" Crit Care Med 24 (1996): 1086-9[32] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals, Raritan, NJ.[33] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[34] Mackay FJ, Dunn NR, Mann RD \"Antidepressants and the serotonin syndrome in general practice.\" Br J Gen Pract 49 (1999): 871-4[35] Perry NK \"Venlafaxine-induced serotonin syndrome with relapse following amitriptyline.\" Postgrad Med J 76 (2000): 254-6[36] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995): 440-2[37] Margolese HC, Chouinard G \"Serotonin syndrome from addition of low-dose trazodone to nefazodone.\" Am J Psychiatry 157 (2000): 1022[38] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006): 1589[39] Boyer EW, Shannon M \"The serotonin syndrome.\" N Engl J Med 352 (2005): 1112-20[40] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995): 481-2[41] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[42] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[43] Dannawi M \"Possible serotonin syndrome after combination of buspirone and St John's Wort.\" J Psychopharmacol 16 (2002): 401[44] Lee J, Franz L, Goforth HW \"Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine.\" Psychosomatics 50 (2009): 638-9[45] Bhatara VS, Magnus RD, Paul KL, Preskorn SH \"Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms.\" Ann Pharmacother 32 (1998): 432-6[46] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992): 1061-6[47] Strouse TB, Kerrihard TN, Forscher CA, Zakowski P \"Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine.\" J Clin Psychopharmacol 26 (2006): 681-683[48] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990): 949-50[49] Packer S, Berman SA \"Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid.\" Am J Psychiatry 164 (2007): 346-7[50] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[51] John L, Perreault MM, Tao T, Blew PG \"Serotonin syndrome associated with nefazodone and paroxetine.\" Ann Emerg Med 29 (1997): 287-9[52] \"Product Information. Imitrex (sumatriptan).\" Glaxo Wellcome, Research Triangle Park, NC.[53] \"Product Information. Oleptro (traZODone).\" Labopharm Inc, Laval, AL.[54] Reeves RR, Bullen JA \"Serotonin syndrome produced by paroxetine and low-dose trazodone.\" Psychosomatics 36 (1995): 159-60[55] Weiner AL \"Meperidine as a potential cause of serotonin syndrome in the emergency department.\" Acad Emerg Med 6 (1999): 156-8[56] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997): 181-2[57] Mathew NT, Tietjen GE, Lucker C \"Serotonin syndrome complicating migraine pharmacotherapy.\" Cephalalgia 16 (1996): 323-7[58] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002): 1647-1648[59] Gardner DM, Lynd LD \"Sumatriptan contraindications and the serotonin syndrome.\" Ann Pharmacother 32 (1998): 33-8[60] Baetz M, Malcolm D \"Serotonin syndrome from fluvoxamine and buspirone.\" Can J Psychiatry 40 (1995): 428-9[61] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007): 199-202[62] Mugele J, Nanagas KA, Tormoehlen LM \"Serotonin Syndrome Associated With MDPV Use: A Case Report.\" Ann Emerg Med (2012):[63] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[64] Thomas CR, Rosenberg M, Blythe V, Meyer WJ 3rd \"Serotonin syndrome and linezolid.\" J Am Acad Child Adolesc Psychiatry 43 (2004): 790[65] Turkel SB, Nadala JG, Wincor MZ \"Possible serotonin syndrome in association with 5-HT3 antagonist agents.\" Psychosomatics 42 (2001): 258-60[66] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008): 521-5[67] Shapiro RE, Tepper SJ \"The serotonin syndrome, triptans, and the potential for drug-drug interactions.\" Headache 47 (2007): 266-9[68] Goldberg RJ, Huk M \"Serotonin syndrome from trazodone and buspirone.\" Psychosomatics 33 (1992): 235-6[69] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990): 213-7[70] Lantz MS, Buchalter E, Giambanco V \"St. John's wort and antidepressant drug interactions in the elderly.\" J Geriatr Psychiatr Neurol 12 (1999): 7-10[71] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[72] Harvey AT, Preskorn SH \"Interactions of serotonin reuptake inhibitors with tricyclic antidepressants.\" Arch Gen Psychiatry 52 (1995): 783-4[73] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[74] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994): 593-7[75] Laird LK \"Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder.\" Psychopharmacol Bull 32 (1996): 569-78[76] Insel TR, Roy BF, Cohen RM, Murphy DL \"Possible development of the serotonin syndrome in man.\" Am J Psychiatry 139 (1982): 954-5[77] Smith DL, Wenegrat BG \"A case report of serotonin syndrome associated with combined nefazodone and fluoxetine.\" J Clin Psychiatry 61 (2000): 146[78] Bernard L, Stern R, Lew D, Hoffmeyer P \"Serotonin syndrome after concomitant treatment with linezolid and citalopram.\" Clin Infect Dis 36 (2003): 1197[79] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001): 2163-75[80] \"Product Information. Zomig (zolmitriptan).\" Zeneca Pharmaceuticals, Wilmington, DE.[81] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[82] \"Product Information. Flexeril (cyclobenzaprine).\" Merck & Co, Inc, West Point, PA.[83] Giese SY, Neborsky R \"Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl.\" Plast Reconstr Surg 107 (2001): 293-4[84] Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Grau S \"Linezolid-associated serotonin syndrome: what we can learn from cases reported so far.\" J Antimicrob Chemother 56 (2005): 1176-8[85] Duggal HS, Fetchko J \"Serotonin syndrome and atypical antipsychotics.\" Am J Psychiatry 159 (2002): 672-3[86] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001): 224-7[87] DeBellis RJ, Schaefer OP, Liquori M, Volturo GA \"Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient.\" J Intensive Care Med 20 (2005): 351-3[88] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[89] Jones SL, Athan E, O'Brien D \"Serotonin syndrome due to co-administration of linezolid and venlafaxine.\" J Antimicrob Chemother 54 (2004): 289-90[90] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[91] Steinberg M, Morin AK \"Mild serotonin syndrome associated with concurrent linezolid and fluoxetine.\" Am J Health Syst Pharm 64 (2007): 59-62[92] Lavery S, Ravi H, McDaniel WW, Pushkin YR \"Linezolid and serotonin syndrome.\" Psychosomatics 42 (2001): 432-4[93] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[94] Hachem RY, Hicks K, Huen A, Raad I \"Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients.\" Clin Infect Dis 37 (2003): E8-E11[95] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[96] Keegan MT, Brown DR, Rabinstein AA \"Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs.\" Anesth Analg 103 (2006): 1466-8[97] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[98] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003): 1511-1512[99] Achamallah NS \"Visual hallucinations after combining fluoxetine and dextromethorphan .\" Am J Psychiatry 149 (1992): 1406[100] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8", "alternatives_a": "Viloxazine", "alternatives_b": "Desflurane, Enflurane, Esketamine, Nitrous oxide", "updated_at": 1767369485}, {"id": 67104, "ingredient1": "Citalopram", "ingredient2": "Sulfamethoxazole", "severity": "Minor", "effect": "Limited data suggest that sulfamethoxazole-trimethoprim (SMX-TMP) may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with SMX-TMP intravenously. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67191/", "reference_text": "[1] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[2] Crouch MA, Limon L, Cassano AT \"Clinical relevance and management of drug-related QT interval prolongation.\" Pharmacotherapy 23 (2003): 881-908[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Wiener I, Rubin D, Martinez E, et al \"QT prolongation and paroxysmal ventricular tachycardia occurring during fever following trimethoprim-sulfamethoxazole administration.\" Mt Sinai J Med 48 (1981): 53-5[5] Lopez JA, Harold JG, Rosenthal MC, Oseran DS, Schapira JN, Peter T \"QT prolongation and torsades de pointes after administration of trimethoprin-sulfamethoxazole.\" Am J Cardiol 59 (1987): 376-7[6] Darpo B \"Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes.\" Eur Heart J Suppl 3(Suppl K) (2001): K70-80[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Phenelzine, Duloxetine, Tranylcypromine, Vilazodone, Paroxetine, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, More", "alternatives_b": "Capreomycin, Rifamycin, Rifapentine, Streptomycin, Cycloserine, Rifabutin, Pyridoxine, Ethionamide, Pretomanid, Aminosalicylic acid, Sulfamethizole, More", "updated_at": 1767369485}, {"id": 67105, "ingredient1": "Citalopram", "ingredient2": "Sulfinpyrazone", "severity": "Moderate", "effect": "Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.", "source": "DDInter", "management_text": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67192/", "reference_text": "[1] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG \"Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin.\" Acta Psychiatr Scand Suppl 350 (1989): 102-6[2] Skop BP, Brown TM \"Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors.\" Psychosomatics 37 (1996): 12-6[3] Settle EC \"Antidepressant drugs: disturbing and potentially dangerous adverse effects.\" J Clin Psychiatry 59 Suppl 16 (1998): 25-30[4] Layton D, Clark DWJ, Pearce GL, Shakir SAW \"Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England.\" Eur J Clin Pharmacol 57 (2001): 167-76[5] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[6] Leung M, Shore R \"Fluvoxamine-associated bleeding.\" Can J Psychiatry 41 (1996): 604-5[7] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[8] Tata LJ, Fortun PJ, Hubbard RB, et al. \"Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?\" Aliment Pharmacol Ther 22 (2005): 175-81[9] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[10] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B \"Paroxetine decreases platelet serotonin storage and platelet function in human beings.\" Clin Pharmacol Ther 68 (2000): 435-42[11] de Abajo FJ, Rodriguez LA, Montero D \"Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study.\" BMJ 319 (1999): 1106-9[12] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[13] Alderman CP, Moritz CK, Ben-Tovim DI \"Abnormal platelet aggregation associated with fluoxetine therapy.\" Ann Pharmacother 26 (1992): 1517-9[14] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[15] Krivy J, Wiener J \"Sertraline and platelet counts in idiopathic thrombocytopenia purpura.\" Lancet 345 (1995): 132[16] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[17] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[18] Pai VB, Kelly MW \"Bruising associated with the use of fluoxetine.\" Ann Pharmacother 30 (1996): 786-8[19] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990): 213-7[20] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ \"Fluoxetine and bleeding in obsessive-compulsive disorder.\" Am J Psychiatry 148 (1991): 949[21] Alderman CP, Seshadri P, Ben-Tovim DI \"Effects of serotonin reuptake inhibitors on hemostasis.\" Ann Pharmacother 30 (1996): 1232-4[22] Humphries JE, Wheby MS, VandenBerg SR \"Fluoxetine and the bleeding time.\" Arch Pathol Lab Med 114 (1990): 727-8[23] Woolfrey S, Gammack NS, Dewar MS, Brown PJ \"Fluoxetine-warfarin interaction.\" BMJ 307 (1993): 241[24] Messiha FS \"Fluoxetine - adverse effects and drug-drug interactions.\" J Toxicol Clin Toxicol 31 (1993): 603-30[25] Ford MA, Anderson ML, Rindone JP, Jaskar DW \"Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin.\" J Clin Psychopharmacol 17 (1997): 110-2[26] Ottervanger JP, Stricker BH, Huls J, Weeda JN \"Bleeding attributed to the intake of paroxetine.\" Am J Psychiatry 151 (1994): 781-2[27] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[28] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH \"Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study.\" Arch Intern Med 163 (2003): 59-64[29] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[30] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[31] Aranth J, Lindberg C \"Bleeding, a side effect of fluoxetine.\" Am J Psychiatry 149 (1992): 412[32] Cerner Multum, Inc. \"Australian Product Information.\" O 0[33] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S \"Intracranial haemorrhage and use of selective serotonin reuptake inhibitors.\" Br J Clin Pharmacol 50 (2000): 43-7[34] de Maistre E, Allart C, Lecompte T, Bollaert PE \"Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors.\" Am J Med 113 (2002): 530-2[35] Claire RJ, Servis ME, Cram DL Jr \"Potential interaction between warfarin sodium and fluoxetine.\" Am J Psychiatry 148 (1991): 1604[36] Dent LA, Orrock MW \"Warfarin-fluoxetine and diazepam-fluoxetine interaction.\" Pharmacotherapy 17 (1997): 170-2[37] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[38] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[39] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[40] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[41] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[42] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Maprotiline, St. John's Wort, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, More", "alternatives_b": "Lesinurad, Febuxostat, Pegloticase, Colchicine, Rasburicase", "updated_at": 1767369485}, {"id": 67106, "ingredient1": "Citalopram", "ingredient2": "Sulindac", "severity": "Moderate", "effect": "Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.", "source": "DDInter", "management_text": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67193/", "reference_text": "[1] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG \"Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin.\" Acta Psychiatr Scand Suppl 350 (1989): 102-6[2] Skop BP, Brown TM \"Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors.\" Psychosomatics 37 (1996): 12-6[3] Settle EC \"Antidepressant drugs: disturbing and potentially dangerous adverse effects.\" J Clin Psychiatry 59 Suppl 16 (1998): 25-30[4] Layton D, Clark DWJ, Pearce GL, Shakir SAW \"Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England.\" Eur J Clin Pharmacol 57 (2001): 167-76[5] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[6] Leung M, Shore R \"Fluvoxamine-associated bleeding.\" Can J Psychiatry 41 (1996): 604-5[7] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[8] Tata LJ, Fortun PJ, Hubbard RB, et al. \"Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?\" Aliment Pharmacol Ther 22 (2005): 175-81[9] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[10] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B \"Paroxetine decreases platelet serotonin storage and platelet function in human beings.\" Clin Pharmacol Ther 68 (2000): 435-42[11] de Abajo FJ, Rodriguez LA, Montero D \"Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study.\" BMJ 319 (1999): 1106-9[12] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[13] Alderman CP, Moritz CK, Ben-Tovim DI \"Abnormal platelet aggregation associated with fluoxetine therapy.\" Ann Pharmacother 26 (1992): 1517-9[14] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[15] Krivy J, Wiener J \"Sertraline and platelet counts in idiopathic thrombocytopenia purpura.\" Lancet 345 (1995): 132[16] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[17] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[18] Pai VB, Kelly MW \"Bruising associated with the use of fluoxetine.\" Ann Pharmacother 30 (1996): 786-8[19] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990): 213-7[20] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ \"Fluoxetine and bleeding in obsessive-compulsive disorder.\" Am J Psychiatry 148 (1991): 949[21] Alderman CP, Seshadri P, Ben-Tovim DI \"Effects of serotonin reuptake inhibitors on hemostasis.\" Ann Pharmacother 30 (1996): 1232-4[22] Humphries JE, Wheby MS, VandenBerg SR \"Fluoxetine and the bleeding time.\" Arch Pathol Lab Med 114 (1990): 727-8[23] Woolfrey S, Gammack NS, Dewar MS, Brown PJ \"Fluoxetine-warfarin interaction.\" BMJ 307 (1993): 241[24] Messiha FS \"Fluoxetine - adverse effects and drug-drug interactions.\" J Toxicol Clin Toxicol 31 (1993): 603-30[25] Ford MA, Anderson ML, Rindone JP, Jaskar DW \"Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin.\" J Clin Psychopharmacol 17 (1997): 110-2[26] Ottervanger JP, Stricker BH, Huls J, Weeda JN \"Bleeding attributed to the intake of paroxetine.\" Am J Psychiatry 151 (1994): 781-2[27] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[28] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH \"Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study.\" Arch Intern Med 163 (2003): 59-64[29] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[30] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[31] Aranth J, Lindberg C \"Bleeding, a side effect of fluoxetine.\" Am J Psychiatry 149 (1992): 412[32] Cerner Multum, Inc. \"Australian Product Information.\" O 0[33] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S \"Intracranial haemorrhage and use of selective serotonin reuptake inhibitors.\" Br J Clin Pharmacol 50 (2000): 43-7[34] de Maistre E, Allart C, Lecompte T, Bollaert PE \"Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors.\" Am J Med 113 (2002): 530-2[35] Claire RJ, Servis ME, Cram DL Jr \"Potential interaction between warfarin sodium and fluoxetine.\" Am J Psychiatry 148 (1991): 1604[36] Dent LA, Orrock MW \"Warfarin-fluoxetine and diazepam-fluoxetine interaction.\" Pharmacotherapy 17 (1997): 170-2[37] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[38] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[39] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[40] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[41] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[42] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Maprotiline, St. John's Wort, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, More", "alternatives_b": "Chondroitin sulfate, Glucosamine", "updated_at": 1767369485}, {"id": 67107, "ingredient1": "Citalopram", "ingredient2": "Sunitinib", "severity": "Major", "effect": "Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.", "mechanism_text": "Synergism", "recommendation": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67194/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm.\" ([2011 Aug 24]):[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm.\" ([2012 Mar 28]):[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[9] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[12] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Kaletra (lopinavir-ritonavir)\" Abbott Pharmaceutical, Abbott Park, IL.[15] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Phenelzine, Duloxetine, Tranylcypromine, Vilazodone, Paroxetine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, More", "alternatives_b": "Dacomitinib, Tepotinib, Selumetinib, Cobimetinib, Capmatinib, Afatinib, Tivozanib, Brigatinib, Axitinib, Ripretinib, Alpelisib, More", "updated_at": 1767369485}, {"id": 67108, "ingredient1": "Citalopram", "ingredient2": "Suvorexant", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67195/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Vilazodone, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Bupropion", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67109, "ingredient1": "Citalopram", "ingredient2": "Tacrine", "severity": "Moderate", "effect": "Acetylcholinesterase inhibitors may have vagotonic effects on the sinoatrial and atrioventricular nodes, which occasionally manifest as bradycardia or heart block (<2%). Because bradycardia is a risk factor for torsade de pointes, a theoretical risk exists when combined with agents that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when acetylcholinesterase inhibitors are used with drugs that can prolong the QT interval. Patients should be monitored for bradycardia, atrioventricular block and syncope, and advised to seek medical attention if they experience dizziness, lightheadedness, fainting, shortness of breath, or slow or irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when acetylcholinesterase inhibitors are used with drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67196/", "reference_text": "[1] \"Product Information. Razadyne (galantamine).\" Johnson and Johnson Medical Inc, Arlington, TX.[2] \"Product Information. Exelon (rivastigmine)\" Novartis Pharmaceuticals, East Hanover, NJ.[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Aricept (donepezil).\" Pfizer US Pharmaceuticals, New York, NY.[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"", "alternatives_a": "Phenelzine, Duloxetine, Tranylcypromine, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, More", "alternatives_b": "Aducanumab", "updated_at": 1767369485}, {"id": 67110, "ingredient1": "Citalopram", "ingredient2": "Tacrolimus", "severity": "Major", "effect": "Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.", "mechanism_text": "Synergism", "recommendation": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67197/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm.\" ([2011 Aug 24]):[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm.\" ([2012 Mar 28]):[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[9] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[12] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Kaletra (lopinavir-ritonavir)\" Abbott Pharmaceutical, Abbott Park, IL.[15] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Phenelzine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Vilazodone, Esketamine", "alternatives_b": "Deoxycholic acid, Calcium gluconate, Magnesium sulfate, Glycopyrronium, Aminobenzoic acid, Ivermectin, Dupilumab, Tralokinumab, Povidone-iodine, Golimumab, Ustekinumab, More", "updated_at": 1767369485}, {"id": 67111, "ingredient1": "Citalopram", "ingredient2": "Tamoxifen", "severity": "Major", "effect": "Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.", "mechanism_text": "Synergism", "recommendation": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67198/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm.\" ([2011 Aug 24]):[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm.\" ([2012 Mar 28]):[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[9] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[12] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Kaletra (lopinavir-ritonavir)\" Abbott Pharmaceutical, Abbott Park, IL.[15] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Phenelzine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone, Esketamine", "alternatives_b": "Darolutamide, Aminoglutethimide", "updated_at": 1767369485}, {"id": 67112, "ingredient1": "Citalopram", "ingredient2": "Tapentadol", "severity": "Major", "effect": "Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John's wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucination, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.", "source": "DDInter", "management_text": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk. Patients should be closely monitored for symptoms of the serotonin syndrome during treatment. Particular caution is advised when increasing the dosages of these agents. The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.", "mechanism_text": "Synergism", "recommendation": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67199/", "reference_text": "[1] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S \"Rare case of serotonin syndrome with therapeutic doses of paroxetine.\" Am J Ther 13 (2006): 550-552[2] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics.\" J Clin Psychopharmacol 10 (1990): 48-50[3] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[4] George TP, Godleski LS \"Possible serotonin syndrome with trazodone addition to fluoxetine.\" Biol Psychiatry 39 (1996): 384-5[5] Fugh-Berman A \"Herb-drug interactions.\" Lancet 355 (2000): 134-8[6] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[7] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[8] Ruiz F \"Fluoxetine and the serotonin syndrome.\" Ann Emerg Med 24 (1994): 983-5[9] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[10] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[11] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[12] Bergeron L, Boule M, Perreault S \"Serotonin toxicity associated with concomitant use of linezolid.\" Ann Pharmacother 39 (2005): 956-61[13] Wigen CL, Goetz MB \"Serotonin syndrome and linezolid.\" Clin Infect Dis 34 (2002): 1651-2[14] Metz A \"Interaction between fluoxetine and buspirone.\" Can J Psychiatry 35 (1990): 722-3[15] Tahir N \"Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram.\" J Am Med Dir Assoc 5 (2004): 111-3[16] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[17] Lane R, Baldwin D \"Selective serotonin reuptake inhibitor--induced serotonin syndrome: review.\" J Clin Psychopharmacol 17 (1997): 208-21[18] \"Product Information. Maxalt (rizatriptan).\" Merck & Co, Inc, West Point, PA.[19] Hammerness P, Parada H, Abrams A \"Linezolid: MAOI Activity and Potential Drug Interactions.\" Psychosomatics 43 (2002): 248-9[20] Morales N, Vermette H \"Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine.\" Psychosomatics 46 (2005): 274-5[21] Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM \"The serotonin syndrome associated wtih paroxetine, an over-the-counter cold remedy, and vascular disease.\" Am J Emerg Med 12 (1994): 642-4[22] Manos GH \"Possible serotonin syndrome associated with buspirone added to fluoxetine.\" Ann Pharmacother 34 (2000): 871-4[23] Gordon JB \"SSRI's and St. John's Wort: possible toxicity?\" Am Fam Physician 57 (1998): 950,953[24] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[25] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997): 175-7[26] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993): 84-8[27] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[28] Gillman PK \"Linezolid and serotonin toxicity.\" Clin Infect Dis 37 (2003): 1274-5[29] Taylor JJ, Wilson JW, Estes LL \"Linezolid and serotonergic drug interactions: a retrospective survey.\" Clin Infect Dis 43 (2006): 180-7[30] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003): 32-5[31] Nijhawan PK, Katz G, Winter S \"Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission.\" Crit Care Med 24 (1996): 1086-9[32] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals, Raritan, NJ.[33] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[34] Mackay FJ, Dunn NR, Mann RD \"Antidepressants and the serotonin syndrome in general practice.\" Br J Gen Pract 49 (1999): 871-4[35] Perry NK \"Venlafaxine-induced serotonin syndrome with relapse following amitriptyline.\" Postgrad Med J 76 (2000): 254-6[36] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995): 440-2[37] Margolese HC, Chouinard G \"Serotonin syndrome from addition of low-dose trazodone to nefazodone.\" Am J Psychiatry 157 (2000): 1022[38] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006): 1589[39] Boyer EW, Shannon M \"The serotonin syndrome.\" N Engl J Med 352 (2005): 1112-20[40] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995): 481-2[41] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[42] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[43] Dannawi M \"Possible serotonin syndrome after combination of buspirone and St John's Wort.\" J Psychopharmacol 16 (2002): 401[44] Lee J, Franz L, Goforth HW \"Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine.\" Psychosomatics 50 (2009): 638-9[45] Bhatara VS, Magnus RD, Paul KL, Preskorn SH \"Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms.\" Ann Pharmacother 32 (1998): 432-6[46] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992): 1061-6[47] Strouse TB, Kerrihard TN, Forscher CA, Zakowski P \"Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine.\" J Clin Psychopharmacol 26 (2006): 681-683[48] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990): 949-50[49] Packer S, Berman SA \"Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid.\" Am J Psychiatry 164 (2007): 346-7[50] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[51] John L, Perreault MM, Tao T, Blew PG \"Serotonin syndrome associated with nefazodone and paroxetine.\" Ann Emerg Med 29 (1997): 287-9[52] \"Product Information. Imitrex (sumatriptan).\" Glaxo Wellcome, Research Triangle Park, NC.[53] \"Product Information. Oleptro (traZODone).\" Labopharm Inc, Laval, AL.[54] Reeves RR, Bullen JA \"Serotonin syndrome produced by paroxetine and low-dose trazodone.\" Psychosomatics 36 (1995): 159-60[55] Weiner AL \"Meperidine as a potential cause of serotonin syndrome in the emergency department.\" Acad Emerg Med 6 (1999): 156-8[56] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997): 181-2[57] Mathew NT, Tietjen GE, Lucker C \"Serotonin syndrome complicating migraine pharmacotherapy.\" Cephalalgia 16 (1996): 323-7[58] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002): 1647-1648[59] Gardner DM, Lynd LD \"Sumatriptan contraindications and the serotonin syndrome.\" Ann Pharmacother 32 (1998): 33-8[60] Baetz M, Malcolm D \"Serotonin syndrome from fluvoxamine and buspirone.\" Can J Psychiatry 40 (1995): 428-9[61] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007): 199-202[62] Mugele J, Nanagas KA, Tormoehlen LM \"Serotonin Syndrome Associated With MDPV Use: A Case Report.\" Ann Emerg Med (2012):[63] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[64] Thomas CR, Rosenberg M, Blythe V, Meyer WJ 3rd \"Serotonin syndrome and linezolid.\" J Am Acad Child Adolesc Psychiatry 43 (2004): 790[65] Turkel SB, Nadala JG, Wincor MZ \"Possible serotonin syndrome in association with 5-HT3 antagonist agents.\" Psychosomatics 42 (2001): 258-60[66] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008): 521-5[67] Shapiro RE, Tepper SJ \"The serotonin syndrome, triptans, and the potential for drug-drug interactions.\" Headache 47 (2007): 266-9[68] Goldberg RJ, Huk M \"Serotonin syndrome from trazodone and buspirone.\" Psychosomatics 33 (1992): 235-6[69] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990): 213-7[70] Lantz MS, Buchalter E, Giambanco V \"St. John's wort and antidepressant drug interactions in the elderly.\" J Geriatr Psychiatr Neurol 12 (1999): 7-10[71] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[72] Harvey AT, Preskorn SH \"Interactions of serotonin reuptake inhibitors with tricyclic antidepressants.\" Arch Gen Psychiatry 52 (1995): 783-4[73] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[74] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994): 593-7[75] Laird LK \"Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder.\" Psychopharmacol Bull 32 (1996): 569-78[76] Insel TR, Roy BF, Cohen RM, Murphy DL \"Possible development of the serotonin syndrome in man.\" Am J Psychiatry 139 (1982): 954-5[77] Smith DL, Wenegrat BG \"A case report of serotonin syndrome associated with combined nefazodone and fluoxetine.\" J Clin Psychiatry 61 (2000): 146[78] Bernard L, Stern R, Lew D, Hoffmeyer P \"Serotonin syndrome after concomitant treatment with linezolid and citalopram.\" Clin Infect Dis 36 (2003): 1197[79] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001): 2163-75[80] \"Product Information. Zomig (zolmitriptan).\" Zeneca Pharmaceuticals, Wilmington, DE.[81] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[82] \"Product Information. Flexeril (cyclobenzaprine).\" Merck & Co, Inc, West Point, PA.[83] Giese SY, Neborsky R \"Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl.\" Plast Reconstr Surg 107 (2001): 293-4[84] Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Grau S \"Linezolid-associated serotonin syndrome: what we can learn from cases reported so far.\" J Antimicrob Chemother 56 (2005): 1176-8[85] Duggal HS, Fetchko J \"Serotonin syndrome and atypical antipsychotics.\" Am J Psychiatry 159 (2002): 672-3[86] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001): 224-7[87] DeBellis RJ, Schaefer OP, Liquori M, Volturo GA \"Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient.\" J Intensive Care Med 20 (2005): 351-3[88] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[89] Jones SL, Athan E, O'Brien D \"Serotonin syndrome due to co-administration of linezolid and venlafaxine.\" J Antimicrob Chemother 54 (2004): 289-90[90] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[91] Steinberg M, Morin AK \"Mild serotonin syndrome associated with concurrent linezolid and fluoxetine.\" Am J Health Syst Pharm 64 (2007): 59-62[92] Lavery S, Ravi H, McDaniel WW, Pushkin YR \"Linezolid and serotonin syndrome.\" Psychosomatics 42 (2001): 432-4[93] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[94] Hachem RY, Hicks K, Huen A, Raad I \"Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients.\" Clin Infect Dis 37 (2003): E8-E11[95] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[96] Keegan MT, Brown DR, Rabinstein AA \"Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs.\" Anesth Analg 103 (2006): 1466-8[97] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[98] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003): 1511-1512[99] Achamallah NS \"Visual hallucinations after combining fluoxetine and dextromethorphan .\" Am J Psychiatry 149 (1992): 1406[100] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8", "alternatives_a": "Viloxazine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67113, "ingredient1": "Citalopram", "ingredient2": "Tasimelteon", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67200/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Vilazodone, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Bupropion", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67114, "ingredient1": "Citalopram", "ingredient2": "Tazemetostat", "severity": "Moderate", "effect": "Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.", "source": "DDInter", "management_text": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67201/", "reference_text": "[1] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG \"Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin.\" Acta Psychiatr Scand Suppl 350 (1989): 102-6[2] Skop BP, Brown TM \"Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors.\" Psychosomatics 37 (1996): 12-6[3] Settle EC \"Antidepressant drugs: disturbing and potentially dangerous adverse effects.\" J Clin Psychiatry 59 Suppl 16 (1998): 25-30[4] Layton D, Clark DWJ, Pearce GL, Shakir SAW \"Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England.\" Eur J Clin Pharmacol 57 (2001): 167-76[5] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[6] Leung M, Shore R \"Fluvoxamine-associated bleeding.\" Can J Psychiatry 41 (1996): 604-5[7] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[8] Tata LJ, Fortun PJ, Hubbard RB, et al. \"Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?\" Aliment Pharmacol Ther 22 (2005): 175-81[9] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[10] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B \"Paroxetine decreases platelet serotonin storage and platelet function in human beings.\" Clin Pharmacol Ther 68 (2000): 435-42[11] de Abajo FJ, Rodriguez LA, Montero D \"Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study.\" BMJ 319 (1999): 1106-9[12] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[13] Alderman CP, Moritz CK, Ben-Tovim DI \"Abnormal platelet aggregation associated with fluoxetine therapy.\" Ann Pharmacother 26 (1992): 1517-9[14] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[15] Krivy J, Wiener J \"Sertraline and platelet counts in idiopathic thrombocytopenia purpura.\" Lancet 345 (1995): 132[16] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[17] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[18] Pai VB, Kelly MW \"Bruising associated with the use of fluoxetine.\" Ann Pharmacother 30 (1996): 786-8[19] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990): 213-7[20] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ \"Fluoxetine and bleeding in obsessive-compulsive disorder.\" Am J Psychiatry 148 (1991): 949[21] Alderman CP, Seshadri P, Ben-Tovim DI \"Effects of serotonin reuptake inhibitors on hemostasis.\" Ann Pharmacother 30 (1996): 1232-4[22] Humphries JE, Wheby MS, VandenBerg SR \"Fluoxetine and the bleeding time.\" Arch Pathol Lab Med 114 (1990): 727-8[23] Woolfrey S, Gammack NS, Dewar MS, Brown PJ \"Fluoxetine-warfarin interaction.\" BMJ 307 (1993): 241[24] Messiha FS \"Fluoxetine - adverse effects and drug-drug interactions.\" J Toxicol Clin Toxicol 31 (1993): 603-30[25] Ford MA, Anderson ML, Rindone JP, Jaskar DW \"Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin.\" J Clin Psychopharmacol 17 (1997): 110-2[26] Ottervanger JP, Stricker BH, Huls J, Weeda JN \"Bleeding attributed to the intake of paroxetine.\" Am J Psychiatry 151 (1994): 781-2[27] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[28] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH \"Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study.\" Arch Intern Med 163 (2003): 59-64[29] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[30] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[31] Aranth J, Lindberg C \"Bleeding, a side effect of fluoxetine.\" Am J Psychiatry 149 (1992): 412[32] Cerner Multum, Inc. \"Australian Product Information.\" O 0[33] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S \"Intracranial haemorrhage and use of selective serotonin reuptake inhibitors.\" Br J Clin Pharmacol 50 (2000): 43-7[34] de Maistre E, Allart C, Lecompte T, Bollaert PE \"Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors.\" Am J Med 113 (2002): 530-2[35] Claire RJ, Servis ME, Cram DL Jr \"Potential interaction between warfarin sodium and fluoxetine.\" Am J Psychiatry 148 (1991): 1604[36] Dent LA, Orrock MW \"Warfarin-fluoxetine and diazepam-fluoxetine interaction.\" Pharmacotherapy 17 (1997): 170-2[37] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[38] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[39] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[40] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[41] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[42] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Phenelzine, Desipramine, Tranylcypromine, Trimipramine, Maprotiline, Isocarboxazid, Oxitriptan, Bupropion, Tryptophan, Amitriptyline, Nortriptyline, More", "alternatives_b": "Pertuzumab, Olaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, Enasidenib, More", "updated_at": 1767369485}, {"id": 67115, "ingredient1": "Citalopram", "ingredient2": "Telaprevir", "severity": "Minor", "effect": "Coadministration with inhibitors of CYP450 3A4 is not expected to significantly affect the pharmacokinetics of citalopram or escitalopram, both of which are partially metabolized by the isoenzyme. Administration of racemic citalopram (40 mg) in combination with the potent CYP450 3A4 inhibitor ketoconazole (200 mg) decreased the ketoconazole peak plasma concentration (Cmax) by 21% and systemic exposure (AUC) by 10%, but did not significantly affect the pharmacokinetics of citalopram.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67202/", "reference_text": "[1] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[2] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[3] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[4] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[6] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Sertraline, Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Doxepin, Duloxetine, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, More", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Zanamivir, Velpatasvir, Dolutegravir, Brincidofovir, Remdesivir, More", "updated_at": 1767369485}, {"id": 67116, "ingredient1": "Citalopram", "ingredient2": "Telavancin", "severity": "Major", "effect": "Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.", "mechanism_text": "Synergism", "recommendation": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67203/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm.\" ([2011 Aug 24]):[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm.\" ([2012 Mar 28]):[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[9] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[12] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Kaletra (lopinavir-ritonavir)\" Abbott Pharmaceutical, Abbott Park, IL.[15] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Phenelzine, Duloxetine, Tranylcypromine, Vilazodone, Paroxetine, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, More", "alternatives_b": "Tinidazole, Bacitracin, Polymyxin B, Oritavancin, Daptomycin, Methenamine, Spectinomycin, Fosfomycin, Tedizolid, Dalbavancin", "updated_at": 1767369485}, {"id": 67117, "ingredient1": "Citalopram", "ingredient2": "Telithromycin", "severity": "Major", "effect": "Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.", "mechanism_text": "Synergism", "recommendation": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67204/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm.\" ([2011 Aug 24]):[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm.\" ([2012 Mar 28]):[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[9] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[12] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Kaletra (lopinavir-ritonavir)\" Abbott Pharmaceutical, Abbott Park, IL.[15] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Phenelzine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Esketamine, Fluvoxamine", "alternatives_b": "Lincomycin, Dirithromycin", "updated_at": 1767369485}, {"id": 67118, "ingredient1": "Citalopram", "ingredient2": "Telotristat ethyl", "severity": "Moderate", "effect": "Coadministration with telotristat ethyl may decrease the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or 2B6 isoenzymes. The proposed mechanism is accelerated clearance due to induction of CYP450 3A4 and/or 2B6 (in vitro) isoenzymes by telotristat ethyl.", "source": "DDInter", "management_text": "When drugs that are known substrates of CYP450 3A4 and/or 2B6 are coadministered with telotristat ethyl, the possibility of a diminished therapeutic response to those drugs should be considered. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs, particularly those with a narrow therapeutic range, whenever telotristat ethyl is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "When drugs that are known substrates of CYP450 3A4 and/or 2B6 are coadministered with telotristat ethyl, the possibility of a diminished therapeutic response to those drugs should be considered.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67205/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Xermelo (telotristat ethyl).\" Lexicon Pharmaceuticals, Inc., The Woodlands, TX.[3] \"Product Information. Xermelo (telotristat ethyl).\" Lexicon Pharmaceuticals, Inc., The Woodlands, TX.", "alternatives_a": "Maprotiline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, Viloxazine, Amoxapine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67119, "ingredient1": "Citalopram", "ingredient2": "Temazepam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67206/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67120, "ingredient1": "Citalopram", "ingredient2": "Temsirolimus", "severity": "Moderate", "effect": "Coadministration of sirolimus or tacrolimus with other drugs that are also metabolized by CYP450 3A4 may result in elevated plasma concentrations of the macrolide immunosuppressant and/or the coadministered drug(s). The mechanism is decreased drug clearance due to competitive inhibition of CYP450 3A4 activity.", "source": "DDInter", "management_text": "Pharmacologic responses and/or plasma drug levels should be monitored more closely whenever a macrolide immunosuppressant or another substrate of CYP450 3A4 is added to or withdrawn from therapy, and the dosage(s) adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic responses and/or plasma drug levels should be monitored more closely whenever a macrolide immunosuppressant or another substrate of CYP450 3A4 is added to or withdrawn from therapy, and the dosage(s) adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67207/", "reference_text": "[1] \"Product Information. Prograf (tacrolimus).\" Fujisawa, Deerfield, IL.[2] \"Product Information. Rapamune (sirolimus)\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[3] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[4] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[6] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[7] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.", "alternatives_a": "Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, Amoxapine, Esketamine, Phenelzine, More", "alternatives_b": "Dacomitinib, Tepotinib, Selumetinib, Cobimetinib, Capmatinib, Afatinib, Tivozanib, Brigatinib, Axitinib, Ripretinib, Alpelisib, More", "updated_at": 1767369485}, {"id": 67121, "ingredient1": "Citalopram", "ingredient2": "Tenecteplase", "severity": "Moderate", "effect": "Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.", "source": "DDInter", "management_text": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67208/", "reference_text": "[1] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG \"Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin.\" Acta Psychiatr Scand Suppl 350 (1989): 102-6[2] Skop BP, Brown TM \"Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors.\" Psychosomatics 37 (1996): 12-6[3] Settle EC \"Antidepressant drugs: disturbing and potentially dangerous adverse effects.\" J Clin Psychiatry 59 Suppl 16 (1998): 25-30[4] Layton D, Clark DWJ, Pearce GL, Shakir SAW \"Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England.\" Eur J Clin Pharmacol 57 (2001): 167-76[5] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[6] Leung M, Shore R \"Fluvoxamine-associated bleeding.\" Can J Psychiatry 41 (1996): 604-5[7] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[8] Tata LJ, Fortun PJ, Hubbard RB, et al. \"Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?\" Aliment Pharmacol Ther 22 (2005): 175-81[9] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[10] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B \"Paroxetine decreases platelet serotonin storage and platelet function in human beings.\" Clin Pharmacol Ther 68 (2000): 435-42[11] de Abajo FJ, Rodriguez LA, Montero D \"Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study.\" BMJ 319 (1999): 1106-9[12] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[13] Alderman CP, Moritz CK, Ben-Tovim DI \"Abnormal platelet aggregation associated with fluoxetine therapy.\" Ann Pharmacother 26 (1992): 1517-9[14] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[15] Krivy J, Wiener J \"Sertraline and platelet counts in idiopathic thrombocytopenia purpura.\" Lancet 345 (1995): 132[16] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[17] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[18] Pai VB, Kelly MW \"Bruising associated with the use of fluoxetine.\" Ann Pharmacother 30 (1996): 786-8[19] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990): 213-7[20] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ \"Fluoxetine and bleeding in obsessive-compulsive disorder.\" Am J Psychiatry 148 (1991): 949[21] Alderman CP, Seshadri P, Ben-Tovim DI \"Effects of serotonin reuptake inhibitors on hemostasis.\" Ann Pharmacother 30 (1996): 1232-4[22] Humphries JE, Wheby MS, VandenBerg SR \"Fluoxetine and the bleeding time.\" Arch Pathol Lab Med 114 (1990): 727-8[23] Woolfrey S, Gammack NS, Dewar MS, Brown PJ \"Fluoxetine-warfarin interaction.\" BMJ 307 (1993): 241[24] Messiha FS \"Fluoxetine - adverse effects and drug-drug interactions.\" J Toxicol Clin Toxicol 31 (1993): 603-30[25] Ford MA, Anderson ML, Rindone JP, Jaskar DW \"Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin.\" J Clin Psychopharmacol 17 (1997): 110-2[26] Ottervanger JP, Stricker BH, Huls J, Weeda JN \"Bleeding attributed to the intake of paroxetine.\" Am J Psychiatry 151 (1994): 781-2[27] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[28] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH \"Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study.\" Arch Intern Med 163 (2003): 59-64[29] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[30] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[31] Aranth J, Lindberg C \"Bleeding, a side effect of fluoxetine.\" Am J Psychiatry 149 (1992): 412[32] Cerner Multum, Inc. \"Australian Product Information.\" O 0[33] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S \"Intracranial haemorrhage and use of selective serotonin reuptake inhibitors.\" Br J Clin Pharmacol 50 (2000): 43-7[34] de Maistre E, Allart C, Lecompte T, Bollaert PE \"Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors.\" Am J Med 113 (2002): 530-2[35] Claire RJ, Servis ME, Cram DL Jr \"Potential interaction between warfarin sodium and fluoxetine.\" Am J Psychiatry 148 (1991): 1604[36] Dent LA, Orrock MW \"Warfarin-fluoxetine and diazepam-fluoxetine interaction.\" Pharmacotherapy 17 (1997): 170-2[37] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[38] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[39] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[40] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[41] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[42] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Protein C, Selexipag", "alternatives_b": "Maprotiline, St. John's Wort, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, More", "updated_at": 1767369485}, {"id": 67122, "ingredient1": "Citalopram", "ingredient2": "Terbutaline", "severity": "Major", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride. It may be appropriate to monitor ECG and serum electrolytes during chronic systemic use or high-dose therapy. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67209/", "reference_text": "[1] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990): 259-61[2] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998): 145-7[3] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982): 726-32[4] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997): 1867-75[5] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986): 619-20[6] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994): 729-33[7] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977): 861-9[8] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981): 723-5[9] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994): 1654-9[10] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[11] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[12] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980): 1225-6[13] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001): 45-51[14] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988): 763-6[15] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998): 1400-5[16] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[17] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987): 65-71[18] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.[19] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[20] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978): 767-9[21] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[22] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006): 582-90[23] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990): 1396-9[24] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977): 174-9[25] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990): 575-9[26] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981): 500-1[27] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003): 1817-24", "alternatives_a": "Paroxetine, St. John's Wort, Nefazodone, Oxitriptan, Viloxazine, Vortioxetine, Tryptophan, Vilazodone, Esketamine, Fluvoxamine", "alternatives_b": "Ephedrine, Mometasone furoate, Umeclidinium, Aclidinium, Mometasone, Glycopyrronium, Ipratropium, Beclomethasone dipropionate", "updated_at": 1767369485}, {"id": 67123, "ingredient1": "Citalopram", "ingredient2": "Terfenadine", "severity": "Major", "effect": "Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.", "mechanism_text": "Synergism", "recommendation": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67210/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm.\" ([2011 Aug 24]):[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm.\" ([2012 Mar 28]):[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[9] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[12] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Kaletra (lopinavir-ritonavir)\" Abbott Pharmaceutical, Abbott Park, IL.[15] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Phenelzine, Duloxetine, Tranylcypromine, Vilazodone, Desvenlafaxine, St. John's Wort, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, More", "alternatives_b": "Azelastine, Ketotifen", "updated_at": 1767369485}, {"id": 67124, "ingredient1": "Citalopram", "ingredient2": "Tetrabenazine", "severity": "Major", "effect": "Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.", "mechanism_text": "Synergism", "recommendation": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67211/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm.\" ([2011 Aug 24]):[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm.\" ([2012 Mar 28]):[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[9] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[12] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Kaletra (lopinavir-ritonavir)\" Abbott Pharmaceutical, Abbott Park, IL.[15] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "alternatives_b": "Dalfampridine, Tafamidis", "updated_at": 1767369485}, {"id": 67125, "ingredient1": "Citalopram", "ingredient2": "Thalidomide", "severity": "Moderate", "effect": "Thalidomide can commonly cause drowsiness/sedation and may have additive effects with other drugs that cause central nervous system (CNS) depression. Thalidomide can cause bradycardia and may have additive effects with other drugs that decrease heart rate. Cases of bradycardia have been associated with thalidomide use, some requiring medical interventions.", "source": "DDInter", "management_text": "Caution is advised when thalidomide is used with other CNS depressants such as anticonvulsants, antihistamines, antidepressants, antipsychotics, anxiolytics, opioids, and sedatives/hypnotics. Caution is advised when thalidomide is used with drugs that can slow the heart rate or induce torsade de pointes arrhythmia. Patients should be monitored for bradycardia, atrioventricular block and syncope, and advised to seek medical attention if they experience dizziness, lightheadedness, fainting, shortness of breath, or slow or irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when thalidomide is used with other CNS depressants such as anticonvulsants, antihistamines, antidepressants, antipsychotics, anxiolytics, opioids, and sedatives/hypnotics.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67212/", "reference_text": "[1] \"Product Information. Thalomid (thalidomide).\" Celgene Corporation, Warren, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[5] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[6] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[7] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, More", "updated_at": 1767369485}, {"id": 67126, "ingredient1": "Citalopram", "ingredient2": "Thiethylperazine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67213/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Sertraline, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Milnacipran, Vortioxetine, Tryptophan, Levomilnacipran, Vilazodone, More", "alternatives_b": "Azelastine, Ketotifen", "updated_at": 1767369485}, {"id": 67127, "ingredient1": "Citalopram", "ingredient2": "Thiopental", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67214/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Vilazodone, Sertraline, Maprotiline, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Milnacipran, Vortioxetine, Trazodone, Levomilnacipran, More", "alternatives_b": "Desflurane, Enflurane, Esketamine, Nitrous oxide", "updated_at": 1767369485}, {"id": 67128, "ingredient1": "Citalopram", "ingredient2": "Thioridazine", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 2D6 may increase the plasma concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, all of which are substrates of the isoenzyme.", "source": "DDInter", "management_text": "The use of thioridazine with drugs that inhibit CYP450 2D6 is considered contraindicated. Depending on the elimination half-life of these drugs, a considerable waiting period may be appropriate following their discontinuation before thioridazine is initiated. For example, the manufacturer of fluoxetine recommends that thioridazine not be administered within 5 weeks after discontinuing fluoxetine because of the drug's long half-life.", "mechanism_text": "Metabolism", "recommendation": "The use of thioridazine with drugs that inhibit CYP450 2D6 is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67215/", "reference_text": "[1] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[2] Greendyke RM, Gulya A \"Effect of pindolol administration on serum levels of thioridazine, haloperidol, phenytoin, and phenobarbital.\" J Clin Psychiatry 49 (1988): 105-7[3] Carrillo JA, Ramos SI, Herraiz AG, Llerena A, Agundez JAG, Berecz R, Duran M, Benitez J \"Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients.\" J Clin Psychopharmacol 19 (1999): 494-9[4] Abernethy DR, Greenblatt DJ, Steel K, Shader RI \"Impairment of hepatic drug oxidation by propoxyphene.\" Ann Intern Med 97 (1982): 223-4[5] Fletcher GF, Kazamias TM \"Cardiotoxic effects of Mellaril: conduction disturbances and supraventricular arrhythmias.\" Am Heart J 78 (1969): 135-8[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[7] \"Product Information. Mellaril (thioridazine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[8] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[9] Silver JM, Yudofsky SC, Kogan M, Katz BL \"Elevation of thioridazine plasma levels by propranolol.\" Am J Psychiatry 143 (1986): 1290-2[10] Hartigan-Go K, Bateman DN, Nyberg G, Martensson E, Thomas SHL \"Concentration-related pharmacodynamic effects of thioridazine and its metabolites in humans.\" Clin Pharmacol Ther 60 (1996): 543-53[11] Greendyke RM, Kanter DR \"Plasma propranolol levels and their effect on plasma thioridazine and haloperidol concentrations.\" J Clin Psychopharmacol 7 (1987): 178-82[12] Thomas M, Maconochie JG, Fletcher E \"The dilemma of the prolonged QT interval in early drug studies.\" Br J Clin Pharmacol 41 (1996): 77-81[13] Cerner Multum, Inc. \"Australian Product Information.\" O 0[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Gleevec (imatinib mesylate).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Oxitriptan, Vilazodone, Vortioxetine, Tryptophan", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67129, "ingredient1": "Citalopram", "ingredient2": "Thiothixene", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67216/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Oxitriptan, Viloxazine, Vortioxetine, Tryptophan, Vilazodone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67130, "ingredient1": "Citalopram", "ingredient2": "Tiagabine", "severity": "Moderate", "effect": "The efficacy of anticonvulsants may be diminished during coadministration with selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitor (SNRIs). Antidepressants including SSRIs and SNRIs can reduce seizure threshold.Coadministration of SSRIs or SNRIs with some anticonvulsants, particularly carbamazepine, eslicarbazepine, oxcarbazepine and valproic acid, may increase the risk of hyponatremia. The risk appears to be dose-related, and elderly patients and patients who are volume depleted (e.g., diuretic use) may be at greater risk.", "source": "DDInter", "management_text": "SSRIs and SNRIs should be avoided in patients with unstable epilepsy, and used cautiously in patients with epilepsy controlled with anticonvulsant medications. Treatment with SSRIs and SNRIs should be discontinued if seizures develop or seizure frequency increases. Patients receiving SSRIs or SNRIs with anticonvulsants, particularly carbamazepine, eslicarbazepine, oxcarbazepine and/or valproic acid, should also have serum sodium levels measured regularly and monitored for development of hyponatremia, particularly when higher dosages of these medications are used. Signs and symptoms of hyponatremia include nausea, vomiting, headache, difficulty concentrating, memory impairment, confusion, malaise, lethargy, muscle weakness or spasms, and unsteadiness. In more severe and/or acute cases, hallucination, syncope, seizure, coma, respiratory arrest, and death may occur.", "mechanism_text": "Antagonism", "recommendation": "SSRIs and SNRIs should be avoided in patients with unstable epilepsy, and used cautiously in patients with epilepsy controlled with anticonvulsant medications.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67217/", "reference_text": "[1] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[2] Belcastro V, Costa C, Striano P \"Levetiracetam-associated hyponatremia.\" Seizure 17 (2008): 389-90[3] Gandhi S, McArthur E, Mamdani MM, et.al \"Antiepileptic drugs and hyponatremia in older adults: Two population-based cohort studies.\" Epilepsia 57 (2016): 2067-79[4] \"Product Information. Aptiom (eslicarbazepine).\" Sunovion Pharmaceuticals Inc, Marlborough, MA.[5] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[6] \"Product Information. Tegretol (carbamazepine).\" Novartis Pharmaceuticals, East Hanover, NJ.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[9] Falhammar H, Lindh JD, Calissendorff J, et.al \"Differences in associations of antiepileptic drugs and hospitalization due to hyponatremia: A population-based case-control study.\" Seizure 59 (2018): 28-33[10] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[11] Bavbek N, Alkan R, Uz E, Kaftan O, Akcay A \"Hyponatremia associated with sodium valproate in a 22-year-old male.\" Nephrol Dial Transplant 23 (2008): epub[12] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[13] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[14] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[15] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[16] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[17] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[18] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[19] Patel KR, Meesala A, Stanilla JK \"Sodium valproate-induced hyponatremia: a case report.\" Prim Care Companion J Clin Psychiatry 12 (2010): epub[20] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[21] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[22] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[23] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[24] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[25] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[26] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[27] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[28] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Oxitriptan, Viloxazine, Tryptophan", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67131, "ingredient1": "Citalopram", "ingredient2": "Ticagrelor", "severity": "Moderate", "effect": "Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.", "source": "DDInter", "management_text": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67218/", "reference_text": "[1] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG \"Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin.\" Acta Psychiatr Scand Suppl 350 (1989): 102-6[2] Skop BP, Brown TM \"Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors.\" Psychosomatics 37 (1996): 12-6[3] Settle EC \"Antidepressant drugs: disturbing and potentially dangerous adverse effects.\" J Clin Psychiatry 59 Suppl 16 (1998): 25-30[4] Layton D, Clark DWJ, Pearce GL, Shakir SAW \"Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England.\" Eur J Clin Pharmacol 57 (2001): 167-76[5] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[6] Leung M, Shore R \"Fluvoxamine-associated bleeding.\" Can J Psychiatry 41 (1996): 604-5[7] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[8] Tata LJ, Fortun PJ, Hubbard RB, et al. \"Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?\" Aliment Pharmacol Ther 22 (2005): 175-81[9] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[10] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B \"Paroxetine decreases platelet serotonin storage and platelet function in human beings.\" Clin Pharmacol Ther 68 (2000): 435-42[11] de Abajo FJ, Rodriguez LA, Montero D \"Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study.\" BMJ 319 (1999): 1106-9[12] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[13] Alderman CP, Moritz CK, Ben-Tovim DI \"Abnormal platelet aggregation associated with fluoxetine therapy.\" Ann Pharmacother 26 (1992): 1517-9[14] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[15] Krivy J, Wiener J \"Sertraline and platelet counts in idiopathic thrombocytopenia purpura.\" Lancet 345 (1995): 132[16] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[17] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[18] Pai VB, Kelly MW \"Bruising associated with the use of fluoxetine.\" Ann Pharmacother 30 (1996): 786-8[19] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990): 213-7[20] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ \"Fluoxetine and bleeding in obsessive-compulsive disorder.\" Am J Psychiatry 148 (1991): 949[21] Alderman CP, Seshadri P, Ben-Tovim DI \"Effects of serotonin reuptake inhibitors on hemostasis.\" Ann Pharmacother 30 (1996): 1232-4[22] Humphries JE, Wheby MS, VandenBerg SR \"Fluoxetine and the bleeding time.\" Arch Pathol Lab Med 114 (1990): 727-8[23] Woolfrey S, Gammack NS, Dewar MS, Brown PJ \"Fluoxetine-warfarin interaction.\" BMJ 307 (1993): 241[24] Messiha FS \"Fluoxetine - adverse effects and drug-drug interactions.\" J Toxicol Clin Toxicol 31 (1993): 603-30[25] Ford MA, Anderson ML, Rindone JP, Jaskar DW \"Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin.\" J Clin Psychopharmacol 17 (1997): 110-2[26] Ottervanger JP, Stricker BH, Huls J, Weeda JN \"Bleeding attributed to the intake of paroxetine.\" Am J Psychiatry 151 (1994): 781-2[27] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[28] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH \"Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study.\" Arch Intern Med 163 (2003): 59-64[29] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[30] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[31] Aranth J, Lindberg C \"Bleeding, a side effect of fluoxetine.\" Am J Psychiatry 149 (1992): 412[32] Cerner Multum, Inc. \"Australian Product Information.\" O 0[33] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S \"Intracranial haemorrhage and use of selective serotonin reuptake inhibitors.\" Br J Clin Pharmacol 50 (2000): 43-7[34] de Maistre E, Allart C, Lecompte T, Bollaert PE \"Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors.\" Am J Med 113 (2002): 530-2[35] Claire RJ, Servis ME, Cram DL Jr \"Potential interaction between warfarin sodium and fluoxetine.\" Am J Psychiatry 148 (1991): 1604[36] Dent LA, Orrock MW \"Warfarin-fluoxetine and diazepam-fluoxetine interaction.\" Pharmacotherapy 17 (1997): 170-2[37] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[38] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[39] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[40] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[41] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[42] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Maprotiline, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, Trimipramine, More", "alternatives_b": "Protein C, Selexipag", "updated_at": 1767369485}, {"id": 67132, "ingredient1": "Citalopram", "ingredient2": "Ticlopidine", "severity": "Major", "effect": "Coadministration with CYP450 2C19 inhibitors may increase the plasma concentrations of citalopram, which is partially metabolized by the isoenzyme. Cases of QT interval prolongation and torsade de pointes have been reported during postmarketing use. In general, the risk of ventricular arrhythmia in association with QT prolongation is largely unpredictable, but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances (e.g., hypokalemia, hypomagnesemia).", "source": "DDInter", "management_text": "Given the risk of dose-dependent QT prolongation, citalopram dosage should not exceed 20 mg/day when prescribed in combination with CYP450 2C19 inhibitors such as cimetidine, esomeprazole, etravirine, felbamate, fluconazole, lansoprazole, letrozole, modafinil, omeprazole, oxcarbazepine, ticlopidine, and voriconazole. Alternatives should be considered when possible, and hypokalemia or hypomagnesemia should be corrected prior to initiation of citalopram treatment and periodically monitored. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, irregular heartbeat, shortness of breath, or syncope.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of dose-dependent QT prolongation, citalopram dosage should not exceed 20 mg/day when prescribed in combination with CYP450 2C19 inhibitors such as cimetidine, esomeprazole, etravirine, felbamate, fluconazole, lansoprazole, letrozole, modafinil, omeprazole, oxcarbazepine, ticlopidine, and voriconazole.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67219/", "reference_text": "[1] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[2] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm.\" ([2011 Aug 24]):[3] Priskorn M, Larsen F, Segonzac A, Moulin M \"Pharmacokinetic interaction study of citalopram and cimetidine in healhy subjects.\" Eur J Clin Pharmacol 52 (1997): 241-2[4] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[6] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[7] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Protein C, Selexipag", "alternatives_b": "Phenelzine, Desipramine, Tranylcypromine, Trimipramine, Maprotiline, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Mirtazapine, Viloxazine, More", "updated_at": 1767369485}, {"id": 67133, "ingredient1": "Citalopram", "ingredient2": "Timolol", "severity": "Moderate", "effect": "Limited clinical data suggest that selective serotonin reuptake inhibitors (SSRIs) may potentiate the pharmacologic effects of some beta-blockers. The proposed mechanism is SSRI inhibition (competitive and/or noncompetitive) of CYP450 2D6, the isoenzyme responsible for the metabolic clearance of beta-blockers such as carvedilol, labetalol, metoprolol, nebivolol, propranolol, and timolol. Paroxetine and norfluoxetine (the active metabolite of fluoxetine), in particular, are potent inhibitors of CYP450 2D6 and may be more likely than other SSRIs to cause the interaction. On the other hand, fluvoxamine is a potent inhibitor of CYP450 1A2 and may significantly interact with propranolol, which is a substrate of both CYP450 2D6 and 1A2.", "source": "DDInter", "management_text": "During concomitant therapy with SSRIs, a lower initial dosage and more cautious titration of the beta-blocker may be appropriate. Cardiac function should be closely monitored and the beta-blocker dosage adjusted accordingly, particularly following initiation, discontinuation or change of dosage of SSRI in patients who are stabilized on their beta-blocker regimen. Due to the long half-life of fluoxetine and its active metabolite, norfluoxetine, the risk of an interaction may exist for an extended period (up to several weeks) after discontinuation of fluoxetine. To avoid the interaction, use of beta-blockers that are primarily eliminated by the kidney such as atenolol, acebutolol, betaxolol, carteolol, and nadolol may be considered.", "mechanism_text": "Metabolism", "recommendation": "During concomitant therapy with SSRIs, a lower initial dosage and more cautious titration of the beta-blocker may be appropriate.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67220/", "reference_text": "[1] Walley T, Pirmohamed M, Proudlove C, Maxwell D \"Interaction of metoprolol and fluoxetine.\" Lancet 341 (1993): 967-8[2] Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE \"The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes.\" Br J Clin Pharmacol 34 (1992): 262-5[3] Kashuba ADM, Nafziger AN, Kearns GL, Leeder JS, Gotschall R, Rocci ML, Kulawy RW, Beck DJ, Bertino JS \"Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping.\" Clin Pharmacol Ther 64 (1998): 257-68[4] Riesenman C \"Antidepressant drug interactions and the cytochrome p450 system: a critical appraisal.\" Pharmacotherapy 15 (1995): s84-99[5] Ereshefsky L \"Treating depression: potential drug-drug interactions: commentary.\" J Clin Psychopharmacol 16 (suppl (1996): s50-3[6] Hemeryck A, Lefebvre RA, DeVriendt C, Belpaire FM \"Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers.\" Clin Pharmacol Ther 67 (2000): 283-91[7] Perucca E, Gatti G, Spina E \"Clinical pharmacokinetics of fluvoxamine.\" Clin Pharmacokinet 27 (1994): 175-90[8] Amchin J, Ereshefsky L, Zarycranski W, Taylor K, Albano D, Klockowski PM \"Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe.\" J Clin Pharmacol 41 (2001): 443-51[9] Nemeroff CB, Devane CL, Pollock BG \"Newer antidepressants and the cytochrome p450 system.\" Am J Psychiatry 153 (1996): 311-20[10] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[11] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[12] Otton SV, Wu D, Joffe RT, Cheung SW, Sellers EM \"Inhibition by fluoxetine of cytochrome P450 2D6 activity.\" Clin Pharmacol Ther 53 (1993): 401-9[13] Brosen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S \"Fluvoxamine is a potent inhibitor of cytochrome P4501A2.\" Biochem Pharmacol 45 (1993): 1211-4[14] Drake WM, Gordon GD \"Heart block in a patient on propranolol and fluoxetine.\" Lancet 343 (1994): 425-6[15] Hemeryck A, DeVriendt CA, Belpaire FM \"Metoprolol-paroxetine interaction in human liver microsomes: Stereoselective aspects and prediction of the in vivo interaction.\" Drug Metab Disposition 29 (2001): 656-63[16] Richelson E \"Pharmacokinetic interactions of antidepressants.\" J Clin Psychiatry 59 (1998): 22-6[17] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[20] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Desipramine, Desvenlafaxine, St. John's Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone, Esketamine, Escitalopram", "alternatives_b": "Esmolol, Betaxolol, Carteolol, Penbutolol, Neostigmine, Acetylcholine, Physostigmine, Betaxolol, Carteolol, Apraclonidine, Guanethidine, Levobunolol", "updated_at": 1767369485}, {"id": 67134, "ingredient1": "Citalopram", "ingredient2": "Tinzaparin", "severity": "Moderate", "effect": "Serotonin reuptake inhibitors may potentiate the risk of bleeding in patients receiving heparin therapy. The exact mechanism is unknown but may involve a pharmacodynamic interaction, as serotonin reuptake inhibitors have been reported to interfere with platelet function.", "source": "DDInter", "management_text": "Caution is recommended if a serotonin reuptake inhibitor is administered with heparin therapy, especially in the elderly and patients with renal impairment. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if a serotonin reuptake inhibitor is administered with heparin therapy, especially in the elderly and patients with renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67221/", "reference_text": "[1] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[2] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[3] Pai VB, Kelly MW \"Bruising associated with the use of fluoxetine.\" Ann Pharmacother 30 (1996): 786-8[4] Skop BP, Brown TM \"Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors.\" Psychosomatics 37 (1996): 12-6[5] Alderman CP, Moritz CK, Ben-Tovim DI \"Abnormal platelet aggregation associated with fluoxetine therapy.\" Ann Pharmacother 26 (1992): 1517-9[6] Krivy J, Wiener J \"Sertraline and platelet counts in idiopathic thrombocytopenia purpura.\" Lancet 345 (1995): 132[7] Layton D, Clark DWJ, Pearce GL, Shakir SAW \"Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England.\" Eur J Clin Pharmacol 57 (2001): 167-76[8] Humphries JE, Wheby MS, VandenBerg SR \"Fluoxetine and the bleeding time.\" Arch Pathol Lab Med 114 (1990): 727-8[9] Ottervanger JP, Stricker BH, Huls J, Weeda JN \"Bleeding attributed to the intake of paroxetine.\" Am J Psychiatry 151 (1994): 781-2[10] Alderman CP, Seshadri P, Ben-Tovim DI \"Effects of serotonin reuptake inhibitors on hemostasis.\" Ann Pharmacother 30 (1996): 1232-4[11] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[12] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[13] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[14] Settle EC \"Antidepressant drugs: disturbing and potentially dangerous adverse effects.\" J Clin Psychiatry 59 Suppl 16 (1998): 25-30[15] Leung M, Shore R \"Fluvoxamine-associated bleeding.\" Can J Psychiatry 41 (1996): 604-5[16] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[17] Messiha FS \"Fluoxetine - adverse effects and drug-drug interactions.\" J Toxicol Clin Toxicol 31 (1993): 603-30[18] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[19] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B \"Paroxetine decreases platelet serotonin storage and platelet function in human beings.\" Clin Pharmacol Ther 68 (2000): 435-42[20] Aranth J, Lindberg C \"Bleeding, a side effect of fluoxetine.\" Am J Psychiatry 149 (1992): 412[21] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[22] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[23] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[24] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ \"Fluoxetine and bleeding in obsessive-compulsive disorder.\" Am J Psychiatry 148 (1991): 949[25] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[26] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[27] de Maistre E, Allart C, Lecompte T, Bollaert PE \"Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors.\" Am J Med 113 (2002): 530-2[28] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[29] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[30] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Maprotiline, St. John's Wort, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, More", "alternatives_b": "Protein C, Selexipag", "updated_at": 1767369485}, {"id": 67135, "ingredient1": "Citalopram", "ingredient2": "Tirofiban", "severity": "Moderate", "effect": "Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.", "source": "DDInter", "management_text": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67222/", "reference_text": "[1] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG \"Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin.\" Acta Psychiatr Scand Suppl 350 (1989): 102-6[2] Skop BP, Brown TM \"Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors.\" Psychosomatics 37 (1996): 12-6[3] Settle EC \"Antidepressant drugs: disturbing and potentially dangerous adverse effects.\" J Clin Psychiatry 59 Suppl 16 (1998): 25-30[4] Layton D, Clark DWJ, Pearce GL, Shakir SAW \"Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England.\" Eur J Clin Pharmacol 57 (2001): 167-76[5] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[6] Leung M, Shore R \"Fluvoxamine-associated bleeding.\" Can J Psychiatry 41 (1996): 604-5[7] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[8] Tata LJ, Fortun PJ, Hubbard RB, et al. \"Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?\" Aliment Pharmacol Ther 22 (2005): 175-81[9] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[10] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B \"Paroxetine decreases platelet serotonin storage and platelet function in human beings.\" Clin Pharmacol Ther 68 (2000): 435-42[11] de Abajo FJ, Rodriguez LA, Montero D \"Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study.\" BMJ 319 (1999): 1106-9[12] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[13] Alderman CP, Moritz CK, Ben-Tovim DI \"Abnormal platelet aggregation associated with fluoxetine therapy.\" Ann Pharmacother 26 (1992): 1517-9[14] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[15] Krivy J, Wiener J \"Sertraline and platelet counts in idiopathic thrombocytopenia purpura.\" Lancet 345 (1995): 132[16] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[17] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[18] Pai VB, Kelly MW \"Bruising associated with the use of fluoxetine.\" Ann Pharmacother 30 (1996): 786-8[19] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990): 213-7[20] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ \"Fluoxetine and bleeding in obsessive-compulsive disorder.\" Am J Psychiatry 148 (1991): 949[21] Alderman CP, Seshadri P, Ben-Tovim DI \"Effects of serotonin reuptake inhibitors on hemostasis.\" Ann Pharmacother 30 (1996): 1232-4[22] Humphries JE, Wheby MS, VandenBerg SR \"Fluoxetine and the bleeding time.\" Arch Pathol Lab Med 114 (1990): 727-8[23] Woolfrey S, Gammack NS, Dewar MS, Brown PJ \"Fluoxetine-warfarin interaction.\" BMJ 307 (1993): 241[24] Messiha FS \"Fluoxetine - adverse effects and drug-drug interactions.\" J Toxicol Clin Toxicol 31 (1993): 603-30[25] Ford MA, Anderson ML, Rindone JP, Jaskar DW \"Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin.\" J Clin Psychopharmacol 17 (1997): 110-2[26] Ottervanger JP, Stricker BH, Huls J, Weeda JN \"Bleeding attributed to the intake of paroxetine.\" Am J Psychiatry 151 (1994): 781-2[27] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[28] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH \"Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study.\" Arch Intern Med 163 (2003): 59-64[29] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[30] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[31] Aranth J, Lindberg C \"Bleeding, a side effect of fluoxetine.\" Am J Psychiatry 149 (1992): 412[32] Cerner Multum, Inc. \"Australian Product Information.\" O 0[33] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S \"Intracranial haemorrhage and use of selective serotonin reuptake inhibitors.\" Br J Clin Pharmacol 50 (2000): 43-7[34] de Maistre E, Allart C, Lecompte T, Bollaert PE \"Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors.\" Am J Med 113 (2002): 530-2[35] Claire RJ, Servis ME, Cram DL Jr \"Potential interaction between warfarin sodium and fluoxetine.\" Am J Psychiatry 148 (1991): 1604[36] Dent LA, Orrock MW \"Warfarin-fluoxetine and diazepam-fluoxetine interaction.\" Pharmacotherapy 17 (1997): 170-2[37] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[38] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[39] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[40] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[41] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[42] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Maprotiline, St. John's Wort, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, More", "alternatives_b": "Protein C, Selexipag", "updated_at": 1767369485}, {"id": 67136, "ingredient1": "Citalopram", "ingredient2": "Tizanidine", "severity": "Major", "effect": "Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.", "mechanism_text": "Synergism", "recommendation": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67223/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm.\" ([2011 Aug 24]):[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm.\" ([2012 Mar 28]):[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[9] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[12] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Kaletra (lopinavir-ritonavir)\" Abbott Pharmaceutical, Abbott Park, IL.[15] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Oxitriptan, Vortioxetine, Milnacipran, Levomilnacipran, Vilazodone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67137, "ingredient1": "Citalopram", "ingredient2": "Tolazamide", "severity": "Moderate", "effect": "The hypoglycemic effect of insulin secretagogues (e.g., sulfonylureas, meglitinides) may be potentiated by certain drugs, including ACE inhibitors, 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinine, quinidine, and ginseng. These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, fibrates, ginseng); stimulating insulin secretion (salicylates, NSAIDs, disopyramide, quinine, quinidine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs). Or, they may increase plasma concentration of insulin secretagogues by displacing them from plasma protein binding sites and/or inhibiting their metabolism (fibrates, NSAIDs, salicylates, sulfonamides).", "source": "DDInter", "management_text": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment. The oral antidiabetic dosage(s) may require adjustment if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their doctor if it occurs. Patients should be observed for loss of glycemic control when these drugs are withdrawn.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67224/", "reference_text": "[1] Christensen LK, Hansen JM, Kristensen M \"Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics.\" Lancet 2 (1963): 1298-301[2] Turtle JR, Burgess JA \"Hypoglycemic action of fenfluramine in diabetes mellitus.\" Diabetes 22 (1973): 858-67[3] Field JB, Ohta M, Boyle C, Remer A \"Potentiation of acetohexamide hypoglycemia by phenylbutazone.\" N Engl J Med 277 (1967): 889-94[4] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V \"Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia.\" Eur J Clin Nutr 57 (2003): 243-8[5] Deeg MA, Lipkin EW \"Hypoglycemia associated with the use of fluoxetine.\" West J Med 164 (1996): 262-3[6] Sjoberg S, Wiholm BE, Gunnarsson R, Emilsson H, Thunberg E, Christenson I, Ostman J \"Lack of pharmacokinetic interaction between glibenclamide and trimethoprim-sulphamethoxazole.\" Diabet Med 4 (1987): 245-7[7] World Health Organization \"WHO Public Assessment Reports (WHOPARs) Available from: URL: https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars.\" ([2020]):[8] Niemi M, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ, Kivisto KT \"Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride.\" Clin Pharmacol Ther 69 (2001): 194-200[9] Ravic M, Johnston A, Turner P \"Clinical pharmacological studies of some possible interactions of lornoxicam with other drugs.\" Postgrad Med J 66 (1990): s30-4[10] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J \"Captopril and insulin sensitivity.\" Ann Intern Med 102 (1985): 134-5[11] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[12] Tran PO, Gleason CE, Robertson RP \"Inhibition of interleukin-1beta-induced COX-2 and EP3 gene expression by sodium salicylate enhances pancreatic islet beta-cell function.\" Diabetes 51 (2002): 1772-8[13] Ahmad S \"Drug interaction induces hypoglycemia.\" J Fam Pract 40 (1995): 540-1[14] Baron SH \"Salicylates as hypoglycemic agents.\" Diabetes Care 5 (1982): 64-71[15] Slade IH, and Iosefa RN \"Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases.\" J Am Geriatr Soc 15 (1967): 948-50[16] \"Product Information. Increlex (mecasermin).\" Tercica Inc, Brisbane, CA.[17] Feher MD, Amiel S \"ACE inhibitors and hypoglycaemia.\" Lancet 346 (1995): 125-6[18] Vuksan V, Sievenpiper JL, Koo VY, et al \"American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus.\" Arch Intern Med 160 (2000): 1009-13[19] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K \"The effect of gemfibrozil on serum lipids in diabetic patients.\" Ann Clin Res 11 (1979): 240-5[20] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[21] Morrison PJ, Rogers HJ, Spector RG, Bradbrook ID, John VA \"Effect of pirprofen on glibenclamide kinetics and response.\" Br J Clin Pharmacol 14 (1982): 123-6[22] Wu B, Sato T, Kiyosue T, Arita M \"Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs.\" Cardiovasc Res 26 (1992): 1095-101[23] Barbato M \"Another problem with Kinidin.\" Med J Aust 141 (1984): 685[24] Phillips RE, Looareesuwan S, White NJ, et al \"Hypoglycaemia and antimalarial drugs: quinidine and release of insulin.\" Br Med J 292 (1986): 1319-21[25] Ahmad S \"Gemfibrozil: interaction with glyburide.\" South Med J 84 (1991): 102[26] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T \"Hypoglycemia induced by interaction between clarithromycin and disopyramide.\" Jpn Heart J 40 (1999): 91-6[27] Strathman I, Schubert EN, Cohen A, Nitzberg DM \"Hypoglycemia in patients receiving disopyramide phosphate.\" Drug Intell Clin Pharm 17 (1983): 635-8[28] Sawka AM, Burgart V, Zimmerman D \"Loss of awareness of hypoglycemia temporally associated with selective serotonin reuptake inhibitors.\" Diabetes Care 24 (2001): 1845-6[29] Wing LM, Miners JO \"Cotrimoxazole as an inhibitor of oxidative drug metabolism: effects of trimethoprim and sulphamethoxazole separately and combined on tolbutamide disposition.\" Br J Clin Pharmacol 20 (1985): 482-5[30] Tremaine LM, Wilner KD, Preskorn SH \"A study of the potential effect of sertraline on the pharmacokinetics and protein binding of tolbutamide.\" Clin Pharmacokinet 32(Suppl 1) (1997): 31-36[31] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[32] Tannenbaum H, Anderson LG, Soeldner JS \"Phenylbutazone-tolbutamide drug interaction.\" N Engl J Med 290 (1974): 344[33] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y \"Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus.\" Br J Clin Pharmacol 17 (1984): 89-91[34] Salmela PI, Sotaniemi EA, Viikari J, et al \"Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism.\" Diabetes Care 4 (1981): 535-40[35] David DS, Steere AC Jr, Pi-Sunyer XF, Sakai S, Clark SB \"Aspirin-induced hypoglycaemia in a patient on haemodialysis.\" Lancet 2 (1971): 1092-3[36] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD \"Fenfluramine increases insulin action in patients with NIDDM.\" Diabetes Care 12 (1989): 252-8[37] Morris AD, Newton RW, Boyle DI, et al. \"ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes.\" Diabetes Care 20 (1997): 1363-7[38] Kradjan WA, Witt DM, Opheim KE, Wood FC \"Lack of interaction between glipizide and co-trimoxazole.\" J Clin Pharmacol 34 (1994): 997-1002[39] Johnson J, Dobmeier M \"Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction.\" DICP 24 (1990): 250-1[40] Pollak PT, Mukherjee SD, Fraser AD \"Sertraline-induced hypoglycemia.\" Ann Pharmacother 35 (2001): 1371-4[41] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[42] Feldman JM, Chapman B \"Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion.\" Diabetologia 11 (1975): 487-94[43] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R \"Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas.\" Metabolism 38 (1989): 179-83[44] Daubresse JC, Luyckx AS, Lefebvre PJ \"Potentiation of hypoglycemic effect of sulfonylureas by clofibrate.\" N Engl J Med 294 (1976): 613[45] Cooper AJ, Ashcroft G \"Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs.\" Lancet 1 (1966): 407-9[46] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[47] Quevedo SF, Krauss DS, Chazan JA, et al \"Fasting hypoglycemia secondary to disopyramide therapy.\" JAMA 245 (1981): 2424[48] Lozada A, Dujovne CA \"Drug interactions with fibric acids.\" Pharmacol Ther 63 (1994): 163-76[49] Shah SJ, Bhandarkar SD, Satoskar RS \"Drug interaction between chlorpropamide and non-steroidal anti-flammatory drugs, ibuprofen and phenylbutazone.\" Int J Clin Pharmacol Ther Toxicol 22 (1984): 470-2[50] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[51] Nikkila EA, Ylikahri R, Huttunen JK \"Gemfibrozil: effect on serum lipids, lipoproteins, postheparin plasma lipase activities and glucose tolerance in primary hypertriglyceridaemia.\" Proc R Soc Med 69 (1976): 58-63[52] Davis TM, Karbwang J, Looareesuwan S, et al \"Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers.\" Br J Clin Pharmacol 30 (1990): 397-403[53] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M \"Lisinopril administration improves insulin action in aged patients with hypertension.\" J Hum Hypertens 9 (1995): 541-6[54] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[55] Hundal RS, Petersen KF, Mayerson AB, et al \"Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes.\" J Clin Invest 109 (2002): 1321-6[56] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[57] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P \"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.\" Am J Med 89 (1990): 811-3[58] de Salcedo I, Gorringe AL, Silva JL, Santos JA \"Gemfibrozil in a group of diabetics.\" Proc R Soc Med 69 (1976): 64-70[59] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[60] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P \"Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension.\" Br J Clin Pharmacol 46 (1998): 467-71[61] Prince RL, Larkins RG, Alford FP \"The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects.\" Metabolism 30 (1981): 293-8[62] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C \"Severe hypoglycemia associated with disopyramide.\" West J Med 138 (1983): 95-7[63] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[64] Ferrari C, Fressati S, Romussi M, et al. \"Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia.\" Metabolism 26 (1977): 129-39[65] Asplund K, Wiholm BE, Lithner F \"Glibenclamide-associated hypoglycaemia: a report on 57 cases.\" Diabetologia 24 (1983): 412-7[66] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A \"Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme.\" Lancet 345 (1995): 1195-8[67] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K \"Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection.\" Eur J Endocrinol 136 (1997): 3046[68] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ \"Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents.\" Br J Clin Pharmacol 7 (1979): 599-603[69] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL \"Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect.\" Int J Obes 7 (1983): 289-97[70] Whitcroft IA, Thomas JM, Rawsthorne A, et al \"Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics.\" Horm Metab Res Suppl 22 (1990): 42-6[71] Rubin M, Zakheim B, Pitchumoni C \"Disopyramide-induced profound hypoglycemia.\" N Y State J Med July,Aug,S (1983): 1057-8[72] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S \"Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release.\" Am J Physiol 265 (1993): c337-42[73] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW \"Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats.\" Diabetes 38 (1989): 499-503[74] \"Product Information. Micronase (glyburide).\" Pharmacia and Upjohn, Kalamazoo, MI.[75] Harrison LC, King-Roach A, Martin FI, Melick RA \"The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue.\" Postgrad Med J 51 Suppl 1 (1975): 110-4[76] Petitpierre B, Perrin L, Rudhardt M, et al \"Behaviour of chlorpropamide in renal insufficiency and under the effect of associated drug therapy.\" Int J Clin Pharmacol 6 (1972): 120-4[77] Pond SM, Birkett DJ, Wade DN \"Mechanisms of inhibition of tolbutamide metabolism: phenylbutazone, oxyphenbutazone, sulfaphenazole.\" Clin Pharmacol Ther 22 (1977): 573-9[78] Sone H, Takahashi A, Yamada N \"Ibuprofen-related hypoglycemia in a patient receiving sulfonylurea.\" Ann Intern Med 134 (2001): 344[79] Giugliano D, Ceriello A, Saccomanno F, et al \"Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus.\" J Clin Endocrinol Metab 61 (1985): 160-6[80] Goldberg IJ, Brown LK, Rayfield EJ \"Disopyramide (norpace)-induced hypoglycemia.\" Am J Med 69 (1980): 463-6[81] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C \"Disopyramide-induced hypoglycemia: case report and review of the literature.\" Fundam Clin Pharmacol 3 (1989): 527-35[82] Aleyassine H, Gardiner RJ \"Dual action of antidepressant drugs (MAO inhibitors) on insulin release.\" Endocrinology 96 (1975): 702-10[83] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL \"Disopyramide-induced hypoglycaemia and increased serum insulin.\" N Z Med J July (1987): 407-8[84] Baciewicz AM, Swafford WB Jr \"Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole.\" Drug Intell Clin Pharm 18 (1984): 309-10[85] Kubacka RT, Antla EJ, Juhl RP, Welshman IR \"Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects.\" Ann Pharmacother 30 (1996): 20-6[86] Johnson JA, Kappel JE, Sharif MN \"Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient.\" Ann Pharmacother 27 (1993): 304-6[87] Aleyassine H, Lee SH \"Inhibition of insulin release by substrates and inhibitors of monoamine oxidase.\" Am J Physiol 222 (1972): 565-9[88] Cattaneo AG, Caviezel F, Pozza G \"Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man.\" Int J Clin Pharmacol Ther Toxicol 28 (1990): 229-34[89] Almirall J, Montoliu J, Torras A, Revert L \"Propoxyphene-induced hypoglycemia in a patient with chronic renal failure.\" Nephron 53 (1989): 273-5[90] Phillips AF, Matty PJ, Porte PJ, Raye JR \"Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb.\" Am J Obstet Gynecol 148 (1984): 481-7[91] Vuksan V, Stavro MP, Sievenpiper JL, et al \"Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes.\" Diabetes Care 23 (2000): 1221-6[92] Richardson T, Foster J, Mawer GE \"Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects.\" Br J Clin Pharmacol 22 (1986): 43-8[93] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P \"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.\" Am J Med 89 (1990): 811-3[94] Lumholtz B, Siersbaek-Nielsen K, Skovsted L, Kampmann J, Hansen JM \"Sulfamethizole-induced inhibition of diphenylhydantoin, tolbutamide, and warfarin metabolism.\" Clin Pharmacol Ther 17 (1975): 731-4[95] Diwan PV, Sastry MS, Satyanarayana NV \"Potentiation of hypoglycemic response of glibenclamide by piroxicam in rats and humans.\" Indian J Exp Biol 30 (1992): 317-9[96] Semel JD, Wortham E, Karl DM \"Fasting hypoglycemia associated with disopyramide.\" Am Heart J 106 (1983): 1160-1[97] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D \"Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia.\" Br J Clin Pharmacol 52 (2001): 456-7[98] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[99] Wiederholt IC, Genco M, Foley JM \"Recurrent episodes of hypoglycemia induced by propoxyphene.\" Neurology 17 (1967): 703-6[100] Hellman B \"Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells.\" Metabolism 23 (1974): 839-46[101] Harris EL \"Adverse reactions to oral antidiabetic agents.\" Br Med J 3 (1971): 29-30[102] Hartmann D, Korn A, Komjati M, Heinz G, Haefelfinger P, Defoin R, Waldhausl WK \"Lack of effect of tenoxicam on dynamic responses to concurrent oral doses of glucose and glibenclamide.\" Br J Clin Pharmacol 30 (1990): 245-52[103] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[104] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[105] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[106] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[107] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[108] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[109] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[110] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[111] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[112] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Duloxetine, Desvenlafaxine, Maprotiline, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Milnacipran, Trazodone, Tryptophan, More", "alternatives_b": "Lixisenatide, Albiglutide, Guar gum, Canagliflozin, Pramlintide, Sitagliptin, Alogliptin, Liraglutide, Troglitazone, Ertugliflozin, Semaglutide, More", "updated_at": 1767369485}, {"id": 67138, "ingredient1": "Citalopram", "ingredient2": "Tolbutamide", "severity": "Moderate", "effect": "The hypoglycemic effect of insulin secretagogues (e.g., sulfonylureas, meglitinides) may be potentiated by certain drugs, including ACE inhibitors, 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinine, quinidine, and ginseng. These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, fibrates, ginseng); stimulating insulin secretion (salicylates, NSAIDs, disopyramide, quinine, quinidine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs). Or, they may increase plasma concentration of insulin secretagogues by displacing them from plasma protein binding sites and/or inhibiting their metabolism (fibrates, NSAIDs, salicylates, sulfonamides).", "source": "DDInter", "management_text": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment. The oral antidiabetic dosage(s) may require adjustment if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their doctor if it occurs. Patients should be observed for loss of glycemic control when these drugs are withdrawn.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67225/", "reference_text": "[1] Christensen LK, Hansen JM, Kristensen M \"Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics.\" Lancet 2 (1963): 1298-301[2] Turtle JR, Burgess JA \"Hypoglycemic action of fenfluramine in diabetes mellitus.\" Diabetes 22 (1973): 858-67[3] Field JB, Ohta M, Boyle C, Remer A \"Potentiation of acetohexamide hypoglycemia by phenylbutazone.\" N Engl J Med 277 (1967): 889-94[4] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V \"Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia.\" Eur J Clin Nutr 57 (2003): 243-8[5] Deeg MA, Lipkin EW \"Hypoglycemia associated with the use of fluoxetine.\" West J Med 164 (1996): 262-3[6] Sjoberg S, Wiholm BE, Gunnarsson R, Emilsson H, Thunberg E, Christenson I, Ostman J \"Lack of pharmacokinetic interaction between glibenclamide and trimethoprim-sulphamethoxazole.\" Diabet Med 4 (1987): 245-7[7] World Health Organization \"WHO Public Assessment Reports (WHOPARs) Available from: URL: https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars.\" ([2020]):[8] Niemi M, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ, Kivisto KT \"Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride.\" Clin Pharmacol Ther 69 (2001): 194-200[9] Ravic M, Johnston A, Turner P \"Clinical pharmacological studies of some possible interactions of lornoxicam with other drugs.\" Postgrad Med J 66 (1990): s30-4[10] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J \"Captopril and insulin sensitivity.\" Ann Intern Med 102 (1985): 134-5[11] \"Product Information. Orinase (tolbutamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[12] Tran PO, Gleason CE, Robertson RP \"Inhibition of interleukin-1beta-induced COX-2 and EP3 gene expression by sodium salicylate enhances pancreatic islet beta-cell function.\" Diabetes 51 (2002): 1772-8[13] Ahmad S \"Drug interaction induces hypoglycemia.\" J Fam Pract 40 (1995): 540-1[14] Baron SH \"Salicylates as hypoglycemic agents.\" Diabetes Care 5 (1982): 64-71[15] Slade IH, and Iosefa RN \"Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases.\" J Am Geriatr Soc 15 (1967): 948-50[16] \"Product Information. Increlex (mecasermin).\" Tercica Inc, Brisbane, CA.[17] Feher MD, Amiel S \"ACE inhibitors and hypoglycaemia.\" Lancet 346 (1995): 125-6[18] Vuksan V, Sievenpiper JL, Koo VY, et al \"American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus.\" Arch Intern Med 160 (2000): 1009-13[19] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K \"The effect of gemfibrozil on serum lipids in diabetic patients.\" Ann Clin Res 11 (1979): 240-5[20] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[21] Morrison PJ, Rogers HJ, Spector RG, Bradbrook ID, John VA \"Effect of pirprofen on glibenclamide kinetics and response.\" Br J Clin Pharmacol 14 (1982): 123-6[22] Wu B, Sato T, Kiyosue T, Arita M \"Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs.\" Cardiovasc Res 26 (1992): 1095-101[23] Barbato M \"Another problem with Kinidin.\" Med J Aust 141 (1984): 685[24] Phillips RE, Looareesuwan S, White NJ, et al \"Hypoglycaemia and antimalarial drugs: quinidine and release of insulin.\" Br Med J 292 (1986): 1319-21[25] Ahmad S \"Gemfibrozil: interaction with glyburide.\" South Med J 84 (1991): 102[26] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T \"Hypoglycemia induced by interaction between clarithromycin and disopyramide.\" Jpn Heart J 40 (1999): 91-6[27] Strathman I, Schubert EN, Cohen A, Nitzberg DM \"Hypoglycemia in patients receiving disopyramide phosphate.\" Drug Intell Clin Pharm 17 (1983): 635-8[28] Sawka AM, Burgart V, Zimmerman D \"Loss of awareness of hypoglycemia temporally associated with selective serotonin reuptake inhibitors.\" Diabetes Care 24 (2001): 1845-6[29] Wing LM, Miners JO \"Cotrimoxazole as an inhibitor of oxidative drug metabolism: effects of trimethoprim and sulphamethoxazole separately and combined on tolbutamide disposition.\" Br J Clin Pharmacol 20 (1985): 482-5[30] Tremaine LM, Wilner KD, Preskorn SH \"A study of the potential effect of sertraline on the pharmacokinetics and protein binding of tolbutamide.\" Clin Pharmacokinet 32(Suppl 1) (1997): 31-36[31] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[32] Tannenbaum H, Anderson LG, Soeldner JS \"Phenylbutazone-tolbutamide drug interaction.\" N Engl J Med 290 (1974): 344[33] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y \"Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus.\" Br J Clin Pharmacol 17 (1984): 89-91[34] Salmela PI, Sotaniemi EA, Viikari J, et al \"Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism.\" Diabetes Care 4 (1981): 535-40[35] David DS, Steere AC Jr, Pi-Sunyer XF, Sakai S, Clark SB \"Aspirin-induced hypoglycaemia in a patient on haemodialysis.\" Lancet 2 (1971): 1092-3[36] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD \"Fenfluramine increases insulin action in patients with NIDDM.\" Diabetes Care 12 (1989): 252-8[37] Morris AD, Newton RW, Boyle DI, et al. \"ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes.\" Diabetes Care 20 (1997): 1363-7[38] Kradjan WA, Witt DM, Opheim KE, Wood FC \"Lack of interaction between glipizide and co-trimoxazole.\" J Clin Pharmacol 34 (1994): 997-1002[39] Johnson J, Dobmeier M \"Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction.\" DICP 24 (1990): 250-1[40] Pollak PT, Mukherjee SD, Fraser AD \"Sertraline-induced hypoglycemia.\" Ann Pharmacother 35 (2001): 1371-4[41] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[42] Feldman JM, Chapman B \"Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion.\" Diabetologia 11 (1975): 487-94[43] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R \"Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas.\" Metabolism 38 (1989): 179-83[44] Daubresse JC, Luyckx AS, Lefebvre PJ \"Potentiation of hypoglycemic effect of sulfonylureas by clofibrate.\" N Engl J Med 294 (1976): 613[45] Cooper AJ, Ashcroft G \"Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs.\" Lancet 1 (1966): 407-9[46] \"Product Information. Starlix (nateglinide)\" Novartis Pharmaceuticals, East Hanover, NJ.[47] Quevedo SF, Krauss DS, Chazan JA, et al \"Fasting hypoglycemia secondary to disopyramide therapy.\" JAMA 245 (1981): 2424[48] Lozada A, Dujovne CA \"Drug interactions with fibric acids.\" Pharmacol Ther 63 (1994): 163-76[49] Shah SJ, Bhandarkar SD, Satoskar RS \"Drug interaction between chlorpropamide and non-steroidal anti-flammatory drugs, ibuprofen and phenylbutazone.\" Int J Clin Pharmacol Ther Toxicol 22 (1984): 470-2[50] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals, Bridgewater, NJ.[51] Nikkila EA, Ylikahri R, Huttunen JK \"Gemfibrozil: effect on serum lipids, lipoproteins, postheparin plasma lipase activities and glucose tolerance in primary hypertriglyceridaemia.\" Proc R Soc Med 69 (1976): 58-63[52] Davis TM, Karbwang J, Looareesuwan S, et al \"Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers.\" Br J Clin Pharmacol 30 (1990): 397-403[53] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M \"Lisinopril administration improves insulin action in aged patients with hypertension.\" J Hum Hypertens 9 (1995): 541-6[54] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[55] Hundal RS, Petersen KF, Mayerson AB, et al \"Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes.\" J Clin Invest 109 (2002): 1321-6[56] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[57] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P \"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.\" Am J Med 89 (1990): 811-3[58] de Salcedo I, Gorringe AL, Silva JL, Santos JA \"Gemfibrozil in a group of diabetics.\" Proc R Soc Med 69 (1976): 64-70[59] \"Product Information. Dymelor (acetohexamide)\" Lilly, Eli and Company, Indianapolis, IN.[60] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P \"Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension.\" Br J Clin Pharmacol 46 (1998): 467-71[61] Prince RL, Larkins RG, Alford FP \"The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects.\" Metabolism 30 (1981): 293-8[62] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C \"Severe hypoglycemia associated with disopyramide.\" West J Med 138 (1983): 95-7[63] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[64] Ferrari C, Fressati S, Romussi M, et al. \"Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia.\" Metabolism 26 (1977): 129-39[65] Asplund K, Wiholm BE, Lithner F \"Glibenclamide-associated hypoglycaemia: a report on 57 cases.\" Diabetologia 24 (1983): 412-7[66] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A \"Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme.\" Lancet 345 (1995): 1195-8[67] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K \"Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection.\" Eur J Endocrinol 136 (1997): 3046[68] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ \"Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents.\" Br J Clin Pharmacol 7 (1979): 599-603[69] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL \"Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect.\" Int J Obes 7 (1983): 289-97[70] Whitcroft IA, Thomas JM, Rawsthorne A, et al \"Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics.\" Horm Metab Res Suppl 22 (1990): 42-6[71] Rubin M, Zakheim B, Pitchumoni C \"Disopyramide-induced profound hypoglycemia.\" N Y State J Med July,Aug,S (1983): 1057-8[72] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S \"Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release.\" Am J Physiol 265 (1993): c337-42[73] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW \"Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats.\" Diabetes 38 (1989): 499-503[74] \"Product Information. Micronase (glyburide).\" Pharmacia and Upjohn, Kalamazoo, MI.[75] Harrison LC, King-Roach A, Martin FI, Melick RA \"The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue.\" Postgrad Med J 51 Suppl 1 (1975): 110-4[76] Petitpierre B, Perrin L, Rudhardt M, et al \"Behaviour of chlorpropamide in renal insufficiency and under the effect of associated drug therapy.\" Int J Clin Pharmacol 6 (1972): 120-4[77] Pond SM, Birkett DJ, Wade DN \"Mechanisms of inhibition of tolbutamide metabolism: phenylbutazone, oxyphenbutazone, sulfaphenazole.\" Clin Pharmacol Ther 22 (1977): 573-9[78] Sone H, Takahashi A, Yamada N \"Ibuprofen-related hypoglycemia in a patient receiving sulfonylurea.\" Ann Intern Med 134 (2001): 344[79] Giugliano D, Ceriello A, Saccomanno F, et al \"Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus.\" J Clin Endocrinol Metab 61 (1985): 160-6[80] Goldberg IJ, Brown LK, Rayfield EJ \"Disopyramide (norpace)-induced hypoglycemia.\" Am J Med 69 (1980): 463-6[81] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C \"Disopyramide-induced hypoglycemia: case report and review of the literature.\" Fundam Clin Pharmacol 3 (1989): 527-35[82] Aleyassine H, Gardiner RJ \"Dual action of antidepressant drugs (MAO inhibitors) on insulin release.\" Endocrinology 96 (1975): 702-10[83] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL \"Disopyramide-induced hypoglycaemia and increased serum insulin.\" N Z Med J July (1987): 407-8[84] Baciewicz AM, Swafford WB Jr \"Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole.\" Drug Intell Clin Pharm 18 (1984): 309-10[85] Kubacka RT, Antla EJ, Juhl RP, Welshman IR \"Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects.\" Ann Pharmacother 30 (1996): 20-6[86] Johnson JA, Kappel JE, Sharif MN \"Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient.\" Ann Pharmacother 27 (1993): 304-6[87] Aleyassine H, Lee SH \"Inhibition of insulin release by substrates and inhibitors of monoamine oxidase.\" Am J Physiol 222 (1972): 565-9[88] Cattaneo AG, Caviezel F, Pozza G \"Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man.\" Int J Clin Pharmacol Ther Toxicol 28 (1990): 229-34[89] Almirall J, Montoliu J, Torras A, Revert L \"Propoxyphene-induced hypoglycemia in a patient with chronic renal failure.\" Nephron 53 (1989): 273-5[90] Phillips AF, Matty PJ, Porte PJ, Raye JR \"Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb.\" Am J Obstet Gynecol 148 (1984): 481-7[91] Vuksan V, Stavro MP, Sievenpiper JL, et al \"Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes.\" Diabetes Care 23 (2000): 1221-6[92] Richardson T, Foster J, Mawer GE \"Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects.\" Br J Clin Pharmacol 22 (1986): 43-8[93] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P \"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.\" Am J Med 89 (1990): 811-3[94] Lumholtz B, Siersbaek-Nielsen K, Skovsted L, Kampmann J, Hansen JM \"Sulfamethizole-induced inhibition of diphenylhydantoin, tolbutamide, and warfarin metabolism.\" Clin Pharmacol Ther 17 (1975): 731-4[95] Diwan PV, Sastry MS, Satyanarayana NV \"Potentiation of hypoglycemic response of glibenclamide by piroxicam in rats and humans.\" Indian J Exp Biol 30 (1992): 317-9[96] Semel JD, Wortham E, Karl DM \"Fasting hypoglycemia associated with disopyramide.\" Am Heart J 106 (1983): 1160-1[97] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D \"Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia.\" Br J Clin Pharmacol 52 (2001): 456-7[98] \"Product Information. Tolinase (tolazamide)\" Pharmacia and Upjohn, Kalamazoo, MI.[99] Wiederholt IC, Genco M, Foley JM \"Recurrent episodes of hypoglycemia induced by propoxyphene.\" Neurology 17 (1967): 703-6[100] Hellman B \"Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells.\" Metabolism 23 (1974): 839-46[101] Harris EL \"Adverse reactions to oral antidiabetic agents.\" Br Med J 3 (1971): 29-30[102] Hartmann D, Korn A, Komjati M, Heinz G, Haefelfinger P, Defoin R, Waldhausl WK \"Lack of effect of tenoxicam on dynamic responses to concurrent oral doses of glucose and glibenclamide.\" Br J Clin Pharmacol 30 (1990): 245-52[103] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[104] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[105] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[106] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[107] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[108] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[109] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[110] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[111] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[112] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Duloxetine, Desvenlafaxine, Maprotiline, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Milnacipran, Trazodone, Tryptophan, More", "alternatives_b": "Methacholine, Hexaminolevulinate, Secretin human, Sermorelin, Sorbitol, Magnesium sulfate, Vitamin A, Metyrapone, Edrophonium, Histamine, Corticorelin, More", "updated_at": 1767369485}, {"id": 67139, "ingredient1": "Citalopram", "ingredient2": "Tolcapone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67226/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Vilazodone, St. John's Wort, Nefazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67140, "ingredient1": "Citalopram", "ingredient2": "Tolmetin", "severity": "Moderate", "effect": "Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.", "source": "DDInter", "management_text": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67227/", "reference_text": "[1] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG \"Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin.\" Acta Psychiatr Scand Suppl 350 (1989): 102-6[2] Skop BP, Brown TM \"Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors.\" Psychosomatics 37 (1996): 12-6[3] Settle EC \"Antidepressant drugs: disturbing and potentially dangerous adverse effects.\" J Clin Psychiatry 59 Suppl 16 (1998): 25-30[4] Layton D, Clark DWJ, Pearce GL, Shakir SAW \"Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England.\" Eur J Clin Pharmacol 57 (2001): 167-76[5] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[6] Leung M, Shore R \"Fluvoxamine-associated bleeding.\" Can J Psychiatry 41 (1996): 604-5[7] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[8] Tata LJ, Fortun PJ, Hubbard RB, et al. \"Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?\" Aliment Pharmacol Ther 22 (2005): 175-81[9] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[10] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B \"Paroxetine decreases platelet serotonin storage and platelet function in human beings.\" Clin Pharmacol Ther 68 (2000): 435-42[11] de Abajo FJ, Rodriguez LA, Montero D \"Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study.\" BMJ 319 (1999): 1106-9[12] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[13] Alderman CP, Moritz CK, Ben-Tovim DI \"Abnormal platelet aggregation associated with fluoxetine therapy.\" Ann Pharmacother 26 (1992): 1517-9[14] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[15] Krivy J, Wiener J \"Sertraline and platelet counts in idiopathic thrombocytopenia purpura.\" Lancet 345 (1995): 132[16] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[17] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[18] Pai VB, Kelly MW \"Bruising associated with the use of fluoxetine.\" Ann Pharmacother 30 (1996): 786-8[19] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990): 213-7[20] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ \"Fluoxetine and bleeding in obsessive-compulsive disorder.\" Am J Psychiatry 148 (1991): 949[21] Alderman CP, Seshadri P, Ben-Tovim DI \"Effects of serotonin reuptake inhibitors on hemostasis.\" Ann Pharmacother 30 (1996): 1232-4[22] Humphries JE, Wheby MS, VandenBerg SR \"Fluoxetine and the bleeding time.\" Arch Pathol Lab Med 114 (1990): 727-8[23] Woolfrey S, Gammack NS, Dewar MS, Brown PJ \"Fluoxetine-warfarin interaction.\" BMJ 307 (1993): 241[24] Messiha FS \"Fluoxetine - adverse effects and drug-drug interactions.\" J Toxicol Clin Toxicol 31 (1993): 603-30[25] Ford MA, Anderson ML, Rindone JP, Jaskar DW \"Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin.\" J Clin Psychopharmacol 17 (1997): 110-2[26] Ottervanger JP, Stricker BH, Huls J, Weeda JN \"Bleeding attributed to the intake of paroxetine.\" Am J Psychiatry 151 (1994): 781-2[27] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[28] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH \"Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study.\" Arch Intern Med 163 (2003): 59-64[29] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[30] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[31] Aranth J, Lindberg C \"Bleeding, a side effect of fluoxetine.\" Am J Psychiatry 149 (1992): 412[32] Cerner Multum, Inc. \"Australian Product Information.\" O 0[33] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S \"Intracranial haemorrhage and use of selective serotonin reuptake inhibitors.\" Br J Clin Pharmacol 50 (2000): 43-7[34] de Maistre E, Allart C, Lecompte T, Bollaert PE \"Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors.\" Am J Med 113 (2002): 530-2[35] Claire RJ, Servis ME, Cram DL Jr \"Potential interaction between warfarin sodium and fluoxetine.\" Am J Psychiatry 148 (1991): 1604[36] Dent LA, Orrock MW \"Warfarin-fluoxetine and diazepam-fluoxetine interaction.\" Pharmacotherapy 17 (1997): 170-2[37] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[38] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[39] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[40] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[41] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[42] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Maprotiline, St. John's Wort, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, More", "alternatives_b": "Chondroitin sulfate, Glucosamine, Tolazoline, Dimethyl sulfoxide", "updated_at": 1767369485}, {"id": 67141, "ingredient1": "Citalopram", "ingredient2": "Tolterodine", "severity": "Minor", "effect": "Coadministration with drugs that are inhibitors of CYP450 2D6 may increase the plasma concentrations of tolterodine, which is primarily metabolized by this isoenzyme in patients that are extensive metabolizers, or EMs (approximately 93% of Caucasians and more than 98% of Asians and individuals of African descent). Moreover, since the active 5-hydroxymethyl metabolite (5-HM) generated by CYP450 2D6 is equipotent compared with tolterodine, and the sum of unbound serum concentrations of tolterodine and 5-HM are only 25% higher during the interaction, little alteration in the overall pharmacologic activity would be expected. Thus, dosage reductions should not be necessary.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67228/", "reference_text": "[1] Brynne N, Svanstrom C, AbergWistedt A, Hallen B, Bertilsson L \"Fluoxetine inhibits the metabolism of tolterodin-pharmacokinetic implications and proposed clinical relevance.\" Br J Clin Pharmacol 48 (1999): 553-63[2] \"Product Information. Detrol (tolterodine).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "St. John's Wort, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Vilazodone, Esketamine", "alternatives_b": "Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Trospium, Mirabegron, Yohimbine, Avanafil, Ammonium chloride, Dimethyl sulfoxide", "updated_at": 1767369485}, {"id": 67142, "ingredient1": "Citalopram", "ingredient2": "Topiramate", "severity": "Moderate", "effect": "The efficacy of anticonvulsants may be diminished during coadministration with selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitor (SNRIs). Antidepressants including SSRIs and SNRIs can reduce seizure threshold.Coadministration of SSRIs or SNRIs with some anticonvulsants, particularly carbamazepine, eslicarbazepine, oxcarbazepine and valproic acid, may increase the risk of hyponatremia. The risk appears to be dose-related, and elderly patients and patients who are volume depleted (e.g., diuretic use) may be at greater risk.", "source": "DDInter", "management_text": "SSRIs and SNRIs should be avoided in patients with unstable epilepsy, and used cautiously in patients with epilepsy controlled with anticonvulsant medications. Treatment with SSRIs and SNRIs should be discontinued if seizures develop or seizure frequency increases. Patients receiving SSRIs or SNRIs with anticonvulsants, particularly carbamazepine, eslicarbazepine, oxcarbazepine and/or valproic acid, should also have serum sodium levels measured regularly and monitored for development of hyponatremia, particularly when higher dosages of these medications are used. Signs and symptoms of hyponatremia include nausea, vomiting, headache, difficulty concentrating, memory impairment, confusion, malaise, lethargy, muscle weakness or spasms, and unsteadiness. In more severe and/or acute cases, hallucination, syncope, seizure, coma, respiratory arrest, and death may occur.", "mechanism_text": "Antagonism", "recommendation": "SSRIs and SNRIs should be avoided in patients with unstable epilepsy, and used cautiously in patients with epilepsy controlled with anticonvulsant medications.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67229/", "reference_text": "[1] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[2] Belcastro V, Costa C, Striano P \"Levetiracetam-associated hyponatremia.\" Seizure 17 (2008): 389-90[3] Gandhi S, McArthur E, Mamdani MM, et.al \"Antiepileptic drugs and hyponatremia in older adults: Two population-based cohort studies.\" Epilepsia 57 (2016): 2067-79[4] \"Product Information. Aptiom (eslicarbazepine).\" Sunovion Pharmaceuticals Inc, Marlborough, MA.[5] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[6] \"Product Information. Tegretol (carbamazepine).\" Novartis Pharmaceuticals, East Hanover, NJ.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[9] Falhammar H, Lindh JD, Calissendorff J, et.al \"Differences in associations of antiepileptic drugs and hospitalization due to hyponatremia: A population-based case-control study.\" Seizure 59 (2018): 28-33[10] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[11] Bavbek N, Alkan R, Uz E, Kaftan O, Akcay A \"Hyponatremia associated with sodium valproate in a 22-year-old male.\" Nephrol Dial Transplant 23 (2008): epub[12] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[13] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[14] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[15] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[16] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[17] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[18] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[19] Patel KR, Meesala A, Stanilla JK \"Sodium valproate-induced hyponatremia: a case report.\" Prim Care Companion J Clin Psychiatry 12 (2010): epub[20] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[21] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[22] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[23] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[24] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[25] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[26] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[27] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[28] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Oxitriptan, Viloxazine, St. John's Wort, Tryptophan", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67143, "ingredient1": "Citalopram", "ingredient2": "Toremifene", "severity": "Major", "effect": "Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.", "mechanism_text": "Synergism", "recommendation": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67230/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm.\" ([2011 Aug 24]):[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm.\" ([2012 Mar 28]):[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[9] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[12] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Kaletra (lopinavir-ritonavir)\" Abbott Pharmaceutical, Abbott Park, IL.[15] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Phenelzine, Duloxetine, Tranylcypromine, Vilazodone, Desvenlafaxine, Isocarboxazid, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, More", "alternatives_b": "Darolutamide, Aminoglutethimide", "updated_at": 1767369485}, {"id": 67144, "ingredient1": "Citalopram", "ingredient2": "Torasemide", "severity": "Moderate", "effect": "Coadministration with diuretics may potentiate the risk of hyponatremia associated with the use of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). Elderly patients and patients taking diuretics or who are otherwise volume-depleted may be at greater risk of developing hyponatremia with SSRIs and SNRIs. Antihypertensive agents such as diuretics may potentiate the orthostatic effect that is occasionally observed upon the initiation of SSRI or SNRI therapy. Syncope and orthostatic hypotension tend to occur within the first week of SNRI/SSRI therapy but can occur at any time during treatment, particularly after a dosage increase. The use of SSRIs or SNRIs may also cause sustained increases in blood pressure and heart rate, which may antagonize the therapeutic effects of antihypertensive medications.", "source": "DDInter", "management_text": "Caution is recommended if SSRIs or SNRIs are prescribed in combination with diuretics, particularly in the elderly. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hyponatremia such as nausea, vomiting, headache, malaise, lethargy, irritability, difficulty concentrating, memory impairment, confusion, weakness, muscle spasm, and unsteadiness (which may lead to falls). More severe and/or acute cases may include hallucination, syncope, seizure, coma, respiratory arrest, and death. Discontinuation of SSRI/SNRI therapy should be considered in patients who develop symptomatic hyponatremia, and appropriate medical intervention instituted as necessary. Patients should also have their blood pressure and pulse monitored before and during SSRI/SNRI therapy, especially during the first few weeks and following a dosage increase. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if SSRIs or SNRIs are prescribed in combination with diuretics, particularly in the elderly.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67231/", "reference_text": "[1] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[2] Jackson C, Carson W, Markowitz J, Mintzer J \"SIADH associated with fluoxetine and sertraline therapy.\" Am J Psychiatry 152 (1995): 809-10[3] Robinson D, Brooks J, Mahler E, Sheikh JI \"SIADH--compulsive drinking or SSRI influence?\" Ann Pharmacother 30 (1996): 885[4] Odeh M, Beny A, Oliven A \"Severe symptomatic hyponatremia during citalopram therapy.\" Am J Med Sci 321 (2001): 159-60[5] Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA \"Fluoxetine as a cause of SIADH.\" Am J Psychiatry 148 (1991): 542-3[6] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[7] Jacob S, Spinler SA \"Hyponatremia associated with selective serotonin-reuptake inhibitors in older adults.\" Ann Pharmacother 40 (2006): 1618-22[8] Fitzgerald MA \"Hyponatremia associated with SSRI use in a 65-year-old woman.\" Nurse Pract 33 (2008): 11-2[9] van Campen JP, Voets AJ \"SIADH caused by paroxetine.\" Ann Pharmacother 30 (1996): 1499[10] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[11] Kessler J, Samuels SC \"Sertraline and hyponatremia.\" N Engl J Med 335 (1996): 524[12] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[13] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[14] Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J \"Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine.\" J Toxicol Clin Toxicol 35 (1997): 93-5[15] Crews JR, Potts NL, Schreiber J, Lipper S \"Hyponatremia in a patient treated with sertraline.\" Am J Psychiatry 150 (1993): 1564[16] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[17] Bradley ME, Foote EF, Lee EN, Merkle L \"Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature.\" Pharmacotherapy 16 (1996): 680-3[18] Odeh M, Seligmann H, Oliven A \"Severe life-threatening hyponatremia during paroxetine therapy.\" J Clin Pharmacol 39 (1999): 1290-1[19] Thornton SL, Resch DS \"SIADH associated with sertraline therapy.\" Am J Psychiatry 152 (1995): 809[20] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[21] \"Selective serotonin reuptake inhibitors and SIADH.\" Med J Aust 164 (1996): 562[22] Bouman WP, Johnson H, TrescoliSerrano C, Jones RG \"Recurrent hyponatremia associated with sertraline and lofepramine.\" Am J Psychiatry 154 (1997): 580[23] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[24] Goddard C, Paton C \"Hyponatraemia associated with paroxetine.\" BMJ 305 (1992): 1332[25] Barclay TS, Lee AJ \"Citalopram-associated SIADH.\" Ann Pharmacother 36 (2002): 1558-63[26] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[27] Covyeou JA, Jackson CW \"Hyponatremia associated with escitalopram.\" N Engl J Med 356 (2007): 94-5[28] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[29] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[30] Schattner A, Skurnik Y \"Fluoxetine-induced SIADH.\" J Am Geriatr Soc 44 (1996): 1413[31] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[32] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[33] Spigset O, hedenmalm K \"Hyponatremia in relation to treatment with antidepressants: a survey of reports in the World Health Organization data base for spontaneous reporting of adverse drug reactions.\" Pharmacotherapy 17 (1997): 348-52[34] Staab JP, Yerkes SA, Cheney EM, Clayton AH \"Transient SIADH associated with fluoxetine.\" Am J Psychiatry 147 (1990): 1569-70[35] Blacksten JV, Birt JA \"Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine.\" Ann Pharmacother 27 (1993): 723-4[36] Llorente MD, Gorelick M, Silverman MA \"Sertraline as the cause of inappropriate antidiuretic hormone secretion.\" J Clin Psychiatry 55 (1994): 543-4[37] Baliga RR, McHardy KC \"Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119].\" Br J Clin Pract 47 (1993): 62-3[38] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[39] Hwang AS, Magraw RM \"Syndrome of inappropriate secretion of antidiuretic hormone due to fluoxetine.\" Am J Psychiatry 146 (1989): 399[40] Cohen BJ, Mahelsky M, Adler L \"More cases of SIADH with fluoxetine.\" Am J Psychiatry 147 (1990): 948-9[41] Ayonrinde OT, Sanfilippo FM \"SSRI antidepressants and SIADH.\" Aust N Z J Psychiatry 31 (1997): 306-7[42] Kazal LA, Jr Hall DL, Miller LG, Noel ML \"Fluoxetine-induced SIADH: a geriatric occurrence?\" J Fam Pract 36 (1993): 341-3[43] Ayonrinde OT, Reutens SG, Sanfilippo FM \"Paroxetine-induced SIADH.\" Med J Aust 163 (1995): 390[44] Chua TP, Vong SK \"Hyponatraemia associated with paroxetine.\" BMJ 306 (1993): 143[45] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Woo MH, Smythe MA \"Association of SIADH with selective serotonin reuptake inhibitors.\" Ann Pharmacother 31 (1997): 108-10[47] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[48] Rosner MH \"Severe hyponatremia associated with the combined use of thiazide diuretics and selective serotonin reuptake inhibitors.\" Am J Med Sci 327 (2004): 109-11[49] Doshi D, Borison R \"Association of transient SIADH with sertraline.\" Am J Psychiatry 151 (1994): 779-80[50] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[51] Madhusoodanan S, Brenner R, Brafman I, Bogunovic O \"Hyponatremia associated with paroxetine use.\" South Med J 92 (1999): 843[52] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[53] Esposito P, Rampino T, Gregorini M, et al. \"Severe symptomatic hyponatremia during sibutramine therapy: a case report.\" Am J Kidney Dis 52 (2008): 137-9[54] Spier SA, Frontera MA \"Unexpected deaths in depressed medical inpatients treated with fluoxetine.\" J Clin Psychiatry 52 (1991): 377-82[55] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[56] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[57] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Tinidazole, Mitapivat, Ascorbic acid, Oxytetracycline, Ciclopirox, Sulfamethizole, Simeprevir, Diazoxide, Econazole, Povidone-iodine, Sulfisoxazole, More", "alternatives_b": "Desipramine, St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Protriptyline, Esketamine", "updated_at": 1767369485}, {"id": 67145, "ingredient1": "Citalopram", "ingredient2": "Tositumomab", "severity": "Moderate", "effect": "Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.", "source": "DDInter", "management_text": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67232/", "reference_text": "[1] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG \"Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin.\" Acta Psychiatr Scand Suppl 350 (1989): 102-6[2] Skop BP, Brown TM \"Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors.\" Psychosomatics 37 (1996): 12-6[3] Settle EC \"Antidepressant drugs: disturbing and potentially dangerous adverse effects.\" J Clin Psychiatry 59 Suppl 16 (1998): 25-30[4] Layton D, Clark DWJ, Pearce GL, Shakir SAW \"Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England.\" Eur J Clin Pharmacol 57 (2001): 167-76[5] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[6] Leung M, Shore R \"Fluvoxamine-associated bleeding.\" Can J Psychiatry 41 (1996): 604-5[7] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[8] Tata LJ, Fortun PJ, Hubbard RB, et al. \"Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?\" Aliment Pharmacol Ther 22 (2005): 175-81[9] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[10] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B \"Paroxetine decreases platelet serotonin storage and platelet function in human beings.\" Clin Pharmacol Ther 68 (2000): 435-42[11] de Abajo FJ, Rodriguez LA, Montero D \"Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study.\" BMJ 319 (1999): 1106-9[12] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[13] Alderman CP, Moritz CK, Ben-Tovim DI \"Abnormal platelet aggregation associated with fluoxetine therapy.\" Ann Pharmacother 26 (1992): 1517-9[14] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[15] Krivy J, Wiener J \"Sertraline and platelet counts in idiopathic thrombocytopenia purpura.\" Lancet 345 (1995): 132[16] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[17] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[18] Pai VB, Kelly MW \"Bruising associated with the use of fluoxetine.\" Ann Pharmacother 30 (1996): 786-8[19] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990): 213-7[20] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ \"Fluoxetine and bleeding in obsessive-compulsive disorder.\" Am J Psychiatry 148 (1991): 949[21] Alderman CP, Seshadri P, Ben-Tovim DI \"Effects of serotonin reuptake inhibitors on hemostasis.\" Ann Pharmacother 30 (1996): 1232-4[22] Humphries JE, Wheby MS, VandenBerg SR \"Fluoxetine and the bleeding time.\" Arch Pathol Lab Med 114 (1990): 727-8[23] Woolfrey S, Gammack NS, Dewar MS, Brown PJ \"Fluoxetine-warfarin interaction.\" BMJ 307 (1993): 241[24] Messiha FS \"Fluoxetine - adverse effects and drug-drug interactions.\" J Toxicol Clin Toxicol 31 (1993): 603-30[25] Ford MA, Anderson ML, Rindone JP, Jaskar DW \"Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin.\" J Clin Psychopharmacol 17 (1997): 110-2[26] Ottervanger JP, Stricker BH, Huls J, Weeda JN \"Bleeding attributed to the intake of paroxetine.\" Am J Psychiatry 151 (1994): 781-2[27] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[28] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH \"Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study.\" Arch Intern Med 163 (2003): 59-64[29] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[30] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[31] Aranth J, Lindberg C \"Bleeding, a side effect of fluoxetine.\" Am J Psychiatry 149 (1992): 412[32] Cerner Multum, Inc. \"Australian Product Information.\" O 0[33] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S \"Intracranial haemorrhage and use of selective serotonin reuptake inhibitors.\" Br J Clin Pharmacol 50 (2000): 43-7[34] de Maistre E, Allart C, Lecompte T, Bollaert PE \"Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors.\" Am J Med 113 (2002): 530-2[35] Claire RJ, Servis ME, Cram DL Jr \"Potential interaction between warfarin sodium and fluoxetine.\" Am J Psychiatry 148 (1991): 1604[36] Dent LA, Orrock MW \"Warfarin-fluoxetine and diazepam-fluoxetine interaction.\" Pharmacotherapy 17 (1997): 170-2[37] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[38] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[39] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[40] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[41] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[42] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Iodide I-131", "alternatives_b": "Maprotiline, St. John's Wort, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, More", "updated_at": 1767369485}, {"id": 67146, "ingredient1": "Citalopram", "ingredient2": "Tranylcypromine", "severity": "Major", "effect": "By inhibiting serotonin metabolism, monoamine oxidase inhibitors (MAOIs) may potentiate the pharmacologic activity of selective serotonin reuptake inhibitors (SSRIs) and increase the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.", "source": "DDInter", "management_text": "In general, SSRIs should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with SSRIs, and vice versa.", "mechanism_text": "Metabolism", "recommendation": "In general, SSRIs should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67233/", "reference_text": "[1] Beasley CM Jr, Masica DN, Heiligenstein JH, Wheadon DE, Zerbe RL \"Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings.\" J Clin Psychopharmacol 13 (1993): 312-20[2] Kline SS, Mauro LS, Scala-Bennett DM, Zick D \"Serotonin syndrome versus neuroleptic malignant death syndrome as a cause of death.\" Clin Pharm 8 (1989): 510-4[3] Bhatara VS, Bandettini FC \"Possible interaction between sertraline and tranylcypromine.\" Clin Pharm 12 (1993): 222-5[4] Schulz R, Antonin KH, Hoffmann E, et al \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989): 528-36[5] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[6] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[7] Suchowersky O, deVries JD \"Interaction of fluoxetine and selegiline.\" Can J Psychiatry 35 (1990): 571-2[8] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[9] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995): 440-2[10] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[11] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth (2005):[12] Suchowersky O, deVries J \"Possible interactions between deprenyl and prozac.\" Can J Neurol Sci 17 (1990): 352-3[13] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990): 213-7[14] Sternbach H \"Danger of MAOI therapy after fluoxetine withdrawal.\" Lancet 2 (1988): 850-1[15] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995): 481-2[16] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[17] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[18] Phillips SD, Ringo P \"Phenelzine and venlafaxine interaction.\" Am J Psychiatry 152 (1995): 1400-1[19] Feighner JP, Boyer WF, Tyler DL, Neborsky RJ \"Adverse consequences of fluoxetine-MAOI combination therapy.\" J Clin Psychiatry 51 (1990): 222-5[20] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[21] Jimenez-Genchi A \"Immediate switching from moclobemide to duloxetine may induce serotonin syndrome.\" J Clin Psychiatry 67 (2006): 1821-1822[22] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[23] Graber MA, Hoehns TB, Perry PJ \"Sertraline-phenelzine drug interaction: a serotonin syndrome reaction.\" Ann Pharmacother 28 (1994): 732-5[24] Ruiz F \"Fluoxetine and the serotonin syndrome.\" Ann Emerg Med 24 (1994): 983-5[25] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[26] Graham PM, Ilett KF \"Danger of MAOI therapy after fluoxetine withdrawal.\" Lancet 2 (1988): 1255-6[27] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[28] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics.\" J Clin Psychopharmacol 10 (1990): 48-50[29] Brannan SK, Talley BJ, Bowden CL \"Sertraline and isocarboxazid cause a serotonin syndrome.\" J Clin Psychopharmacol 14 (1994): 144-5[30] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[31] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[32] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[33] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993): 84-8[34] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[35] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S \"Rare case of serotonin syndrome with therapeutic doses of paroxetine.\" Am J Ther 13 (2006): 550-552[36] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[37] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[38] Zetin M, Plon L, DeAntonio M \"MAOI reaction with powdered protein dietary supplement.\" J Clin Psychiatry 48 (1987): 499[39] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[40] Pohl R, Balon R, Berchou R \"Reaction to chicken nuggets in a patient taking an MAOI.\" Am J Psychiatry 145 (1988): 651[41] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[42] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D \"Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer.\" J Clin Psychopharmacol 14 (1994): 5-14[43] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG \"Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements.\" J Clin Psychopharmacol 11 (1991): 331-2[44] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.[45] Domino EF, Selden EM \"Red wine and reactions.\" J Clin Psychopharmacol 4 (1984): 173-4[46] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[47] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[48] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975): 164-6[49] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[50] Maxwell MB \"Reexamining the dietary restrictions with procarbazine (an MAOI).\" Cancer Nurs 3 (1980): 451-7[51] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995): 211-31[52] Nuessle WF, Norman FC, Miller HE \"Pickled herring and tranylcypromine reaction.\" JAMA 192 (1965): 142-3[53] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[54] Walker JI, Davidson J, Zung WWK \"Patient compliance with MAO Inhibitor therapy.\" J Clin Psychiatry 45 (1984): 78-80[55] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[56] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[57] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[58] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tranylcypromine", "alternatives_b": "Citalopram, Esketamine", "updated_at": 1767369485}, {"id": 67147, "ingredient1": "Citalopram", "ingredient2": "Trazodone", "severity": "Major", "effect": "Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval including tricyclic antidepressants and other antidepressants (e.g., trazodone) may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death. Concomitant use of agents with serotonergic activity including selective serotonin reuptake inhibitors, tricyclic antidepressants, and other antidepressants may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.", "source": "DDInter", "management_text": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure. However, if treatment with citalopram is required in these patients, the labeling recommends that the dosage not exceed 40 mg/day, as higher dosages may have an excessive effect on the QT interval and confer no additional benefit in the treatment of depression. In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk. Patients should be closely monitored for symptoms of the serotonin syndrome during treatment. Particular caution is advised when increasing the dosages of these agents. If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary. Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).", "mechanism_text": "Synergism", "recommendation": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67234/", "reference_text": "[1] Lane R, Baldwin D \"Selective serotonin reuptake inhibitor--induced serotonin syndrome: review.\" J Clin Psychopharmacol 17 (1997): 208-21[2] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993): 84-8[3] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995): 481-2[4] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[5] Insel TR, Roy BF, Cohen RM, Murphy DL \"Possible development of the serotonin syndrome in man.\" Am J Psychiatry 139 (1982): 954-5[6] Laird LK \"Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder.\" Psychopharmacol Bull 32 (1996): 569-78[7] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm.\" ([2011 Aug 24]):[8] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[9] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995): 440-2[10] Nijhawan PK, Katz G, Winter S \"Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission.\" Crit Care Med 24 (1996): 1086-9[11] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[12] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[13] Harvey AT, Preskorn SH \"Interactions of serotonin reuptake inhibitors with tricyclic antidepressants.\" Arch Gen Psychiatry 52 (1995): 783-4[14] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[15] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[16] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[17] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[18] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[20] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[21] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[22] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Viloxazine, Trazodone", "alternatives_b": "Citalopram, Esketamine", "updated_at": 1767369485}, {"id": 67148, "ingredient1": "Citalopram", "ingredient2": "Treprostinil", "severity": "Moderate", "effect": "Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.", "source": "DDInter", "management_text": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67235/", "reference_text": "[1] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG \"Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin.\" Acta Psychiatr Scand Suppl 350 (1989): 102-6[2] Skop BP, Brown TM \"Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors.\" Psychosomatics 37 (1996): 12-6[3] Settle EC \"Antidepressant drugs: disturbing and potentially dangerous adverse effects.\" J Clin Psychiatry 59 Suppl 16 (1998): 25-30[4] Layton D, Clark DWJ, Pearce GL, Shakir SAW \"Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England.\" Eur J Clin Pharmacol 57 (2001): 167-76[5] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[6] Leung M, Shore R \"Fluvoxamine-associated bleeding.\" Can J Psychiatry 41 (1996): 604-5[7] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[8] Tata LJ, Fortun PJ, Hubbard RB, et al. \"Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?\" Aliment Pharmacol Ther 22 (2005): 175-81[9] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[10] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B \"Paroxetine decreases platelet serotonin storage and platelet function in human beings.\" Clin Pharmacol Ther 68 (2000): 435-42[11] de Abajo FJ, Rodriguez LA, Montero D \"Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study.\" BMJ 319 (1999): 1106-9[12] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[13] Alderman CP, Moritz CK, Ben-Tovim DI \"Abnormal platelet aggregation associated with fluoxetine therapy.\" Ann Pharmacother 26 (1992): 1517-9[14] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[15] Krivy J, Wiener J \"Sertraline and platelet counts in idiopathic thrombocytopenia purpura.\" Lancet 345 (1995): 132[16] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[17] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[18] Pai VB, Kelly MW \"Bruising associated with the use of fluoxetine.\" Ann Pharmacother 30 (1996): 786-8[19] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990): 213-7[20] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ \"Fluoxetine and bleeding in obsessive-compulsive disorder.\" Am J Psychiatry 148 (1991): 949[21] Alderman CP, Seshadri P, Ben-Tovim DI \"Effects of serotonin reuptake inhibitors on hemostasis.\" Ann Pharmacother 30 (1996): 1232-4[22] Humphries JE, Wheby MS, VandenBerg SR \"Fluoxetine and the bleeding time.\" Arch Pathol Lab Med 114 (1990): 727-8[23] Woolfrey S, Gammack NS, Dewar MS, Brown PJ \"Fluoxetine-warfarin interaction.\" BMJ 307 (1993): 241[24] Messiha FS \"Fluoxetine - adverse effects and drug-drug interactions.\" J Toxicol Clin Toxicol 31 (1993): 603-30[25] Ford MA, Anderson ML, Rindone JP, Jaskar DW \"Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin.\" J Clin Psychopharmacol 17 (1997): 110-2[26] Ottervanger JP, Stricker BH, Huls J, Weeda JN \"Bleeding attributed to the intake of paroxetine.\" Am J Psychiatry 151 (1994): 781-2[27] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[28] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH \"Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study.\" Arch Intern Med 163 (2003): 59-64[29] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[30] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[31] Aranth J, Lindberg C \"Bleeding, a side effect of fluoxetine.\" Am J Psychiatry 149 (1992): 412[32] Cerner Multum, Inc. \"Australian Product Information.\" O 0[33] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S \"Intracranial haemorrhage and use of selective serotonin reuptake inhibitors.\" Br J Clin Pharmacol 50 (2000): 43-7[34] de Maistre E, Allart C, Lecompte T, Bollaert PE \"Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors.\" Am J Med 113 (2002): 530-2[35] Claire RJ, Servis ME, Cram DL Jr \"Potential interaction between warfarin sodium and fluoxetine.\" Am J Psychiatry 148 (1991): 1604[36] Dent LA, Orrock MW \"Warfarin-fluoxetine and diazepam-fluoxetine interaction.\" Pharmacotherapy 17 (1997): 170-2[37] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[38] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[39] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[40] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[41] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[42] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Desipramine, Trimipramine, Maprotiline, Oxitriptan, Mirtazapine, Bupropion, Viloxazine, Trazodone, Tryptophan, Amitriptyline, Nortriptyline, More", "alternatives_b": "Protein C, Selexipag", "updated_at": 1767369485}, {"id": 67149, "ingredient1": "Citalopram", "ingredient2": "Triamterene", "severity": "Moderate", "effect": "Coadministration with diuretics may potentiate the risk of hyponatremia associated with the use of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). Elderly patients and patients taking diuretics or who are otherwise volume-depleted may be at greater risk of developing hyponatremia with SSRIs and SNRIs. Antihypertensive agents such as diuretics may potentiate the orthostatic effect that is occasionally observed upon the initiation of SSRI or SNRI therapy. Syncope and orthostatic hypotension tend to occur within the first week of SNRI/SSRI therapy but can occur at any time during treatment, particularly after a dosage increase. The use of SSRIs or SNRIs may also cause sustained increases in blood pressure and heart rate, which may antagonize the therapeutic effects of antihypertensive medications.", "source": "DDInter", "management_text": "Caution is recommended if SSRIs or SNRIs are prescribed in combination with diuretics, particularly in the elderly. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hyponatremia such as nausea, vomiting, headache, malaise, lethargy, irritability, difficulty concentrating, memory impairment, confusion, weakness, muscle spasm, and unsteadiness (which may lead to falls). More severe and/or acute cases may include hallucination, syncope, seizure, coma, respiratory arrest, and death. Discontinuation of SSRI/SNRI therapy should be considered in patients who develop symptomatic hyponatremia, and appropriate medical intervention instituted as necessary. Patients should also have their blood pressure and pulse monitored before and during SSRI/SNRI therapy, especially during the first few weeks and following a dosage increase. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if SSRIs or SNRIs are prescribed in combination with diuretics, particularly in the elderly.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67236/", "reference_text": "[1] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[2] Jackson C, Carson W, Markowitz J, Mintzer J \"SIADH associated with fluoxetine and sertraline therapy.\" Am J Psychiatry 152 (1995): 809-10[3] Robinson D, Brooks J, Mahler E, Sheikh JI \"SIADH--compulsive drinking or SSRI influence?\" Ann Pharmacother 30 (1996): 885[4] Odeh M, Beny A, Oliven A \"Severe symptomatic hyponatremia during citalopram therapy.\" Am J Med Sci 321 (2001): 159-60[5] Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA \"Fluoxetine as a cause of SIADH.\" Am J Psychiatry 148 (1991): 542-3[6] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[7] Jacob S, Spinler SA \"Hyponatremia associated with selective serotonin-reuptake inhibitors in older adults.\" Ann Pharmacother 40 (2006): 1618-22[8] Fitzgerald MA \"Hyponatremia associated with SSRI use in a 65-year-old woman.\" Nurse Pract 33 (2008): 11-2[9] van Campen JP, Voets AJ \"SIADH caused by paroxetine.\" Ann Pharmacother 30 (1996): 1499[10] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[11] Kessler J, Samuels SC \"Sertraline and hyponatremia.\" N Engl J Med 335 (1996): 524[12] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[13] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[14] Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J \"Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine.\" J Toxicol Clin Toxicol 35 (1997): 93-5[15] Crews JR, Potts NL, Schreiber J, Lipper S \"Hyponatremia in a patient treated with sertraline.\" Am J Psychiatry 150 (1993): 1564[16] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[17] Bradley ME, Foote EF, Lee EN, Merkle L \"Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature.\" Pharmacotherapy 16 (1996): 680-3[18] Odeh M, Seligmann H, Oliven A \"Severe life-threatening hyponatremia during paroxetine therapy.\" J Clin Pharmacol 39 (1999): 1290-1[19] Thornton SL, Resch DS \"SIADH associated with sertraline therapy.\" Am J Psychiatry 152 (1995): 809[20] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[21] \"Selective serotonin reuptake inhibitors and SIADH.\" Med J Aust 164 (1996): 562[22] Bouman WP, Johnson H, TrescoliSerrano C, Jones RG \"Recurrent hyponatremia associated with sertraline and lofepramine.\" Am J Psychiatry 154 (1997): 580[23] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[24] Goddard C, Paton C \"Hyponatraemia associated with paroxetine.\" BMJ 305 (1992): 1332[25] Barclay TS, Lee AJ \"Citalopram-associated SIADH.\" Ann Pharmacother 36 (2002): 1558-63[26] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[27] Covyeou JA, Jackson CW \"Hyponatremia associated with escitalopram.\" N Engl J Med 356 (2007): 94-5[28] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[29] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[30] Schattner A, Skurnik Y \"Fluoxetine-induced SIADH.\" J Am Geriatr Soc 44 (1996): 1413[31] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[32] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[33] Spigset O, hedenmalm K \"Hyponatremia in relation to treatment with antidepressants: a survey of reports in the World Health Organization data base for spontaneous reporting of adverse drug reactions.\" Pharmacotherapy 17 (1997): 348-52[34] Staab JP, Yerkes SA, Cheney EM, Clayton AH \"Transient SIADH associated with fluoxetine.\" Am J Psychiatry 147 (1990): 1569-70[35] Blacksten JV, Birt JA \"Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine.\" Ann Pharmacother 27 (1993): 723-4[36] Llorente MD, Gorelick M, Silverman MA \"Sertraline as the cause of inappropriate antidiuretic hormone secretion.\" J Clin Psychiatry 55 (1994): 543-4[37] Baliga RR, McHardy KC \"Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119].\" Br J Clin Pract 47 (1993): 62-3[38] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[39] Hwang AS, Magraw RM \"Syndrome of inappropriate secretion of antidiuretic hormone due to fluoxetine.\" Am J Psychiatry 146 (1989): 399[40] Cohen BJ, Mahelsky M, Adler L \"More cases of SIADH with fluoxetine.\" Am J Psychiatry 147 (1990): 948-9[41] Ayonrinde OT, Sanfilippo FM \"SSRI antidepressants and SIADH.\" Aust N Z J Psychiatry 31 (1997): 306-7[42] Kazal LA, Jr Hall DL, Miller LG, Noel ML \"Fluoxetine-induced SIADH: a geriatric occurrence?\" J Fam Pract 36 (1993): 341-3[43] Ayonrinde OT, Reutens SG, Sanfilippo FM \"Paroxetine-induced SIADH.\" Med J Aust 163 (1995): 390[44] Chua TP, Vong SK \"Hyponatraemia associated with paroxetine.\" BMJ 306 (1993): 143[45] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Woo MH, Smythe MA \"Association of SIADH with selective serotonin reuptake inhibitors.\" Ann Pharmacother 31 (1997): 108-10[47] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[48] Rosner MH \"Severe hyponatremia associated with the combined use of thiazide diuretics and selective serotonin reuptake inhibitors.\" Am J Med Sci 327 (2004): 109-11[49] Doshi D, Borison R \"Association of transient SIADH with sertraline.\" Am J Psychiatry 151 (1994): 779-80[50] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[51] Madhusoodanan S, Brenner R, Brafman I, Bogunovic O \"Hyponatremia associated with paroxetine use.\" South Med J 92 (1999): 843[52] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[53] Esposito P, Rampino T, Gregorini M, et al. \"Severe symptomatic hyponatremia during sibutramine therapy: a case report.\" Am J Kidney Dis 52 (2008): 137-9[54] Spier SA, Frontera MA \"Unexpected deaths in depressed medical inpatients treated with fluoxetine.\" J Clin Psychiatry 52 (1991): 377-82[55] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[56] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[57] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Desipramine, St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Finerenone", "updated_at": 1767369485}, {"id": 67150, "ingredient1": "Citalopram", "ingredient2": "Triazolam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67237/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Levomilnacipran, Oxitriptan, Vortioxetine, Milnacipran, Tryptophan, Vilazodone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67151, "ingredient1": "Citalopram", "ingredient2": "Trichlormethiazide", "severity": "Moderate", "effect": "Coadministration with diuretics may potentiate the risk of hyponatremia associated with the use of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). Elderly patients and patients taking diuretics or who are otherwise volume-depleted may be at greater risk of developing hyponatremia with SSRIs and SNRIs. Antihypertensive agents such as diuretics may potentiate the orthostatic effect that is occasionally observed upon the initiation of SSRI or SNRI therapy. Syncope and orthostatic hypotension tend to occur within the first week of SNRI/SSRI therapy but can occur at any time during treatment, particularly after a dosage increase. The use of SSRIs or SNRIs may also cause sustained increases in blood pressure and heart rate, which may antagonize the therapeutic effects of antihypertensive medications.", "source": "DDInter", "management_text": "Caution is recommended if SSRIs or SNRIs are prescribed in combination with diuretics, particularly in the elderly. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hyponatremia such as nausea, vomiting, headache, malaise, lethargy, irritability, difficulty concentrating, memory impairment, confusion, weakness, muscle spasm, and unsteadiness (which may lead to falls). More severe and/or acute cases may include hallucination, syncope, seizure, coma, respiratory arrest, and death. Discontinuation of SSRI/SNRI therapy should be considered in patients who develop symptomatic hyponatremia, and appropriate medical intervention instituted as necessary. Patients should also have their blood pressure and pulse monitored before and during SSRI/SNRI therapy, especially during the first few weeks and following a dosage increase. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if SSRIs or SNRIs are prescribed in combination with diuretics, particularly in the elderly.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67238/", "reference_text": "[1] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[2] Jackson C, Carson W, Markowitz J, Mintzer J \"SIADH associated with fluoxetine and sertraline therapy.\" Am J Psychiatry 152 (1995): 809-10[3] Robinson D, Brooks J, Mahler E, Sheikh JI \"SIADH--compulsive drinking or SSRI influence?\" Ann Pharmacother 30 (1996): 885[4] Odeh M, Beny A, Oliven A \"Severe symptomatic hyponatremia during citalopram therapy.\" Am J Med Sci 321 (2001): 159-60[5] Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA \"Fluoxetine as a cause of SIADH.\" Am J Psychiatry 148 (1991): 542-3[6] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[7] Jacob S, Spinler SA \"Hyponatremia associated with selective serotonin-reuptake inhibitors in older adults.\" Ann Pharmacother 40 (2006): 1618-22[8] Fitzgerald MA \"Hyponatremia associated with SSRI use in a 65-year-old woman.\" Nurse Pract 33 (2008): 11-2[9] van Campen JP, Voets AJ \"SIADH caused by paroxetine.\" Ann Pharmacother 30 (1996): 1499[10] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[11] Kessler J, Samuels SC \"Sertraline and hyponatremia.\" N Engl J Med 335 (1996): 524[12] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[13] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[14] Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J \"Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine.\" J Toxicol Clin Toxicol 35 (1997): 93-5[15] Crews JR, Potts NL, Schreiber J, Lipper S \"Hyponatremia in a patient treated with sertraline.\" Am J Psychiatry 150 (1993): 1564[16] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[17] Bradley ME, Foote EF, Lee EN, Merkle L \"Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature.\" Pharmacotherapy 16 (1996): 680-3[18] Odeh M, Seligmann H, Oliven A \"Severe life-threatening hyponatremia during paroxetine therapy.\" J Clin Pharmacol 39 (1999): 1290-1[19] Thornton SL, Resch DS \"SIADH associated with sertraline therapy.\" Am J Psychiatry 152 (1995): 809[20] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[21] \"Selective serotonin reuptake inhibitors and SIADH.\" Med J Aust 164 (1996): 562[22] Bouman WP, Johnson H, TrescoliSerrano C, Jones RG \"Recurrent hyponatremia associated with sertraline and lofepramine.\" Am J Psychiatry 154 (1997): 580[23] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[24] Goddard C, Paton C \"Hyponatraemia associated with paroxetine.\" BMJ 305 (1992): 1332[25] Barclay TS, Lee AJ \"Citalopram-associated SIADH.\" Ann Pharmacother 36 (2002): 1558-63[26] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[27] Covyeou JA, Jackson CW \"Hyponatremia associated with escitalopram.\" N Engl J Med 356 (2007): 94-5[28] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[29] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[30] Schattner A, Skurnik Y \"Fluoxetine-induced SIADH.\" J Am Geriatr Soc 44 (1996): 1413[31] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[32] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[33] Spigset O, hedenmalm K \"Hyponatremia in relation to treatment with antidepressants: a survey of reports in the World Health Organization data base for spontaneous reporting of adverse drug reactions.\" Pharmacotherapy 17 (1997): 348-52[34] Staab JP, Yerkes SA, Cheney EM, Clayton AH \"Transient SIADH associated with fluoxetine.\" Am J Psychiatry 147 (1990): 1569-70[35] Blacksten JV, Birt JA \"Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine.\" Ann Pharmacother 27 (1993): 723-4[36] Llorente MD, Gorelick M, Silverman MA \"Sertraline as the cause of inappropriate antidiuretic hormone secretion.\" J Clin Psychiatry 55 (1994): 543-4[37] Baliga RR, McHardy KC \"Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119].\" Br J Clin Pract 47 (1993): 62-3[38] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[39] Hwang AS, Magraw RM \"Syndrome of inappropriate secretion of antidiuretic hormone due to fluoxetine.\" Am J Psychiatry 146 (1989): 399[40] Cohen BJ, Mahelsky M, Adler L \"More cases of SIADH with fluoxetine.\" Am J Psychiatry 147 (1990): 948-9[41] Ayonrinde OT, Sanfilippo FM \"SSRI antidepressants and SIADH.\" Aust N Z J Psychiatry 31 (1997): 306-7[42] Kazal LA, Jr Hall DL, Miller LG, Noel ML \"Fluoxetine-induced SIADH: a geriatric occurrence?\" J Fam Pract 36 (1993): 341-3[43] Ayonrinde OT, Reutens SG, Sanfilippo FM \"Paroxetine-induced SIADH.\" Med J Aust 163 (1995): 390[44] Chua TP, Vong SK \"Hyponatraemia associated with paroxetine.\" BMJ 306 (1993): 143[45] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Woo MH, Smythe MA \"Association of SIADH with selective serotonin reuptake inhibitors.\" Ann Pharmacother 31 (1997): 108-10[47] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[48] Rosner MH \"Severe hyponatremia associated with the combined use of thiazide diuretics and selective serotonin reuptake inhibitors.\" Am J Med Sci 327 (2004): 109-11[49] Doshi D, Borison R \"Association of transient SIADH with sertraline.\" Am J Psychiatry 151 (1994): 779-80[50] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[51] Madhusoodanan S, Brenner R, Brafman I, Bogunovic O \"Hyponatremia associated with paroxetine use.\" South Med J 92 (1999): 843[52] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[53] Esposito P, Rampino T, Gregorini M, et al. \"Severe symptomatic hyponatremia during sibutramine therapy: a case report.\" Am J Kidney Dis 52 (2008): 137-9[54] Spier SA, Frontera MA \"Unexpected deaths in depressed medical inpatients treated with fluoxetine.\" J Clin Psychiatry 52 (1991): 377-82[55] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[56] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[57] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Tinidazole, Mitapivat, Ascorbic acid, Oxytetracycline, Ciclopirox, Sulfamethizole, Simeprevir, Diazoxide, Econazole, Povidone-iodine, Sulfisoxazole, More", "updated_at": 1767369485}, {"id": 67152, "ingredient1": "Citalopram", "ingredient2": "Triclabendazole", "severity": "Major", "effect": "Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.", "mechanism_text": "Synergism", "recommendation": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67239/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm.\" ([2011 Aug 24]):[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm.\" ([2012 Mar 28]):[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[9] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[12] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Kaletra (lopinavir-ritonavir)\" Abbott Pharmaceutical, Abbott Park, IL.[15] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Phenelzine, Duloxetine, Tranylcypromine, Vilazodone, Paroxetine, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, More", "alternatives_b": "Praziquantel, Oxamniquine", "updated_at": 1767369485}, {"id": 67153, "ingredient1": "Citalopram", "ingredient2": "Trifluoperazine", "severity": "Major", "effect": "Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.", "mechanism_text": "Synergism", "recommendation": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67240/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm.\" ([2011 Aug 24]):[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm.\" ([2012 Mar 28]):[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[9] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[12] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Kaletra (lopinavir-ritonavir)\" Abbott Pharmaceutical, Abbott Park, IL.[15] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Oxitriptan, Viloxazine, Vortioxetine, Tryptophan, Vilazodone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67154, "ingredient1": "Citalopram", "ingredient2": "Triflupromazine", "severity": "Major", "effect": "Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.", "mechanism_text": "Synergism", "recommendation": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67241/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm.\" ([2011 Aug 24]):[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm.\" ([2012 Mar 28]):[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[9] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[12] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Kaletra (lopinavir-ritonavir)\" Abbott Pharmaceutical, Abbott Park, IL.[15] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Oxitriptan, Viloxazine, Vortioxetine, Tryptophan, Vilazodone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67155, "ingredient1": "Citalopram", "ingredient2": "Trihexyphenidyl", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67242/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67156, "ingredient1": "Alimemazine", "ingredient2": "Citalopram", "severity": "Major", "effect": "Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.", "mechanism_text": "Synergism", "recommendation": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67243/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm.\" ([2011 Aug 24]):[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm.\" ([2012 Mar 28]):[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[9] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[12] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Kaletra (lopinavir-ritonavir)\" Abbott Pharmaceutical, Abbott Park, IL.[15] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "alternatives_b": "Azelastine, Ketotifen", "updated_at": 1767369485}, {"id": 67157, "ingredient1": "Citalopram", "ingredient2": "Trimethadione", "severity": "Moderate", "effect": "The efficacy of anticonvulsants may be diminished during coadministration with selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitor (SNRIs). Antidepressants including SSRIs and SNRIs can reduce seizure threshold.Coadministration of SSRIs or SNRIs with some anticonvulsants, particularly carbamazepine, eslicarbazepine, oxcarbazepine and valproic acid, may increase the risk of hyponatremia. The risk appears to be dose-related, and elderly patients and patients who are volume depleted (e.g., diuretic use) may be at greater risk.", "source": "DDInter", "management_text": "SSRIs and SNRIs should be avoided in patients with unstable epilepsy, and used cautiously in patients with epilepsy controlled with anticonvulsant medications. Treatment with SSRIs and SNRIs should be discontinued if seizures develop or seizure frequency increases. Patients receiving SSRIs or SNRIs with anticonvulsants, particularly carbamazepine, eslicarbazepine, oxcarbazepine and/or valproic acid, should also have serum sodium levels measured regularly and monitored for development of hyponatremia, particularly when higher dosages of these medications are used. Signs and symptoms of hyponatremia include nausea, vomiting, headache, difficulty concentrating, memory impairment, confusion, malaise, lethargy, muscle weakness or spasms, and unsteadiness. In more severe and/or acute cases, hallucination, syncope, seizure, coma, respiratory arrest, and death may occur.", "mechanism_text": "Antagonism", "recommendation": "SSRIs and SNRIs should be avoided in patients with unstable epilepsy, and used cautiously in patients with epilepsy controlled with anticonvulsant medications.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67244/", "reference_text": "[1] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[2] Belcastro V, Costa C, Striano P \"Levetiracetam-associated hyponatremia.\" Seizure 17 (2008): 389-90[3] Gandhi S, McArthur E, Mamdani MM, et.al \"Antiepileptic drugs and hyponatremia in older adults: Two population-based cohort studies.\" Epilepsia 57 (2016): 2067-79[4] \"Product Information. Aptiom (eslicarbazepine).\" Sunovion Pharmaceuticals Inc, Marlborough, MA.[5] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[6] \"Product Information. Tegretol (carbamazepine).\" Novartis Pharmaceuticals, East Hanover, NJ.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[9] Falhammar H, Lindh JD, Calissendorff J, et.al \"Differences in associations of antiepileptic drugs and hospitalization due to hyponatremia: A population-based case-control study.\" Seizure 59 (2018): 28-33[10] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[11] Bavbek N, Alkan R, Uz E, Kaftan O, Akcay A \"Hyponatremia associated with sodium valproate in a 22-year-old male.\" Nephrol Dial Transplant 23 (2008): epub[12] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[13] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[14] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[15] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[16] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[17] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[18] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[19] Patel KR, Meesala A, Stanilla JK \"Sodium valproate-induced hyponatremia: a case report.\" Prim Care Companion J Clin Psychiatry 12 (2010): epub[20] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[21] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[22] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[23] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[24] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[25] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[26] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[27] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[28] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Oxitriptan, Bupropion, Viloxazine, Tryptophan", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67158, "ingredient1": "Citalopram", "ingredient2": "Trimethobenzamide", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67245/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "alternatives_b": "Azelastine, Ketotifen", "updated_at": 1767369485}, {"id": 67159, "ingredient1": "Citalopram", "ingredient2": "Trimipramine", "severity": "Major", "effect": "Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval including tricyclic antidepressants and other antidepressants (e.g., trazodone) may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death. Concomitant use of agents with serotonergic activity including selective serotonin reuptake inhibitors, tricyclic antidepressants, and other antidepressants may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.", "source": "DDInter", "management_text": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure. However, if treatment with citalopram is required in these patients, the labeling recommends that the dosage not exceed 40 mg/day, as higher dosages may have an excessive effect on the QT interval and confer no additional benefit in the treatment of depression. In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk. Patients should be closely monitored for symptoms of the serotonin syndrome during treatment. Particular caution is advised when increasing the dosages of these agents. If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary. Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).", "mechanism_text": "Synergism", "recommendation": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67246/", "reference_text": "[1] Lane R, Baldwin D \"Selective serotonin reuptake inhibitor--induced serotonin syndrome: review.\" J Clin Psychopharmacol 17 (1997): 208-21[2] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993): 84-8[3] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995): 481-2[4] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[5] Insel TR, Roy BF, Cohen RM, Murphy DL \"Possible development of the serotonin syndrome in man.\" Am J Psychiatry 139 (1982): 954-5[6] Laird LK \"Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder.\" Psychopharmacol Bull 32 (1996): 569-78[7] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm.\" ([2011 Aug 24]):[8] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[9] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995): 440-2[10] Nijhawan PK, Katz G, Winter S \"Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission.\" Crit Care Med 24 (1996): 1086-9[11] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[12] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[13] Harvey AT, Preskorn SH \"Interactions of serotonin reuptake inhibitors with tricyclic antidepressants.\" Arch Gen Psychiatry 52 (1995): 783-4[14] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[15] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[16] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[17] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[18] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[20] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[21] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[22] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Trimipramine", "alternatives_b": "Citalopram, Esketamine", "updated_at": 1767369485}, {"id": 67160, "ingredient1": "Citalopram", "ingredient2": "Tripelennamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67247/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Duloxetine, Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "alternatives_b": "Azelastine, Ketotifen, Tetracaine", "updated_at": 1767369485}, {"id": 67161, "ingredient1": "Citalopram", "ingredient2": "Triprolidine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67248/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Vilazodone, Trimipramine, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "alternatives_b": "Azelastine, Ketotifen", "updated_at": 1767369485}, {"id": 67162, "ingredient1": "Citalopram", "ingredient2": "Triptorelin", "severity": "Major", "effect": "Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.", "mechanism_text": "Synergism", "recommendation": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67249/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm.\" ([2011 Aug 24]):[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm.\" ([2012 Mar 28]):[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[9] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[12] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Kaletra (lopinavir-ritonavir)\" Abbott Pharmaceutical, Abbott Park, IL.[15] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Phenelzine, Duloxetine, Tranylcypromine, Vilazodone, Paroxetine, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, More", "alternatives_b": "Megestrol acetate, Ethinylestradiol, Diethylstilbestrol, Medroxyprogesterone acetate", "updated_at": 1767369485}, {"id": 67163, "ingredient1": "Citalopram", "ingredient2": "Troleandomycin", "severity": "Minor", "effect": "Coadministration with inhibitors of CYP450 3A4 is not expected to significantly affect the pharmacokinetics of citalopram or escitalopram, both of which are partially metabolized by the isoenzyme. Administration of racemic citalopram (40 mg) in combination with the potent CYP450 3A4 inhibitor ketoconazole (200 mg) decreased the ketoconazole peak plasma concentration (Cmax) by 21% and systemic exposure (AUC) by 10%, but did not significantly affect the pharmacokinetics of citalopram.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67250/", "reference_text": "[1] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[2] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[3] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[4] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[6] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Maprotiline, St. John's Wort, Milnacipran, Vortioxetine, Doxepin, Duloxetine, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, More", "alternatives_b": "Lincomycin, Dirithromycin", "updated_at": 1767369485}, {"id": 67164, "ingredient1": "Citalopram", "ingredient2": "Tryptophan", "severity": "Major", "effect": "Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucinations, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.", "source": "DDInter", "management_text": "The concomitant use of serotonin reuptake inhibitors and tryptophan should be avoided.", "mechanism_text": "Synergism", "recommendation": "The concomitant use of serotonin reuptake inhibitors and tryptophan should be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67251/", "reference_text": "[1] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[2] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[3] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[4] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[5] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[6] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[7] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[8] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[9] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals, Raritan, NJ.[10] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[11] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[12] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[13] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[14] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[15] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[16] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[17] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[18] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Citalopram, Esketamine", "alternatives_b": "Bupropion, Viloxazine, Esketamine, Tryptophan", "updated_at": 1767369485}, {"id": 67165, "ingredient1": "Citalopram", "ingredient2": "Tucatinib", "severity": "Minor", "effect": "Coadministration with inhibitors of CYP450 3A4 is not expected to significantly affect the pharmacokinetics of citalopram or escitalopram, both of which are partially metabolized by the isoenzyme. Administration of racemic citalopram (40 mg) in combination with the potent CYP450 3A4 inhibitor ketoconazole (200 mg) decreased the ketoconazole peak plasma concentration (Cmax) by 21% and systemic exposure (AUC) by 10%, but did not significantly affect the pharmacokinetics of citalopram.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67252/", "reference_text": "[1] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[2] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[3] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[4] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[6] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Sertraline, Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Doxepin, Duloxetine, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, More", "alternatives_b": "Dacomitinib, Tepotinib, Selumetinib, Cobimetinib, Capmatinib, Afatinib, Tivozanib, Brigatinib, Axitinib, Ripretinib, Alpelisib, More", "updated_at": 1767369485}, {"id": 67166, "ingredient1": "Citalopram", "ingredient2": "Urea", "severity": "Moderate", "effect": "Coadministration with diuretics may potentiate the risk of hyponatremia associated with the use of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). Elderly patients and patients taking diuretics or who are otherwise volume-depleted may be at greater risk of developing hyponatremia with SSRIs and SNRIs. Antihypertensive agents such as diuretics may potentiate the orthostatic effect that is occasionally observed upon the initiation of SSRI or SNRI therapy. Syncope and orthostatic hypotension tend to occur within the first week of SNRI/SSRI therapy but can occur at any time during treatment, particularly after a dosage increase. The use of SSRIs or SNRIs may also cause sustained increases in blood pressure and heart rate, which may antagonize the therapeutic effects of antihypertensive medications.", "source": "DDInter", "management_text": "Caution is recommended if SSRIs or SNRIs are prescribed in combination with diuretics, particularly in the elderly. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hyponatremia such as nausea, vomiting, headache, malaise, lethargy, irritability, difficulty concentrating, memory impairment, confusion, weakness, muscle spasm, and unsteadiness (which may lead to falls). More severe and/or acute cases may include hallucination, syncope, seizure, coma, respiratory arrest, and death. Discontinuation of SSRI/SNRI therapy should be considered in patients who develop symptomatic hyponatremia, and appropriate medical intervention instituted as necessary. Patients should also have their blood pressure and pulse monitored before and during SSRI/SNRI therapy, especially during the first few weeks and following a dosage increase. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if SSRIs or SNRIs are prescribed in combination with diuretics, particularly in the elderly.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67253/", "reference_text": "[1] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[2] Jackson C, Carson W, Markowitz J, Mintzer J \"SIADH associated with fluoxetine and sertraline therapy.\" Am J Psychiatry 152 (1995): 809-10[3] Robinson D, Brooks J, Mahler E, Sheikh JI \"SIADH--compulsive drinking or SSRI influence?\" Ann Pharmacother 30 (1996): 885[4] Odeh M, Beny A, Oliven A \"Severe symptomatic hyponatremia during citalopram therapy.\" Am J Med Sci 321 (2001): 159-60[5] Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA \"Fluoxetine as a cause of SIADH.\" Am J Psychiatry 148 (1991): 542-3[6] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[7] Jacob S, Spinler SA \"Hyponatremia associated with selective serotonin-reuptake inhibitors in older adults.\" Ann Pharmacother 40 (2006): 1618-22[8] Fitzgerald MA \"Hyponatremia associated with SSRI use in a 65-year-old woman.\" Nurse Pract 33 (2008): 11-2[9] van Campen JP, Voets AJ \"SIADH caused by paroxetine.\" Ann Pharmacother 30 (1996): 1499[10] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[11] Kessler J, Samuels SC \"Sertraline and hyponatremia.\" N Engl J Med 335 (1996): 524[12] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[13] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[14] Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J \"Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine.\" J Toxicol Clin Toxicol 35 (1997): 93-5[15] Crews JR, Potts NL, Schreiber J, Lipper S \"Hyponatremia in a patient treated with sertraline.\" Am J Psychiatry 150 (1993): 1564[16] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[17] Bradley ME, Foote EF, Lee EN, Merkle L \"Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature.\" Pharmacotherapy 16 (1996): 680-3[18] Odeh M, Seligmann H, Oliven A \"Severe life-threatening hyponatremia during paroxetine therapy.\" J Clin Pharmacol 39 (1999): 1290-1[19] Thornton SL, Resch DS \"SIADH associated with sertraline therapy.\" Am J Psychiatry 152 (1995): 809[20] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[21] \"Selective serotonin reuptake inhibitors and SIADH.\" Med J Aust 164 (1996): 562[22] Bouman WP, Johnson H, TrescoliSerrano C, Jones RG \"Recurrent hyponatremia associated with sertraline and lofepramine.\" Am J Psychiatry 154 (1997): 580[23] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[24] Goddard C, Paton C \"Hyponatraemia associated with paroxetine.\" BMJ 305 (1992): 1332[25] Barclay TS, Lee AJ \"Citalopram-associated SIADH.\" Ann Pharmacother 36 (2002): 1558-63[26] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[27] Covyeou JA, Jackson CW \"Hyponatremia associated with escitalopram.\" N Engl J Med 356 (2007): 94-5[28] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[29] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[30] Schattner A, Skurnik Y \"Fluoxetine-induced SIADH.\" J Am Geriatr Soc 44 (1996): 1413[31] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[32] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[33] Spigset O, hedenmalm K \"Hyponatremia in relation to treatment with antidepressants: a survey of reports in the World Health Organization data base for spontaneous reporting of adverse drug reactions.\" Pharmacotherapy 17 (1997): 348-52[34] Staab JP, Yerkes SA, Cheney EM, Clayton AH \"Transient SIADH associated with fluoxetine.\" Am J Psychiatry 147 (1990): 1569-70[35] Blacksten JV, Birt JA \"Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine.\" Ann Pharmacother 27 (1993): 723-4[36] Llorente MD, Gorelick M, Silverman MA \"Sertraline as the cause of inappropriate antidiuretic hormone secretion.\" J Clin Psychiatry 55 (1994): 543-4[37] Baliga RR, McHardy KC \"Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119].\" Br J Clin Pract 47 (1993): 62-3[38] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[39] Hwang AS, Magraw RM \"Syndrome of inappropriate secretion of antidiuretic hormone due to fluoxetine.\" Am J Psychiatry 146 (1989): 399[40] Cohen BJ, Mahelsky M, Adler L \"More cases of SIADH with fluoxetine.\" Am J Psychiatry 147 (1990): 948-9[41] Ayonrinde OT, Sanfilippo FM \"SSRI antidepressants and SIADH.\" Aust N Z J Psychiatry 31 (1997): 306-7[42] Kazal LA, Jr Hall DL, Miller LG, Noel ML \"Fluoxetine-induced SIADH: a geriatric occurrence?\" J Fam Pract 36 (1993): 341-3[43] Ayonrinde OT, Reutens SG, Sanfilippo FM \"Paroxetine-induced SIADH.\" Med J Aust 163 (1995): 390[44] Chua TP, Vong SK \"Hyponatraemia associated with paroxetine.\" BMJ 306 (1993): 143[45] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[46] Woo MH, Smythe MA \"Association of SIADH with selective serotonin reuptake inhibitors.\" Ann Pharmacother 31 (1997): 108-10[47] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[48] Rosner MH \"Severe hyponatremia associated with the combined use of thiazide diuretics and selective serotonin reuptake inhibitors.\" Am J Med Sci 327 (2004): 109-11[49] Doshi D, Borison R \"Association of transient SIADH with sertraline.\" Am J Psychiatry 151 (1994): 779-80[50] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[51] Madhusoodanan S, Brenner R, Brafman I, Bogunovic O \"Hyponatremia associated with paroxetine use.\" South Med J 92 (1999): 843[52] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[53] Esposito P, Rampino T, Gregorini M, et al. \"Severe symptomatic hyponatremia during sibutramine therapy: a case report.\" Am J Kidney Dis 52 (2008): 137-9[54] Spier SA, Frontera MA \"Unexpected deaths in depressed medical inpatients treated with fluoxetine.\" J Clin Psychiatry 52 (1991): 377-82[55] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[56] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[57] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Maprotiline, St. John's Wort, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, More", "alternatives_b": "Tromethamine", "updated_at": 1767369485}, {"id": 67167, "ingredient1": "Citalopram", "ingredient2": "Urokinase", "severity": "Moderate", "effect": "Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.", "source": "DDInter", "management_text": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67254/", "reference_text": "[1] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG \"Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin.\" Acta Psychiatr Scand Suppl 350 (1989): 102-6[2] Skop BP, Brown TM \"Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors.\" Psychosomatics 37 (1996): 12-6[3] Settle EC \"Antidepressant drugs: disturbing and potentially dangerous adverse effects.\" J Clin Psychiatry 59 Suppl 16 (1998): 25-30[4] Layton D, Clark DWJ, Pearce GL, Shakir SAW \"Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England.\" Eur J Clin Pharmacol 57 (2001): 167-76[5] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[6] Leung M, Shore R \"Fluvoxamine-associated bleeding.\" Can J Psychiatry 41 (1996): 604-5[7] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[8] Tata LJ, Fortun PJ, Hubbard RB, et al. \"Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?\" Aliment Pharmacol Ther 22 (2005): 175-81[9] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[10] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B \"Paroxetine decreases platelet serotonin storage and platelet function in human beings.\" Clin Pharmacol Ther 68 (2000): 435-42[11] de Abajo FJ, Rodriguez LA, Montero D \"Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study.\" BMJ 319 (1999): 1106-9[12] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[13] Alderman CP, Moritz CK, Ben-Tovim DI \"Abnormal platelet aggregation associated with fluoxetine therapy.\" Ann Pharmacother 26 (1992): 1517-9[14] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[15] Krivy J, Wiener J \"Sertraline and platelet counts in idiopathic thrombocytopenia purpura.\" Lancet 345 (1995): 132[16] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[17] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[18] Pai VB, Kelly MW \"Bruising associated with the use of fluoxetine.\" Ann Pharmacother 30 (1996): 786-8[19] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990): 213-7[20] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ \"Fluoxetine and bleeding in obsessive-compulsive disorder.\" Am J Psychiatry 148 (1991): 949[21] Alderman CP, Seshadri P, Ben-Tovim DI \"Effects of serotonin reuptake inhibitors on hemostasis.\" Ann Pharmacother 30 (1996): 1232-4[22] Humphries JE, Wheby MS, VandenBerg SR \"Fluoxetine and the bleeding time.\" Arch Pathol Lab Med 114 (1990): 727-8[23] Woolfrey S, Gammack NS, Dewar MS, Brown PJ \"Fluoxetine-warfarin interaction.\" BMJ 307 (1993): 241[24] Messiha FS \"Fluoxetine - adverse effects and drug-drug interactions.\" J Toxicol Clin Toxicol 31 (1993): 603-30[25] Ford MA, Anderson ML, Rindone JP, Jaskar DW \"Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin.\" J Clin Psychopharmacol 17 (1997): 110-2[26] Ottervanger JP, Stricker BH, Huls J, Weeda JN \"Bleeding attributed to the intake of paroxetine.\" Am J Psychiatry 151 (1994): 781-2[27] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[28] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH \"Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study.\" Arch Intern Med 163 (2003): 59-64[29] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[30] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[31] Aranth J, Lindberg C \"Bleeding, a side effect of fluoxetine.\" Am J Psychiatry 149 (1992): 412[32] Cerner Multum, Inc. \"Australian Product Information.\" O 0[33] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S \"Intracranial haemorrhage and use of selective serotonin reuptake inhibitors.\" Br J Clin Pharmacol 50 (2000): 43-7[34] de Maistre E, Allart C, Lecompte T, Bollaert PE \"Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors.\" Am J Med 113 (2002): 530-2[35] Claire RJ, Servis ME, Cram DL Jr \"Potential interaction between warfarin sodium and fluoxetine.\" Am J Psychiatry 148 (1991): 1604[36] Dent LA, Orrock MW \"Warfarin-fluoxetine and diazepam-fluoxetine interaction.\" Pharmacotherapy 17 (1997): 170-2[37] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[38] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[39] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[40] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[41] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[42] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Protein C, Selexipag", "alternatives_b": "Maprotiline, St. John's Wort, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, More", "updated_at": 1767369485}, {"id": 67168, "ingredient1": "Citalopram", "ingredient2": "Valbenazine", "severity": "Major", "effect": "Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.", "mechanism_text": "Synergism", "recommendation": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67255/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm.\" ([2011 Aug 24]):[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm.\" ([2012 Mar 28]):[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[9] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[12] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Kaletra (lopinavir-ritonavir)\" Abbott Pharmaceutical, Abbott Park, IL.[15] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Levomilnacipran, Oxitriptan, Vortioxetine, Milnacipran, Tryptophan, Vilazodone", "alternatives_b": "Dalfampridine, Tafamidis", "updated_at": 1767369485}, {"id": 67169, "ingredient1": "Citalopram", "ingredient2": "Valerian", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67256/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67170, "ingredient1": "Citalopram", "ingredient2": "Vandetanib", "severity": "Major", "effect": "Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.", "mechanism_text": "Synergism", "recommendation": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67257/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm.\" ([2011 Aug 24]):[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm.\" ([2012 Mar 28]):[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[9] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[12] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Kaletra (lopinavir-ritonavir)\" Abbott Pharmaceutical, Abbott Park, IL.[15] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Phenelzine, Duloxetine, Tranylcypromine, Vilazodone, Paroxetine, Desvenlafaxine, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, More", "alternatives_b": "Dacomitinib, Tepotinib, Selumetinib, Cobimetinib, Capmatinib, Afatinib, Tivozanib, Brigatinib, Axitinib, Ripretinib, Alpelisib, More", "updated_at": 1767369485}, {"id": 67171, "ingredient1": "Citalopram", "ingredient2": "Vardenafil", "severity": "Major", "effect": "Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.", "mechanism_text": "Synergism", "recommendation": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67258/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm.\" ([2011 Aug 24]):[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm.\" ([2012 Mar 28]):[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[9] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[12] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Kaletra (lopinavir-ritonavir)\" Abbott Pharmaceutical, Abbott Park, IL.[15] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Desvenlafaxine, St. John's Wort, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Vilazodone, Esketamine", "alternatives_b": "Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Trospium, Mirabegron, Yohimbine, Avanafil, Ammonium chloride, Dimethyl sulfoxide", "updated_at": 1767369485}, {"id": 67172, "ingredient1": "Citalopram", "ingredient2": "Vasopressin", "severity": "Moderate", "effect": "The antidiuretic response to vasopressin or desmopressin may be potentiated by certain drugs, including nonsteroidal anti-inflammatory agents, selective serotonin reuptake inhibitors, tricyclic/tetracyclic antidepressants, carbamazepine, chlorpropamide, chlorpromazine, clofibrate, eslicarbazepine, fludrocortisone, haloperidol, lamotrigine, oxcarbazepine, urea, and some antineoplastic agents (e.g., vinca alkaloids, cisplatin, cyclophosphamide). These drugs can occasionally cause fluid retention, in some cases secondary to the syndrome of inappropriate antidiuretic hormone secretion (SIADH). Coadministration with vasopressin or desmopressin may, therefore, increase the risk of water intoxication and/or hyponatremia. Seizure and coma in association with severe hyponatremia have been reported during concomitant use of desmopressin and imipramine or ibuprofen.", "source": "DDInter", "management_text": "Caution is advised when vasopressin or desmopressin is used in combination with drugs that can cause fluid retention or SIADH. Some authorities recommend adjusting vasopressin dosage as needed. Serum electrolytes, especially sodium, as well as BUN and creatinine should be monitored regularly. Patients should be advised to seek medical attention if they develop signs and symptoms of water intoxication or hyponatremia such as anorexia, nausea, vomiting, headache, malaise, lethargy, irritability, difficulty concentrating, memory impairment, confusion, weakness, muscle spasm, unsteadiness (which may lead to falls), anuria, and weight gain. Severe hyponatremia can be life-threatening if it is not promptly diagnosed and treated; therefore, early treatment is important to help prevent progression to seizures, coma, respiratory arrest, and death.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when vasopressin or desmopressin is used in combination with drugs that can cause fluid retention or SIADH.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67259/", "reference_text": "[1] Vanhees SL, Paridaens R, Vansteenkiste JF \"Syndrome of inappropriate antidiuretic hormone associated with chemotherapy-induced tumour lysis in small-cell lung cancer: case report and literature review.\" Ann Oncol 11 (2000): 1061-5[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Kosmidis HV, Bouhoutsou DO, Varvoutsi MC, et al. \"Vincristine overdose: experience with 3 patients.\" Pediatr Hematol Oncol 8 (1991): 171-8[4] Maramattom BV \"Duloxetine-induced syndrome of inappropriate antidiuretic hormone secretion and seizures.\" Neurology 66 (2006): 773-4[5] ten Holt WL, van Iperen CE, Schrijver G, Bartelink AK \"Severe hyponatremia during therapy with fluoxetine.\" Arch Intern Med 156 (1996): 681-2[6] Miller MG \"Tricyclics as a possible cause of hyponatremia in psychiatric patients.\" Am J Psychiatry 146 (1989): 807[7] Petersson I, Nilsson G, Hansson B-G, Hedner T \"Water intoxication associated with non-steroidal anti-inflammatory drug therapy.\" Acta Med Scand 221 (1987): 221-3[8] Nielsen OA, Johannessen AC, Bardrum B \"Oxcarbazepine-induced hyponatremia, a cross-sectional study.\" Epilepsy Res 2 (1988): 269-71[9] Schattner A, Skurnik Y \"Fluoxetine-induced SIADH.\" J Am Geriatr Soc 44 (1996): 1413[10] Tanay A, Firemann Z, Yust I, Abramov AL \"Chlorpropamide-induced syndrome of inappropriate antidiuretic hormone secretion.\" J Am Geriatr Soc 29 (1981): 334-6[11] Catalano G, Kanfer SN, Catalano MC, Alberts VA \"The role of sertraline in a patient with recurrent hyponatremia.\" Gen Hosp Psychiatry 18 (1996): 278-83[12] Kokko H, Hall PD, Afrin LB \"Fentanyl-associated syndrome of inappropriate antidiuretic hormone secretion.\" Pharmacotherapy 22 (2002): 1188-92[13] Chua TP, Vong SK \"Hyponatraemia associated with paroxetine.\" BMJ 306 (1993): 143[14] Giles PD, Seem CC \"Dothiepin and water handling.\" Lancet 2 (1985): 1013[15] Stephens WP, Coe JY, Baylis PH \"Plasma arginine vasopressin concentrations and antidiuretic action of carbamazepine.\" Br Med J 1 (1978): 1445-7[16] el Weshi A, Thieblemont C, Cottin V, Barbet N, Catimel G \"Cisplatin-induced hyponatremia and renal sodium wasting.\" Acta Oncol 34 (1995): 264-5[17] Goldstein L, Barker M, Segall F, Asihene R, Balser S, Lautenbach D, Mccoy M \"Seizure and transient SIADH associated with sertraline.\" Am J Psychiatry 153 (1996): 732[18] Lahr MB \"Hyponatremia during carbamazepine therapy.\" Clin Pharmacol Ther 37 (1985): 693-6[19] Robinson D, Brooks J, Mahler E, Sheikh JI \"SIADH--compulsive drinking or SSRI influence?\" Ann Pharmacother 30 (1996): 885[20] Wilkinson TJ, Begg EJ, Winter AC, Sainsbury R \"Incidence and risk factors for hyponatraemia following treatment with fluoxetine or paroxetine in elderly people.\" Br J Clin Pharmacol 47 (1999): 211-7[21] Kadowaki T, Hagura R, Kajinuma H, et al \"Chlorpropamide-induced hyponatremia: incidence and risk factors.\" Diabetes Care 6 (1983): 468-71[22] Cohen BJ, Mahelsky M, Adler L \"More cases of SIADH with fluoxetine.\" Am J Psychiatry 147 (1990): 948-9[23] Laycock JF, Lewis AF \"Potentiation of the response to vasopressin (pitressin) by treatment with a combination of chlorpropamide and chlorothiazide in Brattleboro rats with hereditary hypothalamic diabetes insipidus.\" Br J Pharmacol 59 (1977): 11-6[24] Settle EC \"Antidepressant drugs: disturbing and potentially dangerous adverse effects.\" J Clin Psychiatry 59 Suppl 16 (1998): 25-30[25] Gandelman MS \"Review of carbamazepine-induced hyponatremia.\" Prog Neuropsychopharmacol Biol Psychiatry 18 (1994): 211-33[26] Ryan M, Adams AG, Larive LL \"Hyponatremia and leukopenia associated with oxcarbazepine following carbamazepine therapy.\" Am J Health Syst Pharm 58 (2001): 1637-9[27] Ananth J, Lin KM \"Siadh: a serious side effect of psychotropic drugs.\" Int J Psychiatry Med 16 (1986): 401-7[28] Rider JM, Mauger TF, Jameson JP, Notman DD \"Water handling in patients receiving haloperidol decanoate.\" Ann Pharmacother 29 (1995): 663-6[29] Wylie KR, Harris SJ, Harrop FM \"Lofepramine-induced hyponatraemia.\" Br J Psychiatry 154 (1989): 419-20[30] Woo MH, Smythe MA \"Association of SIADH with selective serotonin reuptake inhibitors.\" Ann Pharmacother 31 (1997): 108-10[31] Draper B, Berman K \"Tolerability of selective serotonin reuptake inhibitors: issues relevant to the elderly.\" Drugs Aging 25 (2008): 501-19[32] Whittaker JA, Parry DH, Bunch C, Weatherall DJ \"Coma associated with vincristine therapy.\" Br Med J 4 (1973): 335-7[33] Pledger DR, Mathew H \"Hyponatraemia and clomipramine therapy.\" Br J Psychiatry 154 (1989): 263-4[34] Boyd IW \"Hyponatremia with venlafaxine.\" Ann Pharmacother 32 (1998): 981[35] Garrett CA, Simpson TA \"Syndrome of inappropriate antidiuretic hormone associated with vinorelbine therapy.\" Ann Pharmacother 32 (1998): 1306-9[36] Lichtigfeld FJ, Gillman MA \"Dangerous synergism between sedatives and a hyponatraemic state.\" J R Soc Med 83 (1990): 185[37] Woster P, Carrazana EJ \"Oxcarbazepine and hyponatremia.\" Am J Health Syst Pharm 59 (2002): 467[38] McCarron M, Wright GD, Roberts SD \"Water intoxication after low dose cyclophosphamide.\" BMJ 311 (1995): 292[39] Roxanas MG \"Mirtazapine-induced hyponatraemia.\" Med J Aust 179 (2003): 453-4[40] Jacob S, Spinler SA \"Hyponatremia associated with selective serotonin-reuptake inhibitors in older adults.\" Ann Pharmacother 40 (2006): 1618-22[41] \"Product Information. Vasopressin (vasopressin).\" APP (Abraxis Pharmaceutical Products), Schaumberg, IL.[42] Littlewood TJ, Smith AP \"Syndrome of inappropriate antidiuretic hormone secretion due to treatment of lung cancer with cisplatin.\" Thorax 39 (1984): 636-7[43] Ayonrinde OT, Reutens SG, Sanfilippo FM \"Paroxetine-induced SIADH.\" Med J Aust 163 (1995): 390[44] Luzecky MH, Burman KD, Schultz ER \"The syndrome of inappropriate secretion of antidiuretic hormone associated with amitriptyline administration.\" South Med J 67 (1974): 495-7[45] Kosten TR, Camp W \"Inappropriate secretion of antidiuretic hormone in a patient receiving piperazine phenothiazines.\" Psychosomatics 21 (1980): 351,354-5[46] Staab JP, Yerkes SA, Cheney EM, Clayton AH \"Transient SIADH associated with fluoxetine.\" Am J Psychiatry 147 (1990): 1569-70[47] Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J \"Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine.\" J Toxicol Clin Toxicol 35 (1997): 93-5[48] Hamburger S, Langley H, Bowers G \"The syndrome of inappropriate secretion of antidiuretic hormone associated with amitriptyline or trifluoperazine administration.\" J Kans Med Soc 81 (1980): 469-70[49] Kimura T, Ota K, Shoju M et al \"Chlorpropamide-induced ADH release, hyponatremia and central pontine myelinolysis in diabetes mellitus.\" Tohoku J Exp Med 177 (1995): 303-13[50] Cutting HO \"Inappropriate secretion of antidiuretic hormone secondary to vincristine therapy.\" Am J Med 51 (1971): 269-71[51] Kagawa K, Fujitaka K, Isobe T, et al \"Syndrome of inappropriate secretion of ADH (SIADH) following cisplatin administration in a pulmonary adenocarcinoma patient with a malignant pleural effusion.\" Intern Med 40 (2001): 1020-3[52] Bavbek N, Kargili A, Akcay A, Kaya A \"Recurrent hyponatremia associated with citalopram and mirtazapine.\" Am J Kidney Dis 48 (2006): e61-2[53] Bradley ME, Foote EF, Lee EN, Merkle L \"Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature.\" Pharmacotherapy 16 (1996): 680-3[54] Matsumura M, Yamaguchi M, Sato T \"Severe hyponatremia in a patient treated with levomepromazine and carbamazepine.\" Intern Med 40 (2001): 459[55] Rault RM \"Case report: hyponatremia associated with nonsteroidal antiinflammatory drugs.\" Am J Med Sci 305 (1993): 318-20[56] Iyer AV, Krasnow SH, Dufour DR, Arcenas AS \"Sodium-wasting nephropathy caused by cisplatin in a patient with small-cell lung cancer.\" Clin Lung Cancer 5 (2003): 187-9[57] Ayonrinde OT, Sanfilippo FM \"SSRI antidepressants and SIADH.\" Aust N Z J Psychiatry 31 (1997): 306-7[58] \"Product Information. Pitressin (vasopressin).\" Parke-Davis, Morris Plains, NJ.[59] Gupta AK, Saravay SM \"Venlafaxine-induced hyponatremia.\" J Clin Psychopharmacol 17 (1997): 223-5[60] Munro AH, Crompton GK \"Inappropriate antidiuretic hormone secretion in oat-cell carcinoma of bronchus. Aggravation of hyponatraemia by intravenous cyclophosphamide.\" Thorax 27 (1972): 640-2[61] Llorente MD, Gorelick M, Silverman MA \"Sertraline as the cause of inappropriate antidiuretic hormone secretion.\" J Clin Psychiatry 55 (1994): 543-4[62] Hwang AS, Magraw RM \"Syndrome of inappropriate secretion of antidiuretic hormone due to fluoxetine.\" Am J Psychiatry 146 (1989): 399[63] Schwab M, Roder F, Morike K, Thon KP, Klotz U \"Drug-induced hyponatraemia in elderly patients.\" Br J Clin Pharmacol 48 (1999): 105-6[64] Ritch PS \"Cis-dichlorodiammineplatinum II-induced syndrome of inappropriate secretion of antidiuretic hormone.\" Cancer 61 (1988): 448-50[65] Kinzie BJ \"Management of the syndrome of inappropriate secretion of antidiuretic hormone.\" Clin Pharm 6 (1987): 625-33[66] Agrawal NK, Rastogi A, Goyal R, Singh SK \"Sertraline-induced hyponatremia in the elderly.\" CJEM 9 (2007): 415[67] Davison P, Wardrope J \"Acute amitriptyline withdrawal and hyponatraemia. A case report.\" Drug Saf 8 (1993): 78-80[68] Doshi D, Borison R \"Association of transient SIADH with sertraline.\" Am J Psychiatry 151 (1994): 779-80[69] Epstein S, Van Mieghem W, Simson E, Jackson WP \"Chlorpropamide hyponatremia.\" N Engl J Med 286 (1972): 785[70] Sloan RW, Kreider RM, Luderer JR \"The effect of chlorpropamide hyponatremia on mental status in a nursing home population.\" J Fam Pract 16 (1983): 937-42[71] Jayachandran NV, Chandrasekhara PK, Thomas J, Agrawal S, Narsimulu G \"Cyclophosphamide-associated complications: we need to be aware of SIADH and central pontine myelinolysis.\" Rheumatology 48 (2009): 89-90[72] Moses AM, Miller M \"Drug-induced dilutional hyponatremia.\" N Engl J Med 291 (1974): 1234-9[73] Pillans PI, Coulter DM \"Fluoxetine and hyponatraemia - a potential hazard in the elderly.\" N Z Med J 107 (1994): 85-6[74] Thornton SL, Resch DS \"SIADH associated with sertraline therapy.\" Am J Psychiatry 152 (1995): 809[75] Stuart MJ, Cuaso C, Miller M, Oski FA \"Syndrome of recurrent increased secretion of antidiuretic hormone following multiple doses of vincristine.\" Blood 45 (1975): 315-20[76] Aasen G, Frey HM \"Excessive sensitivity to the hyponatremic effect of chlorpropamide in a patient with diabetes mellitus and anterior pituitary insufficiency.\" Acta Med Scand 208 (1980): 233-6[77] Ashton MG, Ball SG, Thomas TH, Lee MR \"Water intoxication associated with carbamazepine tretment.\" Br Med J 1 (1977): 1134-5[78] Smith NJ, Espir ML, Baylis PH \"Raised plasma arginine vasopressin concentration in carbamazepine-induced water intoxication.\" Br Med J 2 (1977): 804[79] Sarret D, Le Berre JP, Zemraoui N \"Tramadol-induced hyponatremia.\" Am J Kidney Dis 52 (2008): 1026; author reply 1027[80] Instituto de Salud Pblica de Chile \"Sistema de Consulta de Productos Registrados. Available from: URL: http://registrosanitario.ispch.gob.cl/\" ([cited 2013]):[81] Madhusoodanan S, Osnos R \"Amitriptyline induced hyponatremia: a case report.\" Mt Sinai J Med 48 (1981): 431-3[82] Mitsch RA, Lee AK \"Syndrome of inappropriate antidiuretic hormone with imipramine.\" Drug Intell Clin Pharm 20 (1986): 787-9[83] Degner D, Grohmann R, Kropp S, et al. \"Severe adverse drug reactions of antidepressants: results of the German multicenter drug surveillance program AMSP.\" Pharmacopsychiatry 37 Suppl 1 (2004): S39-45[84] Masood GR, Karki SD, Patterson WR \"Hyponatremia with venlafaxine.\" Ann Pharmacother 32 (1998): 49-51[85] \"Selective serotonin reuptake inhibitors and SIADH.\" Med J Aust 164 (1996): 562[86] Orbo A, Simonsen E \"Cisplatin-induced sodium and magnesium wastage.\" Eur J Cancer 28A (1992): 1294[87] Kazal LA, Jr Hall DL, Miller LG, Noel ML \"Fluoxetine-induced SIADH: a geriatric occurrence?\" J Fam Pract 36 (1993): 341-3[88] Moses AM, Howanitz J, van Gemert M, Miller M \"Clofibrate-induced antidiuresis.\" J Clin Invest 52 (1973): 535-42[89] Johannessen AC, Nielsen OA \"Hyponatremia induced by oxcarbazepine.\" Epilepsy Res 1 (1987): 155-6[90] Harlow PJ, DeClerck YA, Shore NA, Ortega JA, Carranza A, Heuser E \"A fatal case of inappropriate ADH secretion induced by cyclophosphamide therapy.\" Cancer 44 (1979): 896-8[91] Goddard C, Paton C \"Hyponatraemia associated with paroxetine.\" BMJ 305 (1992): 1332[92] Fort S, Bannister P, Manning A, Bolton R, Losowsky MS \"Inappropriate antidiuretic hormone secretion associated with dothiepin.\" Lancet 2 (1985): 551[93] Zawada ET \"Renal consequences of nonsteroidal antiinflammatory drugs.\" Postgrad Med J 71 (1982): 223-30[94] \"Product Information. DDAVP (desmopressin).\" Rhone-Poulenc Rorer, Collegeville, PA.[95] Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA \"Fluoxetine as a cause of SIADH.\" Am J Psychiatry 148 (1991): 542-3[96] Van Amelsvoort T, Bakshi R, Devaux CB, Schwabe S \"Hyponatremia associated with carbamazepine and oxcarbazepine therapy: a review.\" Epilepsia 35 (1994): 181-8[97] Famularo G, Gasbarrone L, De Virgilio A, Minisola G \"Mirtazapine-associated hyponatremia in an elderly patient.\" Ann Pharmacother 43 (2009): 1144-5[98] O'Sullivan D, Oyebode F \"Hyponatraemia and lofepramine.\" Br J Psychiatry 150 (1987): 720-1[99] Abbott R \"Hyponatremia due to antidepressant medications.\" Ann Emerg Med 12 (1983): 708-10[100] Harris RC \"Cyclooxygenase-2 inhibition and renal physiology.\" Am J Cardiol 89(6 Suppl 1) (2002): 10-7[101] Shang CY, Soong WT, Lin HN \"Hypokalemia with venlafaxine.\" J Clin Psychiatry 63 (2002): 1049-50[102] Guay DR \"Hyponatremia associated with selective serotonin reuptake inhibitors. Available from: URL: http://www.ascp.com/publications/tcp/2000/feb/cr_hypo.shtml.\" ([2000 Feb]):[103] Culine S, Ghosn M, Droz JP \"Inappropriate antidiuretic hormone secretion induced by ifosfamide.\" Eur J Cancer 26 (1990): 922[104] \"Product Information. Vasostrict (vasopressin).\" Par Pharmaceutical Inc, Chestnut Ridge, NY.[105] DeFronzo RA, Braine H, Colvin M, Davis PJ \"Water intoxication in man after cyclophosphamide therapy: time course and relation to drug activation.\" Ann Intern Med 78 (1973): 861-9[106] Cilli AS, Algun E \"Oxcarbazepine-induced syndrome of inappropriate secretion of antidiuretic hormone.\" J Clin Psychiatry 63 (2002): 742[107] Levsky ME, Schwartz JB \"Sertraline-induced hyponatremia in an older patient.\" J Am Geriat Soc 46 (1998): 1582-3[108] Perucca E, Garratt A, Hebdige S, Richens A \"Water intoxication in epileptic patients receiving carbamazepine.\" J Neural Neurosurg Psychiatry 41 (1978): 713-8[109] van Campen JP, Voets AJ \"SIADH caused by paroxetine.\" Ann Pharmacother 30 (1996): 1499[110] Henkin Y, Kaplan Z, Alkan M \"Psychiatric presentation of hyponatremia associated with the use of amitriptyline: a report of two cases.\" Isr J Med Sci 25 (1989): 587-9[111] Bjorck E, Samuelsson J \"Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) after treatment with cyclophosphamide, alpha-interferon and betamethasone in a patient with multiple myeloma.\" Eur J Haematol 56 (1996): 323-5[112] Davis FB, Davis PJ \"Water metabolism in diabetes mellitus.\" Am J Med 70 (1981): 210-4[113] John L, Perreault MM, Tao T, Blew PG \"Serotonin syndrome associated with nefazodone and paroxetine.\" Ann Emerg Med 29 (1997): 287-9[114] \"Product Information. Stimate (desmopressin).\" Forest Pharmaceuticals, St. Louis, MO.[115] Crews JR, Potts NL, Schreiber J, Lipper S \"Hyponatremia in a patient treated with sertraline.\" Am J Psychiatry 150 (1993): 1564[116] Oldham RK, Pomeroy TC \"Vincristine-induced syndrome of inappropriate secretion of antidiuretic hormone.\" South Med J 65 (1972): 1010-2[117] Levin L, Sealy R, Barron J \"Syndrome of inappropriate antidiuretic hormone secretion following cis-dichlorodiammineplatinum II in a patient with malignant thymoma.\" Cancer 50 (1982): 2279-82[118] Garson M \"Syndrome of dilutional hyponatraemia secondary to tricyclic antidepressant.\" Practitioner 222 (1979): 411-2[119] Cinotti GA, Stirati G, Ruggiero F \"Abnormal water retention and symptomatic hyponatraemia in idiopathic diabetes insipidus during chlorpropamide therapy.\" Postgrad Med J 48 (1972): 107-11[120] Ortenzi A, Paggi A, Foschi N, Sabbatini D, Pistoli E \"Oxcarbazepine and adverse events: impact of age, dosage, metabolite serum concentrations and concomitant antiepileptic therapy.\" Funct Neurol 23 (2008): 97-100[121] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[122] Colgate R \"Hyponatraemia and inappropriate secretion of antidiuretic hormone associated with the use of imipramine.\" Br J Psychiatry 163 (1993): 819-22[123] Paliwal V, Garg RK, Kar AM, Singh MK \"Oxcarbazepine induced hyponatremic coma.\" Neurol India 54 (2006): 214-5[124] Nisbet P \"Chlorpropamide-induced hyponatraemia.\" Br Med J 1 (1977): 904[125] Adlakha A, Manocha AP, Bechard DL \"Imipramine-induced syndrome of inappropriate antidiuretic hormone secretion.\" South Med J 84 (1991): 1507-9[126] Kessler J, Samuels SC \"Sertraline and hyponatremia.\" N Engl J Med 335 (1996): 524[127] Hamed M, Mitchell H, Clow DJ \"Hyponatraemic convulsion associated with desmopressin and imipramine treatment.\" BMJ 306 (1993): 1169[128] Henry DA, Lawson DH, Reavey P, Renfrew S \"Hyponatraemia during carbamazepine treatment.\" Br Med J 1 (1977): 83-4[129] Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA \"Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report.\" Arq Neuropsiquiatr 64 (2006): 142-5[130] Zalin AM, Hutchinson CE, Jong M, Matthews K \"Hyponatraemia during treatment with chlorpropamide and Moduretic (amiloride plus hydrochlorothiazide).\" Br Med J (Clin Res Ed) 289 (1984): 659[131] Cantwell BM, Idle M, Millward MJ, Hall G, Lind MJ \"Encephalopathy with hyponatremia and inappropriate arginine vasopressin secretion following an intravenous ifosfamide infusion.\" Ann Oncol 1 (1990): 232[132] Parker WA \"Imipramine-induced syndrome of inappropriate antidiuretic hormone secretion.\" Drug Intell Clin Pharm 18 (1984): 890-4[133] Kruger S, Lindstaedt M \"Duloxetine and hyponatremia: a report of 5 cases.\" J Clin Psychopharmacol 27 (2007): 101-104[134] Cheung NT, Coley S, Sheeran T, Situnayake RD \"Syndrome of inappropriate secretion of antidiuretic hormone induced by diclofenac.\" BMJ 306 (1993): 186[135] Belton K, Thomas SH \"Drug-induced syndrome of inappropriate antidiuretic hormone secretion.\" Postgrad Med J 75 (1999): 509-10[136] Okamoto M, Nako Y, Tachibana A, et al \"Efficacy of phenytoin against hyponatremic seizures due to SIADH after administration of anticancer drugs in a neonate.\" J Perinatol 22 (2002): 247-8[137] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[138] Garcia M, Miller M, Moses AM \"Chlorpropamide-induced water retention in patients with diabetes mellitus.\" Ann Intern Med 75 (1971): 549-54[139] Kuroda H, Kawamura M, Hato T, et al. \"Syndrome of inappropriate secretion of antidiuretic hormone after chemotherapy with vinorelbine.\" Cancer Chemother Pharmacol (2007):[140] Kuz GM, Manssourian A \"Carbamazepine-induced hyponatremia: assessment of risk factors.\" Ann Pharmacother 39 (2005): 1943-6[141] O'Regan S, Carson S, Chesney RW, Drummond KN \"Electrolyte and acid-base disturbances in the management of leukemia.\" Blood 49 (1977): 345-53[142] Robson WL, Leung AK \"Hyponatraemia following desmopressin.\" BMJ 307 (1993): 64-5[143] Bluff DD, Oji N \"SIADH in a patient receiving sertraline.\" Ann Intern Med 123 (1995): 811[144] Baliga RR, McHardy KC \"Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119].\" Br J Clin Pract 47 (1993): 62-3[145] Blacksten JV, Birt JA \"Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine.\" Ann Pharmacother 27 (1993): 723-4[146] Kato A, Sugiura T, Yamamoto T, et al \"Water intoxication induced by low-dose oral cyclophosphamide in a patient with anti-neutrophil cytoplasmic antibody-related glomerulonephritis.\" NDT Plus 1 (2008): 286-8[147] Flint AJ, Crosby J, Genik JL \"Recurrent hyponatremia associated with fluoxetine and paroxetine.\" Am J Psychiatry 153 (1996): 134[148] Egger C, Muehlbacher M, Nickel M, Geretsegger C, Stuppaeck C \"A case of recurrent hyponatremia induced by venlafaxine.\" J Clin Psychopharmacol 26 (2006): 439[149] Otsuka F, Hayashi Y, Ogura T, et al \"Syndrome of inappropriate secretion of antidiuretic hormone following intra-thoracic cisplatin.\" Intern Med 35 (1996): 290-4[150] Nagappa M, Bhat RR, Sudeep K, Mishra SK, Badhe AS, Hemavathi B \"Vincrisitine-induced acute life-threatening hyponatremia resulting in seizure and coma.\" Indian J Crit Care Med 13 (2009): 167-8[151] \"Non-steroidal anti-inflammatory drugs and the kidney.\" Br Med J (Clin Res Ed) 293 (1986): 202-3[152] Leung M, Remick R \"Sertraline-associated hyponatremia.\" Can J Psychiatry 40 (1995): 497-8[153] Webberley MJ, Murray JA \"Life-threatening acute hyponatraemia induced by low dose cyclophosphamide and indomethacin.\" Postgrad Med J 65 (1989): 950-2[154] DeFronzo RA, Colvin OM, Braine H, Robertson GL, Davis PJ \"Proceedings: cyclophosphamide and the kidney.\" Cancer 33 (1974): 483-91[155] Lane RM \"SSRIs and hyponatraemia.\" Br J Clin Pract 51 (1997): 144-6[156] Appel WC \"Possible roles of normeperidine and hyponatremia in a postoperative death.\" Can Med Assoc J 137 (1987): 912-3[157] Bouman WP, Johnson H, TrescoliSerrano C, Jones RG \"Recurrent hyponatremia associated with sertraline and lofepramine.\" Am J Psychiatry 154 (1997): 580[158] Tomiwa K, Mikawa H, Hazama F, Yazawa K, Hosoya R, Ohya T, Nishimura K \"Syndrome of inappropriate secretion of antidiuretic hormone caused by vincristine therapy: a case report of the neuropathology.\" J Neurol 229 (1983): 267-72[159] Dirks AC, van Hyfte DM \"Recurrent hyponatremia after substitution of citalopram with duloxetine.\" J Clin Psychopharmacol 27 (2007): 313[160] Izzedine H, Launay-Vacher V, Ciroldi M, Fardet L, Deray G \"Fanconi and inappropriate secretion of antidiuretic hormone syndromes secondary to venlafaxine therapy.\" Nephron 92 (2002): 944-6[161] Meynaar IA, Peeters AJ, Mulder AH, Ottervanger JP \"Syndrome of inappropriate ADH secretion attributed to the serotonin re-uptake inhibitors, venlafaxine and paroxetine.\" Neth J Med 50 (1997): 243-5[162] \"Inappropriate antidiuretic hormone secretion.\" West J Med 122 (1975): 145-9[163] Palmer BF, Gates JR, Lader M \"Causes and management of hyponatremia.\" Ann Pharmacother 37 (2003): 1694-702[164] Liu BA, Mittmann N, Knowles SR, Shear NH \"Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043.\" CMAJ 155 (1996): 519-27[165] Lazarevic V, Hagg E, Wahlin A \"Hiccups and severe hyponatremia associated with high-dose cyclophosphamide in conditioning regimen for allogeneic stem cell transplantation.\" Am J Hematol 82 (2007): 88[166] Moses AM, Howanitz J, Miller M \"Diuretic action of three sulfonylurea drugs.\" Ann Intern Med 78 (1973): 541-4[167] Safdieh JE, Rudominer R \"A case of hyponatremia induced by duloxetine.\" J Clin Psychopharmacol 26 (2006): 675-676[168] Fonseca VA, Deb M, Gokani SS, Bhandarkar SD \"Chlorpropamide induced syndrome of inappropriate antidiuretic hormone secretion.\" J Postgrad Med 26 (1980): 127-30[169] Weir MR \"Renal effects of nonselective NSAIDs and coxibs.\" Cleve Clin J Med 69(Suppl 1) (2002): SI53-8[170] Nicholson RG, Feldman W \"Hyponatremia in association with vincristine therapy.\" Can Med Assoc J 106 (1972): 356-7[171] Kalff R, Houtkooper MA, Meyer JW, et al \"Carbamazepine and serum sodium levels.\" Epilepsia 24 (1984): 390-7[172] Dong X, Leppik IE, White J, Rarick J \"Hyponatremia from oxcarbazepine and carbamazepine.\" Neurology 65 (2005): 1976-8[173] Bourgeois JA \"Reversible hyponatremia and venlafaxine.\" Psychosomatics 46 (2005): 495-6[174] Purcell P, Valmana A \"Toxic epidermal necrolysis following chlorpromazine ingestion complicated by SIADH.\" Postgrad Med J 72 (1996): 186-9[175] Steinhoff BJ, Stoll KD, Stodieck SR, Paulus W \"Hyponatremic coma under oxcarbazepine therapy.\" Epilepsy Res 11 (1992): 67-70[176] Isojarvi JI, Huuskonen UE, Pakarinen AJ, Vuolteenaho O, Myllyla VV \"The regulation of serum sodium after replacing carbamazepine with oxcarbazepine.\" Epilepsia 42 (2001): 741-5[177] Jackson C, Carson W, Markowitz J, Mintzer J \"SIADH associated with fluoxetine and sertraline therapy.\" Am J Psychiatry 152 (1995): 809-10[178] Bissett D Cornford EJ Sokal M \"Hyponatraemia following cisplatin chemotherapy.\" Acta Oncol 28 (1989): 823[179] Matuk F, Kalyanaraman K \"Inappropriate ADH secretion.\" Arch Neurol 34 (1977): 725[180] Zavagli G Ricci G Tataranni G Mapelli G Abbasciano V \"Life-threatening hyponatremia caused by vinblastine.\" Med Oncol Tumor Pharmacother 5 (1988): 67-9[181] Ljung R \"Use of desmopressin and concomitant use of potentially interacting drugs in elderly patients in Sweden.\" Eur J Clin Pharmacol (2008):[182] Harper KM, Knapp DJ, Criswell HE, Breese GR \"Vasopressin and alcohol: A multifaceted relationship.\" Psychopharmacology (Berl) 235 (2018): 3363-79[183] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[184] Collins GB, Brosnihan KB, Zuti RA, Messina M, Gupta MK \"Neuroendocrine, fluid balance, and thirst responses to alcohol in alcoholics.\" Alcohol Clin Exp Res 16 (1992): 228-32[185] Hirschl MM, Derfler K, Bieglmayer C, et.al \"Hormonal derangements in patients with severe alcohol intoxication.\" Alcohol Clin Exp Res 18 (1994): 761-6[186] \"Product Information. Vasostrict (vasopressin).\" Par Pharmaceutical Inc, Chestnut Ridge, NY.[187] Taivainen H, Laitinen K, Tahtela R, Kilanmaa K, Valimaki MJ \"Role of plasma vasopressin in changes of water balance accompanying acute alcohol intoxication.\" Alcohol Clin Exp Res 19 (1995): 759-62[188] Cerner Multum, Inc. \"Australian Product Information.\" O 0[189] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[190] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[191] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[192] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Phenelzine, Tranylcypromine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, Tryptophan, Bupropion, Esketamine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67173, "ingredient1": "Citalopram", "ingredient2": "Vemurafenib", "severity": "Major", "effect": "Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.", "mechanism_text": "Synergism", "recommendation": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67260/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm.\" ([2011 Aug 24]):[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm.\" ([2012 Mar 28]):[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[9] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[12] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Kaletra (lopinavir-ritonavir)\" Abbott Pharmaceutical, Abbott Park, IL.[15] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Phenelzine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Viloxazine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion, Esketamine", "alternatives_b": "Tinidazole, Mitapivat, Ascorbic acid, Oxytetracycline, Ciclopirox, Sulfamethizole, Simeprevir, Diazoxide, Econazole, Povidone-iodine, Sulfisoxazole, More", "updated_at": 1767369485}, {"id": 67174, "ingredient1": "Citalopram", "ingredient2": "Venlafaxine", "severity": "Major", "effect": "Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval including tricyclic antidepressants and other antidepressants (e.g., trazodone) may result in additive effects and increased risk of ventricular arrhythmias such as torsade de pointes and sudden death. Concomitant use of agents with serotonergic activity including selective serotonin reuptake inhibitors, tricyclic antidepressants, and other antidepressants may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.", "source": "DDInter", "management_text": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure. However, if treatment with citalopram is required in these patients, the labeling recommends that the dosage not exceed 40 mg/day, as higher dosages may have an excessive effect on the QT interval and confer no additional benefit in the treatment of depression. In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk. Patients should be closely monitored for symptoms of the serotonin syndrome during treatment. Particular caution is advised when increasing the dosages of these agents. If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary. Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).", "mechanism_text": "Synergism", "recommendation": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67261/", "reference_text": "[1] Lane R, Baldwin D \"Selective serotonin reuptake inhibitor--induced serotonin syndrome: review.\" J Clin Psychopharmacol 17 (1997): 208-21[2] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993): 84-8[3] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995): 481-2[4] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[5] Insel TR, Roy BF, Cohen RM, Murphy DL \"Possible development of the serotonin syndrome in man.\" Am J Psychiatry 139 (1982): 954-5[6] Laird LK \"Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder.\" Psychopharmacol Bull 32 (1996): 569-78[7] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm.\" ([2011 Aug 24]):[8] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[9] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995): 440-2[10] Nijhawan PK, Katz G, Winter S \"Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission.\" Crit Care Med 24 (1996): 1086-9[11] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[12] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[13] Harvey AT, Preskorn SH \"Interactions of serotonin reuptake inhibitors with tricyclic antidepressants.\" Arch Gen Psychiatry 52 (1995): 783-4[14] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[15] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[16] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[17] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[18] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[19] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[20] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[21] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[22] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Esketamine, Venlafaxine", "alternatives_b": "Citalopram, Esketamine", "updated_at": 1767369485}, {"id": 67175, "ingredient1": "Citalopram", "ingredient2": "Verapamil", "severity": "Minor", "effect": "Coadministration with inhibitors of CYP450 3A4 is not expected to significantly affect the pharmacokinetics of citalopram or escitalopram, both of which are partially metabolized by the isoenzyme. Administration of racemic citalopram (40 mg) in combination with the potent CYP450 3A4 inhibitor ketoconazole (200 mg) decreased the ketoconazole peak plasma concentration (Cmax) by 21% and systemic exposure (AUC) by 10%, but did not significantly affect the pharmacokinetics of citalopram.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67262/", "reference_text": "[1] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[2] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[3] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[4] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[6] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Desvenlafaxine, St. John's Wort, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Esketamine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67176, "ingredient1": "Citalopram", "ingredient2": "Vigabatrin", "severity": "Moderate", "effect": "The efficacy of anticonvulsants may be diminished during coadministration with selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitor (SNRIs). Antidepressants including SSRIs and SNRIs can reduce seizure threshold.Coadministration of SSRIs or SNRIs with some anticonvulsants, particularly carbamazepine, eslicarbazepine, oxcarbazepine and valproic acid, may increase the risk of hyponatremia. The risk appears to be dose-related, and elderly patients and patients who are volume depleted (e.g., diuretic use) may be at greater risk.", "source": "DDInter", "management_text": "SSRIs and SNRIs should be avoided in patients with unstable epilepsy, and used cautiously in patients with epilepsy controlled with anticonvulsant medications. Treatment with SSRIs and SNRIs should be discontinued if seizures develop or seizure frequency increases. Patients receiving SSRIs or SNRIs with anticonvulsants, particularly carbamazepine, eslicarbazepine, oxcarbazepine and/or valproic acid, should also have serum sodium levels measured regularly and monitored for development of hyponatremia, particularly when higher dosages of these medications are used. Signs and symptoms of hyponatremia include nausea, vomiting, headache, difficulty concentrating, memory impairment, confusion, malaise, lethargy, muscle weakness or spasms, and unsteadiness. In more severe and/or acute cases, hallucination, syncope, seizure, coma, respiratory arrest, and death may occur.", "mechanism_text": "Antagonism", "recommendation": "SSRIs and SNRIs should be avoided in patients with unstable epilepsy, and used cautiously in patients with epilepsy controlled with anticonvulsant medications.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67263/", "reference_text": "[1] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[2] Belcastro V, Costa C, Striano P \"Levetiracetam-associated hyponatremia.\" Seizure 17 (2008): 389-90[3] Gandhi S, McArthur E, Mamdani MM, et.al \"Antiepileptic drugs and hyponatremia in older adults: Two population-based cohort studies.\" Epilepsia 57 (2016): 2067-79[4] \"Product Information. Aptiom (eslicarbazepine).\" Sunovion Pharmaceuticals Inc, Marlborough, MA.[5] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[6] \"Product Information. Tegretol (carbamazepine).\" Novartis Pharmaceuticals, East Hanover, NJ.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[9] Falhammar H, Lindh JD, Calissendorff J, et.al \"Differences in associations of antiepileptic drugs and hospitalization due to hyponatremia: A population-based case-control study.\" Seizure 59 (2018): 28-33[10] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[11] Bavbek N, Alkan R, Uz E, Kaftan O, Akcay A \"Hyponatremia associated with sodium valproate in a 22-year-old male.\" Nephrol Dial Transplant 23 (2008): epub[12] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[13] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[14] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[15] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[16] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[17] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[18] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[19] Patel KR, Meesala A, Stanilla JK \"Sodium valproate-induced hyponatremia: a case report.\" Prim Care Companion J Clin Psychiatry 12 (2010): epub[20] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[21] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[22] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[23] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[24] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[25] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[26] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[27] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[28] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Oxitriptan, Bupropion, Viloxazine, Tryptophan", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67177, "ingredient1": "Citalopram", "ingredient2": "Vilazodone", "severity": "Major", "effect": "Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John's wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucination, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.", "source": "DDInter", "management_text": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk. Patients should be closely monitored for symptoms of the serotonin syndrome during treatment. Particular caution is advised when increasing the dosages of these agents. The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.", "mechanism_text": "Synergism", "recommendation": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67264/", "reference_text": "[1] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S \"Rare case of serotonin syndrome with therapeutic doses of paroxetine.\" Am J Ther 13 (2006): 550-552[2] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics.\" J Clin Psychopharmacol 10 (1990): 48-50[3] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[4] George TP, Godleski LS \"Possible serotonin syndrome with trazodone addition to fluoxetine.\" Biol Psychiatry 39 (1996): 384-5[5] Fugh-Berman A \"Herb-drug interactions.\" Lancet 355 (2000): 134-8[6] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[7] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[8] Ruiz F \"Fluoxetine and the serotonin syndrome.\" Ann Emerg Med 24 (1994): 983-5[9] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[10] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[11] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[12] Bergeron L, Boule M, Perreault S \"Serotonin toxicity associated with concomitant use of linezolid.\" Ann Pharmacother 39 (2005): 956-61[13] Wigen CL, Goetz MB \"Serotonin syndrome and linezolid.\" Clin Infect Dis 34 (2002): 1651-2[14] Metz A \"Interaction between fluoxetine and buspirone.\" Can J Psychiatry 35 (1990): 722-3[15] Tahir N \"Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram.\" J Am Med Dir Assoc 5 (2004): 111-3[16] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[17] Lane R, Baldwin D \"Selective serotonin reuptake inhibitor--induced serotonin syndrome: review.\" J Clin Psychopharmacol 17 (1997): 208-21[18] \"Product Information. Maxalt (rizatriptan).\" Merck & Co, Inc, West Point, PA.[19] Hammerness P, Parada H, Abrams A \"Linezolid: MAOI Activity and Potential Drug Interactions.\" Psychosomatics 43 (2002): 248-9[20] Morales N, Vermette H \"Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine.\" Psychosomatics 46 (2005): 274-5[21] Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM \"The serotonin syndrome associated wtih paroxetine, an over-the-counter cold remedy, and vascular disease.\" Am J Emerg Med 12 (1994): 642-4[22] Manos GH \"Possible serotonin syndrome associated with buspirone added to fluoxetine.\" Ann Pharmacother 34 (2000): 871-4[23] Gordon JB \"SSRI's and St. John's Wort: possible toxicity?\" Am Fam Physician 57 (1998): 950,953[24] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[25] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997): 175-7[26] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993): 84-8[27] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[28] Gillman PK \"Linezolid and serotonin toxicity.\" Clin Infect Dis 37 (2003): 1274-5[29] Taylor JJ, Wilson JW, Estes LL \"Linezolid and serotonergic drug interactions: a retrospective survey.\" Clin Infect Dis 43 (2006): 180-7[30] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003): 32-5[31] Nijhawan PK, Katz G, Winter S \"Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission.\" Crit Care Med 24 (1996): 1086-9[32] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals, Raritan, NJ.[33] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[34] Mackay FJ, Dunn NR, Mann RD \"Antidepressants and the serotonin syndrome in general practice.\" Br J Gen Pract 49 (1999): 871-4[35] Perry NK \"Venlafaxine-induced serotonin syndrome with relapse following amitriptyline.\" Postgrad Med J 76 (2000): 254-6[36] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995): 440-2[37] Margolese HC, Chouinard G \"Serotonin syndrome from addition of low-dose trazodone to nefazodone.\" Am J Psychiatry 157 (2000): 1022[38] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006): 1589[39] Boyer EW, Shannon M \"The serotonin syndrome.\" N Engl J Med 352 (2005): 1112-20[40] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995): 481-2[41] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[42] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[43] Dannawi M \"Possible serotonin syndrome after combination of buspirone and St John's Wort.\" J Psychopharmacol 16 (2002): 401[44] Lee J, Franz L, Goforth HW \"Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine.\" Psychosomatics 50 (2009): 638-9[45] Bhatara VS, Magnus RD, Paul KL, Preskorn SH \"Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms.\" Ann Pharmacother 32 (1998): 432-6[46] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992): 1061-6[47] Strouse TB, Kerrihard TN, Forscher CA, Zakowski P \"Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine.\" J Clin Psychopharmacol 26 (2006): 681-683[48] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990): 949-50[49] Packer S, Berman SA \"Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid.\" Am J Psychiatry 164 (2007): 346-7[50] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[51] John L, Perreault MM, Tao T, Blew PG \"Serotonin syndrome associated with nefazodone and paroxetine.\" Ann Emerg Med 29 (1997): 287-9[52] \"Product Information. Imitrex (sumatriptan).\" Glaxo Wellcome, Research Triangle Park, NC.[53] \"Product Information. Oleptro (traZODone).\" Labopharm Inc, Laval, AL.[54] Reeves RR, Bullen JA \"Serotonin syndrome produced by paroxetine and low-dose trazodone.\" Psychosomatics 36 (1995): 159-60[55] Weiner AL \"Meperidine as a potential cause of serotonin syndrome in the emergency department.\" Acad Emerg Med 6 (1999): 156-8[56] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997): 181-2[57] Mathew NT, Tietjen GE, Lucker C \"Serotonin syndrome complicating migraine pharmacotherapy.\" Cephalalgia 16 (1996): 323-7[58] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002): 1647-1648[59] Gardner DM, Lynd LD \"Sumatriptan contraindications and the serotonin syndrome.\" Ann Pharmacother 32 (1998): 33-8[60] Baetz M, Malcolm D \"Serotonin syndrome from fluvoxamine and buspirone.\" Can J Psychiatry 40 (1995): 428-9[61] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007): 199-202[62] Mugele J, Nanagas KA, Tormoehlen LM \"Serotonin Syndrome Associated With MDPV Use: A Case Report.\" Ann Emerg Med (2012):[63] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[64] Thomas CR, Rosenberg M, Blythe V, Meyer WJ 3rd \"Serotonin syndrome and linezolid.\" J Am Acad Child Adolesc Psychiatry 43 (2004): 790[65] Turkel SB, Nadala JG, Wincor MZ \"Possible serotonin syndrome in association with 5-HT3 antagonist agents.\" Psychosomatics 42 (2001): 258-60[66] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008): 521-5[67] Shapiro RE, Tepper SJ \"The serotonin syndrome, triptans, and the potential for drug-drug interactions.\" Headache 47 (2007): 266-9[68] Goldberg RJ, Huk M \"Serotonin syndrome from trazodone and buspirone.\" Psychosomatics 33 (1992): 235-6[69] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990): 213-7[70] Lantz MS, Buchalter E, Giambanco V \"St. John's wort and antidepressant drug interactions in the elderly.\" J Geriatr Psychiatr Neurol 12 (1999): 7-10[71] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[72] Harvey AT, Preskorn SH \"Interactions of serotonin reuptake inhibitors with tricyclic antidepressants.\" Arch Gen Psychiatry 52 (1995): 783-4[73] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[74] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994): 593-7[75] Laird LK \"Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder.\" Psychopharmacol Bull 32 (1996): 569-78[76] Insel TR, Roy BF, Cohen RM, Murphy DL \"Possible development of the serotonin syndrome in man.\" Am J Psychiatry 139 (1982): 954-5[77] Smith DL, Wenegrat BG \"A case report of serotonin syndrome associated with combined nefazodone and fluoxetine.\" J Clin Psychiatry 61 (2000): 146[78] Bernard L, Stern R, Lew D, Hoffmeyer P \"Serotonin syndrome after concomitant treatment with linezolid and citalopram.\" Clin Infect Dis 36 (2003): 1197[79] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001): 2163-75[80] \"Product Information. Zomig (zolmitriptan).\" Zeneca Pharmaceuticals, Wilmington, DE.[81] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[82] \"Product Information. Flexeril (cyclobenzaprine).\" Merck & Co, Inc, West Point, PA.[83] Giese SY, Neborsky R \"Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl.\" Plast Reconstr Surg 107 (2001): 293-4[84] Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Grau S \"Linezolid-associated serotonin syndrome: what we can learn from cases reported so far.\" J Antimicrob Chemother 56 (2005): 1176-8[85] Duggal HS, Fetchko J \"Serotonin syndrome and atypical antipsychotics.\" Am J Psychiatry 159 (2002): 672-3[86] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001): 224-7[87] DeBellis RJ, Schaefer OP, Liquori M, Volturo GA \"Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient.\" J Intensive Care Med 20 (2005): 351-3[88] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[89] Jones SL, Athan E, O'Brien D \"Serotonin syndrome due to co-administration of linezolid and venlafaxine.\" J Antimicrob Chemother 54 (2004): 289-90[90] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[91] Steinberg M, Morin AK \"Mild serotonin syndrome associated with concurrent linezolid and fluoxetine.\" Am J Health Syst Pharm 64 (2007): 59-62[92] Lavery S, Ravi H, McDaniel WW, Pushkin YR \"Linezolid and serotonin syndrome.\" Psychosomatics 42 (2001): 432-4[93] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[94] Hachem RY, Hicks K, Huen A, Raad I \"Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients.\" Clin Infect Dis 37 (2003): E8-E11[95] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[96] Keegan MT, Brown DR, Rabinstein AA \"Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs.\" Anesth Analg 103 (2006): 1466-8[97] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[98] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003): 1511-1512[99] Achamallah NS \"Visual hallucinations after combining fluoxetine and dextromethorphan .\" Am J Psychiatry 149 (1992): 1406[100] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8", "alternatives_a": "Vilazodone, Esketamine", "alternatives_b": "Citalopram, Esketamine", "updated_at": 1767369485}, {"id": 67178, "ingredient1": "Citalopram", "ingredient2": "Vorapaxar", "severity": "Moderate", "effect": "Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.", "source": "DDInter", "management_text": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67265/", "reference_text": "[1] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG \"Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin.\" Acta Psychiatr Scand Suppl 350 (1989): 102-6[2] Skop BP, Brown TM \"Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors.\" Psychosomatics 37 (1996): 12-6[3] Settle EC \"Antidepressant drugs: disturbing and potentially dangerous adverse effects.\" J Clin Psychiatry 59 Suppl 16 (1998): 25-30[4] Layton D, Clark DWJ, Pearce GL, Shakir SAW \"Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England.\" Eur J Clin Pharmacol 57 (2001): 167-76[5] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[6] Leung M, Shore R \"Fluvoxamine-associated bleeding.\" Can J Psychiatry 41 (1996): 604-5[7] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[8] Tata LJ, Fortun PJ, Hubbard RB, et al. \"Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?\" Aliment Pharmacol Ther 22 (2005): 175-81[9] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[10] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B \"Paroxetine decreases platelet serotonin storage and platelet function in human beings.\" Clin Pharmacol Ther 68 (2000): 435-42[11] de Abajo FJ, Rodriguez LA, Montero D \"Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study.\" BMJ 319 (1999): 1106-9[12] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[13] Alderman CP, Moritz CK, Ben-Tovim DI \"Abnormal platelet aggregation associated with fluoxetine therapy.\" Ann Pharmacother 26 (1992): 1517-9[14] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[15] Krivy J, Wiener J \"Sertraline and platelet counts in idiopathic thrombocytopenia purpura.\" Lancet 345 (1995): 132[16] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[17] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[18] Pai VB, Kelly MW \"Bruising associated with the use of fluoxetine.\" Ann Pharmacother 30 (1996): 786-8[19] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990): 213-7[20] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ \"Fluoxetine and bleeding in obsessive-compulsive disorder.\" Am J Psychiatry 148 (1991): 949[21] Alderman CP, Seshadri P, Ben-Tovim DI \"Effects of serotonin reuptake inhibitors on hemostasis.\" Ann Pharmacother 30 (1996): 1232-4[22] Humphries JE, Wheby MS, VandenBerg SR \"Fluoxetine and the bleeding time.\" Arch Pathol Lab Med 114 (1990): 727-8[23] Woolfrey S, Gammack NS, Dewar MS, Brown PJ \"Fluoxetine-warfarin interaction.\" BMJ 307 (1993): 241[24] Messiha FS \"Fluoxetine - adverse effects and drug-drug interactions.\" J Toxicol Clin Toxicol 31 (1993): 603-30[25] Ford MA, Anderson ML, Rindone JP, Jaskar DW \"Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin.\" J Clin Psychopharmacol 17 (1997): 110-2[26] Ottervanger JP, Stricker BH, Huls J, Weeda JN \"Bleeding attributed to the intake of paroxetine.\" Am J Psychiatry 151 (1994): 781-2[27] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[28] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH \"Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study.\" Arch Intern Med 163 (2003): 59-64[29] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[30] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[31] Aranth J, Lindberg C \"Bleeding, a side effect of fluoxetine.\" Am J Psychiatry 149 (1992): 412[32] Cerner Multum, Inc. \"Australian Product Information.\" O 0[33] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S \"Intracranial haemorrhage and use of selective serotonin reuptake inhibitors.\" Br J Clin Pharmacol 50 (2000): 43-7[34] de Maistre E, Allart C, Lecompte T, Bollaert PE \"Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors.\" Am J Med 113 (2002): 530-2[35] Claire RJ, Servis ME, Cram DL Jr \"Potential interaction between warfarin sodium and fluoxetine.\" Am J Psychiatry 148 (1991): 1604[36] Dent LA, Orrock MW \"Warfarin-fluoxetine and diazepam-fluoxetine interaction.\" Pharmacotherapy 17 (1997): 170-2[37] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[38] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[39] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[40] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[41] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[42] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Maprotiline, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, Trimipramine, More", "alternatives_b": "Protein C, Selexipag", "updated_at": 1767369485}, {"id": 67179, "ingredient1": "Citalopram", "ingredient2": "Voriconazole", "severity": "Major", "effect": "Coadministration with CYP450 2C19 inhibitors may increase the plasma concentrations of citalopram, which is partially metabolized by the isoenzyme. Cases of QT interval prolongation and torsade de pointes have been reported during postmarketing use. In general, the risk of ventricular arrhythmia in association with QT prolongation is largely unpredictable, but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances (e.g., hypokalemia, hypomagnesemia).", "source": "DDInter", "management_text": "Given the risk of dose-dependent QT prolongation, citalopram dosage should not exceed 20 mg/day when prescribed in combination with CYP450 2C19 inhibitors such as cimetidine, esomeprazole, etravirine, felbamate, fluconazole, lansoprazole, letrozole, modafinil, omeprazole, oxcarbazepine, ticlopidine, and voriconazole. Alternatives should be considered when possible, and hypokalemia or hypomagnesemia should be corrected prior to initiation of citalopram treatment and periodically monitored. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, irregular heartbeat, shortness of breath, or syncope.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of dose-dependent QT prolongation, citalopram dosage should not exceed 20 mg/day when prescribed in combination with CYP450 2C19 inhibitors such as cimetidine, esomeprazole, etravirine, felbamate, fluconazole, lansoprazole, letrozole, modafinil, omeprazole, oxcarbazepine, ticlopidine, and voriconazole.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67266/", "reference_text": "[1] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[2] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm.\" ([2011 Aug 24]):[3] Priskorn M, Larsen F, Segonzac A, Moulin M \"Pharmacokinetic interaction study of citalopram and cimetidine in healhy subjects.\" Eur J Clin Pharmacol 52 (1997): 241-2[4] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[6] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[7] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Phenelzine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Bupropion, Esketamine, Fluvoxamine", "alternatives_b": "Flucytosine, Anidulafungin, Micafungin, Oteseconazole", "updated_at": 1767369485}, {"id": 67180, "ingredient1": "Citalopram", "ingredient2": "Vortioxetine", "severity": "Major", "effect": "Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John's wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucination, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.", "source": "DDInter", "management_text": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk. Patients should be closely monitored for symptoms of the serotonin syndrome during treatment. Particular caution is advised when increasing the dosages of these agents. The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.", "mechanism_text": "Synergism", "recommendation": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67267/", "reference_text": "[1] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S \"Rare case of serotonin syndrome with therapeutic doses of paroxetine.\" Am J Ther 13 (2006): 550-552[2] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics.\" J Clin Psychopharmacol 10 (1990): 48-50[3] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[4] George TP, Godleski LS \"Possible serotonin syndrome with trazodone addition to fluoxetine.\" Biol Psychiatry 39 (1996): 384-5[5] Fugh-Berman A \"Herb-drug interactions.\" Lancet 355 (2000): 134-8[6] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[7] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[8] Ruiz F \"Fluoxetine and the serotonin syndrome.\" Ann Emerg Med 24 (1994): 983-5[9] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[10] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[11] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[12] Bergeron L, Boule M, Perreault S \"Serotonin toxicity associated with concomitant use of linezolid.\" Ann Pharmacother 39 (2005): 956-61[13] Wigen CL, Goetz MB \"Serotonin syndrome and linezolid.\" Clin Infect Dis 34 (2002): 1651-2[14] Metz A \"Interaction between fluoxetine and buspirone.\" Can J Psychiatry 35 (1990): 722-3[15] Tahir N \"Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram.\" J Am Med Dir Assoc 5 (2004): 111-3[16] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[17] Lane R, Baldwin D \"Selective serotonin reuptake inhibitor--induced serotonin syndrome: review.\" J Clin Psychopharmacol 17 (1997): 208-21[18] \"Product Information. Maxalt (rizatriptan).\" Merck & Co, Inc, West Point, PA.[19] Hammerness P, Parada H, Abrams A \"Linezolid: MAOI Activity and Potential Drug Interactions.\" Psychosomatics 43 (2002): 248-9[20] Morales N, Vermette H \"Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine.\" Psychosomatics 46 (2005): 274-5[21] Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM \"The serotonin syndrome associated wtih paroxetine, an over-the-counter cold remedy, and vascular disease.\" Am J Emerg Med 12 (1994): 642-4[22] Manos GH \"Possible serotonin syndrome associated with buspirone added to fluoxetine.\" Ann Pharmacother 34 (2000): 871-4[23] Gordon JB \"SSRI's and St. John's Wort: possible toxicity?\" Am Fam Physician 57 (1998): 950,953[24] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[25] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997): 175-7[26] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993): 84-8[27] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[28] Gillman PK \"Linezolid and serotonin toxicity.\" Clin Infect Dis 37 (2003): 1274-5[29] Taylor JJ, Wilson JW, Estes LL \"Linezolid and serotonergic drug interactions: a retrospective survey.\" Clin Infect Dis 43 (2006): 180-7[30] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003): 32-5[31] Nijhawan PK, Katz G, Winter S \"Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission.\" Crit Care Med 24 (1996): 1086-9[32] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals, Raritan, NJ.[33] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[34] Mackay FJ, Dunn NR, Mann RD \"Antidepressants and the serotonin syndrome in general practice.\" Br J Gen Pract 49 (1999): 871-4[35] Perry NK \"Venlafaxine-induced serotonin syndrome with relapse following amitriptyline.\" Postgrad Med J 76 (2000): 254-6[36] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995): 440-2[37] Margolese HC, Chouinard G \"Serotonin syndrome from addition of low-dose trazodone to nefazodone.\" Am J Psychiatry 157 (2000): 1022[38] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006): 1589[39] Boyer EW, Shannon M \"The serotonin syndrome.\" N Engl J Med 352 (2005): 1112-20[40] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995): 481-2[41] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[42] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[43] Dannawi M \"Possible serotonin syndrome after combination of buspirone and St John's Wort.\" J Psychopharmacol 16 (2002): 401[44] Lee J, Franz L, Goforth HW \"Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine.\" Psychosomatics 50 (2009): 638-9[45] Bhatara VS, Magnus RD, Paul KL, Preskorn SH \"Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms.\" Ann Pharmacother 32 (1998): 432-6[46] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992): 1061-6[47] Strouse TB, Kerrihard TN, Forscher CA, Zakowski P \"Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine.\" J Clin Psychopharmacol 26 (2006): 681-683[48] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990): 949-50[49] Packer S, Berman SA \"Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid.\" Am J Psychiatry 164 (2007): 346-7[50] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[51] John L, Perreault MM, Tao T, Blew PG \"Serotonin syndrome associated with nefazodone and paroxetine.\" Ann Emerg Med 29 (1997): 287-9[52] \"Product Information. Imitrex (sumatriptan).\" Glaxo Wellcome, Research Triangle Park, NC.[53] \"Product Information. Oleptro (traZODone).\" Labopharm Inc, Laval, AL.[54] Reeves RR, Bullen JA \"Serotonin syndrome produced by paroxetine and low-dose trazodone.\" Psychosomatics 36 (1995): 159-60[55] Weiner AL \"Meperidine as a potential cause of serotonin syndrome in the emergency department.\" Acad Emerg Med 6 (1999): 156-8[56] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997): 181-2[57] Mathew NT, Tietjen GE, Lucker C \"Serotonin syndrome complicating migraine pharmacotherapy.\" Cephalalgia 16 (1996): 323-7[58] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002): 1647-1648[59] Gardner DM, Lynd LD \"Sumatriptan contraindications and the serotonin syndrome.\" Ann Pharmacother 32 (1998): 33-8[60] Baetz M, Malcolm D \"Serotonin syndrome from fluvoxamine and buspirone.\" Can J Psychiatry 40 (1995): 428-9[61] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007): 199-202[62] Mugele J, Nanagas KA, Tormoehlen LM \"Serotonin Syndrome Associated With MDPV Use: A Case Report.\" Ann Emerg Med (2012):[63] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[64] Thomas CR, Rosenberg M, Blythe V, Meyer WJ 3rd \"Serotonin syndrome and linezolid.\" J Am Acad Child Adolesc Psychiatry 43 (2004): 790[65] Turkel SB, Nadala JG, Wincor MZ \"Possible serotonin syndrome in association with 5-HT3 antagonist agents.\" Psychosomatics 42 (2001): 258-60[66] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008): 521-5[67] Shapiro RE, Tepper SJ \"The serotonin syndrome, triptans, and the potential for drug-drug interactions.\" Headache 47 (2007): 266-9[68] Goldberg RJ, Huk M \"Serotonin syndrome from trazodone and buspirone.\" Psychosomatics 33 (1992): 235-6[69] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990): 213-7[70] Lantz MS, Buchalter E, Giambanco V \"St. John's wort and antidepressant drug interactions in the elderly.\" J Geriatr Psychiatr Neurol 12 (1999): 7-10[71] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[72] Harvey AT, Preskorn SH \"Interactions of serotonin reuptake inhibitors with tricyclic antidepressants.\" Arch Gen Psychiatry 52 (1995): 783-4[73] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[74] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994): 593-7[75] Laird LK \"Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder.\" Psychopharmacol Bull 32 (1996): 569-78[76] Insel TR, Roy BF, Cohen RM, Murphy DL \"Possible development of the serotonin syndrome in man.\" Am J Psychiatry 139 (1982): 954-5[77] Smith DL, Wenegrat BG \"A case report of serotonin syndrome associated with combined nefazodone and fluoxetine.\" J Clin Psychiatry 61 (2000): 146[78] Bernard L, Stern R, Lew D, Hoffmeyer P \"Serotonin syndrome after concomitant treatment with linezolid and citalopram.\" Clin Infect Dis 36 (2003): 1197[79] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001): 2163-75[80] \"Product Information. Zomig (zolmitriptan).\" Zeneca Pharmaceuticals, Wilmington, DE.[81] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[82] \"Product Information. Flexeril (cyclobenzaprine).\" Merck & Co, Inc, West Point, PA.[83] Giese SY, Neborsky R \"Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl.\" Plast Reconstr Surg 107 (2001): 293-4[84] Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Grau S \"Linezolid-associated serotonin syndrome: what we can learn from cases reported so far.\" J Antimicrob Chemother 56 (2005): 1176-8[85] Duggal HS, Fetchko J \"Serotonin syndrome and atypical antipsychotics.\" Am J Psychiatry 159 (2002): 672-3[86] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001): 224-7[87] DeBellis RJ, Schaefer OP, Liquori M, Volturo GA \"Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient.\" J Intensive Care Med 20 (2005): 351-3[88] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[89] Jones SL, Athan E, O'Brien D \"Serotonin syndrome due to co-administration of linezolid and venlafaxine.\" J Antimicrob Chemother 54 (2004): 289-90[90] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[91] Steinberg M, Morin AK \"Mild serotonin syndrome associated with concurrent linezolid and fluoxetine.\" Am J Health Syst Pharm 64 (2007): 59-62[92] Lavery S, Ravi H, McDaniel WW, Pushkin YR \"Linezolid and serotonin syndrome.\" Psychosomatics 42 (2001): 432-4[93] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[94] Hachem RY, Hicks K, Huen A, Raad I \"Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients.\" Clin Infect Dis 37 (2003): E8-E11[95] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[96] Keegan MT, Brown DR, Rabinstein AA \"Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs.\" Anesth Analg 103 (2006): 1466-8[97] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[98] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003): 1511-1512[99] Achamallah NS \"Visual hallucinations after combining fluoxetine and dextromethorphan .\" Am J Psychiatry 149 (1992): 1406[100] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8", "alternatives_a": "Viloxazine, Vortioxetine, Esketamine", "alternatives_b": "Citalopram, Esketamine", "updated_at": 1767369485}, {"id": 67181, "ingredient1": "Citalopram", "ingredient2": "Voxelotor", "severity": "Minor", "effect": "Coadministration with inhibitors of CYP450 3A4 is not expected to significantly affect the pharmacokinetics of citalopram or escitalopram, both of which are partially metabolized by the isoenzyme. Administration of racemic citalopram (40 mg) in combination with the potent CYP450 3A4 inhibitor ketoconazole (200 mg) decreased the ketoconazole peak plasma concentration (Cmax) by 21% and systemic exposure (AUC) by 10%, but did not significantly affect the pharmacokinetics of citalopram.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67268/", "reference_text": "[1] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[2] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[3] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[4] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[6] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Sertraline, Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, Viloxazine, Amoxapine, More", "alternatives_b": "Hemin, Conestat alfa, Betibeglogene autotemcel, Hyaluronidase, Human C1-esterase inhibitor, Crizanlizumab, Lanadelumab, Icatibant", "updated_at": 1767369485}, {"id": 67182, "ingredient1": "Citalopram", "ingredient2": "Warfarin", "severity": "Moderate", "effect": "Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.", "source": "DDInter", "management_text": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67269/", "reference_text": "[1] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG \"Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin.\" Acta Psychiatr Scand Suppl 350 (1989): 102-6[2] Skop BP, Brown TM \"Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors.\" Psychosomatics 37 (1996): 12-6[3] Settle EC \"Antidepressant drugs: disturbing and potentially dangerous adverse effects.\" J Clin Psychiatry 59 Suppl 16 (1998): 25-30[4] Layton D, Clark DWJ, Pearce GL, Shakir SAW \"Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England.\" Eur J Clin Pharmacol 57 (2001): 167-76[5] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[6] Leung M, Shore R \"Fluvoxamine-associated bleeding.\" Can J Psychiatry 41 (1996): 604-5[7] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[8] Tata LJ, Fortun PJ, Hubbard RB, et al. \"Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?\" Aliment Pharmacol Ther 22 (2005): 175-81[9] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[10] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B \"Paroxetine decreases platelet serotonin storage and platelet function in human beings.\" Clin Pharmacol Ther 68 (2000): 435-42[11] de Abajo FJ, Rodriguez LA, Montero D \"Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study.\" BMJ 319 (1999): 1106-9[12] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[13] Alderman CP, Moritz CK, Ben-Tovim DI \"Abnormal platelet aggregation associated with fluoxetine therapy.\" Ann Pharmacother 26 (1992): 1517-9[14] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[15] Krivy J, Wiener J \"Sertraline and platelet counts in idiopathic thrombocytopenia purpura.\" Lancet 345 (1995): 132[16] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[17] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[18] Pai VB, Kelly MW \"Bruising associated with the use of fluoxetine.\" Ann Pharmacother 30 (1996): 786-8[19] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990): 213-7[20] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ \"Fluoxetine and bleeding in obsessive-compulsive disorder.\" Am J Psychiatry 148 (1991): 949[21] Alderman CP, Seshadri P, Ben-Tovim DI \"Effects of serotonin reuptake inhibitors on hemostasis.\" Ann Pharmacother 30 (1996): 1232-4[22] Humphries JE, Wheby MS, VandenBerg SR \"Fluoxetine and the bleeding time.\" Arch Pathol Lab Med 114 (1990): 727-8[23] Woolfrey S, Gammack NS, Dewar MS, Brown PJ \"Fluoxetine-warfarin interaction.\" BMJ 307 (1993): 241[24] Messiha FS \"Fluoxetine - adverse effects and drug-drug interactions.\" J Toxicol Clin Toxicol 31 (1993): 603-30[25] Ford MA, Anderson ML, Rindone JP, Jaskar DW \"Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin.\" J Clin Psychopharmacol 17 (1997): 110-2[26] Ottervanger JP, Stricker BH, Huls J, Weeda JN \"Bleeding attributed to the intake of paroxetine.\" Am J Psychiatry 151 (1994): 781-2[27] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[28] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH \"Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study.\" Arch Intern Med 163 (2003): 59-64[29] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[30] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[31] Aranth J, Lindberg C \"Bleeding, a side effect of fluoxetine.\" Am J Psychiatry 149 (1992): 412[32] Cerner Multum, Inc. \"Australian Product Information.\" O 0[33] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S \"Intracranial haemorrhage and use of selective serotonin reuptake inhibitors.\" Br J Clin Pharmacol 50 (2000): 43-7[34] de Maistre E, Allart C, Lecompte T, Bollaert PE \"Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors.\" Am J Med 113 (2002): 530-2[35] Claire RJ, Servis ME, Cram DL Jr \"Potential interaction between warfarin sodium and fluoxetine.\" Am J Psychiatry 148 (1991): 1604[36] Dent LA, Orrock MW \"Warfarin-fluoxetine and diazepam-fluoxetine interaction.\" Pharmacotherapy 17 (1997): 170-2[37] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[38] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[39] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[40] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[41] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[42] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Phenelzine, Tranylcypromine, Maprotiline, Isocarboxazid, Oxitriptan, Tryptophan, Esketamine", "alternatives_b": "Protein C, Selexipag", "updated_at": 1767369485}, {"id": 67183, "ingredient1": "Citalopram", "ingredient2": "Zafirlukast", "severity": "Minor", "effect": "Coadministration with inhibitors of CYP450 3A4 is not expected to significantly affect the pharmacokinetics of citalopram or escitalopram, both of which are partially metabolized by the isoenzyme. Administration of racemic citalopram (40 mg) in combination with the potent CYP450 3A4 inhibitor ketoconazole (200 mg) decreased the ketoconazole peak plasma concentration (Cmax) by 21% and systemic exposure (AUC) by 10%, but did not significantly affect the pharmacokinetics of citalopram.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67270/", "reference_text": "[1] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[2] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[3] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[4] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[6] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Maprotiline, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Isocarboxazid, Viloxazine, Amoxapine, Esketamine, Fluvoxamine, Phenelzine, More", "alternatives_b": "Omalizumab, Tezepelumab, Benralizumab, Reslizumab, Dyphylline, Oxtriphylline, Mepolizumab, Roflumilast, Bromotheophylline", "updated_at": 1767369485}, {"id": 67184, "ingredient1": "Citalopram", "ingredient2": "Zaleplon", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67271/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67185, "ingredient1": "Citalopram", "ingredient2": "Zanubrutinib", "severity": "Moderate", "effect": "Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.", "source": "DDInter", "management_text": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67272/", "reference_text": "[1] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG \"Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin.\" Acta Psychiatr Scand Suppl 350 (1989): 102-6[2] Skop BP, Brown TM \"Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors.\" Psychosomatics 37 (1996): 12-6[3] Settle EC \"Antidepressant drugs: disturbing and potentially dangerous adverse effects.\" J Clin Psychiatry 59 Suppl 16 (1998): 25-30[4] Layton D, Clark DWJ, Pearce GL, Shakir SAW \"Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England.\" Eur J Clin Pharmacol 57 (2001): 167-76[5] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[6] Leung M, Shore R \"Fluvoxamine-associated bleeding.\" Can J Psychiatry 41 (1996): 604-5[7] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[8] Tata LJ, Fortun PJ, Hubbard RB, et al. \"Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?\" Aliment Pharmacol Ther 22 (2005): 175-81[9] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[10] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B \"Paroxetine decreases platelet serotonin storage and platelet function in human beings.\" Clin Pharmacol Ther 68 (2000): 435-42[11] de Abajo FJ, Rodriguez LA, Montero D \"Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study.\" BMJ 319 (1999): 1106-9[12] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[13] Alderman CP, Moritz CK, Ben-Tovim DI \"Abnormal platelet aggregation associated with fluoxetine therapy.\" Ann Pharmacother 26 (1992): 1517-9[14] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[15] Krivy J, Wiener J \"Sertraline and platelet counts in idiopathic thrombocytopenia purpura.\" Lancet 345 (1995): 132[16] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[17] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[18] Pai VB, Kelly MW \"Bruising associated with the use of fluoxetine.\" Ann Pharmacother 30 (1996): 786-8[19] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990): 213-7[20] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ \"Fluoxetine and bleeding in obsessive-compulsive disorder.\" Am J Psychiatry 148 (1991): 949[21] Alderman CP, Seshadri P, Ben-Tovim DI \"Effects of serotonin reuptake inhibitors on hemostasis.\" Ann Pharmacother 30 (1996): 1232-4[22] Humphries JE, Wheby MS, VandenBerg SR \"Fluoxetine and the bleeding time.\" Arch Pathol Lab Med 114 (1990): 727-8[23] Woolfrey S, Gammack NS, Dewar MS, Brown PJ \"Fluoxetine-warfarin interaction.\" BMJ 307 (1993): 241[24] Messiha FS \"Fluoxetine - adverse effects and drug-drug interactions.\" J Toxicol Clin Toxicol 31 (1993): 603-30[25] Ford MA, Anderson ML, Rindone JP, Jaskar DW \"Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin.\" J Clin Psychopharmacol 17 (1997): 110-2[26] Ottervanger JP, Stricker BH, Huls J, Weeda JN \"Bleeding attributed to the intake of paroxetine.\" Am J Psychiatry 151 (1994): 781-2[27] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[28] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH \"Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study.\" Arch Intern Med 163 (2003): 59-64[29] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[30] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[31] Aranth J, Lindberg C \"Bleeding, a side effect of fluoxetine.\" Am J Psychiatry 149 (1992): 412[32] Cerner Multum, Inc. \"Australian Product Information.\" O 0[33] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S \"Intracranial haemorrhage and use of selective serotonin reuptake inhibitors.\" Br J Clin Pharmacol 50 (2000): 43-7[34] de Maistre E, Allart C, Lecompte T, Bollaert PE \"Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors.\" Am J Med 113 (2002): 530-2[35] Claire RJ, Servis ME, Cram DL Jr \"Potential interaction between warfarin sodium and fluoxetine.\" Am J Psychiatry 148 (1991): 1604[36] Dent LA, Orrock MW \"Warfarin-fluoxetine and diazepam-fluoxetine interaction.\" Pharmacotherapy 17 (1997): 170-2[37] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[38] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[39] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[40] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[41] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[42] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Phenelzine, Desipramine, Tranylcypromine, Trimipramine, Maprotiline, Isocarboxazid, Oxitriptan, Mirtazapine, Bupropion, Trazodone, Tryptophan, More", "alternatives_b": "Dacomitinib, Tepotinib, Selumetinib, Cobimetinib, Capmatinib, Afatinib, Tivozanib, Brigatinib, Axitinib, Ripretinib, Alpelisib, More", "updated_at": 1767369485}, {"id": 67186, "ingredient1": "Citalopram", "ingredient2": "Ziconotide", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67273/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "alternatives_b": "Methoxyflurane, Salsalate", "updated_at": 1767369485}, {"id": 67187, "ingredient1": "Citalopram", "ingredient2": "Ziprasidone", "severity": "Major", "effect": "Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.", "mechanism_text": "Synergism", "recommendation": "The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67274/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm.\" ([2011 Aug 24]):[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm.\" ([2012 Mar 28]):[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[6] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[9] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[12] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Kaletra (lopinavir-ritonavir)\" Abbott Pharmaceutical, Abbott Park, IL.[15] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Oxitriptan, Vilazodone, Vortioxetine, Tryptophan", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67188, "ingredient1": "Citalopram", "ingredient2": "Zolmitriptan", "severity": "Major", "effect": "Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John's wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucination, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.", "source": "DDInter", "management_text": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk. Patients should be closely monitored for symptoms of the serotonin syndrome during treatment. Particular caution is advised when increasing the dosages of these agents. The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.", "mechanism_text": "Synergism", "recommendation": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67275/", "reference_text": "[1] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S \"Rare case of serotonin syndrome with therapeutic doses of paroxetine.\" Am J Ther 13 (2006): 550-552[2] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics.\" J Clin Psychopharmacol 10 (1990): 48-50[3] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[4] George TP, Godleski LS \"Possible serotonin syndrome with trazodone addition to fluoxetine.\" Biol Psychiatry 39 (1996): 384-5[5] Fugh-Berman A \"Herb-drug interactions.\" Lancet 355 (2000): 134-8[6] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[7] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[8] Ruiz F \"Fluoxetine and the serotonin syndrome.\" Ann Emerg Med 24 (1994): 983-5[9] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[10] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[11] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[12] Bergeron L, Boule M, Perreault S \"Serotonin toxicity associated with concomitant use of linezolid.\" Ann Pharmacother 39 (2005): 956-61[13] Wigen CL, Goetz MB \"Serotonin syndrome and linezolid.\" Clin Infect Dis 34 (2002): 1651-2[14] Metz A \"Interaction between fluoxetine and buspirone.\" Can J Psychiatry 35 (1990): 722-3[15] Tahir N \"Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram.\" J Am Med Dir Assoc 5 (2004): 111-3[16] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[17] Lane R, Baldwin D \"Selective serotonin reuptake inhibitor--induced serotonin syndrome: review.\" J Clin Psychopharmacol 17 (1997): 208-21[18] \"Product Information. Maxalt (rizatriptan).\" Merck & Co, Inc, West Point, PA.[19] Hammerness P, Parada H, Abrams A \"Linezolid: MAOI Activity and Potential Drug Interactions.\" Psychosomatics 43 (2002): 248-9[20] Morales N, Vermette H \"Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine.\" Psychosomatics 46 (2005): 274-5[21] Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM \"The serotonin syndrome associated wtih paroxetine, an over-the-counter cold remedy, and vascular disease.\" Am J Emerg Med 12 (1994): 642-4[22] Manos GH \"Possible serotonin syndrome associated with buspirone added to fluoxetine.\" Ann Pharmacother 34 (2000): 871-4[23] Gordon JB \"SSRI's and St. John's Wort: possible toxicity?\" Am Fam Physician 57 (1998): 950,953[24] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[25] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997): 175-7[26] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993): 84-8[27] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[28] Gillman PK \"Linezolid and serotonin toxicity.\" Clin Infect Dis 37 (2003): 1274-5[29] Taylor JJ, Wilson JW, Estes LL \"Linezolid and serotonergic drug interactions: a retrospective survey.\" Clin Infect Dis 43 (2006): 180-7[30] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003): 32-5[31] Nijhawan PK, Katz G, Winter S \"Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission.\" Crit Care Med 24 (1996): 1086-9[32] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals, Raritan, NJ.[33] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[34] Mackay FJ, Dunn NR, Mann RD \"Antidepressants and the serotonin syndrome in general practice.\" Br J Gen Pract 49 (1999): 871-4[35] Perry NK \"Venlafaxine-induced serotonin syndrome with relapse following amitriptyline.\" Postgrad Med J 76 (2000): 254-6[36] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995): 440-2[37] Margolese HC, Chouinard G \"Serotonin syndrome from addition of low-dose trazodone to nefazodone.\" Am J Psychiatry 157 (2000): 1022[38] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006): 1589[39] Boyer EW, Shannon M \"The serotonin syndrome.\" N Engl J Med 352 (2005): 1112-20[40] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995): 481-2[41] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[42] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[43] Dannawi M \"Possible serotonin syndrome after combination of buspirone and St John's Wort.\" J Psychopharmacol 16 (2002): 401[44] Lee J, Franz L, Goforth HW \"Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine.\" Psychosomatics 50 (2009): 638-9[45] Bhatara VS, Magnus RD, Paul KL, Preskorn SH \"Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms.\" Ann Pharmacother 32 (1998): 432-6[46] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992): 1061-6[47] Strouse TB, Kerrihard TN, Forscher CA, Zakowski P \"Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine.\" J Clin Psychopharmacol 26 (2006): 681-683[48] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990): 949-50[49] Packer S, Berman SA \"Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid.\" Am J Psychiatry 164 (2007): 346-7[50] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[51] John L, Perreault MM, Tao T, Blew PG \"Serotonin syndrome associated with nefazodone and paroxetine.\" Ann Emerg Med 29 (1997): 287-9[52] \"Product Information. Imitrex (sumatriptan).\" Glaxo Wellcome, Research Triangle Park, NC.[53] \"Product Information. Oleptro (traZODone).\" Labopharm Inc, Laval, AL.[54] Reeves RR, Bullen JA \"Serotonin syndrome produced by paroxetine and low-dose trazodone.\" Psychosomatics 36 (1995): 159-60[55] Weiner AL \"Meperidine as a potential cause of serotonin syndrome in the emergency department.\" Acad Emerg Med 6 (1999): 156-8[56] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997): 181-2[57] Mathew NT, Tietjen GE, Lucker C \"Serotonin syndrome complicating migraine pharmacotherapy.\" Cephalalgia 16 (1996): 323-7[58] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002): 1647-1648[59] Gardner DM, Lynd LD \"Sumatriptan contraindications and the serotonin syndrome.\" Ann Pharmacother 32 (1998): 33-8[60] Baetz M, Malcolm D \"Serotonin syndrome from fluvoxamine and buspirone.\" Can J Psychiatry 40 (1995): 428-9[61] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007): 199-202[62] Mugele J, Nanagas KA, Tormoehlen LM \"Serotonin Syndrome Associated With MDPV Use: A Case Report.\" Ann Emerg Med (2012):[63] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[64] Thomas CR, Rosenberg M, Blythe V, Meyer WJ 3rd \"Serotonin syndrome and linezolid.\" J Am Acad Child Adolesc Psychiatry 43 (2004): 790[65] Turkel SB, Nadala JG, Wincor MZ \"Possible serotonin syndrome in association with 5-HT3 antagonist agents.\" Psychosomatics 42 (2001): 258-60[66] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008): 521-5[67] Shapiro RE, Tepper SJ \"The serotonin syndrome, triptans, and the potential for drug-drug interactions.\" Headache 47 (2007): 266-9[68] Goldberg RJ, Huk M \"Serotonin syndrome from trazodone and buspirone.\" Psychosomatics 33 (1992): 235-6[69] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990): 213-7[70] Lantz MS, Buchalter E, Giambanco V \"St. John's wort and antidepressant drug interactions in the elderly.\" J Geriatr Psychiatr Neurol 12 (1999): 7-10[71] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[72] Harvey AT, Preskorn SH \"Interactions of serotonin reuptake inhibitors with tricyclic antidepressants.\" Arch Gen Psychiatry 52 (1995): 783-4[73] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[74] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994): 593-7[75] Laird LK \"Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder.\" Psychopharmacol Bull 32 (1996): 569-78[76] Insel TR, Roy BF, Cohen RM, Murphy DL \"Possible development of the serotonin syndrome in man.\" Am J Psychiatry 139 (1982): 954-5[77] Smith DL, Wenegrat BG \"A case report of serotonin syndrome associated with combined nefazodone and fluoxetine.\" J Clin Psychiatry 61 (2000): 146[78] Bernard L, Stern R, Lew D, Hoffmeyer P \"Serotonin syndrome after concomitant treatment with linezolid and citalopram.\" Clin Infect Dis 36 (2003): 1197[79] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001): 2163-75[80] \"Product Information. Zomig (zolmitriptan).\" Zeneca Pharmaceuticals, Wilmington, DE.[81] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[82] \"Product Information. Flexeril (cyclobenzaprine).\" Merck & Co, Inc, West Point, PA.[83] Giese SY, Neborsky R \"Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl.\" Plast Reconstr Surg 107 (2001): 293-4[84] Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Grau S \"Linezolid-associated serotonin syndrome: what we can learn from cases reported so far.\" J Antimicrob Chemother 56 (2005): 1176-8[85] Duggal HS, Fetchko J \"Serotonin syndrome and atypical antipsychotics.\" Am J Psychiatry 159 (2002): 672-3[86] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001): 224-7[87] DeBellis RJ, Schaefer OP, Liquori M, Volturo GA \"Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient.\" J Intensive Care Med 20 (2005): 351-3[88] \"Product Information. Zyvox (linezolid)\" Pharmacia and Upjohn, Kalamazoo, MI.[89] Jones SL, Athan E, O'Brien D \"Serotonin syndrome due to co-administration of linezolid and venlafaxine.\" J Antimicrob Chemother 54 (2004): 289-90[90] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[91] Steinberg M, Morin AK \"Mild serotonin syndrome associated with concurrent linezolid and fluoxetine.\" Am J Health Syst Pharm 64 (2007): 59-62[92] Lavery S, Ravi H, McDaniel WW, Pushkin YR \"Linezolid and serotonin syndrome.\" Psychosomatics 42 (2001): 432-4[93] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[94] Hachem RY, Hicks K, Huen A, Raad I \"Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients.\" Clin Infect Dis 37 (2003): E8-E11[95] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[96] Keegan MT, Brown DR, Rabinstein AA \"Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs.\" Anesth Analg 103 (2006): 1466-8[97] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[98] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003): 1511-1512[99] Achamallah NS \"Visual hallucinations after combining fluoxetine and dextromethorphan .\" Am J Psychiatry 149 (1992): 1406[100] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8", "alternatives_a": "Esketamine", "alternatives_b": "Rimegepant, Eptinezumab, Ubrogepant, Galcanezumab, Atogepant, Erenumab, Fremanezumab", "updated_at": 1767369485}, {"id": 67189, "ingredient1": "Citalopram", "ingredient2": "Zolpidem", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67276/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Levomilnacipran, Oxitriptan, Vortioxetine, Milnacipran, Tryptophan, Vilazodone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67190, "ingredient1": "Citalopram", "ingredient2": "Zonisamide", "severity": "Moderate", "effect": "The efficacy of anticonvulsants may be diminished during coadministration with selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitor (SNRIs). Antidepressants including SSRIs and SNRIs can reduce seizure threshold.Coadministration of SSRIs or SNRIs with some anticonvulsants, particularly carbamazepine, eslicarbazepine, oxcarbazepine and valproic acid, may increase the risk of hyponatremia. The risk appears to be dose-related, and elderly patients and patients who are volume depleted (e.g., diuretic use) may be at greater risk.", "source": "DDInter", "management_text": "SSRIs and SNRIs should be avoided in patients with unstable epilepsy, and used cautiously in patients with epilepsy controlled with anticonvulsant medications. Treatment with SSRIs and SNRIs should be discontinued if seizures develop or seizure frequency increases. Patients receiving SSRIs or SNRIs with anticonvulsants, particularly carbamazepine, eslicarbazepine, oxcarbazepine and/or valproic acid, should also have serum sodium levels measured regularly and monitored for development of hyponatremia, particularly when higher dosages of these medications are used. Signs and symptoms of hyponatremia include nausea, vomiting, headache, difficulty concentrating, memory impairment, confusion, malaise, lethargy, muscle weakness or spasms, and unsteadiness. In more severe and/or acute cases, hallucination, syncope, seizure, coma, respiratory arrest, and death may occur.", "mechanism_text": "Antagonism", "recommendation": "SSRIs and SNRIs should be avoided in patients with unstable epilepsy, and used cautiously in patients with epilepsy controlled with anticonvulsant medications.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67277/", "reference_text": "[1] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[2] Belcastro V, Costa C, Striano P \"Levetiracetam-associated hyponatremia.\" Seizure 17 (2008): 389-90[3] Gandhi S, McArthur E, Mamdani MM, et.al \"Antiepileptic drugs and hyponatremia in older adults: Two population-based cohort studies.\" Epilepsia 57 (2016): 2067-79[4] \"Product Information. Aptiom (eslicarbazepine).\" Sunovion Pharmaceuticals Inc, Marlborough, MA.[5] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[6] \"Product Information. Tegretol (carbamazepine).\" Novartis Pharmaceuticals, East Hanover, NJ.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[9] Falhammar H, Lindh JD, Calissendorff J, et.al \"Differences in associations of antiepileptic drugs and hospitalization due to hyponatremia: A population-based case-control study.\" Seizure 59 (2018): 28-33[10] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[11] Bavbek N, Alkan R, Uz E, Kaftan O, Akcay A \"Hyponatremia associated with sodium valproate in a 22-year-old male.\" Nephrol Dial Transplant 23 (2008): epub[12] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[13] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[14] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[15] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[16] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[17] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[18] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[19] Patel KR, Meesala A, Stanilla JK \"Sodium valproate-induced hyponatremia: a case report.\" Prim Care Companion J Clin Psychiatry 12 (2010): epub[20] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[21] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[22] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[23] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[24] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[25] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[26] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[27] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[28] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Oxitriptan, Tryptophan", "alternatives_b": "Tinidazole, Mitapivat, Ascorbic acid, Oxytetracycline, Ciclopirox, Sulfamethizole, Simeprevir, Diazoxide, Econazole, Povidone-iodine, Sulfisoxazole, More", "updated_at": 1767369485}, {"id": 67191, "ingredient1": "Acetohexamide", "ingredient2": "Potassium citrate", "severity": "Minor", "effect": "Alkalinization of the urine may increase the renal clearance of some sulfonylureas for which renal elimination is pH dependent. The clinical significance of this interaction is unknown. Management consists of monitoring blood glucose frequently during the initial period of coadministration. The sulfonylurea dosage should be adjusted as needed and appropriate.", "source": "DDInter", "management_text": "-", "mechanism_text": "Excretion", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67278/", "reference_text": "[1] Neuvonen PJ, Karkkainen S \"Effects of charcoal, sodium bicarbonate, and ammonium chloride on chlorpropamide kinetics.\" Clin Pharmacol Ther 33 (1983): 386-93[2] Kivisto KT, Neuvonen PJ \"Differential effects of sodium bicarbonate and aluminium hydroxide on the absorption and activity of glipizide.\" Eur J Clin Pharmacol 40 (1991): 383-6[3] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[4] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[5] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[6] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[7] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[10] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[11] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Empagliflozin, Dulaglutide, Exenatide, Miglitol, Glimepiride, Albiglutide, Rosiglitazone, More", "alternatives_b": "Potassium chloride, Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67192, "ingredient1": "Aluminum hydroxide", "ingredient2": "Potassium citrate", "severity": "Major", "effect": "The concomitant administration of aluminum-containing products (e.g., antacids and phosphate binders) and citrates may significantly increase serum aluminum concentrations, resulting in toxicity. Citrates enhance the gastrointestinal absorption of aluminum by an unknown mechanism, which may involve the formation of a soluble aluminum-citrate complex. Patients with end-stage renal disease are particularly at risk of developing hyperaluminemia and encephalopathy. Fatalities have been reported.", "source": "DDInter", "management_text": "The concomitant use of aluminum- and citrate-containing products should be avoided in renally impaired patients. Some experts also recommend that healthy patients should separate doses of aluminum-containing antacids and citrates by 2 to 3 hours.", "mechanism_text": "Absorption", "recommendation": "The concomitant use of aluminum- and citrate-containing products should be avoided in renally impaired patients.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67279/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Davies NT \"Anti-nutrient factors affecting mineral utilization.\" Proc Nutr Soc 38 (1979): 121-8[5] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Mangels AR \"Bone nutrients for vegetarians.\" Am J Clin Nutr 100 (2014): epub[9] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"", "alternatives_a": "Magnesium oxide, Magaldrate, Calcium carbonate, Magnesium hydroxide, Magnesium carbonate", "alternatives_b": "Potassium chloride, Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67193, "ingredient1": "Amoxapine", "ingredient2": "Potassium citrate", "severity": "Major", "effect": "Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.", "source": "DDInter", "management_text": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.", "mechanism_text": "Synergism", "recommendation": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67280/", "reference_text": "[1] \"Product Information. K-Dur (potassium chloride).\" Schering Laboratories, Kenilworth, NJ.[2] Wynn V \"Potassium chloride and bowel ulceration.\" Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial.\" Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L \"Ulceration of the small intestine due to slow-release potassium chloride tablets.\" Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ \"Perforation of small bowel due to slow release potassium chloride (slow-K).\" Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ \"Jejunal perforation associated with slow-release potassium chloride therapy.\" South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ \"Ulceration of small intestine and slow-release potassium tablets.\" Br Med J 2 (1975): 746[8] Lambert JR, Newman A \"Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy.\" Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L \"Gastrointestinal lesions and potassium chloride supplements.\" Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA \"Gut lesions due to slow-release KCI tablets.\" N Engl J Med 296 (1977): 111-2[11] \"Product Information. Urocit (potassium citrate).\" Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Effect of potassium chloride supplements on upper gastrointestinal mucosa.\" Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Sanctura (trospium chloride).\" Odyssey Pharmaceutical, East Hanover, NJ.", "alternatives_a": "Citalopram, Sertraline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Isocarboxazid, Viloxazine, Esketamine, More", "alternatives_b": "Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67194, "ingredient1": "Potassium citrate", "ingredient2": "Azatadine", "severity": "Major", "effect": "Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.", "source": "DDInter", "management_text": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.", "mechanism_text": "Synergism", "recommendation": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67281/", "reference_text": "[1] \"Product Information. K-Dur (potassium chloride).\" Schering Laboratories, Kenilworth, NJ.[2] Wynn V \"Potassium chloride and bowel ulceration.\" Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial.\" Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L \"Ulceration of the small intestine due to slow-release potassium chloride tablets.\" Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ \"Perforation of small bowel due to slow release potassium chloride (slow-K).\" Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ \"Jejunal perforation associated with slow-release potassium chloride therapy.\" South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ \"Ulceration of small intestine and slow-release potassium tablets.\" Br Med J 2 (1975): 746[8] Lambert JR, Newman A \"Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy.\" Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L \"Gastrointestinal lesions and potassium chloride supplements.\" Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA \"Gut lesions due to slow-release KCI tablets.\" N Engl J Med 296 (1977): 111-2[11] \"Product Information. Urocit (potassium citrate).\" Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Effect of potassium chloride supplements on upper gastrointestinal mucosa.\" Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Sanctura (trospium chloride).\" Odyssey Pharmaceutical, East Hanover, NJ.", "alternatives_a": "Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67195, "ingredient1": "Belladonna", "ingredient2": "Potassium citrate", "severity": "Major", "effect": "Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.", "source": "DDInter", "management_text": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.", "mechanism_text": "Synergism", "recommendation": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67282/", "reference_text": "[1] \"Product Information. K-Dur (potassium chloride).\" Schering Laboratories, Kenilworth, NJ.[2] Wynn V \"Potassium chloride and bowel ulceration.\" Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial.\" Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L \"Ulceration of the small intestine due to slow-release potassium chloride tablets.\" Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ \"Perforation of small bowel due to slow release potassium chloride (slow-K).\" Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ \"Jejunal perforation associated with slow-release potassium chloride therapy.\" South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ \"Ulceration of small intestine and slow-release potassium tablets.\" Br Med J 2 (1975): 746[8] Lambert JR, Newman A \"Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy.\" Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L \"Gastrointestinal lesions and potassium chloride supplements.\" Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA \"Gut lesions due to slow-release KCI tablets.\" N Engl J Med 296 (1977): 111-2[11] \"Product Information. Urocit (potassium citrate).\" Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Effect of potassium chloride supplements on upper gastrointestinal mucosa.\" Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Sanctura (trospium chloride).\" Odyssey Pharmaceutical, East Hanover, NJ.", "alternatives_a": "Potassium bicarbonate, Potassium gluconate", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67196, "ingredient1": "Bromfenac", "ingredient2": "Potassium citrate", "severity": "Moderate", "effect": "Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) with potassium salts may increase the risk of hyperkalemia. NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system.", "source": "DDInter", "management_text": "Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.g., beta-blockers, cyclosporine, heparin, tacrolimus, and trimethoprim). Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67283/", "reference_text": "[1] \"Product Information. Potassium Chloride ER (potassium chloride).\" Zydus Pharmaceuticals (USA) Inc, Princeton, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. K-Phos Original (potassium acid phosphate).\" Beach Pharmaceuticals, Tampa, FL.[4] \"Product Information. Phospho-Trin 250 Neutral (potassium phosphate-sodium phosphate).\" Patrin Pharma, Skokie, IL.[5] \"Product Information. SSKI (potassium iodide).\" Upsher-Smith Laboratories Inc, Minneapolis, MN.[6] \"Product Information. Potassium Chloride (potassium chloride).\" Pharmaceutical Assoc Inc Div Beach Products, Greenville, SC.", "alternatives_a": "Fluocinolone acetonide, Cortisone, Hydrocortisone, Prednisolone, Betamethasone, Fluorometholone, Triamcinolone, Dexamethasone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67197, "ingredient1": "Chlorcyclizine", "ingredient2": "Potassium citrate", "severity": "Major", "effect": "Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.", "source": "DDInter", "management_text": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.", "mechanism_text": "Synergism", "recommendation": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67284/", "reference_text": "[1] \"Product Information. K-Dur (potassium chloride).\" Schering Laboratories, Kenilworth, NJ.[2] Wynn V \"Potassium chloride and bowel ulceration.\" Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial.\" Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L \"Ulceration of the small intestine due to slow-release potassium chloride tablets.\" Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ \"Perforation of small bowel due to slow release potassium chloride (slow-K).\" Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ \"Jejunal perforation associated with slow-release potassium chloride therapy.\" South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ \"Ulceration of small intestine and slow-release potassium tablets.\" Br Med J 2 (1975): 746[8] Lambert JR, Newman A \"Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy.\" Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L \"Gastrointestinal lesions and potassium chloride supplements.\" Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA \"Gut lesions due to slow-release KCI tablets.\" N Engl J Med 296 (1977): 111-2[11] \"Product Information. Urocit (potassium citrate).\" Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Effect of potassium chloride supplements on upper gastrointestinal mucosa.\" Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Sanctura (trospium chloride).\" Odyssey Pharmaceutical, East Hanover, NJ.", "alternatives_a": "Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67198, "ingredient1": "Chlorpromazine", "ingredient2": "Potassium citrate", "severity": "Major", "effect": "Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.", "source": "DDInter", "management_text": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.", "mechanism_text": "Synergism", "recommendation": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67285/", "reference_text": "[1] \"Product Information. K-Dur (potassium chloride).\" Schering Laboratories, Kenilworth, NJ.[2] Wynn V \"Potassium chloride and bowel ulceration.\" Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial.\" Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L \"Ulceration of the small intestine due to slow-release potassium chloride tablets.\" Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ \"Perforation of small bowel due to slow release potassium chloride (slow-K).\" Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ \"Jejunal perforation associated with slow-release potassium chloride therapy.\" South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ \"Ulceration of small intestine and slow-release potassium tablets.\" Br Med J 2 (1975): 746[8] Lambert JR, Newman A \"Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy.\" Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L \"Gastrointestinal lesions and potassium chloride supplements.\" Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA \"Gut lesions due to slow-release KCI tablets.\" N Engl J Med 296 (1977): 111-2[11] \"Product Information. Urocit (potassium citrate).\" Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Effect of potassium chloride supplements on upper gastrointestinal mucosa.\" Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Sanctura (trospium chloride).\" Odyssey Pharmaceutical, East Hanover, NJ.", "alternatives_a": "Quetiapine, Asenapine, Haloperidol, Pimavanserin, Ziprasidone, Lumateperone, Iloperidone, Risperidone, Amisulpride, Aripiprazole, Droperidol, More", "alternatives_b": "Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67199, "ingredient1": "Citric acid", "ingredient2": "Cinoxacin", "severity": "Moderate", "effect": "Urinary alkalinizers such as citrates may decrease the solubility of fluoroquinolones in the urine and increase the risk of crystalluria.", "source": "DDInter", "management_text": "Concomitant use should generally be avoided. Patients receiving this combination should be monitored for signs of renal toxicity and crystalluria.", "mechanism_text": "Excretion", "recommendation": "Concomitant use should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67286/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.", "alternatives_a": "Delafloxacin", "alternatives_b": "Glutamic acid, Pancrelipase", "updated_at": 1767369485}, {"id": 67200, "ingredient1": "Clemastine", "ingredient2": "Potassium citrate", "severity": "Major", "effect": "Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.", "source": "DDInter", "management_text": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.", "mechanism_text": "Synergism", "recommendation": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67287/", "reference_text": "[1] \"Product Information. K-Dur (potassium chloride).\" Schering Laboratories, Kenilworth, NJ.[2] Wynn V \"Potassium chloride and bowel ulceration.\" Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial.\" Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L \"Ulceration of the small intestine due to slow-release potassium chloride tablets.\" Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ \"Perforation of small bowel due to slow release potassium chloride (slow-K).\" Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ \"Jejunal perforation associated with slow-release potassium chloride therapy.\" South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ \"Ulceration of small intestine and slow-release potassium tablets.\" Br Med J 2 (1975): 746[8] Lambert JR, Newman A \"Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy.\" Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L \"Gastrointestinal lesions and potassium chloride supplements.\" Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA \"Gut lesions due to slow-release KCI tablets.\" N Engl J Med 296 (1977): 111-2[11] \"Product Information. Urocit (potassium citrate).\" Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Effect of potassium chloride supplements on upper gastrointestinal mucosa.\" Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Sanctura (trospium chloride).\" Odyssey Pharmaceutical, East Hanover, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67201, "ingredient1": "Clomipramine", "ingredient2": "Potassium citrate", "severity": "Major", "effect": "Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.", "source": "DDInter", "management_text": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.", "mechanism_text": "Synergism", "recommendation": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67288/", "reference_text": "[1] \"Product Information. K-Dur (potassium chloride).\" Schering Laboratories, Kenilworth, NJ.[2] Wynn V \"Potassium chloride and bowel ulceration.\" Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial.\" Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L \"Ulceration of the small intestine due to slow-release potassium chloride tablets.\" Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ \"Perforation of small bowel due to slow release potassium chloride (slow-K).\" Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ \"Jejunal perforation associated with slow-release potassium chloride therapy.\" South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ \"Ulceration of small intestine and slow-release potassium tablets.\" Br Med J 2 (1975): 746[8] Lambert JR, Newman A \"Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy.\" Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L \"Gastrointestinal lesions and potassium chloride supplements.\" Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA \"Gut lesions due to slow-release KCI tablets.\" N Engl J Med 296 (1977): 111-2[11] \"Product Information. Urocit (potassium citrate).\" Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Effect of potassium chloride supplements on upper gastrointestinal mucosa.\" Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Sanctura (trospium chloride).\" Odyssey Pharmaceutical, East Hanover, NJ.", "alternatives_a": "Citalopram, Sertraline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Isocarboxazid, Viloxazine, Esketamine, More", "alternatives_b": "Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67202, "ingredient1": "Clozapine", "ingredient2": "Potassium citrate", "severity": "Major", "effect": "Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.", "source": "DDInter", "management_text": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.", "mechanism_text": "Synergism", "recommendation": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67289/", "reference_text": "[1] \"Product Information. K-Dur (potassium chloride).\" Schering Laboratories, Kenilworth, NJ.[2] Wynn V \"Potassium chloride and bowel ulceration.\" Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial.\" Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L \"Ulceration of the small intestine due to slow-release potassium chloride tablets.\" Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ \"Perforation of small bowel due to slow release potassium chloride (slow-K).\" Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ \"Jejunal perforation associated with slow-release potassium chloride therapy.\" South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ \"Ulceration of small intestine and slow-release potassium tablets.\" Br Med J 2 (1975): 746[8] Lambert JR, Newman A \"Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy.\" Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L \"Gastrointestinal lesions and potassium chloride supplements.\" Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA \"Gut lesions due to slow-release KCI tablets.\" N Engl J Med 296 (1977): 111-2[11] \"Product Information. Urocit (potassium citrate).\" Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Effect of potassium chloride supplements on upper gastrointestinal mucosa.\" Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Sanctura (trospium chloride).\" Odyssey Pharmaceutical, East Hanover, NJ.", "alternatives_a": "Quetiapine, Asenapine, Haloperidol, Pimavanserin, Ziprasidone, Lumateperone, Iloperidone, Risperidone, Amisulpride, Aripiprazole, Droperidol, More", "alternatives_b": "Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67203, "ingredient1": "Cyclizine", "ingredient2": "Potassium citrate", "severity": "Major", "effect": "Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.", "source": "DDInter", "management_text": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.", "mechanism_text": "Synergism", "recommendation": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67290/", "reference_text": "[1] \"Product Information. K-Dur (potassium chloride).\" Schering Laboratories, Kenilworth, NJ.[2] Wynn V \"Potassium chloride and bowel ulceration.\" Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial.\" Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L \"Ulceration of the small intestine due to slow-release potassium chloride tablets.\" Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ \"Perforation of small bowel due to slow release potassium chloride (slow-K).\" Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ \"Jejunal perforation associated with slow-release potassium chloride therapy.\" South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ \"Ulceration of small intestine and slow-release potassium tablets.\" Br Med J 2 (1975): 746[8] Lambert JR, Newman A \"Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy.\" Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L \"Gastrointestinal lesions and potassium chloride supplements.\" Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA \"Gut lesions due to slow-release KCI tablets.\" N Engl J Med 296 (1977): 111-2[11] \"Product Information. Urocit (potassium citrate).\" Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Effect of potassium chloride supplements on upper gastrointestinal mucosa.\" Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Sanctura (trospium chloride).\" Odyssey Pharmaceutical, East Hanover, NJ.", "alternatives_a": "Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67204, "ingredient1": "Cyclobenzaprine", "ingredient2": "Potassium citrate", "severity": "Major", "effect": "Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.", "source": "DDInter", "management_text": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.", "mechanism_text": "Synergism", "recommendation": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67291/", "reference_text": "[1] \"Product Information. K-Dur (potassium chloride).\" Schering Laboratories, Kenilworth, NJ.[2] Wynn V \"Potassium chloride and bowel ulceration.\" Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial.\" Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L \"Ulceration of the small intestine due to slow-release potassium chloride tablets.\" Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ \"Perforation of small bowel due to slow release potassium chloride (slow-K).\" Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ \"Jejunal perforation associated with slow-release potassium chloride therapy.\" South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ \"Ulceration of small intestine and slow-release potassium tablets.\" Br Med J 2 (1975): 746[8] Lambert JR, Newman A \"Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy.\" Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L \"Gastrointestinal lesions and potassium chloride supplements.\" Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA \"Gut lesions due to slow-release KCI tablets.\" N Engl J Med 296 (1977): 111-2[11] \"Product Information. Urocit (potassium citrate).\" Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Effect of potassium chloride supplements on upper gastrointestinal mucosa.\" Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Sanctura (trospium chloride).\" Odyssey Pharmaceutical, East Hanover, NJ.", "alternatives_a": "Carisoprodol, Chlorzoxazone, Tizanidine, Baclofen, Methocarbamol, Chlormezanone", "alternatives_b": "Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67205, "ingredient1": "Cyproheptadine", "ingredient2": "Potassium citrate", "severity": "Major", "effect": "Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.", "source": "DDInter", "management_text": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.", "mechanism_text": "Synergism", "recommendation": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67292/", "reference_text": "[1] \"Product Information. K-Dur (potassium chloride).\" Schering Laboratories, Kenilworth, NJ.[2] Wynn V \"Potassium chloride and bowel ulceration.\" Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial.\" Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L \"Ulceration of the small intestine due to slow-release potassium chloride tablets.\" Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ \"Perforation of small bowel due to slow release potassium chloride (slow-K).\" Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ \"Jejunal perforation associated with slow-release potassium chloride therapy.\" South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ \"Ulceration of small intestine and slow-release potassium tablets.\" Br Med J 2 (1975): 746[8] Lambert JR, Newman A \"Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy.\" Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L \"Gastrointestinal lesions and potassium chloride supplements.\" Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA \"Gut lesions due to slow-release KCI tablets.\" N Engl J Med 296 (1977): 111-2[11] \"Product Information. Urocit (potassium citrate).\" Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Effect of potassium chloride supplements on upper gastrointestinal mucosa.\" Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Sanctura (trospium chloride).\" Odyssey Pharmaceutical, East Hanover, NJ.", "alternatives_a": "Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67206, "ingredient1": "Darifenacin", "ingredient2": "Potassium citrate", "severity": "Major", "effect": "Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.", "source": "DDInter", "management_text": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.", "mechanism_text": "Synergism", "recommendation": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67293/", "reference_text": "[1] \"Product Information. K-Dur (potassium chloride).\" Schering Laboratories, Kenilworth, NJ.[2] Wynn V \"Potassium chloride and bowel ulceration.\" Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial.\" Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L \"Ulceration of the small intestine due to slow-release potassium chloride tablets.\" Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ \"Perforation of small bowel due to slow release potassium chloride (slow-K).\" Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ \"Jejunal perforation associated with slow-release potassium chloride therapy.\" South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ \"Ulceration of small intestine and slow-release potassium tablets.\" Br Med J 2 (1975): 746[8] Lambert JR, Newman A \"Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy.\" Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L \"Gastrointestinal lesions and potassium chloride supplements.\" Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA \"Gut lesions due to slow-release KCI tablets.\" N Engl J Med 296 (1977): 111-2[11] \"Product Information. Urocit (potassium citrate).\" Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Effect of potassium chloride supplements on upper gastrointestinal mucosa.\" Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Sanctura (trospium chloride).\" Odyssey Pharmaceutical, East Hanover, NJ.", "alternatives_a": "Apomorphine, Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Avanafil, More", "alternatives_b": "Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67207, "ingredient1": "Desipramine", "ingredient2": "Potassium citrate", "severity": "Major", "effect": "Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.", "source": "DDInter", "management_text": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.", "mechanism_text": "Synergism", "recommendation": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67294/", "reference_text": "[1] \"Product Information. K-Dur (potassium chloride).\" Schering Laboratories, Kenilworth, NJ.[2] Wynn V \"Potassium chloride and bowel ulceration.\" Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial.\" Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L \"Ulceration of the small intestine due to slow-release potassium chloride tablets.\" Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ \"Perforation of small bowel due to slow release potassium chloride (slow-K).\" Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ \"Jejunal perforation associated with slow-release potassium chloride therapy.\" South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ \"Ulceration of small intestine and slow-release potassium tablets.\" Br Med J 2 (1975): 746[8] Lambert JR, Newman A \"Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy.\" Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L \"Gastrointestinal lesions and potassium chloride supplements.\" Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA \"Gut lesions due to slow-release KCI tablets.\" N Engl J Med 296 (1977): 111-2[11] \"Product Information. Urocit (potassium citrate).\" Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Effect of potassium chloride supplements on upper gastrointestinal mucosa.\" Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Sanctura (trospium chloride).\" Odyssey Pharmaceutical, East Hanover, NJ.", "alternatives_a": "Citalopram, Sertraline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Isocarboxazid, Viloxazine, Esketamine, More", "alternatives_b": "Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67208, "ingredient1": "Dexbrompheniramine", "ingredient2": "Potassium citrate", "severity": "Major", "effect": "Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.", "source": "DDInter", "management_text": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.", "mechanism_text": "Synergism", "recommendation": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67295/", "reference_text": "[1] \"Product Information. K-Dur (potassium chloride).\" Schering Laboratories, Kenilworth, NJ.[2] Wynn V \"Potassium chloride and bowel ulceration.\" Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial.\" Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L \"Ulceration of the small intestine due to slow-release potassium chloride tablets.\" Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ \"Perforation of small bowel due to slow release potassium chloride (slow-K).\" Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ \"Jejunal perforation associated with slow-release potassium chloride therapy.\" South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ \"Ulceration of small intestine and slow-release potassium tablets.\" Br Med J 2 (1975): 746[8] Lambert JR, Newman A \"Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy.\" Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L \"Gastrointestinal lesions and potassium chloride supplements.\" Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA \"Gut lesions due to slow-release KCI tablets.\" N Engl J Med 296 (1977): 111-2[11] \"Product Information. Urocit (potassium citrate).\" Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Effect of potassium chloride supplements on upper gastrointestinal mucosa.\" Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Sanctura (trospium chloride).\" Odyssey Pharmaceutical, East Hanover, NJ.", "alternatives_a": "Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67209, "ingredient1": "Dicyclomine", "ingredient2": "Potassium citrate", "severity": "Major", "effect": "Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.", "source": "DDInter", "management_text": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.", "mechanism_text": "Synergism", "recommendation": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67296/", "reference_text": "[1] \"Product Information. K-Dur (potassium chloride).\" Schering Laboratories, Kenilworth, NJ.[2] Wynn V \"Potassium chloride and bowel ulceration.\" Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial.\" Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L \"Ulceration of the small intestine due to slow-release potassium chloride tablets.\" Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ \"Perforation of small bowel due to slow release potassium chloride (slow-K).\" Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ \"Jejunal perforation associated with slow-release potassium chloride therapy.\" South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ \"Ulceration of small intestine and slow-release potassium tablets.\" Br Med J 2 (1975): 746[8] Lambert JR, Newman A \"Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy.\" Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L \"Gastrointestinal lesions and potassium chloride supplements.\" Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA \"Gut lesions due to slow-release KCI tablets.\" N Engl J Med 296 (1977): 111-2[11] \"Product Information. Urocit (potassium citrate).\" Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Effect of potassium chloride supplements on upper gastrointestinal mucosa.\" Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Sanctura (trospium chloride).\" Odyssey Pharmaceutical, East Hanover, NJ.", "alternatives_a": "Papaverine, Alosetron, Isometheptene", "alternatives_b": "Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67210, "ingredient1": "Diflunisal", "ingredient2": "Potassium citrate", "severity": "Moderate", "effect": "Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) with potassium salts may increase the risk of hyperkalemia. NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system.", "source": "DDInter", "management_text": "Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.g., beta-blockers, cyclosporine, heparin, tacrolimus, and trimethoprim). Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67297/", "reference_text": "[1] \"Product Information. Potassium Chloride ER (potassium chloride).\" Zydus Pharmaceuticals (USA) Inc, Princeton, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. K-Phos Original (potassium acid phosphate).\" Beach Pharmaceuticals, Tampa, FL.[4] \"Product Information. Phospho-Trin 250 Neutral (potassium phosphate-sodium phosphate).\" Patrin Pharma, Skokie, IL.[5] \"Product Information. SSKI (potassium iodide).\" Upsher-Smith Laboratories Inc, Minneapolis, MN.[6] \"Product Information. Potassium Chloride (potassium chloride).\" Pharmaceutical Assoc Inc Div Beach Products, Greenville, SC.", "alternatives_a": "Acetaminophen, Ziconotide, Methoxyflurane", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67211, "ingredient1": "Dimenhydrinate", "ingredient2": "Potassium citrate", "severity": "Major", "effect": "Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.", "source": "DDInter", "management_text": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.", "mechanism_text": "Synergism", "recommendation": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67298/", "reference_text": "[1] \"Product Information. K-Dur (potassium chloride).\" Schering Laboratories, Kenilworth, NJ.[2] Wynn V \"Potassium chloride and bowel ulceration.\" Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial.\" Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L \"Ulceration of the small intestine due to slow-release potassium chloride tablets.\" Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ \"Perforation of small bowel due to slow release potassium chloride (slow-K).\" Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ \"Jejunal perforation associated with slow-release potassium chloride therapy.\" South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ \"Ulceration of small intestine and slow-release potassium tablets.\" Br Med J 2 (1975): 746[8] Lambert JR, Newman A \"Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy.\" Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L \"Gastrointestinal lesions and potassium chloride supplements.\" Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA \"Gut lesions due to slow-release KCI tablets.\" N Engl J Med 296 (1977): 111-2[11] \"Product Information. Urocit (potassium citrate).\" Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Effect of potassium chloride supplements on upper gastrointestinal mucosa.\" Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Sanctura (trospium chloride).\" Odyssey Pharmaceutical, East Hanover, NJ.", "alternatives_a": "Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67212, "ingredient1": "Diphenhydramine", "ingredient2": "Potassium citrate", "severity": "Major", "effect": "Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.", "source": "DDInter", "management_text": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.", "mechanism_text": "Synergism", "recommendation": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67299/", "reference_text": "[1] \"Product Information. K-Dur (potassium chloride).\" Schering Laboratories, Kenilworth, NJ.[2] Wynn V \"Potassium chloride and bowel ulceration.\" Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial.\" Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L \"Ulceration of the small intestine due to slow-release potassium chloride tablets.\" Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ \"Perforation of small bowel due to slow release potassium chloride (slow-K).\" Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ \"Jejunal perforation associated with slow-release potassium chloride therapy.\" South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ \"Ulceration of small intestine and slow-release potassium tablets.\" Br Med J 2 (1975): 746[8] Lambert JR, Newman A \"Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy.\" Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L \"Gastrointestinal lesions and potassium chloride supplements.\" Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA \"Gut lesions due to slow-release KCI tablets.\" N Engl J Med 296 (1977): 111-2[11] \"Product Information. Urocit (potassium citrate).\" Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Effect of potassium chloride supplements on upper gastrointestinal mucosa.\" Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Sanctura (trospium chloride).\" Odyssey Pharmaceutical, East Hanover, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67213, "ingredient1": "Disopyramide", "ingredient2": "Potassium citrate", "severity": "Major", "effect": "Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.", "source": "DDInter", "management_text": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.", "mechanism_text": "Synergism", "recommendation": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67300/", "reference_text": "[1] \"Product Information. K-Dur (potassium chloride).\" Schering Laboratories, Kenilworth, NJ.[2] Wynn V \"Potassium chloride and bowel ulceration.\" Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial.\" Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L \"Ulceration of the small intestine due to slow-release potassium chloride tablets.\" Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ \"Perforation of small bowel due to slow release potassium chloride (slow-K).\" Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ \"Jejunal perforation associated with slow-release potassium chloride therapy.\" South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ \"Ulceration of small intestine and slow-release potassium tablets.\" Br Med J 2 (1975): 746[8] Lambert JR, Newman A \"Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy.\" Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L \"Gastrointestinal lesions and potassium chloride supplements.\" Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA \"Gut lesions due to slow-release KCI tablets.\" N Engl J Med 296 (1977): 111-2[11] \"Product Information. Urocit (potassium citrate).\" Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Effect of potassium chloride supplements on upper gastrointestinal mucosa.\" Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Sanctura (trospium chloride).\" Odyssey Pharmaceutical, East Hanover, NJ.", "alternatives_a": "Amiodarone, Dronedarone, Lidocaine, Propafenone, Procainamide, Tocainide, Dofetilide, Bretylium, Moricizine, Ibutilide", "alternatives_b": "Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67214, "ingredient1": "Doxepin", "ingredient2": "Potassium citrate", "severity": "Major", "effect": "Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.", "source": "DDInter", "management_text": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.", "mechanism_text": "Synergism", "recommendation": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67301/", "reference_text": "[1] \"Product Information. K-Dur (potassium chloride).\" Schering Laboratories, Kenilworth, NJ.[2] Wynn V \"Potassium chloride and bowel ulceration.\" Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial.\" Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L \"Ulceration of the small intestine due to slow-release potassium chloride tablets.\" Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ \"Perforation of small bowel due to slow release potassium chloride (slow-K).\" Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ \"Jejunal perforation associated with slow-release potassium chloride therapy.\" South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ \"Ulceration of small intestine and slow-release potassium tablets.\" Br Med J 2 (1975): 746[8] Lambert JR, Newman A \"Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy.\" Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L \"Gastrointestinal lesions and potassium chloride supplements.\" Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA \"Gut lesions due to slow-release KCI tablets.\" N Engl J Med 296 (1977): 111-2[11] \"Product Information. Urocit (potassium citrate).\" Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Effect of potassium chloride supplements on upper gastrointestinal mucosa.\" Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Sanctura (trospium chloride).\" Odyssey Pharmaceutical, East Hanover, NJ.", "alternatives_a": "Citalopram, Sertraline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Isocarboxazid, Viloxazine, Esketamine, More", "alternatives_b": "Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67215, "ingredient1": "Doxepin (topical)", "ingredient2": "Potassium citrate", "severity": "Major", "effect": "Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.", "source": "DDInter", "management_text": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.", "mechanism_text": "Synergism", "recommendation": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67302/", "reference_text": "[1] \"Product Information. K-Dur (potassium chloride).\" Schering Laboratories, Kenilworth, NJ.[2] Wynn V \"Potassium chloride and bowel ulceration.\" Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial.\" Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L \"Ulceration of the small intestine due to slow-release potassium chloride tablets.\" Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ \"Perforation of small bowel due to slow release potassium chloride (slow-K).\" Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ \"Jejunal perforation associated with slow-release potassium chloride therapy.\" South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ \"Ulceration of small intestine and slow-release potassium tablets.\" Br Med J 2 (1975): 746[8] Lambert JR, Newman A \"Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy.\" Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L \"Gastrointestinal lesions and potassium chloride supplements.\" Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA \"Gut lesions due to slow-release KCI tablets.\" N Engl J Med 296 (1977): 111-2[11] \"Product Information. Urocit (potassium citrate).\" Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Effect of potassium chloride supplements on upper gastrointestinal mucosa.\" Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Sanctura (trospium chloride).\" Odyssey Pharmaceutical, East Hanover, NJ.", "alternatives_a": "Citalopram, Sertraline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Isocarboxazid, Viloxazine, Esketamine, More", "alternatives_b": "Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67216, "ingredient1": "Doxylamine", "ingredient2": "Potassium citrate", "severity": "Major", "effect": "Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.", "source": "DDInter", "management_text": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.", "mechanism_text": "Synergism", "recommendation": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67303/", "reference_text": "[1] \"Product Information. K-Dur (potassium chloride).\" Schering Laboratories, Kenilworth, NJ.[2] Wynn V \"Potassium chloride and bowel ulceration.\" Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial.\" Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L \"Ulceration of the small intestine due to slow-release potassium chloride tablets.\" Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ \"Perforation of small bowel due to slow release potassium chloride (slow-K).\" Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ \"Jejunal perforation associated with slow-release potassium chloride therapy.\" South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ \"Ulceration of small intestine and slow-release potassium tablets.\" Br Med J 2 (1975): 746[8] Lambert JR, Newman A \"Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy.\" Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L \"Gastrointestinal lesions and potassium chloride supplements.\" Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA \"Gut lesions due to slow-release KCI tablets.\" N Engl J Med 296 (1977): 111-2[11] \"Product Information. Urocit (potassium citrate).\" Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Effect of potassium chloride supplements on upper gastrointestinal mucosa.\" Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Sanctura (trospium chloride).\" Odyssey Pharmaceutical, East Hanover, NJ.", "alternatives_a": "Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67217, "ingredient1": "Drospirenone", "ingredient2": "Potassium citrate", "severity": "Moderate", "effect": "The use of drospirenone may potentiate the risk of hyperkalemia in patients receiving chronic treatment with drugs that can increase serum potassium such as angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, potassium-sparing diuretics, aldosterone antagonists, nonsteroidal anti-inflammatory drugs (NSAIDs), potassium preparations, and miscellaneous agents like cyclosporine, heparin, tacrolimus, and trimethoprim. Drospirenone has antimineralocorticoid activity and may induce hyperkalemia in susceptible patients.", "source": "DDInter", "management_text": "Serum potassium levels should be checked regularly during concomitant therapy with drospirenone and other agents that can increase serum potassium. Particular caution is warranted in patients with renal impairment, diabetes, old age, severe or worsening heart failure, or dehydration. Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Serum potassium levels should be checked regularly during concomitant therapy with drospirenone and other agents that can increase serum potassium.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67304/", "reference_text": "[1] Ponce SP, Jennings AE, Madias NE, Harrington JT \"Drug-induced hyperkalemia.\" Medicine (Baltimore) 64 (1985): 357-70[2] \"Product Information. Yasmin (drospirenone-ethinyl estradiol)\" Berlex Laboratories, Richmond, CA.", "alternatives_a": "Ulipristal, Norethisterone, Norelgestromin, Etonogestrel, Megestrol acetate, Norgestimate, Etynodiol, Estradiol, Levonorgestrel, Medroxyprogesterone acetate, Desogestrel, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67218, "ingredient1": "Enalapril", "ingredient2": "Potassium citrate", "severity": "Major", "effect": "Concomitant use of angiotensin converting enzyme (ACE) inhibitors and potassium salts may increase the risk of hyperkalemia. Inhibition of ACE results in decreased aldosterone secretion, which in turn causes potassium retention.", "source": "DDInter", "management_text": "Caution is advised if ACE inhibitors must be used concurrently with potassium salts, particularly in patients with renal impairment, diabetes, old age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium such as nonsteroidal anti-inflammatory drugs, beta-blockers, cyclosporine, heparin, tacrolimus, trimethoprim, and licorice. The combination should generally be avoided in these patients unless absolutely necessary and the benefits outweigh the potential risks. Serum potassium and renal function should be checked prior to initiating therapy and regularly thereafter. Patients should be given counseling on the appropriate levels of potassium and fluid intake, and advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if ACE inhibitors must be used concurrently with potassium salts, particularly in patients with renal impairment, diabetes, old age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium such as nonsteroidal anti-inflammatory drugs, beta-blockers, cyclosporine, heparin, tacrolimus, trimethoprim, and licorice.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67305/", "reference_text": "[1] \"Product Information. K-Dur (potassium chloride).\" Schering Laboratories, Kenilworth, NJ.[2] Chan TY, Critchley JA \"Life-threatening hyperkalaemia in an elderly patient receiving captopril, furosemide (frusemide) and potassium supplements.\" Drug Saf 7 (1992): 159-61[3] Warren SE, O'Connor DT \"Hyperkalemia resulting from captopril administration.\" JAMA 244 (1980): 2551-2[4] Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS, Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association \"Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association.\" Circulation 104 (2001): 1985-91[5] Large DM, Carr PH, Laing I, Davies M \"Hyperkalaemia in diabetes mellitus--potential hazards of coexisting hyporeninaemic hypoaldosteronism.\" Postgrad Med J 60 (1984): 370-3[6] Schuna AA, Schmidt GR, Pitterle ME \"Serum potassium concentrations after initiation of captopril therapy.\" Clin Pharm 5 (1986): 920-3[7] Perazella MA, Mahnensmith RL \"Hyperkalemia in the elderly: drugs exacerbate impaired potassium homeostasis.\" J Gen Intern Med 12 (1997): 646-56[8] Lawson DH, O'Connor PC, Jick H \"Drug attributed alterations in potassium handling in congestive cardiac failure.\" Eur J Clin Pharmacol 23 (1982): 21-5[9] Perazella MA \"Drug-induced hyperkalemia: old culprits and new offenders.\" Am J Med 109 (2000): 307-14[10] Packer M, Lee WH \"Provocation of hyper- and hypokalemic sudden death during treatment with and withdrawal of converting-enzyme inhibition in severe chronic congestive heart failure.\" Am J Cardiol 57 (1986): 347-8[11] Ray K, Dorman S, Watson R \"Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction.\" J Hum Hypertens 13 (1999): 717-20[12] Ponce SP, Jennings AE, Madias NE, Harrington JT \"Drug-induced hyperkalemia.\" Medicine (Baltimore) 64 (1985): 357-70[13] Burnakis TG, Mioduch HJ \"Combined therapy with captopril and potassium supplementation: a potential for hyperkalemia.\" Arch Intern Med 144 (1984): 2371-2[14] Speirs CJ, Dollery CT, Inman WH, et al \"Postmarketing surveillance of enalapril II: investigation of the potential role of enalapril in deaths with renal failure.\" Br Med J 297 (1988): 830-2[15] Jarman PR, Kehely AM, Mather HM \"Hyperkalaemia in diabetes: prevalence and associations.\" Postgrad Med J 71 (1995): 551-2[16] Obialo CI, Ofili EO, Mirza T \"Hyperkalemia in congestive heart failure patients aged 63 to 85 years with subclinical renal disease.\" Am J Cardiol 90 (2002): 663-5[17] Atlas SA, Case DB, Sealey JE, Laragh JH, McKinstry DN \"Interruption of the renin-angiotensin system in hypertensive patients by captopril induces sustained reduction in aldosterone secretion, potassium retention and natriuresis.\" Hypertension 1 (1979): 279-80[18] Graves JW \"Hyperkalemia due to a potassium-based water softener.\" N Engl J Med 339 (1998): 1790-1[19] Lawson DH \"Adverse reactions to potassium chloride.\" Q J Med 43 (1974): 433-40[20] Good CB, McDermott L \"Diet and serum potassium in patients on ACE inhibitors.\" JAMA 274 (1995): 538[21] Walmsley RN, White GH, Cain M, McCarthy PJ, Booth J \"Hyperkalemia in the elderly.\" Clin Chem 30 (1984): 1409-12[22] Jarman PR, Mather HM \"Diabetes may be independent risk factor for hyperkalaemia.\" BMJ 327 (2003): 812[23] Stoltz ML, Andrews CE Jr \"Severe hyperkalemia during very-low-calorie diets and angiotensin converting enzyme use .\" JAMA 264 (1990): 2737-8[24] Reardon LC, Macpherson DS \"Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry?\" Arch Intern Med 158 (1998): 26-32[25] Ray K, Dorman S, Watson R \"Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction.\" J Hum Hypertens 13 (1999): 717-20[26] \"Product Information. Vasotec (enalapril).\" Merck & Co, Inc, West Point, PA.[27] Good CB, McDermott L \"Diet and serum potassium in patients on ACE inhibitors.\" JAMA 274 (1995): 538", "alternatives_a": "Felodipine, Amlodipine, Verapamil, Bisoprolol, Hydrochlorothiazide, Indapamide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67219, "ingredient1": "Enoxacin", "ingredient2": "Potassium citrate", "severity": "Moderate", "effect": "Urinary alkalinizers such as citrates may decrease the solubility of fluoroquinolones in the urine and increase the risk of crystalluria.", "source": "DDInter", "management_text": "Concomitant use should generally be avoided. Patients receiving this combination should be monitored for signs of renal toxicity and crystalluria.", "mechanism_text": "Excretion", "recommendation": "Concomitant use should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67306/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.", "alternatives_a": "Delafloxacin", "alternatives_b": "Potassium chloride, Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67220, "ingredient1": "Ephedrine (nasal)", "ingredient2": "Potassium citrate", "severity": "Moderate", "effect": "Alkalization of the urine decreases the urinary excretion increases the elimination half-life of ephedrine, pseudoephedrine, and related drugs. Toxicity from long-term use of pseudoephedrine has been demonstrated in patients with persistently alkaline urine.", "source": "DDInter", "management_text": "Patients should be monitored for toxic effects such as tremor, anxiety, insomnia, irritability, or nervousness. Dosage reductions may be required.", "mechanism_text": "Excretion", "recommendation": "Patients should be monitored for toxic effects such as tremor, anxiety, insomnia, irritability, or nervousness.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67307/", "reference_text": "[1] Wilkinson GR, Beckett AH \"Absorption metabolism and excretion of the ephedrines in man. I. The influence of urinary pH and urine volume output.\" J Pharmacol Exp Ther 162 (1968): 139-47[2] Brater DC, Kaojarern S, Benet LZ, et al \"Renal excretion of pseudoephedrine.\" Clin Pharmacol Ther 28 (1980): 690-4[3] Kuntzman RG, Tsai I, Brand L, Mark LC \"The influence of urinary pH on the plasma half-life of pseudoephedrine in man and dog and a sensitive assay for its determination in human plasma.\" Clin Pharmacol Ther 12 (1971): 62-7", "alternatives_a": "Tropicamide, Phenylephrine, Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, More", "alternatives_b": "Potassium chloride, Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67221, "ingredient1": "Eplerenone", "ingredient2": "Potassium citrate", "severity": "Major", "effect": "The principal risk of eplerenone is hyperkalemia. Coadministration with potassium salts or potassium-sparing diuretics may increase this risk due to additive pharmacodynamic effects.", "source": "DDInter", "management_text": "Given the potential for serious, sometimes fatal cardiac arrhythmias associated with hyperkalemia, the use of eplerenone with potassium salts or potassium-sparing diuretics is considered contraindicated.", "mechanism_text": "Synergism", "recommendation": "Given the potential for serious, sometimes fatal cardiac arrhythmias associated with hyperkalemia, the use of eplerenone with potassium salts or potassium-sparing diuretics is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67308/", "reference_text": "[1] Marcy TR, Ripley TL \"Aldosterone antagonists in the treatment of heart failure.\" Am J Health Syst Pharm 63 (2006): 49-58[2] \"Product Information. Inspra (eplerenone).\" Searle, Chicago, IL.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67222, "ingredient1": "Eprosartan", "ingredient2": "Potassium citrate", "severity": "Major", "effect": "Concomitant use of angiotensin II receptor blockers (ARBs) and potassium salts may increase the risk of hyperkalemia. Inhibition of angiotensin II results in decreased aldosterone secretion, which in turn causes potassium retention. Risk factors for developing severe or life-threatening hyperkalemia may include renal impairment, diabetes, old age, severe or worsening heart failure, dehydration, and concomitant use of other agents that block the renin-angiotensin-aldosterone system or otherwise increase serum potassium levels.", "source": "DDInter", "management_text": "Caution is advised if angiotensin II receptor blockers must be used concurrently with potassium salts, particularly in patients with renal impairment, diabetes, old age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium such as nonsteroidal anti-inflammatory drugs, beta-blockers, cyclosporine, heparin, tacrolimus, and trimethoprim. The combination should generally be avoided in these patients unless absolutely necessary and the benefits outweigh the potential risks. Serum potassium and renal function should be checked prior to initiating therapy and regularly thereafter. Patients should be given counseling on the appropriate levels of potassium and fluid intake, and advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if angiotensin II receptor blockers must be used concurrently with potassium salts, particularly in patients with renal impairment, diabetes, old age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium such as nonsteroidal anti-inflammatory drugs, beta-blockers, cyclosporine, heparin, tacrolimus, and trimethoprim.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67309/", "reference_text": "[1] Walmsley RN, White GH, Cain M, McCarthy PJ, Booth J \"Hyperkalemia in the elderly.\" Clin Chem 30 (1984): 1409-12[2] Jarman PR, Mather HM \"Diabetes may be independent risk factor for hyperkalaemia.\" BMJ 327 (2003): 812[3] Obialo CI, Ofili EO, Mirza T \"Hyperkalemia in congestive heart failure patients aged 63 to 85 years with subclinical renal disease.\" Am J Cardiol 90 (2002): 663-5[4] Jarman PR, Kehely AM, Mather HM \"Hyperkalaemia in diabetes: prevalence and associations.\" Postgrad Med J 71 (1995): 551-2[5] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[6] Large DM, Carr PH, Laing I, Davies M \"Hyperkalaemia in diabetes mellitus--potential hazards of coexisting hyporeninaemic hypoaldosteronism.\" Postgrad Med J 60 (1984): 370-3[7] Perazella MA \"Drug-induced hyperkalemia: old culprits and new offenders.\" Am J Med 109 (2000): 307-14[8] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[9] Perazella MA, Mahnensmith RL \"Hyperkalemia in the elderly: drugs exacerbate impaired potassium homeostasis.\" J Gen Intern Med 12 (1997): 646-56[10] Lawson DH \"Adverse reactions to potassium chloride.\" Q J Med 43 (1974): 433-40[11] Lawson DH, O'Connor PC, Jick H \"Drug attributed alterations in potassium handling in congestive cardiac failure.\" Eur J Clin Pharmacol 23 (1982): 21-5[12] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[13] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.", "alternatives_a": "Amlodipine, Sacubitril, Hydrochlorothiazide, Nebivolol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67223, "ingredient1": "Etodolac", "ingredient2": "Potassium citrate", "severity": "Moderate", "effect": "Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) with potassium salts may increase the risk of hyperkalemia. NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system.", "source": "DDInter", "management_text": "Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.g., beta-blockers, cyclosporine, heparin, tacrolimus, and trimethoprim). Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67310/", "reference_text": "[1] \"Product Information. Potassium Chloride ER (potassium chloride).\" Zydus Pharmaceuticals (USA) Inc, Princeton, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. K-Phos Original (potassium acid phosphate).\" Beach Pharmaceuticals, Tampa, FL.[4] \"Product Information. Phospho-Trin 250 Neutral (potassium phosphate-sodium phosphate).\" Patrin Pharma, Skokie, IL.[5] \"Product Information. SSKI (potassium iodide).\" Upsher-Smith Laboratories Inc, Minneapolis, MN.[6] \"Product Information. Potassium Chloride (potassium chloride).\" Pharmaceutical Assoc Inc Div Beach Products, Greenville, SC.", "alternatives_a": "Rabeprazole, Misoprostol, Glucosamine, Chondroitin sulfate, Rofecoxib, Esomeprazole, Celecoxib, Valdecoxib", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67224, "ingredient1": "Fenoprofen", "ingredient2": "Potassium citrate", "severity": "Moderate", "effect": "Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) with potassium salts may increase the risk of hyperkalemia. NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system.", "source": "DDInter", "management_text": "Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.g., beta-blockers, cyclosporine, heparin, tacrolimus, and trimethoprim). Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67311/", "reference_text": "[1] \"Product Information. Potassium Chloride ER (potassium chloride).\" Zydus Pharmaceuticals (USA) Inc, Princeton, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. K-Phos Original (potassium acid phosphate).\" Beach Pharmaceuticals, Tampa, FL.[4] \"Product Information. Phospho-Trin 250 Neutral (potassium phosphate-sodium phosphate).\" Patrin Pharma, Skokie, IL.[5] \"Product Information. SSKI (potassium iodide).\" Upsher-Smith Laboratories Inc, Minneapolis, MN.[6] \"Product Information. Potassium Chloride (potassium chloride).\" Pharmaceutical Assoc Inc Div Beach Products, Greenville, SC.", "alternatives_a": "Rabeprazole, Misoprostol, Glucosamine, Chondroitin sulfate, Rofecoxib, Esomeprazole, Celecoxib, Valdecoxib", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67225, "ingredient1": "Flavoxate", "ingredient2": "Potassium citrate", "severity": "Major", "effect": "Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.", "source": "DDInter", "management_text": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.", "mechanism_text": "Synergism", "recommendation": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67312/", "reference_text": "[1] \"Product Information. K-Dur (potassium chloride).\" Schering Laboratories, Kenilworth, NJ.[2] Wynn V \"Potassium chloride and bowel ulceration.\" Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial.\" Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L \"Ulceration of the small intestine due to slow-release potassium chloride tablets.\" Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ \"Perforation of small bowel due to slow release potassium chloride (slow-K).\" Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ \"Jejunal perforation associated with slow-release potassium chloride therapy.\" South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ \"Ulceration of small intestine and slow-release potassium tablets.\" Br Med J 2 (1975): 746[8] Lambert JR, Newman A \"Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy.\" Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L \"Gastrointestinal lesions and potassium chloride supplements.\" Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA \"Gut lesions due to slow-release KCI tablets.\" N Engl J Med 296 (1977): 111-2[11] \"Product Information. Urocit (potassium citrate).\" Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Effect of potassium chloride supplements on upper gastrointestinal mucosa.\" Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Sanctura (trospium chloride).\" Odyssey Pharmaceutical, East Hanover, NJ.", "alternatives_a": "Apomorphine, Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Avanafil, More", "alternatives_b": "Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67226, "ingredient1": "Flecainide", "ingredient2": "Potassium citrate", "severity": "Minor", "effect": "Agents that alkalinize the urine decrease the renal elimination of flecainide. The result may be increased plasma flecainide levels and increased effectiveness. The patient should be monitored for flecainide toxicity, and plasma flecainide levels should be checked when appropriate. Also, flecainide effectiveness may be decreased when an agent that alkalinizes the urine is discontinued.", "source": "DDInter", "management_text": "-", "mechanism_text": "Excretion", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67313/", "reference_text": "[1] Hertrampf R, Gundert-Remy U, Beckmann J, et al \"Elimination of flecainide as a function of urinary flow rate and pH.\" Eur J Clin Pharmacol 41 (1991): 61-3", "alternatives_a": "Amiodarone, Dronedarone, Lidocaine, Propafenone, Procainamide, Tocainide, Dofetilide, Bretylium, Moricizine, Ibutilide", "alternatives_b": "Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67227, "ingredient1": "Fluphenazine", "ingredient2": "Potassium citrate", "severity": "Major", "effect": "Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.", "source": "DDInter", "management_text": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.", "mechanism_text": "Synergism", "recommendation": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67314/", "reference_text": "[1] \"Product Information. K-Dur (potassium chloride).\" Schering Laboratories, Kenilworth, NJ.[2] Wynn V \"Potassium chloride and bowel ulceration.\" Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial.\" Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L \"Ulceration of the small intestine due to slow-release potassium chloride tablets.\" Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ \"Perforation of small bowel due to slow release potassium chloride (slow-K).\" Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ \"Jejunal perforation associated with slow-release potassium chloride therapy.\" South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ \"Ulceration of small intestine and slow-release potassium tablets.\" Br Med J 2 (1975): 746[8] Lambert JR, Newman A \"Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy.\" Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L \"Gastrointestinal lesions and potassium chloride supplements.\" Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA \"Gut lesions due to slow-release KCI tablets.\" N Engl J Med 296 (1977): 111-2[11] \"Product Information. Urocit (potassium citrate).\" Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Effect of potassium chloride supplements on upper gastrointestinal mucosa.\" Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Sanctura (trospium chloride).\" Odyssey Pharmaceutical, East Hanover, NJ.", "alternatives_a": "Quetiapine, Asenapine, Haloperidol, Pimavanserin, Ziprasidone, Lumateperone, Iloperidone, Risperidone, Amisulpride, Aripiprazole, Droperidol, More", "alternatives_b": "Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67228, "ingredient1": "Flurbiprofen", "ingredient2": "Potassium citrate", "severity": "Moderate", "effect": "Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) with potassium salts may increase the risk of hyperkalemia. NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system.", "source": "DDInter", "management_text": "Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.g., beta-blockers, cyclosporine, heparin, tacrolimus, and trimethoprim). Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67315/", "reference_text": "[1] \"Product Information. Potassium Chloride ER (potassium chloride).\" Zydus Pharmaceuticals (USA) Inc, Princeton, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. K-Phos Original (potassium acid phosphate).\" Beach Pharmaceuticals, Tampa, FL.[4] \"Product Information. Phospho-Trin 250 Neutral (potassium phosphate-sodium phosphate).\" Patrin Pharma, Skokie, IL.[5] \"Product Information. SSKI (potassium iodide).\" Upsher-Smith Laboratories Inc, Minneapolis, MN.[6] \"Product Information. Potassium Chloride (potassium chloride).\" Pharmaceutical Assoc Inc Div Beach Products, Greenville, SC.", "alternatives_a": "Tolazoline, Rabeprazole, Dimethyl sulfoxide, Rabeprazole, Misoprostol, Glucosamine, Chondroitin sulfate, Rofecoxib, Esomeprazole, Celecoxib, Valdecoxib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67229, "ingredient1": "Fosinopril", "ingredient2": "Potassium citrate", "severity": "Major", "effect": "Concomitant use of angiotensin converting enzyme (ACE) inhibitors and potassium salts may increase the risk of hyperkalemia. Inhibition of ACE results in decreased aldosterone secretion, which in turn causes potassium retention.", "source": "DDInter", "management_text": "Caution is advised if ACE inhibitors must be used concurrently with potassium salts, particularly in patients with renal impairment, diabetes, old age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium such as nonsteroidal anti-inflammatory drugs, beta-blockers, cyclosporine, heparin, tacrolimus, trimethoprim, and licorice. The combination should generally be avoided in these patients unless absolutely necessary and the benefits outweigh the potential risks. Serum potassium and renal function should be checked prior to initiating therapy and regularly thereafter. Patients should be given counseling on the appropriate levels of potassium and fluid intake, and advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if ACE inhibitors must be used concurrently with potassium salts, particularly in patients with renal impairment, diabetes, old age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium such as nonsteroidal anti-inflammatory drugs, beta-blockers, cyclosporine, heparin, tacrolimus, trimethoprim, and licorice.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67316/", "reference_text": "[1] \"Product Information. K-Dur (potassium chloride).\" Schering Laboratories, Kenilworth, NJ.[2] Chan TY, Critchley JA \"Life-threatening hyperkalaemia in an elderly patient receiving captopril, furosemide (frusemide) and potassium supplements.\" Drug Saf 7 (1992): 159-61[3] Warren SE, O'Connor DT \"Hyperkalemia resulting from captopril administration.\" JAMA 244 (1980): 2551-2[4] Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS, Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association \"Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association.\" Circulation 104 (2001): 1985-91[5] Large DM, Carr PH, Laing I, Davies M \"Hyperkalaemia in diabetes mellitus--potential hazards of coexisting hyporeninaemic hypoaldosteronism.\" Postgrad Med J 60 (1984): 370-3[6] Schuna AA, Schmidt GR, Pitterle ME \"Serum potassium concentrations after initiation of captopril therapy.\" Clin Pharm 5 (1986): 920-3[7] Perazella MA, Mahnensmith RL \"Hyperkalemia in the elderly: drugs exacerbate impaired potassium homeostasis.\" J Gen Intern Med 12 (1997): 646-56[8] Lawson DH, O'Connor PC, Jick H \"Drug attributed alterations in potassium handling in congestive cardiac failure.\" Eur J Clin Pharmacol 23 (1982): 21-5[9] Perazella MA \"Drug-induced hyperkalemia: old culprits and new offenders.\" Am J Med 109 (2000): 307-14[10] Packer M, Lee WH \"Provocation of hyper- and hypokalemic sudden death during treatment with and withdrawal of converting-enzyme inhibition in severe chronic congestive heart failure.\" Am J Cardiol 57 (1986): 347-8[11] Ray K, Dorman S, Watson R \"Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction.\" J Hum Hypertens 13 (1999): 717-20[12] Ponce SP, Jennings AE, Madias NE, Harrington JT \"Drug-induced hyperkalemia.\" Medicine (Baltimore) 64 (1985): 357-70[13] Burnakis TG, Mioduch HJ \"Combined therapy with captopril and potassium supplementation: a potential for hyperkalemia.\" Arch Intern Med 144 (1984): 2371-2[14] Speirs CJ, Dollery CT, Inman WH, et al \"Postmarketing surveillance of enalapril II: investigation of the potential role of enalapril in deaths with renal failure.\" Br Med J 297 (1988): 830-2[15] Jarman PR, Kehely AM, Mather HM \"Hyperkalaemia in diabetes: prevalence and associations.\" Postgrad Med J 71 (1995): 551-2[16] Obialo CI, Ofili EO, Mirza T \"Hyperkalemia in congestive heart failure patients aged 63 to 85 years with subclinical renal disease.\" Am J Cardiol 90 (2002): 663-5[17] Atlas SA, Case DB, Sealey JE, Laragh JH, McKinstry DN \"Interruption of the renin-angiotensin system in hypertensive patients by captopril induces sustained reduction in aldosterone secretion, potassium retention and natriuresis.\" Hypertension 1 (1979): 279-80[18] Graves JW \"Hyperkalemia due to a potassium-based water softener.\" N Engl J Med 339 (1998): 1790-1[19] Lawson DH \"Adverse reactions to potassium chloride.\" Q J Med 43 (1974): 433-40[20] Good CB, McDermott L \"Diet and serum potassium in patients on ACE inhibitors.\" JAMA 274 (1995): 538[21] Walmsley RN, White GH, Cain M, McCarthy PJ, Booth J \"Hyperkalemia in the elderly.\" Clin Chem 30 (1984): 1409-12[22] Jarman PR, Mather HM \"Diabetes may be independent risk factor for hyperkalaemia.\" BMJ 327 (2003): 812[23] Stoltz ML, Andrews CE Jr \"Severe hyperkalemia during very-low-calorie diets and angiotensin converting enzyme use .\" JAMA 264 (1990): 2737-8[24] Reardon LC, Macpherson DS \"Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry?\" Arch Intern Med 158 (1998): 26-32[25] Ray K, Dorman S, Watson R \"Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction.\" J Hum Hypertens 13 (1999): 717-20[26] \"Product Information. Vasotec (enalapril).\" Merck & Co, Inc, West Point, PA.[27] Good CB, McDermott L \"Diet and serum potassium in patients on ACE inhibitors.\" JAMA 274 (1995): 538", "alternatives_a": "Felodipine, Amlodipine, Verapamil, Bisoprolol, Hydrochlorothiazide, Indapamide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67230, "ingredient1": "Gatifloxacin", "ingredient2": "Potassium citrate", "severity": "Moderate", "effect": "Urinary alkalinizers such as citrates may decrease the solubility of fluoroquinolones in the urine and increase the risk of crystalluria.", "source": "DDInter", "management_text": "Concomitant use should generally be avoided. Patients receiving this combination should be monitored for signs of renal toxicity and crystalluria.", "mechanism_text": "Excretion", "recommendation": "Concomitant use should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67317/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.", "alternatives_a": "Rifamycin, Kanamycin, Ampicillin, Azithromycin, Acyclovir, Netilmicin, Polymyxin B, Famciclovir, Cefuroxime, Trifluridine, Tobramycin, More", "alternatives_b": "Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67231, "ingredient1": "Gemifloxacin", "ingredient2": "Potassium citrate", "severity": "Moderate", "effect": "Urinary alkalinizers such as citrates may decrease the solubility of fluoroquinolones in the urine and increase the risk of crystalluria.", "source": "DDInter", "management_text": "Concomitant use should generally be avoided. Patients receiving this combination should be monitored for signs of renal toxicity and crystalluria.", "mechanism_text": "Excretion", "recommendation": "Concomitant use should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67318/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.", "alternatives_a": "Delafloxacin", "alternatives_b": "Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67232, "ingredient1": "Glipizide", "ingredient2": "Potassium citrate", "severity": "Minor", "effect": "Alkalinization of the urine may increase the renal clearance of some sulfonylureas for which renal elimination is pH dependent. The clinical significance of this interaction is unknown. Management consists of monitoring blood glucose frequently during the initial period of coadministration. The sulfonylurea dosage should be adjusted as needed and appropriate.", "source": "DDInter", "management_text": "-", "mechanism_text": "Excretion", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67319/", "reference_text": "[1] Neuvonen PJ, Karkkainen S \"Effects of charcoal, sodium bicarbonate, and ammonium chloride on chlorpropamide kinetics.\" Clin Pharmacol Ther 33 (1983): 386-93[2] Kivisto KT, Neuvonen PJ \"Differential effects of sodium bicarbonate and aluminium hydroxide on the absorption and activity of glipizide.\" Eur J Clin Pharmacol 40 (1991): 383-6[3] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[4] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[5] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[6] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[7] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[10] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[11] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Empagliflozin, Dulaglutide, Exenatide, Miglitol, Glimepiride, Albiglutide, Rosiglitazone, More", "alternatives_b": "Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67233, "ingredient1": "Glyburide", "ingredient2": "Potassium citrate", "severity": "Minor", "effect": "Alkalinization of the urine may increase the renal clearance of some sulfonylureas for which renal elimination is pH dependent. The clinical significance of this interaction is unknown. Management consists of monitoring blood glucose frequently during the initial period of coadministration. The sulfonylurea dosage should be adjusted as needed and appropriate.", "source": "DDInter", "management_text": "-", "mechanism_text": "Excretion", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67320/", "reference_text": "[1] Neuvonen PJ, Karkkainen S \"Effects of charcoal, sodium bicarbonate, and ammonium chloride on chlorpropamide kinetics.\" Clin Pharmacol Ther 33 (1983): 386-93[2] Kivisto KT, Neuvonen PJ \"Differential effects of sodium bicarbonate and aluminium hydroxide on the absorption and activity of glipizide.\" Eur J Clin Pharmacol 40 (1991): 383-6[3] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[4] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[5] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[6] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[7] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[10] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[11] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Empagliflozin, Dulaglutide, Exenatide, Miglitol, Glimepiride, Albiglutide, Rosiglitazone, More", "alternatives_b": "Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67234, "ingredient1": "Grepafloxacin", "ingredient2": "Potassium citrate", "severity": "Moderate", "effect": "Urinary alkalinizers such as citrates may decrease the solubility of fluoroquinolones in the urine and increase the risk of crystalluria.", "source": "DDInter", "management_text": "Concomitant use should generally be avoided. Patients receiving this combination should be monitored for signs of renal toxicity and crystalluria.", "mechanism_text": "Excretion", "recommendation": "Concomitant use should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67321/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.", "alternatives_a": "Delafloxacin", "alternatives_b": "Potassium chloride, Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67235, "ingredient1": "Hydroxyzine", "ingredient2": "Potassium citrate", "severity": "Major", "effect": "Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.", "source": "DDInter", "management_text": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.", "mechanism_text": "Synergism", "recommendation": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67322/", "reference_text": "[1] \"Product Information. K-Dur (potassium chloride).\" Schering Laboratories, Kenilworth, NJ.[2] Wynn V \"Potassium chloride and bowel ulceration.\" Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial.\" Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L \"Ulceration of the small intestine due to slow-release potassium chloride tablets.\" Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ \"Perforation of small bowel due to slow release potassium chloride (slow-K).\" Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ \"Jejunal perforation associated with slow-release potassium chloride therapy.\" South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ \"Ulceration of small intestine and slow-release potassium tablets.\" Br Med J 2 (1975): 746[8] Lambert JR, Newman A \"Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy.\" Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L \"Gastrointestinal lesions and potassium chloride supplements.\" Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA \"Gut lesions due to slow-release KCI tablets.\" N Engl J Med 296 (1977): 111-2[11] \"Product Information. Urocit (potassium citrate).\" Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Effect of potassium chloride supplements on upper gastrointestinal mucosa.\" Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Sanctura (trospium chloride).\" Odyssey Pharmaceutical, East Hanover, NJ.", "alternatives_a": "Clobazam, Meprobamate, Alprazolam, Lorazepam, Chlordiazepoxide, Halazepam, Clorazepic acid, Buspirone, Diazepam, Oxazepam", "alternatives_b": "Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67236, "ingredient1": "Imipramine", "ingredient2": "Potassium citrate", "severity": "Major", "effect": "Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.", "source": "DDInter", "management_text": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.", "mechanism_text": "Synergism", "recommendation": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67323/", "reference_text": "[1] \"Product Information. K-Dur (potassium chloride).\" Schering Laboratories, Kenilworth, NJ.[2] Wynn V \"Potassium chloride and bowel ulceration.\" Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial.\" Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L \"Ulceration of the small intestine due to slow-release potassium chloride tablets.\" Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ \"Perforation of small bowel due to slow release potassium chloride (slow-K).\" Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ \"Jejunal perforation associated with slow-release potassium chloride therapy.\" South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ \"Ulceration of small intestine and slow-release potassium tablets.\" Br Med J 2 (1975): 746[8] Lambert JR, Newman A \"Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy.\" Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L \"Gastrointestinal lesions and potassium chloride supplements.\" Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA \"Gut lesions due to slow-release KCI tablets.\" N Engl J Med 296 (1977): 111-2[11] \"Product Information. Urocit (potassium citrate).\" Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Effect of potassium chloride supplements on upper gastrointestinal mucosa.\" Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Sanctura (trospium chloride).\" Odyssey Pharmaceutical, East Hanover, NJ.", "alternatives_a": "Citalopram, Sertraline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Isocarboxazid, Viloxazine, Esketamine, More", "alternatives_b": "Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67237, "ingredient1": "Indomethacin", "ingredient2": "Potassium citrate", "severity": "Moderate", "effect": "Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) with potassium salts may increase the risk of hyperkalemia. NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system.", "source": "DDInter", "management_text": "Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.g., beta-blockers, cyclosporine, heparin, tacrolimus, and trimethoprim). Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67324/", "reference_text": "[1] \"Product Information. Potassium Chloride ER (potassium chloride).\" Zydus Pharmaceuticals (USA) Inc, Princeton, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. K-Phos Original (potassium acid phosphate).\" Beach Pharmaceuticals, Tampa, FL.[4] \"Product Information. Phospho-Trin 250 Neutral (potassium phosphate-sodium phosphate).\" Patrin Pharma, Skokie, IL.[5] \"Product Information. SSKI (potassium iodide).\" Upsher-Smith Laboratories Inc, Minneapolis, MN.[6] \"Product Information. Potassium Chloride (potassium chloride).\" Pharmaceutical Assoc Inc Div Beach Products, Greenville, SC.", "alternatives_a": "Fludrocortisone, Fluocinolone acetonide, Hydrocortisone, Prednisolone, Betamethasone, Fluorometholone, Methylprednisolone, Dexamethasone, Rabeprazole, Misoprostol, Glucosamine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67238, "ingredient1": "Insulin human", "ingredient2": "Potassium citrate", "severity": "Minor", "effect": "Limited data suggest that potassium repletion may partially or completely reverse glucose intolerance in some patients with liver cirrhosis. The effect of insulin may be potentiated, and the risk of hypoglycemia increased. The mechanism by which potassium improves glucose tolerance has not been established, but it apparently does not involve a further increase in the already excessive insulin secretion associated with cirrhosis. The implications for glucose intolerance in patients without liver cirrhosis are not known.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67325/", "reference_text": "[1] Hiatt N, Davidson MB, Bonorris G \"The effect of potassium chloride infusion on insulin secretion in vivo.\" Horm Metab Res 4 (1972): 64-8[2] Conn HO \"Cirrhosis and diabetes. IV. Effect of potassium chloride administration on glucose and insulin metabolism.\" Am J Med Sci 259 (1970): 394-404[3] DeFronzo RA, Cooke CR, Andres R, Faloona GR, Davis PJ \"The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man.\" J Clin Invest 55 (1975): 845-55[4] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[5] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[11] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[12] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[13] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Liraglutide, Lixisenatide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67239, "ingredient1": "Insulin aspart (aspart)", "ingredient2": "Potassium citrate", "severity": "Minor", "effect": "Limited data suggest that potassium repletion may partially or completely reverse glucose intolerance in some patients with liver cirrhosis. The effect of insulin may be potentiated, and the risk of hypoglycemia increased. The mechanism by which potassium improves glucose tolerance has not been established, but it apparently does not involve a further increase in the already excessive insulin secretion associated with cirrhosis. The implications for glucose intolerance in patients without liver cirrhosis are not known.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67326/", "reference_text": "[1] Hiatt N, Davidson MB, Bonorris G \"The effect of potassium chloride infusion on insulin secretion in vivo.\" Horm Metab Res 4 (1972): 64-8[2] Conn HO \"Cirrhosis and diabetes. IV. Effect of potassium chloride administration on glucose and insulin metabolism.\" Am J Med Sci 259 (1970): 394-404[3] DeFronzo RA, Cooke CR, Andres R, Faloona GR, Davis PJ \"The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man.\" J Clin Invest 55 (1975): 845-55[4] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[5] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[11] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[12] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[13] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67240, "ingredient1": "Insulin aspart (aspart protamine)", "ingredient2": "Potassium citrate", "severity": "Minor", "effect": "Limited data suggest that potassium repletion may partially or completely reverse glucose intolerance in some patients with liver cirrhosis. The effect of insulin may be potentiated, and the risk of hypoglycemia increased. The mechanism by which potassium improves glucose tolerance has not been established, but it apparently does not involve a further increase in the already excessive insulin secretion associated with cirrhosis. The implications for glucose intolerance in patients without liver cirrhosis are not known.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67327/", "reference_text": "[1] Hiatt N, Davidson MB, Bonorris G \"The effect of potassium chloride infusion on insulin secretion in vivo.\" Horm Metab Res 4 (1972): 64-8[2] Conn HO \"Cirrhosis and diabetes. IV. Effect of potassium chloride administration on glucose and insulin metabolism.\" Am J Med Sci 259 (1970): 394-404[3] DeFronzo RA, Cooke CR, Andres R, Faloona GR, Davis PJ \"The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man.\" J Clin Invest 55 (1975): 845-55[4] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[5] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[11] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[12] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[13] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67241, "ingredient1": "Insulin degludec", "ingredient2": "Potassium citrate", "severity": "Minor", "effect": "Limited data suggest that potassium repletion may partially or completely reverse glucose intolerance in some patients with liver cirrhosis. The effect of insulin may be potentiated, and the risk of hypoglycemia increased. The mechanism by which potassium improves glucose tolerance has not been established, but it apparently does not involve a further increase in the already excessive insulin secretion associated with cirrhosis. The implications for glucose intolerance in patients without liver cirrhosis are not known.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67328/", "reference_text": "[1] Hiatt N, Davidson MB, Bonorris G \"The effect of potassium chloride infusion on insulin secretion in vivo.\" Horm Metab Res 4 (1972): 64-8[2] Conn HO \"Cirrhosis and diabetes. IV. Effect of potassium chloride administration on glucose and insulin metabolism.\" Am J Med Sci 259 (1970): 394-404[3] DeFronzo RA, Cooke CR, Andres R, Faloona GR, Davis PJ \"The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man.\" J Clin Invest 55 (1975): 845-55[4] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[5] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[11] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[12] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[13] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Liraglutide, Lixisenatide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67242, "ingredient1": "Insulin detemir", "ingredient2": "Potassium citrate", "severity": "Minor", "effect": "Limited data suggest that potassium repletion may partially or completely reverse glucose intolerance in some patients with liver cirrhosis. The effect of insulin may be potentiated, and the risk of hypoglycemia increased. The mechanism by which potassium improves glucose tolerance has not been established, but it apparently does not involve a further increase in the already excessive insulin secretion associated with cirrhosis. The implications for glucose intolerance in patients without liver cirrhosis are not known.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67329/", "reference_text": "[1] Hiatt N, Davidson MB, Bonorris G \"The effect of potassium chloride infusion on insulin secretion in vivo.\" Horm Metab Res 4 (1972): 64-8[2] Conn HO \"Cirrhosis and diabetes. IV. Effect of potassium chloride administration on glucose and insulin metabolism.\" Am J Med Sci 259 (1970): 394-404[3] DeFronzo RA, Cooke CR, Andres R, Faloona GR, Davis PJ \"The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man.\" J Clin Invest 55 (1975): 845-55[4] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[5] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[11] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[12] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[13] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Liraglutide, Lixisenatide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67243, "ingredient1": "Insulin glargine", "ingredient2": "Potassium citrate", "severity": "Minor", "effect": "Limited data suggest that potassium repletion may partially or completely reverse glucose intolerance in some patients with liver cirrhosis. The effect of insulin may be potentiated, and the risk of hypoglycemia increased. The mechanism by which potassium improves glucose tolerance has not been established, but it apparently does not involve a further increase in the already excessive insulin secretion associated with cirrhosis. The implications for glucose intolerance in patients without liver cirrhosis are not known.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67330/", "reference_text": "[1] Hiatt N, Davidson MB, Bonorris G \"The effect of potassium chloride infusion on insulin secretion in vivo.\" Horm Metab Res 4 (1972): 64-8[2] Conn HO \"Cirrhosis and diabetes. IV. Effect of potassium chloride administration on glucose and insulin metabolism.\" Am J Med Sci 259 (1970): 394-404[3] DeFronzo RA, Cooke CR, Andres R, Faloona GR, Davis PJ \"The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man.\" J Clin Invest 55 (1975): 845-55[4] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[5] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[11] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[12] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[13] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Liraglutide, Lixisenatide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67244, "ingredient1": "Insulin glulisine", "ingredient2": "Potassium citrate", "severity": "Minor", "effect": "Limited data suggest that potassium repletion may partially or completely reverse glucose intolerance in some patients with liver cirrhosis. The effect of insulin may be potentiated, and the risk of hypoglycemia increased. The mechanism by which potassium improves glucose tolerance has not been established, but it apparently does not involve a further increase in the already excessive insulin secretion associated with cirrhosis. The implications for glucose intolerance in patients without liver cirrhosis are not known.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67331/", "reference_text": "[1] Hiatt N, Davidson MB, Bonorris G \"The effect of potassium chloride infusion on insulin secretion in vivo.\" Horm Metab Res 4 (1972): 64-8[2] Conn HO \"Cirrhosis and diabetes. IV. Effect of potassium chloride administration on glucose and insulin metabolism.\" Am J Med Sci 259 (1970): 394-404[3] DeFronzo RA, Cooke CR, Andres R, Faloona GR, Davis PJ \"The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man.\" J Clin Invest 55 (1975): 845-55[4] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[5] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[11] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[12] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[13] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Liraglutide, Lixisenatide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67245, "ingredient1": "Insulin human (inhalation, rapid acting)", "ingredient2": "Potassium citrate", "severity": "Minor", "effect": "Limited data suggest that potassium repletion may partially or completely reverse glucose intolerance in some patients with liver cirrhosis. The effect of insulin may be potentiated, and the risk of hypoglycemia increased. The mechanism by which potassium improves glucose tolerance has not been established, but it apparently does not involve a further increase in the already excessive insulin secretion associated with cirrhosis. The implications for glucose intolerance in patients without liver cirrhosis are not known.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67332/", "reference_text": "[1] Hiatt N, Davidson MB, Bonorris G \"The effect of potassium chloride infusion on insulin secretion in vivo.\" Horm Metab Res 4 (1972): 64-8[2] Conn HO \"Cirrhosis and diabetes. IV. Effect of potassium chloride administration on glucose and insulin metabolism.\" Am J Med Sci 259 (1970): 394-404[3] DeFronzo RA, Cooke CR, Andres R, Faloona GR, Davis PJ \"The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man.\" J Clin Invest 55 (1975): 845-55[4] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[5] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[11] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[12] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[13] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Liraglutide, Lixisenatide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67246, "ingredient1": "Insulin human (isophane)", "ingredient2": "Potassium citrate", "severity": "Minor", "effect": "Limited data suggest that potassium repletion may partially or completely reverse glucose intolerance in some patients with liver cirrhosis. The effect of insulin may be potentiated, and the risk of hypoglycemia increased. The mechanism by which potassium improves glucose tolerance has not been established, but it apparently does not involve a further increase in the already excessive insulin secretion associated with cirrhosis. The implications for glucose intolerance in patients without liver cirrhosis are not known.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67333/", "reference_text": "[1] Hiatt N, Davidson MB, Bonorris G \"The effect of potassium chloride infusion on insulin secretion in vivo.\" Horm Metab Res 4 (1972): 64-8[2] Conn HO \"Cirrhosis and diabetes. IV. Effect of potassium chloride administration on glucose and insulin metabolism.\" Am J Med Sci 259 (1970): 394-404[3] DeFronzo RA, Cooke CR, Andres R, Faloona GR, Davis PJ \"The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man.\" J Clin Invest 55 (1975): 845-55[4] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[5] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[11] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[12] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[13] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Liraglutide, Lixisenatide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67247, "ingredient1": "Insulin lispro", "ingredient2": "Potassium citrate", "severity": "Minor", "effect": "Limited data suggest that potassium repletion may partially or completely reverse glucose intolerance in some patients with liver cirrhosis. The effect of insulin may be potentiated, and the risk of hypoglycemia increased. The mechanism by which potassium improves glucose tolerance has not been established, but it apparently does not involve a further increase in the already excessive insulin secretion associated with cirrhosis. The implications for glucose intolerance in patients without liver cirrhosis are not known.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67334/", "reference_text": "[1] Hiatt N, Davidson MB, Bonorris G \"The effect of potassium chloride infusion on insulin secretion in vivo.\" Horm Metab Res 4 (1972): 64-8[2] Conn HO \"Cirrhosis and diabetes. IV. Effect of potassium chloride administration on glucose and insulin metabolism.\" Am J Med Sci 259 (1970): 394-404[3] DeFronzo RA, Cooke CR, Andres R, Faloona GR, Davis PJ \"The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man.\" J Clin Invest 55 (1975): 845-55[4] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[5] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[11] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[12] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[13] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Liraglutide, Lixisenatide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67248, "ingredient1": "Insulin lispro (protamine)", "ingredient2": "Potassium citrate", "severity": "Minor", "effect": "Limited data suggest that potassium repletion may partially or completely reverse glucose intolerance in some patients with liver cirrhosis. The effect of insulin may be potentiated, and the risk of hypoglycemia increased. The mechanism by which potassium improves glucose tolerance has not been established, but it apparently does not involve a further increase in the already excessive insulin secretion associated with cirrhosis. The implications for glucose intolerance in patients without liver cirrhosis are not known.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67335/", "reference_text": "[1] Hiatt N, Davidson MB, Bonorris G \"The effect of potassium chloride infusion on insulin secretion in vivo.\" Horm Metab Res 4 (1972): 64-8[2] Conn HO \"Cirrhosis and diabetes. IV. Effect of potassium chloride administration on glucose and insulin metabolism.\" Am J Med Sci 259 (1970): 394-404[3] DeFronzo RA, Cooke CR, Andres R, Faloona GR, Davis PJ \"The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man.\" J Clin Invest 55 (1975): 845-55[4] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[5] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[11] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[12] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[13] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67249, "ingredient1": "Insulin human (regular)", "ingredient2": "Potassium citrate", "severity": "Minor", "effect": "Limited data suggest that potassium repletion may partially or completely reverse glucose intolerance in some patients with liver cirrhosis. The effect of insulin may be potentiated, and the risk of hypoglycemia increased. The mechanism by which potassium improves glucose tolerance has not been established, but it apparently does not involve a further increase in the already excessive insulin secretion associated with cirrhosis. The implications for glucose intolerance in patients without liver cirrhosis are not known.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67336/", "reference_text": "[1] Hiatt N, Davidson MB, Bonorris G \"The effect of potassium chloride infusion on insulin secretion in vivo.\" Horm Metab Res 4 (1972): 64-8[2] Conn HO \"Cirrhosis and diabetes. IV. Effect of potassium chloride administration on glucose and insulin metabolism.\" Am J Med Sci 259 (1970): 394-404[3] DeFronzo RA, Cooke CR, Andres R, Faloona GR, Davis PJ \"The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man.\" J Clin Invest 55 (1975): 845-55[4] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[5] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[11] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[12] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[13] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Liraglutide, Lixisenatide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67250, "ingredient1": "Insulin human (zinc)", "ingredient2": "Potassium citrate", "severity": "Minor", "effect": "Limited data suggest that potassium repletion may partially or completely reverse glucose intolerance in some patients with liver cirrhosis. The effect of insulin may be potentiated, and the risk of hypoglycemia increased. The mechanism by which potassium improves glucose tolerance has not been established, but it apparently does not involve a further increase in the already excessive insulin secretion associated with cirrhosis. The implications for glucose intolerance in patients without liver cirrhosis are not known.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67337/", "reference_text": "[1] Hiatt N, Davidson MB, Bonorris G \"The effect of potassium chloride infusion on insulin secretion in vivo.\" Horm Metab Res 4 (1972): 64-8[2] Conn HO \"Cirrhosis and diabetes. IV. Effect of potassium chloride administration on glucose and insulin metabolism.\" Am J Med Sci 259 (1970): 394-404[3] DeFronzo RA, Cooke CR, Andres R, Faloona GR, Davis PJ \"The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man.\" J Clin Invest 55 (1975): 845-55[4] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[5] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[11] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[12] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[13] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Liraglutide, Lixisenatide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67251, "ingredient1": "Insulin human (zinc extended)", "ingredient2": "Potassium citrate", "severity": "Minor", "effect": "Limited data suggest that potassium repletion may partially or completely reverse glucose intolerance in some patients with liver cirrhosis. The effect of insulin may be potentiated, and the risk of hypoglycemia increased. The mechanism by which potassium improves glucose tolerance has not been established, but it apparently does not involve a further increase in the already excessive insulin secretion associated with cirrhosis. The implications for glucose intolerance in patients without liver cirrhosis are not known.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67338/", "reference_text": "[1] Hiatt N, Davidson MB, Bonorris G \"The effect of potassium chloride infusion on insulin secretion in vivo.\" Horm Metab Res 4 (1972): 64-8[2] Conn HO \"Cirrhosis and diabetes. IV. Effect of potassium chloride administration on glucose and insulin metabolism.\" Am J Med Sci 259 (1970): 394-404[3] DeFronzo RA, Cooke CR, Andres R, Faloona GR, Davis PJ \"The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man.\" J Clin Invest 55 (1975): 845-55[4] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[5] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[6] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[11] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[12] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[13] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Liraglutide, Lixisenatide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67252, "ingredient1": "Irbesartan", "ingredient2": "Potassium citrate", "severity": "Major", "effect": "Concomitant use of angiotensin II receptor blockers (ARBs) and potassium salts may increase the risk of hyperkalemia. Inhibition of angiotensin II results in decreased aldosterone secretion, which in turn causes potassium retention. Risk factors for developing severe or life-threatening hyperkalemia may include renal impairment, diabetes, old age, severe or worsening heart failure, dehydration, and concomitant use of other agents that block the renin-angiotensin-aldosterone system or otherwise increase serum potassium levels.", "source": "DDInter", "management_text": "Caution is advised if angiotensin II receptor blockers must be used concurrently with potassium salts, particularly in patients with renal impairment, diabetes, old age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium such as nonsteroidal anti-inflammatory drugs, beta-blockers, cyclosporine, heparin, tacrolimus, and trimethoprim. The combination should generally be avoided in these patients unless absolutely necessary and the benefits outweigh the potential risks. Serum potassium and renal function should be checked prior to initiating therapy and regularly thereafter. Patients should be given counseling on the appropriate levels of potassium and fluid intake, and advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if angiotensin II receptor blockers must be used concurrently with potassium salts, particularly in patients with renal impairment, diabetes, old age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium such as nonsteroidal anti-inflammatory drugs, beta-blockers, cyclosporine, heparin, tacrolimus, and trimethoprim.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67339/", "reference_text": "[1] Walmsley RN, White GH, Cain M, McCarthy PJ, Booth J \"Hyperkalemia in the elderly.\" Clin Chem 30 (1984): 1409-12[2] Jarman PR, Mather HM \"Diabetes may be independent risk factor for hyperkalaemia.\" BMJ 327 (2003): 812[3] Obialo CI, Ofili EO, Mirza T \"Hyperkalemia in congestive heart failure patients aged 63 to 85 years with subclinical renal disease.\" Am J Cardiol 90 (2002): 663-5[4] Jarman PR, Kehely AM, Mather HM \"Hyperkalaemia in diabetes: prevalence and associations.\" Postgrad Med J 71 (1995): 551-2[5] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[6] Large DM, Carr PH, Laing I, Davies M \"Hyperkalaemia in diabetes mellitus--potential hazards of coexisting hyporeninaemic hypoaldosteronism.\" Postgrad Med J 60 (1984): 370-3[7] Perazella MA \"Drug-induced hyperkalemia: old culprits and new offenders.\" Am J Med 109 (2000): 307-14[8] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[9] Perazella MA, Mahnensmith RL \"Hyperkalemia in the elderly: drugs exacerbate impaired potassium homeostasis.\" J Gen Intern Med 12 (1997): 646-56[10] Lawson DH \"Adverse reactions to potassium chloride.\" Q J Med 43 (1974): 433-40[11] Lawson DH, O'Connor PC, Jick H \"Drug attributed alterations in potassium handling in congestive cardiac failure.\" Eur J Clin Pharmacol 23 (1982): 21-5[12] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[13] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.", "alternatives_a": "Amlodipine, Sacubitril, Hydrochlorothiazide, Nebivolol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67253, "ingredient1": "Potassium citrate", "ingredient2": "Ketoprofen", "severity": "Moderate", "effect": "Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) with potassium salts may increase the risk of hyperkalemia. NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system.", "source": "DDInter", "management_text": "Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.g., beta-blockers, cyclosporine, heparin, tacrolimus, and trimethoprim). Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67340/", "reference_text": "[1] \"Product Information. Potassium Chloride ER (potassium chloride).\" Zydus Pharmaceuticals (USA) Inc, Princeton, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. K-Phos Original (potassium acid phosphate).\" Beach Pharmaceuticals, Tampa, FL.[4] \"Product Information. Phospho-Trin 250 Neutral (potassium phosphate-sodium phosphate).\" Patrin Pharma, Skokie, IL.[5] \"Product Information. SSKI (potassium iodide).\" Upsher-Smith Laboratories Inc, Minneapolis, MN.[6] \"Product Information. Potassium Chloride (potassium chloride).\" Pharmaceutical Assoc Inc Div Beach Products, Greenville, SC.", "alternatives_a": "Rabeprazole, Misoprostol, Glucosamine, Chondroitin sulfate, Rofecoxib, Esomeprazole, Celecoxib, Valdecoxib, Tolazoline, Rabeprazole, Dimethyl sulfoxide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67254, "ingredient1": "Potassium citrate", "ingredient2": "Levofloxacin", "severity": "Moderate", "effect": "Urinary alkalinizers such as citrates may decrease the solubility of fluoroquinolones in the urine and increase the risk of crystalluria.", "source": "DDInter", "management_text": "Concomitant use should generally be avoided. Patients receiving this combination should be monitored for signs of renal toxicity and crystalluria.", "mechanism_text": "Excretion", "recommendation": "Concomitant use should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67341/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.", "alternatives_a": "Delafloxacin, Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, More", "alternatives_b": "Potassium chloride, Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67255, "ingredient1": "Potassium citrate", "ingredient2": "Lisdexamfetamine", "severity": "Moderate", "effect": "Alkalinization of the urine can decrease the renal elimination of amphetamines. Amphetamine effects may be prolonged, and the risk of toxicity may be increased.", "source": "DDInter", "management_text": "Urinary alkalinizers should generally not be used with amphetamines, particularly in an amphetamine overdose situation.", "mechanism_text": "Excretion", "recommendation": "Urinary alkalinizers should generally not be used with amphetamines, particularly in an amphetamine overdose situation.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67342/", "reference_text": "[1] Anggard E, Jonsson LE, Hogmark AL, Gunne LM \"Amphetamine metabolism in amphetamine psychosis.\" Clin Pharmacol Ther 14 (1973): 870-80[2] Wilkinson GR, Beckett AH \"Absorption, metabolism and excretion of the ephedrines in man. I. The influence of urinary pH and urine volume output.\" J Pharmacol Exp Ther 162 (1968): 139-47[3] Davis JM, Kopin IJ, Lemberger L, Axelrod J \"Effects of urinary pH on amphetamine metabolism.\" Ann N Y Acad Sci 179 (1971): 493-501[4] Beckett AH, Rowland M \"Urinary excretion kinetics of amphetamine in man.\" J Pharm Pharmacol 17 (1965): 628-39[5] Beckett AH, Salmon JA, Mitchard M \"The relation between blood levels and urinary excretion of amphetamine under controlled acidic and under fluctuating urinary pH values using [C]amphetamine.\" J Pharm Pharmacol 21 (1969): 251-8[6] Beckett AH, Rowland M, Turner P \"Influence of urinary pH on excretion of amphetamine.\" Lancet 1 (1965): 303[7] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[8] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[9] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Pemoline, Atomoxetine, Solriamfetol, Caffeine, Methylphenidate, Dexmethylphenidate, Armodafinil, Citicoline, Modafinil", "alternatives_b": "Potassium chloride, Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67256, "ingredient1": "Potassium citrate", "ingredient2": "Lisinopril", "severity": "Major", "effect": "Concomitant use of angiotensin converting enzyme (ACE) inhibitors and potassium salts may increase the risk of hyperkalemia. Inhibition of ACE results in decreased aldosterone secretion, which in turn causes potassium retention.", "source": "DDInter", "management_text": "Caution is advised if ACE inhibitors must be used concurrently with potassium salts, particularly in patients with renal impairment, diabetes, old age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium such as nonsteroidal anti-inflammatory drugs, beta-blockers, cyclosporine, heparin, tacrolimus, trimethoprim, and licorice. The combination should generally be avoided in these patients unless absolutely necessary and the benefits outweigh the potential risks. Serum potassium and renal function should be checked prior to initiating therapy and regularly thereafter. Patients should be given counseling on the appropriate levels of potassium and fluid intake, and advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if ACE inhibitors must be used concurrently with potassium salts, particularly in patients with renal impairment, diabetes, old age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium such as nonsteroidal anti-inflammatory drugs, beta-blockers, cyclosporine, heparin, tacrolimus, trimethoprim, and licorice.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67343/", "reference_text": "[1] \"Product Information. K-Dur (potassium chloride).\" Schering Laboratories, Kenilworth, NJ.[2] Chan TY, Critchley JA \"Life-threatening hyperkalaemia in an elderly patient receiving captopril, furosemide (frusemide) and potassium supplements.\" Drug Saf 7 (1992): 159-61[3] Warren SE, O'Connor DT \"Hyperkalemia resulting from captopril administration.\" JAMA 244 (1980): 2551-2[4] Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS, Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association \"Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association.\" Circulation 104 (2001): 1985-91[5] Large DM, Carr PH, Laing I, Davies M \"Hyperkalaemia in diabetes mellitus--potential hazards of coexisting hyporeninaemic hypoaldosteronism.\" Postgrad Med J 60 (1984): 370-3[6] Schuna AA, Schmidt GR, Pitterle ME \"Serum potassium concentrations after initiation of captopril therapy.\" Clin Pharm 5 (1986): 920-3[7] Perazella MA, Mahnensmith RL \"Hyperkalemia in the elderly: drugs exacerbate impaired potassium homeostasis.\" J Gen Intern Med 12 (1997): 646-56[8] Lawson DH, O'Connor PC, Jick H \"Drug attributed alterations in potassium handling in congestive cardiac failure.\" Eur J Clin Pharmacol 23 (1982): 21-5[9] Perazella MA \"Drug-induced hyperkalemia: old culprits and new offenders.\" Am J Med 109 (2000): 307-14[10] Packer M, Lee WH \"Provocation of hyper- and hypokalemic sudden death during treatment with and withdrawal of converting-enzyme inhibition in severe chronic congestive heart failure.\" Am J Cardiol 57 (1986): 347-8[11] Ray K, Dorman S, Watson R \"Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction.\" J Hum Hypertens 13 (1999): 717-20[12] Ponce SP, Jennings AE, Madias NE, Harrington JT \"Drug-induced hyperkalemia.\" Medicine (Baltimore) 64 (1985): 357-70[13] Burnakis TG, Mioduch HJ \"Combined therapy with captopril and potassium supplementation: a potential for hyperkalemia.\" Arch Intern Med 144 (1984): 2371-2[14] Speirs CJ, Dollery CT, Inman WH, et al \"Postmarketing surveillance of enalapril II: investigation of the potential role of enalapril in deaths with renal failure.\" Br Med J 297 (1988): 830-2[15] Jarman PR, Kehely AM, Mather HM \"Hyperkalaemia in diabetes: prevalence and associations.\" Postgrad Med J 71 (1995): 551-2[16] Obialo CI, Ofili EO, Mirza T \"Hyperkalemia in congestive heart failure patients aged 63 to 85 years with subclinical renal disease.\" Am J Cardiol 90 (2002): 663-5[17] Atlas SA, Case DB, Sealey JE, Laragh JH, McKinstry DN \"Interruption of the renin-angiotensin system in hypertensive patients by captopril induces sustained reduction in aldosterone secretion, potassium retention and natriuresis.\" Hypertension 1 (1979): 279-80[18] Graves JW \"Hyperkalemia due to a potassium-based water softener.\" N Engl J Med 339 (1998): 1790-1[19] Lawson DH \"Adverse reactions to potassium chloride.\" Q J Med 43 (1974): 433-40[20] Good CB, McDermott L \"Diet and serum potassium in patients on ACE inhibitors.\" JAMA 274 (1995): 538[21] Walmsley RN, White GH, Cain M, McCarthy PJ, Booth J \"Hyperkalemia in the elderly.\" Clin Chem 30 (1984): 1409-12[22] Jarman PR, Mather HM \"Diabetes may be independent risk factor for hyperkalaemia.\" BMJ 327 (2003): 812[23] Stoltz ML, Andrews CE Jr \"Severe hyperkalemia during very-low-calorie diets and angiotensin converting enzyme use .\" JAMA 264 (1990): 2737-8[24] Reardon LC, Macpherson DS \"Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry?\" Arch Intern Med 158 (1998): 26-32[25] Ray K, Dorman S, Watson R \"Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction.\" J Hum Hypertens 13 (1999): 717-20[26] \"Product Information. Vasotec (enalapril).\" Merck & Co, Inc, West Point, PA.[27] Good CB, McDermott L \"Diet and serum potassium in patients on ACE inhibitors.\" JAMA 274 (1995): 538", "alternatives_a": "Felodipine, Amlodipine, Verapamil, Bisoprolol, Hydrochlorothiazide, Indapamide, Amlodipine, Atorvastatin, Simvastatin, Lovastatin, Rosuvastatin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67257, "ingredient1": "Potassium citrate", "ingredient2": "Lithium carbonate", "severity": "Moderate", "effect": "Urinary alkalinizers may increase excretion of lithium. Plasma lithium levels and therapeutic effects may be decreased.", "source": "DDInter", "management_text": "Monitoring of lithium concentrations and therapeutic effect is recommended during concurrent use.", "mechanism_text": "Others", "recommendation": "Monitoring of lithium concentrations and therapeutic effect is recommended during concurrent use.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67344/", "reference_text": "[1] Forrest JA \"Forced alkaline diuresis for lithium intoxication.\" Postgrad Med J 51 (1975): 189-91[2] Arthur RK \"Lithium levels and \"Soda Bic\".\" Med J Aust 2 (1975): 918[3] Thomsen K, Schou M \"Renal lithium excretion in man.\" Am J Psychol 215 (1968): 823-7[4] McSwiggan C \"Interaction of lithium and bicarbonate.\" Med J Aust 1 (1978): 38-9[5] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[6] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[7] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[8] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Potassium chloride, Potassium bicarbonate, Potassium gluconate", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67258, "ingredient1": "Potassium citrate", "ingredient2": "Lomefloxacin", "severity": "Moderate", "effect": "Urinary alkalinizers such as citrates may decrease the solubility of fluoroquinolones in the urine and increase the risk of crystalluria.", "source": "DDInter", "management_text": "Concomitant use should generally be avoided. Patients receiving this combination should be monitored for signs of renal toxicity and crystalluria.", "mechanism_text": "Excretion", "recommendation": "Concomitant use should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67345/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.", "alternatives_a": "Rifamycin, Kanamycin, Ampicillin, Azithromycin, Acyclovir, Netilmicin, Polymyxin B, Famciclovir, Cefuroxime, Trifluridine, Tobramycin, More", "alternatives_b": "Potassium chloride, Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67259, "ingredient1": "Potassium citrate", "ingredient2": "Losartan", "severity": "Major", "effect": "Concomitant use of angiotensin II receptor blockers (ARBs) and potassium salts may increase the risk of hyperkalemia. Inhibition of angiotensin II results in decreased aldosterone secretion, which in turn causes potassium retention. Risk factors for developing severe or life-threatening hyperkalemia may include renal impairment, diabetes, old age, severe or worsening heart failure, dehydration, and concomitant use of other agents that block the renin-angiotensin-aldosterone system or otherwise increase serum potassium levels.", "source": "DDInter", "management_text": "Caution is advised if angiotensin II receptor blockers must be used concurrently with potassium salts, particularly in patients with renal impairment, diabetes, old age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium such as nonsteroidal anti-inflammatory drugs, beta-blockers, cyclosporine, heparin, tacrolimus, and trimethoprim. The combination should generally be avoided in these patients unless absolutely necessary and the benefits outweigh the potential risks. Serum potassium and renal function should be checked prior to initiating therapy and regularly thereafter. Patients should be given counseling on the appropriate levels of potassium and fluid intake, and advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if angiotensin II receptor blockers must be used concurrently with potassium salts, particularly in patients with renal impairment, diabetes, old age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium such as nonsteroidal anti-inflammatory drugs, beta-blockers, cyclosporine, heparin, tacrolimus, and trimethoprim.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67346/", "reference_text": "[1] Walmsley RN, White GH, Cain M, McCarthy PJ, Booth J \"Hyperkalemia in the elderly.\" Clin Chem 30 (1984): 1409-12[2] Jarman PR, Mather HM \"Diabetes may be independent risk factor for hyperkalaemia.\" BMJ 327 (2003): 812[3] Obialo CI, Ofili EO, Mirza T \"Hyperkalemia in congestive heart failure patients aged 63 to 85 years with subclinical renal disease.\" Am J Cardiol 90 (2002): 663-5[4] Jarman PR, Kehely AM, Mather HM \"Hyperkalaemia in diabetes: prevalence and associations.\" Postgrad Med J 71 (1995): 551-2[5] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[6] Large DM, Carr PH, Laing I, Davies M \"Hyperkalaemia in diabetes mellitus--potential hazards of coexisting hyporeninaemic hypoaldosteronism.\" Postgrad Med J 60 (1984): 370-3[7] Perazella MA \"Drug-induced hyperkalemia: old culprits and new offenders.\" Am J Med 109 (2000): 307-14[8] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[9] Perazella MA, Mahnensmith RL \"Hyperkalemia in the elderly: drugs exacerbate impaired potassium homeostasis.\" J Gen Intern Med 12 (1997): 646-56[10] Lawson DH \"Adverse reactions to potassium chloride.\" Q J Med 43 (1974): 433-40[11] Lawson DH, O'Connor PC, Jick H \"Drug attributed alterations in potassium handling in congestive cardiac failure.\" Eur J Clin Pharmacol 23 (1982): 21-5[12] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[13] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.", "alternatives_a": "Amlodipine, Sacubitril, Hydrochlorothiazide, Nebivolol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67260, "ingredient1": "Potassium citrate", "ingredient2": "Loxapine", "severity": "Major", "effect": "Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.", "source": "DDInter", "management_text": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.", "mechanism_text": "Synergism", "recommendation": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67347/", "reference_text": "[1] \"Product Information. K-Dur (potassium chloride).\" Schering Laboratories, Kenilworth, NJ.[2] Wynn V \"Potassium chloride and bowel ulceration.\" Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial.\" Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L \"Ulceration of the small intestine due to slow-release potassium chloride tablets.\" Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ \"Perforation of small bowel due to slow release potassium chloride (slow-K).\" Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ \"Jejunal perforation associated with slow-release potassium chloride therapy.\" South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ \"Ulceration of small intestine and slow-release potassium tablets.\" Br Med J 2 (1975): 746[8] Lambert JR, Newman A \"Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy.\" Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L \"Gastrointestinal lesions and potassium chloride supplements.\" Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA \"Gut lesions due to slow-release KCI tablets.\" N Engl J Med 296 (1977): 111-2[11] \"Product Information. Urocit (potassium citrate).\" Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Effect of potassium chloride supplements on upper gastrointestinal mucosa.\" Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Sanctura (trospium chloride).\" Odyssey Pharmaceutical, East Hanover, NJ.", "alternatives_a": "Quetiapine, Asenapine, Haloperidol, Pimavanserin, Ziprasidone, Lumateperone, Iloperidone, Risperidone, Amisulpride, Aripiprazole, Droperidol, More", "alternatives_b": "Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67261, "ingredient1": "Potassium citrate", "ingredient2": "Maprotiline", "severity": "Major", "effect": "Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.", "source": "DDInter", "management_text": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.", "mechanism_text": "Synergism", "recommendation": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67348/", "reference_text": "[1] \"Product Information. K-Dur (potassium chloride).\" Schering Laboratories, Kenilworth, NJ.[2] Wynn V \"Potassium chloride and bowel ulceration.\" Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial.\" Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L \"Ulceration of the small intestine due to slow-release potassium chloride tablets.\" Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ \"Perforation of small bowel due to slow release potassium chloride (slow-K).\" Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ \"Jejunal perforation associated with slow-release potassium chloride therapy.\" South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ \"Ulceration of small intestine and slow-release potassium tablets.\" Br Med J 2 (1975): 746[8] Lambert JR, Newman A \"Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy.\" Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L \"Gastrointestinal lesions and potassium chloride supplements.\" Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA \"Gut lesions due to slow-release KCI tablets.\" N Engl J Med 296 (1977): 111-2[11] \"Product Information. Urocit (potassium citrate).\" Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Effect of potassium chloride supplements on upper gastrointestinal mucosa.\" Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Sanctura (trospium chloride).\" Odyssey Pharmaceutical, East Hanover, NJ.", "alternatives_a": "Citalopram, Sertraline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Isocarboxazid, Viloxazine, Esketamine, More", "alternatives_b": "Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67262, "ingredient1": "Potassium citrate", "ingredient2": "Meclizine", "severity": "Major", "effect": "Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.", "source": "DDInter", "management_text": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.", "mechanism_text": "Synergism", "recommendation": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67349/", "reference_text": "[1] \"Product Information. K-Dur (potassium chloride).\" Schering Laboratories, Kenilworth, NJ.[2] Wynn V \"Potassium chloride and bowel ulceration.\" Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial.\" Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L \"Ulceration of the small intestine due to slow-release potassium chloride tablets.\" Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ \"Perforation of small bowel due to slow release potassium chloride (slow-K).\" Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ \"Jejunal perforation associated with slow-release potassium chloride therapy.\" South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ \"Ulceration of small intestine and slow-release potassium tablets.\" Br Med J 2 (1975): 746[8] Lambert JR, Newman A \"Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy.\" Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L \"Gastrointestinal lesions and potassium chloride supplements.\" Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA \"Gut lesions due to slow-release KCI tablets.\" N Engl J Med 296 (1977): 111-2[11] \"Product Information. Urocit (potassium citrate).\" Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Effect of potassium chloride supplements on upper gastrointestinal mucosa.\" Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Sanctura (trospium chloride).\" Odyssey Pharmaceutical, East Hanover, NJ.", "alternatives_a": "Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67263, "ingredient1": "Potassium citrate", "ingredient2": "Meclofenamic acid", "severity": "Moderate", "effect": "Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) with potassium salts may increase the risk of hyperkalemia. NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system.", "source": "DDInter", "management_text": "Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.g., beta-blockers, cyclosporine, heparin, tacrolimus, and trimethoprim). Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67350/", "reference_text": "[1] \"Product Information. Potassium Chloride ER (potassium chloride).\" Zydus Pharmaceuticals (USA) Inc, Princeton, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. K-Phos Original (potassium acid phosphate).\" Beach Pharmaceuticals, Tampa, FL.[4] \"Product Information. Phospho-Trin 250 Neutral (potassium phosphate-sodium phosphate).\" Patrin Pharma, Skokie, IL.[5] \"Product Information. SSKI (potassium iodide).\" Upsher-Smith Laboratories Inc, Minneapolis, MN.[6] \"Product Information. Potassium Chloride (potassium chloride).\" Pharmaceutical Assoc Inc Div Beach Products, Greenville, SC.", "alternatives_a": "Rabeprazole, Misoprostol, Glucosamine, Chondroitin sulfate, Rofecoxib, Esomeprazole, Celecoxib, Valdecoxib, Tolazoline, Rabeprazole, Dimethyl sulfoxide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67264, "ingredient1": "Potassium citrate", "ingredient2": "Mefenamic acid", "severity": "Moderate", "effect": "Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) with potassium salts may increase the risk of hyperkalemia. NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system.", "source": "DDInter", "management_text": "Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.g., beta-blockers, cyclosporine, heparin, tacrolimus, and trimethoprim). Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67351/", "reference_text": "[1] \"Product Information. Potassium Chloride ER (potassium chloride).\" Zydus Pharmaceuticals (USA) Inc, Princeton, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. K-Phos Original (potassium acid phosphate).\" Beach Pharmaceuticals, Tampa, FL.[4] \"Product Information. Phospho-Trin 250 Neutral (potassium phosphate-sodium phosphate).\" Patrin Pharma, Skokie, IL.[5] \"Product Information. SSKI (potassium iodide).\" Upsher-Smith Laboratories Inc, Minneapolis, MN.[6] \"Product Information. Potassium Chloride (potassium chloride).\" Pharmaceutical Assoc Inc Div Beach Products, Greenville, SC.", "alternatives_a": "Rabeprazole, Misoprostol, Glucosamine, Chondroitin sulfate, Rofecoxib, Esomeprazole, Celecoxib, Valdecoxib", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67265, "ingredient1": "Potassium citrate", "ingredient2": "Meloxicam", "severity": "Moderate", "effect": "Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) with potassium salts may increase the risk of hyperkalemia. NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system.", "source": "DDInter", "management_text": "Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.g., beta-blockers, cyclosporine, heparin, tacrolimus, and trimethoprim). Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67352/", "reference_text": "[1] \"Product Information. Potassium Chloride ER (potassium chloride).\" Zydus Pharmaceuticals (USA) Inc, Princeton, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. K-Phos Original (potassium acid phosphate).\" Beach Pharmaceuticals, Tampa, FL.[4] \"Product Information. Phospho-Trin 250 Neutral (potassium phosphate-sodium phosphate).\" Patrin Pharma, Skokie, IL.[5] \"Product Information. SSKI (potassium iodide).\" Upsher-Smith Laboratories Inc, Minneapolis, MN.[6] \"Product Information. Potassium Chloride (potassium chloride).\" Pharmaceutical Assoc Inc Div Beach Products, Greenville, SC.", "alternatives_a": "Ropivacaine, Lidocaine, Chloroprocaine, Levobupivacaine, Bupivacaine, Tetracaine, Mepivacaine, Procaine, Prilocaine, Articaine, Etidocaine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67266, "ingredient1": "Potassium citrate", "ingredient2": "Memantine", "severity": "Minor", "effect": "The concomitant administration of memantine and drugs that alkalinize the urine may decrease the clearance of memantine, resulting in accumulation of memantine and possible increased adverse effects. Memantine clearance decreased by 80% at a urinary pH of 8. The clinical significance is unknown; however, the manufacturer recommends caution.", "source": "DDInter", "management_text": "-", "mechanism_text": "Excretion", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67353/", "reference_text": "[1] \"Product Information. Namenda (memantine).\" Forest Pharmaceuticals, St. Louis, MO.", "alternatives_a": "Rivastigmine, Galantamine, Donepezil, Tacrine, Ginkgo biloba, Aducanumab", "alternatives_b": "Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67267, "ingredient1": "Potassium citrate", "ingredient2": "Mepenzolate", "severity": "Major", "effect": "Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.", "source": "DDInter", "management_text": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.", "mechanism_text": "Synergism", "recommendation": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67354/", "reference_text": "[1] \"Product Information. K-Dur (potassium chloride).\" Schering Laboratories, Kenilworth, NJ.[2] Wynn V \"Potassium chloride and bowel ulceration.\" Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial.\" Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L \"Ulceration of the small intestine due to slow-release potassium chloride tablets.\" Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ \"Perforation of small bowel due to slow release potassium chloride (slow-K).\" Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ \"Jejunal perforation associated with slow-release potassium chloride therapy.\" South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ \"Ulceration of small intestine and slow-release potassium tablets.\" Br Med J 2 (1975): 746[8] Lambert JR, Newman A \"Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy.\" Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L \"Gastrointestinal lesions and potassium chloride supplements.\" Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA \"Gut lesions due to slow-release KCI tablets.\" N Engl J Med 296 (1977): 111-2[11] \"Product Information. Urocit (potassium citrate).\" Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Effect of potassium chloride supplements on upper gastrointestinal mucosa.\" Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Sanctura (trospium chloride).\" Odyssey Pharmaceutical, East Hanover, NJ.", "alternatives_a": "Papaverine, Alosetron, Isometheptene", "alternatives_b": "Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67268, "ingredient1": "Potassium citrate", "ingredient2": "Mesoridazine", "severity": "Major", "effect": "Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.", "source": "DDInter", "management_text": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.", "mechanism_text": "Synergism", "recommendation": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67355/", "reference_text": "[1] \"Product Information. K-Dur (potassium chloride).\" Schering Laboratories, Kenilworth, NJ.[2] Wynn V \"Potassium chloride and bowel ulceration.\" Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial.\" Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L \"Ulceration of the small intestine due to slow-release potassium chloride tablets.\" Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ \"Perforation of small bowel due to slow release potassium chloride (slow-K).\" Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ \"Jejunal perforation associated with slow-release potassium chloride therapy.\" South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ \"Ulceration of small intestine and slow-release potassium tablets.\" Br Med J 2 (1975): 746[8] Lambert JR, Newman A \"Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy.\" Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L \"Gastrointestinal lesions and potassium chloride supplements.\" Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA \"Gut lesions due to slow-release KCI tablets.\" N Engl J Med 296 (1977): 111-2[11] \"Product Information. Urocit (potassium citrate).\" Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Effect of potassium chloride supplements on upper gastrointestinal mucosa.\" Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Sanctura (trospium chloride).\" Odyssey Pharmaceutical, East Hanover, NJ.", "alternatives_a": "Quetiapine, Asenapine, Haloperidol, Pimavanserin, Ziprasidone, Lumateperone, Iloperidone, Risperidone, Amisulpride, Aripiprazole, Droperidol, More", "alternatives_b": "Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67269, "ingredient1": "Potassium citrate", "ingredient2": "Methdilazine", "severity": "Major", "effect": "Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.", "source": "DDInter", "management_text": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.", "mechanism_text": "Synergism", "recommendation": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67356/", "reference_text": "[1] \"Product Information. K-Dur (potassium chloride).\" Schering Laboratories, Kenilworth, NJ.[2] Wynn V \"Potassium chloride and bowel ulceration.\" Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial.\" Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L \"Ulceration of the small intestine due to slow-release potassium chloride tablets.\" Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ \"Perforation of small bowel due to slow release potassium chloride (slow-K).\" Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ \"Jejunal perforation associated with slow-release potassium chloride therapy.\" South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ \"Ulceration of small intestine and slow-release potassium tablets.\" Br Med J 2 (1975): 746[8] Lambert JR, Newman A \"Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy.\" Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L \"Gastrointestinal lesions and potassium chloride supplements.\" Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA \"Gut lesions due to slow-release KCI tablets.\" N Engl J Med 296 (1977): 111-2[11] \"Product Information. Urocit (potassium citrate).\" Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Effect of potassium chloride supplements on upper gastrointestinal mucosa.\" Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Sanctura (trospium chloride).\" Odyssey Pharmaceutical, East Hanover, NJ.", "alternatives_a": "Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67270, "ingredient1": "Potassium citrate", "ingredient2": "Methotrexate", "severity": "Minor", "effect": "Alkalinization of the urine can increase the renal elimination of methotrexate. The pharmacologic effects of methotrexate may be decreased. No special clinical interventions appear to be necessary. In some cases of methotrexate toxicity, this interaction may prove beneficial.", "source": "DDInter", "management_text": "-", "mechanism_text": "Excretion", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67357/", "reference_text": "[1] Sand TE, Jacobsen S \"Effect of urine pH and flow on renal clearance of methotrexate.\" Eur J Clin Pharmacol 19 (1981): 453-6[2] Stoller RG, Hande KR, Jacobs SA, Rosenberg SA, Chabner BA \"Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity.\" N Engl J Med 297 (1977): 630-4[3] Nirenberg A, Mosende C, Mehta BM, Gisolfi AL, Rosen G \"High-dose methotrexate with citrovorum factor rescue: predictive value of serum methotrexate concentrations and corrective measures to avert toxicity.\" Cancer Treat Rep 61 (1977): 779-83[4] Nesher G, Mates M, Zevin S \"Effect of caffeine consumption on efficacy of methotrexate in rheumatoid arthritis.\" Arthritis Rheum 48 (2003): 571-572", "alternatives_a": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More", "alternatives_b": "Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67271, "ingredient1": "Potassium citrate", "ingredient2": "Methotrimeprazine", "severity": "Major", "effect": "Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.", "source": "DDInter", "management_text": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.", "mechanism_text": "Synergism", "recommendation": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67358/", "reference_text": "[1] \"Product Information. K-Dur (potassium chloride).\" Schering Laboratories, Kenilworth, NJ.[2] Wynn V \"Potassium chloride and bowel ulceration.\" Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial.\" Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L \"Ulceration of the small intestine due to slow-release potassium chloride tablets.\" Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ \"Perforation of small bowel due to slow release potassium chloride (slow-K).\" Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ \"Jejunal perforation associated with slow-release potassium chloride therapy.\" South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ \"Ulceration of small intestine and slow-release potassium tablets.\" Br Med J 2 (1975): 746[8] Lambert JR, Newman A \"Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy.\" Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L \"Gastrointestinal lesions and potassium chloride supplements.\" Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA \"Gut lesions due to slow-release KCI tablets.\" N Engl J Med 296 (1977): 111-2[11] \"Product Information. Urocit (potassium citrate).\" Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Effect of potassium chloride supplements on upper gastrointestinal mucosa.\" Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Sanctura (trospium chloride).\" Odyssey Pharmaceutical, East Hanover, NJ.", "alternatives_a": "Quetiapine, Asenapine, Haloperidol, Pimavanserin, Ziprasidone, Lumateperone, Iloperidone, Risperidone, Amisulpride, Aripiprazole, Droperidol, More", "alternatives_b": "Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67272, "ingredient1": "Potassium citrate", "ingredient2": "Mexiletine", "severity": "Moderate", "effect": "Agents that alkalinize the urine reduce the plasma clearance of mexiletine. The result may be increased plasma mexiletine levels and possible toxicity. The clinical significance is unknown.", "source": "DDInter", "management_text": "It is recommended that such drugs be avoided during mexiletine therapy.", "mechanism_text": "Excretion", "recommendation": "It is recommended that such drugs be avoided during mexiletine therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67359/", "reference_text": "[1] Mitchell BG, Clements JA, Pottage A, Prescott LF \"Mexiletine disposition: individual variation in response to urine acidification and alkalinisation.\" Br J Clin Pharmacol 16 (1983): 281-4", "alternatives_a": "Amiodarone, Dronedarone, Lidocaine, Propafenone, Procainamide, Tocainide, Dofetilide, Bretylium, Moricizine, Ibutilide", "alternatives_b": "Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67273, "ingredient1": "Potassium citrate", "ingredient2": "Minocycline", "severity": "Moderate", "effect": "INTERVAL: Alkalinization of the urine may decrease the plasma concentration of some tetracyclines. The mechanism is not completely understood, but may involve increased renal elimination of tetracyclines when the urine becomes alkalinized.", "source": "DDInter", "management_text": "If these drugs must be used together, an alternating dosing schedule is recommended (three to four hours apart).", "mechanism_text": "Excretion", "recommendation": "If these drugs must be used together, an alternating dosing schedule is recommended (three to four hours apart).", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67360/", "reference_text": "[1] Elliott GR \"Sodium bicarbonate and oral tetracycline.\" Clin Pharmacol Ther 13 (1972): 459[2] Jaffe JM, Poust RI, Feld SL, Colaizzi JL \"Influence of repetitive dosing and altered urinary pH on doxycycline excretion in humans.\" J Pharm Sci 63 (1974): 1256-60[3] Jaffe JM, Colaizzi JI, Poust RI, McDonald RH Jr \"Effect of altered urinary pH on tetracycline and doxycycline excretion in humans.\" J Pharmacokinet Biopharm 1 (1973): 267-82[4] \"Product Information. Achromycin (tetracycline).\" Lederle Laboratories, Wayne, NJ.[5] \"Product Information. Declomycin (demeclocycline).\" Lederle Laboratories, Wayne, NJ.", "alternatives_a": "Clindamycin, Vitamin A, Isotretinoin, Dexamethasone, Chloramphenicol, Fluorometholone, Tretinoin, Erythromycin, Dapsone, Methylprednisolone, Azelaic acid, More", "alternatives_b": "Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67274, "ingredient1": "Potassium citrate", "ingredient2": "Moexipril", "severity": "Major", "effect": "Concomitant use of angiotensin converting enzyme (ACE) inhibitors and potassium salts may increase the risk of hyperkalemia. Inhibition of ACE results in decreased aldosterone secretion, which in turn causes potassium retention.", "source": "DDInter", "management_text": "Caution is advised if ACE inhibitors must be used concurrently with potassium salts, particularly in patients with renal impairment, diabetes, old age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium such as nonsteroidal anti-inflammatory drugs, beta-blockers, cyclosporine, heparin, tacrolimus, trimethoprim, and licorice. The combination should generally be avoided in these patients unless absolutely necessary and the benefits outweigh the potential risks. Serum potassium and renal function should be checked prior to initiating therapy and regularly thereafter. Patients should be given counseling on the appropriate levels of potassium and fluid intake, and advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if ACE inhibitors must be used concurrently with potassium salts, particularly in patients with renal impairment, diabetes, old age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium such as nonsteroidal anti-inflammatory drugs, beta-blockers, cyclosporine, heparin, tacrolimus, trimethoprim, and licorice.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67361/", "reference_text": "[1] \"Product Information. K-Dur (potassium chloride).\" Schering Laboratories, Kenilworth, NJ.[2] Chan TY, Critchley JA \"Life-threatening hyperkalaemia in an elderly patient receiving captopril, furosemide (frusemide) and potassium supplements.\" Drug Saf 7 (1992): 159-61[3] Warren SE, O'Connor DT \"Hyperkalemia resulting from captopril administration.\" JAMA 244 (1980): 2551-2[4] Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS, Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association \"Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association.\" Circulation 104 (2001): 1985-91[5] Large DM, Carr PH, Laing I, Davies M \"Hyperkalaemia in diabetes mellitus--potential hazards of coexisting hyporeninaemic hypoaldosteronism.\" Postgrad Med J 60 (1984): 370-3[6] Schuna AA, Schmidt GR, Pitterle ME \"Serum potassium concentrations after initiation of captopril therapy.\" Clin Pharm 5 (1986): 920-3[7] Perazella MA, Mahnensmith RL \"Hyperkalemia in the elderly: drugs exacerbate impaired potassium homeostasis.\" J Gen Intern Med 12 (1997): 646-56[8] Lawson DH, O'Connor PC, Jick H \"Drug attributed alterations in potassium handling in congestive cardiac failure.\" Eur J Clin Pharmacol 23 (1982): 21-5[9] Perazella MA \"Drug-induced hyperkalemia: old culprits and new offenders.\" Am J Med 109 (2000): 307-14[10] Packer M, Lee WH \"Provocation of hyper- and hypokalemic sudden death during treatment with and withdrawal of converting-enzyme inhibition in severe chronic congestive heart failure.\" Am J Cardiol 57 (1986): 347-8[11] Ray K, Dorman S, Watson R \"Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction.\" J Hum Hypertens 13 (1999): 717-20[12] Ponce SP, Jennings AE, Madias NE, Harrington JT \"Drug-induced hyperkalemia.\" Medicine (Baltimore) 64 (1985): 357-70[13] Burnakis TG, Mioduch HJ \"Combined therapy with captopril and potassium supplementation: a potential for hyperkalemia.\" Arch Intern Med 144 (1984): 2371-2[14] Speirs CJ, Dollery CT, Inman WH, et al \"Postmarketing surveillance of enalapril II: investigation of the potential role of enalapril in deaths with renal failure.\" Br Med J 297 (1988): 830-2[15] Jarman PR, Kehely AM, Mather HM \"Hyperkalaemia in diabetes: prevalence and associations.\" Postgrad Med J 71 (1995): 551-2[16] Obialo CI, Ofili EO, Mirza T \"Hyperkalemia in congestive heart failure patients aged 63 to 85 years with subclinical renal disease.\" Am J Cardiol 90 (2002): 663-5[17] Atlas SA, Case DB, Sealey JE, Laragh JH, McKinstry DN \"Interruption of the renin-angiotensin system in hypertensive patients by captopril induces sustained reduction in aldosterone secretion, potassium retention and natriuresis.\" Hypertension 1 (1979): 279-80[18] Graves JW \"Hyperkalemia due to a potassium-based water softener.\" N Engl J Med 339 (1998): 1790-1[19] Lawson DH \"Adverse reactions to potassium chloride.\" Q J Med 43 (1974): 433-40[20] Good CB, McDermott L \"Diet and serum potassium in patients on ACE inhibitors.\" JAMA 274 (1995): 538[21] Walmsley RN, White GH, Cain M, McCarthy PJ, Booth J \"Hyperkalemia in the elderly.\" Clin Chem 30 (1984): 1409-12[22] Jarman PR, Mather HM \"Diabetes may be independent risk factor for hyperkalaemia.\" BMJ 327 (2003): 812[23] Stoltz ML, Andrews CE Jr \"Severe hyperkalemia during very-low-calorie diets and angiotensin converting enzyme use .\" JAMA 264 (1990): 2737-8[24] Reardon LC, Macpherson DS \"Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry?\" Arch Intern Med 158 (1998): 26-32[25] Ray K, Dorman S, Watson R \"Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction.\" J Hum Hypertens 13 (1999): 717-20[26] \"Product Information. Vasotec (enalapril).\" Merck & Co, Inc, West Point, PA.[27] Good CB, McDermott L \"Diet and serum potassium in patients on ACE inhibitors.\" JAMA 274 (1995): 538", "alternatives_a": "Felodipine, Amlodipine, Verapamil, Bisoprolol, Hydrochlorothiazide, Indapamide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67275, "ingredient1": "Potassium citrate", "ingredient2": "Molindone", "severity": "Major", "effect": "Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.", "source": "DDInter", "management_text": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.", "mechanism_text": "Synergism", "recommendation": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67362/", "reference_text": "[1] \"Product Information. K-Dur (potassium chloride).\" Schering Laboratories, Kenilworth, NJ.[2] Wynn V \"Potassium chloride and bowel ulceration.\" Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial.\" Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L \"Ulceration of the small intestine due to slow-release potassium chloride tablets.\" Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ \"Perforation of small bowel due to slow release potassium chloride (slow-K).\" Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ \"Jejunal perforation associated with slow-release potassium chloride therapy.\" South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ \"Ulceration of small intestine and slow-release potassium tablets.\" Br Med J 2 (1975): 746[8] Lambert JR, Newman A \"Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy.\" Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L \"Gastrointestinal lesions and potassium chloride supplements.\" Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA \"Gut lesions due to slow-release KCI tablets.\" N Engl J Med 296 (1977): 111-2[11] \"Product Information. Urocit (potassium citrate).\" Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Effect of potassium chloride supplements on upper gastrointestinal mucosa.\" Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Sanctura (trospium chloride).\" Odyssey Pharmaceutical, East Hanover, NJ.", "alternatives_a": "Quetiapine, Asenapine, Haloperidol, Pimavanserin, Ziprasidone, Lumateperone, Iloperidone, Risperidone, Amisulpride, Aripiprazole, Droperidol, More", "alternatives_b": "Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67276, "ingredient1": "Potassium citrate", "ingredient2": "Moxifloxacin", "severity": "Moderate", "effect": "Urinary alkalinizers such as citrates may decrease the solubility of fluoroquinolones in the urine and increase the risk of crystalluria.", "source": "DDInter", "management_text": "Concomitant use should generally be avoided. Patients receiving this combination should be monitored for signs of renal toxicity and crystalluria.", "mechanism_text": "Excretion", "recommendation": "Concomitant use should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67363/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.", "alternatives_a": "Rifamycin, Kanamycin, Ampicillin, Azithromycin, Acyclovir, Netilmicin, Polymyxin B, Famciclovir, Cefuroxime, Trifluridine, Tobramycin, More", "alternatives_b": "Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67277, "ingredient1": "Potassium citrate", "ingredient2": "Nabumetone", "severity": "Moderate", "effect": "Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) with potassium salts may increase the risk of hyperkalemia. NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system.", "source": "DDInter", "management_text": "Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.g., beta-blockers, cyclosporine, heparin, tacrolimus, and trimethoprim). Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67364/", "reference_text": "[1] \"Product Information. Potassium Chloride ER (potassium chloride).\" Zydus Pharmaceuticals (USA) Inc, Princeton, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. K-Phos Original (potassium acid phosphate).\" Beach Pharmaceuticals, Tampa, FL.[4] \"Product Information. Phospho-Trin 250 Neutral (potassium phosphate-sodium phosphate).\" Patrin Pharma, Skokie, IL.[5] \"Product Information. SSKI (potassium iodide).\" Upsher-Smith Laboratories Inc, Minneapolis, MN.[6] \"Product Information. Potassium Chloride (potassium chloride).\" Pharmaceutical Assoc Inc Div Beach Products, Greenville, SC.", "alternatives_a": "Rabeprazole, Misoprostol, Glucosamine, Chondroitin sulfate, Rofecoxib, Esomeprazole, Celecoxib, Valdecoxib", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67278, "ingredient1": "Potassium citrate", "ingredient2": "Nalidixic acid", "severity": "Moderate", "effect": "Urinary alkalinizers such as citrates may decrease the solubility of fluoroquinolones in the urine and increase the risk of crystalluria.", "source": "DDInter", "management_text": "Concomitant use should generally be avoided. Patients receiving this combination should be monitored for signs of renal toxicity and crystalluria.", "mechanism_text": "Excretion", "recommendation": "Concomitant use should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67365/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.", "alternatives_a": "Delafloxacin", "alternatives_b": "Potassium chloride, Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67279, "ingredient1": "Potassium citrate", "ingredient2": "Naproxen", "severity": "Moderate", "effect": "Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) with potassium salts may increase the risk of hyperkalemia. NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system.", "source": "DDInter", "management_text": "Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.g., beta-blockers, cyclosporine, heparin, tacrolimus, and trimethoprim). Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67366/", "reference_text": "[1] \"Product Information. Potassium Chloride ER (potassium chloride).\" Zydus Pharmaceuticals (USA) Inc, Princeton, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. K-Phos Original (potassium acid phosphate).\" Beach Pharmaceuticals, Tampa, FL.[4] \"Product Information. Phospho-Trin 250 Neutral (potassium phosphate-sodium phosphate).\" Patrin Pharma, Skokie, IL.[5] \"Product Information. SSKI (potassium iodide).\" Upsher-Smith Laboratories Inc, Minneapolis, MN.[6] \"Product Information. Potassium Chloride (potassium chloride).\" Pharmaceutical Assoc Inc Div Beach Products, Greenville, SC.", "alternatives_a": "Ritodrine, Bremelanotide, Flibanserin, Cabergoline, Black cohosh, Bromocriptine, Tolazoline, Rabeprazole, Dimethyl sulfoxide, Rabeprazole, Misoprostol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67280, "ingredient1": "Potassium citrate", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Urinary alkalinizers such as citrates may decrease the solubility of fluoroquinolones in the urine and increase the risk of crystalluria.", "source": "DDInter", "management_text": "Concomitant use should generally be avoided. Patients receiving this combination should be monitored for signs of renal toxicity and crystalluria.", "mechanism_text": "Excretion", "recommendation": "Concomitant use should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67367/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.", "alternatives_a": "Tinidazole, Fluconazole, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, Kanamycin, More", "alternatives_b": "Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67281, "ingredient1": "Potassium citrate", "ingredient2": "Nortriptyline", "severity": "Major", "effect": "Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.", "source": "DDInter", "management_text": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.", "mechanism_text": "Synergism", "recommendation": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67368/", "reference_text": "[1] \"Product Information. K-Dur (potassium chloride).\" Schering Laboratories, Kenilworth, NJ.[2] Wynn V \"Potassium chloride and bowel ulceration.\" Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial.\" Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L \"Ulceration of the small intestine due to slow-release potassium chloride tablets.\" Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ \"Perforation of small bowel due to slow release potassium chloride (slow-K).\" Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ \"Jejunal perforation associated with slow-release potassium chloride therapy.\" South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ \"Ulceration of small intestine and slow-release potassium tablets.\" Br Med J 2 (1975): 746[8] Lambert JR, Newman A \"Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy.\" Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L \"Gastrointestinal lesions and potassium chloride supplements.\" Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA \"Gut lesions due to slow-release KCI tablets.\" N Engl J Med 296 (1977): 111-2[11] \"Product Information. Urocit (potassium citrate).\" Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Effect of potassium chloride supplements on upper gastrointestinal mucosa.\" Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Sanctura (trospium chloride).\" Odyssey Pharmaceutical, East Hanover, NJ.", "alternatives_a": "Citalopram, Sertraline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Isocarboxazid, Viloxazine, Esketamine, More", "alternatives_b": "Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67282, "ingredient1": "Potassium citrate", "ingredient2": "Ofloxacin", "severity": "Moderate", "effect": "Urinary alkalinizers such as citrates may decrease the solubility of fluoroquinolones in the urine and increase the risk of crystalluria.", "source": "DDInter", "management_text": "Concomitant use should generally be avoided. Patients receiving this combination should be monitored for signs of renal toxicity and crystalluria.", "mechanism_text": "Excretion", "recommendation": "Concomitant use should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67369/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.", "alternatives_a": "Delafloxacin, Tinidazole, Fluconazole, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, More", "alternatives_b": "Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67283, "ingredient1": "Potassium citrate", "ingredient2": "Olanzapine", "severity": "Major", "effect": "Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.", "source": "DDInter", "management_text": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.", "mechanism_text": "Synergism", "recommendation": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67370/", "reference_text": "[1] \"Product Information. K-Dur (potassium chloride).\" Schering Laboratories, Kenilworth, NJ.[2] Wynn V \"Potassium chloride and bowel ulceration.\" Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial.\" Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L \"Ulceration of the small intestine due to slow-release potassium chloride tablets.\" Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ \"Perforation of small bowel due to slow release potassium chloride (slow-K).\" Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ \"Jejunal perforation associated with slow-release potassium chloride therapy.\" South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ \"Ulceration of small intestine and slow-release potassium tablets.\" Br Med J 2 (1975): 746[8] Lambert JR, Newman A \"Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy.\" Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L \"Gastrointestinal lesions and potassium chloride supplements.\" Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA \"Gut lesions due to slow-release KCI tablets.\" N Engl J Med 296 (1977): 111-2[11] \"Product Information. Urocit (potassium citrate).\" Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Effect of potassium chloride supplements on upper gastrointestinal mucosa.\" Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Sanctura (trospium chloride).\" Odyssey Pharmaceutical, East Hanover, NJ.", "alternatives_a": "Quetiapine, Asenapine, Haloperidol, Pimavanserin, Ziprasidone, Lumateperone, Iloperidone, Risperidone, Amisulpride, Aripiprazole, Droperidol, More", "alternatives_b": "Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67284, "ingredient1": "Potassium citrate", "ingredient2": "Orphenadrine", "severity": "Major", "effect": "Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.", "source": "DDInter", "management_text": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.", "mechanism_text": "Synergism", "recommendation": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67371/", "reference_text": "[1] \"Product Information. K-Dur (potassium chloride).\" Schering Laboratories, Kenilworth, NJ.[2] Wynn V \"Potassium chloride and bowel ulceration.\" Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial.\" Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L \"Ulceration of the small intestine due to slow-release potassium chloride tablets.\" Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ \"Perforation of small bowel due to slow release potassium chloride (slow-K).\" Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ \"Jejunal perforation associated with slow-release potassium chloride therapy.\" South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ \"Ulceration of small intestine and slow-release potassium tablets.\" Br Med J 2 (1975): 746[8] Lambert JR, Newman A \"Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy.\" Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L \"Gastrointestinal lesions and potassium chloride supplements.\" Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA \"Gut lesions due to slow-release KCI tablets.\" N Engl J Med 296 (1977): 111-2[11] \"Product Information. Urocit (potassium citrate).\" Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Effect of potassium chloride supplements on upper gastrointestinal mucosa.\" Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Sanctura (trospium chloride).\" Odyssey Pharmaceutical, East Hanover, NJ.", "alternatives_a": "Carisoprodol, Chlorzoxazone, Tizanidine, Baclofen, Methocarbamol, Chlormezanone", "alternatives_b": "Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67285, "ingredient1": "Potassium citrate", "ingredient2": "Oxaprozin", "severity": "Moderate", "effect": "Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) with potassium salts may increase the risk of hyperkalemia. NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system.", "source": "DDInter", "management_text": "Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.g., beta-blockers, cyclosporine, heparin, tacrolimus, and trimethoprim). Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67372/", "reference_text": "[1] \"Product Information. Potassium Chloride ER (potassium chloride).\" Zydus Pharmaceuticals (USA) Inc, Princeton, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. K-Phos Original (potassium acid phosphate).\" Beach Pharmaceuticals, Tampa, FL.[4] \"Product Information. Phospho-Trin 250 Neutral (potassium phosphate-sodium phosphate).\" Patrin Pharma, Skokie, IL.[5] \"Product Information. SSKI (potassium iodide).\" Upsher-Smith Laboratories Inc, Minneapolis, MN.[6] \"Product Information. Potassium Chloride (potassium chloride).\" Pharmaceutical Assoc Inc Div Beach Products, Greenville, SC.", "alternatives_a": "Rabeprazole, Misoprostol, Glucosamine, Chondroitin sulfate, Rofecoxib, Esomeprazole, Celecoxib, Valdecoxib", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67286, "ingredient1": "Potassium citrate", "ingredient2": "Oxybutynin", "severity": "Major", "effect": "Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.", "source": "DDInter", "management_text": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.", "mechanism_text": "Synergism", "recommendation": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67373/", "reference_text": "[1] \"Product Information. K-Dur (potassium chloride).\" Schering Laboratories, Kenilworth, NJ.[2] Wynn V \"Potassium chloride and bowel ulceration.\" Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial.\" Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L \"Ulceration of the small intestine due to slow-release potassium chloride tablets.\" Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ \"Perforation of small bowel due to slow release potassium chloride (slow-K).\" Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ \"Jejunal perforation associated with slow-release potassium chloride therapy.\" South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ \"Ulceration of small intestine and slow-release potassium tablets.\" Br Med J 2 (1975): 746[8] Lambert JR, Newman A \"Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy.\" Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L \"Gastrointestinal lesions and potassium chloride supplements.\" Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA \"Gut lesions due to slow-release KCI tablets.\" N Engl J Med 296 (1977): 111-2[11] \"Product Information. Urocit (potassium citrate).\" Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Effect of potassium chloride supplements on upper gastrointestinal mucosa.\" Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Sanctura (trospium chloride).\" Odyssey Pharmaceutical, East Hanover, NJ.", "alternatives_a": "Apomorphine, Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Avanafil, More", "alternatives_b": "Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67287, "ingredient1": "Potassium citrate", "ingredient2": "Oxytetracycline", "severity": "Moderate", "effect": "INTERVAL: Alkalinization of the urine may decrease the plasma concentration of some tetracyclines. The mechanism is not completely understood, but may involve increased renal elimination of tetracyclines when the urine becomes alkalinized.", "source": "DDInter", "management_text": "If these drugs must be used together, an alternating dosing schedule is recommended (three to four hours apart).", "mechanism_text": "Excretion", "recommendation": "If these drugs must be used together, an alternating dosing schedule is recommended (three to four hours apart).", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67374/", "reference_text": "[1] Elliott GR \"Sodium bicarbonate and oral tetracycline.\" Clin Pharmacol Ther 13 (1972): 459[2] Jaffe JM, Poust RI, Feld SL, Colaizzi JL \"Influence of repetitive dosing and altered urinary pH on doxycycline excretion in humans.\" J Pharm Sci 63 (1974): 1256-60[3] Jaffe JM, Colaizzi JI, Poust RI, McDonald RH Jr \"Effect of altered urinary pH on tetracycline and doxycycline excretion in humans.\" J Pharmacokinet Biopharm 1 (1973): 267-82[4] \"Product Information. Achromycin (tetracycline).\" Lederle Laboratories, Wayne, NJ.[5] \"Product Information. Declomycin (demeclocycline).\" Lederle Laboratories, Wayne, NJ.", "alternatives_a": "Tigecycline, Sarecycline, Omadacycline, Eravacycline, Rifamycin, Kanamycin, Ampicillin, Azithromycin, Acyclovir, Netilmicin, Polymyxin B, More", "alternatives_b": "Potassium chloride, Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67288, "ingredient1": "Potassium citrate", "ingredient2": "Perindopril", "severity": "Major", "effect": "Concomitant use of angiotensin converting enzyme (ACE) inhibitors and potassium salts may increase the risk of hyperkalemia. Inhibition of ACE results in decreased aldosterone secretion, which in turn causes potassium retention.", "source": "DDInter", "management_text": "Caution is advised if ACE inhibitors must be used concurrently with potassium salts, particularly in patients with renal impairment, diabetes, old age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium such as nonsteroidal anti-inflammatory drugs, beta-blockers, cyclosporine, heparin, tacrolimus, trimethoprim, and licorice. The combination should generally be avoided in these patients unless absolutely necessary and the benefits outweigh the potential risks. Serum potassium and renal function should be checked prior to initiating therapy and regularly thereafter. Patients should be given counseling on the appropriate levels of potassium and fluid intake, and advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if ACE inhibitors must be used concurrently with potassium salts, particularly in patients with renal impairment, diabetes, old age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium such as nonsteroidal anti-inflammatory drugs, beta-blockers, cyclosporine, heparin, tacrolimus, trimethoprim, and licorice.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67375/", "reference_text": "[1] \"Product Information. K-Dur (potassium chloride).\" Schering Laboratories, Kenilworth, NJ.[2] Chan TY, Critchley JA \"Life-threatening hyperkalaemia in an elderly patient receiving captopril, furosemide (frusemide) and potassium supplements.\" Drug Saf 7 (1992): 159-61[3] Warren SE, O'Connor DT \"Hyperkalemia resulting from captopril administration.\" JAMA 244 (1980): 2551-2[4] Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS, Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association \"Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association.\" Circulation 104 (2001): 1985-91[5] Large DM, Carr PH, Laing I, Davies M \"Hyperkalaemia in diabetes mellitus--potential hazards of coexisting hyporeninaemic hypoaldosteronism.\" Postgrad Med J 60 (1984): 370-3[6] Schuna AA, Schmidt GR, Pitterle ME \"Serum potassium concentrations after initiation of captopril therapy.\" Clin Pharm 5 (1986): 920-3[7] Perazella MA, Mahnensmith RL \"Hyperkalemia in the elderly: drugs exacerbate impaired potassium homeostasis.\" J Gen Intern Med 12 (1997): 646-56[8] Lawson DH, O'Connor PC, Jick H \"Drug attributed alterations in potassium handling in congestive cardiac failure.\" Eur J Clin Pharmacol 23 (1982): 21-5[9] Perazella MA \"Drug-induced hyperkalemia: old culprits and new offenders.\" Am J Med 109 (2000): 307-14[10] Packer M, Lee WH \"Provocation of hyper- and hypokalemic sudden death during treatment with and withdrawal of converting-enzyme inhibition in severe chronic congestive heart failure.\" Am J Cardiol 57 (1986): 347-8[11] Ray K, Dorman S, Watson R \"Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction.\" J Hum Hypertens 13 (1999): 717-20[12] Ponce SP, Jennings AE, Madias NE, Harrington JT \"Drug-induced hyperkalemia.\" Medicine (Baltimore) 64 (1985): 357-70[13] Burnakis TG, Mioduch HJ \"Combined therapy with captopril and potassium supplementation: a potential for hyperkalemia.\" Arch Intern Med 144 (1984): 2371-2[14] Speirs CJ, Dollery CT, Inman WH, et al \"Postmarketing surveillance of enalapril II: investigation of the potential role of enalapril in deaths with renal failure.\" Br Med J 297 (1988): 830-2[15] Jarman PR, Kehely AM, Mather HM \"Hyperkalaemia in diabetes: prevalence and associations.\" Postgrad Med J 71 (1995): 551-2[16] Obialo CI, Ofili EO, Mirza T \"Hyperkalemia in congestive heart failure patients aged 63 to 85 years with subclinical renal disease.\" Am J Cardiol 90 (2002): 663-5[17] Atlas SA, Case DB, Sealey JE, Laragh JH, McKinstry DN \"Interruption of the renin-angiotensin system in hypertensive patients by captopril induces sustained reduction in aldosterone secretion, potassium retention and natriuresis.\" Hypertension 1 (1979): 279-80[18] Graves JW \"Hyperkalemia due to a potassium-based water softener.\" N Engl J Med 339 (1998): 1790-1[19] Lawson DH \"Adverse reactions to potassium chloride.\" Q J Med 43 (1974): 433-40[20] Good CB, McDermott L \"Diet and serum potassium in patients on ACE inhibitors.\" JAMA 274 (1995): 538[21] Walmsley RN, White GH, Cain M, McCarthy PJ, Booth J \"Hyperkalemia in the elderly.\" Clin Chem 30 (1984): 1409-12[22] Jarman PR, Mather HM \"Diabetes may be independent risk factor for hyperkalaemia.\" BMJ 327 (2003): 812[23] Stoltz ML, Andrews CE Jr \"Severe hyperkalemia during very-low-calorie diets and angiotensin converting enzyme use .\" JAMA 264 (1990): 2737-8[24] Reardon LC, Macpherson DS \"Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry?\" Arch Intern Med 158 (1998): 26-32[25] Ray K, Dorman S, Watson R \"Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction.\" J Hum Hypertens 13 (1999): 717-20[26] \"Product Information. Vasotec (enalapril).\" Merck & Co, Inc, West Point, PA.[27] Good CB, McDermott L \"Diet and serum potassium in patients on ACE inhibitors.\" JAMA 274 (1995): 538", "alternatives_a": "Felodipine, Amlodipine, Verapamil, Bisoprolol, Hydrochlorothiazide, Indapamide, Amlodipine, Atorvastatin, Simvastatin, Lovastatin, Rosuvastatin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67289, "ingredient1": "Potassium citrate", "ingredient2": "Perphenazine", "severity": "Major", "effect": "Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.", "source": "DDInter", "management_text": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.", "mechanism_text": "Synergism", "recommendation": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67376/", "reference_text": "[1] \"Product Information. K-Dur (potassium chloride).\" Schering Laboratories, Kenilworth, NJ.[2] Wynn V \"Potassium chloride and bowel ulceration.\" Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial.\" Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L \"Ulceration of the small intestine due to slow-release potassium chloride tablets.\" Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ \"Perforation of small bowel due to slow release potassium chloride (slow-K).\" Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ \"Jejunal perforation associated with slow-release potassium chloride therapy.\" South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ \"Ulceration of small intestine and slow-release potassium tablets.\" Br Med J 2 (1975): 746[8] Lambert JR, Newman A \"Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy.\" Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L \"Gastrointestinal lesions and potassium chloride supplements.\" Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA \"Gut lesions due to slow-release KCI tablets.\" N Engl J Med 296 (1977): 111-2[11] \"Product Information. Urocit (potassium citrate).\" Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Effect of potassium chloride supplements on upper gastrointestinal mucosa.\" Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Sanctura (trospium chloride).\" Odyssey Pharmaceutical, East Hanover, NJ.", "alternatives_a": "Quetiapine, Asenapine, Haloperidol, Pimavanserin, Ziprasidone, Lumateperone, Iloperidone, Risperidone, Amisulpride, Aripiprazole, Droperidol, More", "alternatives_b": "Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67290, "ingredient1": "Potassium citrate", "ingredient2": "Phenindamine", "severity": "Major", "effect": "Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.", "source": "DDInter", "management_text": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.", "mechanism_text": "Synergism", "recommendation": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67377/", "reference_text": "[1] \"Product Information. K-Dur (potassium chloride).\" Schering Laboratories, Kenilworth, NJ.[2] Wynn V \"Potassium chloride and bowel ulceration.\" Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial.\" Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L \"Ulceration of the small intestine due to slow-release potassium chloride tablets.\" Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ \"Perforation of small bowel due to slow release potassium chloride (slow-K).\" Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ \"Jejunal perforation associated with slow-release potassium chloride therapy.\" South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ \"Ulceration of small intestine and slow-release potassium tablets.\" Br Med J 2 (1975): 746[8] Lambert JR, Newman A \"Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy.\" Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L \"Gastrointestinal lesions and potassium chloride supplements.\" Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA \"Gut lesions due to slow-release KCI tablets.\" N Engl J Med 296 (1977): 111-2[11] \"Product Information. Urocit (potassium citrate).\" Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Effect of potassium chloride supplements on upper gastrointestinal mucosa.\" Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Sanctura (trospium chloride).\" Odyssey Pharmaceutical, East Hanover, NJ.", "alternatives_a": "Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67291, "ingredient1": "Potassium citrate", "ingredient2": "Phenylbutazone", "severity": "Moderate", "effect": "Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) with potassium salts may increase the risk of hyperkalemia. NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system.", "source": "DDInter", "management_text": "Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.g., beta-blockers, cyclosporine, heparin, tacrolimus, and trimethoprim). Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67378/", "reference_text": "[1] \"Product Information. Potassium Chloride ER (potassium chloride).\" Zydus Pharmaceuticals (USA) Inc, Princeton, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. K-Phos Original (potassium acid phosphate).\" Beach Pharmaceuticals, Tampa, FL.[4] \"Product Information. Phospho-Trin 250 Neutral (potassium phosphate-sodium phosphate).\" Patrin Pharma, Skokie, IL.[5] \"Product Information. SSKI (potassium iodide).\" Upsher-Smith Laboratories Inc, Minneapolis, MN.[6] \"Product Information. Potassium Chloride (potassium chloride).\" Pharmaceutical Assoc Inc Div Beach Products, Greenville, SC.", "alternatives_a": "Rabeprazole, Misoprostol, Glucosamine, Chondroitin sulfate, Rofecoxib, Esomeprazole, Celecoxib, Valdecoxib, Tolazoline, Rabeprazole, Dimethyl sulfoxide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67292, "ingredient1": "Potassium citrate", "ingredient2": "Pimozide", "severity": "Major", "effect": "Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.", "source": "DDInter", "management_text": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.", "mechanism_text": "Synergism", "recommendation": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67379/", "reference_text": "[1] \"Product Information. K-Dur (potassium chloride).\" Schering Laboratories, Kenilworth, NJ.[2] Wynn V \"Potassium chloride and bowel ulceration.\" Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial.\" Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L \"Ulceration of the small intestine due to slow-release potassium chloride tablets.\" Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ \"Perforation of small bowel due to slow release potassium chloride (slow-K).\" Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ \"Jejunal perforation associated with slow-release potassium chloride therapy.\" South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ \"Ulceration of small intestine and slow-release potassium tablets.\" Br Med J 2 (1975): 746[8] Lambert JR, Newman A \"Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy.\" Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L \"Gastrointestinal lesions and potassium chloride supplements.\" Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA \"Gut lesions due to slow-release KCI tablets.\" N Engl J Med 296 (1977): 111-2[11] \"Product Information. Urocit (potassium citrate).\" Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Effect of potassium chloride supplements on upper gastrointestinal mucosa.\" Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Sanctura (trospium chloride).\" Odyssey Pharmaceutical, East Hanover, NJ.", "alternatives_a": "Quetiapine, Asenapine, Haloperidol, Pimavanserin, Ziprasidone, Lumateperone, Iloperidone, Risperidone, Amisulpride, Aripiprazole, Droperidol, More", "alternatives_b": "Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67293, "ingredient1": "Potassium citrate", "ingredient2": "Piroxicam", "severity": "Moderate", "effect": "Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) with potassium salts may increase the risk of hyperkalemia. NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system.", "source": "DDInter", "management_text": "Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.g., beta-blockers, cyclosporine, heparin, tacrolimus, and trimethoprim). Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67380/", "reference_text": "[1] \"Product Information. Potassium Chloride ER (potassium chloride).\" Zydus Pharmaceuticals (USA) Inc, Princeton, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. K-Phos Original (potassium acid phosphate).\" Beach Pharmaceuticals, Tampa, FL.[4] \"Product Information. Phospho-Trin 250 Neutral (potassium phosphate-sodium phosphate).\" Patrin Pharma, Skokie, IL.[5] \"Product Information. SSKI (potassium iodide).\" Upsher-Smith Laboratories Inc, Minneapolis, MN.[6] \"Product Information. Potassium Chloride (potassium chloride).\" Pharmaceutical Assoc Inc Div Beach Products, Greenville, SC.", "alternatives_a": "Rabeprazole, Misoprostol, Glucosamine, Chondroitin sulfate, Rofecoxib, Esomeprazole, Celecoxib, Valdecoxib, Tolazoline, Rabeprazole, Dimethyl sulfoxide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67294, "ingredient1": "Prochlorperazine", "ingredient2": "Potassium citrate", "severity": "Major", "effect": "Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.", "source": "DDInter", "management_text": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.", "mechanism_text": "Synergism", "recommendation": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67381/", "reference_text": "[1] \"Product Information. K-Dur (potassium chloride).\" Schering Laboratories, Kenilworth, NJ.[2] Wynn V \"Potassium chloride and bowel ulceration.\" Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial.\" Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L \"Ulceration of the small intestine due to slow-release potassium chloride tablets.\" Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ \"Perforation of small bowel due to slow release potassium chloride (slow-K).\" Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ \"Jejunal perforation associated with slow-release potassium chloride therapy.\" South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ \"Ulceration of small intestine and slow-release potassium tablets.\" Br Med J 2 (1975): 746[8] Lambert JR, Newman A \"Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy.\" Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L \"Gastrointestinal lesions and potassium chloride supplements.\" Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA \"Gut lesions due to slow-release KCI tablets.\" N Engl J Med 296 (1977): 111-2[11] \"Product Information. Urocit (potassium citrate).\" Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Effect of potassium chloride supplements on upper gastrointestinal mucosa.\" Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Sanctura (trospium chloride).\" Odyssey Pharmaceutical, East Hanover, NJ.", "alternatives_a": "Quetiapine, Asenapine, Haloperidol, Pimavanserin, Ziprasidone, Lumateperone, Iloperidone, Risperidone, Amisulpride, Aripiprazole, Droperidol, More", "alternatives_b": "Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67295, "ingredient1": "Procyclidine", "ingredient2": "Potassium citrate", "severity": "Major", "effect": "Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.", "source": "DDInter", "management_text": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.", "mechanism_text": "Synergism", "recommendation": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67382/", "reference_text": "[1] \"Product Information. K-Dur (potassium chloride).\" Schering Laboratories, Kenilworth, NJ.[2] Wynn V \"Potassium chloride and bowel ulceration.\" Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial.\" Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L \"Ulceration of the small intestine due to slow-release potassium chloride tablets.\" Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ \"Perforation of small bowel due to slow release potassium chloride (slow-K).\" Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ \"Jejunal perforation associated with slow-release potassium chloride therapy.\" South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ \"Ulceration of small intestine and slow-release potassium tablets.\" Br Med J 2 (1975): 746[8] Lambert JR, Newman A \"Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy.\" Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L \"Gastrointestinal lesions and potassium chloride supplements.\" Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA \"Gut lesions due to slow-release KCI tablets.\" N Engl J Med 296 (1977): 111-2[11] \"Product Information. Urocit (potassium citrate).\" Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Effect of potassium chloride supplements on upper gastrointestinal mucosa.\" Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Sanctura (trospium chloride).\" Odyssey Pharmaceutical, East Hanover, NJ.", "alternatives_a": "Potassium bicarbonate, Potassium gluconate", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67296, "ingredient1": "Promazine", "ingredient2": "Potassium citrate", "severity": "Major", "effect": "Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.", "source": "DDInter", "management_text": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.", "mechanism_text": "Synergism", "recommendation": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67383/", "reference_text": "[1] \"Product Information. K-Dur (potassium chloride).\" Schering Laboratories, Kenilworth, NJ.[2] Wynn V \"Potassium chloride and bowel ulceration.\" Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial.\" Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L \"Ulceration of the small intestine due to slow-release potassium chloride tablets.\" Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ \"Perforation of small bowel due to slow release potassium chloride (slow-K).\" Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ \"Jejunal perforation associated with slow-release potassium chloride therapy.\" South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ \"Ulceration of small intestine and slow-release potassium tablets.\" Br Med J 2 (1975): 746[8] Lambert JR, Newman A \"Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy.\" Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L \"Gastrointestinal lesions and potassium chloride supplements.\" Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA \"Gut lesions due to slow-release KCI tablets.\" N Engl J Med 296 (1977): 111-2[11] \"Product Information. Urocit (potassium citrate).\" Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Effect of potassium chloride supplements on upper gastrointestinal mucosa.\" Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Sanctura (trospium chloride).\" Odyssey Pharmaceutical, East Hanover, NJ.", "alternatives_a": "Quetiapine, Asenapine, Haloperidol, Pimavanserin, Ziprasidone, Lumateperone, Iloperidone, Risperidone, Amisulpride, Aripiprazole, Droperidol, More", "alternatives_b": "Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67297, "ingredient1": "Promethazine", "ingredient2": "Potassium citrate", "severity": "Major", "effect": "Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.", "source": "DDInter", "management_text": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.", "mechanism_text": "Synergism", "recommendation": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67384/", "reference_text": "[1] \"Product Information. K-Dur (potassium chloride).\" Schering Laboratories, Kenilworth, NJ.[2] Wynn V \"Potassium chloride and bowel ulceration.\" Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial.\" Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L \"Ulceration of the small intestine due to slow-release potassium chloride tablets.\" Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ \"Perforation of small bowel due to slow release potassium chloride (slow-K).\" Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ \"Jejunal perforation associated with slow-release potassium chloride therapy.\" South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ \"Ulceration of small intestine and slow-release potassium tablets.\" Br Med J 2 (1975): 746[8] Lambert JR, Newman A \"Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy.\" Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L \"Gastrointestinal lesions and potassium chloride supplements.\" Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA \"Gut lesions due to slow-release KCI tablets.\" N Engl J Med 296 (1977): 111-2[11] \"Product Information. Urocit (potassium citrate).\" Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Effect of potassium chloride supplements on upper gastrointestinal mucosa.\" Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Sanctura (trospium chloride).\" Odyssey Pharmaceutical, East Hanover, NJ.", "alternatives_a": "Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole, Lidocaine, More", "alternatives_b": "Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67298, "ingredient1": "Propantheline", "ingredient2": "Potassium citrate", "severity": "Major", "effect": "Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.", "source": "DDInter", "management_text": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.", "mechanism_text": "Synergism", "recommendation": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67385/", "reference_text": "[1] \"Product Information. K-Dur (potassium chloride).\" Schering Laboratories, Kenilworth, NJ.[2] Wynn V \"Potassium chloride and bowel ulceration.\" Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial.\" Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L \"Ulceration of the small intestine due to slow-release potassium chloride tablets.\" Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ \"Perforation of small bowel due to slow release potassium chloride (slow-K).\" Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ \"Jejunal perforation associated with slow-release potassium chloride therapy.\" South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ \"Ulceration of small intestine and slow-release potassium tablets.\" Br Med J 2 (1975): 746[8] Lambert JR, Newman A \"Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy.\" Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L \"Gastrointestinal lesions and potassium chloride supplements.\" Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA \"Gut lesions due to slow-release KCI tablets.\" N Engl J Med 296 (1977): 111-2[11] \"Product Information. Urocit (potassium citrate).\" Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Effect of potassium chloride supplements on upper gastrointestinal mucosa.\" Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Sanctura (trospium chloride).\" Odyssey Pharmaceutical, East Hanover, NJ.", "alternatives_a": "Papaverine, Alosetron, Isometheptene", "alternatives_b": "Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67299, "ingredient1": "Propiomazine", "ingredient2": "Potassium citrate", "severity": "Major", "effect": "Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.", "source": "DDInter", "management_text": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.", "mechanism_text": "Synergism", "recommendation": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67386/", "reference_text": "[1] \"Product Information. K-Dur (potassium chloride).\" Schering Laboratories, Kenilworth, NJ.[2] Wynn V \"Potassium chloride and bowel ulceration.\" Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial.\" Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L \"Ulceration of the small intestine due to slow-release potassium chloride tablets.\" Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ \"Perforation of small bowel due to slow release potassium chloride (slow-K).\" Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ \"Jejunal perforation associated with slow-release potassium chloride therapy.\" South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ \"Ulceration of small intestine and slow-release potassium tablets.\" Br Med J 2 (1975): 746[8] Lambert JR, Newman A \"Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy.\" Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L \"Gastrointestinal lesions and potassium chloride supplements.\" Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA \"Gut lesions due to slow-release KCI tablets.\" N Engl J Med 296 (1977): 111-2[11] \"Product Information. Urocit (potassium citrate).\" Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Effect of potassium chloride supplements on upper gastrointestinal mucosa.\" Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Sanctura (trospium chloride).\" Odyssey Pharmaceutical, East Hanover, NJ.", "alternatives_a": "Suvorexant, Triazolam, Flurazepam, Methohexital, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, More", "alternatives_b": "Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67300, "ingredient1": "Protriptyline", "ingredient2": "Potassium citrate", "severity": "Major", "effect": "Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.", "source": "DDInter", "management_text": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.", "mechanism_text": "Synergism", "recommendation": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67387/", "reference_text": "[1] \"Product Information. K-Dur (potassium chloride).\" Schering Laboratories, Kenilworth, NJ.[2] Wynn V \"Potassium chloride and bowel ulceration.\" Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial.\" Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L \"Ulceration of the small intestine due to slow-release potassium chloride tablets.\" Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ \"Perforation of small bowel due to slow release potassium chloride (slow-K).\" Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ \"Jejunal perforation associated with slow-release potassium chloride therapy.\" South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ \"Ulceration of small intestine and slow-release potassium tablets.\" Br Med J 2 (1975): 746[8] Lambert JR, Newman A \"Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy.\" Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L \"Gastrointestinal lesions and potassium chloride supplements.\" Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA \"Gut lesions due to slow-release KCI tablets.\" N Engl J Med 296 (1977): 111-2[11] \"Product Information. Urocit (potassium citrate).\" Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Effect of potassium chloride supplements on upper gastrointestinal mucosa.\" Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Sanctura (trospium chloride).\" Odyssey Pharmaceutical, East Hanover, NJ.", "alternatives_a": "Citalopram, Sertraline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Isocarboxazid, Viloxazine, Esketamine, More", "alternatives_b": "Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67301, "ingredient1": "Potassium citrate", "ingredient2": "Mepyramine", "severity": "Major", "effect": "Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.", "source": "DDInter", "management_text": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.", "mechanism_text": "Synergism", "recommendation": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67388/", "reference_text": "[1] \"Product Information. K-Dur (potassium chloride).\" Schering Laboratories, Kenilworth, NJ.[2] Wynn V \"Potassium chloride and bowel ulceration.\" Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial.\" Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L \"Ulceration of the small intestine due to slow-release potassium chloride tablets.\" Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ \"Perforation of small bowel due to slow release potassium chloride (slow-K).\" Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ \"Jejunal perforation associated with slow-release potassium chloride therapy.\" South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ \"Ulceration of small intestine and slow-release potassium tablets.\" Br Med J 2 (1975): 746[8] Lambert JR, Newman A \"Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy.\" Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L \"Gastrointestinal lesions and potassium chloride supplements.\" Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA \"Gut lesions due to slow-release KCI tablets.\" N Engl J Med 296 (1977): 111-2[11] \"Product Information. Urocit (potassium citrate).\" Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Effect of potassium chloride supplements on upper gastrointestinal mucosa.\" Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Sanctura (trospium chloride).\" Odyssey Pharmaceutical, East Hanover, NJ.", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67302, "ingredient1": "Quinapril", "ingredient2": "Potassium citrate", "severity": "Major", "effect": "Concomitant use of angiotensin converting enzyme (ACE) inhibitors and potassium salts may increase the risk of hyperkalemia. Inhibition of ACE results in decreased aldosterone secretion, which in turn causes potassium retention.", "source": "DDInter", "management_text": "Caution is advised if ACE inhibitors must be used concurrently with potassium salts, particularly in patients with renal impairment, diabetes, old age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium such as nonsteroidal anti-inflammatory drugs, beta-blockers, cyclosporine, heparin, tacrolimus, trimethoprim, and licorice. The combination should generally be avoided in these patients unless absolutely necessary and the benefits outweigh the potential risks. Serum potassium and renal function should be checked prior to initiating therapy and regularly thereafter. Patients should be given counseling on the appropriate levels of potassium and fluid intake, and advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if ACE inhibitors must be used concurrently with potassium salts, particularly in patients with renal impairment, diabetes, old age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium such as nonsteroidal anti-inflammatory drugs, beta-blockers, cyclosporine, heparin, tacrolimus, trimethoprim, and licorice.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67389/", "reference_text": "[1] \"Product Information. K-Dur (potassium chloride).\" Schering Laboratories, Kenilworth, NJ.[2] Chan TY, Critchley JA \"Life-threatening hyperkalaemia in an elderly patient receiving captopril, furosemide (frusemide) and potassium supplements.\" Drug Saf 7 (1992): 159-61[3] Warren SE, O'Connor DT \"Hyperkalemia resulting from captopril administration.\" JAMA 244 (1980): 2551-2[4] Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS, Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association \"Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association.\" Circulation 104 (2001): 1985-91[5] Large DM, Carr PH, Laing I, Davies M \"Hyperkalaemia in diabetes mellitus--potential hazards of coexisting hyporeninaemic hypoaldosteronism.\" Postgrad Med J 60 (1984): 370-3[6] Schuna AA, Schmidt GR, Pitterle ME \"Serum potassium concentrations after initiation of captopril therapy.\" Clin Pharm 5 (1986): 920-3[7] Perazella MA, Mahnensmith RL \"Hyperkalemia in the elderly: drugs exacerbate impaired potassium homeostasis.\" J Gen Intern Med 12 (1997): 646-56[8] Lawson DH, O'Connor PC, Jick H \"Drug attributed alterations in potassium handling in congestive cardiac failure.\" Eur J Clin Pharmacol 23 (1982): 21-5[9] Perazella MA \"Drug-induced hyperkalemia: old culprits and new offenders.\" Am J Med 109 (2000): 307-14[10] Packer M, Lee WH \"Provocation of hyper- and hypokalemic sudden death during treatment with and withdrawal of converting-enzyme inhibition in severe chronic congestive heart failure.\" Am J Cardiol 57 (1986): 347-8[11] Ray K, Dorman S, Watson R \"Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction.\" J Hum Hypertens 13 (1999): 717-20[12] Ponce SP, Jennings AE, Madias NE, Harrington JT \"Drug-induced hyperkalemia.\" Medicine (Baltimore) 64 (1985): 357-70[13] Burnakis TG, Mioduch HJ \"Combined therapy with captopril and potassium supplementation: a potential for hyperkalemia.\" Arch Intern Med 144 (1984): 2371-2[14] Speirs CJ, Dollery CT, Inman WH, et al \"Postmarketing surveillance of enalapril II: investigation of the potential role of enalapril in deaths with renal failure.\" Br Med J 297 (1988): 830-2[15] Jarman PR, Kehely AM, Mather HM \"Hyperkalaemia in diabetes: prevalence and associations.\" Postgrad Med J 71 (1995): 551-2[16] Obialo CI, Ofili EO, Mirza T \"Hyperkalemia in congestive heart failure patients aged 63 to 85 years with subclinical renal disease.\" Am J Cardiol 90 (2002): 663-5[17] Atlas SA, Case DB, Sealey JE, Laragh JH, McKinstry DN \"Interruption of the renin-angiotensin system in hypertensive patients by captopril induces sustained reduction in aldosterone secretion, potassium retention and natriuresis.\" Hypertension 1 (1979): 279-80[18] Graves JW \"Hyperkalemia due to a potassium-based water softener.\" N Engl J Med 339 (1998): 1790-1[19] Lawson DH \"Adverse reactions to potassium chloride.\" Q J Med 43 (1974): 433-40[20] Good CB, McDermott L \"Diet and serum potassium in patients on ACE inhibitors.\" JAMA 274 (1995): 538[21] Walmsley RN, White GH, Cain M, McCarthy PJ, Booth J \"Hyperkalemia in the elderly.\" Clin Chem 30 (1984): 1409-12[22] Jarman PR, Mather HM \"Diabetes may be independent risk factor for hyperkalaemia.\" BMJ 327 (2003): 812[23] Stoltz ML, Andrews CE Jr \"Severe hyperkalemia during very-low-calorie diets and angiotensin converting enzyme use .\" JAMA 264 (1990): 2737-8[24] Reardon LC, Macpherson DS \"Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry?\" Arch Intern Med 158 (1998): 26-32[25] Ray K, Dorman S, Watson R \"Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction.\" J Hum Hypertens 13 (1999): 717-20[26] \"Product Information. Vasotec (enalapril).\" Merck & Co, Inc, West Point, PA.[27] Good CB, McDermott L \"Diet and serum potassium in patients on ACE inhibitors.\" JAMA 274 (1995): 538", "alternatives_a": "Felodipine, Amlodipine, Verapamil, Bisoprolol, Hydrochlorothiazide, Indapamide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67303, "ingredient1": "Quinidine", "ingredient2": "Potassium citrate", "severity": "Moderate", "effect": "Coadministration with drugs that can increase urinary pH such as antacids, carbonic anhydrase inhibitors, or urinary alkalinizers may decrease the urinary excretion of quinidine. The proposed mechanism is increased renal tubular reabsorption due to reduced ionization of quinidine in alkaline urine.", "source": "DDInter", "management_text": "Caution is advised if quinidine is used with agents that can increase urinary pH. Quinidine levels may need to be monitored more closely following addition or discontinuation of these agents, and the quinidine dosage adjusted as necessary. Patients should be advised to seek medical attention if they experience symptoms that could indicate quinidine toxicity such as tinnitus, hearing loss, visual disturbances, diarrhea, headache, dizziness, palpitations, syncope, or irregular heartbeats.", "mechanism_text": "Excretion", "recommendation": "Caution is advised if quinidine is used with agents that can increase urinary pH.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67390/", "reference_text": "[1] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[2] Mauro VF, Mauro LS, Fraker TD Jr, Temesy-Armos PN, Somani P \"Effect of aluminum hydroxide gel on quinidine gluconate absorption.\" DICP 24 (1990): 252-4[3] Romankiewicz JA, Reidenberg M, Drayer D, Franklin JE \"The noninterference of aluminum hydroxide gel with quinidine sulfate absorption: An approach to control quinidine-induced diarrhea.\" Am Heart J 96 (1978): 518-20[4] Gerhardt RE, Knouss RF, Thyrum PT, et al \"Quinidine excretion in aciduria and alkaluria.\" Ann Intern Med 71 (1969): 927-33[5] Zinn MB \"Quinidine intoxication from alkali ingestion.\" Tex Med 66 (1970): 64-6[6] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[7] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[8] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[9] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Amiodarone, Dronedarone, Lidocaine, Propafenone, Procainamide, Tocainide, Dofetilide, Bretylium, Moricizine, Ibutilide", "alternatives_b": "Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67304, "ingredient1": "Ramipril", "ingredient2": "Potassium citrate", "severity": "Major", "effect": "Concomitant use of angiotensin converting enzyme (ACE) inhibitors and potassium salts may increase the risk of hyperkalemia. Inhibition of ACE results in decreased aldosterone secretion, which in turn causes potassium retention.", "source": "DDInter", "management_text": "Caution is advised if ACE inhibitors must be used concurrently with potassium salts, particularly in patients with renal impairment, diabetes, old age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium such as nonsteroidal anti-inflammatory drugs, beta-blockers, cyclosporine, heparin, tacrolimus, trimethoprim, and licorice. The combination should generally be avoided in these patients unless absolutely necessary and the benefits outweigh the potential risks. Serum potassium and renal function should be checked prior to initiating therapy and regularly thereafter. Patients should be given counseling on the appropriate levels of potassium and fluid intake, and advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if ACE inhibitors must be used concurrently with potassium salts, particularly in patients with renal impairment, diabetes, old age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium such as nonsteroidal anti-inflammatory drugs, beta-blockers, cyclosporine, heparin, tacrolimus, trimethoprim, and licorice.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67391/", "reference_text": "[1] \"Product Information. K-Dur (potassium chloride).\" Schering Laboratories, Kenilworth, NJ.[2] Chan TY, Critchley JA \"Life-threatening hyperkalaemia in an elderly patient receiving captopril, furosemide (frusemide) and potassium supplements.\" Drug Saf 7 (1992): 159-61[3] Warren SE, O'Connor DT \"Hyperkalemia resulting from captopril administration.\" JAMA 244 (1980): 2551-2[4] Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS, Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association \"Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association.\" Circulation 104 (2001): 1985-91[5] Large DM, Carr PH, Laing I, Davies M \"Hyperkalaemia in diabetes mellitus--potential hazards of coexisting hyporeninaemic hypoaldosteronism.\" Postgrad Med J 60 (1984): 370-3[6] Schuna AA, Schmidt GR, Pitterle ME \"Serum potassium concentrations after initiation of captopril therapy.\" Clin Pharm 5 (1986): 920-3[7] Perazella MA, Mahnensmith RL \"Hyperkalemia in the elderly: drugs exacerbate impaired potassium homeostasis.\" J Gen Intern Med 12 (1997): 646-56[8] Lawson DH, O'Connor PC, Jick H \"Drug attributed alterations in potassium handling in congestive cardiac failure.\" Eur J Clin Pharmacol 23 (1982): 21-5[9] Perazella MA \"Drug-induced hyperkalemia: old culprits and new offenders.\" Am J Med 109 (2000): 307-14[10] Packer M, Lee WH \"Provocation of hyper- and hypokalemic sudden death during treatment with and withdrawal of converting-enzyme inhibition in severe chronic congestive heart failure.\" Am J Cardiol 57 (1986): 347-8[11] Ray K, Dorman S, Watson R \"Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction.\" J Hum Hypertens 13 (1999): 717-20[12] Ponce SP, Jennings AE, Madias NE, Harrington JT \"Drug-induced hyperkalemia.\" Medicine (Baltimore) 64 (1985): 357-70[13] Burnakis TG, Mioduch HJ \"Combined therapy with captopril and potassium supplementation: a potential for hyperkalemia.\" Arch Intern Med 144 (1984): 2371-2[14] Speirs CJ, Dollery CT, Inman WH, et al \"Postmarketing surveillance of enalapril II: investigation of the potential role of enalapril in deaths with renal failure.\" Br Med J 297 (1988): 830-2[15] Jarman PR, Kehely AM, Mather HM \"Hyperkalaemia in diabetes: prevalence and associations.\" Postgrad Med J 71 (1995): 551-2[16] Obialo CI, Ofili EO, Mirza T \"Hyperkalemia in congestive heart failure patients aged 63 to 85 years with subclinical renal disease.\" Am J Cardiol 90 (2002): 663-5[17] Atlas SA, Case DB, Sealey JE, Laragh JH, McKinstry DN \"Interruption of the renin-angiotensin system in hypertensive patients by captopril induces sustained reduction in aldosterone secretion, potassium retention and natriuresis.\" Hypertension 1 (1979): 279-80[18] Graves JW \"Hyperkalemia due to a potassium-based water softener.\" N Engl J Med 339 (1998): 1790-1[19] Lawson DH \"Adverse reactions to potassium chloride.\" Q J Med 43 (1974): 433-40[20] Good CB, McDermott L \"Diet and serum potassium in patients on ACE inhibitors.\" JAMA 274 (1995): 538[21] Walmsley RN, White GH, Cain M, McCarthy PJ, Booth J \"Hyperkalemia in the elderly.\" Clin Chem 30 (1984): 1409-12[22] Jarman PR, Mather HM \"Diabetes may be independent risk factor for hyperkalaemia.\" BMJ 327 (2003): 812[23] Stoltz ML, Andrews CE Jr \"Severe hyperkalemia during very-low-calorie diets and angiotensin converting enzyme use .\" JAMA 264 (1990): 2737-8[24] Reardon LC, Macpherson DS \"Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry?\" Arch Intern Med 158 (1998): 26-32[25] Ray K, Dorman S, Watson R \"Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction.\" J Hum Hypertens 13 (1999): 717-20[26] \"Product Information. Vasotec (enalapril).\" Merck & Co, Inc, West Point, PA.[27] Good CB, McDermott L \"Diet and serum potassium in patients on ACE inhibitors.\" JAMA 274 (1995): 538", "alternatives_a": "Felodipine, Amlodipine, Verapamil, Bisoprolol, Hydrochlorothiazide, Indapamide, Amlodipine, Atorvastatin, Simvastatin, Lovastatin, Rosuvastatin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67305, "ingredient1": "Salsalate", "ingredient2": "Potassium citrate", "severity": "Moderate", "effect": "Agents that cause urinary alkalinization can reduce serum salicylate concentrations in patients receiving anti-inflammatory dosages of aspirin or other salicylates. The mechanism involves reduction in salicylate renal tubular reabsorption due to increased urinary pH, resulting in increased renal salicylate clearance especially above urine pH of 7. This interaction is sometimes exploited in the treatment of salicylate toxicity.", "source": "DDInter", "management_text": "Patients treated chronically with urinary alkalinizers and large doses of salicylates (i.e. 3 g/day or more) should be monitored for potentially diminished or inadequate analgesic and anti-inflammatory effects, and the salicylate dosage adjusted if necessary.", "mechanism_text": "Excretion", "recommendation": "Patients treated chronically with urinary alkalinizers and large doses of salicylates (i.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67392/", "reference_text": "[1] Prescott LF, Balali-Mood M, Critchley JA, Johnstone AF, Proudfoot AT \"Diuresis or urinary alkalinisation for salicylate poisoning?\" Br Med J (Clin Res Ed) 285 (1982): 1383-6[2] Brouwers JRBJ, Desmet PAGM \"Pharmacokinetic-pharmacodynamic drug interactions with nonsteroidal anti-inflammatory drugs.\" Clin Pharmacokinet 27 (1994): 462-85[3] Berg KJ \"Acute effects of acetylsalicylic acid in patients with chronic renal insufficiency.\" Eur J Clin Pharmacol 11 (1977): 111-6[4] Balali-Mood M, Prescott LF \"Failure of alkaline diuresis to enhance diflunisal elimination.\" Br J Clin Pharmacol 10 (1980): 163-5[5] Berg KJ \"Acute acetylsalicylic acid poisoning: treatment with forced alkaline diuresis and diuretics.\" Eur J Clin Pharmacol 12 (1977): 111-6", "alternatives_a": "Acetaminophen, Ziconotide, Methoxyflurane", "alternatives_b": "Potassium chloride, Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67306, "ingredient1": "Scopolamine", "ingredient2": "Potassium citrate", "severity": "Major", "effect": "Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.", "source": "DDInter", "management_text": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.", "mechanism_text": "Synergism", "recommendation": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67393/", "reference_text": "[1] \"Product Information. K-Dur (potassium chloride).\" Schering Laboratories, Kenilworth, NJ.[2] Wynn V \"Potassium chloride and bowel ulceration.\" Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial.\" Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L \"Ulceration of the small intestine due to slow-release potassium chloride tablets.\" Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ \"Perforation of small bowel due to slow release potassium chloride (slow-K).\" Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ \"Jejunal perforation associated with slow-release potassium chloride therapy.\" South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ \"Ulceration of small intestine and slow-release potassium tablets.\" Br Med J 2 (1975): 746[8] Lambert JR, Newman A \"Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy.\" Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L \"Gastrointestinal lesions and potassium chloride supplements.\" Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA \"Gut lesions due to slow-release KCI tablets.\" N Engl J Med 296 (1977): 111-2[11] \"Product Information. Urocit (potassium citrate).\" Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Effect of potassium chloride supplements on upper gastrointestinal mucosa.\" Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Sanctura (trospium chloride).\" Odyssey Pharmaceutical, East Hanover, NJ.", "alternatives_a": "Suvorexant, Triazolam, Flurazepam, Methohexital, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, More", "alternatives_b": "Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67307, "ingredient1": "Solifenacin", "ingredient2": "Potassium citrate", "severity": "Major", "effect": "Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.", "source": "DDInter", "management_text": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.", "mechanism_text": "Synergism", "recommendation": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67394/", "reference_text": "[1] \"Product Information. K-Dur (potassium chloride).\" Schering Laboratories, Kenilworth, NJ.[2] Wynn V \"Potassium chloride and bowel ulceration.\" Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial.\" Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L \"Ulceration of the small intestine due to slow-release potassium chloride tablets.\" Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ \"Perforation of small bowel due to slow release potassium chloride (slow-K).\" Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ \"Jejunal perforation associated with slow-release potassium chloride therapy.\" South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ \"Ulceration of small intestine and slow-release potassium tablets.\" Br Med J 2 (1975): 746[8] Lambert JR, Newman A \"Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy.\" Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L \"Gastrointestinal lesions and potassium chloride supplements.\" Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA \"Gut lesions due to slow-release KCI tablets.\" N Engl J Med 296 (1977): 111-2[11] \"Product Information. Urocit (potassium citrate).\" Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Effect of potassium chloride supplements on upper gastrointestinal mucosa.\" Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Sanctura (trospium chloride).\" Odyssey Pharmaceutical, East Hanover, NJ.", "alternatives_a": "Apomorphine, Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Avanafil, More", "alternatives_b": "Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67308, "ingredient1": "Sparfloxacin", "ingredient2": "Potassium citrate", "severity": "Moderate", "effect": "Urinary alkalinizers such as citrates may decrease the solubility of fluoroquinolones in the urine and increase the risk of crystalluria.", "source": "DDInter", "management_text": "Concomitant use should generally be avoided. Patients receiving this combination should be monitored for signs of renal toxicity and crystalluria.", "mechanism_text": "Excretion", "recommendation": "Concomitant use should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67395/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.", "alternatives_a": "Delafloxacin", "alternatives_b": "Potassium chloride, Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67309, "ingredient1": "Sulindac", "ingredient2": "Potassium citrate", "severity": "Moderate", "effect": "Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) with potassium salts may increase the risk of hyperkalemia. NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system.", "source": "DDInter", "management_text": "Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.g., beta-blockers, cyclosporine, heparin, tacrolimus, and trimethoprim). Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67396/", "reference_text": "[1] \"Product Information. Potassium Chloride ER (potassium chloride).\" Zydus Pharmaceuticals (USA) Inc, Princeton, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. K-Phos Original (potassium acid phosphate).\" Beach Pharmaceuticals, Tampa, FL.[4] \"Product Information. Phospho-Trin 250 Neutral (potassium phosphate-sodium phosphate).\" Patrin Pharma, Skokie, IL.[5] \"Product Information. SSKI (potassium iodide).\" Upsher-Smith Laboratories Inc, Minneapolis, MN.[6] \"Product Information. Potassium Chloride (potassium chloride).\" Pharmaceutical Assoc Inc Div Beach Products, Greenville, SC.", "alternatives_a": "Rabeprazole, Misoprostol, Glucosamine, Chondroitin sulfate, Rofecoxib, Esomeprazole, Celecoxib, Valdecoxib", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67310, "ingredient1": "Telmisartan", "ingredient2": "Potassium citrate", "severity": "Major", "effect": "Concomitant use of angiotensin II receptor blockers (ARBs) and potassium salts may increase the risk of hyperkalemia. Inhibition of angiotensin II results in decreased aldosterone secretion, which in turn causes potassium retention. Risk factors for developing severe or life-threatening hyperkalemia may include renal impairment, diabetes, old age, severe or worsening heart failure, dehydration, and concomitant use of other agents that block the renin-angiotensin-aldosterone system or otherwise increase serum potassium levels.", "source": "DDInter", "management_text": "Caution is advised if angiotensin II receptor blockers must be used concurrently with potassium salts, particularly in patients with renal impairment, diabetes, old age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium such as nonsteroidal anti-inflammatory drugs, beta-blockers, cyclosporine, heparin, tacrolimus, and trimethoprim. The combination should generally be avoided in these patients unless absolutely necessary and the benefits outweigh the potential risks. Serum potassium and renal function should be checked prior to initiating therapy and regularly thereafter. Patients should be given counseling on the appropriate levels of potassium and fluid intake, and advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if angiotensin II receptor blockers must be used concurrently with potassium salts, particularly in patients with renal impairment, diabetes, old age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium such as nonsteroidal anti-inflammatory drugs, beta-blockers, cyclosporine, heparin, tacrolimus, and trimethoprim.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67397/", "reference_text": "[1] Walmsley RN, White GH, Cain M, McCarthy PJ, Booth J \"Hyperkalemia in the elderly.\" Clin Chem 30 (1984): 1409-12[2] Jarman PR, Mather HM \"Diabetes may be independent risk factor for hyperkalaemia.\" BMJ 327 (2003): 812[3] Obialo CI, Ofili EO, Mirza T \"Hyperkalemia in congestive heart failure patients aged 63 to 85 years with subclinical renal disease.\" Am J Cardiol 90 (2002): 663-5[4] Jarman PR, Kehely AM, Mather HM \"Hyperkalaemia in diabetes: prevalence and associations.\" Postgrad Med J 71 (1995): 551-2[5] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.[6] Large DM, Carr PH, Laing I, Davies M \"Hyperkalaemia in diabetes mellitus--potential hazards of coexisting hyporeninaemic hypoaldosteronism.\" Postgrad Med J 60 (1984): 370-3[7] Perazella MA \"Drug-induced hyperkalemia: old culprits and new offenders.\" Am J Med 109 (2000): 307-14[8] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[9] Perazella MA, Mahnensmith RL \"Hyperkalemia in the elderly: drugs exacerbate impaired potassium homeostasis.\" J Gen Intern Med 12 (1997): 646-56[10] Lawson DH \"Adverse reactions to potassium chloride.\" Q J Med 43 (1974): 433-40[11] Lawson DH, O'Connor PC, Jick H \"Drug attributed alterations in potassium handling in congestive cardiac failure.\" Eur J Clin Pharmacol 23 (1982): 21-5[12] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[13] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.", "alternatives_a": "Amlodipine, Sacubitril, Hydrochlorothiazide, Nebivolol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67311, "ingredient1": "Thiethylperazine", "ingredient2": "Potassium citrate", "severity": "Major", "effect": "Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.", "source": "DDInter", "management_text": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.", "mechanism_text": "Synergism", "recommendation": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67398/", "reference_text": "[1] \"Product Information. K-Dur (potassium chloride).\" Schering Laboratories, Kenilworth, NJ.[2] Wynn V \"Potassium chloride and bowel ulceration.\" Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial.\" Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L \"Ulceration of the small intestine due to slow-release potassium chloride tablets.\" Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ \"Perforation of small bowel due to slow release potassium chloride (slow-K).\" Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ \"Jejunal perforation associated with slow-release potassium chloride therapy.\" South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ \"Ulceration of small intestine and slow-release potassium tablets.\" Br Med J 2 (1975): 746[8] Lambert JR, Newman A \"Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy.\" Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L \"Gastrointestinal lesions and potassium chloride supplements.\" Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA \"Gut lesions due to slow-release KCI tablets.\" N Engl J Med 296 (1977): 111-2[11] \"Product Information. Urocit (potassium citrate).\" Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Effect of potassium chloride supplements on upper gastrointestinal mucosa.\" Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Sanctura (trospium chloride).\" Odyssey Pharmaceutical, East Hanover, NJ.", "alternatives_a": "Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67312, "ingredient1": "Thioridazine", "ingredient2": "Potassium citrate", "severity": "Major", "effect": "Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.", "source": "DDInter", "management_text": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.", "mechanism_text": "Synergism", "recommendation": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67399/", "reference_text": "[1] \"Product Information. K-Dur (potassium chloride).\" Schering Laboratories, Kenilworth, NJ.[2] Wynn V \"Potassium chloride and bowel ulceration.\" Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial.\" Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L \"Ulceration of the small intestine due to slow-release potassium chloride tablets.\" Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ \"Perforation of small bowel due to slow release potassium chloride (slow-K).\" Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ \"Jejunal perforation associated with slow-release potassium chloride therapy.\" South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ \"Ulceration of small intestine and slow-release potassium tablets.\" Br Med J 2 (1975): 746[8] Lambert JR, Newman A \"Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy.\" Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L \"Gastrointestinal lesions and potassium chloride supplements.\" Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA \"Gut lesions due to slow-release KCI tablets.\" N Engl J Med 296 (1977): 111-2[11] \"Product Information. Urocit (potassium citrate).\" Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Effect of potassium chloride supplements on upper gastrointestinal mucosa.\" Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Sanctura (trospium chloride).\" Odyssey Pharmaceutical, East Hanover, NJ.", "alternatives_a": "Quetiapine, Asenapine, Haloperidol, Pimavanserin, Ziprasidone, Lumateperone, Iloperidone, Risperidone, Amisulpride, Aripiprazole, Droperidol, More", "alternatives_b": "Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67313, "ingredient1": "Thiothixene", "ingredient2": "Potassium citrate", "severity": "Major", "effect": "Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.", "source": "DDInter", "management_text": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.", "mechanism_text": "Synergism", "recommendation": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67400/", "reference_text": "[1] \"Product Information. K-Dur (potassium chloride).\" Schering Laboratories, Kenilworth, NJ.[2] Wynn V \"Potassium chloride and bowel ulceration.\" Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial.\" Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L \"Ulceration of the small intestine due to slow-release potassium chloride tablets.\" Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ \"Perforation of small bowel due to slow release potassium chloride (slow-K).\" Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ \"Jejunal perforation associated with slow-release potassium chloride therapy.\" South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ \"Ulceration of small intestine and slow-release potassium tablets.\" Br Med J 2 (1975): 746[8] Lambert JR, Newman A \"Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy.\" Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L \"Gastrointestinal lesions and potassium chloride supplements.\" Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA \"Gut lesions due to slow-release KCI tablets.\" N Engl J Med 296 (1977): 111-2[11] \"Product Information. Urocit (potassium citrate).\" Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Effect of potassium chloride supplements on upper gastrointestinal mucosa.\" Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Sanctura (trospium chloride).\" Odyssey Pharmaceutical, East Hanover, NJ.", "alternatives_a": "Quetiapine, Asenapine, Haloperidol, Pimavanserin, Ziprasidone, Lumateperone, Iloperidone, Risperidone, Amisulpride, Aripiprazole, Droperidol, More", "alternatives_b": "Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67314, "ingredient1": "Tolazamide", "ingredient2": "Potassium citrate", "severity": "Minor", "effect": "Alkalinization of the urine may increase the renal clearance of some sulfonylureas for which renal elimination is pH dependent. The clinical significance of this interaction is unknown. Management consists of monitoring blood glucose frequently during the initial period of coadministration. The sulfonylurea dosage should be adjusted as needed and appropriate.", "source": "DDInter", "management_text": "-", "mechanism_text": "Excretion", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67401/", "reference_text": "[1] Neuvonen PJ, Karkkainen S \"Effects of charcoal, sodium bicarbonate, and ammonium chloride on chlorpropamide kinetics.\" Clin Pharmacol Ther 33 (1983): 386-93[2] Kivisto KT, Neuvonen PJ \"Differential effects of sodium bicarbonate and aluminium hydroxide on the absorption and activity of glipizide.\" Eur J Clin Pharmacol 40 (1991): 383-6[3] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[4] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[5] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[6] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[7] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[10] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[11] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Empagliflozin, Dulaglutide, Exenatide, Miglitol, Glimepiride, Albiglutide, Rosiglitazone, More", "alternatives_b": "Potassium chloride, Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67315, "ingredient1": "Tolbutamide", "ingredient2": "Potassium citrate", "severity": "Minor", "effect": "Alkalinization of the urine may increase the renal clearance of some sulfonylureas for which renal elimination is pH dependent. The clinical significance of this interaction is unknown. Management consists of monitoring blood glucose frequently during the initial period of coadministration. The sulfonylurea dosage should be adjusted as needed and appropriate.", "source": "DDInter", "management_text": "-", "mechanism_text": "Excretion", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67402/", "reference_text": "[1] Neuvonen PJ, Karkkainen S \"Effects of charcoal, sodium bicarbonate, and ammonium chloride on chlorpropamide kinetics.\" Clin Pharmacol Ther 33 (1983): 386-93[2] Kivisto KT, Neuvonen PJ \"Differential effects of sodium bicarbonate and aluminium hydroxide on the absorption and activity of glipizide.\" Eur J Clin Pharmacol 40 (1991): 383-6[3] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[4] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[5] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[6] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[7] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[10] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[11] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Sorbitol, Caffeine, Edrophonium, Indocyanine green, Inulin, Hexaminolevulinate, Secretin human, Galactose, Corticorelin, Macimorelin, Methacholine, More", "alternatives_b": "Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67316, "ingredient1": "Tolmetin", "ingredient2": "Potassium citrate", "severity": "Moderate", "effect": "Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) with potassium salts may increase the risk of hyperkalemia. NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system.", "source": "DDInter", "management_text": "Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.g., beta-blockers, cyclosporine, heparin, tacrolimus, and trimethoprim). Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67403/", "reference_text": "[1] \"Product Information. Potassium Chloride ER (potassium chloride).\" Zydus Pharmaceuticals (USA) Inc, Princeton, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. K-Phos Original (potassium acid phosphate).\" Beach Pharmaceuticals, Tampa, FL.[4] \"Product Information. Phospho-Trin 250 Neutral (potassium phosphate-sodium phosphate).\" Patrin Pharma, Skokie, IL.[5] \"Product Information. SSKI (potassium iodide).\" Upsher-Smith Laboratories Inc, Minneapolis, MN.[6] \"Product Information. Potassium Chloride (potassium chloride).\" Pharmaceutical Assoc Inc Div Beach Products, Greenville, SC.", "alternatives_a": "Rabeprazole, Misoprostol, Glucosamine, Chondroitin sulfate, Rofecoxib, Esomeprazole, Celecoxib, Valdecoxib, Tolazoline, Rabeprazole, Dimethyl sulfoxide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67317, "ingredient1": "Tolterodine", "ingredient2": "Potassium citrate", "severity": "Major", "effect": "Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.", "source": "DDInter", "management_text": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.", "mechanism_text": "Synergism", "recommendation": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67404/", "reference_text": "[1] \"Product Information. K-Dur (potassium chloride).\" Schering Laboratories, Kenilworth, NJ.[2] Wynn V \"Potassium chloride and bowel ulceration.\" Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial.\" Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L \"Ulceration of the small intestine due to slow-release potassium chloride tablets.\" Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ \"Perforation of small bowel due to slow release potassium chloride (slow-K).\" Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ \"Jejunal perforation associated with slow-release potassium chloride therapy.\" South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ \"Ulceration of small intestine and slow-release potassium tablets.\" Br Med J 2 (1975): 746[8] Lambert JR, Newman A \"Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy.\" Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L \"Gastrointestinal lesions and potassium chloride supplements.\" Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA \"Gut lesions due to slow-release KCI tablets.\" N Engl J Med 296 (1977): 111-2[11] \"Product Information. Urocit (potassium citrate).\" Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Effect of potassium chloride supplements on upper gastrointestinal mucosa.\" Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Sanctura (trospium chloride).\" Odyssey Pharmaceutical, East Hanover, NJ.", "alternatives_a": "Apomorphine, Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Avanafil, More", "alternatives_b": "Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67318, "ingredient1": "Tolvaptan", "ingredient2": "Potassium citrate", "severity": "Moderate", "effect": "Coadministration with tolvaptan can potentiate the risk of hyperkalemia in patients treated with other drugs that are known to increase serum potassium. Tolvaptan alone can increase serum potassium by causing an acute reduction of the extracellular fluid volume.", "source": "DDInter", "management_text": "Serum potassium levels should be checked regularly during concomitant therapy with tolvaptan and other agents that can increase serum potassium such as ACE inhibitors, angiotensin II receptor antagonists, potassium-sparing diuretics, aldosterone antagonists, and miscellaneous agents like cyclosporin, heparin, tacrolimus, and trimethoprim. Particular caution is warranted in patients with renal impairment, diabetes, old age, severe or worsening heart failure, or dehydration. Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Serum potassium levels should be checked regularly during concomitant therapy with tolvaptan and other agents that can increase serum potassium such as ACE inhibitors, angiotensin II receptor antagonists, potassium-sparing diuretics, aldosterone antagonists, and miscellaneous agents like cyclosporin, heparin, tacrolimus, and trimethoprim.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67405/", "reference_text": "[1] \"Product Information. Samsca (tolvaptan).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[2] \"Product Information. Samsca (tolvaptan).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Conivaptan", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67319, "ingredient1": "Trandolapril", "ingredient2": "Potassium citrate", "severity": "Major", "effect": "Concomitant use of angiotensin converting enzyme (ACE) inhibitors and potassium salts may increase the risk of hyperkalemia. Inhibition of ACE results in decreased aldosterone secretion, which in turn causes potassium retention.", "source": "DDInter", "management_text": "Caution is advised if ACE inhibitors must be used concurrently with potassium salts, particularly in patients with renal impairment, diabetes, old age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium such as nonsteroidal anti-inflammatory drugs, beta-blockers, cyclosporine, heparin, tacrolimus, trimethoprim, and licorice. The combination should generally be avoided in these patients unless absolutely necessary and the benefits outweigh the potential risks. Serum potassium and renal function should be checked prior to initiating therapy and regularly thereafter. Patients should be given counseling on the appropriate levels of potassium and fluid intake, and advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if ACE inhibitors must be used concurrently with potassium salts, particularly in patients with renal impairment, diabetes, old age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium such as nonsteroidal anti-inflammatory drugs, beta-blockers, cyclosporine, heparin, tacrolimus, trimethoprim, and licorice.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67406/", "reference_text": "[1] \"Product Information. K-Dur (potassium chloride).\" Schering Laboratories, Kenilworth, NJ.[2] Chan TY, Critchley JA \"Life-threatening hyperkalaemia in an elderly patient receiving captopril, furosemide (frusemide) and potassium supplements.\" Drug Saf 7 (1992): 159-61[3] Warren SE, O'Connor DT \"Hyperkalemia resulting from captopril administration.\" JAMA 244 (1980): 2551-2[4] Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS, Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association \"Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association.\" Circulation 104 (2001): 1985-91[5] Large DM, Carr PH, Laing I, Davies M \"Hyperkalaemia in diabetes mellitus--potential hazards of coexisting hyporeninaemic hypoaldosteronism.\" Postgrad Med J 60 (1984): 370-3[6] Schuna AA, Schmidt GR, Pitterle ME \"Serum potassium concentrations after initiation of captopril therapy.\" Clin Pharm 5 (1986): 920-3[7] Perazella MA, Mahnensmith RL \"Hyperkalemia in the elderly: drugs exacerbate impaired potassium homeostasis.\" J Gen Intern Med 12 (1997): 646-56[8] Lawson DH, O'Connor PC, Jick H \"Drug attributed alterations in potassium handling in congestive cardiac failure.\" Eur J Clin Pharmacol 23 (1982): 21-5[9] Perazella MA \"Drug-induced hyperkalemia: old culprits and new offenders.\" Am J Med 109 (2000): 307-14[10] Packer M, Lee WH \"Provocation of hyper- and hypokalemic sudden death during treatment with and withdrawal of converting-enzyme inhibition in severe chronic congestive heart failure.\" Am J Cardiol 57 (1986): 347-8[11] Ray K, Dorman S, Watson R \"Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction.\" J Hum Hypertens 13 (1999): 717-20[12] Ponce SP, Jennings AE, Madias NE, Harrington JT \"Drug-induced hyperkalemia.\" Medicine (Baltimore) 64 (1985): 357-70[13] Burnakis TG, Mioduch HJ \"Combined therapy with captopril and potassium supplementation: a potential for hyperkalemia.\" Arch Intern Med 144 (1984): 2371-2[14] Speirs CJ, Dollery CT, Inman WH, et al \"Postmarketing surveillance of enalapril II: investigation of the potential role of enalapril in deaths with renal failure.\" Br Med J 297 (1988): 830-2[15] Jarman PR, Kehely AM, Mather HM \"Hyperkalaemia in diabetes: prevalence and associations.\" Postgrad Med J 71 (1995): 551-2[16] Obialo CI, Ofili EO, Mirza T \"Hyperkalemia in congestive heart failure patients aged 63 to 85 years with subclinical renal disease.\" Am J Cardiol 90 (2002): 663-5[17] Atlas SA, Case DB, Sealey JE, Laragh JH, McKinstry DN \"Interruption of the renin-angiotensin system in hypertensive patients by captopril induces sustained reduction in aldosterone secretion, potassium retention and natriuresis.\" Hypertension 1 (1979): 279-80[18] Graves JW \"Hyperkalemia due to a potassium-based water softener.\" N Engl J Med 339 (1998): 1790-1[19] Lawson DH \"Adverse reactions to potassium chloride.\" Q J Med 43 (1974): 433-40[20] Good CB, McDermott L \"Diet and serum potassium in patients on ACE inhibitors.\" JAMA 274 (1995): 538[21] Walmsley RN, White GH, Cain M, McCarthy PJ, Booth J \"Hyperkalemia in the elderly.\" Clin Chem 30 (1984): 1409-12[22] Jarman PR, Mather HM \"Diabetes may be independent risk factor for hyperkalaemia.\" BMJ 327 (2003): 812[23] Stoltz ML, Andrews CE Jr \"Severe hyperkalemia during very-low-calorie diets and angiotensin converting enzyme use .\" JAMA 264 (1990): 2737-8[24] Reardon LC, Macpherson DS \"Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry?\" Arch Intern Med 158 (1998): 26-32[25] Ray K, Dorman S, Watson R \"Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction.\" J Hum Hypertens 13 (1999): 717-20[26] \"Product Information. Vasotec (enalapril).\" Merck & Co, Inc, West Point, PA.[27] Good CB, McDermott L \"Diet and serum potassium in patients on ACE inhibitors.\" JAMA 274 (1995): 538", "alternatives_a": "Felodipine, Amlodipine, Verapamil, Bisoprolol, Hydrochlorothiazide, Indapamide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67320, "ingredient1": "Triamterene", "ingredient2": "Potassium citrate", "severity": "Major", "effect": "The concomitant use of potassium-sparing diuretics and potassium preparations may result in hyperkalemia.", "source": "DDInter", "management_text": "The use of potassium preparations in patients treated with potassium-sparing diuretics is generally not recommended. Caution is advised if coadministration is required, particularly in patients with renal impairment, diabetes, old age, worsening heart failure, and/or a risk for dehydration. Serum potassium and renal function should be checked regularly, and oral potassium supplementation should be avoided in patients with severe congestive heart failure who have serum potassium levels above 3.5 mEq/L. Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as weakness, listlessness, confusion, tingling of the extremities, and irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "The use of potassium preparations in patients treated with potassium-sparing diuretics is generally not recommended.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67407/", "reference_text": "[1] Shapiro S, Slone D, Lewis GP, Jick H \"Fatal drug reactions among medical inpatients.\" JAMA 216 (1971): 467-72[2] McNay JL, Oran E \"Possible predisposition of diabetic patients to hyperkalemia following administration of potassium-retaining diuretic, amiloride (MK 870).\" Metabolism 19 (1970): 58-70[3] Walmsley RN, White GH, Cain M, McCarthy PJ, Booth J \"Hyperkalemia in the elderly.\" Clin Chem 30 (1984): 1409-12[4] Jarman PR, Kehely AM, Mather HM \"Hyperkalaemia in diabetes: prevalence and associations.\" Postgrad Med J 71 (1995): 551-2[5] Berry C, McMurray JJ \"Serious adverse events experienced by patients with chronic heart failure taking spironolactone.\" Heart 85 (2001): E8[6] Marcy TR, Ripley TL \"Aldosterone antagonists in the treatment of heart failure.\" Am J Health Syst Pharm 63 (2006): 49-58[7] \"Product Information. Aldactone (spironolactone).\" Searle, Skokie, IL.[8] Perazella MA \"Drug-induced hyperkalemia: old culprits and new offenders.\" Am J Med 109 (2000): 307-14[9] Masoudi FA, Gross CP, Wang Y, et al. \"Adoption of spironolactone therapy for older patients with heart failure and left ventricular systolic dysfunction in the United States, 1998-2001.\" Circulation 112 (2005): 39-47[10] Lawson DH, O'Connor PC, Jick H \"Drug attributed alterations in potassium handling in congestive cardiac failure.\" Eur J Clin Pharmacol 23 (1982): 21-5[11] O'Reilly MV, Murnaghan DP, Williams MB \"Transvenous pacemaker failure induced by hyperkalemia.\" JAMA 228 (1974): 336-7[12] Greenblatt DJ, Koch-Weser J \"Adverse reactions to spironolactone: a report from the Boston Collaborative Drug Surveillance Program.\" JAMA 225 (1973): 40-3[13] Lawson DH \"Adverse reactions to potassium chloride.\" Q J Med 43 (1974): 433-40[14] \"Product Information. K-Dur (potassium chloride).\" Schering Laboratories, Kenilworth, NJ.[15] Walker BR, Hoppe RC, Alexander F \"Effect of triamterene on the renal clearance of calcium, magnesium, phosphate, and uric acid in man.\" Clin Pharmacol Ther 13 (1972): 245-50[16] Mashford ML, Robertson MB \"Spironolactone and ammonium and potassium chloride.\" Br Med J 4 (1972): 298-9[17] Perazella MA, Mahnensmith RL \"Hyperkalemia in the elderly: drugs exacerbate impaired potassium homeostasis.\" J Gen Intern Med 12 (1997): 646-56[18] Jarman PR, Mather HM \"Diabetes may be independent risk factor for hyperkalaemia.\" BMJ 327 (2003): 812[19] Martin J, Mourton S, Nicholls G \"Severe hyperkalaemia with prescription of potassium-retaining agents in an elderly patient.\" N Z Med J 116 (2003): U542[20] Ponce SP, Jennings AE, Madias NE, Harrington JT \"Drug-induced hyperkalemia.\" Medicine (Baltimore) 64 (1985): 357-70[21] Svensson M, Gustafsson F, Galatius S, Hildebrandt PR, Atar D \"Hyperkalaemia and impaired renal function in patients taking spironolactone for congestive heart failure: retrospective study.\" BMJ 327 (2003): 1141-2[22] Bozkurt B, Agoston I, Knowlton AA \"Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines.\" J Am Coll Cardiol 41 (2003): 211-4", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67321, "ingredient1": "Trifluoperazine", "ingredient2": "Potassium citrate", "severity": "Major", "effect": "Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.", "source": "DDInter", "management_text": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.", "mechanism_text": "Synergism", "recommendation": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67408/", "reference_text": "[1] \"Product Information. K-Dur (potassium chloride).\" Schering Laboratories, Kenilworth, NJ.[2] Wynn V \"Potassium chloride and bowel ulceration.\" Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial.\" Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L \"Ulceration of the small intestine due to slow-release potassium chloride tablets.\" Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ \"Perforation of small bowel due to slow release potassium chloride (slow-K).\" Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ \"Jejunal perforation associated with slow-release potassium chloride therapy.\" South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ \"Ulceration of small intestine and slow-release potassium tablets.\" Br Med J 2 (1975): 746[8] Lambert JR, Newman A \"Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy.\" Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L \"Gastrointestinal lesions and potassium chloride supplements.\" Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA \"Gut lesions due to slow-release KCI tablets.\" N Engl J Med 296 (1977): 111-2[11] \"Product Information. Urocit (potassium citrate).\" Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Effect of potassium chloride supplements on upper gastrointestinal mucosa.\" Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Sanctura (trospium chloride).\" Odyssey Pharmaceutical, East Hanover, NJ.", "alternatives_a": "Quetiapine, Asenapine, Haloperidol, Pimavanserin, Ziprasidone, Lumateperone, Iloperidone, Risperidone, Amisulpride, Aripiprazole, Droperidol, More", "alternatives_b": "Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67322, "ingredient1": "Triflupromazine", "ingredient2": "Potassium citrate", "severity": "Major", "effect": "Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.", "source": "DDInter", "management_text": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.", "mechanism_text": "Synergism", "recommendation": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67409/", "reference_text": "[1] \"Product Information. K-Dur (potassium chloride).\" Schering Laboratories, Kenilworth, NJ.[2] Wynn V \"Potassium chloride and bowel ulceration.\" Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial.\" Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L \"Ulceration of the small intestine due to slow-release potassium chloride tablets.\" Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ \"Perforation of small bowel due to slow release potassium chloride (slow-K).\" Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ \"Jejunal perforation associated with slow-release potassium chloride therapy.\" South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ \"Ulceration of small intestine and slow-release potassium tablets.\" Br Med J 2 (1975): 746[8] Lambert JR, Newman A \"Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy.\" Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L \"Gastrointestinal lesions and potassium chloride supplements.\" Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA \"Gut lesions due to slow-release KCI tablets.\" N Engl J Med 296 (1977): 111-2[11] \"Product Information. Urocit (potassium citrate).\" Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Effect of potassium chloride supplements on upper gastrointestinal mucosa.\" Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Sanctura (trospium chloride).\" Odyssey Pharmaceutical, East Hanover, NJ.", "alternatives_a": "Quetiapine, Asenapine, Haloperidol, Pimavanserin, Ziprasidone, Lumateperone, Iloperidone, Risperidone, Amisulpride, Aripiprazole, Droperidol, More", "alternatives_b": "Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67323, "ingredient1": "Trihexyphenidyl", "ingredient2": "Potassium citrate", "severity": "Major", "effect": "Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.", "source": "DDInter", "management_text": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.", "mechanism_text": "Synergism", "recommendation": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67410/", "reference_text": "[1] \"Product Information. K-Dur (potassium chloride).\" Schering Laboratories, Kenilworth, NJ.[2] Wynn V \"Potassium chloride and bowel ulceration.\" Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial.\" Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L \"Ulceration of the small intestine due to slow-release potassium chloride tablets.\" Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ \"Perforation of small bowel due to slow release potassium chloride (slow-K).\" Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ \"Jejunal perforation associated with slow-release potassium chloride therapy.\" South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ \"Ulceration of small intestine and slow-release potassium tablets.\" Br Med J 2 (1975): 746[8] Lambert JR, Newman A \"Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy.\" Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L \"Gastrointestinal lesions and potassium chloride supplements.\" Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA \"Gut lesions due to slow-release KCI tablets.\" N Engl J Med 296 (1977): 111-2[11] \"Product Information. Urocit (potassium citrate).\" Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Effect of potassium chloride supplements on upper gastrointestinal mucosa.\" Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Sanctura (trospium chloride).\" Odyssey Pharmaceutical, East Hanover, NJ.", "alternatives_a": "Potassium bicarbonate, Potassium gluconate", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67324, "ingredient1": "Alimemazine", "ingredient2": "Potassium citrate", "severity": "Major", "effect": "Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.", "source": "DDInter", "management_text": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.", "mechanism_text": "Synergism", "recommendation": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67411/", "reference_text": "[1] \"Product Information. K-Dur (potassium chloride).\" Schering Laboratories, Kenilworth, NJ.[2] Wynn V \"Potassium chloride and bowel ulceration.\" Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial.\" Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L \"Ulceration of the small intestine due to slow-release potassium chloride tablets.\" Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ \"Perforation of small bowel due to slow release potassium chloride (slow-K).\" Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ \"Jejunal perforation associated with slow-release potassium chloride therapy.\" South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ \"Ulceration of small intestine and slow-release potassium tablets.\" Br Med J 2 (1975): 746[8] Lambert JR, Newman A \"Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy.\" Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L \"Gastrointestinal lesions and potassium chloride supplements.\" Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA \"Gut lesions due to slow-release KCI tablets.\" N Engl J Med 296 (1977): 111-2[11] \"Product Information. Urocit (potassium citrate).\" Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Effect of potassium chloride supplements on upper gastrointestinal mucosa.\" Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Sanctura (trospium chloride).\" Odyssey Pharmaceutical, East Hanover, NJ.", "alternatives_a": "Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67325, "ingredient1": "Trimethoprim", "ingredient2": "Potassium citrate", "severity": "Major", "effect": "The use of trimethoprim in combination with other potassium-sparing drugs or potassium salts may increase the risk of hyperkalemia. Trimethoprim inhibits sodium reabsorption and potassium excretion by blocking sodium channels in the renal distal tubules.", "source": "DDInter", "management_text": "Serum potassium and sodium levels as well as renal function should be closely monitored during coadministration of trimethoprim with other potassium-sparing drugs or potassium salts, particularly in patients receiving high-dose or long-term trimethoprim treatment and in patients with renal impairment, diabetes, old age, severe or worsening heart failure, or dehydration. A dosage reduction of trimethoprim is recommended in renal dysfunction (50% reduction for CrCl between 15 and 30 mL/min). Patients should be given dietary counseling to avoid excessive intake of potassium-rich foods and salt substitutes, and advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat. Trimethoprim should be discontinued if hyperkalemia occurs.", "mechanism_text": "Excretion", "recommendation": "Serum potassium and sodium levels as well as renal function should be closely monitored during coadministration of trimethoprim with other potassium-sparing drugs or potassium salts, particularly in patients receiving high-dose or long-term trimethoprim treatment and in patients with renal impairment, diabetes, old age, severe or worsening heart failure, or dehydration.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67412/", "reference_text": "[1] Witt JM, Koo JM, Danielson BD \"Effect of standard-dose trimethoprim/sulfamethoxazole on the serum potassium concentration in elderly men.\" Ann Pharmacother 30 (1996): 347-50[2] Canaday DH, Johnson JR \"Hyperkalemia in elderly patients receiving standard doses of trimethoprim-sulfamethoxazole.\" Ann Intern Med 120 (1994): 438[3] Noto H, Kaneko Y, Takano T, Kurokawa K \"Severe hyponatremia and hyperkalemia induced by trimethoprim-sulfamethoxazole in patients with Pneumocystis carinii pneumonia.\" Intern Med 34 (1995): 96-9[4] Perazella MA, Mahnensmith RL \"Trimethoprim-sulfamethoxazole: hyperkalemia is an important complication regardless of dose.\" Clin Nephrol 46 (1996): 187-92[5] Velazquez H, Perazella MA, Wright FS, Ellison DH \"Renal mechanism of trimethoprim-induced hyperkalemia.\" Ann Intern Med 119 (1993): 296-301[6] Marinella MA \"Reversible hyperkalemia associated with trimethoprim-sulfamethoxazole.\" Am J Med Sci 310 (1995): 115-7[7] Marcy TR, Ripley TL \"Aldosterone antagonists in the treatment of heart failure.\" Am J Health Syst Pharm 63 (2006): 49-58[8] Koc M, Bihorac A, Ozener CI, Kantarci G, Akoglu E \"Severe hyperkalemia in two renal transplant recipients treated with standard dose of trimethoprim-sulfamethoxazole.\" Am J Kidney Dis 36 (2000): u59-64[9] Bugge JF \"Severe hyperkalaemia induced by trimethoprim in combination with an angiotensin-converting enzyme inhibitor in a patient with transplanted lungs.\" J Intern Med 240 (1996): 249-51[10] Choi MJ, Fernandez PC, Patnaik A, Coupaye-Gerard B, D'Andrea D, Szerlip H, Kleyman TR \"Brief report: trimethoprim-induced hyperkalemia in a patient with AIDS.\" N Engl J Med 328 (1993): 703-6[11] Thomas RJ \"Severe hyperkalemia with trimethoprim-quinapril.\" Ann Pharmacother 30 (1996): 413-4[12] Marinella MA \"Severe hyperkalemia associated with trimethoprim-sulfamethoxazole and spironolactone.\" Infect Dis Clin Pract 6 (1997): 256-8[13] Smith GW, Cohen SB \"Hyperkalaemia and non-oliguric renal failure associated with trimethoprim.\" Br Med J 308 (1994): 454[14] Eiam-Ong S, Kurtzman NA, Sabatini S \"Studies on the mechanism of trimethoprim-induced hyperkalemia.\" Kidney Int 49 (1996): 1372-8[15] Fouche R, Bernardin G, Roger PM, Corcelle P, Simler JM, Mattei M \"Hyperkaliemia in a patient given high-dose trimethoprim-sulfamethoxazole.\" Presse Med 25 (1996): 2044[16] \"Prevent-ERR: sulfamethoxazole and trimethoprim-induced hyperkalemia.\" ISMP Medication Safety Alert! 13(Dec 4) (2008): 3[17] Pennypacker LC, Mintzer J, Pitner J \"Hyperkalemia in elderly patients receiving standard doses of trimethoprim-sulfamethoxazole.\" Ann Intern Med 120 (1994): 437[18] Modest GA, Price B, Mascoli N \"Hyperkalemia in elderly patients receiving standard doses of trimethoprim-sulfamethoxazole.\" Ann Intern Med 120 (1994): 437[19] Perazella MA \"Drug-induced hyperkalemia: old culprits and new offenders.\" Am J Med 109 (2000): 307-14[20] Martin J, Mourton S, Nicholls G \"Severe hyperkalaemia with prescription of potassium-retaining agents in an elderly patient.\" N Z Med J 116 (2003): U542[21] Greenberg S, Reiser IW, Chou SY \"Hyperkalemia with high-dose trimethoprim-sulfamethoxazole therapy.\" Am J Kidney Dis 22 (1993): 603-6[22] Mori H, Kuroda Y, Imamura S, et al \"Hyponatremia and/or hyperkalemia in patients treated with the standard dose of trimethoprim-sulfamethoxazole.\" Intern Med 42 (2003): 665-9[23] Perazella MA, Mahnensmith RL \"Hyperkalemia in the elderly: drugs exacerbate impaired potassium homeostasis.\" J Gen Intern Med 12 (1997): 646-56[24] Alappan R, Perazella MA, Buller GK \"Hyperkalemia in hospitalized patients treated with trimethoprim-sulfamethoxazole.\" Ann Intern Med 124 (1996): 316-20[25] Perlmutter EP, Sweeney D, Herskovits G, Kleiner M \"Case report: severe hyperkalemia in a geriatric patient receiving standard doses of trimethoprim-sulfamethoxazole.\" Am J Med Sci 311 (1996): 84-5[26] Marinella MA \"Trimethoprim-sulfamethoxazole associated with hyperkalemia.\" West J Med 167 (1997): 356-8[27] Antoniou T, Gomes T, Juurlink DN, Loutfy MR, Glazier RH, Mamdani MM \"Trimethoprim-sulfamethoxazole-induced hyperkalemia in patients receiving inhibitors of the renin-angiotensin system: a population-based study.\" Arch Intern Med 170 (2010): 1045-9[28] Hsu I, Wordell CJ \"Hyperkalemia and high-dose trimethoprim/sulfamethoxazole.\" Ann Pharmacother 29 (1995): 427-9[29] Lin SH, Kuo AA, Yu FC, Lin YF \"Reversible voltage-dependent distal renal tubular acidosis in a patient receiving standaard doses of trimethoprim-sulphamethoxazole.\" Nephrol Dial Transplant 12 (1997): 1031-33[30] Lawson DH, O'Connor PC, Jick H \"Drug attributed alterations in potassium handling in congestive cardiac failure.\" Eur J Clin Pharmacol 23 (1982): 21-5[31] Lawson DH \"Adverse reactions to potassium chloride.\" Q J Med 43 (1974): 433-40[32] Perazella MA, Alappan R, Buller GK \"Hyperkalemia and trimethoprim-sulfamethoxazole.\" Ann Intern Med 125 (1996): 1015[33] \"Product Information. Bactrim (trimethoprim-sulfamethoxazole).\" Roche Laboratories, Nutley, NJ.[34] Mihm LB, Rathbun RC, Resmantargoff BH \"Hyperkalemia associated with high-dose trimethoprim-sulfamethoxazole in a patient with the acquired immunodeficiency syndrome.\" Pharmacotherapy 15 (1995): 793-7[35] Lee SW, Park SW, Kang JM \"Intraoperative hyperkalemia induced by administration of trimethoprim-sulfamethoxazole in a patient receiving angiotensin receptor blockers.\" J Clin Anesth 26 (2014): 427-8", "alternatives_a": "Sulfadiazine, Sulfamethoxazole, Sulfamethizole, Sulfisoxazole, Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Rifapentine, Streptomycin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67326, "ingredient1": "Trimipramine", "ingredient2": "Potassium citrate", "severity": "Major", "effect": "Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.", "source": "DDInter", "management_text": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.", "mechanism_text": "Synergism", "recommendation": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67413/", "reference_text": "[1] \"Product Information. K-Dur (potassium chloride).\" Schering Laboratories, Kenilworth, NJ.[2] Wynn V \"Potassium chloride and bowel ulceration.\" Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial.\" Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L \"Ulceration of the small intestine due to slow-release potassium chloride tablets.\" Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ \"Perforation of small bowel due to slow release potassium chloride (slow-K).\" Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ \"Jejunal perforation associated with slow-release potassium chloride therapy.\" South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ \"Ulceration of small intestine and slow-release potassium tablets.\" Br Med J 2 (1975): 746[8] Lambert JR, Newman A \"Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy.\" Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L \"Gastrointestinal lesions and potassium chloride supplements.\" Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA \"Gut lesions due to slow-release KCI tablets.\" N Engl J Med 296 (1977): 111-2[11] \"Product Information. Urocit (potassium citrate).\" Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Effect of potassium chloride supplements on upper gastrointestinal mucosa.\" Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Sanctura (trospium chloride).\" Odyssey Pharmaceutical, East Hanover, NJ.", "alternatives_a": "Citalopram, Sertraline, Fluoxetine, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Isocarboxazid, Viloxazine, Esketamine, More", "alternatives_b": "Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67327, "ingredient1": "Tripelennamine", "ingredient2": "Potassium citrate", "severity": "Major", "effect": "Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.", "source": "DDInter", "management_text": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.", "mechanism_text": "Synergism", "recommendation": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67414/", "reference_text": "[1] \"Product Information. K-Dur (potassium chloride).\" Schering Laboratories, Kenilworth, NJ.[2] Wynn V \"Potassium chloride and bowel ulceration.\" Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial.\" Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L \"Ulceration of the small intestine due to slow-release potassium chloride tablets.\" Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ \"Perforation of small bowel due to slow release potassium chloride (slow-K).\" Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ \"Jejunal perforation associated with slow-release potassium chloride therapy.\" South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ \"Ulceration of small intestine and slow-release potassium tablets.\" Br Med J 2 (1975): 746[8] Lambert JR, Newman A \"Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy.\" Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L \"Gastrointestinal lesions and potassium chloride supplements.\" Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA \"Gut lesions due to slow-release KCI tablets.\" N Engl J Med 296 (1977): 111-2[11] \"Product Information. Urocit (potassium citrate).\" Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Effect of potassium chloride supplements on upper gastrointestinal mucosa.\" Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Sanctura (trospium chloride).\" Odyssey Pharmaceutical, East Hanover, NJ.", "alternatives_a": "Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole, Lidocaine, Tetracaine", "alternatives_b": "Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67328, "ingredient1": "Triprolidine", "ingredient2": "Potassium citrate", "severity": "Major", "effect": "Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.", "source": "DDInter", "management_text": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.", "mechanism_text": "Synergism", "recommendation": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67415/", "reference_text": "[1] \"Product Information. K-Dur (potassium chloride).\" Schering Laboratories, Kenilworth, NJ.[2] Wynn V \"Potassium chloride and bowel ulceration.\" Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial.\" Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L \"Ulceration of the small intestine due to slow-release potassium chloride tablets.\" Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ \"Perforation of small bowel due to slow release potassium chloride (slow-K).\" Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ \"Jejunal perforation associated with slow-release potassium chloride therapy.\" South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ \"Ulceration of small intestine and slow-release potassium tablets.\" Br Med J 2 (1975): 746[8] Lambert JR, Newman A \"Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy.\" Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L \"Gastrointestinal lesions and potassium chloride supplements.\" Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA \"Gut lesions due to slow-release KCI tablets.\" N Engl J Med 296 (1977): 111-2[11] \"Product Information. Urocit (potassium citrate).\" Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Effect of potassium chloride supplements on upper gastrointestinal mucosa.\" Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Sanctura (trospium chloride).\" Odyssey Pharmaceutical, East Hanover, NJ.", "alternatives_a": "Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67329, "ingredient1": "Trospium", "ingredient2": "Potassium citrate", "severity": "Major", "effect": "Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, the class IA antiarrhythmic disopyramide) may potentiate the risk of upper gastrointestinal injury associated with oral solid formulations of potassium citrate. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents, thereby creating a high localized concentration of potassium ions in the region of a dissolving tablet or capsule and increasing the contact time with GI mucosa. Solid formulations of potassium chloride have been associated with upper GI bleeding and small bowel ulceration, stenosis, perforation, and obstruction.", "source": "DDInter", "management_text": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects. A liquid formulation of potassium citrate should be considered. Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.", "mechanism_text": "Synergism", "recommendation": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67416/", "reference_text": "[1] \"Product Information. K-Dur (potassium chloride).\" Schering Laboratories, Kenilworth, NJ.[2] Wynn V \"Potassium chloride and bowel ulceration.\" Br Med J 5477 (1965): 1546[3] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial.\" Lancet 2 (1982): 1059-61[4] Leijonmarck CE, Raf L \"Ulceration of the small intestine due to slow-release potassium chloride tablets.\" Acta Chir Scand 151 (1985): 273-8[5] Farquharson-Roberts MA, Giddings AE, Nunn AJ \"Perforation of small bowel due to slow release potassium chloride (slow-K).\" Br Med J 3 (1975): 206[6] Lofgren RP, Rothe PR, Carlson GJ \"Jejunal perforation associated with slow-release potassium chloride therapy.\" South Med J 75 (1982): 1154-5[7] Heffernan SJ, Murphy JJ \"Ulceration of small intestine and slow-release potassium tablets.\" Br Med J 2 (1975): 746[8] Lambert JR, Newman A \"Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy.\" Am J Gastroenterol 73 (1980): 508-11[9] Leijonmarck CE, Raf L \"Gastrointestinal lesions and potassium chloride supplements.\" Lancet 1 (1985): 56-7[10] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA \"Gut lesions due to slow-release KCI tablets.\" N Engl J Med 296 (1977): 111-2[11] \"Product Information. Urocit (potassium citrate).\" Mission Pharmacal Company, San Antonio, TX.[12] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Effect of potassium chloride supplements on upper gastrointestinal mucosa.\" Clin Pharmacol Ther 35 (1984): 852-5[13] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Sanctura (trospium chloride).\" Odyssey Pharmaceutical, East Hanover, NJ.", "alternatives_a": "Apomorphine, Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Avanafil, More", "alternatives_b": "Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67330, "ingredient1": "Trovafloxacin", "ingredient2": "Potassium citrate", "severity": "Moderate", "effect": "Urinary alkalinizers such as citrates may decrease the solubility of fluoroquinolones in the urine and increase the risk of crystalluria.", "source": "DDInter", "management_text": "Concomitant use should generally be avoided. Patients receiving this combination should be monitored for signs of renal toxicity and crystalluria.", "mechanism_text": "Excretion", "recommendation": "Concomitant use should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67417/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] \"Product Information. Cipro (ciprofloxacin).\" Bayer, West Haven, CT.", "alternatives_a": "Delafloxacin", "alternatives_b": "Potassium chloride, Potassium bicarbonate, Potassium gluconate", "updated_at": 1767369485}, {"id": 67331, "ingredient1": "Cladribine", "ingredient2": "Acetohydroxamic acid", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67418/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Golimumab, Cyclosporine, Antithymocyte immunoglobulin (rabbit), Ravulizumab, Diroximel fumarate, Methotrexate, Inebilizumab, Belumosudil, Ozanimod, Emapalumab, Natalizumab, More", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "updated_at": 1767369485}, {"id": 67332, "ingredient1": "Human adenovirus e serotype 4 strain cl-68578 antigen", "ingredient2": "Cladribine", "severity": "Moderate", "effect": "There are no data regarding the use of live, unattenuated Adenovirus Type 4 and Type 7 vaccine during treatment with immunosuppressive therapies, including alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. It is not known whether immunosuppressed patients may have an increased risk of adverse reactions or a decreased or suboptimal immunologic response to the vaccine.", "source": "DDInter", "management_text": "The safety and efficacy of live, unattenuated Adenovirus Type 4 and Type 7 vaccine have not been established in patients receiving immunosuppressive therapies. Caution is advised.", "mechanism_text": "Others", "recommendation": "The safety and efficacy of live, unattenuated Adenovirus Type 4 and Type 7 vaccine have not been established in patients receiving immunosuppressive therapies.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67419/", "reference_text": "[1] \"Product Information. Adenovirus Vaccine Type 4 and Type 7 (adenovirus vaccine, live).\" Teva Pharmaceuticals USA, North Wales, PA.", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67333, "ingredient1": "Cladribine", "ingredient2": "Aurothioglucose", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67420/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Secukinumab, Canakinumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67334, "ingredient1": "Cladribine", "ingredient2": "Axicabtagene ciloleucel", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67421/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, More", "alternatives_b": "Pertuzumab, Vismodegib, Ivosidenib, Belzutifan, Sonidegib, Mitotane, Porfimer sodium, Estramustine, Celecoxib, Aminolevulinic acid, Tazemetostat, More", "updated_at": 1767369485}, {"id": 67335, "ingredient1": "Cladribine", "ingredient2": "Bacillus calmette-guerin substrain tice live antigen", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67422/", "reference_text": "[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[2] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur, Swiftwater, PA.[3] \"Product Information. Attenuvax (measles virus vaccine, live, attenuated).\" Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] \"Product Information. Meruvax II (rubella virus vaccine, live).\" Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67336, "ingredient1": "Cladribine", "ingredient2": "Belinostat", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67423/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, More", "alternatives_b": "Pertuzumab, Vismodegib, Ivosidenib, Belzutifan, Sonidegib, Mitotane, Porfimer sodium, Estramustine, Celecoxib, Aminolevulinic acid, Tazemetostat, More", "updated_at": 1767369485}, {"id": 67337, "ingredient1": "Cladribine", "ingredient2": "Bifidobacterium longum infantis", "severity": "Moderate", "effect": "Probiotic use during immunosuppressant or intense antineoplastic therapy may theoretically increase the risk of infections from the live microorganisms contained in probiotic products. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy. It may be advisable to avoid using probiotics, particularly products containing saccharomyces boulardii, in patients who are significantly immunosuppressed.", "mechanism_text": "Others", "recommendation": "Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67424/", "reference_text": "[1] Borriello SP, Hammes WP, Holzapfel W, et.al \"Safety of probiotics that contain lactobacilli or bifidobacteria.\" Clin Infect Dis 36 (2003): 775-80[2] Salminen MK, Tynkkynen S, Rautelin H, et al. \"Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland.\" Clin Infect Dis 35 (2002): 1155-60[3] Schlegel L, Lemerle S, Geslin P \"Lactobacillus species as opportunistic pathogens in immunocompromised patients.\" Eur J Clin Microbiol Infect Dis 17 (1998): 887-8[4] Salminen MK, Rautelin H, Tynkkynen S, et al. \"Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG.\" Clin Infect Dis 38 (2004): 62-9[5] Husni RN, Gordon SM, Washington JA, Longworth DL \"Lactobacillus bacteremia and endocarditis: review of 45 cases.\" Clin Infect Dis 25 (1997): 1048-55[6] Boyle RJ, Robins-Browne RM, Tang ML \"Probiotic use in clinical practice: what are the risks?\" Am J Clin Nutr 83 (2006): 1256-64[7] Lolis N, Veldekis D, Moraitou H, et.al \"Saccharomyces boulardii fungaemia in an intensive care unit patient treated with caspofungin.\" Crit Care 12 (2008): epub[8] Rautio M, Jousimies-Somer H, Kauma H, et al. \"Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG.\" Clin Infect Dis 28 (1999): 1159-60[9] Saxelin M, Chuang NH, Chassy B, et.al \"Lactobacilli and bacteremia in southern Finland, 1989-1992\" Clin Infect Dis 22 (1996): 564-6[10] Oggioni MR, Pozzi G, Valensin PE, Galieni P, Bigazzi C \"Recurrent septicemia in an immunocompromised patient due to probiotic strains of Bacillus subtilis.\" J Clin Microbiol 36 (1998): 325-6[11] Mackay AD, Taylor MB, Kibbler CC, Hamilton-Miller JM \"Lactobacillus endocarditis caused by a probiotic organism.\" Clin Microbiol Infect 5 (1999): 290-2", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67338, "ingredient1": "Cladribine", "ingredient2": "Brexucabtagene autoleucel", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67425/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67339, "ingredient1": "Cladribine", "ingredient2": "Candida albicans", "severity": "Moderate", "effect": "Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity. Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67426/", "reference_text": "[1] \"Product Information. Spherulin (coccidioidin skin test).\" ALK Laboratories Inc, Wallingford, CT.[2] \"Product Information. Tuberculin PPD (Mantoux) (tuberculin purified protein derivative).\" Connaught Laboratories Ltd, Toronto, ON.[3] \"Product Information. Candin (candida albicans extract).\" Nielsen Biosciences Inc, San Diego, CA.[4] \"Product Information. MSTA Mumps Skin Test Antigen (mumps skin test antigen).\" Aventis Pharmaceuticals, Swiftwater, PA.[5] \"Product Information. Multitest CMI (skin test antigens, multiple).\" Aventis Pharmaceuticals, Swiftwater, PA.[6] \"Product Information. Histolyn-Cyl (histoplasmin).\" ALK Laboratories Inc, Wallingford, CT.", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67340, "ingredient1": "Cladribine", "ingredient2": "Vibrio cholerae CVD 103-HgR strain live antigen", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67427/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67341, "ingredient1": "Clofarabine", "ingredient2": "Cladribine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67428/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, More", "alternatives_b": "Cladribine", "updated_at": 1767369485}, {"id": 67342, "ingredient1": "Clozapine", "ingredient2": "Cladribine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67429/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Cyclosporine, Ustekinumab, Anifrolumab, Canakinumab, Secukinumab, Ravulizumab, Diroximel fumarate, Abatacept, Anakinra, Apremilast, Inebilizumab, More", "alternatives_b": "Fluphenazine, Haloperidol, Thiothixene, Risperidone, Amisulpride, Quetiapine, Prochlorperazine, Thioridazine, Lumateperone, Pimozide, Trifluoperazine, More", "updated_at": 1767369485}, {"id": 67343, "ingredient1": "Cobimetinib", "ingredient2": "Cladribine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67430/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, More", "alternatives_b": "Dabrafenib, Dacomitinib, Pexidartinib, Larotrectinib, Fedratinib, Vemurafenib, Lapatinib, Selumetinib, Vandetanib, Afatinib, Encorafenib, More", "updated_at": 1767369485}, {"id": 67344, "ingredient1": "Coccidioides immitis spherule", "ingredient2": "Cladribine", "severity": "Moderate", "effect": "Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity. Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67431/", "reference_text": "[1] \"Product Information. Spherulin (coccidioidin skin test).\" ALK Laboratories Inc, Wallingford, CT.[2] \"Product Information. Tuberculin PPD (Mantoux) (tuberculin purified protein derivative).\" Connaught Laboratories Ltd, Toronto, ON.[3] \"Product Information. Candin (candida albicans extract).\" Nielsen Biosciences Inc, San Diego, CA.[4] \"Product Information. MSTA Mumps Skin Test Antigen (mumps skin test antigen).\" Aventis Pharmaceuticals, Swiftwater, PA.[5] \"Product Information. Multitest CMI (skin test antigens, multiple).\" Aventis Pharmaceuticals, Swiftwater, PA.[6] \"Product Information. Histolyn-Cyl (histoplasmin).\" ALK Laboratories Inc, Wallingford, CT.", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67345, "ingredient1": "Colchicine", "ingredient2": "Cladribine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67432/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Secukinumab, Canakinumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Upadacitinib, Siponimod, Anakinra, More", "alternatives_b": "Lesinurad, Febuxostat, Pegloticase, Sulfinpyrazone, Rasburicase, Probenecid", "updated_at": 1767369485}, {"id": 67346, "ingredient1": "Copanlisib", "ingredient2": "Cladribine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67433/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "Dabrafenib, Dacomitinib, Pexidartinib, Larotrectinib, Fedratinib, Vemurafenib, Lapatinib, Selumetinib, Vandetanib, Afatinib, Encorafenib, More", "updated_at": 1767369485}, {"id": 67347, "ingredient1": "Corticotropin", "ingredient2": "Cladribine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67434/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Somatrem, Somatotropin, Mecasermin rinfabate, Pegvisomant, Somapacitan", "updated_at": 1767369485}, {"id": 67348, "ingredient1": "Cladribine", "ingredient2": "Tetracosactide", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67435/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Somatrem, Somatotropin, Mecasermin rinfabate, Pegvisomant, Somapacitan", "updated_at": 1767369485}, {"id": 67349, "ingredient1": "Cyclophosphamide", "ingredient2": "Cladribine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67436/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67350, "ingredient1": "Cyclosporine", "ingredient2": "Cladribine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67437/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Apremilast, Pirfenidone, Cladribine, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab, Alteplase, More", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More", "updated_at": 1767369485}, {"id": 67351, "ingredient1": "Cytarabine", "ingredient2": "Cladribine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67438/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More", "alternatives_b": "Cladribine, Pertuzumab, Vismodegib, Ivosidenib, Belzutifan, Sonidegib, Mitotane, Porfimer sodium, Estramustine, Celecoxib, Aminolevulinic acid, More", "updated_at": 1767369485}, {"id": 67352, "ingredient1": "Cytarabine (liposomal)", "ingredient2": "Cladribine", "severity": "Moderate", "effect": "The use of cladribine with medications that undergo intracellular phosphorylation may reduce its efficacy by inhibiting its phosphorylation to its active form. The clinical significance of this interaction is unknown.", "source": "DDInter", "management_text": "Concomitant use of cladribine with medications that undergo intracellular phosphorylation should be avoided if possible.", "mechanism_text": "Antagonism", "recommendation": "Concomitant use of cladribine with medications that undergo intracellular phosphorylation should be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67439/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Hivid (zalcitabine).\" Roche Laboratories, Nutley, NJ.", "alternatives_a": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More", "alternatives_b": "Cladribine, Pertuzumab, Vismodegib, Ivosidenib, Belzutifan, Sonidegib, Mitotane, Porfimer sodium, Estramustine, Celecoxib, Aminolevulinic acid, More", "updated_at": 1767369485}, {"id": 67353, "ingredient1": "Dacarbazine", "ingredient2": "Cladribine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67440/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67354, "ingredient1": "Dactinomycin", "ingredient2": "Cladribine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67441/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67355, "ingredient1": "Dapsone", "ingredient2": "Cladribine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67442/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Secukinumab, Canakinumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Abatacept, Upadacitinib, Siponimod, More", "alternatives_b": "Minocycline, Clindamycin, Vitamin A, Isotretinoin, Fluorometholone, Tretinoin, Erythromycin, Azelaic acid, Adapalene, Clofazimine", "updated_at": 1767369485}, {"id": 67356, "ingredient1": "Daratumumab", "ingredient2": "Cladribine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67443/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "updated_at": 1767369485}, {"id": 67357, "ingredient1": "Darolutamide", "ingredient2": "Cladribine", "severity": "Moderate", "effect": "Coadministration with darolutamide may increase the plasma concentrations of drugs that are substrates of the breast cancer resistance protein (BCRP) transporter. The proposed mechanism is decreased clearance due to inhibition of BCRP-mediated intestinal and hepatobiliary efflux by darolutamide.", "source": "DDInter", "management_text": "Concomitant use of darolutamide with drugs that are BCRP substrates should be avoided when possible. If coadministration is required, patients should be monitored carefully for increased adverse reactions of these drugs and dosing adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of darolutamide with drugs that are BCRP substrates should be avoided when possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67444/", "reference_text": "[1] \"Product Information. Nubeqa (darolutamide).\" Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.[2] \"Product Information. Venclexta (venetoclax).\" AbbVie US LLC, North Chicago, IL.[3] \"Product Information. Nubeqa (darolutamide).\" Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.", "alternatives_a": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More", "alternatives_b": "Tamoxifen, Anastrozole, Aminoglutethimide, Letrozole, Toremifene, Fulvestrant, Abarelix, Flutamide, Relugolix, Bicalutamide, Degarelix, More", "updated_at": 1767369485}, {"id": 67358, "ingredient1": "Dasatinib", "ingredient2": "Cladribine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67445/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More", "alternatives_b": "Dabrafenib, Dacomitinib, Pexidartinib, Larotrectinib, Fedratinib, Vemurafenib, Lapatinib, Selumetinib, Vandetanib, Afatinib, Encorafenib, More", "updated_at": 1767369485}, {"id": 67359, "ingredient1": "Daunorubicin", "ingredient2": "Cladribine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67446/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More", "alternatives_b": "Pertuzumab, Vismodegib, Ivosidenib, Belzutifan, Sonidegib, Mitotane, Porfimer sodium, Estramustine, Celecoxib, Aminolevulinic acid, Tazemetostat, More", "updated_at": 1767369485}, {"id": 67360, "ingredient1": "Daunorubicin (liposomal)", "ingredient2": "Cladribine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67447/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More", "alternatives_b": "Pertuzumab, Vismodegib, Ivosidenib, Belzutifan, Sonidegib, Mitotane, Porfimer sodium, Estramustine, Celecoxib, Aminolevulinic acid, Tazemetostat, More", "updated_at": 1767369485}, {"id": 67361, "ingredient1": "Decitabine", "ingredient2": "Cladribine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67448/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, More", "alternatives_b": "Cladribine", "updated_at": 1767369485}, {"id": 67362, "ingredient1": "Deferiprone", "ingredient2": "Cladribine", "severity": "Major", "effect": "Coadministration of deferiprone and other drugs that can cause neutropenia or agranulocytosis may increase the risk and/or severity of hematologic toxicity. Deferiprone alone can cause agranulocytosis, which may be preceded by neutropenia.", "source": "DDInter", "management_text": "Concomitant use of deferiprone with other drugs known to be associated with neutropenia or agranulocytosis should generally be avoided. Otherwise, close monitoring of absolute neutrophil count (ANC) is recommended if coadministration is required.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of deferiprone with other drugs known to be associated with neutropenia or agranulocytosis should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67449/", "reference_text": "[1] \"Product Information. Ferriprox (deferiprone).\" ApoPharma USA Inc, Rockville, MD.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Cyclosporine, Ustekinumab, Anifrolumab, Canakinumab, Secukinumab, Ravulizumab, Diroximel fumarate, Tacrolimus, Abatacept, Siponimod, Apremilast, More", "alternatives_b": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Cobicistat, Deferoxamine, Levoleucovorin, More", "updated_at": 1767369485}, {"id": 67363, "ingredient1": "Deflazacort", "ingredient2": "Cladribine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67450/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, Belumosudil, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67364, "ingredient1": "Denileukin diftitox", "ingredient2": "Cladribine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67451/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Pertuzumab, Vismodegib, Ivosidenib, Belzutifan, Sonidegib, Mitotane, Porfimer sodium, Estramustine, Celecoxib, Aminolevulinic acid, Tazemetostat, More", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, More", "updated_at": 1767369485}, {"id": 67365, "ingredient1": "Denosumab", "ingredient2": "Cladribine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67452/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Voclosporin, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "Tiludronic acid, Alendronic acid, Vosoritide, Etidronic acid, Ibandronate, Cholecalciferol, Burosumab, Risedronic acid, Romosozumab, Zoledronic acid, Pamidronic acid", "updated_at": 1767369485}, {"id": 67366, "ingredient1": "Didanosine", "ingredient2": "Cladribine", "severity": "Moderate", "effect": "The use of cladribine with medications that undergo intracellular phosphorylation may reduce its efficacy by inhibiting its phosphorylation to its active form. The clinical significance of this interaction is unknown.", "source": "DDInter", "management_text": "Concomitant use of cladribine with medications that undergo intracellular phosphorylation should be avoided if possible.", "mechanism_text": "Antagonism", "recommendation": "Concomitant use of cladribine with medications that undergo intracellular phosphorylation should be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67453/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Hivid (zalcitabine).\" Roche Laboratories, Nutley, NJ.", "alternatives_a": "Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Tacrolimus, Abatacept, Upadacitinib, More", "alternatives_b": "Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Telaprevir, Velpatasvir, Rilpivirine, Etravirine, More", "updated_at": 1767369485}, {"id": 67367, "ingredient1": "Dimethyl fumarate", "ingredient2": "Cladribine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67454/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Dimethyl fumarate, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "Apremilast, Pirfenidone, Cladribine, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "updated_at": 1767369485}, {"id": 67368, "ingredient1": "Dinutuximab", "ingredient2": "Cladribine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67455/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Secukinumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "updated_at": 1767369485}, {"id": 67369, "ingredient1": "Diroximel fumarate", "ingredient2": "Cladribine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67456/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Diroximel fumarate, Sutimlimab", "alternatives_b": "Apremilast, Pirfenidone, Cladribine, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "updated_at": 1767369485}, {"id": 67370, "ingredient1": "Docetaxel", "ingredient2": "Cladribine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67457/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67371, "ingredient1": "Doxorubicin", "ingredient2": "Cladribine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67458/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67372, "ingredient1": "Doxorubicin (liposomal)", "ingredient2": "Cladribine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67459/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67373, "ingredient1": "Drospirenone", "ingredient2": "Cladribine", "severity": "Moderate", "effect": "RECOMMENDED: Coadministration with cladribine may reduce the efficacy of hormonal contraceptives. The mechanism has not been established. There are no clinical data regarding the use of cladribine with hormonal contraceptives.", "source": "DDInter", "management_text": "Although the clinical significance of this interaction is unknown, caution is advised when cladribine is prescribed concomitantly with hormonal contraceptives because of the potential to cause fetal harm. Women should avoid becoming pregnant during treatment with cladribine and for at least 6 months after the last dose in each treatment course. Women using hormonal contraceptives should add a barrier method during cladribine dosing and for at least 4 weeks after the last dose in each treatment cycle. In addition, male patients should take precautions to prevent pregnancy of their partner during cladribine dosing and for at least 6 months after the last dose in each treatment course.", "mechanism_text": "Others", "recommendation": "Although the clinical significance of this interaction is unknown, caution is advised when cladribine is prescribed concomitantly with hormonal contraceptives because of the potential to cause fetal harm.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67460/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[8] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[11] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[12] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[13] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[14] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[15] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[16] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[17] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[18] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[19] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[20] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[21] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[22] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[23] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[24] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[25] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[26] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[27] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[28] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[29] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[30] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[31] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[32] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[33] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[34] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[35] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[36] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[37] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[38] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[39] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[40] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Methotrexate, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, Belumosudil, More", "alternatives_b": "Megestrol acetate, Estetrol, Ulipristal, Estradiol, Megestrol acetate, Progesterone, Estradiol", "updated_at": 1767369485}, {"id": 67374, "ingredient1": "Dupilumab", "ingredient2": "Cladribine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67461/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "Minoxidil, Deoxycholic acid, Calcium gluconate, Magnesium sulfate, Glycopyrronium, Pimecrolimus, Aminobenzoic acid, Ivermectin, Caffeine, Diclofenac, Cromoglicic acid, More", "updated_at": 1767369485}, {"id": 67375, "ingredient1": "Durvalumab", "ingredient2": "Cladribine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67462/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "updated_at": 1767369485}, {"id": 67376, "ingredient1": "Duvelisib", "ingredient2": "Cladribine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67463/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, Belimumab, More", "alternatives_b": "Dabrafenib, Dacomitinib, Pexidartinib, Larotrectinib, Fedratinib, Vemurafenib, Lapatinib, Selumetinib, Vandetanib, Afatinib, Encorafenib, More", "updated_at": 1767369485}, {"id": 67377, "ingredient1": "Efalizumab", "ingredient2": "Cladribine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67464/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Apremilast, Pirfenidone, Cladribine, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab, Efalizumab", "updated_at": 1767369485}, {"id": 67378, "ingredient1": "Elotuzumab", "ingredient2": "Cladribine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67465/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Secukinumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "updated_at": 1767369485}, {"id": 67379, "ingredient1": "Eltrombopag", "ingredient2": "Cladribine", "severity": "Moderate", "effect": "Oral bioavailability and systemic exposure of cladribine may be increased by potent inhibitors of breast cancer resistance protein (BCRP) while intracellular distribution and renal elimination of cladribine may be altered by potent inhibitors of equilibrative nucleoside transporter 1 (ENT1) and concentrative nucleoside transporter 3 (CNT3). The mechanism involves inhibition of ENT1, CNT3, and/or BCRP as cladribine is a substrate of each of these transporter systems.", "source": "DDInter", "management_text": "Coadministration of potent ENT1, CNT3, or BCRP transporter inhibitors should be avoided during the 4 to 5-day oral cladribine treatment cycles. If coadministration is required, consider concomitant alternatives that exhibit no or minimal inhibition of ENT1, CNT3, or BCRP. If this is not possible, dose reduction to the minimum mandatory dose, separation in the timing of administration, and careful patient monitoring is recommended.", "mechanism_text": "Absorption, Distribution, Excretion", "recommendation": "Coadministration of potent ENT1, CNT3, or BCRP transporter inhibitors should be avoided during the 4 to 5-day oral cladribine treatment cycles.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67466/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Tacrolimus, More", "alternatives_b": "Romiplostim, Fostamatinib, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, More", "updated_at": 1767369485}, {"id": 67380, "ingredient1": "Emtricitabine", "ingredient2": "Cladribine", "severity": "Moderate", "effect": "The use of cladribine with medications that undergo intracellular phosphorylation may reduce its efficacy by inhibiting its phosphorylation to its active form. The clinical significance of this interaction is unknown.", "source": "DDInter", "management_text": "Concomitant use of cladribine with medications that undergo intracellular phosphorylation should be avoided if possible.", "mechanism_text": "Antagonism", "recommendation": "Concomitant use of cladribine with medications that undergo intracellular phosphorylation should be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67467/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Hivid (zalcitabine).\" Roche Laboratories, Nutley, NJ.", "alternatives_a": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More", "alternatives_b": "Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Telaprevir, Velpatasvir, Rilpivirine, Etravirine, More", "updated_at": 1767369485}, {"id": 67381, "ingredient1": "Enasidenib", "ingredient2": "Cladribine", "severity": "Moderate", "effect": "Based on in vitro data, coadministration with enasidenib may increase the plasma concentrations of drugs that are substrates of the transporters, organic anion transporting polypeptides (OATP) 1B1/1B3 and breast cancer resistance protein (BCRP). The proposed mechanism is decreased clearance due to enasidenib -mediated inhibition of OATP1B1/1B3 and BCRP transporters.", "source": "DDInter", "management_text": "Caution is advised when enasidenib is used concurrently with medications that are substrates of OATP 1B1/1B3 and/or BCRP, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever enasidenib is added to or withdrawn from therapy.", "mechanism_text": "Distribution", "recommendation": "Caution is advised when enasidenib is used concurrently with medications that are substrates of OATP 1B1/1B3 and/or BCRP, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67468/", "reference_text": "[1] \"Product Information. Idhifa (enasidenib).\" Celgene Corporation, Summit, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Mavyret (glecaprevir-pibrentasvir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More", "alternatives_b": "Pertuzumab, Vismodegib, Ivosidenib, Belzutifan, Sonidegib, Mitotane, Porfimer sodium, Estramustine, Celecoxib, Aminolevulinic acid, Tazemetostat, More", "updated_at": 1767369485}, {"id": 67382, "ingredient1": "Enfortumab vedotin", "ingredient2": "Cladribine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67469/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "updated_at": 1767369485}, {"id": 67383, "ingredient1": "Entecavir", "ingredient2": "Cladribine", "severity": "Moderate", "effect": "The use of cladribine with medications that undergo intracellular phosphorylation may reduce its efficacy by inhibiting its phosphorylation to its active form. The clinical significance of this interaction is unknown.", "source": "DDInter", "management_text": "Concomitant use of cladribine with medications that undergo intracellular phosphorylation should be avoided if possible.", "mechanism_text": "Antagonism", "recommendation": "Concomitant use of cladribine with medications that undergo intracellular phosphorylation should be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67470/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Hivid (zalcitabine).\" Roche Laboratories, Nutley, NJ.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, More", "alternatives_b": "Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Telaprevir, Velpatasvir, Rilpivirine, Etravirine, More", "updated_at": 1767369485}, {"id": 67384, "ingredient1": "Entrectinib", "ingredient2": "Cladribine", "severity": "Moderate", "effect": "Coadministration with entrectinib may increase the plasma concentrations of drugs that are substrates of the breast cancer resistance protein (BCRP) transporter. The proposed mechanisms, based on in vitro data, is decreased clearance due to entrectinib-mediated inhibition of BCRP transport protein.", "source": "DDInter", "management_text": "Caution is advised when entrectinib is prescribed with drugs that are BCRP substrates, particularly those with a narrow therapeutic range such as methotrexate, mitoxantrone, topotecan, and lapatinib. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever entrectinib is added to or withdrawn from therapy.", "mechanism_text": "Others", "recommendation": "Caution is advised when entrectinib is prescribed with drugs that are BCRP substrates, particularly those with a narrow therapeutic range such as methotrexate, mitoxantrone, topotecan, and lapatinib.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67471/", "reference_text": "[1] \"Product Information. Rozlytrek (entrectinib).\" Genentech, South San Francisco, CA.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Rozlytrek (entrectinib).\" Genentech, South San Francisco, CA.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Dabrafenib, Dacomitinib, Pexidartinib, Larotrectinib, Fedratinib, Vemurafenib, Lapatinib, Selumetinib, Vandetanib, Afatinib, Encorafenib, More", "updated_at": 1767369485}, {"id": 67385, "ingredient1": "Enzalutamide", "ingredient2": "Cladribine", "severity": "Moderate", "effect": "Cladribine exposure may be decreased by potent inducers of breast cancer resistance protein (BCRP) or P-glycoprotein (P-gp). The mechanism involves induction of BCRP and/or P-gp as cladribine is a substrate of each of these transporter systems. The clinical relevance remains unknown.", "source": "DDInter", "management_text": "Possible decreases in cladribine exposure and efficacy should be considered if potent inducers of BCRP or P-gp are coadministered.", "mechanism_text": "Others", "recommendation": "Possible decreases in cladribine exposure and efficacy should be considered if potent inducers of BCRP or P-gp are coadministered.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67472/", "reference_text": "[1] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8[5] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Tamoxifen, Anastrozole, Aminoglutethimide, Letrozole, Toremifene, Fulvestrant, Abarelix, Flutamide, Relugolix, Bicalutamide, Degarelix, More", "updated_at": 1767369485}, {"id": 67386, "ingredient1": "Epirubicin", "ingredient2": "Cladribine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67473/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67387, "ingredient1": "Eribulin", "ingredient2": "Cladribine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67474/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More", "alternatives_b": "Pertuzumab, Vismodegib, Ivosidenib, Belzutifan, Sonidegib, Mitotane, Porfimer sodium, Estramustine, Celecoxib, Aminolevulinic acid, Tazemetostat, More", "updated_at": 1767369485}, {"id": 67388, "ingredient1": "Etanercept", "ingredient2": "Cladribine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67475/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Apremilast, Pirfenidone, Cladribine, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Etanercept, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "updated_at": 1767369485}, {"id": 67389, "ingredient1": "Ethotoin", "ingredient2": "Cladribine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67476/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Golimumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Tacrolimus, Abatacept, Upadacitinib, More", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, More", "updated_at": 1767369485}, {"id": 67390, "ingredient1": "Etonogestrel", "ingredient2": "Cladribine", "severity": "Moderate", "effect": "RECOMMENDED: Coadministration with cladribine may reduce the efficacy of hormonal contraceptives. The mechanism has not been established. There are no clinical data regarding the use of cladribine with hormonal contraceptives.", "source": "DDInter", "management_text": "Although the clinical significance of this interaction is unknown, caution is advised when cladribine is prescribed concomitantly with hormonal contraceptives because of the potential to cause fetal harm. Women should avoid becoming pregnant during treatment with cladribine and for at least 6 months after the last dose in each treatment course. Women using hormonal contraceptives should add a barrier method during cladribine dosing and for at least 4 weeks after the last dose in each treatment cycle. In addition, male patients should take precautions to prevent pregnancy of their partner during cladribine dosing and for at least 6 months after the last dose in each treatment course.", "mechanism_text": "Others", "recommendation": "Although the clinical significance of this interaction is unknown, caution is advised when cladribine is prescribed concomitantly with hormonal contraceptives because of the potential to cause fetal harm.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67477/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[8] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[11] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[12] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[13] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[14] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[15] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[16] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[17] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[18] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[19] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[20] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[21] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[22] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[23] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[24] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[25] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[26] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[27] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[28] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[29] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[30] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[31] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[32] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[33] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[34] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[35] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[36] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[37] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[38] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[39] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[40] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Methotrexate, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, Belumosudil, More", "alternatives_b": "Megestrol acetate, Estetrol, Ulipristal, Estradiol", "updated_at": 1767369485}, {"id": 67391, "ingredient1": "Etoposide", "ingredient2": "Cladribine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67478/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67392, "ingredient1": "Everolimus", "ingredient2": "Cladribine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67479/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, Belimumab, More", "alternatives_b": "Dabrafenib, Dacomitinib, Pexidartinib, Larotrectinib, Fedratinib, Vemurafenib, Lapatinib, Selumetinib, Vandetanib, Afatinib, Encorafenib, More", "updated_at": 1767369485}, {"id": 67393, "ingredient1": "Cladribine", "ingredient2": "Trastuzumab deruxtecan", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67480/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "updated_at": 1767369485}, {"id": 67394, "ingredient1": "Famciclovir", "ingredient2": "Cladribine", "severity": "Moderate", "effect": "The use of cladribine with medications that undergo intracellular phosphorylation may reduce its efficacy by inhibiting its phosphorylation to its active form. The clinical significance of this interaction is unknown.", "source": "DDInter", "management_text": "Concomitant use of cladribine with medications that undergo intracellular phosphorylation should be avoided if possible.", "mechanism_text": "Antagonism", "recommendation": "Concomitant use of cladribine with medications that undergo intracellular phosphorylation should be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67481/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Hivid (zalcitabine).\" Roche Laboratories, Nutley, NJ.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Telaprevir, Velpatasvir, Rilpivirine, Etravirine, More", "updated_at": 1767369485}, {"id": 67395, "ingredient1": "Felbamate", "ingredient2": "Cladribine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67482/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Golimumab, Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, More", "updated_at": 1767369485}, {"id": 67396, "ingredient1": "Filgrastim", "ingredient2": "Cladribine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67483/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Oprelvekin, Elapegademase, Histamine, Pegademase, Glatiramer", "alternatives_b": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More", "updated_at": 1767369485}, {"id": 67397, "ingredient1": "Fingolimod", "ingredient2": "Cladribine", "severity": "Major", "effect": "Coadministration of fingolimod with antineoplastic, immunosuppressive, or other immune-modulating therapies may increase the risk of infections. Fingolimod causes reversible sequestration of lymphocytes in lymphoid tissues.", "source": "DDInter", "management_text": "The safety and efficacy of fingolimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated. Caution is advised during coadministration. A complete blood count is recommended prior to starting fingolimod if a recent one (i.e., within last 6 months) is not available.", "mechanism_text": "Synergism", "recommendation": "The safety and efficacy of fingolimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67484/", "reference_text": "[1] \"Product Information. Gilenya (fingolimod).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Pegcetacoplan, Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Fingolimod, Eculizumab, Sutimlimab", "alternatives_b": "Apremilast, Pirfenidone, Cladribine, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "updated_at": 1767369485}, {"id": 67398, "ingredient1": "Floxuridine", "ingredient2": "Cladribine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67485/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "Cladribine", "updated_at": 1767369485}, {"id": 67399, "ingredient1": "Flucytosine", "ingredient2": "Cladribine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67486/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Golimumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, Upadacitinib, More", "alternatives_b": "Fluconazole, Caspofungin, Amphotericin B, Itraconazole, Miconazole, Micafungin, Posaconazole, Ketoconazole, Anidulafungin, Voriconazole, Salicylic acid, More", "updated_at": 1767369485}, {"id": 67400, "ingredient1": "Fludarabine", "ingredient2": "Cladribine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67487/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More", "alternatives_b": "Cladribine", "updated_at": 1767369485}, {"id": 67401, "ingredient1": "Fludrocortisone", "ingredient2": "Cladribine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67488/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, More", "alternatives_b": "Fluocinolone acetonide, Fluorometholone, Indomethacin, Fluocinolone acetonide, Diclofenac", "updated_at": 1767369485}, {"id": 67402, "ingredient1": "Fluorouracil", "ingredient2": "Cladribine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67489/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, More", "alternatives_b": "Cladribine", "updated_at": 1767369485}, {"id": 67403, "ingredient1": "Fluticasone", "ingredient2": "Cladribine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67490/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Ipratropium, Cromoglicic acid, Revefenacin, Nedocromil, Tiotropium, Beclomethasone dipropionate, Mometasone furoate, More", "updated_at": 1767369485}, {"id": 67404, "ingredient1": "Glasdegib", "ingredient2": "Cladribine", "severity": "Moderate", "effect": "Coadministration with glasdegib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) efflux transporters.", "source": "DDInter", "management_text": "Caution is advised if glasdegib is coadministered with drugs that are substrates of P-gp and/or BCRP, particularly those with a narrow therapeutic range. Clinical and laboratory monitoring should be considered whenever glasdegib is added to or withdrawn from therapy with these drugs, and dosages adjusted as necessary. Patients should be monitored for the development of adverse effects.", "mechanism_text": "Absorption", "recommendation": "Caution is advised if glasdegib is coadministered with drugs that are substrates of P-gp and/or BCRP, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67491/", "reference_text": "[1] \"Product Information. Daurismo (glasdegib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Daurismo (glasdegib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Pertuzumab, Vismodegib, Ivosidenib, Belzutifan, Sonidegib, Mitotane, Porfimer sodium, Estramustine, Celecoxib, Aminolevulinic acid, Tazemetostat, More", "updated_at": 1767369485}, {"id": 67405, "ingredient1": "Cladribine", "ingredient2": "Sodium aurothiomalate", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67492/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Secukinumab, Canakinumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67406, "ingredient1": "Golimumab", "ingredient2": "Cladribine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67493/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Golimumab, Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "Apremilast, Pirfenidone, Cladribine, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "updated_at": 1767369485}, {"id": 67407, "ingredient1": "Guanidine", "ingredient2": "Cladribine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67494/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Golimumab, Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67408, "ingredient1": "Guselkumab", "ingredient2": "Cladribine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67495/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, More", "alternatives_b": "Apremilast, Pirfenidone, Cladribine, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "updated_at": 1767369485}, {"id": 67409, "ingredient1": "Hepatitis A Vaccine", "ingredient2": "Cladribine", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67496/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67410, "ingredient1": "Hepatitis B Vaccine (Recombinant)", "ingredient2": "Cladribine", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67497/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67411, "ingredient1": "Human papillomavirus type 11 L1 capsid protein antigen", "ingredient2": "Cladribine", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67498/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67412, "ingredient1": "Hydroxyurea", "ingredient2": "Cladribine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67499/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, More", "alternatives_b": "Pertuzumab, Vismodegib, Ivosidenib, Belzutifan, Sonidegib, Mitotane, Porfimer sodium, Estramustine, Celecoxib, Aminolevulinic acid, Tazemetostat, More", "updated_at": 1767369485}, {"id": 67413, "ingredient1": "Ibritumomab tiuxetan", "ingredient2": "Cladribine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67500/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Iodide I-131", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, More", "updated_at": 1767369485}, {"id": 67414, "ingredient1": "Ibrutinib", "ingredient2": "Cladribine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67501/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, More", "alternatives_b": "Dabrafenib, Dacomitinib, Pexidartinib, Larotrectinib, Fedratinib, Vemurafenib, Lapatinib, Selumetinib, Vandetanib, Afatinib, Encorafenib, More", "updated_at": 1767369485}, {"id": 67415, "ingredient1": "Idarubicin", "ingredient2": "Cladribine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67502/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67416, "ingredient1": "Idelalisib", "ingredient2": "Cladribine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67503/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Secukinumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, Belimumab, Emapalumab, More", "alternatives_b": "Dabrafenib, Dacomitinib, Pexidartinib, Larotrectinib, Fedratinib, Vemurafenib, Lapatinib, Selumetinib, Vandetanib, Afatinib, Encorafenib, More", "updated_at": 1767369485}, {"id": 67417, "ingredient1": "Ifosfamide", "ingredient2": "Cladribine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67504/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67418, "ingredient1": "Imatinib", "ingredient2": "Cladribine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67505/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Ozanimod, More", "alternatives_b": "Dabrafenib, Dacomitinib, Pexidartinib, Larotrectinib, Fedratinib, Vemurafenib, Lapatinib, Selumetinib, Vandetanib, Afatinib, Encorafenib, More", "updated_at": 1767369485}, {"id": 67419, "ingredient1": "Inebilizumab", "ingredient2": "Cladribine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67506/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "Apremilast, Pirfenidone, Cladribine, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "updated_at": 1767369485}, {"id": 67420, "ingredient1": "Infliximab", "ingredient2": "Cladribine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67507/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Apremilast, Pirfenidone, Cladribine, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Infliximab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "updated_at": 1767369485}, {"id": 67421, "ingredient1": "Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)", "ingredient2": "Cladribine", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67508/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67422, "ingredient1": "Influenza A virus A/Vietnam/1194/2004 (H5N1) antigen (formaldehyde inactivated)", "ingredient2": "Cladribine", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67509/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67423, "ingredient1": "Inotuzumab ozogamicin", "ingredient2": "Cladribine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67510/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "updated_at": 1767369485}, {"id": 67424, "ingredient1": "Interferon alfa-2a, Recombinant", "ingredient2": "Cladribine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67511/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Secukinumab, Canakinumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Anakinra, Apremilast, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67425, "ingredient1": "Interferon alfa-2b", "ingredient2": "Cladribine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67512/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Oprelvekin, Elapegademase, Histamine, Pegademase, Glatiramer", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Secukinumab, Canakinumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Anakinra, Apremilast, More", "updated_at": 1767369485}, {"id": 67426, "ingredient1": "Interferon alfa-n1", "ingredient2": "Cladribine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67513/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Oprelvekin, Elapegademase, Histamine, Pegademase, Glatiramer", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Secukinumab, Canakinumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Anakinra, Apremilast, More", "updated_at": 1767369485}, {"id": 67427, "ingredient1": "Interferon alfa-n3", "ingredient2": "Cladribine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67514/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Golimumab, Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67428, "ingredient1": "Interferon alfacon-1", "ingredient2": "Cladribine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67515/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Oprelvekin, Elapegademase, Histamine, Pegademase, Glatiramer", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Secukinumab, Canakinumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Anakinra, Apremilast, More", "updated_at": 1767369485}, {"id": 67429, "ingredient1": "Interferon beta-1a", "ingredient2": "Cladribine", "severity": "Moderate", "effect": "The use of cladribine with beta interferons may increase the risk of lymphopenia. The mechanism involves additive risk of lymphopenia.", "source": "DDInter", "management_text": "Concomitant use of cladribine and beta interferons is not recommended.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of cladribine and beta interferons is not recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67516/", "reference_text": "[1] Montalban X, Leist TP, Cohen BA, et.al \"Cladribine tablets added to IFN- in active relapsing MS: The ONWARD study.\" Neurol Neruroimmunol Neuroinflamm 11 (2018): e477[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Oprelvekin, Elapegademase, Histamine, Pegademase, Glatiramer", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Secukinumab, Canakinumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Upadacitinib, Anakinra, More", "updated_at": 1767369485}, {"id": 67430, "ingredient1": "Interferon beta-1b", "ingredient2": "Cladribine", "severity": "Moderate", "effect": "The use of cladribine with beta interferons may increase the risk of lymphopenia. The mechanism involves additive risk of lymphopenia.", "source": "DDInter", "management_text": "Concomitant use of cladribine and beta interferons is not recommended.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of cladribine and beta interferons is not recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67517/", "reference_text": "[1] Montalban X, Leist TP, Cohen BA, et.al \"Cladribine tablets added to IFN- in active relapsing MS: The ONWARD study.\" Neurol Neruroimmunol Neuroinflamm 11 (2018): e477[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Oprelvekin, Elapegademase, Histamine, Pegademase, Glatiramer", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Upadacitinib, More", "updated_at": 1767369485}, {"id": 67431, "ingredient1": "Interferon gamma-1b", "ingredient2": "Cladribine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67518/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Golimumab, Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67432, "ingredient1": "Iobenguane (I-131)", "ingredient2": "Cladribine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67519/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67433, "ingredient1": "Cladribine", "ingredient2": "Tositumomab (I-131)", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67520/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67434, "ingredient1": "Irinotecan", "ingredient2": "Cladribine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67521/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, Belumosudil, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67435, "ingredient1": "Irinotecan (liposomal)", "ingredient2": "Cladribine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67522/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67436, "ingredient1": "Isatuximab", "ingredient2": "Cladribine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67523/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "updated_at": 1767369485}, {"id": 67437, "ingredient1": "Cladribine", "ingredient2": "Ixabepilone", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67524/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67438, "ingredient1": "Cladribine", "ingredient2": "Ixazomib", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67525/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Secukinumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More", "alternatives_b": "Pertuzumab, Vismodegib, Ivosidenib, Belzutifan, Sonidegib, Mitotane, Porfimer sodium, Estramustine, Celecoxib, Aminolevulinic acid, Tazemetostat, More", "updated_at": 1767369485}, {"id": 67439, "ingredient1": "Cladribine", "ingredient2": "Ixekizumab", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67526/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, More", "alternatives_b": "Apremilast, Pirfenidone, Cladribine, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "updated_at": 1767369485}, {"id": 67440, "ingredient1": "Cladribine", "ingredient2": "Lactobacillus acidophilus", "severity": "Moderate", "effect": "Probiotic use during immunosuppressant or intense antineoplastic therapy may theoretically increase the risk of infections from the live microorganisms contained in probiotic products. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy. It may be advisable to avoid using probiotics, particularly products containing saccharomyces boulardii, in patients who are significantly immunosuppressed.", "mechanism_text": "Others", "recommendation": "Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67527/", "reference_text": "[1] Borriello SP, Hammes WP, Holzapfel W, et.al \"Safety of probiotics that contain lactobacilli or bifidobacteria.\" Clin Infect Dis 36 (2003): 775-80[2] Salminen MK, Tynkkynen S, Rautelin H, et al. \"Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland.\" Clin Infect Dis 35 (2002): 1155-60[3] Schlegel L, Lemerle S, Geslin P \"Lactobacillus species as opportunistic pathogens in immunocompromised patients.\" Eur J Clin Microbiol Infect Dis 17 (1998): 887-8[4] Salminen MK, Rautelin H, Tynkkynen S, et al. \"Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG.\" Clin Infect Dis 38 (2004): 62-9[5] Husni RN, Gordon SM, Washington JA, Longworth DL \"Lactobacillus bacteremia and endocarditis: review of 45 cases.\" Clin Infect Dis 25 (1997): 1048-55[6] Boyle RJ, Robins-Browne RM, Tang ML \"Probiotic use in clinical practice: what are the risks?\" Am J Clin Nutr 83 (2006): 1256-64[7] Lolis N, Veldekis D, Moraitou H, et.al \"Saccharomyces boulardii fungaemia in an intensive care unit patient treated with caspofungin.\" Crit Care 12 (2008): epub[8] Rautio M, Jousimies-Somer H, Kauma H, et al. \"Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG.\" Clin Infect Dis 28 (1999): 1159-60[9] Saxelin M, Chuang NH, Chassy B, et.al \"Lactobacilli and bacteremia in southern Finland, 1989-1992\" Clin Infect Dis 22 (1996): 564-6[10] Oggioni MR, Pozzi G, Valensin PE, Galieni P, Bigazzi C \"Recurrent septicemia in an immunocompromised patient due to probiotic strains of Bacillus subtilis.\" J Clin Microbiol 36 (1998): 325-6[11] Mackay AD, Taylor MB, Kibbler CC, Hamilton-Miller JM \"Lactobacillus endocarditis caused by a probiotic organism.\" Clin Microbiol Infect 5 (1999): 290-2", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67441, "ingredient1": "Cladribine", "ingredient2": "Lasmiditan", "severity": "Moderate", "effect": "Coadministration with lasmiditan may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) transporters. The proposed mechanism, based on in vitro data, involves decreased clearance due to inhibition of P-gp and BCRP by lasmiditan.", "source": "DDInter", "management_text": "Concomitant use of lasmiditan with drugs that are P-gp and/or BCRP substrates should be avoided when possible. If coadministration is required, patients should be carefully monitored for increased adverse reactions of these drugs and dosing adjusted as necessary.", "mechanism_text": "Distribution", "recommendation": "Concomitant use of lasmiditan with drugs that are P-gp and/or BCRP substrates should be avoided when possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67528/", "reference_text": "[1] \"Product Information. Reyvow (lasmiditan).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Tacrolimus, More", "alternatives_b": "Frovatriptan, Dihydroergotamine, Rimegepant, Eptinezumab, Atogepant, Eletriptan, Rizatriptan, Ubrogepant, Ergotamine, Clonidine, Naratriptan, More", "updated_at": 1767369485}, {"id": 67442, "ingredient1": "Cladribine", "ingredient2": "Leflunomide", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67529/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Apremilast, Belumosudil, Leflunomide, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "Apremilast, Pirfenidone, Cladribine, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "updated_at": 1767369485}, {"id": 67443, "ingredient1": "Cladribine", "ingredient2": "Lenalidomide", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67530/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More", "alternatives_b": "Apremilast, Pirfenidone, Cladribine, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "updated_at": 1767369485}, {"id": 67444, "ingredient1": "Cladribine", "ingredient2": "Levamisole", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67531/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, More", "alternatives_b": "Thiabendazole, Pyrantel, Ivermectin, Piperazine, Mebendazole", "updated_at": 1767369485}, {"id": 67445, "ingredient1": "Cladribine", "ingredient2": "Linezolid", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67532/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More", "alternatives_b": "Tinidazole, Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Metronidazole, Telavancin, Methenamine, Spectinomycin, Nitrofurantoin, More", "updated_at": 1767369485}, {"id": 67446, "ingredient1": "Cladribine", "ingredient2": "Lomustine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67533/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67447, "ingredient1": "Cladribine", "ingredient2": "Lonafarnib", "severity": "Moderate", "effect": "Coadministration with lonafarnib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) efflux transporter.", "source": "DDInter", "management_text": "Caution is advised when lonafarnib is used concomitantly with drugs that are sensitive P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever lonafarnib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when lonafarnib is used concomitantly with drugs that are sensitive P-gp substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67534/", "reference_text": "[1] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.[2] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 67448, "ingredient1": "Cladribine", "ingredient2": "Lorlatinib", "severity": "Moderate", "effect": "Coadministration of lorlatinib with drugs that are P-glycoprotein (P-gp) substrates may decrease the plasma concentration and pharmacologic effect of the P-gp substrate. The proposed mechanism is induction of P-gp mediated drug efflux by lorlatinib.", "source": "DDInter", "management_text": "Concomitant use of lorlatinib with drugs that are P-gp substrates should generally be avoided, especially those P-gp substrates for which minimal concentration changes may lead to serious therapeutic failures. If coadministration is required, consider dosage adjustments and clinical and laboratory monitoring whenever lorlatinib is added to or withdrawn from therapy.", "mechanism_text": "Excretion", "recommendation": "Concomitant use of lorlatinib with drugs that are P-gp substrates should generally be avoided, especially those P-gp substrates for which minimal concentration changes may lead to serious therapeutic failures.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67535/", "reference_text": "[1] \"Product Information. Lorbrena (lorlatinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Lorbrena (lorlatinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Methotrexate, Abatacept, More", "alternatives_b": "Dabrafenib, Dacomitinib, Pexidartinib, Larotrectinib, Fedratinib, Vemurafenib, Lapatinib, Selumetinib, Vandetanib, Afatinib, Encorafenib, More", "updated_at": 1767369485}, {"id": 67449, "ingredient1": "Cladribine", "ingredient2": "Lurbinectedin", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67536/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, More", "alternatives_b": "Pertuzumab, Vismodegib, Ivosidenib, Belzutifan, Sonidegib, Mitotane, Porfimer sodium, Estramustine, Celecoxib, Aminolevulinic acid, Tazemetostat, More", "updated_at": 1767369485}, {"id": 67450, "ingredient1": "Cladribine", "ingredient2": "Lutetium Lu 177 dotatate", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67537/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67451, "ingredient1": "Cladribine", "ingredient2": "Lyme disease vaccine (recombinant OspA)", "severity": "Moderate", "effect": "The administration of Lyme disease vaccine to immunosuppressed patients may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "The manufacturer suggests considering deferral of vaccination against Lyme disease until 3 months after discontinuation of immunosuppressive therapy. Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "The manufacturer suggests considering deferral of vaccination against Lyme disease until 3 months after discontinuation of immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67538/", "reference_text": "[1] \"Product Information. Lymerix (Lyme disease vaccine).\" SmithKline Beecham, Philadelphia, PA.", "alternatives_a": "Spesolimab, Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Daclizumab, Emapalumab, Eculizumab, Anifrolumab, Deucravacitinib, Ponesimod, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67452, "ingredient1": "Cladribine", "ingredient2": "Measles virus vaccine live attenuated", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67539/", "reference_text": "[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[2] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur, Swiftwater, PA.[3] \"Product Information. Attenuvax (measles virus vaccine, live, attenuated).\" Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] \"Product Information. Meruvax II (rubella virus vaccine, live).\" Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67453, "ingredient1": "Cladribine", "ingredient2": "Mechlorethamine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67540/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67454, "ingredient1": "Cladribine", "ingredient2": "Medroxyprogesterone acetate", "severity": "Moderate", "effect": "RECOMMENDED: Coadministration with cladribine may reduce the efficacy of hormonal contraceptives. The mechanism has not been established. There are no clinical data regarding the use of cladribine with hormonal contraceptives.", "source": "DDInter", "management_text": "Although the clinical significance of this interaction is unknown, caution is advised when cladribine is prescribed concomitantly with hormonal contraceptives because of the potential to cause fetal harm. Women should avoid becoming pregnant during treatment with cladribine and for at least 6 months after the last dose in each treatment course. Women using hormonal contraceptives should add a barrier method during cladribine dosing and for at least 4 weeks after the last dose in each treatment cycle. In addition, male patients should take precautions to prevent pregnancy of their partner during cladribine dosing and for at least 6 months after the last dose in each treatment course.", "mechanism_text": "Others", "recommendation": "Although the clinical significance of this interaction is unknown, caution is advised when cladribine is prescribed concomitantly with hormonal contraceptives because of the potential to cause fetal harm.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67541/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[8] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[11] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[12] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[13] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[14] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[15] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[16] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[17] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[18] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[19] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[20] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[21] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[22] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[23] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[24] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[25] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[26] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[27] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[28] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[29] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[30] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[31] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[32] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[33] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[34] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[35] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[36] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[37] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[38] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[39] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[40] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Methotrexate, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, Belumosudil, More", "alternatives_b": "Megestrol acetate, Estetrol, Ulipristal, Estradiol, Megestrol acetate, Progesterone, Megestrol acetate, Progesterone, Estradiol, Diethylstilbestrol, Histrelin, More", "updated_at": 1767369485}, {"id": 67455, "ingredient1": "Cladribine", "ingredient2": "Melphalan", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67542/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67456, "ingredient1": "Cladribine", "ingredient2": "Meningococcal polysaccharide vaccine group C", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67543/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Spesolimab, Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Daclizumab, Emapalumab, Anifrolumab, Deucravacitinib, Ponesimod, Ravulizumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67457, "ingredient1": "Cladribine", "ingredient2": "Mephenytoin", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67544/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Tacrolimus, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, Belumosudil, More", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, More", "updated_at": 1767369485}, {"id": 67458, "ingredient1": "Cladribine", "ingredient2": "Mercaptopurine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67545/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More", "alternatives_b": "Cladribine, Theophylline, Omalizumab, Tezepelumab, Aminophylline, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Oxtriphylline, More", "updated_at": 1767369485}, {"id": 67459, "ingredient1": "Cladribine", "ingredient2": "Methotrexate", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67546/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Methotrexate, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, More", "alternatives_b": "Apremilast, Pirfenidone, Cladribine, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab, Cladribine", "updated_at": 1767369485}, {"id": 67460, "ingredient1": "Cladribine", "ingredient2": "Methylprednisolone", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67547/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, More", "alternatives_b": "Minocycline, Clindamycin, Vitamin A, Isotretinoin, Fluorometholone, Tretinoin, Erythromycin, Azelaic acid, Adapalene, Fluocinolone acetonide, Fluocinonide, More", "updated_at": 1767369485}, {"id": 67461, "ingredient1": "Cladribine", "ingredient2": "Midostaurin", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67548/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, More", "alternatives_b": "Dabrafenib, Dacomitinib, Pexidartinib, Larotrectinib, Fedratinib, Vemurafenib, Lapatinib, Selumetinib, Vandetanib, Afatinib, Encorafenib, More", "updated_at": 1767369485}, {"id": 67462, "ingredient1": "Cladribine", "ingredient2": "Mitomycin", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67549/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67463, "ingredient1": "Cladribine", "ingredient2": "Mitoxantrone", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67550/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67464, "ingredient1": "Cladribine", "ingredient2": "Mogamulizumab", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67551/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "updated_at": 1767369485}, {"id": 67465, "ingredient1": "Cladribine", "ingredient2": "Monomethyl fumarate", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67552/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67466, "ingredient1": "Cladribine", "ingredient2": "Mumps virus strain B level jeryl lynn live antigen", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67553/", "reference_text": "[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[2] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur, Swiftwater, PA.[3] \"Product Information. Attenuvax (measles virus vaccine, live, attenuated).\" Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] \"Product Information. Meruvax II (rubella virus vaccine, live).\" Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67467, "ingredient1": "Cladribine", "ingredient2": "Muromonab", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67554/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Apremilast, Pirfenidone, Cladribine, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, More", "updated_at": 1767369485}, {"id": 67468, "ingredient1": "Cladribine", "ingredient2": "Mycophenolate mofetil", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67555/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67469, "ingredient1": "Cladribine", "ingredient2": "Mycophenolic acid", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67556/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, More", "alternatives_b": "Apremilast, Pirfenidone, Cladribine, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "updated_at": 1767369485}, {"id": 67470, "ingredient1": "Cladribine", "ingredient2": "Natalizumab", "severity": "Major", "effect": "Concomitant or recent use of immunosuppressant, immunomodulating, or antineoplastic agents in patients treated with natalizumab may increase the risk of infections including progressive multifocal leukoencephalopathy (PML), a severely disabling, potentially fatal opportunistic viral infection of the brain.", "source": "DDInter", "management_text": "The safety and efficacy of natalizumab in combination with immunosuppressant, immunomodulating, antineoplastic or other myelosuppressive agents have not been established. In general, patients receiving chronic therapy with such agents should not be treated with natalizumab due to potentially increased risk of PML and other serious infections. Typical symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body, clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes. Due to the long half-life of natalizumab, immune effects are possible for up to 2 to 3 months following its discontinuation.", "mechanism_text": "Synergism", "recommendation": "The safety and efficacy of natalizumab in combination with immunosuppressant, immunomodulating, antineoplastic or other myelosuppressive agents have not been established.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67557/", "reference_text": "[1] \"Product Information. Tysabri (natalizumab).\" Elan Pharmaceutical/Athena Neurosciences Inc, South San Francisco, CA.", "alternatives_a": "Apremilast, Pirfenidone, Cladribine, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Natalizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "updated_at": 1767369485}, {"id": 67471, "ingredient1": "Cladribine", "ingredient2": "Naxitamab", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67558/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67472, "ingredient1": "Cladribine", "ingredient2": "Nelarabine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67559/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "Cladribine", "updated_at": 1767369485}, {"id": 67473, "ingredient1": "Cladribine", "ingredient2": "Nilotinib", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67560/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More", "alternatives_b": "Dabrafenib, Dacomitinib, Pexidartinib, Larotrectinib, Fedratinib, Vemurafenib, Lapatinib, Selumetinib, Vandetanib, Afatinib, Encorafenib, More", "updated_at": 1767369485}, {"id": 67474, "ingredient1": "Cladribine", "ingredient2": "Nimodipine", "severity": "Moderate", "effect": "Oral bioavailability and systemic exposure of cladribine may be increased by potent inhibitors of breast cancer resistance protein (BCRP) while intracellular distribution and renal elimination of cladribine may be altered by potent inhibitors of equilibrative nucleoside transporter 1 (ENT1) and concentrative nucleoside transporter 3 (CNT3). The mechanism involves inhibition of ENT1, CNT3, and/or BCRP as cladribine is a substrate of each of these transporter systems.", "source": "DDInter", "management_text": "Coadministration of potent ENT1, CNT3, or BCRP transporter inhibitors should be avoided during the 4 to 5-day oral cladribine treatment cycles. If coadministration is required, consider concomitant alternatives that exhibit no or minimal inhibition of ENT1, CNT3, or BCRP. If this is not possible, dose reduction to the minimum mandatory dose, separation in the timing of administration, and careful patient monitoring is recommended.", "mechanism_text": "Absorption, Distribution, Excretion", "recommendation": "Coadministration of potent ENT1, CNT3, or BCRP transporter inhibitors should be avoided during the 4 to 5-day oral cladribine treatment cycles.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67561/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, Upadacitinib, Apremilast, Inebilizumab, Belumosudil, More", "alternatives_b": "Felodipine, Amlodipine, Nisoldipine, Nicardipine, Isradipine, Clevidipine, Levamlodipine, Celecoxib, Mibefradil", "updated_at": 1767369485}, {"id": 67475, "ingredient1": "Cladribine", "ingredient2": "Niraparib", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67562/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, More", "alternatives_b": "Pertuzumab, Vismodegib, Ivosidenib, Belzutifan, Sonidegib, Mitotane, Porfimer sodium, Estramustine, Celecoxib, Aminolevulinic acid, Tazemetostat, More", "updated_at": 1767369485}, {"id": 67476, "ingredient1": "Cladribine", "ingredient2": "Norgestrel", "severity": "Moderate", "effect": "RECOMMENDED: Coadministration with cladribine may reduce the efficacy of hormonal contraceptives. The mechanism has not been established. There are no clinical data regarding the use of cladribine with hormonal contraceptives.", "source": "DDInter", "management_text": "Although the clinical significance of this interaction is unknown, caution is advised when cladribine is prescribed concomitantly with hormonal contraceptives because of the potential to cause fetal harm. Women should avoid becoming pregnant during treatment with cladribine and for at least 6 months after the last dose in each treatment course. Women using hormonal contraceptives should add a barrier method during cladribine dosing and for at least 4 weeks after the last dose in each treatment cycle. In addition, male patients should take precautions to prevent pregnancy of their partner during cladribine dosing and for at least 6 months after the last dose in each treatment course.", "mechanism_text": "Others", "recommendation": "Although the clinical significance of this interaction is unknown, caution is advised when cladribine is prescribed concomitantly with hormonal contraceptives because of the potential to cause fetal harm.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67563/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[8] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[11] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[12] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[13] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[14] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[15] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[16] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[17] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[18] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[19] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[20] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[21] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[22] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[23] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[24] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[25] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[26] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[27] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[28] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[29] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[30] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[31] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[32] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[33] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[34] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[35] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[36] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[37] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[38] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[39] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[40] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Methotrexate, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, Belumosudil, More", "alternatives_b": "Megestrol acetate, Progesterone, Estradiol, Megestrol acetate, Estetrol, Ulipristal, Estradiol", "updated_at": 1767369485}, {"id": 67477, "ingredient1": "Cladribine", "ingredient2": "Obinutuzumab", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67564/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "updated_at": 1767369485}, {"id": 67478, "ingredient1": "Cladribine", "ingredient2": "Ocrelizumab", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67565/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ocrelizumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "Apremilast, Pirfenidone, Cladribine, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "updated_at": 1767369485}, {"id": 67479, "ingredient1": "Cladribine", "ingredient2": "Ofatumumab", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67566/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "updated_at": 1767369485}, {"id": 67480, "ingredient1": "Cladribine", "ingredient2": "Olaparib", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67567/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, More", "alternatives_b": "Pertuzumab, Vismodegib, Ivosidenib, Belzutifan, Sonidegib, Mitotane, Porfimer sodium, Estramustine, Celecoxib, Aminolevulinic acid, Tazemetostat, More", "updated_at": 1767369485}, {"id": 67481, "ingredient1": "Cladribine", "ingredient2": "Olaratumab", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67568/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "updated_at": 1767369485}, {"id": 67482, "ingredient1": "Cladribine", "ingredient2": "Omacetaxine mepesuccinate", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67569/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "Pertuzumab, Vismodegib, Ivosidenib, Belzutifan, Sonidegib, Mitotane, Porfimer sodium, Estramustine, Celecoxib, Aminolevulinic acid, Tazemetostat, More", "updated_at": 1767369485}, {"id": 67483, "ingredient1": "Cladribine", "ingredient2": "Osimertinib", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67570/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More", "alternatives_b": "Dabrafenib, Dacomitinib, Pexidartinib, Larotrectinib, Fedratinib, Vemurafenib, Lapatinib, Selumetinib, Vandetanib, Afatinib, Encorafenib, More", "updated_at": 1767369485}, {"id": 67484, "ingredient1": "Cladribine", "ingredient2": "Oxaliplatin", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67571/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, More", "alternatives_b": "Pertuzumab, Vismodegib, Ivosidenib, Belzutifan, Sonidegib, Mitotane, Porfimer sodium, Estramustine, Celecoxib, Aminolevulinic acid, Tazemetostat, More", "updated_at": 1767369485}, {"id": 67485, "ingredient1": "Cladribine", "ingredient2": "Ozanimod", "severity": "Major", "effect": "Coadministration of ozanimod with antineoplastic, immunosuppressive, or other immune-modulating therapies may increase the risk of unintended additive immunosuppressive effects. Ozanimod causes reversible sequestration of lymphocytes in lymphoid tissues. The safety and efficacy of ozanimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated.", "source": "DDInter", "management_text": "Concomitant use of ozanimod with antineoplastic, immunosuppressive, or immune-modulating agents should be avoided according to some authorities (UK); however, other authorities (AU, US) advise caution and close monitoring during coadministration and for up to 3 months after the last dose of ozanimod. When switching from drugs with prolonged immune effects to ozanimod, the half-life and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects while at the same time minimizing risk of disease reactivation.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of ozanimod with antineoplastic, immunosuppressive, or immune-modulating agents should be avoided according to some authorities (UK); however, other authorities (AU, US) advise caution and close monitoring during coadministration and for up to 3 months after the last dose of ozanimod.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67572/", "reference_text": "[1] \"Product Information. Zeposia (ozanimod).\" Celgene Corporation, Summit, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Zeposia (ozanimod).\" Celgene Corporation, Summit, NJ.", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Ozanimod, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "Apremilast, Pirfenidone, Cladribine, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "updated_at": 1767369485}, {"id": 67486, "ingredient1": "Cladribine", "ingredient2": "Paclitaxel (protein-bound)", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67573/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67487, "ingredient1": "Cladribine", "ingredient2": "Palbociclib", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67574/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, Belumosudil, More", "alternatives_b": "Dabrafenib, Dacomitinib, Pexidartinib, Larotrectinib, Fedratinib, Vemurafenib, Lapatinib, Selumetinib, Vandetanib, Afatinib, Encorafenib, More", "updated_at": 1767369485}, {"id": 67488, "ingredient1": "Cladribine", "ingredient2": "Palifermin", "severity": "Moderate", "effect": "INTERVAL: In a clinical trial, administration of palifermin within 24 hours of chemotherapy resulted in increased severity and duration of oral mucositis, presumably due to increased sensitivity of the rapidly dividing epithelial cells in the immediate post-chemotherapy period.", "source": "DDInter", "management_text": "Palifermin should not be administered within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.", "mechanism_text": "Others", "recommendation": "Palifermin should not be administered within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67575/", "reference_text": "[1] \"Product Information. Kepivance (palifermin).\" Shire US Inc, Florence, KY.", "alternatives_a": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Cobicistat, Deferoxamine, Levoleucovorin, More", "alternatives_b": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More", "updated_at": 1767369485}, {"id": 67489, "ingredient1": "Cladribine", "ingredient2": "Panobinostat", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67576/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, More", "alternatives_b": "Pertuzumab, Vismodegib, Ivosidenib, Belzutifan, Sonidegib, Mitotane, Porfimer sodium, Estramustine, Celecoxib, Aminolevulinic acid, Tazemetostat, More", "updated_at": 1767369485}, {"id": 67490, "ingredient1": "Cladribine", "ingredient2": "Paramethadione", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67577/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Golimumab, Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, More", "updated_at": 1767369485}, {"id": 67491, "ingredient1": "Cladribine", "ingredient2": "Pazopanib", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67578/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More", "alternatives_b": "Dabrafenib, Dacomitinib, Pexidartinib, Larotrectinib, Fedratinib, Vemurafenib, Lapatinib, Selumetinib, Vandetanib, Afatinib, Encorafenib, More", "updated_at": 1767369485}, {"id": 67492, "ingredient1": "Cladribine", "ingredient2": "Pegfilgrastim", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67579/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Oprelvekin, Elapegademase, Histamine, Pegademase, Glatiramer", "alternatives_b": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More", "updated_at": 1767369485}, {"id": 67493, "ingredient1": "Cladribine", "ingredient2": "Peginterferon alfa-2a", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67580/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Oprelvekin, Elapegademase, Histamine, Pegademase, Glatiramer", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Secukinumab, Canakinumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Anakinra, Apremilast, More", "updated_at": 1767369485}, {"id": 67494, "ingredient1": "Cladribine", "ingredient2": "Peginterferon alfa-2b", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67581/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Oprelvekin, Elapegademase, Histamine, Pegademase, Glatiramer", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Secukinumab, Canakinumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Anakinra, Apremilast, More", "updated_at": 1767369485}, {"id": 67495, "ingredient1": "Cladribine", "ingredient2": "Peginterferon beta-1a", "severity": "Moderate", "effect": "The use of cladribine with beta interferons may increase the risk of lymphopenia. The mechanism involves additive risk of lymphopenia.", "source": "DDInter", "management_text": "Concomitant use of cladribine and beta interferons is not recommended.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of cladribine and beta interferons is not recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67582/", "reference_text": "[1] Montalban X, Leist TP, Cohen BA, et.al \"Cladribine tablets added to IFN- in active relapsing MS: The ONWARD study.\" Neurol Neruroimmunol Neuroinflamm 11 (2018): e477[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Secukinumab, Canakinumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Upadacitinib, Anakinra, More", "alternatives_b": "Oprelvekin, Elapegademase, Histamine, Pegademase, Glatiramer", "updated_at": 1767369485}, {"id": 67496, "ingredient1": "Cladribine", "ingredient2": "Pemetrexed", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67583/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, More", "alternatives_b": "Cladribine", "updated_at": 1767369485}, {"id": 67497, "ingredient1": "Cladribine", "ingredient2": "Penicillamine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67584/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Golimumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Tacrolimus, Abatacept, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67498, "ingredient1": "Cladribine", "ingredient2": "Pentamidine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67585/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Golimumab, Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Miltefosine, Nifurtimox, Benznidazole", "updated_at": 1767369485}, {"id": 67499, "ingredient1": "Cladribine", "ingredient2": "Pentostatin", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67586/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, More", "alternatives_b": "Pertuzumab, Vismodegib, Ivosidenib, Belzutifan, Sonidegib, Mitotane, Porfimer sodium, Estramustine, Celecoxib, Aminolevulinic acid, Tazemetostat, More", "updated_at": 1767369485}, {"id": 67500, "ingredient1": "Cladribine", "ingredient2": "Phenylbutazone", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67587/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Golimumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, Upadacitinib, More", "alternatives_b": "Rabeprazole, Ketoprofen, Diclofenac, Piroxicam, Rofecoxib, Meclofenamic acid, Etodolac, Ketorolac, Misoprostol, Glucosamine, Oxaprozin, More", "updated_at": 1767369485}, {"id": 67501, "ingredient1": "Cladribine", "ingredient2": "Phenytoin", "severity": "Moderate", "effect": "Cladribine exposure may be decreased by potent inducers of breast cancer resistance protein (BCRP) or P-glycoprotein (P-gp). The mechanism involves induction of BCRP and/or P-gp as cladribine is a substrate of each of these transporter systems. The clinical relevance remains unknown.", "source": "DDInter", "management_text": "Possible decreases in cladribine exposure and efficacy should be considered if potent inducers of BCRP or P-gp are coadministered.", "mechanism_text": "Others", "recommendation": "Possible decreases in cladribine exposure and efficacy should be considered if potent inducers of BCRP or P-gp are coadministered.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67588/", "reference_text": "[1] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8[5] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Inebilizumab, Ozanimod, Belimumab, Sutimlimab, Risankizumab, Antilymphocyte immunoglobulin (horse), More", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, More", "updated_at": 1767369485}, {"id": 67502, "ingredient1": "Cladribine", "ingredient2": "Plicamycin", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67589/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67503, "ingredient1": "Cladribine", "ingredient2": "Polatuzumab vedotin", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67590/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Secukinumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "updated_at": 1767369485}, {"id": 67504, "ingredient1": "Cladribine", "ingredient2": "Poliovirus type 1 antigen (formaldehyde inactivated)", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67591/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67505, "ingredient1": "Cladribine", "ingredient2": "Pomalidomide", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67592/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, More", "alternatives_b": "Apremilast, Pirfenidone, Cladribine, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "updated_at": 1767369485}, {"id": 67506, "ingredient1": "Cladribine", "ingredient2": "Ponatinib", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67593/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More", "alternatives_b": "Dabrafenib, Dacomitinib, Pexidartinib, Larotrectinib, Fedratinib, Vemurafenib, Lapatinib, Selumetinib, Vandetanib, Afatinib, Encorafenib, More", "updated_at": 1767369485}, {"id": 67507, "ingredient1": "Cladribine", "ingredient2": "Pralatrexate", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67594/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "Cladribine", "updated_at": 1767369485}, {"id": 67508, "ingredient1": "Cladribine", "ingredient2": "Prednisolone", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67595/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, More", "alternatives_b": "Mometasone furoate, Amcinonide, Fluocinolone acetonide, Hydrocortisone butyrate, Fluocinonide, Fluorometholone, Clobetasol, Beclomethasone dipropionate, Fluorometholone, Indomethacin, Fluocinolone acetonide, More", "updated_at": 1767369485}, {"id": 67509, "ingredient1": "Cladribine", "ingredient2": "Prednisone", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67596/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, More", "alternatives_b": "Cromoglicic acid, Olsalazine, Sulfasalazine, Balsalazide, Beclomethasone dipropionate, Mesalazine", "updated_at": 1767369485}, {"id": 67510, "ingredient1": "Cladribine", "ingredient2": "Primaquine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67597/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Abatacept, More", "alternatives_b": "Artesunate, Mefloquine, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Halofantrine, Quinine, Proguanil, More", "updated_at": 1767369485}, {"id": 67511, "ingredient1": "Cladribine", "ingredient2": "Procainamide", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67598/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, Belumosudil, More", "alternatives_b": "Quinidine, Amiodarone, Dronedarone, Lidocaine, Propafenone, Flecainide, Disopyramide, Mexiletine, Dofetilide, Bretylium, Moricizine, Ibutilide", "updated_at": 1767369485}, {"id": 67512, "ingredient1": "Cladribine", "ingredient2": "Procarbazine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67599/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "Pertuzumab, Vismodegib, Ivosidenib, Belzutifan, Sonidegib, Mitotane, Porfimer sodium, Estramustine, Celecoxib, Aminolevulinic acid, Tazemetostat, More", "updated_at": 1767369485}, {"id": 67513, "ingredient1": "Cladribine", "ingredient2": "Radium Ra 223 dichloride", "severity": "Moderate", "effect": "The concomitant use of bone marrow depressants and radium Ra 223 dichloride may have additive myelosuppressive effects.", "source": "DDInter", "management_text": "Patients should be monitored for excessive bone marrow suppression during treatment with radium Ra 223 dichloride. Dose reductions of the other bone marrow depressants may be necessary. Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms. The safety and efficacy of concomitant use of chemotherapy have not been established.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored for excessive bone marrow suppression during treatment with radium Ra 223 dichloride.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67600/", "reference_text": "[1] \"Product Information. Xofigo (radium Ra 223 dichloride).\" Bayer Pharmaceutical Inc, West Haven, CT.", "alternatives_a": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67514, "ingredient1": "Cladribine", "ingredient2": "Reserpine", "severity": "Moderate", "effect": "Oral bioavailability and systemic exposure of cladribine may be increased by potent inhibitors of breast cancer resistance protein (BCRP) while intracellular distribution and renal elimination of cladribine may be altered by potent inhibitors of equilibrative nucleoside transporter 1 (ENT1) and concentrative nucleoside transporter 3 (CNT3). The mechanism involves inhibition of ENT1, CNT3, and/or BCRP as cladribine is a substrate of each of these transporter systems.", "source": "DDInter", "management_text": "Coadministration of potent ENT1, CNT3, or BCRP transporter inhibitors should be avoided during the 4 to 5-day oral cladribine treatment cycles. If coadministration is required, consider concomitant alternatives that exhibit no or minimal inhibition of ENT1, CNT3, or BCRP. If this is not possible, dose reduction to the minimum mandatory dose, separation in the timing of administration, and careful patient monitoring is recommended.", "mechanism_text": "Absorption, Distribution, Excretion", "recommendation": "Coadministration of potent ENT1, CNT3, or BCRP transporter inhibitors should be avoided during the 4 to 5-day oral cladribine treatment cycles.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67601/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Prazosin, Rauwolfia serpentina root, Hydralazine, Clonidine, Guanethidine, Deserpidine, Guanfacine, Rauwolfia serpentina root, Methyldopa, Clonidine, Deserpidine", "alternatives_b": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More", "updated_at": 1767369485}, {"id": 67515, "ingredient1": "Cladribine", "ingredient2": "Ribavirin", "severity": "Moderate", "effect": "The use of cladribine with medications that undergo intracellular phosphorylation may reduce its efficacy by inhibiting its phosphorylation to its active form. The clinical significance of this interaction is unknown.", "source": "DDInter", "management_text": "Concomitant use of cladribine with medications that undergo intracellular phosphorylation should be avoided if possible.", "mechanism_text": "Antagonism", "recommendation": "Concomitant use of cladribine with medications that undergo intracellular phosphorylation should be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67602/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Hivid (zalcitabine).\" Roche Laboratories, Nutley, NJ.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Telaprevir, Velpatasvir, Rilpivirine, Etravirine, More", "updated_at": 1767369485}, {"id": 67516, "ingredient1": "Cladribine", "ingredient2": "Ribociclib", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67603/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More", "alternatives_b": "Dabrafenib, Dacomitinib, Pexidartinib, Larotrectinib, Fedratinib, Vemurafenib, Lapatinib, Selumetinib, Vandetanib, Afatinib, Encorafenib, More", "updated_at": 1767369485}, {"id": 67517, "ingredient1": "Cladribine", "ingredient2": "Rifampicin", "severity": "Moderate", "effect": "Cladribine exposure may be decreased by potent inducers of breast cancer resistance protein (BCRP) or P-glycoprotein (P-gp). The mechanism involves induction of BCRP and/or P-gp as cladribine is a substrate of each of these transporter systems. The clinical relevance remains unknown.", "source": "DDInter", "management_text": "Possible decreases in cladribine exposure and efficacy should be considered if potent inducers of BCRP or P-gp are coadministered.", "mechanism_text": "Others", "recommendation": "Possible decreases in cladribine exposure and efficacy should be considered if potent inducers of BCRP or P-gp are coadministered.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67604/", "reference_text": "[1] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8[5] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Abatacept, Anakinra, Inebilizumab, More", "alternatives_b": "Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Streptomycin, Trimethoprim, Cycloserine, Rifabutin, Isoniazid, Ethambutol, More", "updated_at": 1767369485}, {"id": 67518, "ingredient1": "Cladribine", "ingredient2": "Rifapentine", "severity": "Moderate", "effect": "Cladribine exposure may be decreased by potent inducers of breast cancer resistance protein (BCRP) or P-glycoprotein (P-gp). The mechanism involves induction of BCRP and/or P-gp as cladribine is a substrate of each of these transporter systems. The clinical relevance remains unknown.", "source": "DDInter", "management_text": "Possible decreases in cladribine exposure and efficacy should be considered if potent inducers of BCRP or P-gp are coadministered.", "mechanism_text": "Others", "recommendation": "Possible decreases in cladribine exposure and efficacy should be considered if potent inducers of BCRP or P-gp are coadministered.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67605/", "reference_text": "[1] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8[5] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Streptomycin, Trimethoprim, Cycloserine, Rifabutin, Isoniazid, Ethambutol, More", "updated_at": 1767369485}, {"id": 67519, "ingredient1": "Cladribine", "ingredient2": "Rilonacept", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67606/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Rilonacept, Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "Apremilast, Pirfenidone, Cladribine, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "updated_at": 1767369485}, {"id": 67520, "ingredient1": "Cladribine", "ingredient2": "Risankizumab", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67607/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, More", "alternatives_b": "Apremilast, Pirfenidone, Cladribine, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "updated_at": 1767369485}, {"id": 67521, "ingredient1": "Cladribine", "ingredient2": "Ritonavir", "severity": "Moderate", "effect": "Oral bioavailability and systemic exposure of cladribine may be increased by potent inhibitors of breast cancer resistance protein (BCRP) while intracellular distribution and renal elimination of cladribine may be altered by potent inhibitors of equilibrative nucleoside transporter 1 (ENT1) and concentrative nucleoside transporter 3 (CNT3). The mechanism involves inhibition of ENT1, CNT3, and/or BCRP as cladribine is a substrate of each of these transporter systems.", "source": "DDInter", "management_text": "Coadministration of potent ENT1, CNT3, or BCRP transporter inhibitors should be avoided during the 4 to 5-day oral cladribine treatment cycles. If coadministration is required, consider concomitant alternatives that exhibit no or minimal inhibition of ENT1, CNT3, or BCRP. If this is not possible, dose reduction to the minimum mandatory dose, separation in the timing of administration, and careful patient monitoring is recommended.", "mechanism_text": "Absorption, Distribution, Excretion", "recommendation": "Coadministration of potent ENT1, CNT3, or BCRP transporter inhibitors should be avoided during the 4 to 5-day oral cladribine treatment cycles.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67608/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Telaprevir, Velpatasvir, Rilpivirine, Etravirine, More", "updated_at": 1767369485}, {"id": 67522, "ingredient1": "Cladribine", "ingredient2": "Rituximab", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67609/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Secukinumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, More", "updated_at": 1767369485}, {"id": 67523, "ingredient1": "Cladribine", "ingredient2": "Roflumilast", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67610/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Voclosporin, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "Theophylline, Omalizumab, Tezepelumab, Aminophylline, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Oxtriphylline, Mepolizumab, More", "updated_at": 1767369485}, {"id": 67524, "ingredient1": "Cladribine", "ingredient2": "Romidepsin", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67611/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More", "alternatives_b": "Pertuzumab, Vismodegib, Ivosidenib, Belzutifan, Sonidegib, Mitotane, Porfimer sodium, Estramustine, Celecoxib, Aminolevulinic acid, Tazemetostat, More", "updated_at": 1767369485}, {"id": 67525, "ingredient1": "Cladribine", "ingredient2": "Rotavirus vaccine", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67612/", "reference_text": "[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[2] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur, Swiftwater, PA.[3] \"Product Information. Attenuvax (measles virus vaccine, live, attenuated).\" Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] \"Product Information. Meruvax II (rubella virus vaccine, live).\" Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67526, "ingredient1": "Cladribine", "ingredient2": "Rubella virus vaccine", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67613/", "reference_text": "[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[2] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur, Swiftwater, PA.[3] \"Product Information. Attenuvax (measles virus vaccine, live, attenuated).\" Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] \"Product Information. Meruvax II (rubella virus vaccine, live).\" Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67527, "ingredient1": "Cladribine", "ingredient2": "Rucaparib", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67614/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More", "alternatives_b": "Pertuzumab, Vismodegib, Ivosidenib, Belzutifan, Sonidegib, Mitotane, Porfimer sodium, Estramustine, Celecoxib, Aminolevulinic acid, Tazemetostat, More", "updated_at": 1767369485}, {"id": 67528, "ingredient1": "Cladribine", "ingredient2": "Ruxolitinib", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67615/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, More", "alternatives_b": "Dabrafenib, Dacomitinib, Pexidartinib, Larotrectinib, Fedratinib, Vemurafenib, Lapatinib, Selumetinib, Vandetanib, Afatinib, Encorafenib, More", "updated_at": 1767369485}, {"id": 67529, "ingredient1": "Cladribine", "ingredient2": "Sacituzumab govitecan", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67616/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "updated_at": 1767369485}, {"id": 67530, "ingredient1": "Cladribine", "ingredient2": "Samarium (153Sm) lexidronam", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67617/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67531, "ingredient1": "Cladribine", "ingredient2": "Sargramostim", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67618/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Oprelvekin, Elapegademase, Histamine, Pegademase, Glatiramer", "alternatives_b": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More", "updated_at": 1767369485}, {"id": 67532, "ingredient1": "Cladribine", "ingredient2": "Sarilumab", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67619/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Apremilast, Inebilizumab, Belumosudil, Thalidomide, Belimumab, Emapalumab, More", "alternatives_b": "Apremilast, Pirfenidone, Cladribine, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "updated_at": 1767369485}, {"id": 67533, "ingredient1": "Cladribine", "ingredient2": "Pfizer-BioNTech Covid-19 Vaccine", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67620/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Spesolimab, Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Daclizumab, Emapalumab, Eculizumab, Anifrolumab, Deucravacitinib, Ponesimod, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67534, "ingredient1": "Cladribine", "ingredient2": "Satralizumab", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67621/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Apremilast, Inebilizumab, Belumosudil, Thalidomide, Belimumab, Emapalumab, More", "alternatives_b": "Apremilast, Pirfenidone, Cladribine, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "updated_at": 1767369485}, {"id": 67535, "ingredient1": "Cladribine", "ingredient2": "Secukinumab", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67622/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, More", "alternatives_b": "Apremilast, Pirfenidone, Cladribine, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "updated_at": 1767369485}, {"id": 67536, "ingredient1": "Cladribine", "ingredient2": "Selinexor", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67623/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "Pertuzumab, Vismodegib, Ivosidenib, Belzutifan, Sonidegib, Mitotane, Porfimer sodium, Estramustine, Celecoxib, Aminolevulinic acid, Tazemetostat, More", "updated_at": 1767369485}, {"id": 67537, "ingredient1": "Cladribine", "ingredient2": "Siltuximab", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67624/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, More", "alternatives_b": "Apremilast, Pirfenidone, Cladribine, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "updated_at": 1767369485}, {"id": 67538, "ingredient1": "Cladribine", "ingredient2": "Siponimod", "severity": "Major", "effect": "Coadministration of siponimod with antineoplastic, immunosuppressive, or other immune-modulating therapies may increase the risk of unintended additive immunosuppressive effects.", "source": "DDInter", "management_text": "The safety and efficacy of siponimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated. Caution is advised during coadministration and for 3 to 4 weeks after the last dose of siponimod. When switching from drugs with prolonged immune effects to siponimod, the half-life and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects while at the same time minimizing risk of disease reactivation.", "mechanism_text": "Synergism", "recommendation": "The safety and efficacy of siponimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67625/", "reference_text": "[1] \"Product Information. Mayzent (siponimod).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Siponimod, Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "Apremilast, Pirfenidone, Cladribine, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "updated_at": 1767369485}, {"id": 67539, "ingredient1": "Cladribine", "ingredient2": "Sipuleucel-T", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67626/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "Oprelvekin, Elapegademase, Histamine, Pegademase, Glatiramer", "updated_at": 1767369485}, {"id": 67540, "ingredient1": "Cladribine", "ingredient2": "Sirolimus", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67627/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, Belimumab, Emapalumab, Sutimlimab, More", "alternatives_b": "Alteplase, Ascorbic acid, Vitamin A, Potassium Iodide, Acetylcysteine, Nandrolone, Heparin, Apremilast, Pirfenidone, Cladribine, Belumosudil, More", "updated_at": 1767369485}, {"id": 67541, "ingredient1": "Cladribine", "ingredient2": "Smallpox (Vaccinia) Vaccine, Live", "severity": "Major", "effect": "The administration of live smallpox virus vaccine during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Routine, nonemergency smallpox vaccination is contraindicated in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued for at least 3 months in most cases. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).", "mechanism_text": "Others", "recommendation": "Routine, nonemergency smallpox vaccination is contraindicated in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67628/", "reference_text": "[1] \"Product Information. Dryvax (smallpox vaccine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] CDC. Centers for Disease Control and Prevention \"Smallpox vaccination clinic guide. Logistical considerations and guidance for state and local planning for emergency, large-scale, voluntary administration of smallpox vaccine in response to a smallpox outbreak. Available from: URL: http://www.bt.cdc.gov\" ([2002 Oct 16]):", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67542, "ingredient1": "Cladribine", "ingredient2": "Sodium phosphate, monobasic (p32)", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67629/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67543, "ingredient1": "Cladribine", "ingredient2": "St. John's Wort", "severity": "Moderate", "effect": "Cladribine exposure may be decreased by potent inducers of breast cancer resistance protein (BCRP) or P-glycoprotein (P-gp). The mechanism involves induction of BCRP and/or P-gp as cladribine is a substrate of each of these transporter systems. The clinical relevance remains unknown.", "source": "DDInter", "management_text": "Possible decreases in cladribine exposure and efficacy should be considered if potent inducers of BCRP or P-gp are coadministered.", "mechanism_text": "Others", "recommendation": "Possible decreases in cladribine exposure and efficacy should be considered if potent inducers of BCRP or P-gp are coadministered.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67630/", "reference_text": "[1] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8[5] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Citalopram, Sertraline, Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, Viloxazine, More", "updated_at": 1767369485}, {"id": 67544, "ingredient1": "Cladribine", "ingredient2": "Stavudine", "severity": "Moderate", "effect": "The use of cladribine with medications that undergo intracellular phosphorylation may reduce its efficacy by inhibiting its phosphorylation to its active form. The clinical significance of this interaction is unknown.", "source": "DDInter", "management_text": "Concomitant use of cladribine with medications that undergo intracellular phosphorylation should be avoided if possible.", "mechanism_text": "Antagonism", "recommendation": "Concomitant use of cladribine with medications that undergo intracellular phosphorylation should be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67631/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Hivid (zalcitabine).\" Roche Laboratories, Nutley, NJ.", "alternatives_a": "Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, Upadacitinib, More", "alternatives_b": "Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Telaprevir, Velpatasvir, Rilpivirine, Etravirine, More", "updated_at": 1767369485}, {"id": 67545, "ingredient1": "Cladribine", "ingredient2": "Streptozocin", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67632/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67546, "ingredient1": "Cladribine", "ingredient2": "Strontium chloride Sr-89", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67633/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67547, "ingredient1": "Cladribine", "ingredient2": "Sulindac", "severity": "Moderate", "effect": "Oral bioavailability and systemic exposure of cladribine may be increased by potent inhibitors of breast cancer resistance protein (BCRP) while intracellular distribution and renal elimination of cladribine may be altered by potent inhibitors of equilibrative nucleoside transporter 1 (ENT1) and concentrative nucleoside transporter 3 (CNT3). The mechanism involves inhibition of ENT1, CNT3, and/or BCRP as cladribine is a substrate of each of these transporter systems.", "source": "DDInter", "management_text": "Coadministration of potent ENT1, CNT3, or BCRP transporter inhibitors should be avoided during the 4 to 5-day oral cladribine treatment cycles. If coadministration is required, consider concomitant alternatives that exhibit no or minimal inhibition of ENT1, CNT3, or BCRP. If this is not possible, dose reduction to the minimum mandatory dose, separation in the timing of administration, and careful patient monitoring is recommended.", "mechanism_text": "Absorption, Distribution, Excretion", "recommendation": "Coadministration of potent ENT1, CNT3, or BCRP transporter inhibitors should be avoided during the 4 to 5-day oral cladribine treatment cycles.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67634/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Rabeprazole, Ketoprofen, Diclofenac, Piroxicam, Rofecoxib, Meclofenamic acid, Etodolac, Ketorolac, Misoprostol, Glucosamine, Oxaprozin, More", "updated_at": 1767369485}, {"id": 67548, "ingredient1": "Cladribine", "ingredient2": "Tacrolimus", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67635/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More", "alternatives_b": "Minoxidil, Deoxycholic acid, Calcium gluconate, Magnesium sulfate, Glycopyrronium, Pimecrolimus, Aminobenzoic acid, Ivermectin, Caffeine, Diclofenac, Cromoglicic acid, More", "updated_at": 1767369485}, {"id": 67549, "ingredient1": "Cladribine", "ingredient2": "Tafasitamab", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67636/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "updated_at": 1767369485}, {"id": 67550, "ingredient1": "Cladribine", "ingredient2": "Talazoparib", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67637/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Inebilizumab, Belumosudil, Thalidomide, More", "alternatives_b": "Pertuzumab, Vismodegib, Ivosidenib, Belzutifan, Sonidegib, Mitotane, Porfimer sodium, Estramustine, Celecoxib, Aminolevulinic acid, Tazemetostat, More", "updated_at": 1767369485}, {"id": 67551, "ingredient1": "Cladribine", "ingredient2": "Talimogene laherparepvec", "severity": "Major", "effect": "Talimogene laherparepvec is a live, attenuated herpes simplex virus. Administration during immunosuppressant or intense antineoplastic therapy may be associated with a risk of potentially life-threatening disseminated herpetic infection due to enhanced virus replication in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Talimogene laherparepvec should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Treatment with talimogene laherparepvec may need to be deferred until after such therapy is discontinued and the patient's immune system has sufficiently recovered.", "mechanism_text": "Synergism", "recommendation": "Talimogene laherparepvec should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67638/", "reference_text": "[1] \"Product Information. Imlygic (talimogene laherparepvec).\" Amgen USA, Thousand Oaks, CA.", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "Pertuzumab, Vismodegib, Ivosidenib, Belzutifan, Sonidegib, Mitotane, Porfimer sodium, Estramustine, Celecoxib, Aminolevulinic acid, Tazemetostat, More", "updated_at": 1767369485}, {"id": 67552, "ingredient1": "Cladribine", "ingredient2": "Tedizolid", "severity": "Moderate", "effect": "Coadministration with oral tedizolid may increase the plasma concentrations and the risk of adverse effects of orally administered drugs that are substrates of the breast cancer resistance protein (BCRP) transporter. The proposed mechanism is decreased clearance due to inhibition of BCRP-mediated intestinal efflux by tedizolid.", "source": "DDInter", "management_text": "Consider temporarily interrupting treatment with the BCRP substrate during treatment with tedizolid, especially for BCRP substrates with a narrow therapeutic index. If coadministration cannot be avoided, monitor for adverse reactions related to concomitantly administered BCRP substrate.", "mechanism_text": "Absorption", "recommendation": "Consider temporarily interrupting treatment with the BCRP substrate during treatment with tedizolid, especially for BCRP substrates with a narrow therapeutic index.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67639/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Sivextro (tedizolid).\" Cubist Pharmaceuticals Inc, Lexington, MA.[3] \"Product Information. Venclexta (venetoclax).\" AbbVie US LLC, North Chicago, IL.", "alternatives_a": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Tacrolimus, More", "alternatives_b": "Tinidazole, Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Metronidazole, Telavancin, Methenamine, Spectinomycin, Nitrofurantoin, More", "updated_at": 1767369485}, {"id": 67553, "ingredient1": "Cladribine", "ingredient2": "Telbivudine", "severity": "Moderate", "effect": "The use of cladribine with medications that undergo intracellular phosphorylation may reduce its efficacy by inhibiting its phosphorylation to its active form. The clinical significance of this interaction is unknown.", "source": "DDInter", "management_text": "Concomitant use of cladribine with medications that undergo intracellular phosphorylation should be avoided if possible.", "mechanism_text": "Antagonism", "recommendation": "Concomitant use of cladribine with medications that undergo intracellular phosphorylation should be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67640/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Hivid (zalcitabine).\" Roche Laboratories, Nutley, NJ.", "alternatives_a": "Ustekinumab, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Canakinumab, Secukinumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, Upadacitinib, Siponimod, More", "alternatives_b": "Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Telaprevir, Velpatasvir, Rilpivirine, Etravirine, More", "updated_at": 1767369485}, {"id": 67554, "ingredient1": "Cladribine", "ingredient2": "Temozolomide", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67641/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67555, "ingredient1": "Cladribine", "ingredient2": "Temsirolimus", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67642/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, Belimumab, Emapalumab, More", "alternatives_b": "Dabrafenib, Dacomitinib, Pexidartinib, Larotrectinib, Fedratinib, Vemurafenib, Lapatinib, Selumetinib, Vandetanib, Afatinib, Encorafenib, More", "updated_at": 1767369485}, {"id": 67556, "ingredient1": "Cladribine", "ingredient2": "Teniposide", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67643/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67557, "ingredient1": "Cladribine", "ingredient2": "Teriflunomide", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67644/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Teriflunomide, Apremilast, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "Apremilast, Pirfenidone, Cladribine, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "updated_at": 1767369485}, {"id": 67558, "ingredient1": "Cladribine", "ingredient2": "Thalidomide", "severity": "Major", "effect": "Coadministration of thalidomide with glucocorticoids and/or antineoplastic agents in the treatment of malignancy may potentiate the risk of thromboembolism. The exact mechanism is unknown but likely multifactorial.", "source": "DDInter", "management_text": "Close monitoring for DVT or pulmonary embolism is recommended in patients who require thalidomide therapy in combination with glucocorticoids and/or cytotoxic agents. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain, shortness of breath, and pain or swelling in the arms or legs. Prophylaxis with anticoagulants such as low-molecular weight heparins or warfarin may be appropriate, but the decision to take thromboprophylactic measures should be made after careful assessment of underlying risk factors. If a thromboembolic event occurs during therapy with thalidomide, treatment must be discontinued and standard anticoagulation therapy started. Once anticoagulation is stabilized and complications of the thromboembolic event under control, thalidomide may be restarted at the original dose if benefit is deemed to outweigh the risks.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for DVT or pulmonary embolism is recommended in patients who require thalidomide therapy in combination with glucocorticoids and/or cytotoxic agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67645/", "reference_text": "[1] Fine HA, Wen PY, Maher EA, et al. \"Phase II Trial of Thalidomide and Carmustine for Patients With Recurrent High-Grade Gliomas.\" J Clin Oncol 21 (2003): 2299-304[2] Zangari M, Siegel E, Barlogie B, et al \"Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy.\" Blood 100 (2002): 1168-71[3] Figg WD, Arlen P, Gulley J, et al. \"A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer.\" Semin Oncol 28(4 Suppl 15) (2001): 62-6[4] Desai AA, Vogelzang NJ, Rini BI, Ansari R, Krauss S, Stadler WM \"A high rate of venous thromboembolism in a multi-institutional Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma.\" Cancer 95 (2002): 1629-36[5] Urbauer E, Kaufmann H, Nosslinger T, Raderer M, Drach J \"Thromboembolic events during treatment with thalidomide.\" Blood 99 (2002): 4247-8[6] Lee CK, Barlogie B, Munshi N, et al \"DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma.\" J Clin Oncol 21 (2003): 2732-9[7] Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R \"Thalidomide alone or with dexamethasone for previously untreated multiple myeloma.\" J Clin Oncol 21 (2003): 16-9[8] \"Product Information. Thalomid (thalidomide).\" Celgene Corporation, Warren, NJ.[9] Cavo M, Zamagni E, Cellini C, et al. \"Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy.\" Blood 100 (2002): 2272-3[10] Bennett CL, Nebeker JR, Samore MH, et al \"The Research on Adverse Drug Events and Reports (RADAR) project.\" JAMA 293 (2005): 2131-40[11] Zangari M, Anaissie E, Barlogie B, et al \"Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.\" Blood 98 (2001): 1614-5[12] Rajkumar SV, Hayman S, Gertz MA, et al. \"Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.\" J Clin Oncol 20 (2002): 4319-23[13] Osman K, Comenzo R, Rajkumar SV \"Deep venous thrombosis and thalidomide therapy for multiple myeloma.\" N Engl J Med 344 (2001): 1951-2[14] Zangari M, Barlogie B, Anaissie E, et al \"Deep vein thrombosis in patients with mutiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation.\" Br J Haematol 126 (2004): 715-21[15] Escudier B, Lassau N, Leborgne S, Angevin E, Laplanche A \"Thalidomide and venous thrombosis.\" Ann Intern Med 136 (2002): 711[16] Bennett CL, Schumock GT, Desai AA, et al \"Thalidomide-associated deep vein thrombosis and pulmonary embolism.\" Am J Med 113 (2002): 603-6[17] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[20] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, Belimumab, More", "alternatives_b": "Apremilast, Pirfenidone, Cladribine, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "updated_at": 1767369485}, {"id": 67559, "ingredient1": "Cladribine", "ingredient2": "Tioguanine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67646/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More", "alternatives_b": "Cladribine", "updated_at": 1767369485}, {"id": 67560, "ingredient1": "Cladribine", "ingredient2": "Thiotepa", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67647/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67561, "ingredient1": "Cladribine", "ingredient2": "Tildrakizumab", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67648/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, More", "alternatives_b": "Apremilast, Pirfenidone, Cladribine, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "updated_at": 1767369485}, {"id": 67562, "ingredient1": "Cladribine", "ingredient2": "Tisagenlecleucel", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67649/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, More", "alternatives_b": "Pertuzumab, Vismodegib, Ivosidenib, Belzutifan, Sonidegib, Mitotane, Porfimer sodium, Estramustine, Celecoxib, Aminolevulinic acid, Tazemetostat, More", "updated_at": 1767369485}, {"id": 67563, "ingredient1": "Cladribine", "ingredient2": "Tocainide", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67650/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Golimumab, Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Quinidine, Amiodarone, Dronedarone, Lidocaine, Propafenone, Flecainide, Disopyramide, Mexiletine, Dofetilide, Bretylium, Moricizine, Ibutilide", "updated_at": 1767369485}, {"id": 67564, "ingredient1": "Cladribine", "ingredient2": "Tocilizumab", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67651/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More", "alternatives_b": "Apremilast, Pirfenidone, Cladribine, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "updated_at": 1767369485}, {"id": 67565, "ingredient1": "Cladribine", "ingredient2": "Tofacitinib", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67652/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Baricitinib, Tofacitinib, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "Apremilast, Pirfenidone, Cladribine, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "updated_at": 1767369485}, {"id": 67566, "ingredient1": "Cladribine", "ingredient2": "Tolvaptan", "severity": "Moderate", "effect": "Coadministration with tolvaptan may increase the plasma concentrations of drugs that are substrates of P-glycoprotein (P-gp). The proposed mechanism is decreased clearance due to inhibition of P-glycoprotein-mediated drug efflux in the intestine, liver, and/or kidney by tolvaptan.", "source": "DDInter", "management_text": "Caution is advised when tolvaptan is prescribed with drugs that are P-gp substrates, particularly those with a narrow therapeutic range such as digoxin and dabigatran etexilate. Alternatives should be considered whenever possible. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate following the initiation or discontinuation of tolvaptan. The prescribing information for the coadministered drug should be consulted for specific dosing recommendations.", "mechanism_text": "Distribution", "recommendation": "Caution is advised when tolvaptan is prescribed with drugs that are P-gp substrates, particularly those with a narrow therapeutic range such as digoxin and dabigatran etexilate.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67653/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Jynarque (tolvaptan).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[4] \"Product Information. Samsca (tolvaptan).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[5] \"Product Information. Samsca (tolvaptan).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Tacrolimus, More", "alternatives_b": "Conivaptan", "updated_at": 1767369485}, {"id": 67567, "ingredient1": "Cladribine", "ingredient2": "Topotecan", "severity": "Moderate", "effect": "The use of topotecan with other cytotoxic agents is likely to result in greater myelosuppression due to additive or synergistic pharmacologic effects. Severe neutropenia and neutropenic sepsis resulting in death were reported with topotecan and cisplatin.", "source": "DDInter", "management_text": "Caution is advised if topotecan is used with other cytotoxic agents. Dosage reductions may be required, and bone marrow function should be closely monitored. Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if topotecan is used with other cytotoxic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67654/", "reference_text": "[1] \"Product Information. Hycamtin (topotecan).\" SmithKline Beecham, Philadelphia, PA.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67568, "ingredient1": "Cladribine", "ingredient2": "Tositumomab", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67655/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Iodide I-131", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, More", "updated_at": 1767369485}, {"id": 67569, "ingredient1": "Cladribine", "ingredient2": "Trabectedin", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67656/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67570, "ingredient1": "Cladribine", "ingredient2": "Trastuzumab", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67657/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, More", "updated_at": 1767369485}, {"id": 67571, "ingredient1": "Cladribine", "ingredient2": "Triamcinolone (ophthalmic)", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67658/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Anifrolumab, Secukinumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, More", "alternatives_b": "Mometasone furoate, Amcinonide, Fluocinolone acetonide, Hydrocortisone butyrate, Fluocinonide, Fluorometholone, Clobetasol, Beclomethasone dipropionate, Mupirocin, Mometasone furoate, Epinephrine, More", "updated_at": 1767369485}, {"id": 67572, "ingredient1": "Cladribine", "ingredient2": "Trichophyton mentagrophytes", "severity": "Moderate", "effect": "Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity. Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67659/", "reference_text": "[1] \"Product Information. Spherulin (coccidioidin skin test).\" ALK Laboratories Inc, Wallingford, CT.[2] \"Product Information. Tuberculin PPD (Mantoux) (tuberculin purified protein derivative).\" Connaught Laboratories Ltd, Toronto, ON.[3] \"Product Information. Candin (candida albicans extract).\" Nielsen Biosciences Inc, San Diego, CA.[4] \"Product Information. MSTA Mumps Skin Test Antigen (mumps skin test antigen).\" Aventis Pharmaceuticals, Swiftwater, PA.[5] \"Product Information. Multitest CMI (skin test antigens, multiple).\" Aventis Pharmaceuticals, Swiftwater, PA.[6] \"Product Information. Histolyn-Cyl (histoplasmin).\" ALK Laboratories Inc, Wallingford, CT.", "alternatives_a": "Spesolimab, Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Daclizumab, Emapalumab, Anifrolumab, Deucravacitinib, Ponesimod, Ravulizumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67573, "ingredient1": "Cladribine", "ingredient2": "Trimethadione", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67660/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Golimumab, Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, More", "updated_at": 1767369485}, {"id": 67574, "ingredient1": "Cladribine", "ingredient2": "Trimetrexate", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67661/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "Tinidazole, Quinacrine, Metronidazole, Secnidazole, Atovaquone, Furazolidone, Nitazoxanide", "updated_at": 1767369485}, {"id": 67575, "ingredient1": "Cladribine", "ingredient2": "Tuberculin purified protein derivative", "severity": "Moderate", "effect": "Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity. Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67662/", "reference_text": "[1] \"Product Information. Spherulin (coccidioidin skin test).\" ALK Laboratories Inc, Wallingford, CT.[2] \"Product Information. Tuberculin PPD (Mantoux) (tuberculin purified protein derivative).\" Connaught Laboratories Ltd, Toronto, ON.[3] \"Product Information. Candin (candida albicans extract).\" Nielsen Biosciences Inc, San Diego, CA.[4] \"Product Information. MSTA Mumps Skin Test Antigen (mumps skin test antigen).\" Aventis Pharmaceuticals, Swiftwater, PA.[5] \"Product Information. Multitest CMI (skin test antigens, multiple).\" Aventis Pharmaceuticals, Swiftwater, PA.[6] \"Product Information. Histolyn-Cyl (histoplasmin).\" ALK Laboratories Inc, Wallingford, CT.", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67576, "ingredient1": "Cladribine", "ingredient2": "Typhoid vaccine (inactivated)", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67663/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67577, "ingredient1": "Cladribine", "ingredient2": "Typhoid vaccine (live)", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67664/", "reference_text": "[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[2] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur, Swiftwater, PA.[3] \"Product Information. Attenuvax (measles virus vaccine, live, attenuated).\" Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] \"Product Information. Meruvax II (rubella virus vaccine, live).\" Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Spesolimab, Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Daclizumab, Anifrolumab, Deucravacitinib, Ponesimod, Ravulizumab, Voclosporin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67578, "ingredient1": "Cladribine", "ingredient2": "Upadacitinib", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67665/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Upadacitinib, Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "Apremilast, Pirfenidone, Cladribine, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "updated_at": 1767369485}, {"id": 67579, "ingredient1": "Cladribine", "ingredient2": "Uracil mustard", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67666/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67580, "ingredient1": "Cladribine", "ingredient2": "Ustekinumab", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67667/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ustekinumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "Apremilast, Pirfenidone, Cladribine, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "updated_at": 1767369485}, {"id": 67581, "ingredient1": "Cladribine", "ingredient2": "Valaciclovir", "severity": "Moderate", "effect": "The use of cladribine with medications that undergo intracellular phosphorylation may reduce its efficacy by inhibiting its phosphorylation to its active form. The clinical significance of this interaction is unknown.", "source": "DDInter", "management_text": "Concomitant use of cladribine with medications that undergo intracellular phosphorylation should be avoided if possible.", "mechanism_text": "Antagonism", "recommendation": "Concomitant use of cladribine with medications that undergo intracellular phosphorylation should be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67668/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Hivid (zalcitabine).\" Roche Laboratories, Nutley, NJ.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, More", "alternatives_b": "Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Telaprevir, Velpatasvir, Rilpivirine, Etravirine, More", "updated_at": 1767369485}, {"id": 67582, "ingredient1": "Cladribine", "ingredient2": "Valganciclovir", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67669/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Siponimod, Anakinra, More", "alternatives_b": "Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Telaprevir, Velpatasvir, Rilpivirine, Etravirine, More", "updated_at": 1767369485}, {"id": 67583, "ingredient1": "Cladribine", "ingredient2": "Valrubicin", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67670/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Golimumab, Cyclosporine, Antithymocyte immunoglobulin (rabbit), Ravulizumab, Diroximel fumarate, Methotrexate, Inebilizumab, Belumosudil, Ozanimod, Emapalumab, Natalizumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67584, "ingredient1": "Cladribine", "ingredient2": "Varicella Zoster Vaccine (Recombinant)", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67671/", "reference_text": "[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[2] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur, Swiftwater, PA.[3] \"Product Information. Attenuvax (measles virus vaccine, live, attenuated).\" Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] \"Product Information. Meruvax II (rubella virus vaccine, live).\" Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67585, "ingredient1": "Cladribine", "ingredient2": "Vedolizumab", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67672/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "Apremilast, Pirfenidone, Cladribine, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "updated_at": 1767369485}, {"id": 67586, "ingredient1": "Cladribine", "ingredient2": "Venetoclax", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67673/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, Belimumab, More", "alternatives_b": "Pertuzumab, Vismodegib, Ivosidenib, Belzutifan, Sonidegib, Mitotane, Porfimer sodium, Estramustine, Celecoxib, Aminolevulinic acid, Tazemetostat, More", "updated_at": 1767369485}, {"id": 67587, "ingredient1": "Cladribine", "ingredient2": "Vinblastine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67674/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67588, "ingredient1": "Cladribine", "ingredient2": "Vincristine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67675/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67589, "ingredient1": "Cladribine", "ingredient2": "Vincristine (liposome)", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67676/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67590, "ingredient1": "Cladribine", "ingredient2": "Vinorelbine", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67677/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67591, "ingredient1": "Cladribine", "ingredient2": "Vitamin E", "severity": "Moderate", "effect": "The potential effects of vitamin E on cancer chemotherapy and radiation have not been established. Because vitamin E is an antioxidant, pharmacologic doses could theoretically interfere with radiation therapy and chemotherapeutic agents whose cytotoxic mechanism depends on generation of reactive oxygen species (ROS) that damage DNA and proteins, including but not limited to alkylating agents (e.g., busulfan, cyclophosphamide, melphalan), anthracyclines (e.g., doxorubicin, epirubicin), platinum coordination complexes (e.g., cisplatin, carboplatin), DNA topoisomerase inhibitors (e.g., etoposide, teniposide, irinotecan, topotecan), and photodynamic agents (e.g., porfimer). On the other hand, vitamin E may help reduce oxidative stress associated with more aggressive cancers and protect non-cancer cells from oxidative damage generated by cancer treatments, which can enhance patient tolerance and lessen the need for reducing dosage or duration of treatment.", "source": "DDInter", "management_text": "Until more information is available, vitamin E supplementation should preferably be avoided in patients undergoing cancer chemotherapy or radiation treatment. Clinicians should closely monitor antitumor response if vitamin E is used in these patients. No specific dosing of vitamin E has been established for uses other than to treat vitamin E deficiency. There has been evidence suggesting possible adverse health effects including increased risk of heart failure and mortality in association with long-term use of 400 IU/day or greater.", "mechanism_text": "Others", "recommendation": "Until more information is available, vitamin E supplementation should preferably be avoided in patients undergoing cancer chemotherapy or radiation treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67678/", "reference_text": "[1] Conklin KA \"Cancer chemotherapy and antioxidants.\" J Nutr 134 (2004): 3201S-4S[2] Labriola D, Livingston R \"Possible interactions between dietary antioxidants and chemotherapy.\" Oncology (Williston Park) 13 (1999): 1003-8; discussion 1008, 1011-2[3] D'Andrea GM \"Use of antioxidants during chemotherapy and radiotherapy should be avoided.\" CA Cancer J Clin 55 (2005): 319-21[4] Pace A, Savarese A, Picardo M, et al \"Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy.\" J Clin Oncol 21 (2003): 927-31[5] Therapeutic Research Faculty \"Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com.\" ([1995-2008...]):[6] Prasad KN \"Rationale for using high-dose multiple dietary antioxidants as an adjunct to radiation therapy and chemotherapy.\" J Nutr 134 (2004): 3182S-3S[7] Whittaker JA, Al-Ismail SA \"Effect of digoxin and vitamin E in preventing cardiac damage caused by doxorubicin in acute myeloid leukaemia.\" Br Med J (Clin Res Ed) 288 (1984): 283-4[8] Block KI, Koch AC, Mead MN, Tothy PK, Newman RA, Gyllenhaal C \"Impact of antioxidant supplementation on chemotherapeutic toxicity: a systematic review of the evidence from randomized controlled trials.\" Int J Cancer 123 (2008): 1227-39[9] Lonn E, Bosch J, Yusuf S, et al. \"Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial.\" JAMA 293 (2005): 1338-47", "alternatives_a": "Alemtuzumab, Siponimod, Pegcetacoplan, Apremilast, Pirfenidone, Belumosudil, Ozanimod, Teprotumumab, Thalidomide, Pomalidomide, Emapalumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67592, "ingredient1": "Cladribine", "ingredient2": "Yellow Fever Vaccine", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67679/", "reference_text": "[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[2] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur, Swiftwater, PA.[3] \"Product Information. Attenuvax (measles virus vaccine, live, attenuated).\" Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] \"Product Information. Meruvax II (rubella virus vaccine, live).\" Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67593, "ingredient1": "Cladribine", "ingredient2": "Zalcitabine", "severity": "Moderate", "effect": "The use of cladribine with medications that undergo intracellular phosphorylation may reduce its efficacy by inhibiting its phosphorylation to its active form. The clinical significance of this interaction is unknown.", "source": "DDInter", "management_text": "Concomitant use of cladribine with medications that undergo intracellular phosphorylation should be avoided if possible.", "mechanism_text": "Antagonism", "recommendation": "Concomitant use of cladribine with medications that undergo intracellular phosphorylation should be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67680/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Hivid (zalcitabine).\" Roche Laboratories, Nutley, NJ.", "alternatives_a": "Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Tacrolimus, Abatacept, More", "alternatives_b": "Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Telaprevir, Velpatasvir, Rilpivirine, Etravirine, More", "updated_at": 1767369485}, {"id": 67594, "ingredient1": "Cladribine", "ingredient2": "Zanubrutinib", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67681/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, More", "alternatives_b": "Dabrafenib, Dacomitinib, Pexidartinib, Larotrectinib, Fedratinib, Vemurafenib, Lapatinib, Selumetinib, Vandetanib, Afatinib, Encorafenib, More", "updated_at": 1767369485}, {"id": 67595, "ingredient1": "Cladribine", "ingredient2": "Aflibercept", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67682/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, More", "alternatives_b": "Bevacizumab, Verteporfin, Pertuzumab, Vismodegib, Ivosidenib, Belzutifan, Sonidegib, Mitotane, Porfimer sodium, Estramustine, Celecoxib, More", "updated_at": 1767369485}, {"id": 67596, "ingredient1": "Abarelix", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Long-term androgen deprivation therapy can prolong the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).", "source": "DDInter", "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.", "mechanism_text": "Synergism", "recommendation": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67683/", "reference_text": "[1] \"Product Information. Vantas (histrelin).\" Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc), Lexington, MA.[2] \"Product Information. Zoladex (goserelin).\" Zeneca Pharmaceuticals, Wilmington, DE.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Trelstar (triptorelin)\" Pharmacia and Upjohn, Kalamazoo, MI.[5] \"Product Information. Firmagon (degarelix).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Lupron (leuprolide).\" TAP Pharmaceuticals Inc, Deerfield, IL.[7] \"Product Information. Eligard (leuprolide).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[8] \"Product Information. Plenaxis (abarelix).\" Praecis Pharmaceuticals Inc, Waltham, MA.", "alternatives_a": "Anastrozole, Aminoglutethimide, Exemestane, Fulvestrant", "alternatives_b": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, More", "updated_at": 1767369485}, {"id": 67597, "ingredient1": "Clarithromycin", "ingredient2": "Acetohexamide", "severity": "Moderate", "effect": "Limited data suggest that clarithromycin may potentiate the hypoglycemic effect of sulfonylureas in susceptible individuals such as the elderly and patients with renal impairment. The exact mechanism is unknown but may involve clarithromycin displacement of sulfonylureas from plasma protein binding sites.", "source": "DDInter", "management_text": "Clarithromycin should be prescribed cautiously to diabetic patients with renal impairment who are receiving sulfonylurea therapy, particularly if they are also elderly. Patients should be advised to regularly monitor their blood sugar and counseled on how to recognize and treat hypoglycemia, which may include symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, and palpitations. The physician should be notified if an interaction is suspected.", "mechanism_text": "Distribution", "recommendation": "Clarithromycin should be prescribed cautiously to diabetic patients with renal impairment who are receiving sulfonylurea therapy, particularly if they are also elderly.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67684/", "reference_text": "[1] Bussing R, Gende A \"Severe hypoglycemia from clarithromycin-sulfonylurea drug interaction.\" Diabetes Care 25 (2002): 1659-61[2] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[3] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[4] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[5] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[6] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[12] Cheng KL, Nafziger AN, Peloquin CA, Amsden GW \"Effect of grapefruit juice on clarithromycin pharmacokinetics.\" Antimicrob Agents Chemother 42 (1998): 927-9", "alternatives_a": "Guar gum", "alternatives_b": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Vonoprazan, Amoxicillin, Lansoprazole, More", "updated_at": 1767369485}, {"id": 67598, "ingredient1": "Aminophylline", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Coadministration with certain macrolide antibiotics may increase the serum concentrations of theophylline, which may result in toxicity. The proposed mechanism is macrolide inhibition of CYP450 3A4, the isoenzyme partially responsible for the metabolic clearance of theophylline.", "source": "DDInter", "management_text": "Pharmacologic response and serum theophylline levels should be monitored more closely whenever a macrolide antibiotic is added to or withdrawn from therapy, and the methylxanthine dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response and serum theophylline levels should be monitored more closely whenever a macrolide antibiotic is added to or withdrawn from therapy, and the methylxanthine dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67685/", "reference_text": "[1] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part I).\" Clin Pharmacokinet 20 (1991): 66-80[2] Amsden GW \"Erythromycin, clarithromycin, and azithromycin: are the differences real?\" Clin Ther 18 (1996): 56-72[3] Amsden GW \"Macrolides versus azalides: a drug interaction update.\" Ann Pharmacother 29 (1995): 906-17[4] Principi N, Esposito S \"Comparative tolerability of erythromycin and newer macrolide antibacterials in paediatric: Patients.\" Drug Safety 20 (1999): 25-41[5] Descotes J, Andre P, Evreux JC \"Pharmacokinetic drug interactions with macrolide antibiotics.\" J Antimicrob Chemother 15 (1985): 659-64[6] Rockwood RP, Embardo LS \"Theophylline, ciprofloxacin, erythromycin: a potentially harmful regimen.\" Ann Pharmacother 27 (1993): 651-2[7] von Rosenstiel NA, Adam D \"Macrolide antibacterials. Drug interactions of clinical significance.\" Drug Saf 13 (1995): 105-22[8] Reisz G, Pingleton SK, Melethil S, Ryan PB \"The effect of erythromycin on theophylline pharmacokinetics in chronic bronchitis.\" Am Rev Respir Dis 127 (1983): 581-4[9] Jonkman JH, Upton RA \"Pharmacokinetic drug interactions with theophylline.\" Clin Pharmacokinet 9 (1984): 309-34[10] Ludden TM \"Pharmacokinetic interactions of the macrolide antibiotics.\" Clin Pharmacokinet 10 (1985): 63-79[11] Hildebrandt R, Moller H, Gundert-Remy U \"Influence of theophylline on the renal clearance of erythromycin.\" Int J Clin Pharmacol Ther Toxicol 25 (1987): 601-4[12] May DC, Jarboe CH, Ellenburg DT, et al \"The effects of erythromycin on theophylline elimination in normal males.\" J Clin Pharmacol 22 (1982): 125-30[13] Gillum JG, Israel DS, Scott RB, Climo MW, Polk RE \"Effect of combination therapy with ciprofloxacin and clarithromycin on theophylline pharmacokinetics in healthy volunteers.\" Antimicrob Agents Chemother 40 (1996): 1715-6[14] Richer C, Mathieu M, Bah H, Thuillez C, Duroux P, Giudicelli JF \"Theophylline kinetics and ventilatory flow in bronchial asthma and chronic airflow obstruction: influence of erythromycin.\" Clin Pharmacol Ther 31 (1982): 579-86[15] Pfeifer HJ, Greenblatt DJ, Friedman P \"Effects of three antibiotics on theophylline kinetics.\" Clin Pharmacol Ther 26 (1979): 36-40[16] Prince RA, Wing DS, Weinberger MM, et al \"Effect of erythromycin on theophylline kinetics.\" J Allergy Clin Immunol 68 (1981): 427-31[17] Kozak PP, Cummins LH, Gillman SH \"Administration of erythromycin to patients on theophylline.\" J Allergy Clin Immunol 60 (1977): 149-51[18] Zarowitz BJ, Szefler SJ, Lasezkay GM \"Effect of erythromycin base on theophylline kinetics.\" Clin Pharmacol Ther 29 (1981): 601-5[19] Bachmann K, Nunlee M, Martin M, et al \"Changes in the steady-state pharmacokinetics of theophylline during treatment with dirithromycin.\" J Clin Pharmacol 30 (1990): 1001-5[20] Maddux MS, Leeds NH, Organek HW, Hasegawa GR, Bauman JL \"The effect of erythromycin on theophylline pharmacokinetics at steady state.\" Chest 81 (1982): 563-5[21] Pollak PT, Slayter KL \"Reduced serum theophylline concentrations after discontinuation of azithromycin: evidence for an unusual interaction.\" Pharmacotherapy 17 (1997): 827-9[22] Wiggins J, Arbab O, Ayres JG, Skinner C \"Elevated serum theophylline concentration following cessation of erythromycin treatment.\" Eur J Respir Dis 68 (1986): 298-300[23] Kamada AK, Hill MR, Brenner AM, Szefler SJ \"Effect of low-dose troleandomycin on theophylline clearance: implications for therapeutic drug monitoring.\" Pharmacotherapy 12 (1992): 98-102[24] Parish RA, Haulman NJ, Burns RM \"Interaction of theophylline with erythromycin base in a patient with seizure activity.\" Pediatrics 72 (1983): 828-30[25] Branigan TA, Robbins RA, Cady WJ, et al \"The effects of erythromycin on the absorption and disposition kinetics of theophylline.\" Eur J Clin Pharmacol 21 (1981): 115-20[26] Renton KW, Gray JD, Hung OR \"Depression of theophylline elimination by erythromycin.\" Clin Pharmacol Ther 30 (1981): 422-6[27] Bachmann K, Jauregui L, Sides G, Sullivan TJ \"Steady-state pharmacokinetics of theophylline in COPD patients treated with dirithromycin.\" J Clin Pharmacol 33 (1993): 861-5[28] Peters DH, Friedel HA, McTavish D \"Azithromycin: a review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy.\" Drugs 44 (1992): 750-99[29] Iliopoulou A, Aldhous ME, Johnston A, Turner P \"Pharmacokinetic interaction between theophylline and erythromycin.\" Br J Clin Pharmacol 14 (1982): 495-9[30] Nahata M \"Drug interactions with azithromycin and the macrolides: an overview.\" J Antimicrob Chemother 37 Suppl C (1996): 133-42[31] Tenenbein M \"Theophylline toxicity due to drug interaction.\" J Emerg Med 7 (1989): 249-51[32] Paulsen O, Hoglund P, Nilsson LG, Bengtsson HI \"The interaction of erythromycin with theophylline.\" Eur J Clin Pharmacol 32 (1987): 493-8", "alternatives_a": "Tinidazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Esomeprazole, Vonoprazan, Amoxicillin, Telithromycin, More", "alternatives_b": "Omalizumab, Tezepelumab, Benralizumab, Caffeine, Reslizumab, Dyphylline, Mepolizumab, Roflumilast, Bromotheophylline", "updated_at": 1767369485}, {"id": 67599, "ingredient1": "Amoxapine", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67686/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[16] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Phenelzine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Vortioxetine, Milnacipran, Tryptophan, Esketamine", "alternatives_b": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Nizatidine, Esomeprazole, More", "updated_at": 1767369485}, {"id": 67600, "ingredient1": "Amprenavir", "ingredient2": "Clarithromycin", "severity": "Minor", "effect": "Drugs that act as both substrate and inhibitor of the CYP450 3A4 isoenzyme may alter the plasma concentration of amprenavir. Amprenavir may increase blood levels of the CYP450 3A4 inhibitor. The extent of the alterations in serum drug levels is unknown and the clinical significance is uncertain. When concomitant therapy is required, the patient should be monitored for adverse effects of both drugs and dose adjustments made when indicated.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67687/", "reference_text": "[1] Falloon J, Piscitelli S, Vogel S, Sadler B, Mitsuya H, Kavlick MF, Yoshimura K, Rogers M, LaFon S, Manion DJ, Lane HC, Masur \"Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: Pharmacokinetic drug interactions and antiviral activity.\" Clin Infect Dis 30 (2000): 313-8[2] Polk RE, Crouch MA, Israel DS, et al. \"Pharmacokinetic interaction between ketoconazole and amprenavir after single doses in healthy men.\" Pharmacotherapy 19 (1999): 1378-84[3] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[4] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome, Research Triangle Pk, NC.[5] Demarles D, Gillotin C, Bonaventure-Paci S, Vincent I, Fosse S, Taburet AM \"Single-dose pharmacokinetics of amprenavir coadministered with grapefruit juice.\" Antimicrob Agents Chemother 46 (2002): 1589-1590", "alternatives_a": "Glecaprevir, Tenofovir alafenamide, Cabotegravir, Lenacapavir, Velpatasvir, Voxilaprevir, Maribavir, Pibrentasvir, Rimantadine, Elvitegravir, Valganciclovir, More", "alternatives_b": "Pantoprazole, Levofloxacin, Tetracycline, Rabeprazole, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Famotidine, Nizatidine, Esomeprazole, More", "updated_at": 1767369485}, {"id": 67601, "ingredient1": "Anisindione", "ingredient2": "Clarithromycin", "severity": "Major", "effect": "Coadministration with clarithromycin or erythromycin may infrequently but substantially enhance the hypoprothrombinemic effect of warfarin and other coumarin anticoagulants. The exact mechanism of interaction is unknown. Data from clinical studies have not supported a significant, predictable pharmacodynamic or pharmacokinetic interaction in general. Although both macrolides are potent inhibitors of CYP450 3A4 and can inhibit metabolism of the R(+) enantiomer of warfarin, the overall effect on racemic warfarin pharmacokinetics appears to be minor.", "source": "DDInter", "management_text": "Given the potential for clinically significant interaction and even fatality in the occasional, susceptible patient, close monitoring is recommended if clarithromycin or erythromycin is prescribed during coumarin anticoagulant therapy. The INR should be checked frequently and coumarin dosage adjusted accordingly, particularly following initiation or discontinuation of macrolide therapy in patients who are stabilized on their anticoagulant regimen. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools. The same precaution may be applicable during therapy with other oral anticoagulants (e.g., indandiones) and other similar macrolides (e.g., troleandomycin), although clinical data are lacking.", "mechanism_text": "Metabolism", "recommendation": "Given the potential for clinically significant interaction and even fatality in the occasional, susceptible patient, close monitoring is recommended if clarithromycin or erythromycin is prescribed during coumarin anticoagulant therapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67688/", "reference_text": "[1] O'Donnell D \"Antibiotic-induced potentiation of oral anticoagulant agents.\" Med J Aust 150 (1989): 163-4[2] Hassell D, Utt JK \"Suspected interaction: warfarin and erythromycin.\" South Med J 78 (1985): 1015-6[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Grau E, Real E, Pastor E \"Interaction between clarithromycin and oral anticoagulants.\" Ann Pharmacother 30 (1996): 1495-6[5] Kiran N, Azam S, Dhakam S \"Clarithromycin induced digoxin toxicity: case report and review.\" J Pak Med Assoc 54 (2004): 440-1[6] Gooderham MJ, Bolli P, Fernandez PG \"Concomitant digoxin toxicity and warfarin interaction in a patient receiving clarithromycin.\" Ann Pharmacother 33 (1999): 796-9[7] Schwartz J, Bachmann K, Perrigo E \"Interaction between warfarin and erythromycin.\" South Med J 76 (1983): 91-3[8] Visser LE, Penning-Van Bees FJ, Harrie Kasbergen AA, et al. \"Overanticoagulation associated with combined use of antibacterial drugs and acenocoumarol or phenprocoumon anticoagulants.\" Thromb Haemost 88 (2002): 705-10[9] Bartle WR \"Possible warfarin-erythromycin interaction.\" Arch Intern Med 140 (1980): 985-7[10] Grau E, Fontcuberta J, Felez J \"Erythromycin-oral anticoagulants interaction.\" Arch Intern Med 146 (1986): 1639[11] Recker MW, Kier KL \"Potential interaction between clarithromycin and warfarin.\" Ann Pharmacother 31 (1997): 996-8[12] Sato RI, Gray DR, Brown SE \"Warfarin interaction with erythromycin.\" Arch Intern Med 144 (1984): 2413-4[13] Weibert RT, Lorentz SM, Townsend RJ, et al \"Effect of erythromycin in patients receiving long-term warfarin therapy.\" Clin Pharm 8 (1989): 210-4[14] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[15] Husserl FE \"Erythromycin-warfarin interaction.\" Arch Intern Med 143 (1983): 1831, 1836[16] Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E \"The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.\" Chest 126(3 Suppl) (2004): 204S-233S[17] Loeliger EA, van der Esch B, Mattern MJ, Hemker HC \"The biological disappearance rate of prothrombin, factors VII, IX and X from plasma in hypothyroidism, hyperthyroidism, and during fever.\" Thromb Diath Haemorrh 10 (1963): 267-77[18] Bachmann K, Schwartz JI, Forney R Jr, Frogameni A, Jauregui LE \"The effect of erythromycin on the disposition kinetics of warfarin.\" Pharmacology 28 (1984): 171-6[19] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[20] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[21] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[22] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[23] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[24] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[25] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[26] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[27] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[28] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[29] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[30] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[31] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[32] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[33] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[34] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[35] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[36] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[37] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[38] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[39] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[40] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[41] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[42] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[43] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[44] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[45] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[46] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[47] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[48] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[49] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[50] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[51] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[52] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[53] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[54] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[55] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5", "alternatives_a": "Misoprostol, Bismuth subcitrate potassium, Famotidine, Nizatidine, Ranitidine, Vonoprazan, Dirithromycin, Lincomycin, Troleandomycin, Clindamycin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67602, "ingredient1": "Clarithromycin", "ingredient2": "Astemizole", "severity": "Major", "effect": "Coadministration with the ketolide, telithromycin, as well as certain macrolide antibiotics may significantly increase the plasma concentrations of astemizole and terfenadine. The mechanism is inhibition of CYP450 3A4, the isoenzyme responsible for the metabolic clearance of astemizole and terfenadine. High plasma levels of these agents have been associated with prolongation of the QT interval on the ECG; ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes; cardiac arrest; and sudden death. Macrolides that may significantly inhibit CYP450 3A4 include clarithromycin, erythromycin, and troleandomycin. Azithromycin and dirithromycin are generally believed to have little, if any, effect on CYP450 3A4.", "source": "DDInter", "management_text": "Given the potential for serious and life-threatening adverse cardiac events associated with increased plasma levels of astemizole and terfenadine, the use of these agents with clarithromycin, erythromycin, troleandomycin, or telithromycin is considered contraindicated. Loratadine, cetirizine, or fexofenadine may be safer alternatives during therapy with telithromycin or macrolides. Depending on organism susceptibility, azithromycin and dirithromycin may be appropriate alternatives during therapy with astemizole or terfenadine.", "mechanism_text": "Metabolism", "recommendation": "Given the potential for serious and life-threatening adverse cardiac events associated with increased plasma levels of astemizole and terfenadine, the use of these agents with clarithromycin, erythromycin, troleandomycin, or telithromycin is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67689/", "reference_text": "[1] Ament PW, Paterson A \"Drug interactions with the nonsedating antihistamines.\" Am Fam Physician 56 (1997): 223[2] Brannan MD, Reidenberg P, Radwanski E, et al \"Loratadine administered concomitantly with erythromycin: pharmacokinetic and electrocardiographic evaluations.\" Clin Pharmacol Ther 58 (1995): 269-78[3] Jurima-Romet M, Crawford K, Cyr T, Inaba T \"Terfenadine metabolism in human liver. In vitro inhibition by macrolide antibiotics and azole antifungals.\" Drug Metab Dispos 22 (1994): 849-57[4] European Agency for the Evaluation of Medicinal Products. Committee for Proprietary Medicinal Products \"European Public Assessment Report Ketek (telithromycin) (Rev. 2) Available from: URL: http:www.emea.eu.int/humandocs/Humans/EPAR/Ketek/Ketek.htm.\" ([2001]):[5] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[6] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675[7] Biglin KE, Faraon MS, Constance TD, Lieh-Lai M \"Drug-induced torsades de pointes: a possible interaction of terfenadine and erythromycin.\" Ann Pharmacother 28 (1994): 282[8] Nahata M \"Drug interactions with azithromycin and the macrolides: an overview.\" J Antimicrob Chemother 37 ( Suppl (1996): 133-42[9] Amsden GW \"Macrolides versus azalides: a drug interaction update.\" Ann Pharmacother 29 (1995): 906-17[10] Harris S, Hilligoss DM, Colangelo PM, Eller M, Okerholm R \"Azithromycin and terfenadine: lack of drug interaction.\" Clin Pharmacol Ther 58 (1995): 310-5[11] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[12] Kemp JP \"Decreased antihistamine metabolism.\" Ann Allergy 69 (1992): 533[13] \"Product Information. Hismanal (astemizole).\" Janssen Pharmaceutica, Titusville, NJ.[14] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[15] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[16] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[17] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[18] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[19] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[20] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[21] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[22] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[25] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[26] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[27] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[28] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[29] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675[30] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[31] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9", "alternatives_a": "Mepyramine, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Dexbrompheniramine, Clemastine, Doxylamine, Meclizine, Cyclizine, More", "alternatives_b": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Nizatidine, Esomeprazole, More", "updated_at": 1767369485}, {"id": 67603, "ingredient1": "Clarithromycin", "ingredient2": "Bacampicillin", "severity": "Minor", "effect": "Although some in vitro data indicate synergism between macrolide antibiotics and penicillins, other in vitro data indicate antagonism. When these drugs are given together, neither has predictable therapeutic efficacy. Data are available for erythromycin, although theoretically this interaction could occur with any macrolide. Except for monitoring of the effectiveness of antibiotic therapy, no special precautions appear to be necessary.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67690/", "reference_text": "[1] Strom J \"Penicillin and erythromycin singly and in combination in scarlatina therapy and the interference between them.\" Antibiot Chemother 11 (1961): 694-7[2] Cohn JR, Jungkind DL, Baker JS \"In vitro antagonism by erythromycin of the bactericidal action of antimicrobial agents against common respiratory pathogens.\" Antimicrob Agents Chemother 18 (1980): 872-6[3] Penn RL, Ward TT, Steigbigel RT \"Effects of erythromycin in combination with penicillin, ampicillin, or gentamicin on the growth of listeria monocytogenes.\" Antimicrob Agents Chemother 22 (1982): 289-94", "alternatives_a": "Tinidazole, Levofloxacin, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Rifabutin, Vonoprazan, Amoxicillin, Telithromycin, Lincomycin, More", "alternatives_b": "Tazobactam, Sulbactam", "updated_at": 1767369485}, {"id": 67604, "ingredient1": "Clarithromycin", "ingredient2": "Bedaquiline", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of bedaquiline, which is primarily metabolized by CYP450 3A4 to its less active N-monodesmethyl metabolite, M2. Bedaquiline can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Concomitant use of potent CYP450 3A4 inhibitors such as ceritinib, clarithromycin, ketoconazole, posaconazole, saquinavir, telithromycin, and voriconazole given systemically for more than 14 consecutive days should generally be avoided during treatment with bedaquiline unless the benefit is anticipated to outweigh the risk. Because these agents may also cause QT interval prolongation, caution is recommended when they are used together with bedaquiline. ECG, serum electrolytes (potassium, magnesium, calcium), and liver function tests (ALT, AST, alkaline phosphatase, bilirubin) should be monitored before starting bedaquiline therapy and periodically during treatment in accordance with the product labeling. Hypokalemia, hypomagnesemia, and hypocalcemia must be corrected prior to bedaquiline administration. All QT-prolonging drugs including bedaquiline should be interrupted in patients who develop clinically significant ventricular arrhythmia or a QTcF interval greater than 500 msec confirmed by repeat ECG.", "mechanism_text": "Metabolism, Synergism", "recommendation": "Concomitant use of potent CYP450 3A4 inhibitors such as ceritinib, clarithromycin, ketoconazole, posaconazole, saquinavir, telithromycin, and voriconazole given systemically for more than 14 consecutive days should generally be avoided during treatment with bedaquiline unless the benefit is anticipated to outweigh the risk.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67691/", "reference_text": "[1] \"Product Information. Sirturo (bedaquiline).\" Janssen Pharmaceuticals, Titusville, NJ.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[3] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[4] \"Product Information. Sirturo (bedaquiline).\" Janssen Pharmaceuticals, Titusville, NJ.", "alternatives_a": "Tinidazole, Pantoprazole, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Cimetidine, Esomeprazole, Ranitidine, Nizatidine, More", "alternatives_b": "Capreomycin, Rifamycin, Cycloserine, Pyridoxine, Ethionamide, Pretomanid, Aminosalicylic acid", "updated_at": 1767369485}, {"id": 67605, "ingredient1": "Clarithromycin", "ingredient2": "Bepridil", "severity": "Major", "effect": "Class IA (e.g., disopyramide, quinidine, procainamide) and class III (e.g., amiodarone, dofetilide, sotalol) antiarrhythmic agents can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks. Caution and clinical monitoring are recommended if concomitant use is required. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67692/", "reference_text": "[1] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[2] Yamreudeewong W, DeBisschop M, Martin L, Lower D \"Potentially Significant Drug Interactions of Class III Antiarrhythmic Drugs.\" Drug Saf 26 (2003): 421-38[3] \"Product Information. Norpace (disopyramide).\" Searle, Skokie, IL.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Betapace (sotalol).\" Berlex, Richmond, CA.[6] \"Product Information. Procan SR (procainamide).\" Parke-Davis, Morris Plains, NJ.[7] Maxa JL, Hebeler RF, Adeeko MA \"Torsades de pointes following concurrent amiodarone and levofloxacin therapy.\" Proc (Bayl Univ Med Cent) 19 (2006): 345-6[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] \"Product Information. Cordarone (amiodarone).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[10] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[11] \"Product Information. Vascor (bepridil).\" McNeil Pharmaceutical, Raritan, NJ.[12] \"Product Information. Quiniglute (quinidine).\" Berlex, Richmond, CA.[13] Trujillo TC, Nolan PE \"Antiarrhythmic agents - Drug interactions of clinical significance.\" Drug Safety 23 (2000): 509-32[14] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[15] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[16] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[17] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[18] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[19] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[20] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[21] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[22] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[25] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[26] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[27] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[28] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[29] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[30] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[31] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[32] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[33] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[34] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[35] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[36] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[37] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[38] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[39] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[40] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[41] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[42] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[43] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[44] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[45] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Cimetidine, Esomeprazole, Ranitidine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67606, "ingredient1": "Clarithromycin", "ingredient2": "Berotralstat", "severity": "Major", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may significantly increase the plasma concentrations of berotralstat. Berotralstat is a substrate of both P-gp and BCRP.", "source": "DDInter", "management_text": "The dosage of berotralstat should be reduced to 110 mg once daily in patients requiring chronic coadministration with P-gp and/or BCRP inhibitors. Patients should be advised to contact their physician if they experience undue adverse effects of berotralstat such as abdominal pain, vomiting, or diarrhea. Patients should seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.", "mechanism_text": "Absorption", "recommendation": "The dosage of berotralstat should be reduced to 110 mg once daily in patients requiring chronic coadministration with P-gp and/or BCRP inhibitors.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67693/", "reference_text": "[1] \"Product Information. Orladeyo (berotralstat).\" BioCryst Pharmaceuticals Inc, Durham, NC.[2] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[3] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[4] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[5] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Rabeprazole, Dexlansoprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, Sucralfate, More", "alternatives_b": "Hemin, Conestat alfa, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Human C1-esterase inhibitor, Crizanlizumab, Lanadelumab, Icatibant", "updated_at": 1767369485}, {"id": 67607, "ingredient1": "Clarithromycin", "ingredient2": "Bifidobacterium longum infantis", "severity": "Moderate", "effect": "INTERVAL: Coadministration of oral probiotic preparations with oral antibiotics may reduce the efficacy of the probiotic. It has been theorized that concomitant antibiotics may kill the live organisms found in lactobacillus-, bacillus coagulans-, and bifidobacteria-containing oral probiotic preparations. However, the clinical significance of the interaction has not been established.", "source": "DDInter", "management_text": "Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.", "mechanism_text": "Others", "recommendation": "Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67694/", "reference_text": "[1] Clarion Brands, Inc. \"Florajen Probiotics. Available from: URL: https://www.florajen.com/products/florajen-women.\" ([2018]):", "alternatives_a": "Tinidazole, Pantoprazole, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Famotidine, Rifabutin, Cimetidine, Esomeprazole, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67608, "ingredient1": "Clarithromycin", "ingredient2": "Boceprevir", "severity": "Moderate", "effect": "Coadministration of a macrolide or ketolide antibiotic (clarithromycin, erythromycin, telithromycin) with a hepatitis C virus (HCV) NS3/4A protease inhibitor (boceprevir, telaprevir) is expected to increase the plasma concentrations of both drugs. The mechanism may involve both competitive and noncompetitive inhibition of CYP450 3A4, since these drugs are all substrates as well as inhibitors of the isoenzyme. No pharmacokinetic data are currently available. Clinically, high plasma levels of macrolide or ketolide antibiotics may increase the risk of QT interval prolongation and torsade de pointes arrhythmia.", "source": "DDInter", "management_text": "Caution and close clinical monitoring are recommended if clarithromycin, erythromycin, or telithromycin are used in combination with a HCV NS3/4A protease inhibitor. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, or syncope.", "mechanism_text": "Metabolism", "recommendation": "Caution and close clinical monitoring are recommended if clarithromycin, erythromycin, or telithromycin are used in combination with a HCV NS3/4A protease inhibitor.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67695/", "reference_text": "[1] \"Product Information. Victrelis (boceprevir).\" Schering-Plough Corporation, Kenilworth, NJ.[2] \"Product Information. Incivek (telaprevir).\" Vertex Pharmaceuticals, Cambridge, MA.[3] \"Product Information. Incivek (telaprevir).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Pantoprazole, Levofloxacin, Tetracycline, Rabeprazole, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Cimetidine, More", "alternatives_b": "Glecaprevir, Tenofovir alafenamide, Cabotegravir, Lenacapavir, Velpatasvir, Voxilaprevir, Maribavir, Pibrentasvir, Rimantadine, Elvitegravir, Valganciclovir, More", "updated_at": 1767369485}, {"id": 67609, "ingredient1": "Clarithromycin", "ingredient2": "Carbenicillin", "severity": "Minor", "effect": "Although some in vitro data indicate synergism between macrolide antibiotics and penicillins, other in vitro data indicate antagonism. When these drugs are given together, neither has predictable therapeutic efficacy. Data are available for erythromycin, although theoretically this interaction could occur with any macrolide. Except for monitoring of the effectiveness of antibiotic therapy, no special precautions appear to be necessary.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67696/", "reference_text": "[1] Strom J \"Penicillin and erythromycin singly and in combination in scarlatina therapy and the interference between them.\" Antibiot Chemother 11 (1961): 694-7[2] Cohn JR, Jungkind DL, Baker JS \"In vitro antagonism by erythromycin of the bactericidal action of antimicrobial agents against common respiratory pathogens.\" Antimicrob Agents Chemother 18 (1980): 872-6[3] Penn RL, Ward TT, Steigbigel RT \"Effects of erythromycin in combination with penicillin, ampicillin, or gentamicin on the growth of listeria monocytogenes.\" Antimicrob Agents Chemother 22 (1982): 289-94", "alternatives_a": "Tazobactam, Sulbactam", "alternatives_b": "Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, More", "updated_at": 1767369485}, {"id": 67610, "ingredient1": "Frangula purshiana bark", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67697/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Schaefer DC, Cheskin LJ \"Constipation in the elderly.\" Am Fam Physician 58 (1998): 907-14[4] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993): 138-45[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998): 517-8", "alternatives_a": "Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Sucralfate, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67611, "ingredient1": "Clarithromycin", "ingredient2": "Castor oil", "severity": "Moderate", "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67698/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Schaefer DC, Cheskin LJ \"Constipation in the elderly.\" Am Fam Physician 58 (1998): 907-14[4] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993): 138-45[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998): 517-8", "alternatives_a": "Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Sucralfate, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 67612, "ingredient1": "Clarithromycin", "ingredient2": "Cerivastatin", "severity": "Major", "effect": "Some macrolide antibiotics inhibit CYP450 3A4 and may elevate the plasma concentrations of HMG-CoA reductase inhibitors that are metabolized by the isoenzyme. Macrolides that may significantly inhibit CYP450 3A4 include troleandomycin, erythromycin, and clarithromycin.", "source": "DDInter", "management_text": "The benefits of using HMG-CoA reductase inhibitors that are metabolized by CYP450 3A4 in combination with medications that can inhibit the isoenzyme such as clarithromycin and erythromycin should be carefully weighed against the potentially increased risk of myopathy including rhabdomyolysis. A lower dosage of the HMG-CoA reductase inhibitor should be considered if concomitant use is required. Atorvastatin labeling recommends that the dosage not exceed 20 mg/day when used in combination with clarithromycin. Fluvastatin, pitavastatin, and rosuvastatin may be safer alternatives, since they are not metabolized by CYP450 3A4. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.", "mechanism_text": "Metabolism", "recommendation": "The benefits of using HMG-CoA reductase inhibitors that are metabolized by CYP450 3A4 in combination with medications that can inhibit the isoenzyme such as clarithromycin and erythromycin should be carefully weighed against the potentially increased risk of myopathy including rhabdomyolysis.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67699/", "reference_text": "[1] Kantola T, Kivisto KT, Neuvonen PJ \"Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations.\" Clin Pharmacol Ther 64 (1998): 177-82[2] Ayanian JZ, Fuchs CS, Stone RM \"Lovastatin and rhabdomyolysis.\" Ann Intern Med 109 (1988): 682-3[3] \"Product Information. Zocor (simvastatin).\" Merck & Co, Inc, West Point, PA.[4] Williams D, Feely J \"Pharmacokinetic-Pharmacodynamic Drug Interactions with HMG-CoA Reductase Inhibitors.\" Clin Pharmacokinet 41 (2002): 343-70[5] Neuvonen PJ, Backman JT, Niemi M \"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.\" Clin Pharmacokinet 47 (2008): 463-74[6] Corpier CL, Jones PH, Suki WN, et al. \"Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients.\" JAMA 260 (1988): 239-41[7] Amsden GW, Kuye O, Wei GC \"A study of the interaction potential of azithromycin and clarithromycin with atorvastatin in healthy volunteers.\" J Clin Pharmacol 42 (2002): 444-9[8] Siedlik PH, Olson SC, Yang BB, Stern RH \"Erythromycin coadministration increases plasma atorvastatin concentrations.\" J Clin Pharmacol 39 (1999): 501-4[9] Ayanian JZ, Fuchs CS, Stone RM \"Lovastatin and rhabdomyolysis.\" Ann Intern Med 109 (1988): 682-3[10] Chouhan UM, Chakrabarti S, Millward LJ \"Simvastatin interaction with clarithromycin and amiodarone causing myositis.\" Ann Pharmacother 39 (2005): 1760-1[11] \"Product Information. Baycol (cerivastatin).\" Bayer, West Haven, CT.[12] Westphal JF \"Macrolide - induced clinically relevant drug interactions with cytochrome P-450 (CYP) 3A4: an update focused on clarithromycin, azithromycin, and dirithromycin.\" Br J Clin Pharmacol 50 (2000): 285-95[13] Garnett WR \"Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors.\" Am J Health Syst Pharm 52 (1995): 1639-45[14] Grunden JW, Fisher KA \"Lovastatin-induced rhabdomyolysis possibly associated with clarithromycin and azithromycin.\" Ann Pharmacother 31 (1997): 859-63[15] \"Product Information. Lipitor (atorvastatin).\" Parke-Davis, Morris Plains, NJ.[16] Wong PW, Dillard TA, Kroenke K \"Multiple organ toxicity from addition of erythromycin to long-term lovastatin therapy.\" South Med J 91 (1998): 202-5[17] \"Product Information. Mevacor (lovastatin).\" Merck & Co, Inc, West Point, PA.[18] East C, Alivizatos PA, Grundy SM, Jones PH, Farmer JA \"Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation.\" N Engl J Med 318 (1988): 47-8[19] Omar MA, Wilson JP \"FDA adverse event reports on statin-associated rhabdomyolysis.\" Ann Pharmacother 36 (2002): 288-95[20] Lee AJ, Maddix DS \"Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin.\" Ann Pharmacother 35 (2001): 26-31[21] Spach DH, Bauwens JE, Clark CD, Burke WG \"Rhabdomyolysis associated with lovastatin and erythromycin use.\" West J Med 154 (1991): 213-5[22] Huynh T, Cordato D, Yang F, et al. \"HMG coA reductase-inhibitor-related myopathy and the influence of drug interactions.\" Intern Med J 32(9-10) (2002): 486-90[23] Sipe BE, Jones RJ, Bokhart GH \"Rhabdomyolysis Causing AV Blockade Due to Possible Atorvastatin, Esomeprazole, and Clarithromycin Interaction.\" Ann Pharmacother 37 (2003): 808-11[24] Cooper JM, Jones AL \"Neuroleptic malignant syndrome or a statin drug reaction? A case report.\" Clin Neuropharmacol 32 (2009): 348-9[25] Welling PG, Huang H, Hewitt PF, Lyons LL \"Bioavailability of erythromycin stearate: influence of food and fluid volume.\" J Pharm Sci 67 (1978): 764-6[26] Welling PG \"Influence of food and diet on gastrointestinal drug absorption: a review.\" J Pharmacokinet Biopharm 5 (1977): 291-334[27] Randinitis EJ, Sedman AJ, Welling PG, Kinkel AW \"Effect of a high-fat meal on the bioavailability of a polymer-coated erythromycin particle tablet formulation.\" J Clin Pharmacol 29 (1989): 79-84[28] Coyne TC, Shum S, Chun AH, Jeansonne L, Shirkey HC \"Bioavailability of erythromycin ethylsuccinate in pediatric patients.\" J Clin Pharmacol 18 (1978): 194-202[29] Malmborg AS \"Effect of food on absorption of erythromycin. A study of two derivatives, the stearate and the base.\" J Antimicrob Chemother 5 (1979): 591-9[30] Welling PG, Elliott RL, Pitterle ME, et al \"Plasma levels following single and repeated doses of erythromycin estolate and erythromycin stearate.\" J Pharm Sci 68 (1979): 150-5[31] Kanazawa S, Ohkubo T, Sugawara K \"The effects of grapefruit juice on the pharmacokinetics of erythromycin.\" Eur J Clin Pharmacol 56 (2001): 799-803[32] Richter WO, Jacob BG, Schwandt P \"Interaction between fibre and lovastatin.\" Lancet 338 (1991): 706[33] \"Product Information. Lipitor (atorvastatin).\" Parke-Davis, Morris Plains, NJ.[34] Boberg M, Angerbauer R, Fey P, Kanhai WK, Karl W, Kern A, Ploschke J, Radtke M \"Metabolism of cerivastatin by human liver microsomes in vitro. Characterization of primary metabolic pathways and of cytochrome P45 isozymes involved.\" Drug Metab Dispos 25 (1997): 321-31[35] McMillan K \"Considerations in the formulary selection of hydroxymethylglutaryl coenzyme a reductase inhibitors.\" Am J Health Syst Pharm 53 (1996): 2206-14[36] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[37] Neuvonen PJ, Backman JT, Niemi M \"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.\" Clin Pharmacokinet 47 (2008): 463-74[38] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27", "alternatives_a": "Gemfibrozil, Fenofibric acid, Pitavastatin, Evinacumab, Evolocumab, Dextrothyroxine, Cholestyramine, Clofibrate, Colestipol, Bempedoic acid, Colesevelam, More", "alternatives_b": "Amoxicillin, Tetracycline, Rabeprazole, Dexlansoprazole, Sucralfate, Bismuth subcitrate potassium, Famotidine, Rifabutin, Nizatidine, Esomeprazole, Levofloxacin, More", "updated_at": 1767369485}, {"id": 67613, "ingredient1": "Clarithromycin", "ingredient2": "Chlorpromazine", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67700/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[16] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Loxapine, Molindone, Thiothixene", "alternatives_b": "Tinidazole, Tetracycline, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Nizatidine, Esomeprazole, Vonoprazan, Amoxicillin, Dirithromycin, More", "updated_at": 1767369485}, {"id": 67614, "ingredient1": "Clarithromycin", "ingredient2": "Cisapride", "severity": "Major", "effect": "Coadministration with the ketolide, telithromycin, as well as certain macrolide antibiotics may significantly increase the plasma concentrations of cisapride. The mechanism is inhibition of cisapride metabolism via CYP450 3A4. High plasma levels of cisapride have been associated with prolongation of the QT interval on the ECG; ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes; cardiac arrest; and sudden death. Macrolides that may significantly inhibit CYP450 3A4 include clarithromycin, erythromycin, and troleandomycin. Azithromycin and dirithromycin are generally believed to have little, if any, effect on CYP450 3A4.", "source": "DDInter", "management_text": "Given the potential for serious and life-threatening adverse cardiac events associated with increased plasma levels of cisapride, the use of cisapride with clarithromycin, erythromycin, troleandomycin, or telithromycin is considered contraindicated.", "mechanism_text": "Metabolism", "recommendation": "Given the potential for serious and life-threatening adverse cardiac events associated with increased plasma levels of cisapride, the use of cisapride with clarithromycin, erythromycin, troleandomycin, or telithromycin is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67701/", "reference_text": "[1] Desta Z, Soukhova N, Mahal SK, Flockhart DA \"Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies.\" Drug Metab Dispos 28 (2000): 789-800[2] \"Product Information. Propulsid (cisapride).\" Janssen Pharmaceutica, Titusville, NJ.[3] Sekkarie MA \"Torsades de pointes in two chronic renal failure patients treated with cisapride and clarithromycin.\" Am J Kidney Dis 30 (1997): 437-9[4] Jenkins IR, Gibson J \"Cisapride, erythromycin and arrhythmia.\" Anaesth Intensive Care 24 (1996): 728[5] Trinkle R \"Comment: syncopal episodes associated with cisapride.\" Ann Pharmacother 33 (1999): 251[6] Lewin MB, Bryant RM, Fenrich AL, Grifka RG \"Cisapride-induced long QT interval.\" J Pediatr 128 (1996): 279-81[7] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[8] Gray VS \"Syncopal episodes associated with cisapride and concurrent drugs.\" Ann Pharmacother 32 (1998): 648-51[9] vanHaarst AD, vantKlooster GAE, vanGerven JMA, Schoemaker RC, vanOene JC, Burggraaf J, Coene MC, Cohen AF \"The influence of cisapride and clarithromycin on QT intervals in healthy volunteers.\" Clin Pharmacol Ther 64 (1998): 542-6[10] Hill SL, Evangelista JK, Pizzi AM, Mobassaleh M, Fulton DR, Berul CI \"Proarrhythmia associated with cisapride in children.\" Pediatrics 101 (1998): 1053-6[11] Amsden GW \"Macrolides versus azalides: a drug interaction update.\" Ann Pharmacother 29 (1995): 906-17[12] Vitola J, Vukanovic J, Roden DM \"Cisapride-induced torsades de pointes.\" J Cardiovasc Electrophysiol 9 (1998): 1109-13[13] Bran S, Murray WA, Hirsch IB, Palmer JP \"Long QT syndrome during high-dose cisapride.\" Arch Intern Med 155 (1995): 765-8[14] Michalets EL \"Update: clinically significant cytochrome P-450 drug interactions.\" Pharmacotherapy 18 (1998): 84-112[15] Piquette RK \"Torsade de pointes induced by cisapride/clarithromycin interaction.\" Ann Pharmacother 33 (1999): 22-6[16] Michalets EL, Williams CR \"Drug interactions with cisapride: clinical implications.\" Clin Pharmacokinet 39 (2000): 49-75[17] European Agency for the Evaluation of Medicinal Products. Committee for Proprietary Medicinal Products \"European Public Assessment Report Ketek (telithromycin) (Rev. 2) Available from: URL: http:www.emea.eu.int/humandocs/Humans/EPAR/Ketek/Ketek.htm.\" ([2001]):[18] \"Product Information. Ketek (telithromycin).\" Aventis Pharmaceuticals, Bridgewater, NJ.[19] Bedford TA, Rowbotham DJ \"Cisapride: drug interactions of clinical significance.\" Drug Saf 15 (1996): 167-75[20] Lewin MB, Bryant RM, Fenrich AL, Grifka RG \"Cisapride-induced long QT interval.\" J Pediatr 128 (1996): 279-81[21] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[22] Kivisto KT, Lilja TJ, Backman JT, Neuvonen PJ \"Repeated consumption of grapefruit juice considerably increases plasma concentrations of cisapride.\" Clin Pharmacol Ther 66 (1999): 448-53[23] Michalets EL, Williams CR \"Drug interactions with cisapride: clinical implications.\" Clin Pharmacokinet 39 (2000): 49-75[24] Hill SL, Evangelista JK, Pizzi AM, Mobassaleh M, Fulton DR, Berul CI \"Proarrhythmia associated with cisapride in children.\" Pediatrics 101 (1998): 1053-6[25] Bran S, Murray WA, Hirsch IB, Palmer JP \"Long QT syndrome during high-dose cisapride.\" Arch Intern Med 155 (1995): 765-8[26] Gross AS, Goh YD, Addison RS, Shenfield GM \"Influence of grapefruit juice on cisapride pharmacokinetics.\" Clin Pharmacol Ther 65 (1999): 395-401[27] Offman EM, Freeman DJ, Dresser GK, Munoz C, Bend JR, Bailey DG \"Red wine-cisapride interaction: Comparison with grapefruit juice.\" Clin Pharmacol Ther 70 (2001): 17-23[28] \"Product Information. Propulsid (cisapride).\" Janssen Pharmaceutica, Titusville, NJ.[29] Desta Z, Soukhova N, Mahal SK, Flockhart DA \"Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies.\" Drug Metab Dispos 28 (2000): 789-800", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Nizatidine, Esomeprazole, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67615, "ingredient1": "Clindamycin", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Coadministration with strong CYP450 3A4 inhibitors may increase plasma concentrations and the risk of adverse effects of clindamycin, which is metabolized predominantly by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if clindamycin is used concomitantly with strong CYP450 3A4 inhibitors. The possibility of adverse reactions to clindamycin should be considered during coadministration with strong CYP450 3A4 inhibitors. Dosage adjustments as well as clinical and laboratory monitoring of clindamycin should be considered whenever a strong CYP450 3A4 inhibitor is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if clindamycin is used concomitantly with strong CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67702/", "reference_text": "[1] \"Product Information. Cleocin (clindamycin).\" Pharmacia and Upjohn, Kalamazoo, MI.[2] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.", "alternatives_a": "Vitamin A, Isotretinoin, Fluorometholone, Azelaic acid, Adapalene, Clarithromycin, Lincomycin, Troleandomycin, Dirithromycin, Tinidazole, Ascorbic acid, More", "alternatives_b": "Tinidazole, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Cimetidine, Esomeprazole, Nizatidine, Vonoprazan, Levofloxacin, Dirithromycin, Lincomycin, Clindamycin", "updated_at": 1767369485}, {"id": 67616, "ingredient1": "Clobazam", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Macrolide antibiotics may increase and prolong the CNS effects of certain benzodiazepines. The mechanism is inhibition of CYP450 3A4 hepatic oxidation of the benzodiazepines.", "source": "DDInter", "management_text": "Patients receiving this combination should be monitored for excessive or prolonged sedation. Non-interacting benzodiazepines or antimicrobials may be considered as alternatives.", "mechanism_text": "Metabolism", "recommendation": "Patients receiving this combination should be monitored for excessive or prolonged sedation.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67703/", "reference_text": "[1] Warot D, Bergougnan L, Lamiable D, et al \"Troleandomycin-triazolam interaction in healthy volunteers: pharmacokinetic and psychometric evaluation.\" Eur J Clin Pharmacol 32 (1987): 389-93[2] Yeates RA, Laufen H, Zimmermann T, Schumacher T \"Pharmacokinetic and pharmacodynamic interaction study between midazolam and the macrolide antibiotics, erythromycin clarithromycin, and the azalide azithromycin.\" Int J Clin Pharmacol Ther 35 (1997): 577-9[3] Mattila MJ, Idanpaanheikkila JJ, Tornwall M, Vanakoski J \"Oral single doses of erythromycin and roxithromycin may increase the effects of midazolam on human performance.\" Pharmacol Toxicol 73 (1993): 180-5[4] Zimmermann T, Yeates RA, Laufen H, Scharpf F, Leitold M, Wildfeuer A \"Influence of the antibiotics erythromycin and azithromycin on the pharmacokinetics and pharmacodynamics of midazolam.\" Arzneimittelforschung 46 (1996): 213-7[5] Yasui N, Otani K, Kaneko S, et al \"A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: in vivo evidence for the involvement of CYP3a4 in alprazolam metabolism.\" Clin Pharmacol Ther 59 (1996): 514-9[6] Yeates RA, Laufen H, Zimmermann T \"Interaction between midazolam and clarithromycin: comparison with azithromycin.\" Int J Clin Pharmacol Ther 34 (1996): 400-5[7] Gorski JC, Jones DR, HaehnerDaniels BD, Hamman MA, OMara EM, Hall SD \"The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin.\" Clin Pharmacol Ther 64 (1998): 133-43[8] Phillips JP, Antal EJ, Smith RB \"A pharmacokinetic drug interaction between erythromycin and triazolam.\" J Clin Psychopharmacol 6 (1986): 297-9[9] Wrighton SA, Ring BJ \"Inhibition of human CYP3A catalyzed 1'-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine.\" Pharm Res 11 (1994): 921-4[10] Kanamitsu S, Ito K, Green CE, Tyson CA, Shimada N, Sugiyama Y \"Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4.\" Pharmaceut Res 17 (2000): 419-26[11] Ito K, Ogihara K, Kanamitsu SI, Itoh T \"Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes.\" Drug Metab Dispos 31 (2003): 945-954[12] Amsden GW \"Macrolides versus azalides: a drug interaction update.\" Ann Pharmacother 29 (1995): 906-17[13] Luurila H, Olkkola KT, Neuvonen PJ \"Interaction between erythromycin and the benzodiazepines diazepam and flunitrazepam.\" Pharmacol Toxicol 78 (1996): 117-22[14] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[15] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[16] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[17] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Meprobamate", "alternatives_b": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, More", "updated_at": 1767369485}, {"id": 67617, "ingredient1": "Clofarabine", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "The liver is a known target organ for clofarabine toxicity, and concomitant use of other potentially hepatotoxic agents may increase the risk of liver injury. Severe and fatal hepatotoxicity has occurred with the use of clofarabine alone.", "source": "DDInter", "management_text": "Concomitant use of clofarabine with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Hepatic function should be monitored during clofarabine administration, and therapy discontinued if grade 3 to 4 liver enzyme or bilirubin elevations occur. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of clofarabine with other potentially hepatotoxic agents should be avoided whenever possible (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67704/", "reference_text": "[1] \"Product Information. Clolar (clofarabine).\" sanofi-aventis, Bridgewater, NJ.", "alternatives_a": "Fluorouracil, Cladribine, Trifluridine, Floxuridine, Nelarabine, Pralatrexate, Decitabine, Azacitidine, Capecitabine", "alternatives_b": "Tinidazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, Ranitidine, More", "updated_at": 1767369485}, {"id": 67618, "ingredient1": "Clofazimine", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Clofazimine may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is recommended if clofazimine is used in combination with other drugs that can prolong the QT interval. Consider monitoring electrocardiograms, particularly in patients receiving clofazimine dosages greater than 100 mg/day, and discontinue QT-prolonging medications if clinically significant ventricular arrhythmia is noted or if QTcF interval >=500 ms is observed. If syncope occurs, obtain an ECG to detect QT prolongation.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if clofazimine is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67705/", "reference_text": "[1] \"Product Information. Lamprene (clofazimine).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[3] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67619, "ingredient1": "Clomipramine", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67706/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[16] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Tinidazole, Tetracycline, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Nizatidine, Vonoprazan, Amoxicillin, Dirithromycin, More", "alternatives_b": "Phenelzine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Vortioxetine, Milnacipran, Tryptophan, Esketamine", "updated_at": 1767369485}, {"id": 67620, "ingredient1": "Clonazepam", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Macrolide antibiotics may increase and prolong the CNS effects of certain benzodiazepines. The mechanism is inhibition of CYP450 3A4 hepatic oxidation of the benzodiazepines.", "source": "DDInter", "management_text": "Patients receiving this combination should be monitored for excessive or prolonged sedation. Non-interacting benzodiazepines or antimicrobials may be considered as alternatives.", "mechanism_text": "Metabolism", "recommendation": "Patients receiving this combination should be monitored for excessive or prolonged sedation.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67707/", "reference_text": "[1] Warot D, Bergougnan L, Lamiable D, et al \"Troleandomycin-triazolam interaction in healthy volunteers: pharmacokinetic and psychometric evaluation.\" Eur J Clin Pharmacol 32 (1987): 389-93[2] Yeates RA, Laufen H, Zimmermann T, Schumacher T \"Pharmacokinetic and pharmacodynamic interaction study between midazolam and the macrolide antibiotics, erythromycin clarithromycin, and the azalide azithromycin.\" Int J Clin Pharmacol Ther 35 (1997): 577-9[3] Mattila MJ, Idanpaanheikkila JJ, Tornwall M, Vanakoski J \"Oral single doses of erythromycin and roxithromycin may increase the effects of midazolam on human performance.\" Pharmacol Toxicol 73 (1993): 180-5[4] Zimmermann T, Yeates RA, Laufen H, Scharpf F, Leitold M, Wildfeuer A \"Influence of the antibiotics erythromycin and azithromycin on the pharmacokinetics and pharmacodynamics of midazolam.\" Arzneimittelforschung 46 (1996): 213-7[5] Yasui N, Otani K, Kaneko S, et al \"A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: in vivo evidence for the involvement of CYP3a4 in alprazolam metabolism.\" Clin Pharmacol Ther 59 (1996): 514-9[6] Yeates RA, Laufen H, Zimmermann T \"Interaction between midazolam and clarithromycin: comparison with azithromycin.\" Int J Clin Pharmacol Ther 34 (1996): 400-5[7] Gorski JC, Jones DR, HaehnerDaniels BD, Hamman MA, OMara EM, Hall SD \"The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin.\" Clin Pharmacol Ther 64 (1998): 133-43[8] Phillips JP, Antal EJ, Smith RB \"A pharmacokinetic drug interaction between erythromycin and triazolam.\" J Clin Psychopharmacol 6 (1986): 297-9[9] Wrighton SA, Ring BJ \"Inhibition of human CYP3A catalyzed 1'-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine.\" Pharm Res 11 (1994): 921-4[10] Kanamitsu S, Ito K, Green CE, Tyson CA, Shimada N, Sugiyama Y \"Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4.\" Pharmaceut Res 17 (2000): 419-26[11] Ito K, Ogihara K, Kanamitsu SI, Itoh T \"Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes.\" Drug Metab Dispos 31 (2003): 945-954[12] Amsden GW \"Macrolides versus azalides: a drug interaction update.\" Ann Pharmacother 29 (1995): 906-17[13] Luurila H, Olkkola KT, Neuvonen PJ \"Interaction between erythromycin and the benzodiazepines diazepam and flunitrazepam.\" Pharmacol Toxicol 78 (1996): 117-22[14] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[15] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[16] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[17] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tiagabine, Brivaracetam, Rufinamide, Methsuximide, Paramethadione, Fenfluramine, Eslicarbazepine, Phensuximide, Methylphenobarbital, Phenacemide, Primidone, More", "alternatives_b": "Tinidazole, Dexlansoprazole, Bismuth subcitrate potassium, Esomeprazole, Vonoprazan, Levofloxacin, Lincomycin, Dirithromycin", "updated_at": 1767369485}, {"id": 67621, "ingredient1": "Clopidogrel", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "The concomitant administration of some macrolide antibiotics may reduce the metabolic activation of the prodrug clopidogrel and its antiplatelet effects. The proposed mechanism is inhibition of CYP450 3A4 enzymatic activity, which is responsible for the conversion of clopidogrel to its active metabolite.", "source": "DDInter", "management_text": "Until more information is available, monitoring for altered efficacy of clopidogrel may be advisable if a macrolide is coadministered with clopidogrel. Azithromycin and dirithromycin do not inhibit CYP450 3A4 and are theoretically not expected to interact with clopidogrel.", "mechanism_text": "Metabolism", "recommendation": "Until more information is available, monitoring for altered efficacy of clopidogrel may be advisable if a macrolide is coadministered with clopidogrel.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67708/", "reference_text": "[1] Lau WC, Waskell LA, Watkins PB, et al. \"Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction.\" Circulation 107 (2003): 32-7[2] Clarke TA, Waskell LA \"The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin.\" Drug Metab Dispos 31 (2003): 53-9", "alternatives_a": "Iloprost, Lepirudin, Urokinase, Cangrelor, Caplacizumab, Argatroban, Prasugrel, Desirudin, Eptifibatide, Streptokinase, Tinzaparin, More", "alternatives_b": "Tinidazole, Bismuth subcitrate potassium, Levofloxacin, Rifabutin, Lincomycin, Dirithromycin", "updated_at": 1767369485}, {"id": 67622, "ingredient1": "Clorazepic acid", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Macrolide antibiotics may increase and prolong the CNS effects of certain benzodiazepines. The mechanism is inhibition of CYP450 3A4 hepatic oxidation of the benzodiazepines.", "source": "DDInter", "management_text": "Patients receiving this combination should be monitored for excessive or prolonged sedation. Non-interacting benzodiazepines or antimicrobials may be considered as alternatives.", "mechanism_text": "Metabolism", "recommendation": "Patients receiving this combination should be monitored for excessive or prolonged sedation.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67709/", "reference_text": "[1] Warot D, Bergougnan L, Lamiable D, et al \"Troleandomycin-triazolam interaction in healthy volunteers: pharmacokinetic and psychometric evaluation.\" Eur J Clin Pharmacol 32 (1987): 389-93[2] Yeates RA, Laufen H, Zimmermann T, Schumacher T \"Pharmacokinetic and pharmacodynamic interaction study between midazolam and the macrolide antibiotics, erythromycin clarithromycin, and the azalide azithromycin.\" Int J Clin Pharmacol Ther 35 (1997): 577-9[3] Mattila MJ, Idanpaanheikkila JJ, Tornwall M, Vanakoski J \"Oral single doses of erythromycin and roxithromycin may increase the effects of midazolam on human performance.\" Pharmacol Toxicol 73 (1993): 180-5[4] Zimmermann T, Yeates RA, Laufen H, Scharpf F, Leitold M, Wildfeuer A \"Influence of the antibiotics erythromycin and azithromycin on the pharmacokinetics and pharmacodynamics of midazolam.\" Arzneimittelforschung 46 (1996): 213-7[5] Yasui N, Otani K, Kaneko S, et al \"A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: in vivo evidence for the involvement of CYP3a4 in alprazolam metabolism.\" Clin Pharmacol Ther 59 (1996): 514-9[6] Yeates RA, Laufen H, Zimmermann T \"Interaction between midazolam and clarithromycin: comparison with azithromycin.\" Int J Clin Pharmacol Ther 34 (1996): 400-5[7] Gorski JC, Jones DR, HaehnerDaniels BD, Hamman MA, OMara EM, Hall SD \"The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin.\" Clin Pharmacol Ther 64 (1998): 133-43[8] Phillips JP, Antal EJ, Smith RB \"A pharmacokinetic drug interaction between erythromycin and triazolam.\" J Clin Psychopharmacol 6 (1986): 297-9[9] Wrighton SA, Ring BJ \"Inhibition of human CYP3A catalyzed 1'-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine.\" Pharm Res 11 (1994): 921-4[10] Kanamitsu S, Ito K, Green CE, Tyson CA, Shimada N, Sugiyama Y \"Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4.\" Pharmaceut Res 17 (2000): 419-26[11] Ito K, Ogihara K, Kanamitsu SI, Itoh T \"Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes.\" Drug Metab Dispos 31 (2003): 945-954[12] Amsden GW \"Macrolides versus azalides: a drug interaction update.\" Ann Pharmacother 29 (1995): 906-17[13] Luurila H, Olkkola KT, Neuvonen PJ \"Interaction between erythromycin and the benzodiazepines diazepam and flunitrazepam.\" Pharmacol Toxicol 78 (1996): 117-22[14] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[15] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[16] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[17] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Meprobamate", "alternatives_b": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, More", "updated_at": 1767369485}, {"id": 67623, "ingredient1": "Cloxacillin", "ingredient2": "Clarithromycin", "severity": "Minor", "effect": "Although some in vitro data indicate synergism between macrolide antibiotics and penicillins, other in vitro data indicate antagonism. When these drugs are given together, neither has predictable therapeutic efficacy. Data are available for erythromycin, although theoretically this interaction could occur with any macrolide. Except for monitoring of the effectiveness of antibiotic therapy, no special precautions appear to be necessary.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67710/", "reference_text": "[1] Strom J \"Penicillin and erythromycin singly and in combination in scarlatina therapy and the interference between them.\" Antibiot Chemother 11 (1961): 694-7[2] Cohn JR, Jungkind DL, Baker JS \"In vitro antagonism by erythromycin of the bactericidal action of antimicrobial agents against common respiratory pathogens.\" Antimicrob Agents Chemother 18 (1980): 872-6[3] Penn RL, Ward TT, Steigbigel RT \"Effects of erythromycin in combination with penicillin, ampicillin, or gentamicin on the growth of listeria monocytogenes.\" Antimicrob Agents Chemother 22 (1982): 289-94", "alternatives_a": "Tazobactam, Sulbactam", "alternatives_b": "Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, More", "updated_at": 1767369485}, {"id": 67624, "ingredient1": "Clozapine", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "The concomitant administration of some macrolides may result in decreased clearance of clozapine and increased risk of toxicity. The mechanism of this interaction is suspected to be inhibition of the CYP450 hepatic metabolism of clozapine.", "source": "DDInter", "management_text": "While clinical data are limited, clinical and laboratory monitoring may be appropriate whenever a macrolide is added to or withdrawn from therapy. Alternatively, azithromycin and dirithromycin may be considered, as they do not inhibit CYP450 and are not expected to affect clozapine metabolism. Patients should be advised to report symptoms such as somnolence, disorientation, slurred speech, seizures, uncontrolled movements, dizziness, irregular heartbeat, palpitations, fever, or hypersalivation to their physician.", "mechanism_text": "Metabolism", "recommendation": "While clinical data are limited, clinical and laboratory monitoring may be appropriate whenever a macrolide is added to or withdrawn from therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67711/", "reference_text": "[1] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Funderburg LG, Vertrees JE, True JE, Miller AL \"Seizure following addition of erythromycin to clozapine treatment.\" Am J Psychiatry 151 (1994): 1840-1[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[6] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Loxapine, Molindone, Thiothixene", "alternatives_b": "Tinidazole, Tetracycline, Dexlansoprazole, Bismuth subcitrate potassium, Nizatidine, Vonoprazan, Lincomycin, Dirithromycin", "updated_at": 1767369485}, {"id": 67625, "ingredient1": "Cobicistat", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Coadministration of a macrolide or ketolide antibiotic (clarithromycin, erythromycin, telithromycin) with cobicistat is expected to increase the plasma concentrations of both drugs. The mechanism may involve both competitive and noncompetitive inhibition of CYP450 3A4, since these drugs are all substrates as well as inhibitors of the isoenzyme. No pharmacokinetic data are currently available. Clinically, high plasma levels of macrolide or ketolide antibiotics may increase the risk of QT interval prolongation and torsade de pointes arrhythmia.", "source": "DDInter", "management_text": "Caution and close clinical monitoring are recommended if clarithromycin, erythromycin, or telithromycin are used in combination with cobicistat. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope. Some authorities recommend avoiding the concomitant use of fixed combination antiretroviral products containing cobicistat with these antibiotics. For clarithromycin, a dosage reduction by 50% has been recommended in patients with CrCl between 30 and 60 mL/min. However, in patients receiving atazanavir or ritonavir concomitantly with clarithromycin, it has been suggested that the dose of clarithromycin be reduced by 75% in patients with a CrCl of less than 30 mL/min. A similar dosage reduction may be appropriate when clarithromycin is used with cobicistat.", "mechanism_text": "Metabolism", "recommendation": "Caution and close clinical monitoring are recommended if clarithromycin, erythromycin, or telithromycin are used in combination with cobicistat.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67712/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov).\" Gilead Sciences, Foster City, CA.[3] \"Product Information. Biaxin (clarithromycin).\" Abbott Pharmaceutical, Abbott Park, IL.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, More", "alternatives_b": "Glecaprevir, Tenofovir alafenamide, Cabotegravir, Lenacapavir, Velpatasvir, Voxilaprevir, Maribavir, Pibrentasvir, Rimantadine, Elvitegravir, Valganciclovir, More", "updated_at": 1767369485}, {"id": 67626, "ingredient1": "Cobimetinib", "ingredient2": "Clarithromycin", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of cobimetinib, which is primarily metabolized by the isoenzyme. The risk and/or severity of adverse effects such as diarrhea, nausea, vomiting, stomatitis, hemorrhage, cardiomyopathy, rash, photosensitivity, retinopathy, retinal vein occlusion, liver enzyme abnormalities, and rhabdomyolysis may be increased.", "source": "DDInter", "management_text": "Concomitant use of cobimetinib with potent CYP450 3A4 inhibitors should generally be avoided. Some authorities recommend avoiding concomitant use of cobimetinib during and for 2 weeks after treatment with itraconazole.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of cobimetinib with potent CYP450 3A4 inhibitors should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67713/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Cotellic (cobimetinib).\" Genentech, South San Francisco, CA.[3] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[4] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[5] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[6] \"Product Information. Cotellic (cobimetinib).\" Genentech, South San Francisco, CA.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, More", "alternatives_b": "Alpelisib, Trametinib, Dacomitinib, Tivozanib, Alectinib", "updated_at": 1767369485}, {"id": 67627, "ingredient1": "Colchicine", "ingredient2": "Clarithromycin", "severity": "Major", "effect": "Coadministration of colchicine with clarithromycin may significantly increase the serum concentrations of colchicine. The proposed mechanism is inhibition of the CYP450 3A4-mediated metabolism and P-glycoprotein (P-gp)-mediated transport of colchicine by clarithromycin. Clinical toxicity including myopathy, neuropathy, multiorgan failure, and pancytopenia may occur.", "source": "DDInter", "management_text": "Due to the risk of life-threatening and fatal toxicity, concomitant use of colchicine with clarithromycin should generally be avoided if possible. Otherwise, caution is advised. Coadministration of colchicine with clarithromycin in patients with renal or hepatic impairment is considered contraindicated. In patients with normal renal and hepatic function, the dosage of colchicine should be reduced when used with potent CYP450 3A4 inhibitors or within 14 days of using them. For the treatment of acute gout flares, the recommended dosage is 0.6 mg for one dose, followed by 0.3 mg one hour later. Administration should not be repeated for at least three days. For the prophylaxis of gout flares, the adjusted dosage should be 0.3 mg once a day if the original regimen was 0.6 mg twice a day, and 0.3 mg once every other day if the original regimen was 0.6 once a day. For the treatment of familial Mediterranean fever, the maximum dosage of colchicine is 0.6 mg/day (may be given as 0.3 mg twice a day) when used in the presence of potent CYP450 3A4 inhibitors. Patients should be advised to contact their physician if they experience symptoms of toxicity such as abdominal pain, nausea, vomiting, diarrhea, fatigue, myalgia, asthenia, hyporeflexia, paraesthesia, and numbness.", "mechanism_text": "Metabolism", "recommendation": "Due to the risk of life-threatening and fatal toxicity, concomitant use of colchicine with clarithromycin should generally be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67714/", "reference_text": "[1] Cheng VC, Ho PL, Yuen KY \"Two probable cases of serious drug interaction between clarithromycin and colchicine.\" South Med J 98 (2005): 811-3[2] McKinnell J, Tayek JA \"Short term treatment with clarithromycin resulting in colchicine-induced rhabdomyolysis.\" J Clin Rheumatol 15 (2009): 303-5[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Wilbur K, Makowsky M \"Colchicine myotoxicity: case reports and literature review.\" Pharmacotherapy 24 (2004): 1784-92[5] Rollot F, Pajot O, Chauvelot-Moachon L, Nazal EM, Kelaidi C, Blanche P \"Acute colchicine intoxication during clarithromycin administration.\" Ann Pharmacother 38 (2004): 2074-7[6] Putterman C, Ben-Chetrit E, Caraco Y, Levy M \"Colchicine intoxication: clinical pharmacology, risk factors, features, and management.\" Semin Arthritis Rheum 21 (1991): 143-55[7] van der Velden W, Huussen J, Ter Laak H, de Sevaux R \"Colchicine-induced neuromyopathy in a patient with chronic renal failure: the role of clarithromycin.\" Neth J Med 66 (2008): 204-6[8] \"Product Information. Victrelis (boceprevir).\" Schering-Plough Corporation, Kenilworth, NJ.[9] \"Colchicine: serious interactions.\" Prescrire Int 17 (2008): 151-3[10] \"Product Information. Incivek (telaprevir).\" Vertex Pharmaceuticals, Cambridge, MA.[11] \"Severe colchicine-macrolide interactions.\" Prescrire Int 12 (2003): 18-9[12] Schiff D, Drislane FW \"Rapid-onset colchicine myoneuropathy.\" Arthritis Rheum 35 (1992): 1535-6[13] Cohen O, Locketz G, Hershko AY, Gorshtein A, Levy Y \"Colchicine-clarithromycin-induced rhabdomyolysis in Familial Mediterranean Fever patients under treatment for Helicobacter pylori.\" Rheumatol Int (2015):[14] Dogukan A, Oymak FS, Taskapan H, Guven M, Tokgoz B, Utas C \"Acute fatal colchicine intoxication in a patient on continuous ambulatory peritoneal dialysis (CAPD). Possible role of clarithromycin administration.\" Clin Nephrol 55 (2001): 181-2[15] \"Product Information. Biaxin (clarithromycin).\" Abbott Pharmaceutical, Abbott Park, IL.[16] Akdag I, Ersoy A, Kahvecioglu S, Gullulu M, Dilek K \"Acute colchicine intoxication during clarithromycin administration in patients with chronic renal failure.\" J Nephrol 19 (2006): 515-7[17] Tateishi T, Soucek P, Caraco Y, Guengerich FP, Wood AJ \"Colchicine biotransformation by human liver microsomes. Identification of CYP3A4 as the major isoform responsible for colchicine demethylation.\" Biochem Pharmacol 53 (1996): 111-6[18] Cerner Multum, Inc. \"Australian Product Information.\" O 0[19] \"Product Information. Colcrys (colchicine).\" AR Scientific Inc, Philadelphia, PA.[20] Boomershine KH \"Colchicine-induced rhabdomyolysis.\" Ann Pharmacother 36 (2002): 824-6[21] Pettinger WA \"Clonidine, a new antihypertensive drug.\" N Engl J Med 293 (1975): 1179-80[22] Hung IF, Wu AK, Cheng VC, et al. \"Fatal interaction between clarithromycin and colchicine in patients with renal insufficiency: a retrospective study.\" Clin Infect Dis 41 (2005): 291-300[23] Goldbart A, Press J, Sofer S, Kapelushnik J \"Near fatal acute colchicine intoxication in a child. A case report.\" Eur J Pediatr 159 (2000): 895-7[24] Akdag I, Ersoy A, Kahvecioglu S, Gullulu M, Dilek K \"Acute colchicine intoxication during clarithromycin administration in patients with chronic renal failure.\" J Nephrol 19 (2006): 515-7[25] Dogukan A, Oymak FS, Taskapan H, Guven M, Tokgoz B, Utas C \"Acute fatal colchicine intoxication in a patient on continuous ambulatory peritoneal dialysis (CAPD). Possible role of clarithromycin administration.\" Clin Nephrol 55 (2001): 181-2[26] Cheng VC, Ho PL, Yuen KY \"Two probable cases of serious drug interaction between clarithromycin and colchicine.\" South Med J 98 (2005): 811-3[27] McKinnell J, Tayek JA \"Short term treatment with clarithromycin resulting in colchicine-induced rhabdomyolysis.\" J Clin Rheumatol 15 (2009): 303-5[28] Caraco Y, Putterman C, Rahamimov R, Ben-Chetrit E \"Acute colchicine intoxication: possible role of erythromycin administration.\" J Rheumatol 19 (1992): 494-6[29] Rollot F, Pajot O, Chauvelot-Moachon L, Nazal EM, Kelaidi C, Blanche P \"Acute colchicine intoxication during clarithromycin administration.\" Ann Pharmacother 38 (2004): 2074-7[30] Wilbur K, Makowsky M \"Colchicine myotoxicity: case reports and literature review.\" Pharmacotherapy 24 (2004): 1784-92[31] Schiff D, Drislane FW \"Rapid-onset colchicine myoneuropathy.\" Arthritis Rheum 35 (1992): 1535-6[32] Boomershine KH \"Colchicine-induced rhabdomyolysis.\" Ann Pharmacother 36 (2002): 824-6[33] van der Velden W, Huussen J, Ter Laak H, de Sevaux R \"Colchicine-induced neuromyopathy in a patient with chronic renal failure: the role of clarithromycin.\" Neth J Med 66 (2008): 204-6[34] Hung IF, Wu AK, Cheng VC, et al. \"Fatal interaction between clarithromycin and colchicine in patients with renal insufficiency: a retrospective study.\" Clin Infect Dis 41 (2005): 291-300[35] Pettinger WA \"Clonidine, a new antihypertensive drug.\" N Engl J Med 293 (1975): 1179-80[36] Tateishi T, Soucek P, Caraco Y, Guengerich FP, Wood AJ \"Colchicine biotransformation by human liver microsomes. Identification of CYP3A4 as the major isoform responsible for colchicine demethylation.\" Biochem Pharmacol 53 (1996): 111-6[37] Dahan A, Amidon GL \"Grapefruit juice and its constitueants augment colchicine intestinal absorption: potential hazardous interaction and the role of p-glycoprotein.\" Pharm Res 26 (2009): 883-92[38] \"Colchicine: serious interactions.\" Prescrire Int 17 (2008): 151-3[39] Putterman C, Ben-Chetrit E, Caraco Y, Levy M \"Colchicine intoxication: clinical pharmacology, risk factors, features, and management.\" Semin Arthritis Rheum 21 (1991): 143-55[40] \"Product Information. Colcrys (colchicine).\" AR Scientific Inc, Philadelphia, PA.[41] \"Severe colchicine-macrolide interactions.\" Prescrire Int 12 (2003): 18-9[42] Cheng KL, Nafziger AN, Peloquin CA, Amsden GW \"Effect of grapefruit juice on clarithromycin pharmacokinetics.\" Antimicrob Agents Chemother 42 (1998): 927-9", "alternatives_a": "Pantoprazole, Levofloxacin, Tetracycline, Rabeprazole, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Famotidine, Rifabutin, Nizatidine, More", "alternatives_b": "Lesinurad, Febuxostat, Pegloticase, Sulfinpyrazone, Rasburicase, Probenecid", "updated_at": 1767369485}, {"id": 67628, "ingredient1": "Conivaptan", "ingredient2": "Clarithromycin", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of vasopressin receptor antagonists conivaptan and tolvaptan, both of which are almost exclusively metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of conivaptan or tolvaptan with potent CYP450 3A4 inhibitors is considered contraindicated. Some authorities recommend avoiding concomitant use of conivaptan or tolvaptan during and for 2 weeks after treatment with itraconazole.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of conivaptan or tolvaptan with potent CYP450 3A4 inhibitors is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67715/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[3] \"Product Information. Samsca (tolvaptan).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[4] \"Product Information. Vaprisol (conivaptan).\" Cumberland Pharmaceuticals Inc, Nashville, TN.[5] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[6] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[7] \"Product Information. Samsca (tolvaptan).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Pantoprazole, Levofloxacin, Tetracycline, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Cimetidine, Esomeprazole, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67629, "ingredient1": "Conjugated estrogens (topical)", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "RECOMMENDED: The effectiveness of estrogen-containing oral contraceptives may be impaired by concomitant treatment with antimicrobial agents. Most antimicrobials, with the exception of the rifamycins and possibly griseofulvin, do not induce hepatic enzymes and have not been shown to significantly increase the clearance of oral contraceptive estrogens. Certain macrolide antibiotics (e.g., erythromycin, clarithromycin) may increase the plasma concentrations and the risk of adverse effects of estrogens and progestogens. The mechanism is decreased clearance of the hormones due to inhibition of CYP450 3A4 activity by the macrolide antibiotic. Concomitant administration with erythromycin may increase the estradiol exposure by approximately 50%.", "source": "DDInter", "management_text": "Until further data are available, women using oral contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant antimicrobial therapy. During concomitant therapy with erythromycin or clarithromycin, patients should be observed for increased or altered pharmacologic response to estrogens and progestogens, and dosage(s) adjusted accordingly as necessary.", "mechanism_text": "Metabolism", "recommendation": "Until further data are available, women using oral contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant antimicrobial therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67716/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception. Available from: URL: file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf.\" ([2012, Jan 1]):[4] \"Product Information. Angeliq (drospirenone-estradiol).\" Berlex Laboratories, Wayne, NJ.[5] \"Product Information. Ortho-Est (estropipate).\" Ortho McNeil Pharmaceutical, Raritan, NJ.[6] \"Product Information. Premarin (conjugated estrogens).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[7] \"Product Information. Yasmin (drospirenone-ethinyl estradiol)\" Berlex Laboratories, Richmond, CA.[8] Welling PG, Huang H, Hewitt PF, Lyons LL \"Bioavailability of erythromycin stearate: influence of food and fluid volume.\" J Pharm Sci 67 (1978): 764-6[9] Welling PG \"Influence of food and diet on gastrointestinal drug absorption: a review.\" J Pharmacokinet Biopharm 5 (1977): 291-334[10] Randinitis EJ, Sedman AJ, Welling PG, Kinkel AW \"Effect of a high-fat meal on the bioavailability of a polymer-coated erythromycin particle tablet formulation.\" J Clin Pharmacol 29 (1989): 79-84[11] Coyne TC, Shum S, Chun AH, Jeansonne L, Shirkey HC \"Bioavailability of erythromycin ethylsuccinate in pediatric patients.\" J Clin Pharmacol 18 (1978): 194-202[12] Malmborg AS \"Effect of food on absorption of erythromycin. A study of two derivatives, the stearate and the base.\" J Antimicrob Chemother 5 (1979): 591-9[13] Welling PG, Elliott RL, Pitterle ME, et al \"Plasma levels following single and repeated doses of erythromycin estolate and erythromycin stearate.\" J Pharm Sci 68 (1979): 150-5[14] Kanazawa S, Ohkubo T, Sugawara K \"The effects of grapefruit juice on the pharmacokinetics of erythromycin.\" Eur J Clin Pharmacol 56 (2001): 799-803[15] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[16] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Bazedoxifene", "alternatives_b": "Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, More", "updated_at": 1767369485}, {"id": 67630, "ingredient1": "Copanlisib", "ingredient2": "Clarithromycin", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 and P-glycoprotein (P-gp) may increase the plasma concentrations of copanlisib, which is a substrate of both the isoenzyme and efflux transporter.", "source": "DDInter", "management_text": "The manufacturer recommends reducing the copanlisib dose to 45 mg when concomitant use with potent CYP450 3A4 inhibitors cannot be avoided.", "mechanism_text": "Metabolism", "recommendation": "The manufacturer recommends reducing the copanlisib dose to 45 mg when concomitant use with potent CYP450 3A4 inhibitors cannot be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67717/", "reference_text": "[1] \"Product Information. Aliqopa (copanlisib).\" Bayer Pharmaceutical Inc, West Haven, CT.[2] \"Product Information. Aliqopa (copanlisib).\" Bayer Pharmaceutical Inc, West Haven, CT.", "alternatives_a": "Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, More", "alternatives_b": "Alpelisib, Trametinib, Dacomitinib, Tivozanib, Alectinib", "updated_at": 1767369485}, {"id": 67631, "ingredient1": "Crizotinib", "ingredient2": "Clarithromycin", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of crizotinib, which is primarily metabolized by the isoenzyme. Because crizotinib is associated with concentration-dependent prolongation of the QT interval, increased levels may potentiate the risk of ventricular arrhythmias such as torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Concomitant use of crizotinib with potent CYP450 3A4 inhibitors should generally be avoided. Some authorities recommend avoiding concomitant use of crizotinib during and for 2 weeks after treatment with itraconazole.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of crizotinib with potent CYP450 3A4 inhibitors should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67718/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[3] \"Product Information. Xalkori (crizotinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.[4] \"Product Information. Xalkori (crizotinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.[5] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[6] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Pantoprazole, Tetracycline, Rabeprazole, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Cimetidine, Esomeprazole, Ranitidine, Nizatidine, More", "alternatives_b": "Alpelisib, Trametinib, Dacomitinib, Tivozanib, Alectinib", "updated_at": 1767369485}, {"id": 67632, "ingredient1": "Cyclosporine", "ingredient2": "Clarithromycin", "severity": "Major", "effect": "Coadministration with macrolide antibiotics that are potent inhibitors of CYP450 3A4 may significantly increase the blood concentrations of cyclosporine, which is primarily metabolized by the isoenzyme. The risk of nephro- and neurotoxicity associated with cyclosporine may be increased. Macrolides that may significantly inhibit CYP450 3A4 include troleandomycin, erythromycin, and clarithromycin.", "source": "DDInter", "management_text": "Caution is advised if cyclosporine is used with macrolide antibiotics that are potent inhibitors of CYP450 3A4. Cyclosporine blood levels and renal function should be checked frequently and the dosage adjusted accordingly, particularly following initiation or discontinuation of macrolide therapy in patients who are stabilized on their cyclosporine regimen. Patients should be advised to notify their doctor if they experience possible signs of cyclosporine toxicity such as nausea, vomiting, diarrhea, abdominal pain, dizziness, fatigue, headache, tremors, and convulsions. Alternative antibiotics that do not interfere with cyclosporine metabolism should be considered whenever possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cyclosporine is used with macrolide antibiotics that are potent inhibitors of CYP450 3A4.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67719/", "reference_text": "[1] Ptachcinski RJ, Carpenter BJ, Burckart GJ, Venkataramanan R, Rosenthal J \"Effect of erythromycin on cyclosporine levels.\" N Engl J Med 313 (1985): 1416-7[2] Cockburn IT, Krupp P \"An appraisal of drug interactions with sandimmun.\" Transplant Proc 21 (1989): 3845-50[3] Gomez E, Sanchez JE, Aguado S, Grande JA \"Interaction between azithromycin and cyclosporin?\" Nephron 73 (1996): 724[4] \"Product Information. Sandimmune (cyclosporine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[5] Nahata M \"Drug interactions with azithromycin and the macrolides: an overview.\" J Antimicrob Chemother 37 ( Suppl (1996): 133-42[6] Gupta SK, Bakran A, Johnson RW, Rowland M \"Cyclosporin-erythromycin interaction in renal transplant patients.\" Br J Clin Pharmacol 27 (1989): 475-81[7] Grino JM, Sabate I, Castelao AM, et al \"Erythromycin and cyclosporine.\" Ann Intern Med 105 (1986): 467-8[8] Wadhwa NK, Schroeder TJ, O'Flaherty E, et al \"Interaction between erythromycin and cyclosporine in a kidney and pancreas allograft recipient.\" Ther Drug Monit 9 (1987): 123-5[9] Yee GC, McGuire TR \"Pharmacokinetic drug interactions with cyclosporin (Part I).\" Clin Pharmacokinet 19 (1990): 319-32[10] Kohan DE \"Possible interaction between cyclosporine and erythromycin.\" N Engl J Med 314 (1986): 448[11] Ljutic D, Rumboldt Z \"Possible interaction between azithromycin and cyclosporin: a case report.\" Nephron 70 (1995): 130[12] Amsden GW \"Macrolides versus azalides: a drug interaction update.\" Ann Pharmacother 29 (1995): 906-17[13] Spicer ST, Liddle C, Chapman JR, Barclay P, Nankivell BJ, Thomas P, O'Connell PJ \"The mechanism of cyclosporine toxicity induced by clarithromycin.\" Br J Clin Pharmacol 43 (1997): 194-6[14] Kessler M, Louis J, Renoult E, et al \"Interaction between cyclosporin and erythromycin in a kidney transplant patient.\" Eur J Clin Pharmacol 30 (1986): 633-4[15] Freeman DJ, Martell R, Carruthers SG, et al \"Cyclosporin-erythromycin interaction in normal subjects.\" Br J Clin Pharmacol 23 (1987): 776-8[16] Ferrari SL, Goffin E, Mourad M, Wallemacq P, Squifflet JP, Pirson Y \"The interaction between clarithromycin and cyclosporine in kidney transplant recipients.\" Transplantation 58 (1994): 725-7[17] Murray BM, Edwards L, Morse GD, et al \"Clinically important interaction of cyclosporine and erythromycin.\" Transplantation 43 (1987): 602-4[18] Zylber-Katz E \"Multiple drug interactions with cyclosporine in a heart transplant patient.\" Ann Pharmacother 29 (1995): 127-31[19] Sketris IS, Wright MR, West ML \"Possible role of the intestinal p-450 enzyme system in a cyclosporine clarithromycin interaction.\" Pharmacotherapy 16 (1996): 301-5[20] Fabre I, Fabre G, Maurel P, et al \"Metabolism of cyclosporin A. Interaction of the macrolide antibiotic, erythromycin, using rabbit hepatocytes and microsomal fractions.\" Drug Metab Dispos 16 (1988): 296-301[21] Knower MT, LabellaWalker K, McFadden PM, Kantrow SP, Valentine VG \"Clarithromycin for safe and cost-effective reduction of cyclosporine doses in lung allograft recipients.\" South Med J 93 (2000): 1087-92[22] Jensen CW, Flechner SM, Van Buren CT, et al. \"Exacerbation of cyclosporin toxicity by concomitant administration of erythromycin.\" Transplantation 43 (1987): 263-70[23] Gersema LM, Porter CB, Russell EH \"Suspected drug interaction between cyclosporine and clarithromycin.\" J Heart Lung Transplant 13 (1994): 343-5[24] Homma S, Takahashi KI, Nihei S, Kato F, Sugihara S, Nunoda S \"The successful management of respiratory complications with long-term, low-dose macrolide administration in pediatric heart transplant recipients.\" Int Heart J (2014):[25] Ducharme MP, Warbasse LH, Edwards DJ \"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice.\" Clin Pharmacol Ther 57 (1995): 485-91[26] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG \"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients.\" Transplantation 62 (1996): 123-5[27] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[28] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[29] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[30] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN \"The effect of meal composition on cyclosporine absorption.\" Transplantation 52 (1991): 1087-9[31] Tsunoda SM, Harris RZ, Christians U, et al. \"Red wine decreases cyclosporine bioavailability.\" Clin Pharmacol Ther 70 (2001): 462-7[32] Yee GC, Stanley DL, Pessa LJ, et al. \"Effect of grrapefruit juice on blood cyclosporin concentration.\" Lancet 345 (1995): 955-6[33] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ \"Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases.\" J Rheumatol 24 (1997): 49-54[34] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G \"Influence of purple grape juice in cyclosporine availability.\" J Ren Nutr 20 (2010): 309-13[35] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB \"Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients.\" Clin Pharmacol Ther 57 (1995): 425-33[36] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF \"The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients.\" Clin Pharmacol Ther 57 (1995): 318-24[37] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ \"Trough concentrations of cyclosporine in blood following administration with grapefruit juice.\" Br J Clin Pharmacol 36 (1993): 457-9", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Anakinra, More", "alternatives_b": "Vonoprazan, Bismuth subcitrate potassium, Levofloxacin, Lincomycin, Dirithromycin", "updated_at": 1767369485}, {"id": 67633, "ingredient1": "Dabrafenib", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Coadministration with potent inhibitors of CYP450 3A4 and/or 2C8 may increase the plasma concentrations of dabrafenib and its active metabolites. Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are substrates of CYP450 3A4, including many of the known inhibitors of the isoenzyme such as conivaptan, delavirdine, nefazodone, telithromycin, and most azole antifungal agents, macrolide antibiotics, and protease inhibitors.", "source": "DDInter", "management_text": "The use of dabrafenib with potent CYP450 2C8 inhibitors such as gemfibrozil or potent CYP450 3A4 inhibitors such as ceritinib, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, telithromycin, and most protease inhibitors and azole antifungal agents should generally be avoided if possible. Some authorities recommend avoiding concomitant use of dabrafenib during and for 2 weeks after treatment with itraconazole. Otherwise, patients should be closely monitored for development of adverse effects such as febrile reactions (high fever or fever accompanied by rigors, hypotension, dehydration, or renal failure), hyperglycemia, uveitis, and cutaneous malignancies (e.g., squamous cell carcinoma, keratoacanthoma, melanoma).", "mechanism_text": "Metabolism", "recommendation": "The use of dabrafenib with potent CYP450 2C8 inhibitors such as gemfibrozil or potent CYP450 3A4 inhibitors such as ceritinib, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, telithromycin, and most protease inhibitors and azole antifungal agents should generally be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67720/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[5] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[6] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Pantoprazole, Levofloxacin, Tetracycline, Rabeprazole, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Esomeprazole, Amoxicillin, More", "alternatives_b": "Alpelisib, Trametinib, Dacomitinib, Tivozanib, Alectinib", "updated_at": 1767369485}, {"id": 67634, "ingredient1": "Daclatasvir", "ingredient2": "Clarithromycin", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of daclatasvir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "A reduction in the dosage of daclatasvir to 30 mg once daily is recommended when used with potent CYP450 3A4 inhibitors.", "mechanism_text": "Metabolism", "recommendation": "A reduction in the dosage of daclatasvir to 30 mg once daily is recommended when used with potent CYP450 3A4 inhibitors.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67721/", "reference_text": "[1] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb, Princeton, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[4] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, More", "alternatives_b": "Glecaprevir, Tenofovir alafenamide, Cabotegravir, Lenacapavir, Velpatasvir, Voxilaprevir, Maribavir, Pibrentasvir, Rimantadine, Elvitegravir, Valganciclovir, More", "updated_at": 1767369485}, {"id": 67635, "ingredient1": "Dapagliflozin", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Concomitant use of insulin and other antidiabetic agents with clarithromycin may cause significant hypoglycemia. There have been rare reports of hypoglycemia in patients treated with clarithromycin, some of whom were taking oral hypoglycemic agents or insulin. The exact mechanism of interaction has not been established. With certain hypoglycemic drugs such as nateglinide, pioglitazone, repaglinide and rosiglitazone, inhibition of the CYP450 3A4 isoenzyme by clarithromycin may be involved.", "source": "DDInter", "management_text": "Caution is advised if clarithromycin is prescribed to patients receiving antidiabetic agents. Patients should be advised to regularly monitor their blood sugar and counseled on how to recognize and treat hypoglycemia, which may include symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if clarithromycin is prescribed to patients receiving antidiabetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67722/", "reference_text": "[1] Otsuka SH \"Severe hypoglycemia from helicobacter pylori triple-drug therapy and insulin detemir drug interaction.\" Pharmacotherapy 33 (2013): e45-9[2] Niemi M, Neuvonen PJ, Kivisto KT \"The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide.\" Clin Pharmacol Ther 70 (2001): 58-65[3] Schelleman H, Bilker WB, Brensinger CM, Wan F, Hennessy S \"Anti-infectives and the risk of severe hypoglycemia in users of glipizide or glyburide.\" Clin Pharmacol Ther 88 (2010): 214-22[4] Khamaisi M, Leitersdorf E \"Severe hypoglycemia from clarithromycin-repaglinide drug interaction.\" Pharmacotherapy 28 (2008): 682-4[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Leiba A, Leibowitz A, Grossman E \"An unusual case of hypoglycemia in a diabetic patient.\" Ann Emerg Med 44 (2004): 427-8[7] Bussing R, Gende A \"Severe hypoglycemia from clarithromycin-sulfonylurea drug interaction.\" Diabetes Care 25 (2002): 1659-61[8] \"Product Information. Biaxin (clarithromycin).\" Abbott Pharmaceutical, Abbott Park, IL.[9] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[10] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[11] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[12] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[13] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[14] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[15] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[16] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[17] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[18] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[19] Cheng KL, Nafziger AN, Peloquin CA, Amsden GW \"Effect of grapefruit juice on clarithromycin pharmacokinetics.\" Antimicrob Agents Chemother 42 (1998): 927-9", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Rifabutin, Cimetidine, More", "alternatives_b": "Guar gum", "updated_at": 1767369485}, {"id": 67636, "ingredient1": "Darifenacin", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of darifenacin, which is partially metabolized by the isoenzyme. Darifenacin is also metabolized by CYP450 2D6, but 3A4 is the major pathway of metabolism in so-called poor metabolizers of 2D6 (approximately 7% of Caucasians and 2% of Asians and those of African descent).", "source": "DDInter", "management_text": "The dosage of darifenacin should not exceed 7.5 mg/day when used with CYP450 3A4 inhibitors such as ketolide and certain macrolide antibiotics.", "mechanism_text": "Metabolism", "recommendation": "The dosage of darifenacin should not exceed 7.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67723/", "reference_text": "[1] \"Product Information. Enablex (darifenacin).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Phenyl salicylate, Ammonium chloride, Dimethyl sulfoxide", "alternatives_b": "Tinidazole, Levofloxacin, Tetracycline, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Nizatidine, Esomeprazole, Amoxicillin, More", "updated_at": 1767369485}, {"id": 67637, "ingredient1": "Darolutamide", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Coadministration with potent inhibitors of CYP450 3A4 that can also inhibit P-glycoprotein (P-gp) may significantly increase the plasma concentrations of darolutamide, which is a substrate of both the isoenzyme and the efflux transporter.", "source": "DDInter", "management_text": "Caution is advised when darolutamide is used with dual P-gp and potent CYP450 3A4 inhibitors. Patients should be monitored more frequently for adverse effects such as fatigue, hypertension, neutropenia and abnormal liver function tests, and the darolutamide dosage adjusted as necessary in accordance with the product labeling.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when darolutamide is used with dual P-gp and potent CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67724/", "reference_text": "[1] \"Product Information. Nubeqa (darolutamide).\" Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.[2] \"Product Information. Nubeqa (darolutamide).\" Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Nizatidine, More", "alternatives_b": "Anastrozole, Aminoglutethimide, Exemestane, Fulvestrant", "updated_at": 1767369485}, {"id": 67638, "ingredient1": "Darunavir", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Coadministration with darunavir/ritonavir may increase the plasma concentrations of clarithromycin. The mechanism is inhibition of CYP450 3A4, the isoenzyme responsible for the metabolic clearance of clarithromycin.Clarithromycin had no significant effect on the pharmacokinetics of darunavir.", "source": "DDInter", "management_text": "No dosage adjustment of clarithromycin or darunavir is required during coadministration in patients with normal renal function. However, clarithromycin dosage should be reduced by 50% in patients with moderate renal impairment (CrCl 30 to 60 mL/min) and 75% in patients with more severe renal impairment (CrCl below 30 mL/min).", "mechanism_text": "Metabolism", "recommendation": "No dosage adjustment of clarithromycin or darunavir is required during coadministration in patients with normal renal function.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67725/", "reference_text": "[1] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[2] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc, Bridgewater, NJ.[3] Cheng KL, Nafziger AN, Peloquin CA, Amsden GW \"Effect of grapefruit juice on clarithromycin pharmacokinetics.\" Antimicrob Agents Chemother 42 (1998): 927-9", "alternatives_a": "Pantoprazole, Levofloxacin, Tetracycline, Rabeprazole, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Cimetidine, More", "alternatives_b": "Glecaprevir, Tenofovir alafenamide, Cabotegravir, Lenacapavir, Velpatasvir, Voxilaprevir, Maribavir, Pibrentasvir, Rimantadine, Elvitegravir, Valganciclovir, More", "updated_at": 1767369485}, {"id": 67639, "ingredient1": "Dasatinib", "ingredient2": "Clarithromycin", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of dasatinib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of dasatinib with potent CYP450 3A4 inhibitors should generally be avoided. Some authorities recommend avoiding concomitant use of dasatinib during and for 2 weeks after treatment with itraconazole. Close monitoring for toxicity (e.g., myelosuppression, bleeding complications, fluid retention, excessive slowing of heart rate or other conduction disturbances) and a reduction of dasatinib dosage to a range of 20 to 40 mg daily should be considered if there are no alternatives and concomitant use with these agents is necessary.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of dasatinib with potent CYP450 3A4 inhibitors should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67726/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[3] \"Product Information. Sprycel (dasatinib).\" Bristol-Myers Squibb, Princeton, NJ.[4] \"Product Information. Sprycel (dasatinib).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[8] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Tetracycline, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Amoxicillin, Dirithromycin, Lincomycin, Clindamycin", "alternatives_b": "Alpelisib, Trametinib, Dacomitinib, Tivozanib, Alectinib", "updated_at": 1767369485}, {"id": 67640, "ingredient1": "Daunorubicin", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of daunorubicin and idarubicin, both of which are substrates of the efflux transporter also known as ABCB1 or MDR1. The interaction has been studied with cyclosporine, a potent P-gp inhibitor, in attempt to overcome multidrug resistance in MDR1-overexpressing tumors.", "source": "DDInter", "management_text": "Caution is advised if daunorubicin or idarubicin is prescribed in combination with a P-gp inhibitor. Patients should be closely monitored for increased adverse effects including cardiotoxicity and myelosuppression.", "mechanism_text": "Absorption", "recommendation": "Caution is advised if daunorubicin or idarubicin is prescribed in combination with a P-gp inhibitor.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67727/", "reference_text": "[1] \"Product Information. Daunoxome (daunorubicin liposomal).\" Nexstar Pharmaceuticals Inc, Boulder, CO.[2] \"Product Information. Idamycin (idarubicin).\" Pharmacia and Upjohn, Kalamazoo, MI.[3] \"Multum Information Services, Inc. Expert Review Panel\"[4] \"Product Information. Cerubidine (daunorubicin).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] \"Product Information. Incivek (telaprevir).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Dactinomycin, Mitomycin, Valrubicin, Plicamycin, Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Ixazomib, More", "alternatives_b": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, More", "updated_at": 1767369485}, {"id": 67641, "ingredient1": "Daunorubicin (liposomal)", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of daunorubicin and idarubicin, both of which are substrates of the efflux transporter also known as ABCB1 or MDR1. The interaction has been studied with cyclosporine, a potent P-gp inhibitor, in attempt to overcome multidrug resistance in MDR1-overexpressing tumors.", "source": "DDInter", "management_text": "Caution is advised if daunorubicin or idarubicin is prescribed in combination with a P-gp inhibitor. Patients should be closely monitored for increased adverse effects including cardiotoxicity and myelosuppression.", "mechanism_text": "Absorption", "recommendation": "Caution is advised if daunorubicin or idarubicin is prescribed in combination with a P-gp inhibitor.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67728/", "reference_text": "[1] \"Product Information. Daunoxome (daunorubicin liposomal).\" Nexstar Pharmaceuticals Inc, Boulder, CO.[2] \"Product Information. Idamycin (idarubicin).\" Pharmacia and Upjohn, Kalamazoo, MI.[3] \"Multum Information Services, Inc. Expert Review Panel\"[4] \"Product Information. Cerubidine (daunorubicin).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] \"Product Information. Incivek (telaprevir).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Dactinomycin, Mitomycin, Valrubicin, Plicamycin, Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Ixazomib, More", "alternatives_b": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, More", "updated_at": 1767369485}, {"id": 67642, "ingredient1": "Deferasirox", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Coadministration with deferasirox may decrease the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism may involve induction of CYP450 3A4 activity by deferasirox, although in vitro, the drug has been shown to inhibit CYP450 3A4.", "source": "DDInter", "management_text": "Caution is advised if deferasirox must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever deferasirox is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if deferasirox must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67729/", "reference_text": "[1] Skerjanec A, Wang J, Maren K, Rojkjaer L \"Investigation of the pharmacokinetic interactions of deferasirox, a once-daily oral iron chelator, with midazolam, rifampin, and repaglinide in healthy volunteers.\" J Clin Pharmacol 50 (2010): 205-13[2] \"Product Information. Exjade (deferasirox).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Exjade (deferasirox).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Pantoprazole, Levofloxacin, Tetracycline, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Cimetidine, Esomeprazole, Ranitidine, More", "alternatives_b": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Deferoxamine, Levoleucovorin, Arginine, More", "updated_at": 1767369485}, {"id": 67643, "ingredient1": "Deflazacort", "ingredient2": "Clarithromycin", "severity": "Major", "effect": "Coadministration with potent or moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of 21-desdeflazacort, the active metabolite of deflazacort that is formed by esterases after oral administration and further metabolized by CYP450 3A4 to several inactive metabolites.", "source": "DDInter", "management_text": "The manufacturer suggests using one-third of the recommended dosage of deflazacort when coadministered with potent or moderate CYP450 3A4 inhibitors. Some authorities recommend avoiding concomitant use of deflazacort and CYP450 3A inhibitors unless the benefit outweighs the risk, in which case patients should be monitored for systemic corticosteroid side effects.", "mechanism_text": "Metabolism", "recommendation": "The manufacturer suggests using one-third of the recommended dosage of deflazacort when coadministered with potent or moderate CYP450 3A4 inhibitors.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67730/", "reference_text": "[1] \"Product Information. Emflaza (deflazacort).\" Marathon Pharmaceuticals, Deerfield, IL.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Cimetidine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67644, "ingredient1": "Degarelix", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Long-term androgen deprivation therapy can prolong the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).", "source": "DDInter", "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.", "mechanism_text": "Synergism", "recommendation": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67731/", "reference_text": "[1] \"Product Information. Vantas (histrelin).\" Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc), Lexington, MA.[2] \"Product Information. Zoladex (goserelin).\" Zeneca Pharmaceuticals, Wilmington, DE.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Trelstar (triptorelin)\" Pharmacia and Upjohn, Kalamazoo, MI.[5] \"Product Information. Firmagon (degarelix).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Lupron (leuprolide).\" TAP Pharmaceuticals Inc, Deerfield, IL.[7] \"Product Information. Eligard (leuprolide).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[8] \"Product Information. Plenaxis (abarelix).\" Praecis Pharmaceuticals Inc, Waltham, MA.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, More", "alternatives_b": "Anastrozole, Aminoglutethimide, Exemestane, Fulvestrant", "updated_at": 1767369485}, {"id": 67645, "ingredient1": "Delavirdine", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Concomitant administration of delavirdine and clarithromycin has been shown to increase the area under the plasma concentration-time curve (AUC) of clarithromycin by 100%. The mechanism may be related to inhibition of CYP450 3A4 hepatic metabolism.", "source": "DDInter", "management_text": "Close clinical monitoring for toxicity is recommended if this combination is used. The manufacturer recommends dose adjustments for clarithromycin in patients with renal insufficiency: Reduce the dose by 50% for patients with a creatinine clearance of 30 to 60 mL/min, and reduce by 75% for patients with creatinine clearance less than 30 mL/min.", "mechanism_text": "Metabolism", "recommendation": "Close clinical monitoring for toxicity is recommended if this combination is used.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67732/", "reference_text": "[1] \"Product Information. Rescriptor (delavirdine).\" Pharmacia and Upjohn, Kalamazoo, MI.[2] Cheng KL, Nafziger AN, Peloquin CA, Amsden GW \"Effect of grapefruit juice on clarithromycin pharmacokinetics.\" Antimicrob Agents Chemother 42 (1998): 927-9", "alternatives_a": "Glecaprevir, Tenofovir alafenamide, Cabotegravir, Lenacapavir, Velpatasvir, Voxilaprevir, Maribavir, Pibrentasvir, Rimantadine, Elvitegravir, Valganciclovir, More", "alternatives_b": "Tinidazole, Levofloxacin, Tetracycline, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Vonoprazan, Amoxicillin, Lincomycin, Azithromycin, Dirithromycin", "updated_at": 1767369485}, {"id": 67646, "ingredient1": "Desipramine", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67733/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[16] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Phenelzine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Vortioxetine, Milnacipran, Tryptophan, Esketamine", "alternatives_b": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Nizatidine, Esomeprazole, More", "updated_at": 1767369485}, {"id": 67647, "ingredient1": "Deutetrabenazine", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Deutetrabenazine has been associated with modest QT interval prolongation. In addition, central nervous system (CNS)-depressant effects may be additively or synergistically increased in patients taking deutetrabenazine with certain other drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "Coadministration of deutetrabenazine with other drugs that can prolong the QT interval should generally be avoided. Deutetrabenazine is not recommended for use in patients with congenital long QT syndrome or with arrhythmias associated with a prolonged QT interval. If concomitant use is required, assessment of baseline QT interval and periodic monitoring during therapy may be considered. In addition, dosage reduction may be considered in patients on concurrent therapy with a strong CYP450 2D6 inhibitor, or in patients who are poor metabolizers of CYP450 2D6.", "mechanism_text": "Metabolism, Synergism", "recommendation": "Coadministration of deutetrabenazine with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67734/", "reference_text": "[1] \"Product Information. Austedo (deutetrabenazine).\" Teva Pharmaceuticals USA, North Wales, PA.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[3] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, More", "alternatives_b": "Dextromethorphan, Dalfampridine, Sodium oxybate, Riluzole, Inotersen, Amifampridine, Tafamidis", "updated_at": 1767369485}, {"id": 67648, "ingredient1": "Dexamethasone (nasal)", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme. The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations. Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy. Cushing's syndrome and adrenal insufficiency have been attributed to the interaction.", "source": "DDInter", "management_text": "The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors. When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical \"buffalo\" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.", "mechanism_text": "Metabolism", "recommendation": "The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67735/", "reference_text": "[1] Edsbacker S, Andersson T \"Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease.\" Clin Pharmacokinet 43 (2004): 803-21[2] Finkenbine RD, Frye MD \"Case of psychosis due to prednisone-clarithromycin interaction.\" Gen Hosp Psychiat 20 (1998): 325-6[3] Soldatos G, Sztal-Mazer S, Woolley I, Stockigt J \"Exogenous glucocorticoid excess as a result of ritonavir-fluticasone interaction.\" Intern Med J 35 (2005): 67-8[4] Kandrotas RJ, Slaughter RL, Brass C, Jusko WJ \"Ketoconazole effects on methylprednisolone disposition and their joint suppression of endogenous cortisol.\" Clin Pharmacol Ther 42 (1987): 465-70[5] Raaska K, Niemi M, Neuvonen M, Neuvonen PJ, Kivisto KT \"Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole.\" Clin Pharmacol Ther 72 (2002): 362-369[6] Ulrich B, Frey FJ, Speck RF, Frey BM \"Pharmacokinetics/pharmacodynamics of ketoconazole-prednisolone interaction.\" J Pharmacol Exp Ther 260 (1992): 487-90[7] Zurcher RM, Frey BM, Frey FJ \"Impact of ketoconazole on the metabolism of prednisolone.\" Clin Pharmacol Ther 45 (1989): 366-72[8] Busse KH, Formentini E, Alfaro RM, Kovacs JA, Penzak SR \"Influence of antiretroviral drugs on the pharmacokinetics of prednisolone in HIV-infected individuals.\" J Acquir Immune Defic Syndr 48 (2008): 561-6[9] Yamashita SK, Ludwig EA, Middleton E Jr, Jusko WJ \"Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone.\" Clin Pharmacol Ther 49 (1991): 558-70[10] Hillebrand-Haverkort ME, Prummel MF, ten Veen JH \"Ritonavir-induced Cushing's syndrome in a patient treated with nasal fluticasone.\" AIDS 13 (1999): 1803[11] Kotlyar M, Brewer ER, Golding M, Carson SW \"Nefazodone inhibits methylprednisolone disposition and enhances its adrenal-suppressant effect.\" J Clin Psychopharmacol 23 (2003): 652-6[12] Itkin IH, Menzel ML \"The use of macrolide antibiotic substances in the treatment of asthma.\" J Allergy Clin Immunol 45 (1970): 146-62[13] Skov M, Main KM, Sillesen IB, Muller J, Koch C, Lanng S \"Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide.\" Eur Respir J 20 (2002): 127-33[14] Samaras K, Pett S, Gowers A, McMurchie M, Cooper DA \"Iatrogenic Cushing's syndrome with osteoporosis and secondary adrenal failure in HIV-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: six cases.\" J Clin Endocrinol Metab 90 (2005): 4394-8[15] Garey KW, Rubinstein I, Gotfried MH, Khan IJ, Varma S, Danziger LH \"Long-term clarithromycin decreases prednisone requirements in elderly patients with prednisone-dependent asthma.\" Chest 118 (2000): 1826-7[16] Glynn AM, Slaughter RL, Brass C, et al \"Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretion.\" Clin Pharmacol Ther 39 (1986): 654-9[17] LaForce CF, Szefler SJ, Miller MF, Ebling W, Brenner M \"Inhibition of methylprednisolone elimination in the presence of erythromycin therapy.\" J Allergy Clin Immunol 72 (1983): 34-9[18] Lebrun-Vignes B, Archer VC, Diquest B, et al. \"Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects.\" Br J Clin Pharmacol 51 (2001): 443-50[19] Varis T, Kivisto KT, Neuvonen PJ \"The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone.\" Eur J Clin Pharmacol 56 (2000): 57-60[20] Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN \"Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole.\" Ann Pharmacother 38 (2004): 46-9[21] Gupta SK, Dube MP \"Exogenous Cushing syndrome mimicking human immunodeficiency virus lipodystrophy.\" Clin Infect Dis 35 (2002): E69-71[22] Varis T, Kaukonen KM, Kivisto KT, Neuvonen PJ \"Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole.\" Clin Pharmacol Ther 64 (1998): 363-8[23] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[24] Couturier J, Steele M, Hussey L, Pawliuk G \"Steroid-induced mania in an adolescent: risk factors and management.\" Can J Clin Pharmacol 8 (2001): 109-12[25] Varis T, Backman JT, Kivisto KT, Neuvonen PJ \"Diltiazem and mibefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone.\" Clin Pharmacol Ther 67 (2000): 215-21[26] Bhumbra NA, Sahloff EG, Oehrtman SJ, Horner JM \"Exogenous Cushing syndrome with inhaled fluticasone in a child receiving lopinavir/ritonavir.\" Ann Pharmacother 41 (2007): 1306-9[27] Main KM, Skov M, Sillesen IB, et al. \"Cushing's syndrome due to pharmacological interaction in a cystic fibrosis patient.\" Acta Paediatr 91 (2002): 1008-11[28] Penzak SR, Formentini E, Alfaro RM, Long M, Natarajan V, Kovacs J \"Prednisolone pharmacokinetics in the presence and absence of ritonavir after oral prednisone administration to healthy volunteers.\" J Acquir Immune Defic Syndr 40 (2005): 573-80[29] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[30] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.", "alternatives_a": "Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, More", "alternatives_b": "Mupirocin, Mometasone furoate, Vitamin A, Ephedrine, Ipratropium, Hyaluronic acid, Nedocromil, Phenylephrine, Beclomethasone dipropionate, Mometasone furoate, Fluorometholone, More", "updated_at": 1767369485}, {"id": 67649, "ingredient1": "Dexamethasone (ophthalmic)", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme. The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations. Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy. Cushing's syndrome and adrenal insufficiency have been attributed to the interaction.", "source": "DDInter", "management_text": "The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors. When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical \"buffalo\" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.", "mechanism_text": "Metabolism", "recommendation": "The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67736/", "reference_text": "[1] Edsbacker S, Andersson T \"Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease.\" Clin Pharmacokinet 43 (2004): 803-21[2] Finkenbine RD, Frye MD \"Case of psychosis due to prednisone-clarithromycin interaction.\" Gen Hosp Psychiat 20 (1998): 325-6[3] Soldatos G, Sztal-Mazer S, Woolley I, Stockigt J \"Exogenous glucocorticoid excess as a result of ritonavir-fluticasone interaction.\" Intern Med J 35 (2005): 67-8[4] Kandrotas RJ, Slaughter RL, Brass C, Jusko WJ \"Ketoconazole effects on methylprednisolone disposition and their joint suppression of endogenous cortisol.\" Clin Pharmacol Ther 42 (1987): 465-70[5] Raaska K, Niemi M, Neuvonen M, Neuvonen PJ, Kivisto KT \"Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole.\" Clin Pharmacol Ther 72 (2002): 362-369[6] Ulrich B, Frey FJ, Speck RF, Frey BM \"Pharmacokinetics/pharmacodynamics of ketoconazole-prednisolone interaction.\" J Pharmacol Exp Ther 260 (1992): 487-90[7] Zurcher RM, Frey BM, Frey FJ \"Impact of ketoconazole on the metabolism of prednisolone.\" Clin Pharmacol Ther 45 (1989): 366-72[8] Busse KH, Formentini E, Alfaro RM, Kovacs JA, Penzak SR \"Influence of antiretroviral drugs on the pharmacokinetics of prednisolone in HIV-infected individuals.\" J Acquir Immune Defic Syndr 48 (2008): 561-6[9] Yamashita SK, Ludwig EA, Middleton E Jr, Jusko WJ \"Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone.\" Clin Pharmacol Ther 49 (1991): 558-70[10] Hillebrand-Haverkort ME, Prummel MF, ten Veen JH \"Ritonavir-induced Cushing's syndrome in a patient treated with nasal fluticasone.\" AIDS 13 (1999): 1803[11] Kotlyar M, Brewer ER, Golding M, Carson SW \"Nefazodone inhibits methylprednisolone disposition and enhances its adrenal-suppressant effect.\" J Clin Psychopharmacol 23 (2003): 652-6[12] Itkin IH, Menzel ML \"The use of macrolide antibiotic substances in the treatment of asthma.\" J Allergy Clin Immunol 45 (1970): 146-62[13] Skov M, Main KM, Sillesen IB, Muller J, Koch C, Lanng S \"Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide.\" Eur Respir J 20 (2002): 127-33[14] Samaras K, Pett S, Gowers A, McMurchie M, Cooper DA \"Iatrogenic Cushing's syndrome with osteoporosis and secondary adrenal failure in HIV-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: six cases.\" J Clin Endocrinol Metab 90 (2005): 4394-8[15] Garey KW, Rubinstein I, Gotfried MH, Khan IJ, Varma S, Danziger LH \"Long-term clarithromycin decreases prednisone requirements in elderly patients with prednisone-dependent asthma.\" Chest 118 (2000): 1826-7[16] Glynn AM, Slaughter RL, Brass C, et al \"Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretion.\" Clin Pharmacol Ther 39 (1986): 654-9[17] LaForce CF, Szefler SJ, Miller MF, Ebling W, Brenner M \"Inhibition of methylprednisolone elimination in the presence of erythromycin therapy.\" J Allergy Clin Immunol 72 (1983): 34-9[18] Lebrun-Vignes B, Archer VC, Diquest B, et al. \"Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects.\" Br J Clin Pharmacol 51 (2001): 443-50[19] Varis T, Kivisto KT, Neuvonen PJ \"The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone.\" Eur J Clin Pharmacol 56 (2000): 57-60[20] Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN \"Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole.\" Ann Pharmacother 38 (2004): 46-9[21] Gupta SK, Dube MP \"Exogenous Cushing syndrome mimicking human immunodeficiency virus lipodystrophy.\" Clin Infect Dis 35 (2002): E69-71[22] Varis T, Kaukonen KM, Kivisto KT, Neuvonen PJ \"Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole.\" Clin Pharmacol Ther 64 (1998): 363-8[23] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[24] Couturier J, Steele M, Hussey L, Pawliuk G \"Steroid-induced mania in an adolescent: risk factors and management.\" Can J Clin Pharmacol 8 (2001): 109-12[25] Varis T, Backman JT, Kivisto KT, Neuvonen PJ \"Diltiazem and mibefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone.\" Clin Pharmacol Ther 67 (2000): 215-21[26] Bhumbra NA, Sahloff EG, Oehrtman SJ, Horner JM \"Exogenous Cushing syndrome with inhaled fluticasone in a child receiving lopinavir/ritonavir.\" Ann Pharmacother 41 (2007): 1306-9[27] Main KM, Skov M, Sillesen IB, et al. \"Cushing's syndrome due to pharmacological interaction in a cystic fibrosis patient.\" Acta Paediatr 91 (2002): 1008-11[28] Penzak SR, Formentini E, Alfaro RM, Long M, Natarajan V, Kovacs J \"Prednisolone pharmacokinetics in the presence and absence of ritonavir after oral prednisone administration to healthy volunteers.\" J Acquir Immune Defic Syndr 40 (2005): 573-80[29] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[30] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.", "alternatives_a": "Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, More", "alternatives_b": "Mupirocin, Mometasone furoate, Vitamin A, Ephedrine, Ipratropium, Hyaluronic acid, Nedocromil, Phenylephrine, Beclomethasone dipropionate, Mometasone furoate, Fluorometholone, More", "updated_at": 1767369485}, {"id": 67650, "ingredient1": "Dexlansoprazole", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Coadministration with clarithromycin may increase the plasma concentrations of lansoprazole. The proposed mechanism is clarithromycin inhibition of intestinal (first-pass) and hepatic metabolism of lansoprazole via CYP450 3A4. Although lansoprazole is primarily metabolized by CYP450 2C19 in the liver, 3A4-mediated metabolism is the predominant pathway in individuals who are 2C19-deficient (approximately 3% to 5% of the Caucasian and 17% to 20% of the Asian population). Additionally, inhibition of P-glycoprotein intestinal efflux transporter by clarithromycin may also contribute to the interaction, resulting in increased bioavailability of lansoprazole.", "source": "DDInter", "management_text": "Although lansoprazole is generally well tolerated, caution may be advised during coadministration with clarithromycin, particularly if higher dosages of one or both drugs are used. Dosage adjustment may be necessary in patients who experience excessive adverse effects of lansoprazole.", "mechanism_text": "Metabolism", "recommendation": "Although lansoprazole is generally well tolerated, caution may be advised during coadministration with clarithromycin, particularly if higher dosages of one or both drugs are used.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67737/", "reference_text": "[1] Miura M, Tada H, Yasui-Furukori N, et al. \"Effect of clarithromycin on the enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes.\" Chirality 17 (2005): 338-344[2] Saito M, Yasui-Furukori N, Uno T, et al. \"Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes.\" Br J Clin Pharmacol 59 (2005): 302-9[3] Ushiama H, Echizen H, Nachi S, Ohnishi A \"Dose-dependent inhibition of CYP3A activity by clarithromycin during Helicobacter pylori eradication therapy assessed by changes in plasma lansoprazole levels and partial cortisol clearance to 6beta-hydroxycortisol.\" Clin Pharmacol Ther 72 (2002): 33-43[4] Cheng KL, Nafziger AN, Peloquin CA, Amsden GW \"Effect of grapefruit juice on clarithromycin pharmacokinetics.\" Antimicrob Agents Chemother 42 (1998): 927-9", "alternatives_a": "Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, More", "alternatives_b": "Tinidazole, Bismuth subcitrate potassium, Vonoprazan, Clarithromycin", "updated_at": 1767369485}, {"id": 67651, "ingredient1": "Diazepam", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Macrolide antibiotics may increase and prolong the CNS effects of certain benzodiazepines. The mechanism is inhibition of CYP450 3A4 hepatic oxidation of the benzodiazepines.", "source": "DDInter", "management_text": "Patients receiving this combination should be monitored for excessive or prolonged sedation. Non-interacting benzodiazepines or antimicrobials may be considered as alternatives.", "mechanism_text": "Metabolism", "recommendation": "Patients receiving this combination should be monitored for excessive or prolonged sedation.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67738/", "reference_text": "[1] Warot D, Bergougnan L, Lamiable D, et al \"Troleandomycin-triazolam interaction in healthy volunteers: pharmacokinetic and psychometric evaluation.\" Eur J Clin Pharmacol 32 (1987): 389-93[2] Yeates RA, Laufen H, Zimmermann T, Schumacher T \"Pharmacokinetic and pharmacodynamic interaction study between midazolam and the macrolide antibiotics, erythromycin clarithromycin, and the azalide azithromycin.\" Int J Clin Pharmacol Ther 35 (1997): 577-9[3] Mattila MJ, Idanpaanheikkila JJ, Tornwall M, Vanakoski J \"Oral single doses of erythromycin and roxithromycin may increase the effects of midazolam on human performance.\" Pharmacol Toxicol 73 (1993): 180-5[4] Zimmermann T, Yeates RA, Laufen H, Scharpf F, Leitold M, Wildfeuer A \"Influence of the antibiotics erythromycin and azithromycin on the pharmacokinetics and pharmacodynamics of midazolam.\" Arzneimittelforschung 46 (1996): 213-7[5] Yasui N, Otani K, Kaneko S, et al \"A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: in vivo evidence for the involvement of CYP3a4 in alprazolam metabolism.\" Clin Pharmacol Ther 59 (1996): 514-9[6] Yeates RA, Laufen H, Zimmermann T \"Interaction between midazolam and clarithromycin: comparison with azithromycin.\" Int J Clin Pharmacol Ther 34 (1996): 400-5[7] Gorski JC, Jones DR, HaehnerDaniels BD, Hamman MA, OMara EM, Hall SD \"The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin.\" Clin Pharmacol Ther 64 (1998): 133-43[8] Phillips JP, Antal EJ, Smith RB \"A pharmacokinetic drug interaction between erythromycin and triazolam.\" J Clin Psychopharmacol 6 (1986): 297-9[9] Wrighton SA, Ring BJ \"Inhibition of human CYP3A catalyzed 1'-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine.\" Pharm Res 11 (1994): 921-4[10] Kanamitsu S, Ito K, Green CE, Tyson CA, Shimada N, Sugiyama Y \"Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4.\" Pharmaceut Res 17 (2000): 419-26[11] Ito K, Ogihara K, Kanamitsu SI, Itoh T \"Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes.\" Drug Metab Dispos 31 (2003): 945-954[12] Amsden GW \"Macrolides versus azalides: a drug interaction update.\" Ann Pharmacother 29 (1995): 906-17[13] Luurila H, Olkkola KT, Neuvonen PJ \"Interaction between erythromycin and the benzodiazepines diazepam and flunitrazepam.\" Pharmacol Toxicol 78 (1996): 117-22[14] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[15] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[16] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[17] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Meprobamate", "alternatives_b": "Tinidazole, Dexlansoprazole, Bismuth subcitrate potassium, Vonoprazan, Levofloxacin, Lincomycin, Dirithromycin", "updated_at": 1767369485}, {"id": 67652, "ingredient1": "Dicloxacillin", "ingredient2": "Clarithromycin", "severity": "Minor", "effect": "Although some in vitro data indicate synergism between macrolide antibiotics and penicillins, other in vitro data indicate antagonism. When these drugs are given together, neither has predictable therapeutic efficacy. Data are available for erythromycin, although theoretically this interaction could occur with any macrolide. Except for monitoring of the effectiveness of antibiotic therapy, no special precautions appear to be necessary.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67739/", "reference_text": "[1] Strom J \"Penicillin and erythromycin singly and in combination in scarlatina therapy and the interference between them.\" Antibiot Chemother 11 (1961): 694-7[2] Cohn JR, Jungkind DL, Baker JS \"In vitro antagonism by erythromycin of the bactericidal action of antimicrobial agents against common respiratory pathogens.\" Antimicrob Agents Chemother 18 (1980): 872-6[3] Penn RL, Ward TT, Steigbigel RT \"Effects of erythromycin in combination with penicillin, ampicillin, or gentamicin on the growth of listeria monocytogenes.\" Antimicrob Agents Chemother 22 (1982): 289-94", "alternatives_a": "Tazobactam, Sulbactam", "alternatives_b": "Tinidazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Bismuth subcitrate potassium, Famotidine, Rifabutin, Cimetidine, Esomeprazole, Nizatidine, More", "updated_at": 1767369485}, {"id": 67653, "ingredient1": "Dicoumarol", "ingredient2": "Clarithromycin", "severity": "Major", "effect": "Coadministration with clarithromycin or erythromycin may infrequently but substantially enhance the hypoprothrombinemic effect of warfarin and other coumarin anticoagulants. The exact mechanism of interaction is unknown. Data from clinical studies have not supported a significant, predictable pharmacodynamic or pharmacokinetic interaction in general. Although both macrolides are potent inhibitors of CYP450 3A4 and can inhibit metabolism of the R(+) enantiomer of warfarin, the overall effect on racemic warfarin pharmacokinetics appears to be minor.", "source": "DDInter", "management_text": "Given the potential for clinically significant interaction and even fatality in the occasional, susceptible patient, close monitoring is recommended if clarithromycin or erythromycin is prescribed during coumarin anticoagulant therapy. The INR should be checked frequently and coumarin dosage adjusted accordingly, particularly following initiation or discontinuation of macrolide therapy in patients who are stabilized on their anticoagulant regimen. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools. The same precaution may be applicable during therapy with other oral anticoagulants (e.g., indandiones) and other similar macrolides (e.g., troleandomycin), although clinical data are lacking.", "mechanism_text": "Metabolism", "recommendation": "Given the potential for clinically significant interaction and even fatality in the occasional, susceptible patient, close monitoring is recommended if clarithromycin or erythromycin is prescribed during coumarin anticoagulant therapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67740/", "reference_text": "[1] O'Donnell D \"Antibiotic-induced potentiation of oral anticoagulant agents.\" Med J Aust 150 (1989): 163-4[2] Hassell D, Utt JK \"Suspected interaction: warfarin and erythromycin.\" South Med J 78 (1985): 1015-6[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Grau E, Real E, Pastor E \"Interaction between clarithromycin and oral anticoagulants.\" Ann Pharmacother 30 (1996): 1495-6[5] Kiran N, Azam S, Dhakam S \"Clarithromycin induced digoxin toxicity: case report and review.\" J Pak Med Assoc 54 (2004): 440-1[6] Gooderham MJ, Bolli P, Fernandez PG \"Concomitant digoxin toxicity and warfarin interaction in a patient receiving clarithromycin.\" Ann Pharmacother 33 (1999): 796-9[7] Schwartz J, Bachmann K, Perrigo E \"Interaction between warfarin and erythromycin.\" South Med J 76 (1983): 91-3[8] Visser LE, Penning-Van Bees FJ, Harrie Kasbergen AA, et al. \"Overanticoagulation associated with combined use of antibacterial drugs and acenocoumarol or phenprocoumon anticoagulants.\" Thromb Haemost 88 (2002): 705-10[9] Bartle WR \"Possible warfarin-erythromycin interaction.\" Arch Intern Med 140 (1980): 985-7[10] Grau E, Fontcuberta J, Felez J \"Erythromycin-oral anticoagulants interaction.\" Arch Intern Med 146 (1986): 1639[11] Recker MW, Kier KL \"Potential interaction between clarithromycin and warfarin.\" Ann Pharmacother 31 (1997): 996-8[12] Sato RI, Gray DR, Brown SE \"Warfarin interaction with erythromycin.\" Arch Intern Med 144 (1984): 2413-4[13] Weibert RT, Lorentz SM, Townsend RJ, et al \"Effect of erythromycin in patients receiving long-term warfarin therapy.\" Clin Pharm 8 (1989): 210-4[14] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[15] Husserl FE \"Erythromycin-warfarin interaction.\" Arch Intern Med 143 (1983): 1831, 1836[16] Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E \"The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.\" Chest 126(3 Suppl) (2004): 204S-233S[17] Loeliger EA, van der Esch B, Mattern MJ, Hemker HC \"The biological disappearance rate of prothrombin, factors VII, IX and X from plasma in hypothyroidism, hyperthyroidism, and during fever.\" Thromb Diath Haemorrh 10 (1963): 267-77[18] Bachmann K, Schwartz JI, Forney R Jr, Frogameni A, Jauregui LE \"The effect of erythromycin on the disposition kinetics of warfarin.\" Pharmacology 28 (1984): 171-6[19] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[20] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[21] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[22] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[23] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[24] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[25] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[26] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[27] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[28] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[29] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[30] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[31] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[32] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[33] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[34] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[35] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[36] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[37] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[38] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[39] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[40] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[41] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[42] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[43] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[44] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[45] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[46] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[47] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[48] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[49] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[50] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[51] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[52] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[53] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[54] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[55] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5", "alternatives_a": "Iloprost, Lepirudin, Urokinase, Cangrelor, Caplacizumab, Argatroban, Prasugrel, Desirudin, Eptifibatide, Streptokinase, Tinzaparin, More", "alternatives_b": "Misoprostol, Bismuth subcitrate potassium, Famotidine, Nizatidine, Vonoprazan, Dirithromycin, Lincomycin, Troleandomycin, Clindamycin", "updated_at": 1767369485}, {"id": 67654, "ingredient1": "Dienestrol (topical)", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "RECOMMENDED: The effectiveness of estrogen-containing oral contraceptives may be impaired by concomitant treatment with antimicrobial agents. Most antimicrobials, with the exception of the rifamycins and possibly griseofulvin, do not induce hepatic enzymes and have not been shown to significantly increase the clearance of oral contraceptive estrogens. Certain macrolide antibiotics (e.g., erythromycin, clarithromycin) may increase the plasma concentrations and the risk of adverse effects of estrogens and progestogens. The mechanism is decreased clearance of the hormones due to inhibition of CYP450 3A4 activity by the macrolide antibiotic. Concomitant administration with erythromycin may increase the estradiol exposure by approximately 50%.", "source": "DDInter", "management_text": "Until further data are available, women using oral contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant antimicrobial therapy. During concomitant therapy with erythromycin or clarithromycin, patients should be observed for increased or altered pharmacologic response to estrogens and progestogens, and dosage(s) adjusted accordingly as necessary.", "mechanism_text": "Metabolism", "recommendation": "Until further data are available, women using oral contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant antimicrobial therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67741/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception. Available from: URL: file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf.\" ([2012, Jan 1]):[4] \"Product Information. Angeliq (drospirenone-estradiol).\" Berlex Laboratories, Wayne, NJ.[5] \"Product Information. Ortho-Est (estropipate).\" Ortho McNeil Pharmaceutical, Raritan, NJ.[6] \"Product Information. Premarin (conjugated estrogens).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[7] \"Product Information. Yasmin (drospirenone-ethinyl estradiol)\" Berlex Laboratories, Richmond, CA.[8] Welling PG, Huang H, Hewitt PF, Lyons LL \"Bioavailability of erythromycin stearate: influence of food and fluid volume.\" J Pharm Sci 67 (1978): 764-6[9] Welling PG \"Influence of food and diet on gastrointestinal drug absorption: a review.\" J Pharmacokinet Biopharm 5 (1977): 291-334[10] Randinitis EJ, Sedman AJ, Welling PG, Kinkel AW \"Effect of a high-fat meal on the bioavailability of a polymer-coated erythromycin particle tablet formulation.\" J Clin Pharmacol 29 (1989): 79-84[11] Coyne TC, Shum S, Chun AH, Jeansonne L, Shirkey HC \"Bioavailability of erythromycin ethylsuccinate in pediatric patients.\" J Clin Pharmacol 18 (1978): 194-202[12] Malmborg AS \"Effect of food on absorption of erythromycin. A study of two derivatives, the stearate and the base.\" J Antimicrob Chemother 5 (1979): 591-9[13] Welling PG, Elliott RL, Pitterle ME, et al \"Plasma levels following single and repeated doses of erythromycin estolate and erythromycin stearate.\" J Pharm Sci 68 (1979): 150-5[14] Kanazawa S, Ohkubo T, Sugawara K \"The effects of grapefruit juice on the pharmacokinetics of erythromycin.\" Eur J Clin Pharmacol 56 (2001): 799-803[15] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[16] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67655, "ingredient1": "Diethylstilbestrol", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "RECOMMENDED: The effectiveness of estrogen-containing oral contraceptives may be impaired by concomitant treatment with antimicrobial agents. Most antimicrobials, with the exception of the rifamycins and possibly griseofulvin, do not induce hepatic enzymes and have not been shown to significantly increase the clearance of oral contraceptive estrogens. Certain macrolide antibiotics (e.g., erythromycin, clarithromycin) may increase the plasma concentrations and the risk of adverse effects of estrogens and progestogens. The mechanism is decreased clearance of the hormones due to inhibition of CYP450 3A4 activity by the macrolide antibiotic. Concomitant administration with erythromycin may increase the estradiol exposure by approximately 50%.", "source": "DDInter", "management_text": "Until further data are available, women using oral contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant antimicrobial therapy. During concomitant therapy with erythromycin or clarithromycin, patients should be observed for increased or altered pharmacologic response to estrogens and progestogens, and dosage(s) adjusted accordingly as necessary.", "mechanism_text": "Metabolism", "recommendation": "Until further data are available, women using oral contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant antimicrobial therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67742/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception. Available from: URL: file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf.\" ([2012, Jan 1]):[4] \"Product Information. Angeliq (drospirenone-estradiol).\" Berlex Laboratories, Wayne, NJ.[5] \"Product Information. Ortho-Est (estropipate).\" Ortho McNeil Pharmaceutical, Raritan, NJ.[6] \"Product Information. Premarin (conjugated estrogens).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[7] \"Product Information. Yasmin (drospirenone-ethinyl estradiol)\" Berlex Laboratories, Richmond, CA.[8] Welling PG, Huang H, Hewitt PF, Lyons LL \"Bioavailability of erythromycin stearate: influence of food and fluid volume.\" J Pharm Sci 67 (1978): 764-6[9] Welling PG \"Influence of food and diet on gastrointestinal drug absorption: a review.\" J Pharmacokinet Biopharm 5 (1977): 291-334[10] Randinitis EJ, Sedman AJ, Welling PG, Kinkel AW \"Effect of a high-fat meal on the bioavailability of a polymer-coated erythromycin particle tablet formulation.\" J Clin Pharmacol 29 (1989): 79-84[11] Coyne TC, Shum S, Chun AH, Jeansonne L, Shirkey HC \"Bioavailability of erythromycin ethylsuccinate in pediatric patients.\" J Clin Pharmacol 18 (1978): 194-202[12] Malmborg AS \"Effect of food on absorption of erythromycin. A study of two derivatives, the stearate and the base.\" J Antimicrob Chemother 5 (1979): 591-9[13] Welling PG, Elliott RL, Pitterle ME, et al \"Plasma levels following single and repeated doses of erythromycin estolate and erythromycin stearate.\" J Pharm Sci 68 (1979): 150-5[14] Kanazawa S, Ohkubo T, Sugawara K \"The effects of grapefruit juice on the pharmacokinetics of erythromycin.\" Eur J Clin Pharmacol 56 (2001): 799-803[15] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[16] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Bazedoxifene", "alternatives_b": "Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, More", "updated_at": 1767369485}, {"id": 67656, "ingredient1": "Digitoxin", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Macrolide antibiotics that inhibit P-glycoprotein may increase the plasma concentrations of digoxin. The proposed mechanism is inhibition of the P-glycoprotein-mediated intestinal efflux and/or renal tubular secretion of digoxin. The interaction has been described in numerous case reports in the medical literature, the majority of which involved clarithromycin, a potent P-glycoprotein inhibitor. Some patients have shown clinical signs consistent with digoxin toxicity, including potentially fatal arrhythmias. Exposure to macrolides, specifically clarithromycin, azithromycin and erythromycin, has been identified as a risk factor for digoxin toxicity.", "source": "DDInter", "management_text": "Caution is advised when digoxin or digitoxin is used in combination with macrolide antibiotics that are inhibitors of P-glycoprotein. Serum digitalis levels and pharmacologic effects should be closely monitored and the dosage adjusted accordingly, particularly following initiation or discontinuation of the macrolide in patients who are stabilized on their digitalis regimen. Patients should be advised to notify their physician if they experience signs of digitalis toxicity such as nausea, anorexia, visual disturbances, slow pulse, or irregular heartbeats.", "mechanism_text": "Absorption, Excretion", "recommendation": "Caution is advised when digoxin or digitoxin is used in combination with macrolide antibiotics that are inhibitors of P-glycoprotein.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67743/", "reference_text": "[1] Lindenbaum J, Rund DG, Butler VP Jr, Tse-Eng D, Saha JR \"Inactivation of digoxin by the gut flora: reversal by antibiotic therapy.\" N Engl J Med 305 (1981): 789-94[2] Ten Eick AP, Sallee D, Preminger T, Weiss A, Reed MD \"Possible drug interaction between digoxin and azithromycin in a young child.\" Clin Drug Investig 20 (2000): 61-4[3] Lindenbaum J, Tse-Eng D, Butler VP, Rund DG \"Urinary excretion of reduced metabolites of digoxin.\" Am J Med 71 (1981): 67-74[4] Nawarskas JJ, McCarthy DM, Spinler SA \"Digoxin toxicity secondary to clarithromycin therapy.\" Ann Pharmacother 31 (1997): 864-6[5] Chan AL, Wang MT, Su CY, Tsai FH \"Risk of digoxin intoxication caused by clarithromycin-digoxin interactions in heart failure patients: a population-based study.\" Eur J Clin Pharmacol 65 (2009): 1237-43[6] Ford A, Smith LC, Baltch AL, Smith RP \"Clarithromycin-induced digoxin toxicity in a patient with AIDS.\" Clin Infect Dis 21 (1995): 1051-2[7] Hughes J, Crowe A \"Inhibition of P-glycoprotein-mediated efflux of digoxin and its metabolites by macrolide antibiotics.\" J Pharmacol Sci 113 (2010): 315-24[8] Corallo CE, Rogers IR \"Roxithromycin-induced digoxin toxicity.\" Med J Aust 165 (1996): 433-4[9] Friedman HS, Bonventre MV \"Erythromycin-induced digoxin toxicity.\" Chest 82 (1982): 202[10] Tanaka H, Matsumoto K, Ueno K, et al. \"Effect of clarithromycin on steady-state digoxin concentrations.\" Ann Pharmacother 37 (2003): 178-81[11] Rodin SM, Johnson BF \"Pharmacokinetic interactions with digoxin.\" Clin Pharmacokinet 15 (1988): 227-44[12] Brown BA, Wallace RJ, Griffith DE, Warden R \"Clarithromycin-associated digoxin toxicity in the elderly.\" Clin Infect Dis 24 (1997): 92-3[13] Rengelshausen J, Goggelmann C, Burhenne J, et al. \"Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin-clarithromycin interaction.\" Br J Clin Pharmacol 56 (2003): 32-38[14] Nordt SP, Williams SR, Manoguerra AS, Clark RF \"Clarithromycin induced digoxin toxicity.\" J Accid Emerg Med 15 (1998): 194-5[15] Laberge P, Martineau P \"Clarithromycin-induced digoxin intoxication.\" Ann Pharmacother 31 (1997): 999-1002[16] Midoneck SR, Etingin O \"Clarithromycin-related toxic effects of digoxin.\" N Engl J Med 333 (1995): 1505[17] Trivedi S, Hyman J, Lichstein E \"Clarithromycin and digoxin toxicity.\" Ann Intern Med 128 (1998): 604[18] Wakasugi H, Yano I, Ito T, Hashida T, Futami T, Nohara R, Sasayama S, Inui K \"Effect of clarithromycin on renal excretion of digoxin: Interaction with P-glycoprotein.\" Clin Pharmacol Ther 64 (1998): 123-8[19] Maxwell DL, Gilmour-White SK, Hall MR \"Digoxin toxicity due to interaction of digoxin with erythromycin.\" BMJ 298 (1989): 572[20] Guerriero SE, Ehrenpreis E, Gallagher KL \"Two cases of clarithromycin-induced digoxin toxicity.\" Pharmacotherapy 17 (1997): 1035-7[21] Bizjak ED, Mauro VF \"Digoxin-macrolide drug interaction.\" Ann Pharmacother 31 (1997): 1077-82[22] Drescher S, Glaeser H, Murdter T, Hitzl M, Eichelbaum M, Fromm MF \"P-glycoprotein-mediated intestinal and biliary digoxin transport in humans.\" Clin Pharmacol Ther 73 (2003): 223-31[23] Eberl S, Renner B, Neubert A, et al. \"Role of p-glycoprotein inhibition for drug interactions : evidence from in vitro and pharmacoepidemiological studies.\" Clin Pharmacokinet 46 (2007): 1039-49[24] Hui J, Wang YMC, Chandrasekaran A, Geraets DR, Caldwell JH, Robertson LW, Reuning RH \"Disposition of tablet and capsule formulations of digoxin in the elderly.\" Pharmacotherapy 14 (1994): 607-12[25] Gomes T, Mamdani MM, Juurlink DN \"Macrolide-induced digoxin toxicity: a population-based study.\" Clin Pharmacol Ther 86 (2009): 383-6[26] Amsden GW \"Macrolides versus azalides: a drug interaction update.\" Ann Pharmacother 29 (1995): 906-17[27] Hirata S, Izumi S, Furukubo T, et al. \"Interactions between clarithromycin and digoxin in patients with end-stage renal disease.\" Int J Clin Pharmacol Ther 43 (2005): 30-6[28] Gurley BJ, Swain A, Williams DK, Barone G, Battu SK \"Gauging the clinical significance of P-glycoprotein-mediated herb-drug interactions: comparative effects of St. John's wort, Echinacea, clarithromycin, and rifampin on digoxin pharmacokinetics.\" Mol Nutr Food Res 52 (2008): 772-9[29] Morton MR, Cooper JW \"Erythromycin-induced digoxin toxicity.\" DICP 23 (1989): 668-70[30] Thalhammer F, Hollenstein UM, Locker GJ, et al \"Azithromycin-related toxic effects of digitoxin.\" Br J Clin Pharmacol 45 (1998): 91-2[31] Balayssac D, Authier N, Cayre A, Coudore F \"Does inhibition of P-glycoprotein lead to drug-drug interactions?\" Toxicol Lett 156 (2005): 319-29[32] Lee CY, Marcotte F, Giraldeau G, Koren G, Juneau M, Tardif JC \"Digoxin toxicity precipitated by clarithromycin use: case presentation and concise review of the literature.\" Can J Cardiol 27 (2011): 870 e15-6[33] Alkadi H, Mosfer M, Alkatheri M \"Clarithromycin and azithromicin induced-digoxin toxicity in patients under digoxin therapy.\" Clin Res Cardiol 96 (2007): 424[34] Kiran N, Azam S, Dhakam S \"Clarithromycin induced digoxin toxicity: case report and review.\" J Pak Med Assoc 54 (2004): 440-1[35] Kurata Y, Ieiri I, Kimura M, et al. \"Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein.\" Clin Pharmacol Ther 72 (2002): 209-19[36] Ten Eick AP, Reed MD \"Hidden dangers of coadministration of antibiotics and digoxin in children: focus on azithromycin.\" Curr Ther Res 61 (2000): 148-60[37] Gooderham MJ, Bolli P, Fernandez PG \"Concomitant digoxin toxicity and warfarin interaction in a patient receiving clarithromycin.\" Ann Pharmacother 33 (1999): 796-9[38] \"Product Information. Lanoxicaps (digoxin).\" Glaxo Wellcome, Research Triangle Park, NC.[39] Zapater P, Reus S, Tello A, Torrus D, Perez-Mateo M, Horga JF \"A prospective study of the clarithromycin-digoxin interaction in elderly patients.\" J Antimicrob Chemother 50 (2002): 601-6[40] Juurlink DN, Mamdani M, Kopp A, Laupacis A, Redelmeier DA \"Drug-drug interactions among elderly patients hospitalized for drug toxicity.\" JAMA 289 (2003): 1652-8[41] Tsutsumi K, Kotegawa T, Kuranari M, et al. \"The effect of erythromycin and clarithromycin on the pharmacokinetics of intravenous digoxin in healthy volunteers.\" J Clin Pharmacol 42 (2002): 1159-64[42] Welling PG, Huang H, Hewitt PF, Lyons LL \"Bioavailability of erythromycin stearate: influence of food and fluid volume.\" J Pharm Sci 67 (1978): 764-6[43] Welling PG \"Influence of food and diet on gastrointestinal drug absorption: a review.\" J Pharmacokinet Biopharm 5 (1977): 291-334[44] Randinitis EJ, Sedman AJ, Welling PG, Kinkel AW \"Effect of a high-fat meal on the bioavailability of a polymer-coated erythromycin particle tablet formulation.\" J Clin Pharmacol 29 (1989): 79-84[45] Coyne TC, Shum S, Chun AH, Jeansonne L, Shirkey HC \"Bioavailability of erythromycin ethylsuccinate in pediatric patients.\" J Clin Pharmacol 18 (1978): 194-202[46] Malmborg AS \"Effect of food on absorption of erythromycin. A study of two derivatives, the stearate and the base.\" J Antimicrob Chemother 5 (1979): 591-9[47] Welling PG, Elliott RL, Pitterle ME, et al \"Plasma levels following single and repeated doses of erythromycin estolate and erythromycin stearate.\" J Pharm Sci 68 (1979): 150-5[48] Kanazawa S, Ohkubo T, Sugawara K \"The effects of grapefruit juice on the pharmacokinetics of erythromycin.\" Eur J Clin Pharmacol 56 (2001): 799-803", "alternatives_a": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Nizatidine, Esomeprazole, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67657, "ingredient1": "Digoxin", "ingredient2": "Clarithromycin", "severity": "Major", "effect": "Coadministration with clarithromycin may significantly increase the plasma concentrations of digoxin. The proposed mechanism is clarithromycin inhibition of the P-glycoprotein-mediated intestinal efflux and/or renal tubular secretion of digoxin.", "source": "DDInter", "management_text": "Caution is advised if digoxin must be used in combination with clarithromycin. Serum digoxin levels and pharmacologic effects should be closely monitored and the dosage adjusted accordingly, particularly following initiation or discontinuation of clarithromycin in patients who are stabilized on their digitalis regimen. Patients should be advised to notify their physician if they experience signs of digoxin toxicity such as nausea, anorexia, visual disturbances, slow pulse, or irregular heartbeats.", "mechanism_text": "Excretion", "recommendation": "Caution is advised if digoxin must be used in combination with clarithromycin.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67744/", "reference_text": "[1] Chan AL, Wang MT, Su CY, Tsai FH \"Risk of digoxin intoxication caused by clarithromycin-digoxin interactions in heart failure patients: a population-based study.\" Eur J Clin Pharmacol 65 (2009): 1237-43[2] Nawarskas JJ, McCarthy DM, Spinler SA \"Digoxin toxicity secondary to clarithromycin therapy.\" Ann Pharmacother 31 (1997): 864-6[3] Lindenbaum J, Tse-Eng D, Butler VP, Rund DG \"Urinary excretion of reduced metabolites of digoxin.\" Am J Med 71 (1981): 67-74[4] Brown BA, Wallace RJ, Griffith DE, Warden R \"Clarithromycin-associated digoxin toxicity in the elderly.\" Clin Infect Dis 24 (1997): 92-3[5] Tanaka H, Matsumoto K, Ueno K, et al. \"Effect of clarithromycin on steady-state digoxin concentrations.\" Ann Pharmacother 37 (2003): 178-81[6] Rodin SM, Johnson BF \"Pharmacokinetic interactions with digoxin.\" Clin Pharmacokinet 15 (1988): 227-44[7] Alkadi H, Mosfer M, Alkatheri M \"Clarithromycin and azithromicin induced-digoxin toxicity in patients under digoxin therapy.\" Clin Res Cardiol 96 (2007): 424[8] Lee CY, Marcotte F, Giraldeau G, Koren G, Juneau M, Tardif JC \"Digoxin toxicity precipitated by clarithromycin use: case presentation and concise review of the literature.\" Can J Cardiol 27 (2011): 870 e15-6[9] Zapater P, Reus S, Tello A, Torrus D, Perez-Mateo M, Horga JF \"A prospective study of the clarithromycin-digoxin interaction in elderly patients.\" J Antimicrob Chemother 50 (2002): 601-6[10] Rengelshausen J, Goggelmann C, Burhenne J, et al. \"Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin-clarithromycin interaction.\" Br J Clin Pharmacol 56 (2003): 32-38[11] Guerriero SE, Ehrenpreis E, Gallagher KL \"Two cases of clarithromycin-induced digoxin toxicity.\" Pharmacotherapy 17 (1997): 1035-7[12] Nordt SP, Williams SR, Manoguerra AS, Clark RF \"Clarithromycin induced digoxin toxicity.\" J Accid Emerg Med 15 (1998): 194-5[13] Wakasugi H, Yano I, Ito T, Hashida T, Futami T, Nohara R, Sasayama S, Inui K \"Effect of clarithromycin on renal excretion of digoxin: Interaction with P-glycoprotein.\" Clin Pharmacol Ther 64 (1998): 123-8[14] Kiran N, Azam S, Dhakam S \"Clarithromycin induced digoxin toxicity: case report and review.\" J Pak Med Assoc 54 (2004): 440-1[15] Gooderham MJ, Bolli P, Fernandez PG \"Concomitant digoxin toxicity and warfarin interaction in a patient receiving clarithromycin.\" Ann Pharmacother 33 (1999): 796-9[16] Kurata Y, Ieiri I, Kimura M, et al. \"Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein.\" Clin Pharmacol Ther 72 (2002): 209-19[17] Midoneck SR, Etingin O \"Clarithromycin-related toxic effects of digoxin.\" N Engl J Med 333 (1995): 1505[18] \"Product Information. Lanoxicaps (digoxin).\" Glaxo Wellcome, Research Triangle Park, NC.[19] Eberl S, Renner B, Neubert A, et al. \"Role of p-glycoprotein inhibition for drug interactions : evidence from in vitro and pharmacoepidemiological studies.\" Clin Pharmacokinet 46 (2007): 1039-49[20] Amsden GW \"Macrolides versus azalides: a drug interaction update.\" Ann Pharmacother 29 (1995): 906-17[21] Gomes T, Mamdani MM, Juurlink DN \"Macrolide-induced digoxin toxicity: a population-based study.\" Clin Pharmacol Ther 86 (2009): 383-6[22] Bizjak ED, Mauro VF \"Digoxin-macrolide drug interaction.\" Ann Pharmacother 31 (1997): 1077-82[23] Drescher S, Glaeser H, Murdter T, Hitzl M, Eichelbaum M, Fromm MF \"P-glycoprotein-mediated intestinal and biliary digoxin transport in humans.\" Clin Pharmacol Ther 73 (2003): 223-31[24] \"Product Information. Biaxin (clarithromycin).\" Abbott Pharmaceutical, Abbott Park, IL.[25] Hui J, Wang YMC, Chandrasekaran A, Geraets DR, Caldwell JH, Robertson LW, Reuning RH \"Disposition of tablet and capsule formulations of digoxin in the elderly.\" Pharmacotherapy 14 (1994): 607-12[26] Tsutsumi K, Kotegawa T, Kuranari M, et al. \"The effect of erythromycin and clarithromycin on the pharmacokinetics of intravenous digoxin in healthy volunteers.\" J Clin Pharmacol 42 (2002): 1159-64[27] Hirata S, Izumi S, Furukubo T, et al. \"Interactions between clarithromycin and digoxin in patients with end-stage renal disease.\" Int J Clin Pharmacol Ther 43 (2005): 30-6[28] Juurlink DN, Mamdani M, Kopp A, Laupacis A, Redelmeier DA \"Drug-drug interactions among elderly patients hospitalized for drug toxicity.\" JAMA 289 (2003): 1652-8[29] Lindenbaum J, Rund DG, Butler VP Jr, Tse-Eng D, Saha JR \"Inactivation of digoxin by the gut flora: reversal by antibiotic therapy.\" N Engl J Med 305 (1981): 789-94[30] Hughes J, Crowe A \"Inhibition of P-glycoprotein-mediated efflux of digoxin and its metabolites by macrolide antibiotics.\" J Pharmacol Sci 113 (2010): 315-24[31] Ford A, Smith LC, Baltch AL, Smith RP \"Clarithromycin-induced digoxin toxicity in a patient with AIDS.\" Clin Infect Dis 21 (1995): 1051-2[32] Balayssac D, Authier N, Cayre A, Coudore F \"Does inhibition of P-glycoprotein lead to drug-drug interactions?\" Toxicol Lett 156 (2005): 319-29[33] Laberge P, Martineau P \"Clarithromycin-induced digoxin intoxication.\" Ann Pharmacother 31 (1997): 999-1002[34] Trivedi S, Hyman J, Lichstein E \"Clarithromycin and digoxin toxicity.\" Ann Intern Med 128 (1998): 604[35] Gurley BJ, Swain A, Williams DK, Barone G, Battu SK \"Gauging the clinical significance of P-glycoprotein-mediated herb-drug interactions: comparative effects of St. John's wort, Echinacea, clarithromycin, and rifampin on digoxin pharmacokinetics.\" Mol Nutr Food Res 52 (2008): 772-9[36] Cheng KL, Nafziger AN, Peloquin CA, Amsden GW \"Effect of grapefruit juice on clarithromycin pharmacokinetics.\" Antimicrob Agents Chemother 42 (1998): 927-9[37] Darcy PF \"Nutrient-drug interactions.\" Adverse Drug React Toxicol Rev 14 (1995): 233-54[38] Becquemont L, Verstuyft C, Kerb R, et al. \"Effect of grapefruit juice on digoxin pharmacokinetics in humans.\" Clin Pharmacol Ther 70 (2001): 311-6", "alternatives_a": "Tinidazole, Bismuth subcitrate potassium, Rifabutin, Vonoprazan, Levofloxacin, Dirithromycin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67658, "ingredient1": "Dihydroergotamine", "ingredient2": "Clarithromycin", "severity": "Major", "effect": "Coadministration with certain macrolide antibiotics may significantly increase the plasma concentrations of ergot derivatives. The mechanism is macrolide inhibition of CYP450 3A4, the isoenzyme responsible for the metabolic clearance of ergotamine and related drugs. Macrolides that may significantly inhibit CYP450 3A4 include clarithromycin, erythromycin and troleandomycin, and clinical ergotism has been reported in patients receiving ergotamine or dihydroergotamine with these agents.", "source": "DDInter", "management_text": "Given the potential for ergot toxicity characterized by peripheral vasospasm, ischemia, thrombosis, tachycardia and hypertension, concomitant use of ergot derivatives with clarithromycin, erythromycin, or troleandomycin is considered contraindicated. Although clinical data have not been reported, some manufacturers also consider the combination of cabergoline with macrolides contraindicated or to be avoided on theoretical grounds. Azithromycin may be a safer alternative during therapy with ergot derivatives.", "mechanism_text": "Metabolism", "recommendation": "Given the potential for ergot toxicity characterized by peripheral vasospasm, ischemia, thrombosis, tachycardia and hypertension, concomitant use of ergot derivatives with clarithromycin, erythromycin, or troleandomycin is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67745/", "reference_text": "[1] Matthews NT, Havill JH \"Ergotism with therapeutic doses of ergotamine tartrate.\" N Z Med J 89 (1979): 476-7[2] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[3] Ghali R, De Lean J, Douville Y, Noel HP, Labbe R \"Erythromycin-associated ergotamine intoxication: arteriographic and electrophysiologic analysis of a rare cause of severe ischemia of the lower extremities and associated ischemic neuropathy.\" Ann Vasc Surg 7 (1993): 291-6[4] Srisuma S, Lavonas EJ, Wananukul W \"Ergotism and factitious hypotension associated with interaction of ergotamine with CYP3A4 inhibitors.\" Clin Toxicol (Phila) (2014): 1-4[5] Horowitz RS, Dart RC, Gomez HF \"Clinical ergotism with lingual ischemia induced by clarithromycin-ergotamine interaction.\" Arch Intern Med 156 (1996): 456-8[6] Francis H, Tyndall A, Webb J \"Severe vascular spasm due to erythromycin-ergotamine interaction.\" Clin Rheumatol 3 (1984): 243-6[7] Hayton AC \"Precipitation of acute ergotism by triacetyloleandomycin.\" N Z Med J 69 (1969): 42[8] \"Product Information. Migranal (dihydroergotamine nasal).\" Novartis Pharmaceuticals, East Hanover, NJ.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Cafergot (caffeine-ergotamine).\" Novartis Pharmaceuticals, East Hanover, NJ.[11] Eadie MJ \"Clinically significant drug interactions with agents specific for migraine attacks.\" Cns Drugs 15 (2001): 105-18[12] Leroy F, Asseman P, Pruvost P, Adnet P, Lacroix D, Thery C \"Dihydroergotamine-erythromycin-induced ergotism.\" Ann Intern Med 109 (1988): 249[13] Bird PA, Sturgess AD \"Clinical ergotism with severe bilateral upper limb ischaemia precipitated by an erythromycin - ergotamine drug interaction.\" Aust N Z J Med 30 (2000): 635-6[14] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[15] Ausband SC, Goodman PE \"An unusual case of clarithromycin associated ergotism.\" J Emerg Med 4 (2001): 411-3[16] Nakatsuka A, Nagai M, Yabe H, et al. \"Effect of clarithromycin on the pharmacokinetics of cabergoline in healthy controls and in patients with Parkinson's disease.\" J Pharmacol Sci 100 (2006): 59-64[17] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[18] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[19] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[20] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[21] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[22] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[23] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[24] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[25] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[26] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[27] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[28] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[29] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[30] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[31] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[32] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[33] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[34] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[35] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[36] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[37] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[38] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[39] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[40] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[41] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[42] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[43] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[44] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[45] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[46] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[47] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[48] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8", "alternatives_a": "Frovatriptan, Eptinezumab, Lasmiditan, Rizatriptan, Galcanezumab, Zolmitriptan, Erenumab, Fremanezumab", "alternatives_b": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Nizatidine, More", "updated_at": 1767369485}, {"id": 67659, "ingredient1": "Disopyramide", "ingredient2": "Clarithromycin", "severity": "Major", "effect": "Disopyramide can cause dose-related prolongation of the QT interval. Coadministration with other agents that can prolong the QT interval such as macrolide antibiotics may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In general, the risk of an individual agent or a combination of agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances (e.g., hypokalemia, hypomagnesemia). Some macrolides such as clarithromycin, erythromycin, and troleandomycin are also potent inhibitors of CYP450 3A4 and may significantly inhibit the metabolism of disopyramide, which is thought to be a substrate of the isoenzyme.", "source": "DDInter", "management_text": "The concurrent use of disopyramide with other medications that can prolong the QT interval should generally be avoided unless benefits are anticipated to outweigh the risks. Caution and clinical monitoring are recommended if these agents are prescribed together, especially to patients with underlying risk factors. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.", "mechanism_text": "Metabolism, Synergism", "recommendation": "The concurrent use of disopyramide with other medications that can prolong the QT interval should generally be avoided unless benefits are anticipated to outweigh the risks.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67746/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Erythrocin Lactobionate (erythromycin).\" Abbott Pharmaceutical, Abbott Park, IL.[3] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T \"Hypoglycemia induced by interaction between clarithromycin and disopyramide.\" Jpn Heart J 40 (1999): 91-6[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Hayashi Y, Ikeda U, Hashimoto T, Watanabe T, Mitsuhashi T, Shimada K \"Torsades de pointes ventricular tachycardia induced by clarithromycin and disopyramide in the presence of hypokalemia.\" Pacing Clin Electrophysiol 22(4 Pt 1) (1999): 672-4[6] Choudhury L, Grais IM, Passman RS \"Torsades de pointes due to drug interaction between disopyramide and clarithromycin.\" Heart Dis 1 (1999): 206-7[7] Ragosta M, Weihl AC, Rosenfeld LE \"Potentially fatal interaction between erythromycin and disopyramide.\" Am J Med 86 (1989): 465-6[8] \"Product Information. Zithromax (azithromycin).\" Pfizer US Pharmaceuticals, New York, NY.[9] Gitler B, Berger LS, Buffa SD \"Torsades de pointes induced by erythromycin.\" Chest 105 (1994): 368-72[10] \"Product Information. Biaxin (clarithromycin).\" Abbott Pharmaceutical, Abbott Park, IL.[11] Lee KL, Jim MH, Tang SC, Tai YT \"QT prolongation and torsades de pointes associated with clarithromycin.\" Am J Med 104 (1998): 395-6[12] Echizen H, Kawasaki H, Chiba K, Tani M, Ishizaki T \"A potent inhibitory effect of erythromycin and other macrolide antibiotics on the mono-n-dealkylation metabolism of disopyramide with human liver microsomes.\" J Pharmacol Exp Ther 264 (1993): 1425-31[13] Paar D, Terjung B, Sauerbruch T \"Life-threatening interaction between clarithromycin and disopyramide.\" Lancet 349 (1997): 326-7[14] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[15] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[16] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[17] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[18] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[19] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[20] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[21] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[22] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[23] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[24] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[25] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[26] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[27] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[28] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[29] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[30] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[31] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[32] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[33] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[34] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[35] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[36] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[37] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[38] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[39] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[40] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[41] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[42] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[43] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[44] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[45] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402", "alternatives_a": "Tocainide, Moricizine, Bretylium", "alternatives_b": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Nizatidine, Esomeprazole, Vonoprazan, More", "updated_at": 1767369485}, {"id": 67660, "ingredient1": "Clarithromycin", "ingredient2": "Valproic acid", "severity": "Moderate", "effect": "A single case has been reported in which a patient developed seizures associated with elevated blood valproate levels after erythromycin was added to a stable valproate regimen. The seizures and elevated valproate levels resolved after both drugs were withheld. The patient subsequently tolerated her usual valproate dosage. The mechanism is suspected to be inhibition of the hepatic metabolism of valproate.", "source": "DDInter", "management_text": "While more data are needed, clinicians are encouraged to be aware that this interaction is possible when macrolide antimicrobial agents and valproate are coadministered. Patients should be advised to notify their physicians if they experience weakness, fatigue, confusion, ataxia, increased seizures, nausea, or vomiting.", "mechanism_text": "Metabolism", "recommendation": "While more data are needed, clinicians are encouraged to be aware that this interaction is possible when macrolide antimicrobial agents and valproate are coadministered.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67747/", "reference_text": "[1] Redington K, Wells C, Petito F \"Erythromycin and valproate interaction.\" Ann Intern Med 116 (1992): 877-8[2] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tiagabine, Brivaracetam, Rufinamide, Methsuximide, Paramethadione, Fenfluramine, Eslicarbazepine, Phensuximide, Methylphenobarbital, Phenacemide, Primidone, More", "alternatives_b": "Tinidazole, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Vonoprazan, Levofloxacin, Lincomycin, Dirithromycin", "updated_at": 1767369485}, {"id": 67661, "ingredient1": "Docetaxel", "ingredient2": "Clarithromycin", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 or dual CYP450 3A4 and P-glycoprotein (P-gp) inhibitors may significantly increase the plasma concentrations of docetaxel, which is a substrate of both CYP450 3A4 and P-gp.", "source": "DDInter", "management_text": "Concomitant use of docetaxel with CYP450 3A4 inhibitors, particularly potent inhibitors or dual CYP450 3A4 and P-gp inhibitors such as itraconazole, ketoconazole, posaconazole, conivaptan, ceritinib, idelalisib, nefazodone, cobicistat, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics, should generally be avoided. Some authorities recommend avoiding concomitant use of docetaxel during and for 2 weeks after treatment with itraconazole. If concomitant use is required, a reduced dosage of docetaxel should be considered. Based on extrapolation from the pharmacokinetic study in 7 cancer patients, a 50% reduction in the docetaxel dose may be reasonable. Patients should be closely monitored for the development of docetaxel toxicity such as myelosuppression, stomatitis, neurotoxicity (e.g., paraesthesia, dysesthesia, pain), myalgia, asthenia, fluid retention, nausea, vomiting, and diarrhea.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of docetaxel with CYP450 3A4 inhibitors, particularly potent inhibitors or dual CYP450 3A4 and P-gp inhibitors such as itraconazole, ketoconazole, posaconazole, conivaptan, ceritinib, idelalisib, nefazodone, cobicistat, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics, should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67748/", "reference_text": "[1] Starr SP, Hammann F, Gotta V, et al. \"Pharmacokinetic interaction between taxanes and amiodarone leading to severe toxicity.\" Br J Clin Pharmacol 450 (2016): 22-27[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Yong WP, Wang LZ, Tham LS, et al. \"A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancers.\" Cancer Chemother Pharmacol 62 (2008): 243-51[5] Vodovar D, Arnaout M, Mongardon N, et al. \"Severe docetaxel overdose induced by pharmacokinetic interaction with dronedarone.\" J Clin Oncol 29 (2011): e694-5[6] McInnes GT, Brodie MJ \"Drug interactions that matter: a critical reappraisal.\" Drugs 36 (1988): 83-110[7] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[8] Engels FK, Mathot RA, Loos WJ, van Schaik RH, Verweij J \"Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel.\" Cancer Biol Ther 5 (2006): 833-9[9] Aronson JK, Grahame-Smith DG \"Clinical pharmacology: adverse drug interactions.\" Br Med J 282 (1981): 288-91[10] \"Product Information. Taxotere (docetaxel).\" Rhone-Poulenc Rorer, Collegeville, PA.[11] \"Product Information. Taxotere (docetaxel).\" Rhone-Poulenc Rorer, Collegeville, PA.[12] Cerner Multum, Inc. \"Australian Product Information.\" O 0[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] Engels FK, Mathot RA, Loos WJ, van Schaik RH, Verweij J \"Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel.\" Cancer Biol Ther 5 (2006): 833-9[15] Valenzuela B, Rebollo J, Perez T, Brugarolas A, Perez-Ruixo JJ \"Effect of grapefruit juice on the pharmacokinetics of docetaxel in cancer patients: a case report.\" Br J Clin Pharmacol (2011):[16] Aronson JK, Grahame-Smith DG \"Clinical pharmacology: adverse drug interactions.\" Br Med J 282 (1981): 288-91[17] McInnes GT, Brodie MJ \"Drug interactions that matter: a critical reappraisal.\" Drugs 36 (1988): 83-110[18] Starr SP, Hammann F, Gotta V, et al. \"Pharmacokinetic interaction between taxanes and amiodarone leading to severe toxicity.\" Br J Clin Pharmacol 450 (2016): 22-27[19] Yong WP, Wang LZ, Tham LS, et al. \"A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancers.\" Cancer Chemother Pharmacol 62 (2008): 243-51[20] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[21] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tetracycline, Dexlansoprazole, Bismuth subcitrate potassium, Nizatidine, Esomeprazole, Vonoprazan, Lincomycin, Dirithromycin", "alternatives_b": "Topotecan, Teniposide", "updated_at": 1767369485}, {"id": 67662, "ingredient1": "Dofetilide", "ingredient2": "Clarithromycin", "severity": "Major", "effect": "Like other class III antiarrhythmic agents, dofetilide can cause dose-related QT interval prolongation. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of dofetilide with other drugs that can prolong the QT interval has not been studied and is not recommended.", "mechanism_text": "Synergism", "recommendation": "Coadministration of dofetilide with other drugs that can prolong the QT interval has not been studied and is not recommended.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67749/", "reference_text": "[1] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Tikosyn (dofetilide)\" Pfizer US Pharmaceuticals, Atlanta, GA.[5] \"Product Information. Tikosyn (dofetilide)\" Pfizer US Pharmaceuticals, Atlanta, GA.[6] \"Product Information. Kaletra (lopinavir-ritonavir)\" Abbott Pharmaceutical, Abbott Park, IL.[7] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[8] \"Product Information. Tikosyn (dofetilide)\" Pfizer US Pharmaceuticals, Atlanta, GA.", "alternatives_a": "Tocainide, Moricizine, Bretylium", "alternatives_b": "Tinidazole, Tetracycline, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Nizatidine, Esomeprazole, Amoxicillin, Lincomycin, Dirithromycin", "updated_at": 1767369485}, {"id": 67663, "ingredient1": "Dolasetron", "ingredient2": "Clarithromycin", "severity": "Major", "effect": "Dolasetron can cause dose-related prolongation of the QT interval via its pharmacologically active metabolite, hydrodolasetron. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is recommended if dolasetron is used in combination with cumulative high-dose anthracycline therapy or other drugs that can prolong the QT interval. ECG monitoring may be appropriate in high-risk patients. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if dolasetron is used in combination with cumulative high-dose anthracycline therapy or other drugs that can prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67750/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Anzemet (dolasetron).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[4] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[5] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[6] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Scopolamine, Nabilone, Rolapitant, Dronabinol", "alternatives_b": "Tinidazole, Tetracycline, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Nizatidine, Esomeprazole, Vonoprazan, Amoxicillin, Dirithromycin, Lincomycin, More", "updated_at": 1767369485}, {"id": 67664, "ingredient1": "Donepezil", "ingredient2": "Clarithromycin", "severity": "Minor", "effect": "Coadministration with inhibitors of CYP450 2D6 and/or 3A4 may increase the plasma concentrations of donepezil, which is primarily metabolized by these isoenzymes.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67751/", "reference_text": "[1] Tiseo PJ, Perdomo CA, Friedhoff LT \"Concurrent administration of donepezil HCl and ketoconazole: assessment of pharmacokinetic changes following single and multiple doses.\" Br J Clin Pharmacol 46 (1998): 30-4[2] \"Product Information. Aricept (donepezil).\" Pfizer US Pharmaceuticals, New York, NY.[3] Rojas-Fernandez C, Fisher C \"Drug interactions and donepezil.\" J Am Geriat Soc 40 (2000): 597-8", "alternatives_a": "Memantine, Ginkgo biloba, Aducanumab", "alternatives_b": "Tinidazole, Tetracycline, Dexlansoprazole, Bismuth subcitrate potassium, Esomeprazole, Dirithromycin, Lincomycin, Clindamycin", "updated_at": 1767369485}, {"id": 67665, "ingredient1": "Doravirine", "ingredient2": "Clarithromycin", "severity": "Minor", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of doravirine, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67752/", "reference_text": "[1] \"Product Information. Pifeltro (doravirine).\" Merck & Company Inc, Whitehouse Station, NJ.", "alternatives_a": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, More", "alternatives_b": "Glecaprevir, Tenofovir alafenamide, Cabotegravir, Lenacapavir, Velpatasvir, Voxilaprevir, Maribavir, Pibrentasvir, Rimantadine, Elvitegravir, Valganciclovir, More", "updated_at": 1767369485}, {"id": 67666, "ingredient1": "Doxazosin", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations and effects of doxazosin. In vitro studies suggest that the primary pathway for elimination of doxazosin is via CYP450 3A4.", "source": "DDInter", "management_text": "Caution is advised if doxazosin is used concomitantly with potent CYP450 3A4 inhibitors. Blood pressure and pharmacologic response to doxazosin should be monitored closely whenever a potent CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the doxazosin dosage adjusted if necessary. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, orthostasis, syncope, or tachycardia. Patients should also avoid driving or operating hazardous machinery until they know how the medication affects them.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if doxazosin is used concomitantly with potent CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67753/", "reference_text": "[1] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[2] \"Product Information. Cardura (doxazosin).\" Pfizer US Pharmaceuticals, New York, NY.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[5] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Guanethidine", "alternatives_b": "Tinidazole, Dexlansoprazole, Bismuth subcitrate potassium, Rifabutin, Esomeprazole, Vonoprazan, Levofloxacin, Dirithromycin", "updated_at": 1767369485}, {"id": 67667, "ingredient1": "Doxepin", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67754/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[16] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Phenelzine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Vortioxetine, Milnacipran, Tryptophan, Esketamine, Clemastine, Tetracaine, More", "alternatives_b": "Tinidazole, Tetracycline, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Esomeprazole, Vonoprazan, Dirithromycin, Lincomycin, Troleandomycin, Clindamycin", "updated_at": 1767369485}, {"id": 67668, "ingredient1": "Doxorubicin", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67755/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[16] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Dactinomycin, Mitomycin, Valrubicin, Plicamycin", "alternatives_b": "Tinidazole, Tetracycline, Dexlansoprazole, Bismuth subcitrate potassium, Esomeprazole, Vonoprazan, Lincomycin, Troleandomycin, Dirithromycin", "updated_at": 1767369485}, {"id": 67669, "ingredient1": "Doxorubicin (liposomal)", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67756/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[16] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Dactinomycin, Mitomycin, Valrubicin, Plicamycin", "alternatives_b": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Cimetidine, Esomeprazole, Ranitidine, More", "updated_at": 1767369485}, {"id": 67670, "ingredient1": "Dronedarone", "ingredient2": "Clarithromycin", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of dronedarone, which is primarily metabolized by the isoenzyme. Because dronedarone is associated with concentration-dependent prolongation of the QT interval, increased levels may potentiate the risk of ventricular arrhythmias such as torsade de pointes and sudden death.", "source": "DDInter", "management_text": "The use of dronedarone in combination with potent CYP450 3A4 inhibitors such as itraconazole, ketoconazole, voriconazole, nefazodone, cyclosporine, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics is considered contraindicated. Patients currently receiving these agents should stop taking them before starting treatment with dronedarone. Some authorities consider concomitant administration of dronedarone and itraconazole to be contraindicated during and for 2 weeks after treatment with itraconazole.", "mechanism_text": "Metabolism", "recommendation": "The use of dronedarone in combination with potent CYP450 3A4 inhibitors such as itraconazole, ketoconazole, voriconazole, nefazodone, cyclosporine, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67757/", "reference_text": "[1] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Multaq (dronedarone).\" sanofi-aventis , Bridgewater, NJ.[4] \"Product Information. Multaq (dronedarone).\" sanofi-aventis , Bridgewater, NJ.[5] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[6] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Pantoprazole, Tetracycline, Rabeprazole, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Nizatidine, Esomeprazole, Ranitidine, Vonoprazan, More", "alternatives_b": "Tocainide, Moricizine, Bretylium", "updated_at": 1767369485}, {"id": 67671, "ingredient1": "Droperidol", "ingredient2": "Clarithromycin", "severity": "Major", "effect": "The use of droperidol has been associated with QT interval prolongation, torsade de pointes and other serious arrhythmias, and sudden death. The concurrent administration of agents that can produce hypokalemia and/or hypomagnesemia (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins), drugs known to increase the QT interval (e.g., phenothiazines, tricyclic antidepressants, antiarrhythmic agents, etc.), certain other drugs (benzodiazepines, volatile anesthetics, intravenous opiates), or alcohol abuse may increase the risk of prolonged QT syndrome.", "source": "DDInter", "management_text": "The manufacturer recommends extreme caution if droperidol must be given concomitantly with these agents. The dosage of droperidol should be individualized and titrated to the desired effect. Routine vital sign and ECG monitoring is recommended. When droperidol is used in combination with other drugs that cause CNS and/or respiratory depression, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "mechanism_text": "Synergism", "recommendation": "The manufacturer recommends extreme caution if droperidol must be given concomitantly with these agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67758/", "reference_text": "[1] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[2] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[3] \"Product Information. Inapsine (droperidol).\" Janssen Pharmaceutica, Titusville, NJ.[4] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Lemma GL, Desta Z, Jones DR, Gorski JC, Hall SD \"Droperidol is predominantly metabolized by human CYP3A enzymes.\" Clin Pharmacol Ther 73 (2003): 16[10] \"Product Information. Droperidol (droperidol).\" Abbott Pharmaceutical, Abbott Park, IL.[11] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[12] Cerner Multum, Inc \"ANVISA Bulrio Eletrnico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[13] \"Product Information. Inapsine (droperidol).\" Janssen Pharmaceutica, Titusville, NJ.[14] \"Product Information. Kaletra (lopinavir-ritonavir)\" Abbott Pharmaceutical, Abbott Park, IL.[15] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Loxapine, Molindone, Thiothixene", "alternatives_b": "Tinidazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Cimetidine, Esomeprazole, Nizatidine, Vonoprazan, More", "updated_at": 1767369485}, {"id": 67672, "ingredient1": "Drospirenone", "ingredient2": "Clarithromycin", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of drospirenone which is primarily metabolized by the isoenzyme. High exposure to drospirenone may potentiate the risk hyperkalemia. Drospirenone has antimineralocorticoid activity and can induce hyperkalemia in susceptible patients.", "source": "DDInter", "management_text": "Caution and close clinical monitoring are recommended, especially in patients requiring long-term use and those at increased risk for hyperkalemia (e.g., patients with renal impairment, those receiving potassium-sparing medications). Because of the risk for hyperkalemia, concomitant use with certain CYP450 3A4 inhibitors such as boceprevir or atazanavir boosted with cobicistat, is considered contraindicated by the manufacturers. Consider checking potassium levels during the first treatment cycle of concomitant drospirenone use and then periodically as indicated.", "mechanism_text": "Metabolism", "recommendation": "Caution and close clinical monitoring are recommended, especially in patients requiring long-term use and those at increased risk for hyperkalemia (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67759/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Victrelis (boceprevir).\" Schering-Plough Corporation, Kenilworth, NJ.[3] \"Product Information. Symtuza (cobicistat/darunavir/emtricitabine/tenof).\" Janssen Pharmaceuticals, Titusville, NJ.[4] \"Product Information. Yasmin (drospirenone-ethinyl estradiol)\" Berlex Laboratories, Richmond, CA.[5] \"Product Information. Slynd (drospirenone).\" Exeltis USA, Inc., Chatham, NJ.[6] \"Product Information. Prezcobix (cobicistat-darunavir).\" Janssen Pharmaceuticals, Titusville, NJ.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, More", "alternatives_b": "Estetrol", "updated_at": 1767369485}, {"id": 67673, "ingredient1": "Dulaglutide", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Concomitant use of insulin and other antidiabetic agents with clarithromycin may cause significant hypoglycemia. There have been rare reports of hypoglycemia in patients treated with clarithromycin, some of whom were taking oral hypoglycemic agents or insulin. The exact mechanism of interaction has not been established. With certain hypoglycemic drugs such as nateglinide, pioglitazone, repaglinide and rosiglitazone, inhibition of the CYP450 3A4 isoenzyme by clarithromycin may be involved.", "source": "DDInter", "management_text": "Caution is advised if clarithromycin is prescribed to patients receiving antidiabetic agents. Patients should be advised to regularly monitor their blood sugar and counseled on how to recognize and treat hypoglycemia, which may include symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if clarithromycin is prescribed to patients receiving antidiabetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67760/", "reference_text": "[1] Otsuka SH \"Severe hypoglycemia from helicobacter pylori triple-drug therapy and insulin detemir drug interaction.\" Pharmacotherapy 33 (2013): e45-9[2] Niemi M, Neuvonen PJ, Kivisto KT \"The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide.\" Clin Pharmacol Ther 70 (2001): 58-65[3] Schelleman H, Bilker WB, Brensinger CM, Wan F, Hennessy S \"Anti-infectives and the risk of severe hypoglycemia in users of glipizide or glyburide.\" Clin Pharmacol Ther 88 (2010): 214-22[4] Khamaisi M, Leitersdorf E \"Severe hypoglycemia from clarithromycin-repaglinide drug interaction.\" Pharmacotherapy 28 (2008): 682-4[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Leiba A, Leibowitz A, Grossman E \"An unusual case of hypoglycemia in a diabetic patient.\" Ann Emerg Med 44 (2004): 427-8[7] Bussing R, Gende A \"Severe hypoglycemia from clarithromycin-sulfonylurea drug interaction.\" Diabetes Care 25 (2002): 1659-61[8] \"Product Information. Biaxin (clarithromycin).\" Abbott Pharmaceutical, Abbott Park, IL.[9] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[10] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[11] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[12] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[13] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[14] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[15] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[16] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[17] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[18] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[19] Cheng KL, Nafziger AN, Peloquin CA, Amsden GW \"Effect of grapefruit juice on clarithromycin pharmacokinetics.\" Antimicrob Agents Chemother 42 (1998): 927-9", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Rifabutin, Cimetidine, More", "alternatives_b": "Guar gum", "updated_at": 1767369485}, {"id": 67674, "ingredient1": "Dutasteride", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Based on in vitro data, coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of dutasteride, which is metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The possibility of prolonged and/or increased pharmacologic effects of dutasteride should be considered during concomitant therapy with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, nefazodone, cobicistat, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics.", "mechanism_text": "Metabolism", "recommendation": "The possibility of prolonged and/or increased pharmacologic effects of dutasteride should be considered during concomitant therapy with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, nefazodone, cobicistat, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67761/", "reference_text": "[1] \"Product Information. Duagen (dutasteride).\" GlaxoSmithKline Healthcare, Pittsburgh, PA.", "alternatives_a": "Tinidazole, Levofloxacin, Tetracycline, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Nizatidine, Esomeprazole, Amoxicillin, Dirithromycin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67675, "ingredient1": "Duvelisib", "ingredient2": "Clarithromycin", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of duvelisib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The dosage of duvelisib should be reduced to 15 mg twice daily when used with potent CYP450 3A4 inhibitors. Patients should be closely monitored for the development of toxicities such as diarrhea, colitis, neutropenia, thrombocytopenia, pneumonitis, infections, cutaneous reactions and hepatotoxicity, and the dosing adjusted or discontinued in accordance with the duvelisib product labeling.", "mechanism_text": "Metabolism", "recommendation": "The dosage of duvelisib should be reduced to 15 mg twice daily when used with potent CYP450 3A4 inhibitors.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67762/", "reference_text": "[1] \"Product Information. Copiktra (duvelisib).\" Verastem, Inc., Needham, MA.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[3] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tetracycline, Levofloxacin, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Nizatidine, Ranitidine, Vonoprazan, More", "alternatives_b": "Alpelisib, Trametinib, Dacomitinib, Tivozanib, Alectinib", "updated_at": 1767369485}, {"id": 67676, "ingredient1": "Echinacea", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Coadministration with echinacea may alter the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 3A4. Echinacea appears to inhibit intestinal CYP450 3A4, which would lead to an increase in oral midazolam (a sensitive 3A4 substrate) bioavailability; however, plasma levels of midazolam following oral administration do not appear to be affected by echinacea. In contrast, it appears that echinacea may also induce hepatic CYP450 3A4; thereby increasing the hepatic clearance of drugs that are substrates of CYP450 3A4.", "source": "DDInter", "management_text": "In general, patients should be advised to consult their healthcare provider before using any herbal or alternative medicines. If echinacea is prescribed with a drug that is a CYP450 3A4 substrate, the possibility of an altered (increased or decreased) therapeutic response should be considered. Patients should be monitored more closely following the addition or withdrawal of echinacea and the dosage of the CYP450 3A4 substrate adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "In general, patients should be advised to consult their healthcare provider before using any herbal or alternative medicines.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67763/", "reference_text": "[1] Gorski JC, Huang SM, Pinto A, et al. \"The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo.\" Clin Pharmacol Ther 75 (2004): 89-100[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Pantoprazole, Levofloxacin, Tetracycline, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Cimetidine, Esomeprazole, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67677, "ingredient1": "Edoxaban", "ingredient2": "Clarithromycin", "severity": "Major", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of edoxaban, which is a substrate of the efflux transporter.", "source": "DDInter", "management_text": "When used for the treatment of deep vein thrombosis and pulmonary embolism, the manufacturer recommends that edoxaban dosage be reduced to 30 mg once daily in patients receiving concomitant treatment with certain P-gp inhibitors including azithromycin, clarithromycin, erythromycin, oral itraconazole, oral ketoconazole, quinidine, and verapamil. This dosage recommendation is based on data from a clinical study, the Hokusai VTE study, and is limited to use with the specific P-gp inhibitors mentioned.", "mechanism_text": "Absorption", "recommendation": "When used for the treatment of deep vein thrombosis and pulmonary embolism, the manufacturer recommends that edoxaban dosage be reduced to 30 mg once daily in patients receiving concomitant treatment with certain P-gp inhibitors including azithromycin, clarithromycin, erythromycin, oral itraconazole, oral ketoconazole, quinidine, and verapamil.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67764/", "reference_text": "[1] Mendell J, Zahir H, Matsushima N, et al. \"Drug-Drug Interaction Studies of Cardiovascular Drugs Involving P-Glycoprotein, an Efflux Transporter, on the Pharmacokinetics of Edoxaban, an Oral Factor Xa Inhibitor.\" Am J Cardiovasc Drugs (2013):[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Savaysa (edoxaban).\" Daiichi Sankyo, Inc., Parsippany, NJ.[4] Parasrampuria DA, Mendell J, Shi M, Matsushima N, Zahir H, Truitt K \"Edoxaban drugdrug interactions with ketoconazole, erythromycin, and cyclosporine.\" Br J Clin Pharmacol 0 (2016): epub[5] Mendell J, Zahir H, Matsushima N, et al. \"Drug-Drug Interaction Studies of Cardiovascular Drugs Involving P-Glycoprotein, an Efflux Transporter, on the Pharmacokinetics of Edoxaban, an Oral Factor Xa Inhibitor.\" Am J Cardiovasc Drugs (2013):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] \"Product Information. Savaysa (edoxaban).\" Daiichi Sankyo, Inc., Parsippany, NJ.[8] Parasrampuria DA, Mendell J, Shi M, Matsushima N, Zahir H, Truitt K \"Edoxaban drugdrug interactions with ketoconazole, erythromycin, and cyclosporine.\" Br J Clin Pharmacol 0 (2016): epub[9] \"Product Information. Mavyret (glecaprevir-pibrentasvir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, More", "alternatives_b": "Iloprost, Lepirudin, Urokinase, Cangrelor, Caplacizumab, Argatroban, Prasugrel, Desirudin, Eptifibatide, Streptokinase, Tinzaparin, More", "updated_at": 1767369485}, {"id": 67678, "ingredient1": "Efavirenz", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Efavirenz has been shown to decrease the area under the plasma concentration-time curve of clarithromycin (500 mg every 12 hours) by 39%. This interaction is attributable to the enhanced metabolism of clarithromycin caused by efavirenz.", "source": "DDInter", "management_text": "The manufacturer recommends that alternative therapy such as azithromycin be considered. No dosage adjustments are recommended. If concomitant therapy cannot be avoided, the patient should be monitored for decreased therapeutic effect of clarithromycin.", "mechanism_text": "Metabolism", "recommendation": "The manufacturer recommends that alternative therapy such as azithromycin be considered.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67765/", "reference_text": "[1] \"Product Information. Sustiva (efavirenz).\" DuPont Pharmaceuticals, Wilmington, DE.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Sustiva (efavirenz).\" DuPont Pharmaceuticals, Wilmington, DE.[5] Cheng KL, Nafziger AN, Peloquin CA, Amsden GW \"Effect of grapefruit juice on clarithromycin pharmacokinetics.\" Antimicrob Agents Chemother 42 (1998): 927-9", "alternatives_a": "Glecaprevir, Tenofovir alafenamide, Cabotegravir, Lenacapavir, Velpatasvir, Voxilaprevir, Maribavir, Pibrentasvir, Rimantadine, Elvitegravir, Valganciclovir, More", "alternatives_b": "Tinidazole, Tetracycline, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Cimetidine, Esomeprazole, Nizatidine, Amoxicillin, Lincomycin, Dirithromycin", "updated_at": 1767369485}, {"id": 67679, "ingredient1": "Elagolix", "ingredient2": "Clarithromycin", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of elagolix, which is a substrate of the isoenzyme. Increased exposure to elagolix may increase the risk of serious adverse effects such as bone loss, suicidal ideation and behavior, exacerbation of mood disorders, and hepatic transaminase elevations.", "source": "DDInter", "management_text": "Concomitant use of elagolix 200 mg twice daily with potent CYP450 3A4 inhibitors for more than 1 month, or elagolix 150 mg once daily with potent CYP450 3A4 inhibitors for more than 6 months, is not recommended.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of elagolix 200 mg twice daily with potent CYP450 3A4 inhibitors for more than 1 month, or elagolix 150 mg once daily with potent CYP450 3A4 inhibitors for more than 6 months, is not recommended.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67766/", "reference_text": "[1] \"Product Information. Orilissa (elagolix).\" AbbVie US LLC, North Chicago, IL.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[3] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, More", "alternatives_b": "Nafarelin, Octreotide, Cetrorelix, Ganirelix, Lanreotide, Gonadorelin", "updated_at": 1767369485}, {"id": 67680, "ingredient1": "Eletriptan", "ingredient2": "Clarithromycin", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of eletriptan, which is primarily metabolized by the isoenzyme. Clinically, this interaction may result in increased risk of vasospastic reactions associated with the use of 5-HT1 receptor agonists, such as coronary artery vasospasm, peripheral vascular ischemia, and colonic ischemia.", "source": "DDInter", "management_text": "Eletriptan should not be used within at least 72 hours of treatment with potent CYP450 3A4 inhibitors. Alternatively, other 5-HT1 receptor agonists that are not metabolized by CYP450 3A4 may be considered, such as frovatriptan, naratriptan, rizatriptan, sumatriptan, and zolmitriptan.", "mechanism_text": "Metabolism", "recommendation": "Eletriptan should not be used within at least 72 hours of treatment with potent CYP450 3A4 inhibitors.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67767/", "reference_text": "[1] \"Product Information. Relpax (eletriptan).\" Pfizer U.S. Pharmaceuticals, New York, NY.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[3] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Frovatriptan, Eptinezumab, Lasmiditan, Rizatriptan, Galcanezumab, Zolmitriptan, Erenumab, Fremanezumab", "alternatives_b": "Tinidazole, Levofloxacin, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Rifabutin, Nizatidine, Esomeprazole, Amoxicillin, More", "updated_at": 1767369485}, {"id": 67681, "ingredient1": "Eliglustat", "ingredient2": "Clarithromycin", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat at substantially elevated plasma concentrations is predicted to cause prolongation of the PR, QTc and QRS cardiac intervals, which may increase the risk of bradycardia, atrioventricular block, cardiac arrest, and serious ventricular arrhythmias such as torsade de pointes.", "source": "DDInter", "management_text": "The use of eliglustat with a potent CYP450 3A4 inhibitor is considered contraindicated in CYP450 2D6 poor metabolizers (PMs) and intermediate metabolizers (IMs). The contraindication is extended to extensive metabolizers (EMs) when a moderate or potent CYP450 2D6 inhibitor is given concomitantly with a moderate or potent CYP450 3A4 inhibitor. In the absence of a concomitant CYP450 2D6 inhibitor, eliglustat may be prescribed at a reduced dosage of 84 mg once daily to EMs treated with a potent CYP450 3A4 inhibitor. Potent CYP450 3A4 inhibitors include itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, ceritinib, idelalisib, mibefradil, nefazodone, cobicistat, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics. Potent and moderate CYP450 2D6 inhibitors include abiraterone, bupropion, celecoxib, cimetidine, cinacalcet, clobazam, darifenacin, diphenhydramine, dronedarone, duloxetine, flecainide, fluoxetine, methotrimeprazine, mirabegron, paroxetine, propafenone, propoxyphene, quinidine, ranolazine, sertraline, and terbinafine. Some drugs such as cobicistat, delavirdine, mibefradil, and ritonavir are dual CYP450 3A4 and 2D6 inhibitors, and they should not be used with eliglustat in any patient regardless of their CYP450 2D6 metabolizer status.", "mechanism_text": "Metabolism", "recommendation": "The use of eliglustat with a potent CYP450 3A4 inhibitor is considered contraindicated in CYP450 2D6 poor metabolizers (PMs) and intermediate metabolizers (IMs).", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67768/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[3] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation, Cambridge, MA.[6] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[7] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 67682, "ingredient1": "Eluxadoline", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "It is not known whether, and to what extent, eluxadoline may be metabolized by CYP450 isoenzymes and may interact with inhibitors of CYP450 isoenzymes.", "source": "DDInter", "management_text": "As a precautionary measure due to incomplete information on the metabolism of eluxadoline, the manufacturer recommends caution during coadministration with potent inhibitors of various CYP450 isoenzymes. Patients should be monitored for adverse effects such as sedation, nausea, vomiting, constipation, abdominal pain, liver enzyme elevations, and pancreatitis,", "mechanism_text": "Metabolism", "recommendation": "As a precautionary measure due to incomplete information on the metabolism of eluxadoline, the manufacturer recommends caution during coadministration with potent inhibitors of various CYP450 isoenzymes.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67769/", "reference_text": "[1] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[2] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc., Parsippany, NJ.[3] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.", "alternatives_a": "Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, More", "alternatives_b": "Opium, Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 67683, "ingredient1": "Empagliflozin", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Concomitant use of insulin and other antidiabetic agents with clarithromycin may cause significant hypoglycemia. There have been rare reports of hypoglycemia in patients treated with clarithromycin, some of whom were taking oral hypoglycemic agents or insulin. The exact mechanism of interaction has not been established. With certain hypoglycemic drugs such as nateglinide, pioglitazone, repaglinide and rosiglitazone, inhibition of the CYP450 3A4 isoenzyme by clarithromycin may be involved.", "source": "DDInter", "management_text": "Caution is advised if clarithromycin is prescribed to patients receiving antidiabetic agents. Patients should be advised to regularly monitor their blood sugar and counseled on how to recognize and treat hypoglycemia, which may include symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if clarithromycin is prescribed to patients receiving antidiabetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67770/", "reference_text": "[1] Otsuka SH \"Severe hypoglycemia from helicobacter pylori triple-drug therapy and insulin detemir drug interaction.\" Pharmacotherapy 33 (2013): e45-9[2] Niemi M, Neuvonen PJ, Kivisto KT \"The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide.\" Clin Pharmacol Ther 70 (2001): 58-65[3] Schelleman H, Bilker WB, Brensinger CM, Wan F, Hennessy S \"Anti-infectives and the risk of severe hypoglycemia in users of glipizide or glyburide.\" Clin Pharmacol Ther 88 (2010): 214-22[4] Khamaisi M, Leitersdorf E \"Severe hypoglycemia from clarithromycin-repaglinide drug interaction.\" Pharmacotherapy 28 (2008): 682-4[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Leiba A, Leibowitz A, Grossman E \"An unusual case of hypoglycemia in a diabetic patient.\" Ann Emerg Med 44 (2004): 427-8[7] Bussing R, Gende A \"Severe hypoglycemia from clarithromycin-sulfonylurea drug interaction.\" Diabetes Care 25 (2002): 1659-61[8] \"Product Information. Biaxin (clarithromycin).\" Abbott Pharmaceutical, Abbott Park, IL.[9] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[10] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[11] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[12] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[13] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[14] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[15] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[16] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[17] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[18] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[19] Cheng KL, Nafziger AN, Peloquin CA, Amsden GW \"Effect of grapefruit juice on clarithromycin pharmacokinetics.\" Antimicrob Agents Chemother 42 (1998): 927-9", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Rifabutin, Cimetidine, More", "alternatives_b": "Guar gum", "updated_at": 1767369485}, {"id": 67684, "ingredient1": "Encorafenib", "ingredient2": "Clarithromycin", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of encorafenib, which is primarily metabolized by the isoenzyme. Increased exposure to encorafenib may increase the risk of serious and life-threatening adverse effects such as hemorrhage, uveitis, QT prolongation, hepatotoxicity, dermatologic reactions, and new malignancies.", "source": "DDInter", "management_text": "Concomitant use of encorafenib with potent CYP450 3A4 inhibitors should generally be avoided. If coadministration is required, the manufacturer recommends reducing the encorafenib dose to one-third of the dose used prior to addition of the potent CYP450 3A4 inhibitor. After the inhibitor has been discontinued for 3 to 5 elimination half-lives, the encorafenib dose that was taken prior to initiating the inhibitor may be resumed.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of encorafenib with potent CYP450 3A4 inhibitors should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67771/", "reference_text": "[1] \"Product Information. Braftovi (encorafenib).\" Array BioPharma Inc., Boulder, CO.[2] \"Product Information. Braftovi (encorafenib).\" Array BioPharma Inc., Boulder, CO.[3] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Cimetidine, Esomeprazole, Ranitidine, More", "alternatives_b": "Alpelisib, Trametinib, Dacomitinib, Tivozanib, Alectinib", "updated_at": 1767369485}, {"id": 67685, "ingredient1": "Enfortumab vedotin", "ingredient2": "Clarithromycin", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of unconjugated monomethyl auristatin E (MMAE), the anti-mitotic and cytotoxic component of enfortumab vedotin. Enfortumab vedotin is an antibody-drug conjugate (ADC) that releases MMAE via proteolytic cleavage, and MMAE has been shown in vitro to be primarily metabolized by CYP450 3A4.", "source": "DDInter", "management_text": "Caution is advised when enfortumab vedotin is used concomitantly with potent CYP450 3A4 inhibitors. Patients should be closely monitored for development or exacerbation of toxicities such as peripheral neuropathy, hyperglycemia, dermatologic reactions (maculopapular rash, pruritus, symmetrical drug-related intertriginous and flexural exanthema (SDRIFE), bullous dermatitis, exfoliative dermatitis, palmar-plantar erythrodysesthesia), and ocular disorders (dry eyes, keratitis, blurred vision, limbal stem cell deficiency), and the dosing of enfortumab vedotin adjusted or withheld as necessary in accordance with the product labeling.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when enfortumab vedotin is used concomitantly with potent CYP450 3A4 inhibitors.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67772/", "reference_text": "[1] Han TH, Gopal AK, Ramchandren R, et al. \"CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies.\" J Clin Pharmacol 53 (2013): 866-77[2] \"Product Information. Adcetris (brentuximab vedotin).\" Seattle Genetics Inc, Bothell, WA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Padcev (enfortumab vedotin).\" Seattle Genetics Inc, Bothell, WA.[5] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.", "alternatives_a": "Pantoprazole, Levofloxacin, Tetracycline, Rabeprazole, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Famotidine, Cimetidine, Esomeprazole, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 67686, "ingredient1": "Entrectinib", "ingredient2": "Clarithromycin", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of entrectinib, which is primarily metabolized by the isoenzyme. Increased exposure to entrectinib may increase the risk and/or severity of adverse effects such as cognitive impairment, mood disorders, dizziness, sleep disturbances, liver enzyme elevations, hyperuricemia, congestive heart failure, edema, myocarditis, QT prolongation, vision problems, anemia, and neutropenia.", "source": "DDInter", "management_text": "Concomitant use of entrectinib with potent (or moderate) CYP450 3A4 inhibitors should be avoided when possible. If coadministration is necessary, the dosage of entrectinib should be reduced to 100 mg once daily for adults and pediatrics patients (12 years and older) with a body surface area (BSA) greater than 1.5 m2. Following discontinuation, and after an appropriate washout period of the CYP450 3A4 inhibitor (i.e., 3 to 5 half-lives), the entrectinib dosage taken prior to initiating the CYP450 3A4 inhibitor may be resumed. For pediatric patients with a body surface area of 1.5 m2 or less, concomitant use of entrectinib with potent (or moderate) CYP450 3A4 inhibitors should be avoided.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of entrectinib with potent (or moderate) CYP450 3A4 inhibitors should be avoided when possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67773/", "reference_text": "[1] \"Product Information. Rozlytrek (entrectinib).\" Genentech, South San Francisco, CA.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Rozlytrek (entrectinib).\" Genentech, South San Francisco, CA.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Nizatidine, Esomeprazole, Ranitidine, More", "alternatives_b": "Alpelisib, Trametinib, Dacomitinib, Tivozanib, Alectinib", "updated_at": 1767369485}, {"id": 67687, "ingredient1": "Enzalutamide", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Coadministration with enzalutamide may decrease the plasma concentrations of drugs that are substrates of CYP450 3A4, 2C9, 2C19, and/or P-glycoprotein (P-gp) efflux transporter. The proposed mechanism involves accelerated clearance via these routes due to enzalutamide-mediated induction. The resulting plasma concentrations will depend on the sensitivity of the affected drugs to these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when enzalutamide is used concomitantly with drugs that are substrates of CYP450 3A4, 2C9, 2C19, and/or P-gp, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever enzalutamide is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when enzalutamide is used concomitantly with drugs that are substrates of CYP450 3A4, 2C9, 2C19, and/or P-gp, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67774/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Xtandi (enzalutamide).\" Astellas Pharma US, Inc, Deerfield, IL.[3] Benoist G, van Oort I, et al \"Drug-drug interaction potential in men treated with enzalutamide: Mind the gap.\" Br J Clin Pharmacol 0 (2017): epub[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Tetracycline, Sucralfate, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Cimetidine, Nizatidine, Ranitidine, Amoxicillin, Lincomycin, Dirithromycin", "alternatives_b": "Anastrozole, Aminoglutethimide, Exemestane, Fulvestrant", "updated_at": 1767369485}, {"id": 67688, "ingredient1": "Epirubicin", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67775/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[16] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Dactinomycin, Mitomycin, Valrubicin, Plicamycin", "alternatives_b": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Nizatidine, Esomeprazole, More", "updated_at": 1767369485}, {"id": 67689, "ingredient1": "Eplerenone", "ingredient2": "Clarithromycin", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations and risk of adverse reactions of eplerenone, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of eplerenone with potent CYP450 3A4 inhibitors is considered contraindicated. Some authorities consider concomitant administration of eplerenone and itraconazole to be contraindicated during and for 2 weeks after treatment with itraconazole.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of eplerenone with potent CYP450 3A4 inhibitors is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67776/", "reference_text": "[1] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[2] \"Product Information. Inspra (eplerenone).\" Searle, Chicago, IL.[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Amiloride, Triamterene", "alternatives_b": "Tinidazole, Levofloxacin, Tetracycline, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Rifabutin, Cimetidine, Esomeprazole, Ranitidine, More", "updated_at": 1767369485}, {"id": 67690, "ingredient1": "Eravacycline", "ingredient2": "Clarithromycin", "severity": "Minor", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of eravacycline, which undergoes oxidation by CYP450 3A4 and flavin monoxygenase (FMO).", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67777/", "reference_text": "[1] \"Product Information. Xerava (eravacycline).\" Tetraphase Pharmaceuticals, Inc, Watertown, MA.", "alternatives_a": "Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, More", "alternatives_b": "Omadacycline, Sarecycline, Oxytetracycline, Demeclocycline", "updated_at": 1767369485}, {"id": 67691, "ingredient1": "Erdafitinib", "ingredient2": "Clarithromycin", "severity": "Major", "effect": "Coadministration of erdafitinib with potent inhibitors of CYP450 2C9 or 3A4 may increase the plasma concentrations and risk of toxicity of erdafitinib, which is a substrate of these isoenzymes.", "source": "DDInter", "management_text": "Coadministration of erdafitinib with potent inhibitors of CYP450 2C9 or 3A4 should generally be avoided. If concomitant use is unavoidable, patients should be closely monitored for the development of adverse effects. Dosage adjustments as well as clinical and laboratory monitoring of erdafitinib should be considered whenever a CYP450 2C9 or 3A4 inhibitor is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Coadministration of erdafitinib with potent inhibitors of CYP450 2C9 or 3A4 should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67778/", "reference_text": "[1] \"Product Information. Balversa (erdafitinib).\" Janssen Products, LP, Horsham, PA.", "alternatives_a": "Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, More", "alternatives_b": "Alpelisib, Trametinib, Dacomitinib, Tivozanib, Alectinib", "updated_at": 1767369485}, {"id": 67692, "ingredient1": "Ergometrine", "ingredient2": "Clarithromycin", "severity": "Major", "effect": "Coadministration with certain macrolide antibiotics may significantly increase the plasma concentrations of ergot derivatives. The mechanism is macrolide inhibition of CYP450 3A4, the isoenzyme responsible for the metabolic clearance of ergotamine and related drugs. Macrolides that may significantly inhibit CYP450 3A4 include clarithromycin, erythromycin and troleandomycin, and clinical ergotism has been reported in patients receiving ergotamine or dihydroergotamine with these agents.", "source": "DDInter", "management_text": "Given the potential for ergot toxicity characterized by peripheral vasospasm, ischemia, thrombosis, tachycardia and hypertension, concomitant use of ergot derivatives with clarithromycin, erythromycin, or troleandomycin is considered contraindicated. Although clinical data have not been reported, some manufacturers also consider the combination of cabergoline with macrolides contraindicated or to be avoided on theoretical grounds. Azithromycin may be a safer alternative during therapy with ergot derivatives.", "mechanism_text": "Metabolism", "recommendation": "Given the potential for ergot toxicity characterized by peripheral vasospasm, ischemia, thrombosis, tachycardia and hypertension, concomitant use of ergot derivatives with clarithromycin, erythromycin, or troleandomycin is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67779/", "reference_text": "[1] Matthews NT, Havill JH \"Ergotism with therapeutic doses of ergotamine tartrate.\" N Z Med J 89 (1979): 476-7[2] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[3] Ghali R, De Lean J, Douville Y, Noel HP, Labbe R \"Erythromycin-associated ergotamine intoxication: arteriographic and electrophysiologic analysis of a rare cause of severe ischemia of the lower extremities and associated ischemic neuropathy.\" Ann Vasc Surg 7 (1993): 291-6[4] Srisuma S, Lavonas EJ, Wananukul W \"Ergotism and factitious hypotension associated with interaction of ergotamine with CYP3A4 inhibitors.\" Clin Toxicol (Phila) (2014): 1-4[5] Horowitz RS, Dart RC, Gomez HF \"Clinical ergotism with lingual ischemia induced by clarithromycin-ergotamine interaction.\" Arch Intern Med 156 (1996): 456-8[6] Francis H, Tyndall A, Webb J \"Severe vascular spasm due to erythromycin-ergotamine interaction.\" Clin Rheumatol 3 (1984): 243-6[7] Hayton AC \"Precipitation of acute ergotism by triacetyloleandomycin.\" N Z Med J 69 (1969): 42[8] \"Product Information. Migranal (dihydroergotamine nasal).\" Novartis Pharmaceuticals, East Hanover, NJ.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Cafergot (caffeine-ergotamine).\" Novartis Pharmaceuticals, East Hanover, NJ.[11] Eadie MJ \"Clinically significant drug interactions with agents specific for migraine attacks.\" Cns Drugs 15 (2001): 105-18[12] Leroy F, Asseman P, Pruvost P, Adnet P, Lacroix D, Thery C \"Dihydroergotamine-erythromycin-induced ergotism.\" Ann Intern Med 109 (1988): 249[13] Bird PA, Sturgess AD \"Clinical ergotism with severe bilateral upper limb ischaemia precipitated by an erythromycin - ergotamine drug interaction.\" Aust N Z J Med 30 (2000): 635-6[14] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[15] Ausband SC, Goodman PE \"An unusual case of clarithromycin associated ergotism.\" J Emerg Med 4 (2001): 411-3[16] Nakatsuka A, Nagai M, Yabe H, et al. \"Effect of clarithromycin on the pharmacokinetics of cabergoline in healthy controls and in patients with Parkinson's disease.\" J Pharmacol Sci 100 (2006): 59-64[17] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[18] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[19] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[20] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[21] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[22] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[23] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[24] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[25] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[26] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[27] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[28] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[29] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[30] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[31] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[32] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[33] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[34] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[35] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[36] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[37] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[38] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[39] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[40] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[41] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[42] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[43] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[44] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[45] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[46] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[47] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[48] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8", "alternatives_a": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Nizatidine, More", "alternatives_b": "Dinoprostone", "updated_at": 1767369485}, {"id": 67693, "ingredient1": "Ergotamine", "ingredient2": "Clarithromycin", "severity": "Major", "effect": "Coadministration with certain macrolide antibiotics may significantly increase the plasma concentrations of ergot derivatives. The mechanism is macrolide inhibition of CYP450 3A4, the isoenzyme responsible for the metabolic clearance of ergotamine and related drugs. Macrolides that may significantly inhibit CYP450 3A4 include clarithromycin, erythromycin and troleandomycin, and clinical ergotism has been reported in patients receiving ergotamine or dihydroergotamine with these agents.", "source": "DDInter", "management_text": "Given the potential for ergot toxicity characterized by peripheral vasospasm, ischemia, thrombosis, tachycardia and hypertension, concomitant use of ergot derivatives with clarithromycin, erythromycin, or troleandomycin is considered contraindicated. Although clinical data have not been reported, some manufacturers also consider the combination of cabergoline with macrolides contraindicated or to be avoided on theoretical grounds. Azithromycin may be a safer alternative during therapy with ergot derivatives.", "mechanism_text": "Metabolism", "recommendation": "Given the potential for ergot toxicity characterized by peripheral vasospasm, ischemia, thrombosis, tachycardia and hypertension, concomitant use of ergot derivatives with clarithromycin, erythromycin, or troleandomycin is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67780/", "reference_text": "[1] Matthews NT, Havill JH \"Ergotism with therapeutic doses of ergotamine tartrate.\" N Z Med J 89 (1979): 476-7[2] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[3] Ghali R, De Lean J, Douville Y, Noel HP, Labbe R \"Erythromycin-associated ergotamine intoxication: arteriographic and electrophysiologic analysis of a rare cause of severe ischemia of the lower extremities and associated ischemic neuropathy.\" Ann Vasc Surg 7 (1993): 291-6[4] Srisuma S, Lavonas EJ, Wananukul W \"Ergotism and factitious hypotension associated with interaction of ergotamine with CYP3A4 inhibitors.\" Clin Toxicol (Phila) (2014): 1-4[5] Horowitz RS, Dart RC, Gomez HF \"Clinical ergotism with lingual ischemia induced by clarithromycin-ergotamine interaction.\" Arch Intern Med 156 (1996): 456-8[6] Francis H, Tyndall A, Webb J \"Severe vascular spasm due to erythromycin-ergotamine interaction.\" Clin Rheumatol 3 (1984): 243-6[7] Hayton AC \"Precipitation of acute ergotism by triacetyloleandomycin.\" N Z Med J 69 (1969): 42[8] \"Product Information. Migranal (dihydroergotamine nasal).\" Novartis Pharmaceuticals, East Hanover, NJ.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Cafergot (caffeine-ergotamine).\" Novartis Pharmaceuticals, East Hanover, NJ.[11] Eadie MJ \"Clinically significant drug interactions with agents specific for migraine attacks.\" Cns Drugs 15 (2001): 105-18[12] Leroy F, Asseman P, Pruvost P, Adnet P, Lacroix D, Thery C \"Dihydroergotamine-erythromycin-induced ergotism.\" Ann Intern Med 109 (1988): 249[13] Bird PA, Sturgess AD \"Clinical ergotism with severe bilateral upper limb ischaemia precipitated by an erythromycin - ergotamine drug interaction.\" Aust N Z J Med 30 (2000): 635-6[14] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[15] Ausband SC, Goodman PE \"An unusual case of clarithromycin associated ergotism.\" J Emerg Med 4 (2001): 411-3[16] Nakatsuka A, Nagai M, Yabe H, et al. \"Effect of clarithromycin on the pharmacokinetics of cabergoline in healthy controls and in patients with Parkinson's disease.\" J Pharmacol Sci 100 (2006): 59-64[17] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[18] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[19] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[20] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[21] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[22] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[23] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[24] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[25] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[26] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[27] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[28] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[29] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[30] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[31] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[32] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[33] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[34] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[35] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[36] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[37] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[38] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[39] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[40] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[41] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[42] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[43] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[44] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[45] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[46] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[47] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[48] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8", "alternatives_a": "Frovatriptan, Eptinezumab, Lasmiditan, Rizatriptan, Galcanezumab, Zolmitriptan, Erenumab, Fremanezumab", "alternatives_b": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Nizatidine, More", "updated_at": 1767369485}, {"id": 67694, "ingredient1": "Eribulin", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Eribulin may cause prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is recommended if eribulin is used in combination with other drugs that can prolong the QT interval. Baseline and periodic monitoring of electrocardiograms and serum electrolytes (potassium, magnesium) should be considered, and hypokalemia or hypomagnesemia corrected prior to initiating treatment with eribulin. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if eribulin is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67781/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Halaven (eribulin).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Pantoprazole, Tetracycline, Rabeprazole, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, Ranitidine, More", "alternatives_b": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Mitotane, Niraparib, Porfimer sodium, More", "updated_at": 1767369485}, {"id": 67695, "ingredient1": "Erlotinib", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of erlotinib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if erlotinib must be used with potent CYP450 3A4 inhibitors. A dosage reduction or temporary interruption of therapy should be considered in patients who experience undue adverse effects of erlotinib such as severe diarrhea (i.e., that which is unresponsive to loperamide or results in dehydration), severe skin reactions, or severe liver function test abnormalities.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if erlotinib must be used with potent CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67782/", "reference_text": "[1] Li J, Zhao M, He P, Hidalgo M, Baker SD \"Differential metabolism of gefitinib and erlotinib by human cytochrome p450 enzymes.\" Clin Cancer Res 13 (2007): 3731-7[2] \"Product Information. Tarceva (erlotinib).\" Genentech, South San Francisco, CA.[3] Li J, Zhao M, He P, Hidalgo M, Baker SD \"Differential metabolism of gefitinib and erlotinib by human cytochrome p450 enzymes.\" Clin Cancer Res 13 (2007): 3731-7[4] \"Product Information. Tarceva (erlotinib).\" Genentech, South San Francisco, CA.", "alternatives_a": "Alpelisib, Trametinib, Dacomitinib, Tivozanib, Alectinib", "alternatives_b": "Tinidazole, Levofloxacin, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Amoxicillin, Lincomycin, Azithromycin, Dirithromycin", "updated_at": 1767369485}, {"id": 67696, "ingredient1": "Ertugliflozin", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Concomitant use of insulin and other antidiabetic agents with clarithromycin may cause significant hypoglycemia. There have been rare reports of hypoglycemia in patients treated with clarithromycin, some of whom were taking oral hypoglycemic agents or insulin. The exact mechanism of interaction has not been established. With certain hypoglycemic drugs such as nateglinide, pioglitazone, repaglinide and rosiglitazone, inhibition of the CYP450 3A4 isoenzyme by clarithromycin may be involved.", "source": "DDInter", "management_text": "Caution is advised if clarithromycin is prescribed to patients receiving antidiabetic agents. Patients should be advised to regularly monitor their blood sugar and counseled on how to recognize and treat hypoglycemia, which may include symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if clarithromycin is prescribed to patients receiving antidiabetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67783/", "reference_text": "[1] Otsuka SH \"Severe hypoglycemia from helicobacter pylori triple-drug therapy and insulin detemir drug interaction.\" Pharmacotherapy 33 (2013): e45-9[2] Niemi M, Neuvonen PJ, Kivisto KT \"The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide.\" Clin Pharmacol Ther 70 (2001): 58-65[3] Schelleman H, Bilker WB, Brensinger CM, Wan F, Hennessy S \"Anti-infectives and the risk of severe hypoglycemia in users of glipizide or glyburide.\" Clin Pharmacol Ther 88 (2010): 214-22[4] Khamaisi M, Leitersdorf E \"Severe hypoglycemia from clarithromycin-repaglinide drug interaction.\" Pharmacotherapy 28 (2008): 682-4[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Leiba A, Leibowitz A, Grossman E \"An unusual case of hypoglycemia in a diabetic patient.\" Ann Emerg Med 44 (2004): 427-8[7] Bussing R, Gende A \"Severe hypoglycemia from clarithromycin-sulfonylurea drug interaction.\" Diabetes Care 25 (2002): 1659-61[8] \"Product Information. Biaxin (clarithromycin).\" Abbott Pharmaceutical, Abbott Park, IL.[9] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[10] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[11] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[12] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[13] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[14] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[15] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[16] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[17] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[18] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[19] Cheng KL, Nafziger AN, Peloquin CA, Amsden GW \"Effect of grapefruit juice on clarithromycin pharmacokinetics.\" Antimicrob Agents Chemother 42 (1998): 927-9", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Rifabutin, Cimetidine, More", "alternatives_b": "Guar gum", "updated_at": 1767369485}, {"id": 67697, "ingredient1": "Erythromycin", "ingredient2": "Clarithromycin", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of erythromycin, which is primarily metabolized by the isoenzyme. The use of erythromycin has been associated with dose-related prolongation of the QT interval, thus elevated plasma levels of the drug may potentiate the risk of ventricular arrhythmias such as ventricular tachycardia and torsade de pointes. In addition, erythromycin may increase the plasma concentrations of drugs that are substrates of CYP450 3A4.", "source": "DDInter", "management_text": "Concomitant use of erythromycin with potent CYP450 3A4 inhibitors should generally be avoided.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of erythromycin with potent CYP450 3A4 inhibitors should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67784/", "reference_text": "[1] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[2] Ray WA, Murray KT, Meredith S, Narasimhulu SS, Hall K, Stein CM \"Oral erythromycin and the risk of sudden death from cardiac causes.\" N Engl J Med 351 (2004): 1089-96[3] Welling PG, Huang H, Hewitt PF, Lyons LL \"Bioavailability of erythromycin stearate: influence of food and fluid volume.\" J Pharm Sci 67 (1978): 764-6[4] Welling PG \"Influence of food and diet on gastrointestinal drug absorption: a review.\" J Pharmacokinet Biopharm 5 (1977): 291-334[5] Randinitis EJ, Sedman AJ, Welling PG, Kinkel AW \"Effect of a high-fat meal on the bioavailability of a polymer-coated erythromycin particle tablet formulation.\" J Clin Pharmacol 29 (1989): 79-84[6] Coyne TC, Shum S, Chun AH, Jeansonne L, Shirkey HC \"Bioavailability of erythromycin ethylsuccinate in pediatric patients.\" J Clin Pharmacol 18 (1978): 194-202[7] Malmborg AS \"Effect of food on absorption of erythromycin. A study of two derivatives, the stearate and the base.\" J Antimicrob Chemother 5 (1979): 591-9[8] Welling PG, Elliott RL, Pitterle ME, et al \"Plasma levels following single and repeated doses of erythromycin estolate and erythromycin stearate.\" J Pharm Sci 68 (1979): 150-5[9] Kanazawa S, Ohkubo T, Sugawara K \"The effects of grapefruit juice on the pharmacokinetics of erythromycin.\" Eur J Clin Pharmacol 56 (2001): 799-803[10] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[11] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Clarithromycin, Lincomycin, Troleandomycin, Dirithromycin, Vitamin A, Isotretinoin, Fluorometholone, Azelaic acid, Adapalene, Rifamycin, Oxytetracycline, More", "alternatives_b": "Tinidazole, Dexlansoprazole, Bismuth subcitrate potassium, Nizatidine, Esomeprazole, Vonoprazan, Erythromycin, Dirithromycin", "updated_at": 1767369485}, {"id": 67698, "ingredient1": "Escitalopram", "ingredient2": "Clarithromycin", "severity": "Major", "effect": "Escitalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is recommended if escitalopram is used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. When escitalopram is used in combination with other drugs that cause CNS and/or respiratory depression, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their doctor if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if escitalopram is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67785/", "reference_text": "[1] Castro VM, Clements CC, Murphy SN, et al. \"QT interval and antidepressant use: a cross sectional study of electronic health records.\" BMJ 346 (2013): f288[2] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[3] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[4] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[9] Health Canada \"Antidepressant Cipralex (escitalopram): Updated information regarding dose-related heart risk. Available from: URL: http://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/_2012/2012_63-eng.php.\" ([2012 May 7]):[10] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[12] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[13] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Phenelzine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Vortioxetine, Milnacipran, Tryptophan, Esketamine", "alternatives_b": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Nizatidine, Ranitidine, More", "updated_at": 1767369485}, {"id": 67699, "ingredient1": "Esomeprazole", "ingredient2": "Clarithromycin", "severity": "Minor", "effect": "Clarithromycin may increase the plasma concentration of esomeprazole. The mechanism may be related to clarithromycin inhibition of hepatic cytochrome P450 enzymes responsible for esomeprazole metabolism. The systemic exposure (AUC) to esomeprazole doubled after coadministration with clarithromycin 500 mg twice daily. The clinical significance is unknown and dose adjustments are not required.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67786/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Nexium (esomeprazole)\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[4] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[5] Cheng KL, Nafziger AN, Peloquin CA, Amsden GW \"Effect of grapefruit juice on clarithromycin pharmacokinetics.\" Antimicrob Agents Chemother 42 (1998): 927-9", "alternatives_a": "Tinidazole, Bismuth subcitrate potassium, Vonoprazan, Clarithromycin, Fenoprofen, Meclofenamic acid, Phenylbutazone, Glucosamine, Chondroitin sulfate, Piroxicam, Flurbiprofen, More", "alternatives_b": "Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, More", "updated_at": 1767369485}, {"id": 67700, "ingredient1": "Estazolam", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Macrolide antibiotics may increase and prolong the CNS effects of certain benzodiazepines. The mechanism is inhibition of CYP450 3A4 hepatic oxidation of the benzodiazepines.", "source": "DDInter", "management_text": "Patients receiving this combination should be monitored for excessive or prolonged sedation. Non-interacting benzodiazepines or antimicrobials may be considered as alternatives.", "mechanism_text": "Metabolism", "recommendation": "Patients receiving this combination should be monitored for excessive or prolonged sedation.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67787/", "reference_text": "[1] Warot D, Bergougnan L, Lamiable D, et al \"Troleandomycin-triazolam interaction in healthy volunteers: pharmacokinetic and psychometric evaluation.\" Eur J Clin Pharmacol 32 (1987): 389-93[2] Yeates RA, Laufen H, Zimmermann T, Schumacher T \"Pharmacokinetic and pharmacodynamic interaction study between midazolam and the macrolide antibiotics, erythromycin clarithromycin, and the azalide azithromycin.\" Int J Clin Pharmacol Ther 35 (1997): 577-9[3] Mattila MJ, Idanpaanheikkila JJ, Tornwall M, Vanakoski J \"Oral single doses of erythromycin and roxithromycin may increase the effects of midazolam on human performance.\" Pharmacol Toxicol 73 (1993): 180-5[4] Zimmermann T, Yeates RA, Laufen H, Scharpf F, Leitold M, Wildfeuer A \"Influence of the antibiotics erythromycin and azithromycin on the pharmacokinetics and pharmacodynamics of midazolam.\" Arzneimittelforschung 46 (1996): 213-7[5] Yasui N, Otani K, Kaneko S, et al \"A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: in vivo evidence for the involvement of CYP3a4 in alprazolam metabolism.\" Clin Pharmacol Ther 59 (1996): 514-9[6] Yeates RA, Laufen H, Zimmermann T \"Interaction between midazolam and clarithromycin: comparison with azithromycin.\" Int J Clin Pharmacol Ther 34 (1996): 400-5[7] Gorski JC, Jones DR, HaehnerDaniels BD, Hamman MA, OMara EM, Hall SD \"The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin.\" Clin Pharmacol Ther 64 (1998): 133-43[8] Phillips JP, Antal EJ, Smith RB \"A pharmacokinetic drug interaction between erythromycin and triazolam.\" J Clin Psychopharmacol 6 (1986): 297-9[9] Wrighton SA, Ring BJ \"Inhibition of human CYP3A catalyzed 1'-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine.\" Pharm Res 11 (1994): 921-4[10] Kanamitsu S, Ito K, Green CE, Tyson CA, Shimada N, Sugiyama Y \"Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4.\" Pharmaceut Res 17 (2000): 419-26[11] Ito K, Ogihara K, Kanamitsu SI, Itoh T \"Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes.\" Drug Metab Dispos 31 (2003): 945-954[12] Amsden GW \"Macrolides versus azalides: a drug interaction update.\" Ann Pharmacother 29 (1995): 906-17[13] Luurila H, Olkkola KT, Neuvonen PJ \"Interaction between erythromycin and the benzodiazepines diazepam and flunitrazepam.\" Pharmacol Toxicol 78 (1996): 117-22[14] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[15] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[16] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[17] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tinidazole, Levofloxacin, Tetracycline, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Esomeprazole, Vonoprazan, Amoxicillin, Dirithromycin, More", "alternatives_b": "Methohexital, Methylphenobarbital, Pentobarbital, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, Paraldehyde, Ethchlorvynol, Amobarbital, More", "updated_at": 1767369485}, {"id": 67701, "ingredient1": "Esterified estrogens", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "RECOMMENDED: The effectiveness of estrogen-containing oral contraceptives may be impaired by concomitant treatment with antimicrobial agents. Most antimicrobials, with the exception of the rifamycins and possibly griseofulvin, do not induce hepatic enzymes and have not been shown to significantly increase the clearance of oral contraceptive estrogens. Certain macrolide antibiotics (e.g., erythromycin, clarithromycin) may increase the plasma concentrations and the risk of adverse effects of estrogens and progestogens. The mechanism is decreased clearance of the hormones due to inhibition of CYP450 3A4 activity by the macrolide antibiotic. Concomitant administration with erythromycin may increase the estradiol exposure by approximately 50%.", "source": "DDInter", "management_text": "Until further data are available, women using oral contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant antimicrobial therapy. During concomitant therapy with erythromycin or clarithromycin, patients should be observed for increased or altered pharmacologic response to estrogens and progestogens, and dosage(s) adjusted accordingly as necessary.", "mechanism_text": "Metabolism", "recommendation": "Until further data are available, women using oral contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant antimicrobial therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67788/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception. Available from: URL: file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf.\" ([2012, Jan 1]):[4] \"Product Information. Angeliq (drospirenone-estradiol).\" Berlex Laboratories, Wayne, NJ.[5] \"Product Information. Ortho-Est (estropipate).\" Ortho McNeil Pharmaceutical, Raritan, NJ.[6] \"Product Information. Premarin (conjugated estrogens).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[7] \"Product Information. Yasmin (drospirenone-ethinyl estradiol)\" Berlex Laboratories, Richmond, CA.[8] Welling PG, Huang H, Hewitt PF, Lyons LL \"Bioavailability of erythromycin stearate: influence of food and fluid volume.\" J Pharm Sci 67 (1978): 764-6[9] Welling PG \"Influence of food and diet on gastrointestinal drug absorption: a review.\" J Pharmacokinet Biopharm 5 (1977): 291-334[10] Randinitis EJ, Sedman AJ, Welling PG, Kinkel AW \"Effect of a high-fat meal on the bioavailability of a polymer-coated erythromycin particle tablet formulation.\" J Clin Pharmacol 29 (1989): 79-84[11] Coyne TC, Shum S, Chun AH, Jeansonne L, Shirkey HC \"Bioavailability of erythromycin ethylsuccinate in pediatric patients.\" J Clin Pharmacol 18 (1978): 194-202[12] Malmborg AS \"Effect of food on absorption of erythromycin. A study of two derivatives, the stearate and the base.\" J Antimicrob Chemother 5 (1979): 591-9[13] Welling PG, Elliott RL, Pitterle ME, et al \"Plasma levels following single and repeated doses of erythromycin estolate and erythromycin stearate.\" J Pharm Sci 68 (1979): 150-5[14] Kanazawa S, Ohkubo T, Sugawara K \"The effects of grapefruit juice on the pharmacokinetics of erythromycin.\" Eur J Clin Pharmacol 56 (2001): 799-803[15] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[16] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67702, "ingredient1": "Estradiol (topical)", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "RECOMMENDED: The effectiveness of estrogen-containing oral contraceptives may be impaired by concomitant treatment with antimicrobial agents. Most antimicrobials, with the exception of the rifamycins and possibly griseofulvin, do not induce hepatic enzymes and have not been shown to significantly increase the clearance of oral contraceptive estrogens. Certain macrolide antibiotics (e.g., erythromycin, clarithromycin) may increase the plasma concentrations and the risk of adverse effects of estrogens and progestogens. The mechanism is decreased clearance of the hormones due to inhibition of CYP450 3A4 activity by the macrolide antibiotic. Concomitant administration with erythromycin may increase the estradiol exposure by approximately 50%.", "source": "DDInter", "management_text": "Until further data are available, women using oral contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant antimicrobial therapy. During concomitant therapy with erythromycin or clarithromycin, patients should be observed for increased or altered pharmacologic response to estrogens and progestogens, and dosage(s) adjusted accordingly as necessary.", "mechanism_text": "Metabolism", "recommendation": "Until further data are available, women using oral contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant antimicrobial therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67789/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception. Available from: URL: file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf.\" ([2012, Jan 1]):[4] \"Product Information. Angeliq (drospirenone-estradiol).\" Berlex Laboratories, Wayne, NJ.[5] \"Product Information. Ortho-Est (estropipate).\" Ortho McNeil Pharmaceutical, Raritan, NJ.[6] \"Product Information. Premarin (conjugated estrogens).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[7] \"Product Information. Yasmin (drospirenone-ethinyl estradiol)\" Berlex Laboratories, Richmond, CA.[8] Welling PG, Huang H, Hewitt PF, Lyons LL \"Bioavailability of erythromycin stearate: influence of food and fluid volume.\" J Pharm Sci 67 (1978): 764-6[9] Welling PG \"Influence of food and diet on gastrointestinal drug absorption: a review.\" J Pharmacokinet Biopharm 5 (1977): 291-334[10] Randinitis EJ, Sedman AJ, Welling PG, Kinkel AW \"Effect of a high-fat meal on the bioavailability of a polymer-coated erythromycin particle tablet formulation.\" J Clin Pharmacol 29 (1989): 79-84[11] Coyne TC, Shum S, Chun AH, Jeansonne L, Shirkey HC \"Bioavailability of erythromycin ethylsuccinate in pediatric patients.\" J Clin Pharmacol 18 (1978): 194-202[12] Malmborg AS \"Effect of food on absorption of erythromycin. A study of two derivatives, the stearate and the base.\" J Antimicrob Chemother 5 (1979): 591-9[13] Welling PG, Elliott RL, Pitterle ME, et al \"Plasma levels following single and repeated doses of erythromycin estolate and erythromycin stearate.\" J Pharm Sci 68 (1979): 150-5[14] Kanazawa S, Ohkubo T, Sugawara K \"The effects of grapefruit juice on the pharmacokinetics of erythromycin.\" Eur J Clin Pharmacol 56 (2001): 799-803[15] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[16] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Bazedoxifene, Prasterone, Methyltestosterone, Estetrol, Nafarelin, Octreotide, Cetrorelix, Ganirelix, Lanreotide, Gonadorelin", "alternatives_b": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, More", "updated_at": 1767369485}, {"id": 67703, "ingredient1": "Estrone", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "RECOMMENDED: The effectiveness of estrogen-containing oral contraceptives may be impaired by concomitant treatment with antimicrobial agents. Most antimicrobials, with the exception of the rifamycins and possibly griseofulvin, do not induce hepatic enzymes and have not been shown to significantly increase the clearance of oral contraceptive estrogens. Certain macrolide antibiotics (e.g., erythromycin, clarithromycin) may increase the plasma concentrations and the risk of adverse effects of estrogens and progestogens. The mechanism is decreased clearance of the hormones due to inhibition of CYP450 3A4 activity by the macrolide antibiotic. Concomitant administration with erythromycin may increase the estradiol exposure by approximately 50%.", "source": "DDInter", "management_text": "Until further data are available, women using oral contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant antimicrobial therapy. During concomitant therapy with erythromycin or clarithromycin, patients should be observed for increased or altered pharmacologic response to estrogens and progestogens, and dosage(s) adjusted accordingly as necessary.", "mechanism_text": "Metabolism", "recommendation": "Until further data are available, women using oral contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant antimicrobial therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67790/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception. Available from: URL: file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf.\" ([2012, Jan 1]):[4] \"Product Information. Angeliq (drospirenone-estradiol).\" Berlex Laboratories, Wayne, NJ.[5] \"Product Information. Ortho-Est (estropipate).\" Ortho McNeil Pharmaceutical, Raritan, NJ.[6] \"Product Information. Premarin (conjugated estrogens).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[7] \"Product Information. Yasmin (drospirenone-ethinyl estradiol)\" Berlex Laboratories, Richmond, CA.[8] Welling PG, Huang H, Hewitt PF, Lyons LL \"Bioavailability of erythromycin stearate: influence of food and fluid volume.\" J Pharm Sci 67 (1978): 764-6[9] Welling PG \"Influence of food and diet on gastrointestinal drug absorption: a review.\" J Pharmacokinet Biopharm 5 (1977): 291-334[10] Randinitis EJ, Sedman AJ, Welling PG, Kinkel AW \"Effect of a high-fat meal on the bioavailability of a polymer-coated erythromycin particle tablet formulation.\" J Clin Pharmacol 29 (1989): 79-84[11] Coyne TC, Shum S, Chun AH, Jeansonne L, Shirkey HC \"Bioavailability of erythromycin ethylsuccinate in pediatric patients.\" J Clin Pharmacol 18 (1978): 194-202[12] Malmborg AS \"Effect of food on absorption of erythromycin. A study of two derivatives, the stearate and the base.\" J Antimicrob Chemother 5 (1979): 591-9[13] Welling PG, Elliott RL, Pitterle ME, et al \"Plasma levels following single and repeated doses of erythromycin estolate and erythromycin stearate.\" J Pharm Sci 68 (1979): 150-5[14] Kanazawa S, Ohkubo T, Sugawara K \"The effects of grapefruit juice on the pharmacokinetics of erythromycin.\" Eur J Clin Pharmacol 56 (2001): 799-803[15] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[16] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Bazedoxifene", "alternatives_b": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, More", "updated_at": 1767369485}, {"id": 67704, "ingredient1": "Estrone sulfate", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "RECOMMENDED: The effectiveness of estrogen-containing oral contraceptives may be impaired by concomitant treatment with antimicrobial agents. Most antimicrobials, with the exception of the rifamycins and possibly griseofulvin, do not induce hepatic enzymes and have not been shown to significantly increase the clearance of oral contraceptive estrogens. Certain macrolide antibiotics (e.g., erythromycin, clarithromycin) may increase the plasma concentrations and the risk of adverse effects of estrogens and progestogens. The mechanism is decreased clearance of the hormones due to inhibition of CYP450 3A4 activity by the macrolide antibiotic. Concomitant administration with erythromycin may increase the estradiol exposure by approximately 50%.", "source": "DDInter", "management_text": "Until further data are available, women using oral contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant antimicrobial therapy. During concomitant therapy with erythromycin or clarithromycin, patients should be observed for increased or altered pharmacologic response to estrogens and progestogens, and dosage(s) adjusted accordingly as necessary.", "mechanism_text": "Metabolism", "recommendation": "Until further data are available, women using oral contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant antimicrobial therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67791/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception. Available from: URL: file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf.\" ([2012, Jan 1]):[4] \"Product Information. Angeliq (drospirenone-estradiol).\" Berlex Laboratories, Wayne, NJ.[5] \"Product Information. Ortho-Est (estropipate).\" Ortho McNeil Pharmaceutical, Raritan, NJ.[6] \"Product Information. Premarin (conjugated estrogens).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[7] \"Product Information. Yasmin (drospirenone-ethinyl estradiol)\" Berlex Laboratories, Richmond, CA.[8] Welling PG, Huang H, Hewitt PF, Lyons LL \"Bioavailability of erythromycin stearate: influence of food and fluid volume.\" J Pharm Sci 67 (1978): 764-6[9] Welling PG \"Influence of food and diet on gastrointestinal drug absorption: a review.\" J Pharmacokinet Biopharm 5 (1977): 291-334[10] Randinitis EJ, Sedman AJ, Welling PG, Kinkel AW \"Effect of a high-fat meal on the bioavailability of a polymer-coated erythromycin particle tablet formulation.\" J Clin Pharmacol 29 (1989): 79-84[11] Coyne TC, Shum S, Chun AH, Jeansonne L, Shirkey HC \"Bioavailability of erythromycin ethylsuccinate in pediatric patients.\" J Clin Pharmacol 18 (1978): 194-202[12] Malmborg AS \"Effect of food on absorption of erythromycin. A study of two derivatives, the stearate and the base.\" J Antimicrob Chemother 5 (1979): 591-9[13] Welling PG, Elliott RL, Pitterle ME, et al \"Plasma levels following single and repeated doses of erythromycin estolate and erythromycin stearate.\" J Pharm Sci 68 (1979): 150-5[14] Kanazawa S, Ohkubo T, Sugawara K \"The effects of grapefruit juice on the pharmacokinetics of erythromycin.\" Eur J Clin Pharmacol 56 (2001): 799-803[15] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[16] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67705, "ingredient1": "Estrone sulfate (topical)", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "RECOMMENDED: The effectiveness of estrogen-containing oral contraceptives may be impaired by concomitant treatment with antimicrobial agents. Most antimicrobials, with the exception of the rifamycins and possibly griseofulvin, do not induce hepatic enzymes and have not been shown to significantly increase the clearance of oral contraceptive estrogens. Certain macrolide antibiotics (e.g., erythromycin, clarithromycin) may increase the plasma concentrations and the risk of adverse effects of estrogens and progestogens. The mechanism is decreased clearance of the hormones due to inhibition of CYP450 3A4 activity by the macrolide antibiotic. Concomitant administration with erythromycin may increase the estradiol exposure by approximately 50%.", "source": "DDInter", "management_text": "Until further data are available, women using oral contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant antimicrobial therapy. During concomitant therapy with erythromycin or clarithromycin, patients should be observed for increased or altered pharmacologic response to estrogens and progestogens, and dosage(s) adjusted accordingly as necessary.", "mechanism_text": "Metabolism", "recommendation": "Until further data are available, women using oral contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant antimicrobial therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67792/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception. Available from: URL: file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf.\" ([2012, Jan 1]):[4] \"Product Information. Angeliq (drospirenone-estradiol).\" Berlex Laboratories, Wayne, NJ.[5] \"Product Information. Ortho-Est (estropipate).\" Ortho McNeil Pharmaceutical, Raritan, NJ.[6] \"Product Information. Premarin (conjugated estrogens).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[7] \"Product Information. Yasmin (drospirenone-ethinyl estradiol)\" Berlex Laboratories, Richmond, CA.[8] Welling PG, Huang H, Hewitt PF, Lyons LL \"Bioavailability of erythromycin stearate: influence of food and fluid volume.\" J Pharm Sci 67 (1978): 764-6[9] Welling PG \"Influence of food and diet on gastrointestinal drug absorption: a review.\" J Pharmacokinet Biopharm 5 (1977): 291-334[10] Randinitis EJ, Sedman AJ, Welling PG, Kinkel AW \"Effect of a high-fat meal on the bioavailability of a polymer-coated erythromycin particle tablet formulation.\" J Clin Pharmacol 29 (1989): 79-84[11] Coyne TC, Shum S, Chun AH, Jeansonne L, Shirkey HC \"Bioavailability of erythromycin ethylsuccinate in pediatric patients.\" J Clin Pharmacol 18 (1978): 194-202[12] Malmborg AS \"Effect of food on absorption of erythromycin. A study of two derivatives, the stearate and the base.\" J Antimicrob Chemother 5 (1979): 591-9[13] Welling PG, Elliott RL, Pitterle ME, et al \"Plasma levels following single and repeated doses of erythromycin estolate and erythromycin stearate.\" J Pharm Sci 68 (1979): 150-5[14] Kanazawa S, Ohkubo T, Sugawara K \"The effects of grapefruit juice on the pharmacokinetics of erythromycin.\" Eur J Clin Pharmacol 56 (2001): 799-803[15] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[16] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67706, "ingredient1": "Eszopiclone", "ingredient2": "Clarithromycin", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of both zopiclone and its pharmacologically active S(-) enantiomer, eszopiclone. Zopiclone has been shown in vitro to be metabolized by CYP450 3A4 and CYP450 2C8, while eszopiclone is primarily metabolized by CYP450 3A4 and 2E1 via demethylation and oxidation.", "source": "DDInter", "management_text": "Due to increased risk of next-day psychomotor impairment, the dosages of eszopiclone and zopiclone should be reduced when used with potent CYP450 3A4 inhibitors. The manufacturers recommend that total dose of eszopiclone not exceed 2 mg. An initial dose of 3.75 mg is recommended for zopiclone, which may be increased up to 5 mg if clinically indicated. Patients should be advised to avoid driving or operating hazardous machinery until they know how these medications affect them, preferably at least 12 hours after administration of the hypnotic.", "mechanism_text": "Metabolism", "recommendation": "Due to increased risk of next-day psychomotor impairment, the dosages of eszopiclone and zopiclone should be reduced when used with potent CYP450 3A4 inhibitors.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67793/", "reference_text": "[1] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[2] \"Product Information. Imovane (zopiclone).\" Rhone-Poulenc Rorer Canada Inc, Laval, IN.[3] Alderman CP, Gebauer MG, Gilbert AL, Condon JT \"Possible interaction of zopiclone and nefazodone.\" Ann Pharmacother 35 (2001): 1378-80[4] Becquemont L, Mouajjah S, Escaffre O, Beaune P, Funck-Bretano C, Jaillon P \"Cytochrome P-450 3A4 and 2C8 are involved in zopiclone metabolism.\" Drug Metab Dispos 27 (1999): 1068-73[5] \"Product Information. Lunesta (eszopiclone).\" Sepracor Inc, Marlborough, MA.[6] \"Product Information. Lunesta (eszopiclone).\" Sepracor Inc, Marlborough, MA.[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Methohexital, Methylphenobarbital, Pentobarbital, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, Paraldehyde, Ethchlorvynol, Amobarbital, More", "alternatives_b": "Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, More", "updated_at": 1767369485}, {"id": 67707, "ingredient1": "Ethotoin", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Coadministration with phenytoin may reduce the plasma concentrations and antimicrobial efficacy of erythromycin and other macrolide antibiotics. The mechanism is induction of CYP450 3A metabolism by phenytoin. Additionally, plasma concentrations of phenytoin may be increased.", "source": "DDInter", "management_text": "If concomitant use is medically necessary, caution and monitoring for altered efficacy and safety of both medications is recommended.", "mechanism_text": "Metabolism", "recommendation": "If concomitant use is medically necessary, caution and monitoring for altered efficacy and safety of both medications is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67794/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Milne RW, Coulthard K, Nation RL, et al \"Lack of effect of erythromycin on the pharmacokinetics of single oral doses of phenytoin.\" Br J Clin Pharmacol 26 (1988): 330-3[4] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[5] Bachmann K, Schwartz JI, Forney RB Jr, Jauregui L \"Single dose phenytoin clearance during erythromycin treatment.\" Res Commun Chem Pathol Pharmacol 46 (1984): 207-17[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Fleisher D, Sheth N, Kou JH \"Phenytoin interaction with enteral feedings administered through nasogastric tubes.\" JPEN J Parenter Enteral Nutr 14 (1990): 513-6[9] Krueger KA, Garnett WR, Comstock TJ, Fitzsimmons WE, Karnes HT, Pellock JM \"Effect of two administration schedules of an enteral nutrient formula on phenytoin bioavailability.\" Epilepsia 28 (1987): 706-12[10] Haley CJ, Nelson J \"Phenytoin-enteral feeding interaction.\" DICP 23 (1989): 796-8[11] Faraji B, Yu PP \"Serum phenytoin levels of patients on gastrostomy tube feeding.\" J Neurosci Nurs 30 (1998): 55-9[12] Au Yeung SC, Ensom MH \"Phenytoin and enteral feedings: does evidence support an interaction?\" Ann Pharmacother 34 (2000): 896-905[13] Sandor P, Sellers EM, Dumbrell M, Khouw V \"Effect of short- and long-term alcohol use on phenytoin kinetics in chronic alcoholics.\" Clin Pharmacol Ther 30 (1981): 390-7[14] Ozuna J, Friel P \"Effect of enteral tube feeding on serum phenytoin levels.\" J Neurosurg Nurs 16 (1984): 289-91[15] Guidry JR, Eastwood TF, Curry SC \"Phenytoin absorption in volunteers receiving selected enteral feedings.\" West J Med 150 (1989): 659-61[16] Marvel ME, Bertino JS \"Comparative effects of an elemental and a complex enteral feeding formulation on the absorption of phenytoin suspension.\" JPEN J Parenter Enteral Nutr 15 (1991): 316-8[17] \"Product Information. Dilantin (phenytoin).\" Parke-Davis, Morris Plains, NJ.[18] Doak KK, Haas CE, Dunnigan KJ, et al. \"Bioavailability of phenytoin acid and phenytoin sodium with enteral feedings.\" Pharmacotherapy 18 (1998): 637-45[19] Rodman DP, Stevenson TL, Ray TR \"Phenytoin malabsorption after jejunostomy tube delivery.\" Pharmacotherapy 15 (1995): 801-5[20] Sellers EM, Holloway MR \"Drug kinetics and alcohol ingestion.\" Clin Pharmacokinet 3 (1978): 440-52[21] Holtz L, Milton J, Sturek JK \"Compatibility of medications with enteral feedings.\" JPEN J Parenter Enteral Nutr 11 (1987): 183-6", "alternatives_a": "Tiagabine, Brivaracetam, Rufinamide, Methsuximide, Paramethadione, Fenfluramine, Eslicarbazepine, Phensuximide, Methylphenobarbital, Phenacemide, Primidone, More", "alternatives_b": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Cimetidine, More", "updated_at": 1767369485}, {"id": 67708, "ingredient1": "Etonogestrel", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "RECOMMENDED: The effectiveness of estrogen-containing oral contraceptives may be impaired by concomitant treatment with antimicrobial agents. Most antimicrobials, with the exception of the rifamycins and possibly griseofulvin, do not induce hepatic enzymes and have not been shown to significantly increase the clearance of oral contraceptive estrogens. Certain macrolide antibiotics (e.g., erythromycin, clarithromycin) may increase the plasma concentrations and the risk of adverse effects of estrogens and progestogens. The mechanism is decreased clearance of the hormones due to inhibition of CYP450 3A4 activity by the macrolide antibiotic. Concomitant administration with erythromycin may increase the estradiol exposure by approximately 50%.", "source": "DDInter", "management_text": "Until further data are available, women using oral contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant antimicrobial therapy. During concomitant therapy with erythromycin or clarithromycin, patients should be observed for increased or altered pharmacologic response to estrogens and progestogens, and dosage(s) adjusted accordingly as necessary.", "mechanism_text": "Metabolism", "recommendation": "Until further data are available, women using oral contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant antimicrobial therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67795/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception. Available from: URL: file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf.\" ([2012, Jan 1]):[4] \"Product Information. Angeliq (drospirenone-estradiol).\" Berlex Laboratories, Wayne, NJ.[5] \"Product Information. Ortho-Est (estropipate).\" Ortho McNeil Pharmaceutical, Raritan, NJ.[6] \"Product Information. Premarin (conjugated estrogens).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[7] \"Product Information. Yasmin (drospirenone-ethinyl estradiol)\" Berlex Laboratories, Richmond, CA.[8] Welling PG, Huang H, Hewitt PF, Lyons LL \"Bioavailability of erythromycin stearate: influence of food and fluid volume.\" J Pharm Sci 67 (1978): 764-6[9] Welling PG \"Influence of food and diet on gastrointestinal drug absorption: a review.\" J Pharmacokinet Biopharm 5 (1977): 291-334[10] Randinitis EJ, Sedman AJ, Welling PG, Kinkel AW \"Effect of a high-fat meal on the bioavailability of a polymer-coated erythromycin particle tablet formulation.\" J Clin Pharmacol 29 (1989): 79-84[11] Coyne TC, Shum S, Chun AH, Jeansonne L, Shirkey HC \"Bioavailability of erythromycin ethylsuccinate in pediatric patients.\" J Clin Pharmacol 18 (1978): 194-202[12] Malmborg AS \"Effect of food on absorption of erythromycin. A study of two derivatives, the stearate and the base.\" J Antimicrob Chemother 5 (1979): 591-9[13] Welling PG, Elliott RL, Pitterle ME, et al \"Plasma levels following single and repeated doses of erythromycin estolate and erythromycin stearate.\" J Pharm Sci 68 (1979): 150-5[14] Kanazawa S, Ohkubo T, Sugawara K \"The effects of grapefruit juice on the pharmacokinetics of erythromycin.\" Eur J Clin Pharmacol 56 (2001): 799-803[15] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[16] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Estetrol", "alternatives_b": "Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, More", "updated_at": 1767369485}, {"id": 67709, "ingredient1": "Etravirine", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Coadministration with etravirine may decrease the plasma concentrations of clarithromycin and increase concentrations of the active metabolite, 14-hydroxy-clarithromycin. The mechanism is etravirine induction of CYP450 3A4, the isoenzyme that metabolizes clarithromycin to 14-hydroxy-clarithromycin.", "source": "DDInter", "management_text": "Because 14-hydroxy-clarithromycin has demonstrated reduced activity relative to the parent drug against Mycobacterium avium complex (MAC), overall activity against this pathogen may be altered during coadministration of clarithromycin with etravirine. Therefore, alternatives to clarithromycin (e.g., azithromycin) should be considered for the treatment of MAC in patients receiving etravirine.", "mechanism_text": "Metabolism", "recommendation": "Because 14-hydroxy-clarithromycin has demonstrated reduced activity relative to the parent drug against Mycobacterium avium complex (MAC), overall activity against this pathogen may be altered during coadministration of clarithromycin with etravirine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67796/", "reference_text": "[1] \"Product Information. Intelence (etravirine).\" Ortho Biotech Inc, Bridgewater, NJ.[2] \"Product Information. Intelence (etravirine).\" Ortho Biotech Inc, Bridgewater, NJ.[3] Cheng KL, Nafziger AN, Peloquin CA, Amsden GW \"Effect of grapefruit juice on clarithromycin pharmacokinetics.\" Antimicrob Agents Chemother 42 (1998): 927-9", "alternatives_a": "Tetracycline, Levofloxacin, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Famotidine, Nizatidine, Amoxicillin, Lansoprazole, Dirithromycin, More", "alternatives_b": "Glecaprevir, Tenofovir alafenamide, Cabotegravir, Lenacapavir, Velpatasvir, Voxilaprevir, Maribavir, Pibrentasvir, Rimantadine, Elvitegravir, Valganciclovir, More", "updated_at": 1767369485}, {"id": 67710, "ingredient1": "Everolimus", "ingredient2": "Clarithromycin", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 and P-glycoprotein may significantly increase the plasma concentrations of everolimus following oral administration. Everolimus is a substrate of both the CYP450 3A4 isoenzyme and P-glycoprotein drug efflux transporter, thus their inhibition in the intestine can enhance the absorption of everolimus. The risk of side effects such as pneumonitis, stomatitis, infection, dyspnea, diarrhea, anemia, leucopenia, thrombocytopenia, hyperglycemia, and hyperlipidemia may be increased.", "source": "DDInter", "management_text": "Concomitant use of everolimus with potent inhibitors of CYP450 3A4 and P-glycoprotein should generally be avoided. Some authorities recommend avoiding concomitant use of everolimus during and for 2 weeks after treatment with itraconazole.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of everolimus with potent inhibitors of CYP450 3A4 and P-glycoprotein should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67797/", "reference_text": "[1] \"Product Information. Afinitor (everolimus).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[4] Homma S, Takahashi KI, Nihei S, Kato F, Sugihara S, Nunoda S \"The successful management of respiratory complications with long-term, low-dose macrolide administration in pediatric heart transplant recipients.\" Int Heart J (2014):[5] \"Product Information. Afinitor (everolimus).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, More", "alternatives_b": "Alpelisib, Trametinib, Dacomitinib, Tivozanib, Alectinib, Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, More", "updated_at": 1767369485}, {"id": 67711, "ingredient1": "Exenatide", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Concomitant use of insulin and other antidiabetic agents with clarithromycin may cause significant hypoglycemia. There have been rare reports of hypoglycemia in patients treated with clarithromycin, some of whom were taking oral hypoglycemic agents or insulin. The exact mechanism of interaction has not been established. With certain hypoglycemic drugs such as nateglinide, pioglitazone, repaglinide and rosiglitazone, inhibition of the CYP450 3A4 isoenzyme by clarithromycin may be involved.", "source": "DDInter", "management_text": "Caution is advised if clarithromycin is prescribed to patients receiving antidiabetic agents. Patients should be advised to regularly monitor their blood sugar and counseled on how to recognize and treat hypoglycemia, which may include symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if clarithromycin is prescribed to patients receiving antidiabetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67798/", "reference_text": "[1] Otsuka SH \"Severe hypoglycemia from helicobacter pylori triple-drug therapy and insulin detemir drug interaction.\" Pharmacotherapy 33 (2013): e45-9[2] Niemi M, Neuvonen PJ, Kivisto KT \"The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide.\" Clin Pharmacol Ther 70 (2001): 58-65[3] Schelleman H, Bilker WB, Brensinger CM, Wan F, Hennessy S \"Anti-infectives and the risk of severe hypoglycemia in users of glipizide or glyburide.\" Clin Pharmacol Ther 88 (2010): 214-22[4] Khamaisi M, Leitersdorf E \"Severe hypoglycemia from clarithromycin-repaglinide drug interaction.\" Pharmacotherapy 28 (2008): 682-4[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Leiba A, Leibowitz A, Grossman E \"An unusual case of hypoglycemia in a diabetic patient.\" Ann Emerg Med 44 (2004): 427-8[7] Bussing R, Gende A \"Severe hypoglycemia from clarithromycin-sulfonylurea drug interaction.\" Diabetes Care 25 (2002): 1659-61[8] \"Product Information. Biaxin (clarithromycin).\" Abbott Pharmaceutical, Abbott Park, IL.[9] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[10] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[11] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[12] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[13] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[14] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[15] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[16] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[17] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[18] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[19] Cheng KL, Nafziger AN, Peloquin CA, Amsden GW \"Effect of grapefruit juice on clarithromycin pharmacokinetics.\" Antimicrob Agents Chemother 42 (1998): 927-9", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Rifabutin, Cimetidine, More", "alternatives_b": "Guar gum", "updated_at": 1767369485}, {"id": 67712, "ingredient1": "Ezogabine", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67799/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[16] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, More", "alternatives_b": "Tiagabine, Brivaracetam, Rufinamide, Methsuximide, Paramethadione, Fenfluramine, Eslicarbazepine, Phensuximide, Methylphenobarbital, Phenacemide, Primidone, More", "updated_at": 1767369485}, {"id": 67713, "ingredient1": "Fedratinib", "ingredient2": "Clarithromycin", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of fedratinib, which is a substrate of the isoenzyme. The risk of adverse reactions such as anemia, thrombocytopenia, diarrhea, nausea, vomiting, and liver (ALT, AST) and pancreatic (amylase, lipase) enzyme elevations may increase.", "source": "DDInter", "management_text": "Coadministration of fedratinib with potent CYP450 3A4 inhibitors should be avoided. However, if coadministration with a potent CYP450 3A4 inhibitor is necessary, the manufacturer recommends that the dose of fedratinib be reduced to 200 mg once daily. Patients should be advised to notify their health care professional if signs and symptoms of anemia, thrombocytopenia, or gastrointestinal, hepatic, or pancreatic toxicity develop. Further dosage adjustment may be required based on patient tolerance and response. When/if concomitant therapy with a potent CYP450 3A4 inhibitor is ceased, the dose of fedratinib should first be increased to 300 mg once daily for two weeks an then increased to 400 mg once daily thereafter as tolerated.", "mechanism_text": "Metabolism", "recommendation": "Coadministration of fedratinib with potent CYP450 3A4 inhibitors should be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67800/", "reference_text": "[1] \"Product Information. Inrebic (fedratinib).\" Celgene Corporation, Summit, NJ.[2] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[3] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[4] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[5] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[6] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[7] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[11] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[12] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[13] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[14] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[15] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[16] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[18] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[19] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[20] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[21] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[22] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[23] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[24] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[25] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[26] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[27] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[28] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[29] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[30] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[31] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[32] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[33] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Tetracycline, Levofloxacin, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Nizatidine, Ranitidine, Vonoprazan, More", "alternatives_b": "Alpelisib, Trametinib, Dacomitinib, Tivozanib, Alectinib", "updated_at": 1767369485}, {"id": 67714, "ingredient1": "Felodipine", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Coadministration of felodipine and erythromycin may increase felodipine serum concentrations. The presumed mechanism is inhibition of CYP450 3A4 metabolism by erythromycin. Troleandomycin and clarithromycin may also affect felodipine levels.", "source": "DDInter", "management_text": "When macrolide antibiotics are coadministered with felodipine, patients should be monitored for adverse effects such as flushing, ankle edema, or palpitations. Azithromycin and dirithromycin do not inhibit CYP450 and may be considered as alternatives.", "mechanism_text": "Metabolism", "recommendation": "When macrolide antibiotics are coadministered with felodipine, patients should be monitored for adverse effects such as flushing, ankle edema, or palpitations.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67801/", "reference_text": "[1] Liedholm H, Nordin G \"Erythromycin-felodipine interaction.\" DICP 25 (1991): 1007-8[2] Bailey DG, Bend JR, Arnold JMO, Tran LT, Spence JD \"Erythromycin-felodipine interaction: magnitude, mechanism, and comparison with grapefruit juice.\" Clin Pharmacol Ther 60 (1996): 25-33[3] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[4] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[6] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[7] \"Product Information. Procardia (nifedipine).\" Pfizer US Pharmaceuticals, New York, NY.[8] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[9] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[10] Edgar B, Bailey D, Bergstrand R, Johnsson G, Regardh CG \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics of felodipine--and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[11] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[12] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[13] Fuhr U, Muller-Peltzer H, Kern R, et al. \"Effects of grapefruit juice and smoking on verapamil concentrations in steady state.\" Eur J Clin Pharmacol 58 (2002): 45-53[14] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[15] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[16] \"Product Information. Sular (nisoldipine).\" Zeneca Pharmaceuticals, Wilmington, DE.[17] Ho PC, Ghose K, Saville D, Wanwimolruk S \"Effect of grapefruit juice on pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy volunteers.\" Eur J Clin Pharmacol 56 (2000): 693-8[18] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[19] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[20] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[21] \"Product Information. Plendil (felodipine).\" Merck & Co, Inc, West Point, PA.", "alternatives_a": "Nebivolol, Clevidipine, Nisoldipine, Nicardipine, Moexipril, Perindopril, Benazepril, Trandolapril, Fosinopril", "alternatives_b": "Tinidazole, Tetracycline, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Nizatidine, Esomeprazole, Vonoprazan, Levofloxacin, Dirithromycin", "updated_at": 1767369485}, {"id": 67715, "ingredient1": "Fesoterodine", "ingredient2": "Clarithromycin", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of fesoterodine's active metabolite, 5-hydroxymethyl tolterodine, which is partially metabolized by the isoenzyme. The possibility of prolonged and/or increased pharmacologic effects of fesoterodine should be considered. Because 5-hydroxymethyl tolterodine is also metabolized by CYP450 2D6, the clinical significance of the interaction may be greater in patients who are CYP450 2D6-deficient, or so-called poor metabolizers of CYP450 2D6 who may rely more on the 3A4 metabolic pathway for clearance of the drug.", "source": "DDInter", "management_text": "The dosage of fesoterodine should not exceed 4 mg/day when used with potent CYP450 3A4 inhibitors. Close clinical and laboratory monitoring is advised whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy. Patients should be advised to contact their physician if they experience potential adverse effects of fesoterodine such as irregular heartbeat, blurry vision, difficulty urinating, dry mouth, headache, drowsiness, dizziness, gastrointestinal upset, or constipation. The product labeling for itraconazole (a potent CYP450 3A4 inhibitor) states that concomitant use with fesoterodine is contraindicated in patients with moderate to severe renal or hepatic impairment during and for 2 weeks after treatment with itraconazole.", "mechanism_text": "Metabolism", "recommendation": "The dosage of fesoterodine should not exceed 4 mg/day when used with potent CYP450 3A4 inhibitors.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67802/", "reference_text": "[1] \"Product Information. Toviaz (fesoterodine).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Sporonox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[5] \"Product Information. Toviaz (fesoterodine).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, More", "alternatives_b": "Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Phenyl salicylate, Ammonium chloride, Dimethyl sulfoxide", "updated_at": 1767369485}, {"id": 67716, "ingredient1": "Fexofenadine", "ingredient2": "Clarithromycin", "severity": "Minor", "effect": "Coadministration with erythromycin has been shown to increase the oral bioavailability of fexofenadine. The proposed mechanism is erythromycin inhibition of the intestinal efflux of fexofenadine via P-glycoprotein transporter. In addition, erythromycin may decrease biliary excretion of fexofenadine. Fexofenadine had no effect on the pharmacokinetics of erythromycin.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption, Excretion", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67803/", "reference_text": "[1] \"Product Information. Allegra (fexofenadine).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[2] \"Product Information. Allegra-D (fexofenadine-pseudoephedrine).\" Chattem Consumer Products, Chattanooga, TN.[3] Bailey DG, Dresser GK, Munoz C, Freemar DJ, Kim RB \"Reduction of fexofenadine bioavailability by fruit juices.\" Clin Pharmacol Ther 69 (2001): PI-82[4] Dresser GK, Bailey DG, Leake BF, et al. \"Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine.\" Clin Pharmacol Ther 71 (2002): 11-20", "alternatives_a": "Mepyramine, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Dexbrompheniramine, Clemastine, Doxylamine, Meclizine, Cyclizine, More", "alternatives_b": "Tinidazole, Dexlansoprazole, Bismuth subcitrate potassium, Rifabutin, Esomeprazole, Vonoprazan, Levofloxacin, Lincomycin, Dirithromycin", "updated_at": 1767369485}, {"id": 67717, "ingredient1": "Fidaxomicin", "ingredient2": "Clarithromycin", "severity": "Minor", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of fidaxomicin and its main metabolite, OP-1118, both of which are substrates of the intestinal efflux transporter. Theoretically, concentrations of fidaxomicin and OP-1118 may also be decreased at the site of action (i.e., gastrointestinal tract) due to P-gp inhibition.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67804/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Dificid (fidaxomicin).\" Optimer Pharmaceuticals, San Diego, CA.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Dificid (fidaxomicin).\" Optimer Pharmaceuticals, San Diego, CA.[7] \"Product Information. Mavyret (glecaprevir-pibrentasvir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, More", "alternatives_b": "Polymyxin B, Rifamycin, Paromomycin, Rifaximin", "updated_at": 1767369485}, {"id": 67718, "ingredient1": "Fingolimod", "ingredient2": "Clarithromycin", "severity": "Major", "effect": "Due to its significant bradycardic effects, the risk of QT prolongation and torsade de pointes arrhythmia may be increased during initiation of fingolimod treatment in patients receiving drugs that prolong the QT interval. Fingolimod can cause a decrease in heart rate during initiation of therapy that is apparent within an hour of the first dose and maximal at approximately 6 hours postdose in most cases, but occasionally up to 20 hours after the first dose.", "source": "DDInter", "management_text": "Fingolimod has not been studied in patients receiving drugs that can prolong the QT interval. Because bradycardia and AV block are recognized risk factors for QT prolongation and torsade de pointes arrhythmia, close monitoring is recommended during initiation of fingolimod treatment in patients receiving concomitant drugs that can prolong the QT interval, patients with significant QT prolongation (QTc >470 msec in females or >450 msec in males), or patients with relevant risk factors for QT prolongation (e.g., hypokalemia, hypomagnesemia, congenital QT prolongation).", "mechanism_text": "Synergism", "recommendation": "Fingolimod has not been studied in patients receiving drugs that can prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67805/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] \"Product Information. Gilenya (fingolimod).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Revised recommendations for cardiovascular monitoring and use of multiple sclerosis drug Gilenya (fingolimod). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm303192.htm#data.\" ([2012 May 14]):[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Esomeprazole, Vonoprazan, More", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Anakinra, More", "updated_at": 1767369485}, {"id": 67719, "ingredient1": "Flecainide", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67806/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[16] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Tocainide, Moricizine, Bretylium", "alternatives_b": "Tinidazole, Tetracycline, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Nizatidine, Esomeprazole, Vonoprazan, Amoxicillin, More", "updated_at": 1767369485}, {"id": 67720, "ingredient1": "Flibanserin", "ingredient2": "Clarithromycin", "severity": "Major", "effect": "Coadministration with moderate and potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of flibanserin, which is primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 2C19. High plasma levels of flibanserin may increase the risk of severe hypotension, syncope, and central nervous system depression.", "source": "DDInter", "management_text": "Concomitant use of flibanserin with moderate or potent CYP450 3A4 inhibitors is considered contraindicated. When initiating flibanserin following treatment with a moderate or potent CYP450 3A4 inhibitor, the manufacturer recommends waiting until 2 weeks after the last dose of CYP450 3A4 inhibitor. Conversely, if a moderate or potent CYP450 3A4 inhibitor is required during flibanserin therapy, flibanserin should be discontinued at least 2 days before starting the CYP450 3A4 inhibitor.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of flibanserin with moderate or potent CYP450 3A4 inhibitors is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67807/", "reference_text": "[1] \"Product Information. Addyi (flibanserin).\" Sprout Pharmaceuticals, Raleigh, NC.[2] \"Product Information. Addyi (flibanserin).\" Sprout Pharmaceuticals, Raleigh, NC.", "alternatives_a": "Tinidazole, Levofloxacin, Tetracycline, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Nizatidine, Amoxicillin, Dirithromycin, More", "alternatives_b": "Bremelanotide", "updated_at": 1767369485}, {"id": 67721, "ingredient1": "Fluconazole", "ingredient2": "Clarithromycin", "severity": "Minor", "effect": "Fluconazole may increase plasma concentrations of clarithromycin when coadministered. The mechanism of the interaction is unknown. Observation for clarithromycin adverse effects is recommended if these drugs are given together.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67808/", "reference_text": "[1] Gustavson LE, Shi H, Palmer RN, Siepman NC, Craft JC \"Drug interactions between claarithromycin and fluconazole in healthy subjects.\" Clin Pharmacol Ther 59 (1996): 185[2] Cheng KL, Nafziger AN, Peloquin CA, Amsden GW \"Effect of grapefruit juice on clarithromycin pharmacokinetics.\" Antimicrob Agents Chemother 42 (1998): 927-9", "alternatives_a": "Tinidazole, Cefixime, Secnidazole, Flucytosine, Anidulafungin, Micafungin, Oteseconazole, Salicylic acid, Selenium Sulfide, Thiabendazole, Griseofulvin, More", "alternatives_b": "Tinidazole, Bismuth subcitrate potassium, Vonoprazan, Lincomycin, Dirithromycin", "updated_at": 1767369485}, {"id": 67722, "ingredient1": "Fludrocortisone", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme. The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations. Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy. Cushing's syndrome and adrenal insufficiency have been attributed to the interaction.", "source": "DDInter", "management_text": "The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors. When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical \"buffalo\" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.", "mechanism_text": "Metabolism", "recommendation": "The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67809/", "reference_text": "[1] Edsbacker S, Andersson T \"Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease.\" Clin Pharmacokinet 43 (2004): 803-21[2] Finkenbine RD, Frye MD \"Case of psychosis due to prednisone-clarithromycin interaction.\" Gen Hosp Psychiat 20 (1998): 325-6[3] Soldatos G, Sztal-Mazer S, Woolley I, Stockigt J \"Exogenous glucocorticoid excess as a result of ritonavir-fluticasone interaction.\" Intern Med J 35 (2005): 67-8[4] Kandrotas RJ, Slaughter RL, Brass C, Jusko WJ \"Ketoconazole effects on methylprednisolone disposition and their joint suppression of endogenous cortisol.\" Clin Pharmacol Ther 42 (1987): 465-70[5] Raaska K, Niemi M, Neuvonen M, Neuvonen PJ, Kivisto KT \"Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole.\" Clin Pharmacol Ther 72 (2002): 362-369[6] Ulrich B, Frey FJ, Speck RF, Frey BM \"Pharmacokinetics/pharmacodynamics of ketoconazole-prednisolone interaction.\" J Pharmacol Exp Ther 260 (1992): 487-90[7] Zurcher RM, Frey BM, Frey FJ \"Impact of ketoconazole on the metabolism of prednisolone.\" Clin Pharmacol Ther 45 (1989): 366-72[8] Busse KH, Formentini E, Alfaro RM, Kovacs JA, Penzak SR \"Influence of antiretroviral drugs on the pharmacokinetics of prednisolone in HIV-infected individuals.\" J Acquir Immune Defic Syndr 48 (2008): 561-6[9] Yamashita SK, Ludwig EA, Middleton E Jr, Jusko WJ \"Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone.\" Clin Pharmacol Ther 49 (1991): 558-70[10] Hillebrand-Haverkort ME, Prummel MF, ten Veen JH \"Ritonavir-induced Cushing's syndrome in a patient treated with nasal fluticasone.\" AIDS 13 (1999): 1803[11] Kotlyar M, Brewer ER, Golding M, Carson SW \"Nefazodone inhibits methylprednisolone disposition and enhances its adrenal-suppressant effect.\" J Clin Psychopharmacol 23 (2003): 652-6[12] Itkin IH, Menzel ML \"The use of macrolide antibiotic substances in the treatment of asthma.\" J Allergy Clin Immunol 45 (1970): 146-62[13] Skov M, Main KM, Sillesen IB, Muller J, Koch C, Lanng S \"Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide.\" Eur Respir J 20 (2002): 127-33[14] Samaras K, Pett S, Gowers A, McMurchie M, Cooper DA \"Iatrogenic Cushing's syndrome with osteoporosis and secondary adrenal failure in HIV-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: six cases.\" J Clin Endocrinol Metab 90 (2005): 4394-8[15] Garey KW, Rubinstein I, Gotfried MH, Khan IJ, Varma S, Danziger LH \"Long-term clarithromycin decreases prednisone requirements in elderly patients with prednisone-dependent asthma.\" Chest 118 (2000): 1826-7[16] Glynn AM, Slaughter RL, Brass C, et al \"Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretion.\" Clin Pharmacol Ther 39 (1986): 654-9[17] LaForce CF, Szefler SJ, Miller MF, Ebling W, Brenner M \"Inhibition of methylprednisolone elimination in the presence of erythromycin therapy.\" J Allergy Clin Immunol 72 (1983): 34-9[18] Lebrun-Vignes B, Archer VC, Diquest B, et al. \"Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects.\" Br J Clin Pharmacol 51 (2001): 443-50[19] Varis T, Kivisto KT, Neuvonen PJ \"The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone.\" Eur J Clin Pharmacol 56 (2000): 57-60[20] Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN \"Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole.\" Ann Pharmacother 38 (2004): 46-9[21] Gupta SK, Dube MP \"Exogenous Cushing syndrome mimicking human immunodeficiency virus lipodystrophy.\" Clin Infect Dis 35 (2002): E69-71[22] Varis T, Kaukonen KM, Kivisto KT, Neuvonen PJ \"Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole.\" Clin Pharmacol Ther 64 (1998): 363-8[23] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[24] Couturier J, Steele M, Hussey L, Pawliuk G \"Steroid-induced mania in an adolescent: risk factors and management.\" Can J Clin Pharmacol 8 (2001): 109-12[25] Varis T, Backman JT, Kivisto KT, Neuvonen PJ \"Diltiazem and mibefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone.\" Clin Pharmacol Ther 67 (2000): 215-21[26] Bhumbra NA, Sahloff EG, Oehrtman SJ, Horner JM \"Exogenous Cushing syndrome with inhaled fluticasone in a child receiving lopinavir/ritonavir.\" Ann Pharmacother 41 (2007): 1306-9[27] Main KM, Skov M, Sillesen IB, et al. \"Cushing's syndrome due to pharmacological interaction in a cystic fibrosis patient.\" Acta Paediatr 91 (2002): 1008-11[28] Penzak SR, Formentini E, Alfaro RM, Long M, Natarajan V, Kovacs J \"Prednisolone pharmacokinetics in the presence and absence of ritonavir after oral prednisone administration to healthy volunteers.\" J Acquir Immune Defic Syndr 40 (2005): 573-80[29] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[30] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.", "alternatives_a": "Fluocinolone acetonide, Fluocinolone acetonide, Fluorometholone", "alternatives_b": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Cimetidine, More", "updated_at": 1767369485}, {"id": 67723, "ingredient1": "Flunisolide (nasal)", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme. The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations. Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy. Cushing's syndrome and adrenal insufficiency have been attributed to the interaction.", "source": "DDInter", "management_text": "The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors. When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical \"buffalo\" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.", "mechanism_text": "Metabolism", "recommendation": "The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67810/", "reference_text": "[1] Edsbacker S, Andersson T \"Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease.\" Clin Pharmacokinet 43 (2004): 803-21[2] Finkenbine RD, Frye MD \"Case of psychosis due to prednisone-clarithromycin interaction.\" Gen Hosp Psychiat 20 (1998): 325-6[3] Soldatos G, Sztal-Mazer S, Woolley I, Stockigt J \"Exogenous glucocorticoid excess as a result of ritonavir-fluticasone interaction.\" Intern Med J 35 (2005): 67-8[4] Kandrotas RJ, Slaughter RL, Brass C, Jusko WJ \"Ketoconazole effects on methylprednisolone disposition and their joint suppression of endogenous cortisol.\" Clin Pharmacol Ther 42 (1987): 465-70[5] Raaska K, Niemi M, Neuvonen M, Neuvonen PJ, Kivisto KT \"Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole.\" Clin Pharmacol Ther 72 (2002): 362-369[6] Ulrich B, Frey FJ, Speck RF, Frey BM \"Pharmacokinetics/pharmacodynamics of ketoconazole-prednisolone interaction.\" J Pharmacol Exp Ther 260 (1992): 487-90[7] Zurcher RM, Frey BM, Frey FJ \"Impact of ketoconazole on the metabolism of prednisolone.\" Clin Pharmacol Ther 45 (1989): 366-72[8] Busse KH, Formentini E, Alfaro RM, Kovacs JA, Penzak SR \"Influence of antiretroviral drugs on the pharmacokinetics of prednisolone in HIV-infected individuals.\" J Acquir Immune Defic Syndr 48 (2008): 561-6[9] Yamashita SK, Ludwig EA, Middleton E Jr, Jusko WJ \"Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone.\" Clin Pharmacol Ther 49 (1991): 558-70[10] Hillebrand-Haverkort ME, Prummel MF, ten Veen JH \"Ritonavir-induced Cushing's syndrome in a patient treated with nasal fluticasone.\" AIDS 13 (1999): 1803[11] Kotlyar M, Brewer ER, Golding M, Carson SW \"Nefazodone inhibits methylprednisolone disposition and enhances its adrenal-suppressant effect.\" J Clin Psychopharmacol 23 (2003): 652-6[12] Itkin IH, Menzel ML \"The use of macrolide antibiotic substances in the treatment of asthma.\" J Allergy Clin Immunol 45 (1970): 146-62[13] Skov M, Main KM, Sillesen IB, Muller J, Koch C, Lanng S \"Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide.\" Eur Respir J 20 (2002): 127-33[14] Samaras K, Pett S, Gowers A, McMurchie M, Cooper DA \"Iatrogenic Cushing's syndrome with osteoporosis and secondary adrenal failure in HIV-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: six cases.\" J Clin Endocrinol Metab 90 (2005): 4394-8[15] Garey KW, Rubinstein I, Gotfried MH, Khan IJ, Varma S, Danziger LH \"Long-term clarithromycin decreases prednisone requirements in elderly patients with prednisone-dependent asthma.\" Chest 118 (2000): 1826-7[16] Glynn AM, Slaughter RL, Brass C, et al \"Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretion.\" Clin Pharmacol Ther 39 (1986): 654-9[17] LaForce CF, Szefler SJ, Miller MF, Ebling W, Brenner M \"Inhibition of methylprednisolone elimination in the presence of erythromycin therapy.\" J Allergy Clin Immunol 72 (1983): 34-9[18] Lebrun-Vignes B, Archer VC, Diquest B, et al. \"Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects.\" Br J Clin Pharmacol 51 (2001): 443-50[19] Varis T, Kivisto KT, Neuvonen PJ \"The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone.\" Eur J Clin Pharmacol 56 (2000): 57-60[20] Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN \"Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole.\" Ann Pharmacother 38 (2004): 46-9[21] Gupta SK, Dube MP \"Exogenous Cushing syndrome mimicking human immunodeficiency virus lipodystrophy.\" Clin Infect Dis 35 (2002): E69-71[22] Varis T, Kaukonen KM, Kivisto KT, Neuvonen PJ \"Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole.\" Clin Pharmacol Ther 64 (1998): 363-8[23] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[24] Couturier J, Steele M, Hussey L, Pawliuk G \"Steroid-induced mania in an adolescent: risk factors and management.\" Can J Clin Pharmacol 8 (2001): 109-12[25] Varis T, Backman JT, Kivisto KT, Neuvonen PJ \"Diltiazem and mibefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone.\" Clin Pharmacol Ther 67 (2000): 215-21[26] Bhumbra NA, Sahloff EG, Oehrtman SJ, Horner JM \"Exogenous Cushing syndrome with inhaled fluticasone in a child receiving lopinavir/ritonavir.\" Ann Pharmacother 41 (2007): 1306-9[27] Main KM, Skov M, Sillesen IB, et al. \"Cushing's syndrome due to pharmacological interaction in a cystic fibrosis patient.\" Acta Paediatr 91 (2002): 1008-11[28] Penzak SR, Formentini E, Alfaro RM, Long M, Natarajan V, Kovacs J \"Prednisolone pharmacokinetics in the presence and absence of ritonavir after oral prednisone administration to healthy volunteers.\" J Acquir Immune Defic Syndr 40 (2005): 573-80[29] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[30] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.", "alternatives_a": "Mupirocin, Mometasone furoate, Vitamin A, Ephedrine, Ipratropium, Hyaluronic acid, Nedocromil, Phenylephrine, Beclomethasone dipropionate, Mometasone furoate, Umeclidinium, More", "alternatives_b": "Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, More", "updated_at": 1767369485}, {"id": 67724, "ingredient1": "Fluorometholone (ophthalmic)", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme. The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations. Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy. Cushing's syndrome and adrenal insufficiency have been attributed to the interaction.", "source": "DDInter", "management_text": "The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors. When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical \"buffalo\" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.", "mechanism_text": "Metabolism", "recommendation": "The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67811/", "reference_text": "[1] Edsbacker S, Andersson T \"Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease.\" Clin Pharmacokinet 43 (2004): 803-21[2] Finkenbine RD, Frye MD \"Case of psychosis due to prednisone-clarithromycin interaction.\" Gen Hosp Psychiat 20 (1998): 325-6[3] Soldatos G, Sztal-Mazer S, Woolley I, Stockigt J \"Exogenous glucocorticoid excess as a result of ritonavir-fluticasone interaction.\" Intern Med J 35 (2005): 67-8[4] Kandrotas RJ, Slaughter RL, Brass C, Jusko WJ \"Ketoconazole effects on methylprednisolone disposition and their joint suppression of endogenous cortisol.\" Clin Pharmacol Ther 42 (1987): 465-70[5] Raaska K, Niemi M, Neuvonen M, Neuvonen PJ, Kivisto KT \"Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole.\" Clin Pharmacol Ther 72 (2002): 362-369[6] Ulrich B, Frey FJ, Speck RF, Frey BM \"Pharmacokinetics/pharmacodynamics of ketoconazole-prednisolone interaction.\" J Pharmacol Exp Ther 260 (1992): 487-90[7] Zurcher RM, Frey BM, Frey FJ \"Impact of ketoconazole on the metabolism of prednisolone.\" Clin Pharmacol Ther 45 (1989): 366-72[8] Busse KH, Formentini E, Alfaro RM, Kovacs JA, Penzak SR \"Influence of antiretroviral drugs on the pharmacokinetics of prednisolone in HIV-infected individuals.\" J Acquir Immune Defic Syndr 48 (2008): 561-6[9] Yamashita SK, Ludwig EA, Middleton E Jr, Jusko WJ \"Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone.\" Clin Pharmacol Ther 49 (1991): 558-70[10] Hillebrand-Haverkort ME, Prummel MF, ten Veen JH \"Ritonavir-induced Cushing's syndrome in a patient treated with nasal fluticasone.\" AIDS 13 (1999): 1803[11] Kotlyar M, Brewer ER, Golding M, Carson SW \"Nefazodone inhibits methylprednisolone disposition and enhances its adrenal-suppressant effect.\" J Clin Psychopharmacol 23 (2003): 652-6[12] Itkin IH, Menzel ML \"The use of macrolide antibiotic substances in the treatment of asthma.\" J Allergy Clin Immunol 45 (1970): 146-62[13] Skov M, Main KM, Sillesen IB, Muller J, Koch C, Lanng S \"Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide.\" Eur Respir J 20 (2002): 127-33[14] Samaras K, Pett S, Gowers A, McMurchie M, Cooper DA \"Iatrogenic Cushing's syndrome with osteoporosis and secondary adrenal failure in HIV-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: six cases.\" J Clin Endocrinol Metab 90 (2005): 4394-8[15] Garey KW, Rubinstein I, Gotfried MH, Khan IJ, Varma S, Danziger LH \"Long-term clarithromycin decreases prednisone requirements in elderly patients with prednisone-dependent asthma.\" Chest 118 (2000): 1826-7[16] Glynn AM, Slaughter RL, Brass C, et al \"Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretion.\" Clin Pharmacol Ther 39 (1986): 654-9[17] LaForce CF, Szefler SJ, Miller MF, Ebling W, Brenner M \"Inhibition of methylprednisolone elimination in the presence of erythromycin therapy.\" J Allergy Clin Immunol 72 (1983): 34-9[18] Lebrun-Vignes B, Archer VC, Diquest B, et al. \"Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects.\" Br J Clin Pharmacol 51 (2001): 443-50[19] Varis T, Kivisto KT, Neuvonen PJ \"The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone.\" Eur J Clin Pharmacol 56 (2000): 57-60[20] Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN \"Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole.\" Ann Pharmacother 38 (2004): 46-9[21] Gupta SK, Dube MP \"Exogenous Cushing syndrome mimicking human immunodeficiency virus lipodystrophy.\" Clin Infect Dis 35 (2002): E69-71[22] Varis T, Kaukonen KM, Kivisto KT, Neuvonen PJ \"Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole.\" Clin Pharmacol Ther 64 (1998): 363-8[23] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[24] Couturier J, Steele M, Hussey L, Pawliuk G \"Steroid-induced mania in an adolescent: risk factors and management.\" Can J Clin Pharmacol 8 (2001): 109-12[25] Varis T, Backman JT, Kivisto KT, Neuvonen PJ \"Diltiazem and mibefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone.\" Clin Pharmacol Ther 67 (2000): 215-21[26] Bhumbra NA, Sahloff EG, Oehrtman SJ, Horner JM \"Exogenous Cushing syndrome with inhaled fluticasone in a child receiving lopinavir/ritonavir.\" Ann Pharmacother 41 (2007): 1306-9[27] Main KM, Skov M, Sillesen IB, et al. \"Cushing's syndrome due to pharmacological interaction in a cystic fibrosis patient.\" Acta Paediatr 91 (2002): 1008-11[28] Penzak SR, Formentini E, Alfaro RM, Long M, Natarajan V, Kovacs J \"Prednisolone pharmacokinetics in the presence and absence of ritonavir after oral prednisone administration to healthy volunteers.\" J Acquir Immune Defic Syndr 40 (2005): 573-80[29] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[30] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.", "alternatives_a": "Mometasone furoate, Fluorometholone, Mometasone furoate, Amcinonide, Fluocinolone acetonide, Hydrocortisone butyrate, Fluocinonide, Fluorometholone, Beclomethasone dipropionate, Salicylic acid, Fluocinolone acetonide, More", "alternatives_b": "Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, More", "updated_at": 1767369485}, {"id": 67725, "ingredient1": "Fluoxetine", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "The use of some macrolide antibiotics has been associated with increased blood levels of some selective serotonin reuptake inhibitors (SSRIs), resulting in excessive serotonergic effects or serotonin syndrome. The mechanism is inhibition of the CYP450 3A4 isoenzyme, which metabolizes SSRIs.", "source": "DDInter", "management_text": "In cases where both drugs are necessary, one could consider using a macrolide antibiotic that does not inhibit CYP450 3A4, such as azithromycin or dirithromycin.", "mechanism_text": "Metabolism", "recommendation": "In cases where both drugs are necessary, one could consider using a macrolide antibiotic that does not inhibit CYP450 3A4, such as azithromycin or dirithromycin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67812/", "reference_text": "[1] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[2] Pollak PT, Slayter KL \"Delirium probably induced by clarithromycin in a patient receiving fluoxetine - reply.\" Ann Pharmacother 30 (1996): 1200[3] Timothy P, Sketris IS, Mackenzie SL, Hewlett TJ \"Delirium probably induced by clarithromycin in a patient receiving fluoxetine.\" Ann Pharmacother 29 (1995): 486-8[4] Tracy TS, Cupp MJ \"Delirium probably induced by clarithromycin in a patient receiving fluoxetine - comment.\" Ann Pharmacother 30 (1996): 1199-200[5] Lee DO, Lee CD \"Serotonin syndrome in a child associated with erythromycin and sertraline.\" Pharmacotherapy 19 (1999): 894-6[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Ueda N, Yoshimura R, Umene-Nakano W, et al. \"Grapefruit juice alters plasma sertraline levels after single ingestion of sertraline in healthy volunteers.\" World J Biol Psychiatry 10(4 Pt 3) (2009): 832-5[8] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[9] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9", "alternatives_a": "Phenelzine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Vortioxetine, Milnacipran, Tryptophan, Esketamine", "alternatives_b": "Tinidazole, Tetracycline, Dexlansoprazole, Bismuth subcitrate potassium, Rifabutin, Esomeprazole, Vonoprazan, Lincomycin, Dirithromycin", "updated_at": 1767369485}, {"id": 67726, "ingredient1": "Fluphenazine", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67813/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[16] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Loxapine, Molindone, Thiothixene", "alternatives_b": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, Nizatidine, More", "updated_at": 1767369485}, {"id": 67727, "ingredient1": "Flurazepam", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Macrolide antibiotics may increase and prolong the CNS effects of certain benzodiazepines. The mechanism is inhibition of CYP450 3A4 hepatic oxidation of the benzodiazepines.", "source": "DDInter", "management_text": "Patients receiving this combination should be monitored for excessive or prolonged sedation. Non-interacting benzodiazepines or antimicrobials may be considered as alternatives.", "mechanism_text": "Metabolism", "recommendation": "Patients receiving this combination should be monitored for excessive or prolonged sedation.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67814/", "reference_text": "[1] Warot D, Bergougnan L, Lamiable D, et al \"Troleandomycin-triazolam interaction in healthy volunteers: pharmacokinetic and psychometric evaluation.\" Eur J Clin Pharmacol 32 (1987): 389-93[2] Yeates RA, Laufen H, Zimmermann T, Schumacher T \"Pharmacokinetic and pharmacodynamic interaction study between midazolam and the macrolide antibiotics, erythromycin clarithromycin, and the azalide azithromycin.\" Int J Clin Pharmacol Ther 35 (1997): 577-9[3] Mattila MJ, Idanpaanheikkila JJ, Tornwall M, Vanakoski J \"Oral single doses of erythromycin and roxithromycin may increase the effects of midazolam on human performance.\" Pharmacol Toxicol 73 (1993): 180-5[4] Zimmermann T, Yeates RA, Laufen H, Scharpf F, Leitold M, Wildfeuer A \"Influence of the antibiotics erythromycin and azithromycin on the pharmacokinetics and pharmacodynamics of midazolam.\" Arzneimittelforschung 46 (1996): 213-7[5] Yasui N, Otani K, Kaneko S, et al \"A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: in vivo evidence for the involvement of CYP3a4 in alprazolam metabolism.\" Clin Pharmacol Ther 59 (1996): 514-9[6] Yeates RA, Laufen H, Zimmermann T \"Interaction between midazolam and clarithromycin: comparison with azithromycin.\" Int J Clin Pharmacol Ther 34 (1996): 400-5[7] Gorski JC, Jones DR, HaehnerDaniels BD, Hamman MA, OMara EM, Hall SD \"The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin.\" Clin Pharmacol Ther 64 (1998): 133-43[8] Phillips JP, Antal EJ, Smith RB \"A pharmacokinetic drug interaction between erythromycin and triazolam.\" J Clin Psychopharmacol 6 (1986): 297-9[9] Wrighton SA, Ring BJ \"Inhibition of human CYP3A catalyzed 1'-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine.\" Pharm Res 11 (1994): 921-4[10] Kanamitsu S, Ito K, Green CE, Tyson CA, Shimada N, Sugiyama Y \"Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4.\" Pharmaceut Res 17 (2000): 419-26[11] Ito K, Ogihara K, Kanamitsu SI, Itoh T \"Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes.\" Drug Metab Dispos 31 (2003): 945-954[12] Amsden GW \"Macrolides versus azalides: a drug interaction update.\" Ann Pharmacother 29 (1995): 906-17[13] Luurila H, Olkkola KT, Neuvonen PJ \"Interaction between erythromycin and the benzodiazepines diazepam and flunitrazepam.\" Pharmacol Toxicol 78 (1996): 117-22[14] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[15] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[16] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[17] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Methohexital, Methylphenobarbital, Pentobarbital, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, Paraldehyde, Ethchlorvynol, Amobarbital, More", "alternatives_b": "Tinidazole, Levofloxacin, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Nizatidine, Esomeprazole, More", "updated_at": 1767369485}, {"id": 67728, "ingredient1": "Flutamide", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Long-term androgen deprivation therapy can prolong the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).", "source": "DDInter", "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.", "mechanism_text": "Synergism", "recommendation": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67815/", "reference_text": "[1] \"Product Information. Vantas (histrelin).\" Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc), Lexington, MA.[2] \"Product Information. Zoladex (goserelin).\" Zeneca Pharmaceuticals, Wilmington, DE.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Trelstar (triptorelin)\" Pharmacia and Upjohn, Kalamazoo, MI.[5] \"Product Information. Firmagon (degarelix).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Lupron (leuprolide).\" TAP Pharmaceuticals Inc, Deerfield, IL.[7] \"Product Information. Eligard (leuprolide).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[8] \"Product Information. Plenaxis (abarelix).\" Praecis Pharmaceuticals Inc, Waltham, MA.", "alternatives_a": "Anastrozole, Aminoglutethimide, Exemestane, Fulvestrant", "alternatives_b": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, More", "updated_at": 1767369485}, {"id": 67729, "ingredient1": "Fluticasone", "ingredient2": "Clarithromycin", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may increase the systemic exposure to fluticasone following intranasal administration or oral inhalation. Fluticasone undergoes extensive first-pass and systemic metabolism via CYP450 3A4, thus inhibition of the isoenzyme may significantly increase systemic bioavailability of the drug. However, the extent of interaction may depend on route of fluticasone administration and the specific formulation.", "source": "DDInter", "management_text": "Concomitant use of most orally inhaled fluticasone preparations with potent CYP450 3A4 inhibitors is not recommended unless the potential benefit outweighs the risk of systemic side effects. Alternatives to fluticasone should be considered whenever possible. A less potent, less lipophilic, and/or shorter-acting agent such as beclomethasone or flunisolide may be appropriate. The lowest effective dosage of orally inhaled corticosteroid should be used, and further adjustments made as necessary according to therapeutic response and tolerance. Intranasal fluticasone and fluticasone furoate-vilanterol oral inhalation powder may be used cautiously in combination with potent CYP450 3A4 inhibitors except ritonavir.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of most orally inhaled fluticasone preparations with potent CYP450 3A4 inhibitors is not recommended unless the potential benefit outweighs the risk of systemic side effects.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67816/", "reference_text": "[1] \"Product Information. Veramyst (fluticasone nasal).\" GlaxoSmithKline, Research Triangle Park, NC.[2] Valin N, De Castro N, Garrait V, Bergeron A, Bouche C, Molina JM \"Iatrogenic Cushing's syndrome in HIV-infected patients receiving ritonavir and inhaled fluticasone: description of 4 new cases and review of the literature.\" J Int Assoc Physicians AIDS Care 8 (2009): 113-21[3] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[4] Lonnebo A, Grahnen A, Jansson B, Brundin RM, Lingandersson A, Eckernas SA \"An assessment of the systemic effects of single and repeated doses of inhaled fluticasone propionate and inhaled budesonide in healthy volunteers.\" Eur J Clin Pharmacol 49 (1996): 459-63[5] Soldatos G, Sztal-Mazer S, Woolley I, Stockigt J \"Exogenous glucocorticoid excess as a result of ritonavir-fluticasone interaction.\" Intern Med J 35 (2005): 67-8[6] Nocent C, Raherison C, Dupon M, Taytard A \"Unexpected effects of inhaled fluticasone in an HIV patient with asthma.\" J Asthma 41 (2004): 793-5[7] Li AM \"Ritonavir and fluticasone: Beware of this potentially fatal combination.\" J Pediatr 148 (2006): 294-5[8] Woods DR, Arun CS, Corris PA, Perros P \"Cushing's syndrome without excess cortisol.\" BMJ 332 (2006): 469-70[9] Jinno S, Goshima C \"Progression of Kaposi sarcoma associated with iatrogenic Cushing syndrome in a person with HIV/AIDS.\" AIDS Read 18 (2008): 100-4[10] Boorsma M, Andersson N, Larsson P, Ullman A \"Assessment of the relative systemic potency of inihaled fluticasone and budesonide.\" Eur Respir J 9 (1996): 1427-32[11] Samaras K, Pett S, Gowers A, McMurchie M, Cooper DA \"Iatrogenic Cushing's syndrome with osteoporosis and secondary adrenal failure in HIV-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: six cases.\" J Clin Endocrinol Metab 90 (2005): 4394-8[12] Schmid C, Naef R, Speich R, Boehler A \"Addition of inhaled fluticasone propionate to systemic immunosuppression after lung transplantation: Cushing's Syndrome in patients on itraconazole comedication.\" Transplantation 76 (2003): 263-4[13] Daveluy A, Raignoux C, Miremont-Salame G, et al. \"Drug interactions between inhaled corticosteroids and enzymatic inhibitors.\" Eur J Clin Pharmacol (2009):[14] Pessanha TM, Campos JM, Barros AC, Pone MV, Garrido JR, Pone SM \"Iatrogenic Cushing's syndrome in a adolescent with AIDSs on ritonavir and inhaled fluticasone. case report and literature review.\" AIDS 21 (2007): 529-32[15] Rouanet I, Peyriere H, Mauboussin JM, Vincent D \"Cushing's syndrome in a patient treated by ritonavir/lopinavir and inhaled fluticasone.\" HIV Med 4 (2003): 149-50[16] Todd GR, Acerini CL, Ross-Russell, Zahra S, Warner JT, McCance D \"Survey of adrenal crisis associated witwh inhaled corticosteroids in the United Kingdom.\" Arch Dis Child 87 (2002): 457-61[17] Lipworth BJ \"Systemic adverse effects of inhaled corticosteroid therapy - A systematic review and meta-analysis.\" Arch Intern Med 159 (1999): 941-55[18] Grahnen A, Eckernas SA, Brundin RM, Ling-Andersson A \"An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers.\" Br J Clin Pharmacol 38 (1994): 521-5[19] Pearce RE, Leeder JS, Kearns GL \"Biotransformation of fluticasone: in vitro characterization.\" Drug Metab Dispos 34 (2006): 1035-40[20] Vassiliadi D, Tsagarakis S \"Unusual causes of Cushing's syndrome.\" Arq Bras Endocrinol Metabol 51 (2007): 1245-52[21] Bernecker C, West TB, Mansmann G, Scherbaum WA, Willenberg HS \"Hypercortisolism caused by ritonavir associated inhibition of CYP 3A4 under inhalative glucocorticoid therapy. 2 case reports and a review of the literature.\" Exp Clin Endocrinol Diabetes 120 (2012): 125-7[22] Fardon TC, Lee DK, Haggart K, McFarlane LC, Lipworth BJ \"Adrenal suppression with dry powder formulations of fluticasone propionate and mometasone furoate.\" Am J Respir Crit Care Med 170 (2004): 960-6[23] Parmar JS, Howell T, Kelly J, Bilton D \"Profound adrenal suppression secondary to treatment with low dose inhaled steroids and itraconazole in allergic bronchopulmonary aspergillosis in cystic fibrosis.\" Thorax 57 (2002): 749-50[24] \"Product Information. Flonase (fluticasone).\" Glaxo Wellcome, Research Triangle Park, NC.[25] Brus R \"Effects of high-dose inhaled corticosteroids on plasma cortisol consentrations in healthy adults.\" Arch Intern Med 159 (1999): 1903-8[26] Arrington-Sanders R, Hutton N, Siberry GK \"Ritonavir-fluticasone interaction causing Cushing syndrome in HIV-infected children and adolescents.\" Pediatr Infect Dis J 25 (2006): 1044-1048[27] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[28] Kedem E, Shahar E, Hassoun G, Pollack S \"Iatrogenic Cushing's syndrome due to coadministration of ritonavir and inhaled budesonide in an asthmatic human immunodeficiency virus infected patient.\" J Asthma 47 (2010): 830-1[29] Bhumbra NA, Sahloff EG, Oehrtman SJ, Horner JM \"Exogenous Cushing syndrome with inhaled fluticasone in a child receiving lopinavir/ritonavir.\" Ann Pharmacother 41 (2007): 1306-9[30] Molimard M, Girodet PO, Pollet C, et al. \"Inhaled corticosteroids and adrenal insufficiency: prevalence and clinical presentation.\" Drug Saf 31 (2008): 769-74[31] Hillebrand-Haverkort ME, Prummel MF, ten Veen JH \"Ritonavir-induced Cushing's syndrome in a patient treated with nasal fluticasone.\" AIDS 13 (1999): 1803[32] Kempsford R, Norris V, Siederer S \"Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD.\" Pulm Pharmacol Ther 26 (2013): 256-64[33] Sastre J \"Pharmacology of fluticasone propionate.\" J Investig Allergol Clin Immunol 7 (1997): 382-4[34] Gupta SK, Dube MP \"Exogenous Cushing syndrome mimicking human immunodeficiency virus lipodystrophy.\" Clin Infect Dis 35 (2002): E69-71[35] Johnson SR, Marion AA, Vrchoticky T, Emmanuel PJ, Lujan-Zilbermann J \"Cushing syndrome with secondary adrenal insufficiency from concomitant therapy with ritonavir and fluticasone.\" J Pediatr 148 (2006): 386-388[36] Kelly HW \"Comparison of inhaled corticosteroids.\" Ann Pharmacother 32 (1998): 220-32[37] \"Product Information. Flovent (fluticasone).\" Glaxo Wellcome, Research Triangle Park, NC.[38] Gillett MJ, Cameron PU, Nguyen HV, Hurley DM, Mallal SA \"Iatrogenic Cushing's syndrome in an HIV-infected patient treated with ritonavir and inhaled fluticasone.\" AIDS 19 (2005): 740-1[39] Naef R, Schmid C, Hofer M, Minder S, Speich R, Boehler A \"Itraconazole comedication increases systemic levels of inhaled fluticasone in lung transplant recipients.\" Respiration 74 (2007): 418-22[40] Foisy MM, Yakiwchuk EM, Chiu I, Singh AE \"Adrenal suppression and Cushing's syndrome secondary to an interaction between ritonavir and fluticasone: a review of the literature.\" HIV Med 9 (2008): 389-96", "alternatives_a": "Tinidazole, Dexlansoprazole, Bismuth subcitrate potassium, Rifabutin, Esomeprazole, Vonoprazan, Levofloxacin, Lincomycin, Dirithromycin", "alternatives_b": "Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Ipratropium, Revefenacin, Nedocromil, Beclomethasone dipropionate, Mometasone furoate, Amcinonide, Fluocinolone acetonide, More", "updated_at": 1767369485}, {"id": 67730, "ingredient1": "Gatifloxacin", "ingredient2": "Clarithromycin", "severity": "Major", "effect": "Certain quinolones, including gatifloxacin and moxifloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).", "source": "DDInter", "management_text": "Coadministration of gatifloxacin or moxifloxacin with other drugs that can prolong the QT interval should generally be avoided. Caution and clinical monitoring are recommended if concomitant use is required. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of the quinolone, recommended dosages and intravenous infusion rates should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of gatifloxacin or moxifloxacin with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67817/", "reference_text": "[1] Siepmann M, Kirch W \"Drug points - Tachycardia associated with moxifloxacin.\" Br Med J 322 (2001): 23[2] Ansari SR, Chopra N \"Gatifloxacin and Prolonged QT Interval.\" Am J Med Sci 327 (2004): 55-6[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R \"Effects of three fluoroquinolones on QT interval in healthy adults after single doses.\" Clin Pharmacol Ther 73 (2003): 292-303[5] Oliphant CM, Green GM \"Quinolones: a comprehensive review.\" Am Fam Physician 65 (2002): 455-64[6] \"Product Information. Tequin (gatifloxacin)\" Bristol-Myers Squibb, Princeton, NJ.[7] Owens RC \"QT Prolongation with Antimicrobial Agents : Understanding the Significance.\" Drugs 64 (2004): 1091-124[8] Owens RC Jr, Ambrose PG \"Torsades de pointes associated with fluoroquinolones.\" Pharmacotherapy 22 (2002): 663-8; discussion 668-72[9] Dale KM, Lertsburapa K, Kluger J, White CM \"Moxifloxacin and torsade de pointes.\" Ann Pharmacother 41 (2007): 336-40[10] Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB \"Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors.\" Clin Infect Dis 34 (2002): 861-3[11] Katritsis D, Camm AJ \"Quinolones: cardioprotective or cardiotoxic.\" Pacing Clin Electrophysiol 26 (2003): 2317-20[12] Ball P \"Quinolone-induced QT interval prolongation: a not-so-unexpected class effect.\" J Antimicrob Chemother 45 (2000): 557-9[13] Iannini PB, Circiumaru I \"Gatifloxacin-induced QTc prolongation and ventricular tachycardia.\" Pharmacotherapy 21 (2001): 361-2[14] Tsikouris JP, Peeters MJ, Cox CD, Meyerrose GE, Seifert CF \"Effects of three fluoroquinolones on QT analysis after standard treatment courses.\" Ann Noninvasive Electrocardiol 11 (2006): 52-6[15] Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C \"Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects.\" Clin Pharmacol Ther 68 (2000): 658-66[16] Owens RC \"Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes.\" Pharmacotherapy 21 (2001): 301-19[17] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[18] Falagas ME, Rafailidis PI, Rosmarakis ES \"Arrhythmias associated with fluoroquinolone therapy.\" Int J Antimicrob Agents 29 (2007): 374-9[19] \"Product Information. Avelox (moxifloxacin)\" Bayer, West Haven, CT.[20] White CM, Grant EM, Quintiliani R \"Moxifloxacin does increase the corrected QT interval.\" Clin Infect Dis 33 (2001): 1441-2[21] Stahlmann R \"Clinical toxicological aspects of fluoroquinolones.\" Toxicol Lett 127 (2002): 269-77[22] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[23] Frothingham R \"Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.\" Pharmacotherapy 21 (2001): 1468-72[24] Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H \"Risk of torsades de pointes with non-cardiac drugs.\" BMJ 322 (2001): 46-7[25] Cerner Multum, Inc. \"Australian Product Information.\" O 0[26] Kang J, Wang L, Chen XL, Triggle DJ, Rampe D \"Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.\" Mol Pharmacol 59 (2001): 122-6[27] \"Product Information. Tequin (gatifloxacin)\" Bristol-Myers Squibb, Princeton, NJ.[28] Wallace AW, Victory JM, Amsden GW \"Lack of bioequivalence of gatifloxacin when coadministered with calcium-fortified orange juice in healthy volunteers.\" J Clin Pharmacol 43 (2003): 92-6", "alternatives_a": "Rifamycin, Oxytetracycline, Netilmicin, Polymyxin B, Sulfamethizole, Trifluridine, Sulfisoxazole, Povidone-iodine, Enoxacin, Nalidixic acid, Cinoxacin, More", "alternatives_b": "Tinidazole, Tetracycline, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, Vonoprazan, Levofloxacin, Lincomycin, More", "updated_at": 1767369485}, {"id": 67731, "ingredient1": "Glasdegib", "ingredient2": "Clarithromycin", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of glasdegib, which is primarily metabolized by the isoenzyme. Increased exposure to glasdegib may increase the risk of serious adverse effects such as QT interval prolongation, anemia, febrile neutropenia, thrombocytopenia, hemorrhage, edema, and mucositis.", "source": "DDInter", "management_text": "Concomitant use of glasdegib with potent CYP450 3A4 inhibitors should generally be avoided. Alternative agents with no or minimal CYP450 3A4 inhibitory potential are recommended whenever possible. Otherwise, close monitoring for increased adverse effects is advisable, including more frequent ECG monitoring.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of glasdegib with potent CYP450 3A4 inhibitors should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67818/", "reference_text": "[1] \"Product Information. Daurismo (glasdegib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] \"Product Information. Daurismo (glasdegib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Nizatidine, Esomeprazole, Ranitidine, More", "alternatives_b": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Mitotane, Niraparib, Porfimer sodium, More", "updated_at": 1767369485}, {"id": 67732, "ingredient1": "Glimepiride", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Limited data suggest that clarithromycin may potentiate the hypoglycemic effect of sulfonylureas in susceptible individuals such as the elderly and patients with renal impairment. The exact mechanism is unknown but may involve clarithromycin displacement of sulfonylureas from plasma protein binding sites.", "source": "DDInter", "management_text": "Clarithromycin should be prescribed cautiously to diabetic patients with renal impairment who are receiving sulfonylurea therapy, particularly if they are also elderly. Patients should be advised to regularly monitor their blood sugar and counseled on how to recognize and treat hypoglycemia, which may include symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, and palpitations. The physician should be notified if an interaction is suspected.", "mechanism_text": "Distribution", "recommendation": "Clarithromycin should be prescribed cautiously to diabetic patients with renal impairment who are receiving sulfonylurea therapy, particularly if they are also elderly.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67819/", "reference_text": "[1] Bussing R, Gende A \"Severe hypoglycemia from clarithromycin-sulfonylurea drug interaction.\" Diabetes Care 25 (2002): 1659-61[2] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[3] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[4] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[5] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[6] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[12] Cheng KL, Nafziger AN, Peloquin CA, Amsden GW \"Effect of grapefruit juice on clarithromycin pharmacokinetics.\" Antimicrob Agents Chemother 42 (1998): 927-9", "alternatives_a": "Guar gum", "alternatives_b": "Tinidazole, Tetracycline, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Vonoprazan, Lincomycin, Troleandomycin, Dirithromycin", "updated_at": 1767369485}, {"id": 67733, "ingredient1": "Glipizide", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Limited data suggest that clarithromycin may potentiate the hypoglycemic effect of sulfonylureas in susceptible individuals such as the elderly and patients with renal impairment. The exact mechanism is unknown but may involve clarithromycin displacement of sulfonylureas from plasma protein binding sites.", "source": "DDInter", "management_text": "Clarithromycin should be prescribed cautiously to diabetic patients with renal impairment who are receiving sulfonylurea therapy, particularly if they are also elderly. Patients should be advised to regularly monitor their blood sugar and counseled on how to recognize and treat hypoglycemia, which may include symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, and palpitations. The physician should be notified if an interaction is suspected.", "mechanism_text": "Distribution", "recommendation": "Clarithromycin should be prescribed cautiously to diabetic patients with renal impairment who are receiving sulfonylurea therapy, particularly if they are also elderly.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67820/", "reference_text": "[1] Bussing R, Gende A \"Severe hypoglycemia from clarithromycin-sulfonylurea drug interaction.\" Diabetes Care 25 (2002): 1659-61[2] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[3] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[4] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[5] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[6] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[12] Cheng KL, Nafziger AN, Peloquin CA, Amsden GW \"Effect of grapefruit juice on clarithromycin pharmacokinetics.\" Antimicrob Agents Chemother 42 (1998): 927-9", "alternatives_a": "Guar gum", "alternatives_b": "Tinidazole, Tetracycline, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Vonoprazan, Telithromycin, Lincomycin, Troleandomycin, Dirithromycin", "updated_at": 1767369485}, {"id": 67734, "ingredient1": "Glyburide", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Limited data suggest that clarithromycin may potentiate the hypoglycemic effect of sulfonylureas in susceptible individuals such as the elderly and patients with renal impairment. The exact mechanism is unknown but may involve clarithromycin displacement of sulfonylureas from plasma protein binding sites.", "source": "DDInter", "management_text": "Clarithromycin should be prescribed cautiously to diabetic patients with renal impairment who are receiving sulfonylurea therapy, particularly if they are also elderly. Patients should be advised to regularly monitor their blood sugar and counseled on how to recognize and treat hypoglycemia, which may include symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, and palpitations. The physician should be notified if an interaction is suspected.", "mechanism_text": "Distribution", "recommendation": "Clarithromycin should be prescribed cautiously to diabetic patients with renal impairment who are receiving sulfonylurea therapy, particularly if they are also elderly.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67821/", "reference_text": "[1] Bussing R, Gende A \"Severe hypoglycemia from clarithromycin-sulfonylurea drug interaction.\" Diabetes Care 25 (2002): 1659-61[2] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[3] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[4] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[5] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[6] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[12] Cheng KL, Nafziger AN, Peloquin CA, Amsden GW \"Effect of grapefruit juice on clarithromycin pharmacokinetics.\" Antimicrob Agents Chemother 42 (1998): 927-9", "alternatives_a": "Guar gum", "alternatives_b": "Tinidazole, Tetracycline, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Vonoprazan, Telithromycin, Lincomycin, Troleandomycin, Dirithromycin", "updated_at": 1767369485}, {"id": 67735, "ingredient1": "Glycerin", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67822/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Schaefer DC, Cheskin LJ \"Constipation in the elderly.\" Am Fam Physician 58 (1998): 907-14[4] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993): 138-45[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998): 517-8", "alternatives_a": "Tinidazole, Pantoprazole, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Rifabutin, Cimetidine, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 67736, "ingredient1": "Goserelin", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Long-term androgen deprivation therapy can prolong the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).", "source": "DDInter", "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.", "mechanism_text": "Synergism", "recommendation": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67823/", "reference_text": "[1] \"Product Information. Vantas (histrelin).\" Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc), Lexington, MA.[2] \"Product Information. Zoladex (goserelin).\" Zeneca Pharmaceuticals, Wilmington, DE.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Trelstar (triptorelin)\" Pharmacia and Upjohn, Kalamazoo, MI.[5] \"Product Information. Firmagon (degarelix).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Lupron (leuprolide).\" TAP Pharmaceuticals Inc, Deerfield, IL.[7] \"Product Information. Eligard (leuprolide).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[8] \"Product Information. Plenaxis (abarelix).\" Praecis Pharmaceuticals Inc, Waltham, MA.", "alternatives_a": "Tinidazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, Nizatidine, Vonoprazan, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67737, "ingredient1": "Granisetron", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67824/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[16] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Scopolamine, Nabilone, Rolapitant, Dronabinol", "alternatives_b": "Tinidazole, Tetracycline, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Nizatidine, Esomeprazole, Vonoprazan, Amoxicillin, Lincomycin, More", "updated_at": 1767369485}, {"id": 67738, "ingredient1": "Grepafloxacin", "ingredient2": "Clarithromycin", "severity": "Major", "effect": "Grepafloxacin can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of grepafloxacin with other drugs that can prolong the QT interval is considered contraindicated.", "mechanism_text": "Synergism", "recommendation": "Coadministration of grepafloxacin with other drugs that can prolong the QT interval is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67825/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[4] Thomas M, Maconochie JG, Fletcher E \"The dilemma of the prolonged QT interval in early drug studies.\" Br J Clin Pharmacol 41 (1996): 77-81[5] Lode H, Vogel F, Elies W \"Grepafloxacin: A review of its safety profile based on clinical trials and postmarketing surveillance.\" Clin Ther 21 (1999): 61-74[6] Ball P \"Quinolone-induced QT interval prolongation: a not-so-unexpected class effect.\" J Antimicrob Chemother 45 (2000): 557-9[7] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"", "alternatives_a": "Enoxacin, Nalidixic acid, Cinoxacin, Trovafloxacin, Delafloxacin", "alternatives_b": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Cimetidine, Esomeprazole, Ranitidine, More", "updated_at": 1767369485}, {"id": 67739, "ingredient1": "Guanfacine", "ingredient2": "Clarithromycin", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of guanfacine, which is primarily metabolized by the isoenzyme. The risk of adverse reactions such as hypotension, bradycardia, and sedation may increase.", "source": "DDInter", "management_text": "Caution and dosage adjustment are advised when guanfacine is administered with potent and moderate CYP450 3A4 inhibitors. For extended-release guanfacine, the manufacturers recommend reducing the dosage to half the recommended level during concomitant use . Further dosage adjustments may be required based on patient tolerance and response.", "mechanism_text": "Metabolism", "recommendation": "Caution and dosage adjustment are advised when guanfacine is administered with potent and moderate CYP450 3A4 inhibitors.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67826/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Intuniv (guanfacine).\" Shire US Inc, Florence, KY.[3] \"Product Information. Tenex (guanfacine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Intuniv (guanfacine).\" Shire US Inc, Florence, KY.", "alternatives_a": "Rauwolfia serpentina root, Reserpine, Methyldopa, Deserpidine", "alternatives_b": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, More", "updated_at": 1767369485}, {"id": 67740, "ingredient1": "Halazepam", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Macrolide antibiotics may increase and prolong the CNS effects of certain benzodiazepines. The mechanism is inhibition of CYP450 3A4 hepatic oxidation of the benzodiazepines.", "source": "DDInter", "management_text": "Patients receiving this combination should be monitored for excessive or prolonged sedation. Non-interacting benzodiazepines or antimicrobials may be considered as alternatives.", "mechanism_text": "Metabolism", "recommendation": "Patients receiving this combination should be monitored for excessive or prolonged sedation.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67827/", "reference_text": "[1] Warot D, Bergougnan L, Lamiable D, et al \"Troleandomycin-triazolam interaction in healthy volunteers: pharmacokinetic and psychometric evaluation.\" Eur J Clin Pharmacol 32 (1987): 389-93[2] Yeates RA, Laufen H, Zimmermann T, Schumacher T \"Pharmacokinetic and pharmacodynamic interaction study between midazolam and the macrolide antibiotics, erythromycin clarithromycin, and the azalide azithromycin.\" Int J Clin Pharmacol Ther 35 (1997): 577-9[3] Mattila MJ, Idanpaanheikkila JJ, Tornwall M, Vanakoski J \"Oral single doses of erythromycin and roxithromycin may increase the effects of midazolam on human performance.\" Pharmacol Toxicol 73 (1993): 180-5[4] Zimmermann T, Yeates RA, Laufen H, Scharpf F, Leitold M, Wildfeuer A \"Influence of the antibiotics erythromycin and azithromycin on the pharmacokinetics and pharmacodynamics of midazolam.\" Arzneimittelforschung 46 (1996): 213-7[5] Yasui N, Otani K, Kaneko S, et al \"A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: in vivo evidence for the involvement of CYP3a4 in alprazolam metabolism.\" Clin Pharmacol Ther 59 (1996): 514-9[6] Yeates RA, Laufen H, Zimmermann T \"Interaction between midazolam and clarithromycin: comparison with azithromycin.\" Int J Clin Pharmacol Ther 34 (1996): 400-5[7] Gorski JC, Jones DR, HaehnerDaniels BD, Hamman MA, OMara EM, Hall SD \"The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin.\" Clin Pharmacol Ther 64 (1998): 133-43[8] Phillips JP, Antal EJ, Smith RB \"A pharmacokinetic drug interaction between erythromycin and triazolam.\" J Clin Psychopharmacol 6 (1986): 297-9[9] Wrighton SA, Ring BJ \"Inhibition of human CYP3A catalyzed 1'-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine.\" Pharm Res 11 (1994): 921-4[10] Kanamitsu S, Ito K, Green CE, Tyson CA, Shimada N, Sugiyama Y \"Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4.\" Pharmaceut Res 17 (2000): 419-26[11] Ito K, Ogihara K, Kanamitsu SI, Itoh T \"Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes.\" Drug Metab Dispos 31 (2003): 945-954[12] Amsden GW \"Macrolides versus azalides: a drug interaction update.\" Ann Pharmacother 29 (1995): 906-17[13] Luurila H, Olkkola KT, Neuvonen PJ \"Interaction between erythromycin and the benzodiazepines diazepam and flunitrazepam.\" Pharmacol Toxicol 78 (1996): 117-22[14] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[15] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[16] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[17] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Meprobamate", "alternatives_b": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, More", "updated_at": 1767369485}, {"id": 67741, "ingredient1": "Halofantrine", "ingredient2": "Clarithromycin", "severity": "Major", "effect": "Halofantrine can cause dose-related prolongation of the QT interval at recommended therapeutic doses. QTc interval prolongation and death have been reported during combination use of halofantrine and mefloquine. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of halofantrine with other drugs that can prolong the QT interval is considered contraindicated.", "mechanism_text": "Synergism", "recommendation": "Coadministration of halofantrine with other drugs that can prolong the QT interval is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67828/", "reference_text": "[1] \"Product Information. Lariam (mefloquine).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Halfan (halofantrine).\" GlaxoSmithKline, Philadelphia, PA.[4] Nosten F, ter Kuile FO, Luxemburger C, et al \"Cardiac effects of antimalarial treatment with halofantrine.\" Lancet 341 (1993): 1054-6[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Sudden death in a traveler following halofantrine administration--Togo, 2000.\" MMWR Morb Mortal Wkly Rep 50 (2001): 169-70, 179[7] Giao PT, de Vries PJ \"Pharmacokinetic interactions of antimalarial agents.\" Clin Pharmacokinet 40 (2001): 343-73[8] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[9] Abernethy DR, Wesche DL, Barbey JT, et al. \"Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation.\" Br J Clin Pharmacol 51 (2001): 231-7[10] Giao PT, de Vries PJ \"Pharmacokinetic interactions of antimalarial agents.\" Clin Pharmacokinet 40 (2001): 343-73[11] \"Product Information. Halfan (halofantrine).\" GlaxoSmithKline, Philadelphia, PA.[12] Abernethy DR, Wesche DL, Barbey JT, et al. \"Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation.\" Br J Clin Pharmacol 51 (2001): 231-7[13] Charbit B, Becquemont L, Lepere B, Peytavin G, Funck-Bretano C \"Pharmacokinetic and pharmacodynamic interaction between grapefruit juice and halofantrine.\" Clin Pharmacol Ther 72 (2002): 514-23", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Nizatidine, Esomeprazole, More", "alternatives_b": "Artesunate, Pyrimethamine, Tafenoquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 67742, "ingredient1": "Haloperidol", "ingredient2": "Clarithromycin", "severity": "Major", "effect": "Haloperidol can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Haloperidol treatment alone has been associated with a number of reported cases of torsade de pointes and sudden death. In addition, certain agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants) may have additive parasympatholytic and central nervous system-depressant effects when used in combination with haloperidol. Excessive parasympatholytic effects may include paralytic ileus, hyperthermia, mydriasis, blurred vision, tachycardia, urinary retention, psychosis, and seizures.", "source": "DDInter", "management_text": "Caution is recommended if haloperidol is used in combination with other drugs that can prolong the QT interval, particularly when administered intravenously or at higher than recommended dosages.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if haloperidol is used in combination with other drugs that can prolong the QT interval, particularly when administered intravenously or at higher than recommended dosages.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67829/", "reference_text": "[1] Huyse F, van Schijndel RS \"Haloperidol and cardiac arrest.\" Lancet 2 (1988): 568-9[2] \"Product Information. Haldol (haloperidol).\" McNeil Pharmaceutical, Raritan, NJ.[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] O'Brien JM, Rockwood RP, Suh KI \"Haloperidol-induced torsade de pointes.\" Ann Pharmacother 33 (1999): 1046-9[7] Wilt JL, Minnema AM, Johnson RF, Rosenblum AM \"Torsade de pointes associated with the use of intravenous haloperidol.\" Ann Intern Med 119 (1993): 391-4[8] Hatta K, Takahashi T, Nakamura H, Yamashiro H, Asukai N, Matsuzaki I, Yonezawa Y \"The association between intravenous haloperidol and prolonged QT interval.\" J Clin Psychopharmacol 21 (2001): 257-61[9] Metzger E, Friedman R \"Prolongation of the corrected QT and torsades de pointes cardiac arrhythmia associated with intravenous haloperidol in the medically ill.\" J Clin Psychopharmacol 13 (1993): 128-32[10] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Loxapine, Molindone, Thiothixene", "alternatives_b": "Tinidazole, Tetracycline, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Cimetidine, Esomeprazole, Nizatidine, Vonoprazan, Lincomycin, Troleandomycin, Dirithromycin", "updated_at": 1767369485}, {"id": 67743, "ingredient1": "Halothane", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67830/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[16] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Thiopental, Remifentanil, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Enflurane, Esketamine, Etomidate, Ketamine", "alternatives_b": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Cimetidine, Esomeprazole, Ranitidine, More", "updated_at": 1767369485}, {"id": 67744, "ingredient1": "Histrelin", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Long-term androgen deprivation therapy can prolong the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).", "source": "DDInter", "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.", "mechanism_text": "Synergism", "recommendation": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67831/", "reference_text": "[1] \"Product Information. Vantas (histrelin).\" Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc), Lexington, MA.[2] \"Product Information. Zoladex (goserelin).\" Zeneca Pharmaceuticals, Wilmington, DE.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Trelstar (triptorelin)\" Pharmacia and Upjohn, Kalamazoo, MI.[5] \"Product Information. Firmagon (degarelix).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Lupron (leuprolide).\" TAP Pharmaceuticals Inc, Deerfield, IL.[7] \"Product Information. Eligard (leuprolide).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[8] \"Product Information. Plenaxis (abarelix).\" Praecis Pharmaceuticals Inc, Waltham, MA.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67745, "ingredient1": "Hydroxychloroquine", "ingredient2": "Clarithromycin", "severity": "Major", "effect": "Chloroquine and hydroxychloroquine can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Because COVID-19 may disproportionately affect the elderly and individuals with preexisting heart disease, and cardiac complications such as myocarditis and cardiomyopathy as well as organ failure may occur in patients with severe COVID-19, it appears likely that hospitalized patients with COVID-19 may represent a particularly susceptible and high-risk population, and other, less critically ill patients may not have the same arrhythmic risk.", "source": "DDInter", "management_text": "Coadministration of chloroquine or hydroxychloroquine with other drugs that can prolong the QT interval should generally be avoided, particularly in patients with baseline QT prolongation (e.g., QTc >=500 msec) or congenital long QT syndrome. Close monitoring of QTc interval, electrolyte levels, and renal and hepatic function is recommended if concomitant use is required and benefits are anticipated to outweigh the risks. Electrolyte abnormalities should be corrected prior to initiating treatment with chloroquine or hydroxychloroquine. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. Because chloroquine and hydroxychloroquine are eliminated slowly from the body, the potential for drug interactions should be observed for a prolonged period following their discontinuation.", "mechanism_text": "Synergism", "recommendation": "Coadministration of chloroquine or hydroxychloroquine with other drugs that can prolong the QT interval should generally be avoided, particularly in patients with baseline QT prolongation (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67832/", "reference_text": "[1] Mercuro NJ, Yen CF, Shim DJ, et.al \"Risk of QT interval prolongation associated with the use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19)\" JAMA Cardiol May 1:e201834 (2020): epub ahead of print[2] \"Product Information. Hydroxychloroquine Sulfate (hydroxychloroquine).\" Prasco Laboratories, Cincinnati, OH.[3] US Food and Drug Administration \"FACT SHEET FOR HEALTH CARE PROVIDERS EMERGENCY USE AUTHORIZATION (EUA) OF HYDROXYCHLOROQUINE SULFATE SUPPLIED FROM THE STRATEGIC NATIONAL STOCKPILE FOR TREATMENT OF COVID-19 IN CERTAIN HOSPITALIZED PATIENTS. Available from: URL: https://www.fda.gov/media/\" ({2020, Apr 27]):[4] \"Product Information. Plaquenil (R). (hydroxychloroquine).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[5] \"Product Information. Chloroquine Phosphate (chloroquine).\" West-Ward Pharmaceutical Corporation, Eatontown, NJ.[6] Bessiere F, Roccia H, Deliniere A, et.al \"Assessment of QT intervals in a case series of patients with coronavirus disease 2019 (COVID-19) infection treated with hydroxychloroquine alone or in combination with azithromycin in an intensive care unit.\" JAMA Cardiol May 1 (2020): epub ahead of print[7] National Institutes of Health (NIH) \"Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. Available from: URL: https://covid19treatmentguidelines.nih.gov/\" ([2020, Apr 21]):[8] Sacher F, Fauchier L, Boveda S, et.al \"Use of drugs with potential cardiac effect in the setting of SARS-CoV-2 infection.\" Arch Cardiovasc Dis Apr 24 (2020): epub ahead of print[9] Kapoor A, Pandurangi U, Arora V, et.al \"Cardiovascular risks of hydroxychloroquine in treatment and prophylaxis of COVID-19 patients: A scientific statement from the Indian Heart Rhythm Society.\" Indian Pacing Electorphysiol J Apr 8 (2020): epub ahead of print[10] Borba MGS, Val FFA, Sampaio VS, et.al \"Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 1 (SARS-CoV-2) infection: A randomized clinical trial.\" JAMA Netw Open Apr 1 (2020): epub ahead of print[11] Sapp JL, Alqarawi W, MacIntyre CJ, et.al \"Guidance on minimizing risk of drug-induced ventricular arrhythmia during treatment of COVID-19: A statement from the Canadian Heart Rhythm Society.\" Can J Cardiol Apr 8 (2020): epub ahead of print[12] Smit C, Peeters MYM, van den Anker JN, Knibbe CAJ \"Chloroquine for SARS-CoV-2: Implications of its unique pharmacokinetic and safety properties.\" Clin Pharmacokinet Ar 18 (2020): epub ahead of print[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] Javelot H, El-Hage W, Meyer G, Becker G, Michel B, Hingray C \"COVID-19 and (hydroxy)chloroquine-azithromycin combination: should we take the risk for our patients?\" Br J Clin Pharmacol Apr 29 (2020): epub ahead of print[15] US Food and Drug Administration \"Hydroxychloroquine or Chloroquine for COVID-19: Drug Safety Communication - FDA Cautions Against Use Outside of the Hospital Setting or a Clinical Trial Due to Risk of Heart Rhythm Problems. Available from: URL: https://www.fda.gov/safety/medical-product-\" ([2020, Apr 24]):[16] Giudicessi JR, Noseworthy PA, Friedman PA, Ackerman MJ \"Urgent guidance for navigating and circumventing the QTc-prolonging and torsadogenic potential of possible pharmacotherapies for coronavirus disease 19 (COVID-19)\" Mayo Clin Proc Apr 7 (2020): epub ahead of print[17] Roden DM, Harrington RA, Poppas A, Russo AM \"Considerations for drug interactions on QTc in exploratory COVID-19 (Coroanvirus disease 2019) treatment.\" Heart Rhythm Apr 14 (2020): epub ahead of print[18] mitra RL, Greenstein SA, Epstein lm \"An algorithm for managing QT prolongation in coronavirus disease 2019 (COVID-19) patients treated with either chloroquine or hydroxychloroquine in conjunction with azithromycin; Possible benefits of intravenous lidocaine.\" HeartRythm Case Rep Apr 1 (2020): epub ahead of print[19] US Food and Drug Administration \"FACT SHEET FOR HEALTH CARE PROVIDERS EMERGENCY USE AUTHORIZATION (EUA) OF CHLOROQUINE PHOSPHATE SUPPLIED FROM THE STRATEGIC NATIONAL STOCKPILE FOR TREATMENT OF COVID-19 IN CERTAIN HOSPITALIZED PATIENTS. Available from: URL: https://www.fda.gov/media/13653\" ([2020, Apr 27]):[20] Saleh M, Gabriels J, ChangD, et.al \"The effect of chloroquine, hydroxychloroquine and azithromycin on the corrected QT interval in patients with SARS-CoV-2 infection.\" Circ Arrhythm Electrophysiol Apr 29 (2020): epub ahead of print[21] Bonow RO, Hernandez AF, Turakhia M \"Hydroxychloroquine, coronavirus disease 2019, and QT prolongation.\" JAMA Cardiol May 1 (2020): epub ahead of print[22] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Vonoprazan, Bismuth subcitrate potassium, Dexlansoprazole, Esomeprazole, Lincomycin, Dirithromycin", "alternatives_b": "Artesunate, Pyrimethamine, Tafenoquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 67746, "ingredient1": "Hydroxyzine", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67833/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[16] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Meprobamate", "alternatives_b": "Tinidazole, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Esomeprazole, Vonoprazan, Lincomycin, Troleandomycin, Dirithromycin", "updated_at": 1767369485}, {"id": 67747, "ingredient1": "Ibrutinib", "ingredient2": "Clarithromycin", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ibrutinib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The use of ibrutinib in combination with potent CYP450 3A4 inhibitors such as itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, nefazodone, cobicistat, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics should generally be avoided, particularly those that are intended for chronic administration. Some authorities recommend avoiding concomitant use of ibrutinib during and for 2 weeks after treatment with itraconazole. Alternative agents with no or minimal CYP450 3A4 inhibitory potential are recommended whenever possible. If no alternatives exist and the CYP450 3A4 inhibitor is used short-term for 7 days or less, consider interrupting or delaying initiation of ibrutinib treatment until therapy with the inhibitor is complete. Patients should be closely monitored for signs of ibrutinib toxicity such as myelosuppression, bleeding, infection, and renal impairment.", "mechanism_text": "Metabolism", "recommendation": "The use of ibrutinib in combination with potent CYP450 3A4 inhibitors such as itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, nefazodone, cobicistat, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics should generally be avoided, particularly those that are intended for chronic administration.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67834/", "reference_text": "[1] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[2] \"Product Information. Imbruvica (ibrutinib).\" Pharmacyclics Inc, Sunnyvale, CA.[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Imbruvica (ibrutinib).\" Pharmacyclics Inc, Sunnyvale, CA.[6] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.", "alternatives_a": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, More", "alternatives_b": "Alpelisib, Trametinib, Dacomitinib, Tivozanib, Alectinib", "updated_at": 1767369485}, {"id": 67748, "ingredient1": "Ibutilide", "ingredient2": "Clarithromycin", "severity": "Major", "effect": "Macrolide antibiotics including azithromycin, clarithromycin, and erythromycin have been associated with prolongation of the QT interval and infrequent cases of cardiac arrhythmia. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Elderly patients may also be more susceptible to drug-associated effects on the QT interval.", "source": "DDInter", "management_text": "The use of macrolide antibiotics in patients receiving class IA or class III antiarrhythmic agents antiarrhythmic agents should generally be avoided unless benefits are anticipated to outweigh the risks. Caution and clinical monitoring are recommended if these agents are prescribed together, especially to patients with underlying risk factors. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "The use of macrolide antibiotics in patients receiving class IA or class III antiarrhythmic agents antiarrhythmic agents should generally be avoided unless benefits are anticipated to outweigh the risks.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67835/", "reference_text": "[1] \"Product Information. Erythrocin Lactobionate (erythromycin).\" Abbott Pharmaceutical, Abbott Park, IL.[2] Lee KL, Jim MH, Tang SC, Tai YT \"QT prolongation and torsades de pointes associated with clarithromycin.\" Am J Med 104 (1998): 395-6[3] \"Product Information. Biaxin (clarithromycin).\" Abbott Pharmaceutical, Abbott Park, IL.[4] Gitler B, Berger LS, Buffa SD \"Torsades de pointes induced by erythromycin.\" Chest 105 (1994): 368-72[5] \"Product Information. ERYC (erythromycin).\" Parke-Davis, Morris Plains, NJ.[6] \"Product Information. Zithromax (azithromycin).\" Pfizer US Pharmaceuticals, New York, NY.[7] Welling PG, Huang H, Hewitt PF, Lyons LL \"Bioavailability of erythromycin stearate: influence of food and fluid volume.\" J Pharm Sci 67 (1978): 764-6[8] Welling PG \"Influence of food and diet on gastrointestinal drug absorption: a review.\" J Pharmacokinet Biopharm 5 (1977): 291-334[9] Randinitis EJ, Sedman AJ, Welling PG, Kinkel AW \"Effect of a high-fat meal on the bioavailability of a polymer-coated erythromycin particle tablet formulation.\" J Clin Pharmacol 29 (1989): 79-84[10] Coyne TC, Shum S, Chun AH, Jeansonne L, Shirkey HC \"Bioavailability of erythromycin ethylsuccinate in pediatric patients.\" J Clin Pharmacol 18 (1978): 194-202[11] Malmborg AS \"Effect of food on absorption of erythromycin. A study of two derivatives, the stearate and the base.\" J Antimicrob Chemother 5 (1979): 591-9[12] Welling PG, Elliott RL, Pitterle ME, et al \"Plasma levels following single and repeated doses of erythromycin estolate and erythromycin stearate.\" J Pharm Sci 68 (1979): 150-5[13] Kanazawa S, Ohkubo T, Sugawara K \"The effects of grapefruit juice on the pharmacokinetics of erythromycin.\" Eur J Clin Pharmacol 56 (2001): 799-803", "alternatives_a": "Tocainide, Moricizine, Bretylium", "alternatives_b": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, More", "updated_at": 1767369485}, {"id": 67749, "ingredient1": "Idarubicin", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of daunorubicin and idarubicin, both of which are substrates of the efflux transporter also known as ABCB1 or MDR1. The interaction has been studied with cyclosporine, a potent P-gp inhibitor, in attempt to overcome multidrug resistance in MDR1-overexpressing tumors.", "source": "DDInter", "management_text": "Caution is advised if daunorubicin or idarubicin is prescribed in combination with a P-gp inhibitor. Patients should be closely monitored for increased adverse effects including cardiotoxicity and myelosuppression.", "mechanism_text": "Absorption", "recommendation": "Caution is advised if daunorubicin or idarubicin is prescribed in combination with a P-gp inhibitor.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67836/", "reference_text": "[1] \"Product Information. Daunoxome (daunorubicin liposomal).\" Nexstar Pharmaceuticals Inc, Boulder, CO.[2] \"Product Information. Idamycin (idarubicin).\" Pharmacia and Upjohn, Kalamazoo, MI.[3] \"Multum Information Services, Inc. Expert Review Panel\"[4] \"Product Information. Cerubidine (daunorubicin).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] \"Product Information. Incivek (telaprevir).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Dactinomycin, Mitomycin, Valrubicin, Plicamycin", "alternatives_b": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, More", "updated_at": 1767369485}, {"id": 67750, "ingredient1": "Idelalisib", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Coadministration of idelalisib with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. The use of idelalisib has been associated with elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) greater than 5 times the upper limit of normal. Coadministration with inhibitors of CYP450 3A4 and/or P-glycoprotein (P-gp) may increase the plasma concentrations of idelalisib, which is a substrate of both the isoenzyme and efflux transporter.", "source": "DDInter", "management_text": "The use of idelalisib with other potentially hepatotoxic agents such as azole antifungal agents, macrolide antibiotics, nefazodone, ritonavir, and telithromycin should be avoided whenever possible. In addition, these agents are potent CYP450 3A4/P-gp inhibitors and may increase the toxicity of idelalisib. Caution is advised if coadministration is required. Patients should be closely monitored for hepatotoxicity and other toxicities of idelalisib such as diarrhea, colitis, intestinal perforation, pneumonitis, neutropenia and thrombocytopenia, and the dosing adjusted or interrupted as necessary. Patients should have serum ALT, AST, and bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling. Permanent discontinuation of idelalisib is recommended in those who experience recurrent hepatotoxicity following dosage reduction. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.", "mechanism_text": "Metabolism, Synergism", "recommendation": "The use of idelalisib with other potentially hepatotoxic agents such as azole antifungal agents, macrolide antibiotics, nefazodone, ritonavir, and telithromycin should be avoided whenever possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67837/", "reference_text": "[1] \"Product Information. Zydelig (idelalisib).\" Gilead Sciences, Foster City, CA.", "alternatives_a": "Pantoprazole, Rabeprazole, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Cimetidine, Esomeprazole, Ranitidine, More", "alternatives_b": "Alpelisib, Trametinib, Dacomitinib, Tivozanib, Alectinib", "updated_at": 1767369485}, {"id": 67751, "ingredient1": "Iloperidone", "ingredient2": "Clarithromycin", "severity": "Major", "effect": "Iloperidone may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of iloperidone with other drugs that can prolong the QT interval should generally be avoided. Caution and clinical monitoring are recommended if concomitant use is required. Patients should have regular ECGs and be monitored for arrhythmias when QT interval is prolonged. Persistent QTc measurements exceeding 500 msec will require suspension of iloperidone therapy and immediate action to correct any concomitant risk factors before resuming treatment.", "mechanism_text": "Synergism", "recommendation": "Coadministration of iloperidone with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67838/", "reference_text": "[1] \"Product Information. Exforge HCT (amlodipine/hydrochlorothiazide/valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[7] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[8] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, More", "alternatives_b": "Loxapine, Molindone, Thiothixene", "updated_at": 1767369485}, {"id": 67752, "ingredient1": "Imatinib", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Imatinib is a substrate of the CYP450 3A4 isoenzyme as well as a potent competitive inhibitor of the CYP450 2C9, 2D6 and 3A4 isoenzymes. Some drugs that are known inhibitors of CYP450 3A4 are also metabolized by one or more of the isoenzymes inhibited by imatinib. Theoretically, coadministration of imatinib with those drugs may result in mutually elevated plasma drug concentrations due to competitive and noncompetitive inhibition of CYP450 activities.", "source": "DDInter", "management_text": "The possibility of prolonged and/or increased pharmacologic effects of imatinib, including serious adverse effects such as edema, hematologic toxicity and immunosuppression, should be considered during concomitant therapy, particularly with potent CYP450 3A4 inhibitors such as ketoconazole, itraconazole, ritonavir, nefazodone, and erythromycin. In addition, clinical and laboratory monitoring for potentially increased pharmacologic effects of coadministered medications is recommended, especially those with a narrow therapeutic range.", "mechanism_text": "Metabolism", "recommendation": "The possibility of prolonged and/or increased pharmacologic effects of imatinib, including serious adverse effects such as edema, hematologic toxicity and immunosuppression, should be considered during concomitant therapy, particularly with potent CYP450 3A4 inhibitors such as ketoconazole, itraconazole, ritonavir, nefazodone, and erythromycin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67839/", "reference_text": "[1] \"Product Information. Gleevec (imatinib mesylate).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Gleevec (imatinib mesylate).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Alpelisib, Trametinib, Dacomitinib, Tivozanib, Alectinib", "alternatives_b": "Tinidazole, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Nizatidine, Esomeprazole, Levofloxacin, Dirithromycin, Lincomycin, Azithromycin, Clindamycin", "updated_at": 1767369485}, {"id": 67753, "ingredient1": "Imipramine", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67840/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[16] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Phenelzine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Vortioxetine, Milnacipran, Tryptophan, Esketamine", "alternatives_b": "Tinidazole, Tetracycline, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Nizatidine, Vonoprazan, Amoxicillin, Dirithromycin, Lincomycin, More", "updated_at": 1767369485}, {"id": 67754, "ingredient1": "Indacaterol", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.", "source": "DDInter", "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67841/", "reference_text": "[1] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990): 575-9[6] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003): 1817-24[8] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998): 145-7[11] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990): 1396-9[16] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.[17] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006): 582-90[19] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[20] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[21] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001): 45-51[26] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986): 619-20", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Rifabutin, Cimetidine, More", "alternatives_b": "Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Ipratropium, Beclomethasone dipropionate", "updated_at": 1767369485}, {"id": 67755, "ingredient1": "Indinavir", "ingredient2": "Clarithromycin", "severity": "Minor", "effect": "Coadministration of indinavir (800 mg every eight hours) and clarithromycin (500 mg every 12 hours) for one week increased the area under the plasma concentration-time curve (AUC) of indinavir by 29%. The AUC of clarithromycin increased 53%. The mechanism of this interaction is related to inhibition of CYP450 3A4 hepatic metabolism. The patient should be monitored for drug-related toxicities and be advised to report symptoms such as nausea, vomiting, diarrhea, flank or back pain, or hematuria. Dose reductions may be necessary if evidence of an interaction is observed. Azithromycin and dirithromycin are not expected to interact and may be considered as alternatives.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67842/", "reference_text": "[1] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[2] Boruchoff SE, Sturgill MG, Grasing KW, et al. \"The steady-state disposition of indinavir is not altered by the concomitant administration of clarithromycin.\" Clin Pharmacol Ther 67 (2000): 351-9[3] Yeh KC, Deutsch PJ, Haddix H, Hesney M, Hoagland V, Ju WD, Justice SJ, Osborne B, Sterrett AT, Stone JA, Woolf E, Waldman S \"Single-dose pharmacokinetics of indinavir and the effect of food.\" Antimicrob Agents Chemother 42 (1998): 332-8[4] Shelton MJ, Wynn HE, Newitt RG, DiFrancesco R \"Effects of grapefruit juice on pharmacokinetic exposure to indinavir in HIV-positive subjects.\" J Clin Pharmacol 41 (2001): 435-42[5] \"Product Information. Crixivan (indinavir).\" Merck & Co, Inc, West Point, PA.[6] Cheng KL, Nafziger AN, Peloquin CA, Amsden GW \"Effect of grapefruit juice on clarithromycin pharmacokinetics.\" Antimicrob Agents Chemother 42 (1998): 927-9", "alternatives_a": "Glecaprevir, Tenofovir alafenamide, Cabotegravir, Lenacapavir, Velpatasvir, Voxilaprevir, Maribavir, Pibrentasvir, Rimantadine, Elvitegravir, Valganciclovir, More", "alternatives_b": "Tinidazole, Levofloxacin, Tetracycline, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Cimetidine, Nizatidine, Amoxicillin, More", "updated_at": 1767369485}, {"id": 67756, "ingredient1": "Indium In-111 oxyquinoline", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Certain medications may decrease chemotaxis and cause false-negative results with Indium In-111-labeled leukocyte studies.", "source": "DDInter", "management_text": "Clinicians should be aware of possible diagnostic interference in patients who are on long-term antibiotic treatment, corticosteroids, interleukin-2, parenteral nutrition, or high doses or supratherapeutic concentrations of lidocaine or procainamide.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of possible diagnostic interference in patients who are on long-term antibiotic treatment, corticosteroids, interleukin-2, parenteral nutrition, or high doses or supratherapeutic concentrations of lidocaine or procainamide.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67843/", "reference_text": "[1] \"Product Information. Indium Oxyquinoline In-111 (indium oxyquinoline In-111).\" GE Healthcare, Princeton, NJ.", "alternatives_a": "Pantoprazole, Rabeprazole, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Famotidine, Cimetidine, Esomeprazole, Ranitidine, Nizatidine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67757, "ingredient1": "Inotuzumab ozogamicin", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Inotuzumab ozogamicin may cause prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of inotuzumab ozogamicin with other drugs that can prolong the QT interval should generally be avoided. Caution and clinical monitoring are recommended if concomitant use cannot be avoided or if inotuzumab ozogamicin is used in patients with other risk factors for QT prolongation. The manufacturer suggests obtaining electrocardiograms and serum electrolytes at baseline and regularly during treatment.", "mechanism_text": "Synergism", "recommendation": "Coadministration of inotuzumab ozogamicin with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67844/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Besponsa (inotuzumab ozogamicin).\" Wyeth Laboratories, Philadelphia, PA.[3] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[4] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 67758, "ingredient1": "Insulin human", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Concomitant use of insulin and other antidiabetic agents with clarithromycin may cause significant hypoglycemia. There have been rare reports of hypoglycemia in patients treated with clarithromycin, some of whom were taking oral hypoglycemic agents or insulin. The exact mechanism of interaction has not been established. With certain hypoglycemic drugs such as nateglinide, pioglitazone, repaglinide and rosiglitazone, inhibition of the CYP450 3A4 isoenzyme by clarithromycin may be involved.", "source": "DDInter", "management_text": "Caution is advised if clarithromycin is prescribed to patients receiving antidiabetic agents. Patients should be advised to regularly monitor their blood sugar and counseled on how to recognize and treat hypoglycemia, which may include symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if clarithromycin is prescribed to patients receiving antidiabetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67845/", "reference_text": "[1] Otsuka SH \"Severe hypoglycemia from helicobacter pylori triple-drug therapy and insulin detemir drug interaction.\" Pharmacotherapy 33 (2013): e45-9[2] Niemi M, Neuvonen PJ, Kivisto KT \"The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide.\" Clin Pharmacol Ther 70 (2001): 58-65[3] Schelleman H, Bilker WB, Brensinger CM, Wan F, Hennessy S \"Anti-infectives and the risk of severe hypoglycemia in users of glipizide or glyburide.\" Clin Pharmacol Ther 88 (2010): 214-22[4] Khamaisi M, Leitersdorf E \"Severe hypoglycemia from clarithromycin-repaglinide drug interaction.\" Pharmacotherapy 28 (2008): 682-4[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Leiba A, Leibowitz A, Grossman E \"An unusual case of hypoglycemia in a diabetic patient.\" Ann Emerg Med 44 (2004): 427-8[7] Bussing R, Gende A \"Severe hypoglycemia from clarithromycin-sulfonylurea drug interaction.\" Diabetes Care 25 (2002): 1659-61[8] \"Product Information. Biaxin (clarithromycin).\" Abbott Pharmaceutical, Abbott Park, IL.[9] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[10] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[11] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[12] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[13] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[14] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[15] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[16] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[17] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[18] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[19] Cheng KL, Nafziger AN, Peloquin CA, Amsden GW \"Effect of grapefruit juice on clarithromycin pharmacokinetics.\" Antimicrob Agents Chemother 42 (1998): 927-9", "alternatives_a": "Tinidazole, Pantoprazole, Dexlansoprazole, Rabeprazole, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Rifabutin, Cimetidine, Esomeprazole, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67759, "ingredient1": "Insulin aspart (aspart)", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Concomitant use of insulin and other antidiabetic agents with clarithromycin may cause significant hypoglycemia. There have been rare reports of hypoglycemia in patients treated with clarithromycin, some of whom were taking oral hypoglycemic agents or insulin. The exact mechanism of interaction has not been established. With certain hypoglycemic drugs such as nateglinide, pioglitazone, repaglinide and rosiglitazone, inhibition of the CYP450 3A4 isoenzyme by clarithromycin may be involved.", "source": "DDInter", "management_text": "Caution is advised if clarithromycin is prescribed to patients receiving antidiabetic agents. Patients should be advised to regularly monitor their blood sugar and counseled on how to recognize and treat hypoglycemia, which may include symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if clarithromycin is prescribed to patients receiving antidiabetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67846/", "reference_text": "[1] Otsuka SH \"Severe hypoglycemia from helicobacter pylori triple-drug therapy and insulin detemir drug interaction.\" Pharmacotherapy 33 (2013): e45-9[2] Niemi M, Neuvonen PJ, Kivisto KT \"The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide.\" Clin Pharmacol Ther 70 (2001): 58-65[3] Schelleman H, Bilker WB, Brensinger CM, Wan F, Hennessy S \"Anti-infectives and the risk of severe hypoglycemia in users of glipizide or glyburide.\" Clin Pharmacol Ther 88 (2010): 214-22[4] Khamaisi M, Leitersdorf E \"Severe hypoglycemia from clarithromycin-repaglinide drug interaction.\" Pharmacotherapy 28 (2008): 682-4[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Leiba A, Leibowitz A, Grossman E \"An unusual case of hypoglycemia in a diabetic patient.\" Ann Emerg Med 44 (2004): 427-8[7] Bussing R, Gende A \"Severe hypoglycemia from clarithromycin-sulfonylurea drug interaction.\" Diabetes Care 25 (2002): 1659-61[8] \"Product Information. Biaxin (clarithromycin).\" Abbott Pharmaceutical, Abbott Park, IL.[9] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[10] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[11] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[12] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[13] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[14] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[15] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[16] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[17] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[18] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[19] Cheng KL, Nafziger AN, Peloquin CA, Amsden GW \"Effect of grapefruit juice on clarithromycin pharmacokinetics.\" Antimicrob Agents Chemother 42 (1998): 927-9", "alternatives_a": "Tinidazole, Pantoprazole, Dexlansoprazole, Rabeprazole, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Rifabutin, Cimetidine, Esomeprazole, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67760, "ingredient1": "Insulin aspart (aspart protamine)", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Concomitant use of insulin and other antidiabetic agents with clarithromycin may cause significant hypoglycemia. There have been rare reports of hypoglycemia in patients treated with clarithromycin, some of whom were taking oral hypoglycemic agents or insulin. The exact mechanism of interaction has not been established. With certain hypoglycemic drugs such as nateglinide, pioglitazone, repaglinide and rosiglitazone, inhibition of the CYP450 3A4 isoenzyme by clarithromycin may be involved.", "source": "DDInter", "management_text": "Caution is advised if clarithromycin is prescribed to patients receiving antidiabetic agents. Patients should be advised to regularly monitor their blood sugar and counseled on how to recognize and treat hypoglycemia, which may include symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if clarithromycin is prescribed to patients receiving antidiabetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67847/", "reference_text": "[1] Otsuka SH \"Severe hypoglycemia from helicobacter pylori triple-drug therapy and insulin detemir drug interaction.\" Pharmacotherapy 33 (2013): e45-9[2] Niemi M, Neuvonen PJ, Kivisto KT \"The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide.\" Clin Pharmacol Ther 70 (2001): 58-65[3] Schelleman H, Bilker WB, Brensinger CM, Wan F, Hennessy S \"Anti-infectives and the risk of severe hypoglycemia in users of glipizide or glyburide.\" Clin Pharmacol Ther 88 (2010): 214-22[4] Khamaisi M, Leitersdorf E \"Severe hypoglycemia from clarithromycin-repaglinide drug interaction.\" Pharmacotherapy 28 (2008): 682-4[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Leiba A, Leibowitz A, Grossman E \"An unusual case of hypoglycemia in a diabetic patient.\" Ann Emerg Med 44 (2004): 427-8[7] Bussing R, Gende A \"Severe hypoglycemia from clarithromycin-sulfonylurea drug interaction.\" Diabetes Care 25 (2002): 1659-61[8] \"Product Information. Biaxin (clarithromycin).\" Abbott Pharmaceutical, Abbott Park, IL.[9] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[10] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[11] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[12] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[13] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[14] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[15] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[16] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[17] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[18] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[19] Cheng KL, Nafziger AN, Peloquin CA, Amsden GW \"Effect of grapefruit juice on clarithromycin pharmacokinetics.\" Antimicrob Agents Chemother 42 (1998): 927-9", "alternatives_a": "Tinidazole, Pantoprazole, Dexlansoprazole, Rabeprazole, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Rifabutin, Cimetidine, Esomeprazole, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67761, "ingredient1": "Insulin degludec", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Concomitant use of insulin and other antidiabetic agents with clarithromycin may cause significant hypoglycemia. There have been rare reports of hypoglycemia in patients treated with clarithromycin, some of whom were taking oral hypoglycemic agents or insulin. The exact mechanism of interaction has not been established. With certain hypoglycemic drugs such as nateglinide, pioglitazone, repaglinide and rosiglitazone, inhibition of the CYP450 3A4 isoenzyme by clarithromycin may be involved.", "source": "DDInter", "management_text": "Caution is advised if clarithromycin is prescribed to patients receiving antidiabetic agents. Patients should be advised to regularly monitor their blood sugar and counseled on how to recognize and treat hypoglycemia, which may include symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if clarithromycin is prescribed to patients receiving antidiabetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67848/", "reference_text": "[1] Otsuka SH \"Severe hypoglycemia from helicobacter pylori triple-drug therapy and insulin detemir drug interaction.\" Pharmacotherapy 33 (2013): e45-9[2] Niemi M, Neuvonen PJ, Kivisto KT \"The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide.\" Clin Pharmacol Ther 70 (2001): 58-65[3] Schelleman H, Bilker WB, Brensinger CM, Wan F, Hennessy S \"Anti-infectives and the risk of severe hypoglycemia in users of glipizide or glyburide.\" Clin Pharmacol Ther 88 (2010): 214-22[4] Khamaisi M, Leitersdorf E \"Severe hypoglycemia from clarithromycin-repaglinide drug interaction.\" Pharmacotherapy 28 (2008): 682-4[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Leiba A, Leibowitz A, Grossman E \"An unusual case of hypoglycemia in a diabetic patient.\" Ann Emerg Med 44 (2004): 427-8[7] Bussing R, Gende A \"Severe hypoglycemia from clarithromycin-sulfonylurea drug interaction.\" Diabetes Care 25 (2002): 1659-61[8] \"Product Information. Biaxin (clarithromycin).\" Abbott Pharmaceutical, Abbott Park, IL.[9] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[10] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[11] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[12] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[13] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[14] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[15] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[16] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[17] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[18] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[19] Cheng KL, Nafziger AN, Peloquin CA, Amsden GW \"Effect of grapefruit juice on clarithromycin pharmacokinetics.\" Antimicrob Agents Chemother 42 (1998): 927-9", "alternatives_a": "Tinidazole, Pantoprazole, Dexlansoprazole, Rabeprazole, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Rifabutin, Cimetidine, Esomeprazole, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67762, "ingredient1": "Insulin detemir", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Concomitant use of insulin and other antidiabetic agents with clarithromycin may cause significant hypoglycemia. There have been rare reports of hypoglycemia in patients treated with clarithromycin, some of whom were taking oral hypoglycemic agents or insulin. The exact mechanism of interaction has not been established. With certain hypoglycemic drugs such as nateglinide, pioglitazone, repaglinide and rosiglitazone, inhibition of the CYP450 3A4 isoenzyme by clarithromycin may be involved.", "source": "DDInter", "management_text": "Caution is advised if clarithromycin is prescribed to patients receiving antidiabetic agents. Patients should be advised to regularly monitor their blood sugar and counseled on how to recognize and treat hypoglycemia, which may include symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if clarithromycin is prescribed to patients receiving antidiabetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67849/", "reference_text": "[1] Otsuka SH \"Severe hypoglycemia from helicobacter pylori triple-drug therapy and insulin detemir drug interaction.\" Pharmacotherapy 33 (2013): e45-9[2] Niemi M, Neuvonen PJ, Kivisto KT \"The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide.\" Clin Pharmacol Ther 70 (2001): 58-65[3] Schelleman H, Bilker WB, Brensinger CM, Wan F, Hennessy S \"Anti-infectives and the risk of severe hypoglycemia in users of glipizide or glyburide.\" Clin Pharmacol Ther 88 (2010): 214-22[4] Khamaisi M, Leitersdorf E \"Severe hypoglycemia from clarithromycin-repaglinide drug interaction.\" Pharmacotherapy 28 (2008): 682-4[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Leiba A, Leibowitz A, Grossman E \"An unusual case of hypoglycemia in a diabetic patient.\" Ann Emerg Med 44 (2004): 427-8[7] Bussing R, Gende A \"Severe hypoglycemia from clarithromycin-sulfonylurea drug interaction.\" Diabetes Care 25 (2002): 1659-61[8] \"Product Information. Biaxin (clarithromycin).\" Abbott Pharmaceutical, Abbott Park, IL.[9] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[10] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[11] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[12] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[13] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[14] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[15] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[16] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[17] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[18] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[19] Cheng KL, Nafziger AN, Peloquin CA, Amsden GW \"Effect of grapefruit juice on clarithromycin pharmacokinetics.\" Antimicrob Agents Chemother 42 (1998): 927-9", "alternatives_a": "Tinidazole, Pantoprazole, Dexlansoprazole, Rabeprazole, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Rifabutin, Cimetidine, Esomeprazole, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67763, "ingredient1": "Insulin glargine", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Concomitant use of insulin and other antidiabetic agents with clarithromycin may cause significant hypoglycemia. There have been rare reports of hypoglycemia in patients treated with clarithromycin, some of whom were taking oral hypoglycemic agents or insulin. The exact mechanism of interaction has not been established. With certain hypoglycemic drugs such as nateglinide, pioglitazone, repaglinide and rosiglitazone, inhibition of the CYP450 3A4 isoenzyme by clarithromycin may be involved.", "source": "DDInter", "management_text": "Caution is advised if clarithromycin is prescribed to patients receiving antidiabetic agents. Patients should be advised to regularly monitor their blood sugar and counseled on how to recognize and treat hypoglycemia, which may include symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if clarithromycin is prescribed to patients receiving antidiabetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67850/", "reference_text": "[1] Otsuka SH \"Severe hypoglycemia from helicobacter pylori triple-drug therapy and insulin detemir drug interaction.\" Pharmacotherapy 33 (2013): e45-9[2] Niemi M, Neuvonen PJ, Kivisto KT \"The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide.\" Clin Pharmacol Ther 70 (2001): 58-65[3] Schelleman H, Bilker WB, Brensinger CM, Wan F, Hennessy S \"Anti-infectives and the risk of severe hypoglycemia in users of glipizide or glyburide.\" Clin Pharmacol Ther 88 (2010): 214-22[4] Khamaisi M, Leitersdorf E \"Severe hypoglycemia from clarithromycin-repaglinide drug interaction.\" Pharmacotherapy 28 (2008): 682-4[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Leiba A, Leibowitz A, Grossman E \"An unusual case of hypoglycemia in a diabetic patient.\" Ann Emerg Med 44 (2004): 427-8[7] Bussing R, Gende A \"Severe hypoglycemia from clarithromycin-sulfonylurea drug interaction.\" Diabetes Care 25 (2002): 1659-61[8] \"Product Information. Biaxin (clarithromycin).\" Abbott Pharmaceutical, Abbott Park, IL.[9] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[10] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[11] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[12] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[13] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[14] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[15] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[16] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[17] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[18] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[19] Cheng KL, Nafziger AN, Peloquin CA, Amsden GW \"Effect of grapefruit juice on clarithromycin pharmacokinetics.\" Antimicrob Agents Chemother 42 (1998): 927-9", "alternatives_a": "Tinidazole, Pantoprazole, Dexlansoprazole, Rabeprazole, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Rifabutin, Cimetidine, Esomeprazole, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67764, "ingredient1": "Insulin glulisine", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Concomitant use of insulin and other antidiabetic agents with clarithromycin may cause significant hypoglycemia. There have been rare reports of hypoglycemia in patients treated with clarithromycin, some of whom were taking oral hypoglycemic agents or insulin. The exact mechanism of interaction has not been established. With certain hypoglycemic drugs such as nateglinide, pioglitazone, repaglinide and rosiglitazone, inhibition of the CYP450 3A4 isoenzyme by clarithromycin may be involved.", "source": "DDInter", "management_text": "Caution is advised if clarithromycin is prescribed to patients receiving antidiabetic agents. Patients should be advised to regularly monitor their blood sugar and counseled on how to recognize and treat hypoglycemia, which may include symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if clarithromycin is prescribed to patients receiving antidiabetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67851/", "reference_text": "[1] Otsuka SH \"Severe hypoglycemia from helicobacter pylori triple-drug therapy and insulin detemir drug interaction.\" Pharmacotherapy 33 (2013): e45-9[2] Niemi M, Neuvonen PJ, Kivisto KT \"The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide.\" Clin Pharmacol Ther 70 (2001): 58-65[3] Schelleman H, Bilker WB, Brensinger CM, Wan F, Hennessy S \"Anti-infectives and the risk of severe hypoglycemia in users of glipizide or glyburide.\" Clin Pharmacol Ther 88 (2010): 214-22[4] Khamaisi M, Leitersdorf E \"Severe hypoglycemia from clarithromycin-repaglinide drug interaction.\" Pharmacotherapy 28 (2008): 682-4[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Leiba A, Leibowitz A, Grossman E \"An unusual case of hypoglycemia in a diabetic patient.\" Ann Emerg Med 44 (2004): 427-8[7] Bussing R, Gende A \"Severe hypoglycemia from clarithromycin-sulfonylurea drug interaction.\" Diabetes Care 25 (2002): 1659-61[8] \"Product Information. Biaxin (clarithromycin).\" Abbott Pharmaceutical, Abbott Park, IL.[9] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[10] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[11] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[12] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[13] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[14] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[15] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[16] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[17] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[18] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[19] Cheng KL, Nafziger AN, Peloquin CA, Amsden GW \"Effect of grapefruit juice on clarithromycin pharmacokinetics.\" Antimicrob Agents Chemother 42 (1998): 927-9", "alternatives_a": "Tinidazole, Pantoprazole, Dexlansoprazole, Rabeprazole, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Rifabutin, Cimetidine, Esomeprazole, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67765, "ingredient1": "Insulin human (inhalation, rapid acting)", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Concomitant use of insulin and other antidiabetic agents with clarithromycin may cause significant hypoglycemia. There have been rare reports of hypoglycemia in patients treated with clarithromycin, some of whom were taking oral hypoglycemic agents or insulin. The exact mechanism of interaction has not been established. With certain hypoglycemic drugs such as nateglinide, pioglitazone, repaglinide and rosiglitazone, inhibition of the CYP450 3A4 isoenzyme by clarithromycin may be involved.", "source": "DDInter", "management_text": "Caution is advised if clarithromycin is prescribed to patients receiving antidiabetic agents. Patients should be advised to regularly monitor their blood sugar and counseled on how to recognize and treat hypoglycemia, which may include symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if clarithromycin is prescribed to patients receiving antidiabetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67852/", "reference_text": "[1] Otsuka SH \"Severe hypoglycemia from helicobacter pylori triple-drug therapy and insulin detemir drug interaction.\" Pharmacotherapy 33 (2013): e45-9[2] Niemi M, Neuvonen PJ, Kivisto KT \"The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide.\" Clin Pharmacol Ther 70 (2001): 58-65[3] Schelleman H, Bilker WB, Brensinger CM, Wan F, Hennessy S \"Anti-infectives and the risk of severe hypoglycemia in users of glipizide or glyburide.\" Clin Pharmacol Ther 88 (2010): 214-22[4] Khamaisi M, Leitersdorf E \"Severe hypoglycemia from clarithromycin-repaglinide drug interaction.\" Pharmacotherapy 28 (2008): 682-4[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Leiba A, Leibowitz A, Grossman E \"An unusual case of hypoglycemia in a diabetic patient.\" Ann Emerg Med 44 (2004): 427-8[7] Bussing R, Gende A \"Severe hypoglycemia from clarithromycin-sulfonylurea drug interaction.\" Diabetes Care 25 (2002): 1659-61[8] \"Product Information. Biaxin (clarithromycin).\" Abbott Pharmaceutical, Abbott Park, IL.[9] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[10] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[11] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[12] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[13] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[14] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[15] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[16] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[17] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[18] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[19] Cheng KL, Nafziger AN, Peloquin CA, Amsden GW \"Effect of grapefruit juice on clarithromycin pharmacokinetics.\" Antimicrob Agents Chemother 42 (1998): 927-9", "alternatives_a": "Tinidazole, Pantoprazole, Dexlansoprazole, Rabeprazole, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Rifabutin, Cimetidine, Esomeprazole, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67766, "ingredient1": "Insulin human (isophane)", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Concomitant use of insulin and other antidiabetic agents with clarithromycin may cause significant hypoglycemia. There have been rare reports of hypoglycemia in patients treated with clarithromycin, some of whom were taking oral hypoglycemic agents or insulin. The exact mechanism of interaction has not been established. With certain hypoglycemic drugs such as nateglinide, pioglitazone, repaglinide and rosiglitazone, inhibition of the CYP450 3A4 isoenzyme by clarithromycin may be involved.", "source": "DDInter", "management_text": "Caution is advised if clarithromycin is prescribed to patients receiving antidiabetic agents. Patients should be advised to regularly monitor their blood sugar and counseled on how to recognize and treat hypoglycemia, which may include symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if clarithromycin is prescribed to patients receiving antidiabetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67853/", "reference_text": "[1] Otsuka SH \"Severe hypoglycemia from helicobacter pylori triple-drug therapy and insulin detemir drug interaction.\" Pharmacotherapy 33 (2013): e45-9[2] Niemi M, Neuvonen PJ, Kivisto KT \"The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide.\" Clin Pharmacol Ther 70 (2001): 58-65[3] Schelleman H, Bilker WB, Brensinger CM, Wan F, Hennessy S \"Anti-infectives and the risk of severe hypoglycemia in users of glipizide or glyburide.\" Clin Pharmacol Ther 88 (2010): 214-22[4] Khamaisi M, Leitersdorf E \"Severe hypoglycemia from clarithromycin-repaglinide drug interaction.\" Pharmacotherapy 28 (2008): 682-4[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Leiba A, Leibowitz A, Grossman E \"An unusual case of hypoglycemia in a diabetic patient.\" Ann Emerg Med 44 (2004): 427-8[7] Bussing R, Gende A \"Severe hypoglycemia from clarithromycin-sulfonylurea drug interaction.\" Diabetes Care 25 (2002): 1659-61[8] \"Product Information. Biaxin (clarithromycin).\" Abbott Pharmaceutical, Abbott Park, IL.[9] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[10] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[11] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[12] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[13] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[14] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[15] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[16] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[17] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[18] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[19] Cheng KL, Nafziger AN, Peloquin CA, Amsden GW \"Effect of grapefruit juice on clarithromycin pharmacokinetics.\" Antimicrob Agents Chemother 42 (1998): 927-9", "alternatives_a": "Tinidazole, Pantoprazole, Dexlansoprazole, Rabeprazole, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Rifabutin, Cimetidine, Esomeprazole, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67767, "ingredient1": "Insulin lispro", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Concomitant use of insulin and other antidiabetic agents with clarithromycin may cause significant hypoglycemia. There have been rare reports of hypoglycemia in patients treated with clarithromycin, some of whom were taking oral hypoglycemic agents or insulin. The exact mechanism of interaction has not been established. With certain hypoglycemic drugs such as nateglinide, pioglitazone, repaglinide and rosiglitazone, inhibition of the CYP450 3A4 isoenzyme by clarithromycin may be involved.", "source": "DDInter", "management_text": "Caution is advised if clarithromycin is prescribed to patients receiving antidiabetic agents. Patients should be advised to regularly monitor their blood sugar and counseled on how to recognize and treat hypoglycemia, which may include symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if clarithromycin is prescribed to patients receiving antidiabetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67854/", "reference_text": "[1] Otsuka SH \"Severe hypoglycemia from helicobacter pylori triple-drug therapy and insulin detemir drug interaction.\" Pharmacotherapy 33 (2013): e45-9[2] Niemi M, Neuvonen PJ, Kivisto KT \"The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide.\" Clin Pharmacol Ther 70 (2001): 58-65[3] Schelleman H, Bilker WB, Brensinger CM, Wan F, Hennessy S \"Anti-infectives and the risk of severe hypoglycemia in users of glipizide or glyburide.\" Clin Pharmacol Ther 88 (2010): 214-22[4] Khamaisi M, Leitersdorf E \"Severe hypoglycemia from clarithromycin-repaglinide drug interaction.\" Pharmacotherapy 28 (2008): 682-4[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Leiba A, Leibowitz A, Grossman E \"An unusual case of hypoglycemia in a diabetic patient.\" Ann Emerg Med 44 (2004): 427-8[7] Bussing R, Gende A \"Severe hypoglycemia from clarithromycin-sulfonylurea drug interaction.\" Diabetes Care 25 (2002): 1659-61[8] \"Product Information. Biaxin (clarithromycin).\" Abbott Pharmaceutical, Abbott Park, IL.[9] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[10] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[11] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[12] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[13] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[14] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[15] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[16] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[17] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[18] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[19] Cheng KL, Nafziger AN, Peloquin CA, Amsden GW \"Effect of grapefruit juice on clarithromycin pharmacokinetics.\" Antimicrob Agents Chemother 42 (1998): 927-9", "alternatives_a": "Tinidazole, Pantoprazole, Dexlansoprazole, Rabeprazole, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Rifabutin, Cimetidine, Esomeprazole, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67768, "ingredient1": "Insulin lispro (protamine)", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Concomitant use of insulin and other antidiabetic agents with clarithromycin may cause significant hypoglycemia. There have been rare reports of hypoglycemia in patients treated with clarithromycin, some of whom were taking oral hypoglycemic agents or insulin. The exact mechanism of interaction has not been established. With certain hypoglycemic drugs such as nateglinide, pioglitazone, repaglinide and rosiglitazone, inhibition of the CYP450 3A4 isoenzyme by clarithromycin may be involved.", "source": "DDInter", "management_text": "Caution is advised if clarithromycin is prescribed to patients receiving antidiabetic agents. Patients should be advised to regularly monitor their blood sugar and counseled on how to recognize and treat hypoglycemia, which may include symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if clarithromycin is prescribed to patients receiving antidiabetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67855/", "reference_text": "[1] Otsuka SH \"Severe hypoglycemia from helicobacter pylori triple-drug therapy and insulin detemir drug interaction.\" Pharmacotherapy 33 (2013): e45-9[2] Niemi M, Neuvonen PJ, Kivisto KT \"The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide.\" Clin Pharmacol Ther 70 (2001): 58-65[3] Schelleman H, Bilker WB, Brensinger CM, Wan F, Hennessy S \"Anti-infectives and the risk of severe hypoglycemia in users of glipizide or glyburide.\" Clin Pharmacol Ther 88 (2010): 214-22[4] Khamaisi M, Leitersdorf E \"Severe hypoglycemia from clarithromycin-repaglinide drug interaction.\" Pharmacotherapy 28 (2008): 682-4[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Leiba A, Leibowitz A, Grossman E \"An unusual case of hypoglycemia in a diabetic patient.\" Ann Emerg Med 44 (2004): 427-8[7] Bussing R, Gende A \"Severe hypoglycemia from clarithromycin-sulfonylurea drug interaction.\" Diabetes Care 25 (2002): 1659-61[8] \"Product Information. Biaxin (clarithromycin).\" Abbott Pharmaceutical, Abbott Park, IL.[9] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[10] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[11] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[12] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[13] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[14] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[15] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[16] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[17] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[18] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[19] Cheng KL, Nafziger AN, Peloquin CA, Amsden GW \"Effect of grapefruit juice on clarithromycin pharmacokinetics.\" Antimicrob Agents Chemother 42 (1998): 927-9", "alternatives_a": "Tinidazole, Pantoprazole, Dexlansoprazole, Rabeprazole, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Rifabutin, Cimetidine, Esomeprazole, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67769, "ingredient1": "Insulin human (regular)", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Concomitant use of insulin and other antidiabetic agents with clarithromycin may cause significant hypoglycemia. There have been rare reports of hypoglycemia in patients treated with clarithromycin, some of whom were taking oral hypoglycemic agents or insulin. The exact mechanism of interaction has not been established. With certain hypoglycemic drugs such as nateglinide, pioglitazone, repaglinide and rosiglitazone, inhibition of the CYP450 3A4 isoenzyme by clarithromycin may be involved.", "source": "DDInter", "management_text": "Caution is advised if clarithromycin is prescribed to patients receiving antidiabetic agents. Patients should be advised to regularly monitor their blood sugar and counseled on how to recognize and treat hypoglycemia, which may include symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if clarithromycin is prescribed to patients receiving antidiabetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67856/", "reference_text": "[1] Otsuka SH \"Severe hypoglycemia from helicobacter pylori triple-drug therapy and insulin detemir drug interaction.\" Pharmacotherapy 33 (2013): e45-9[2] Niemi M, Neuvonen PJ, Kivisto KT \"The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide.\" Clin Pharmacol Ther 70 (2001): 58-65[3] Schelleman H, Bilker WB, Brensinger CM, Wan F, Hennessy S \"Anti-infectives and the risk of severe hypoglycemia in users of glipizide or glyburide.\" Clin Pharmacol Ther 88 (2010): 214-22[4] Khamaisi M, Leitersdorf E \"Severe hypoglycemia from clarithromycin-repaglinide drug interaction.\" Pharmacotherapy 28 (2008): 682-4[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Leiba A, Leibowitz A, Grossman E \"An unusual case of hypoglycemia in a diabetic patient.\" Ann Emerg Med 44 (2004): 427-8[7] Bussing R, Gende A \"Severe hypoglycemia from clarithromycin-sulfonylurea drug interaction.\" Diabetes Care 25 (2002): 1659-61[8] \"Product Information. Biaxin (clarithromycin).\" Abbott Pharmaceutical, Abbott Park, IL.[9] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[10] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[11] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[12] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[13] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[14] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[15] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[16] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[17] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[18] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[19] Cheng KL, Nafziger AN, Peloquin CA, Amsden GW \"Effect of grapefruit juice on clarithromycin pharmacokinetics.\" Antimicrob Agents Chemother 42 (1998): 927-9", "alternatives_a": "Tinidazole, Pantoprazole, Dexlansoprazole, Rabeprazole, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Rifabutin, Cimetidine, Esomeprazole, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67770, "ingredient1": "Insulin human (zinc)", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Concomitant use of insulin and other antidiabetic agents with clarithromycin may cause significant hypoglycemia. There have been rare reports of hypoglycemia in patients treated with clarithromycin, some of whom were taking oral hypoglycemic agents or insulin. The exact mechanism of interaction has not been established. With certain hypoglycemic drugs such as nateglinide, pioglitazone, repaglinide and rosiglitazone, inhibition of the CYP450 3A4 isoenzyme by clarithromycin may be involved.", "source": "DDInter", "management_text": "Caution is advised if clarithromycin is prescribed to patients receiving antidiabetic agents. Patients should be advised to regularly monitor their blood sugar and counseled on how to recognize and treat hypoglycemia, which may include symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if clarithromycin is prescribed to patients receiving antidiabetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67857/", "reference_text": "[1] Otsuka SH \"Severe hypoglycemia from helicobacter pylori triple-drug therapy and insulin detemir drug interaction.\" Pharmacotherapy 33 (2013): e45-9[2] Niemi M, Neuvonen PJ, Kivisto KT \"The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide.\" Clin Pharmacol Ther 70 (2001): 58-65[3] Schelleman H, Bilker WB, Brensinger CM, Wan F, Hennessy S \"Anti-infectives and the risk of severe hypoglycemia in users of glipizide or glyburide.\" Clin Pharmacol Ther 88 (2010): 214-22[4] Khamaisi M, Leitersdorf E \"Severe hypoglycemia from clarithromycin-repaglinide drug interaction.\" Pharmacotherapy 28 (2008): 682-4[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Leiba A, Leibowitz A, Grossman E \"An unusual case of hypoglycemia in a diabetic patient.\" Ann Emerg Med 44 (2004): 427-8[7] Bussing R, Gende A \"Severe hypoglycemia from clarithromycin-sulfonylurea drug interaction.\" Diabetes Care 25 (2002): 1659-61[8] \"Product Information. Biaxin (clarithromycin).\" Abbott Pharmaceutical, Abbott Park, IL.[9] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[10] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[11] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[12] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[13] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[14] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[15] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[16] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[17] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[18] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[19] Cheng KL, Nafziger AN, Peloquin CA, Amsden GW \"Effect of grapefruit juice on clarithromycin pharmacokinetics.\" Antimicrob Agents Chemother 42 (1998): 927-9", "alternatives_a": "Tinidazole, Pantoprazole, Dexlansoprazole, Rabeprazole, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Rifabutin, Cimetidine, Esomeprazole, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67771, "ingredient1": "Insulin human (zinc extended)", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Concomitant use of insulin and other antidiabetic agents with clarithromycin may cause significant hypoglycemia. There have been rare reports of hypoglycemia in patients treated with clarithromycin, some of whom were taking oral hypoglycemic agents or insulin. The exact mechanism of interaction has not been established. With certain hypoglycemic drugs such as nateglinide, pioglitazone, repaglinide and rosiglitazone, inhibition of the CYP450 3A4 isoenzyme by clarithromycin may be involved.", "source": "DDInter", "management_text": "Caution is advised if clarithromycin is prescribed to patients receiving antidiabetic agents. Patients should be advised to regularly monitor their blood sugar and counseled on how to recognize and treat hypoglycemia, which may include symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if clarithromycin is prescribed to patients receiving antidiabetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67858/", "reference_text": "[1] Otsuka SH \"Severe hypoglycemia from helicobacter pylori triple-drug therapy and insulin detemir drug interaction.\" Pharmacotherapy 33 (2013): e45-9[2] Niemi M, Neuvonen PJ, Kivisto KT \"The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide.\" Clin Pharmacol Ther 70 (2001): 58-65[3] Schelleman H, Bilker WB, Brensinger CM, Wan F, Hennessy S \"Anti-infectives and the risk of severe hypoglycemia in users of glipizide or glyburide.\" Clin Pharmacol Ther 88 (2010): 214-22[4] Khamaisi M, Leitersdorf E \"Severe hypoglycemia from clarithromycin-repaglinide drug interaction.\" Pharmacotherapy 28 (2008): 682-4[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Leiba A, Leibowitz A, Grossman E \"An unusual case of hypoglycemia in a diabetic patient.\" Ann Emerg Med 44 (2004): 427-8[7] Bussing R, Gende A \"Severe hypoglycemia from clarithromycin-sulfonylurea drug interaction.\" Diabetes Care 25 (2002): 1659-61[8] \"Product Information. Biaxin (clarithromycin).\" Abbott Pharmaceutical, Abbott Park, IL.[9] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[10] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[11] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[12] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[13] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[14] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[15] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[16] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[17] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[18] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[19] Cheng KL, Nafziger AN, Peloquin CA, Amsden GW \"Effect of grapefruit juice on clarithromycin pharmacokinetics.\" Antimicrob Agents Chemother 42 (1998): 927-9", "alternatives_a": "Tinidazole, Pantoprazole, Dexlansoprazole, Rabeprazole, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Rifabutin, Cimetidine, Esomeprazole, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67772, "ingredient1": "Interferon beta-1a", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Coadministration of beta interferons with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Use of beta interferons has been associated with rare cases of liver injury, including autoimmune hepatitis and severe liver damage leading to hepatic failure, some of which required transplantation.", "source": "DDInter", "management_text": "The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; other interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.", "mechanism_text": "Synergism", "recommendation": "The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67859/", "reference_text": "[1] \"Product Information. Plegridy (peginterferon beta-1a).\" Biogen Idec Inc, Cambridge, MA.[2] \"Product Information. Betaseron (interferon beta-1b).\" Berlex, Richmond, CA.[3] \"Product Information. Rebif (interferon beta-1a).\" Serono Laboratories Inc, Norwell, MA.[4] \"Product Information. Avonex (interferon beta-1a).\" Biogen, Cambridge, MA.", "alternatives_a": "Interferon alfa-n1, Oprelvekin, Sipuleucel-T, Elapegademase, Peginterferon alfa-2a, Ropeginterferon alfa-2b, Interferon alfacon-1, Sargramostim, Histamine, Aldesleukin, Pegademase, More", "alternatives_b": "Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Sucralfate, More", "updated_at": 1767369485}, {"id": 67773, "ingredient1": "Interferon beta-1b", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Coadministration of beta interferons with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Use of beta interferons has been associated with rare cases of liver injury, including autoimmune hepatitis and severe liver damage leading to hepatic failure, some of which required transplantation.", "source": "DDInter", "management_text": "The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; other interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.", "mechanism_text": "Synergism", "recommendation": "The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67860/", "reference_text": "[1] \"Product Information. Plegridy (peginterferon beta-1a).\" Biogen Idec Inc, Cambridge, MA.[2] \"Product Information. Betaseron (interferon beta-1b).\" Berlex, Richmond, CA.[3] \"Product Information. Rebif (interferon beta-1a).\" Serono Laboratories Inc, Norwell, MA.[4] \"Product Information. Avonex (interferon beta-1a).\" Biogen, Cambridge, MA.", "alternatives_a": "Interferon alfa-n1, Oprelvekin, Sipuleucel-T, Elapegademase, Peginterferon alfa-2a, Ropeginterferon alfa-2b, Interferon alfacon-1, Sargramostim, Histamine, Aldesleukin, Pegademase, More", "alternatives_b": "Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Sucralfate, More", "updated_at": 1767369485}, {"id": 67774, "ingredient1": "Irinotecan", "ingredient2": "Clarithromycin", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of irinotecan and its active metabolite, SN-38. CYP450 3A4 is the isoenzyme responsible for the metabolic conversion of irinotecan to its inactive metabolite, APC. Inhibition of APC formation results in more irinotecan metabolism to SN-38, an active and toxic metabolite. High plasma levels of irinotecan and SN-38 may increase the risk of potentially fatal toxicities such as severe diarrhea, neutropenia, sepsis, and thromboembolism.", "source": "DDInter", "management_text": "Concomitant use of irinotecan with potent CYP450 3A4 inhibitors should generally be avoided. Potent CYP450 3A4 inhibitors should be discontinued for at least one week before initiation of treatment with irinotecan.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of irinotecan with potent CYP450 3A4 inhibitors should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67861/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Phansalker S, Desai AA, Bell D, et al \"High-priority drug-drug interactions for use in electronic health records.\" J Am Med Inform Assoc 19 (2012): 735-43[3] Corona G, Vaccher E, Sandron S, et al. \"Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma.\" Clin Pharmacol Ther 83 (2008): 601-6[4] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[7] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"", "alternatives_a": "Topotecan, Teniposide", "alternatives_b": "Tinidazole, Tetracycline, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Nizatidine, Esomeprazole, Vonoprazan, Amoxicillin, Lincomycin, Azithromycin, Dirithromycin", "updated_at": 1767369485}, {"id": 67775, "ingredient1": "Irinotecan (liposomal)", "ingredient2": "Clarithromycin", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of irinotecan and its active metabolite, SN-38. CYP450 3A4 is the isoenzyme responsible for the metabolic conversion of irinotecan to its inactive metabolite, APC. Inhibition of APC formation results in more irinotecan metabolism to SN-38, an active and toxic metabolite. High plasma levels of irinotecan and SN-38 may increase the risk of potentially fatal toxicities such as severe diarrhea, neutropenia, sepsis, and thromboembolism.", "source": "DDInter", "management_text": "Concomitant use of irinotecan with potent CYP450 3A4 inhibitors should generally be avoided. Potent CYP450 3A4 inhibitors should be discontinued for at least one week before initiation of treatment with irinotecan.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of irinotecan with potent CYP450 3A4 inhibitors should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67862/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Phansalker S, Desai AA, Bell D, et al \"High-priority drug-drug interactions for use in electronic health records.\" J Am Med Inform Assoc 19 (2012): 735-43[3] Corona G, Vaccher E, Sandron S, et al. \"Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma.\" Clin Pharmacol Ther 83 (2008): 601-6[4] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn, Kalamazoo, MI.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Onivyde (irinotecan liposomal).\" Merrimack Pharmaceuticals, Cambridge, MA.[7] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"", "alternatives_a": "Topotecan, Teniposide", "alternatives_b": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, More", "updated_at": 1767369485}, {"id": 67776, "ingredient1": "Isavuconazonium", "ingredient2": "Clarithromycin", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of isavuconazole, which is primarily metabolized by CYP450 3A4 and 3A5 and subsequently by uridine diphosphate glucuronosyltransferases (UGT).", "source": "DDInter", "management_text": "Concomitant use of isavuconazonium sulfate with potent CYP450 3A4 inhibitors is considered contraindicated. Ritonavir given at low dosages as a pharmacokinetic booster may be used with caution, but is contraindicated at high dosages (e.g., 400 mg every 12 hours).", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of isavuconazonium sulfate with potent CYP450 3A4 inhibitors is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67863/", "reference_text": "[1] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc, Deerfield, IL.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[3] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Pantoprazole, Levofloxacin, Tetracycline, Rabeprazole, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Nizatidine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67777, "ingredient1": "Isoetharine", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.", "source": "DDInter", "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67864/", "reference_text": "[1] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990): 575-9[6] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003): 1817-24[8] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998): 145-7[11] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990): 1396-9[16] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.[17] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006): 582-90[19] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[20] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[21] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001): 45-51[26] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986): 619-20", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Rifabutin, Cimetidine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67778, "ingredient1": "Isoprenaline", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.", "source": "DDInter", "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67865/", "reference_text": "[1] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990): 575-9[6] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003): 1817-24[8] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998): 145-7[11] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990): 1396-9[16] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.[17] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006): 582-90[19] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[20] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[21] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001): 45-51[26] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986): 619-20", "alternatives_a": "Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More", "alternatives_b": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Rifabutin, Cimetidine, More", "updated_at": 1767369485}, {"id": 67779, "ingredient1": "Isradipine", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Coadministration of isradipine and erythromycin or clarithromycin may increase isradipine serum concentrations. The presumed mechanism is inhibition of CYP450 3A4 metabolism by the macrolide antibiotics.", "source": "DDInter", "management_text": "When macrolide antibiotics are coadministered with isradipine, patients should be monitored for adverse effects such as flushing, ankle edema, or palpitations.", "mechanism_text": "Metabolism", "recommendation": "When macrolide antibiotics are coadministered with isradipine, patients should be monitored for adverse effects such as flushing, ankle edema, or palpitations.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67866/", "reference_text": "[1] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Welling PG, Huang H, Hewitt PF, Lyons LL \"Bioavailability of erythromycin stearate: influence of food and fluid volume.\" J Pharm Sci 67 (1978): 764-6[4] Welling PG \"Influence of food and diet on gastrointestinal drug absorption: a review.\" J Pharmacokinet Biopharm 5 (1977): 291-334[5] Randinitis EJ, Sedman AJ, Welling PG, Kinkel AW \"Effect of a high-fat meal on the bioavailability of a polymer-coated erythromycin particle tablet formulation.\" J Clin Pharmacol 29 (1989): 79-84[6] Coyne TC, Shum S, Chun AH, Jeansonne L, Shirkey HC \"Bioavailability of erythromycin ethylsuccinate in pediatric patients.\" J Clin Pharmacol 18 (1978): 194-202[7] Malmborg AS \"Effect of food on absorption of erythromycin. A study of two derivatives, the stearate and the base.\" J Antimicrob Chemother 5 (1979): 591-9[8] Welling PG, Elliott RL, Pitterle ME, et al \"Plasma levels following single and repeated doses of erythromycin estolate and erythromycin stearate.\" J Pharm Sci 68 (1979): 150-5[9] Kanazawa S, Ohkubo T, Sugawara K \"The effects of grapefruit juice on the pharmacokinetics of erythromycin.\" Eur J Clin Pharmacol 56 (2001): 799-803[10] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[13] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[14] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[15] \"Product Information. Procardia (nifedipine).\" Pfizer US Pharmaceuticals, New York, NY.[16] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[17] Edgar B, Bailey D, Bergstrand R, Johnsson G, Regardh CG \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics of felodipine--and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[18] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[19] \"Product Information. Plendil (felodipine).\" Merck & Co, Inc, West Point, PA.[20] Fuhr U, Muller-Peltzer H, Kern R, et al. \"Effects of grapefruit juice and smoking on verapamil concentrations in steady state.\" Eur J Clin Pharmacol 58 (2002): 45-53[21] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[22] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[23] \"Product Information. Sular (nisoldipine).\" Zeneca Pharmaceuticals, Wilmington, DE.[24] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[25] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[26] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[27] Ho PC, Ghose K, Saville D, Wanwimolruk S \"Effect of grapefruit juice on pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy volunteers.\" Eur J Clin Pharmacol 56 (2000): 693-8[28] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94", "alternatives_a": "Clevidipine, Nisoldipine, Nicardipine", "alternatives_b": "Tinidazole, Levofloxacin, Tetracycline, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Nizatidine, Esomeprazole, Vonoprazan, More", "updated_at": 1767369485}, {"id": 67780, "ingredient1": "Istradefylline", "ingredient2": "Clarithromycin", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations and risk of adverse effects of istradefylline, which is primarily metabolized by CYP450 3A4 and 1A1.", "source": "DDInter", "management_text": "The manufacturer suggests that the maximum dose of istradefylline when coadministered with potent CYP450 3A4 inhibitors be reduced to 20 mg once daily. Patients should be monitored for adverse effects including dyskinesia, impulse control issues, dizziness, constipation, nausea, hallucinations, and insomnia.", "mechanism_text": "Metabolism", "recommendation": "The manufacturer suggests that the maximum dose of istradefylline when coadministered with potent CYP450 3A4 inhibitors be reduced to 20 mg once daily.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67867/", "reference_text": "[1] \"Product Information. Nourianz (istradefylline).\" Kyowa Kirin, Inc, Bedminster, NJ.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[3] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[4] \"Product Information. Nourianz (istradefylline).\" Kyowa Kirin, Inc, Bedminster, NJ.", "alternatives_a": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67781, "ingredient1": "Itraconazole", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Coadministration of itraconazole and the macrolide antibiotics may result in elevated plasma concentrations of itraconazole. The mechanism is decreased clearance of itraconazole due to competitive inhibition of CYP450 3A4 enzymatic activity by the macrolide agents.", "source": "DDInter", "management_text": "Caution is advised if itraconazole must be used concomitantly with erythromycin or clarithromycin. Patients should be advised to notify their physician if they experience possible symptoms of itraconazole toxicity, such as nausea, vomiting, diarrhea, abdominal pain, or headache. Alternative macrolide antibiotics such as azithromycin or dirithromycin, which do not inhibit CYP450, may be appropriate.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if itraconazole must be used concomitantly with erythromycin or clarithromycin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67868/", "reference_text": "[1] Auclair B, Berning SE, Huitt GA, Peloquin CP \"Potential interaction between itraconazole and clarithromycin.\" Pharmacotherapy 19 (1999): 1439-44[2] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[3] \"Product Information. Sporanox oral solution (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[4] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[5] Van Peer A, Woestenborghs R, Heykants J, et al \"The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects.\" Eur J Clin Pharmacol 36 (1989): 423-6[6] Penzak SR, Gubbins PO, Gurley BJ, Wang PL, Saccente M \"Grapefruit juice decreases the systemic availability of itraconazole capsules in healthy volunteers.\" Ther Drug Monit 21 (1999): 304-9[7] Katz HI \"Drug interactions of the newer oral antifungal agents.\" Br J Dermatol 141 (1999): 26-32[8] Kawakami M, Suzuki K, Ishizuka T, Hidaka T, Matsuki Y, Nakamura H \"Effect of grapefruit juice on pharmacokinetics of itraconazole in healthy subjects.\" Int J Clin Pharmacol Ther 36 (1998): 306-8[9] Barone JA, Koh JG, Bierman RH, Colaizzi JL, Swanson KA, Gaffar MC, Moskovitz BL, Mechlinski W, Van de Velde V \"Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers.\" Antimicrob Agents Chemother 37 (1993): 778-84[10] Wishart JM \"The influence of food on the pharmacokinetics of itraconazole in patients with superficial fungal infection.\" J Am Acad Dermatol 17 (1987): 220-3[11] Zimmermann T, Yeates RA, Albrecht M, Laufen H, Wildfeuer A \"Influence of concomitant food intake on the gastrointestinal absorption of fluconazole and itraconazole in japanese subjects.\" Int J Clin Pharmacol Res 14 (1994): 87-93[12] Barone JA, Moskotitz BL, Guarnieri J, Hassell AE, Colaizzi JL, Bierman RH, Jessen L \"Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers.\" Pharmacotherapy 18 (1998): 295-301", "alternatives_a": "Flucytosine, Anidulafungin, Micafungin, Oteseconazole", "alternatives_b": "Tinidazole, Levofloxacin, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Amoxicillin, Lincomycin, Dirithromycin", "updated_at": 1767369485}, {"id": 67782, "ingredient1": "Ivabradine", "ingredient2": "Clarithromycin", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ivabradine, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of ivabradine with potent CYP450 3A4 inhibitors is considered contraindicated. Some authorities consider concomitant administration of ivabradine and itraconazole to be contraindicated during and for 2 weeks after treatment with itraconazole.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of ivabradine with potent CYP450 3A4 inhibitors is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67869/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[4] \"Product Information. Corlanor (ivabradine).\" Amgen USA, Thousand Oaks, CA.[5] \"Product Information. Corlanor (ivabradine).\" Amgen USA, Thousand Oaks, CA.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Esomeprazole, Amoxicillin, More", "alternatives_b": "Regadenoson, Alprostadil, Ubidecarenone, Nebivolol", "updated_at": 1767369485}, {"id": 67783, "ingredient1": "Ivacaftor", "ingredient2": "Clarithromycin", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ivacaftor, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "For ivacaftor -The ivacaftor dose should be reduced from 1 tablet or 1 packet of oral granules twice a day to 1 tablet or 1 packet of oral granules twice a week (i.e., every 3 to 4 days) during coadministration with potent CYP450 3A4 inhibitors. For example, a patient taking ivacaftor 150 mg tablet twice a day should reduce their ivacaftor dose to a 150 mg tablet twice a week and a patient taking ivacaftor 50 mg oral granule packet twice a day should reduce their ivacaftor dose to 50 mg oral granule packet twice a week, etc.", "mechanism_text": "Metabolism", "recommendation": "For ivacaftor -The ivacaftor dose should be reduced from 1 tablet or 1 packet of oral granules twice a day to 1 tablet or 1 packet of oral granules twice a week (i.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67870/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[3] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[6] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[7] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[8] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[9] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[10] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[11] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[12] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, More", "alternatives_b": "Nitric Oxide, Doxapram, Elexacaftor", "updated_at": 1767369485}, {"id": 67784, "ingredient1": "Ivermectin", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ivermectin and the risk of adverse effects. The proposed mechanism, based on in vitro data, is decreased clearance due to inhibition of CYP450 3A4, the primary isoenzyme responsible for the metabolic clearance of ivermectin.", "source": "DDInter", "management_text": "Caution is advised when ivermectin must be used concomitantly with potent CYP450 3A4 inhibitors. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever a potent CYP450 3A4 inhibitor is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when ivermectin must be used concomitantly with potent CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67871/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Zeng Z, Andrew NW, Arison BH, Luffer-Atlas D, Wang RW \"Identification of cytochrome P4503A4 as the major enzyme responsible for the metabolism of ivermectin by human liver microsomes.\" Xenobiotica 28 (1998): 313-21[3] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[4] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Thiabendazole, Levamisole, Pyrantel, Piperazine, Mebendazole, Albendazole, Minoxidil, Deoxycholic acid, Calcium gluconate, Magnesium sulfate, Glycopyrronium, More", "alternatives_b": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Rifabutin, More", "updated_at": 1767369485}, {"id": 67785, "ingredient1": "Clarithromycin", "ingredient2": "Ivosidenib", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ivosidenib, which is primarily metabolized by the isoenzyme. Coadministration with ivosidenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4, including many of the known potent inhibitors of the isoenzyme such as clarithromycin, conivaptan, delavirdine, idelalisib, itraconazole, ketoconazole, nefazodone, posaconazole, telithromycin, and all protease inhibitors. Ivosidenib is an inducer of CYP450 3A4 and induces its own metabolism following multiple dosing.", "source": "DDInter", "management_text": "Concomitant use of ivosidenib with potent CYP450 3A4 inhibitors, particularly those that are also substrates of CYP450 3A4, should generally be avoided. If coadministration is required, a reduction of the ivosidenib dosage to 250 mg once daily is recommended. Following discontinuation of the potent inhibitor for at least 5 half-lives, ivosidenib therapy should be returned to the recommended dosage of 500 mg once daily. Monitoring of electrocardiograms and electrolytes should be conducted regularly.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of ivosidenib with potent CYP450 3A4 inhibitors, particularly those that are also substrates of CYP450 3A4, should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67872/", "reference_text": "[1] \"Product Information. Tibsovo (ivosidenib).\" Agios Pharmaceuticals, Cambridge, MA.[2] \"Product Information. Tibsovo (ivosidenib).\" Agios Pharmaceuticals, Cambridge, MA.[3] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[4] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, More", "alternatives_b": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Mitotane, Niraparib, Porfimer sodium, More", "updated_at": 1767369485}, {"id": 67786, "ingredient1": "Clarithromycin", "ingredient2": "Ixabepilone", "severity": "Moderate", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ixabepilone, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of ixabepilone with potent CYP450 3A4 inhibitors should generally be avoided. If coadministration is necessary, a reduction of the ixabepilone dosage to 20 mg/m2 should be considered. Based on pharmacokinetic studies, this dosage is predicted to adjust the ixabepilone systemic exposure (AUC) to the range observed without inhibitors. However, clinical data are lacking. Following discontinuation of the potent CYP450 3A4 inhibitor, a washout period of approximately one week should be allowed before the ixabepilone dosage is adjusted upward to the indicated dosage.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of ixabepilone with potent CYP450 3A4 inhibitors should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67873/", "reference_text": "[1] \"Product Information. Ixempra (ixabepilone).\" Bristol-Myers Squibb, Princeton, NJ.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[3] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[4] \"Product Information. Ixempra (ixabepilone).\" Bristol-Myers Squibb, Princeton, NJ.", "alternatives_a": "Pantoprazole, Levofloxacin, Tetracycline, Rabeprazole, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Famotidine, Nizatidine, Esomeprazole, More", "alternatives_b": "Dactinomycin, Mitomycin, Valrubicin, Plicamycin", "updated_at": 1767369485}, {"id": 67787, "ingredient1": "Clarithromycin", "ingredient2": "Ketoconazole", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67874/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[16] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Lactic acid, Methazolamide, Trichlormethiazide, Probenecid, Tioconazole, Brinzolamide, Furazolidone, More", "alternatives_b": "Tinidazole, Misoprostol, Bismuth subcitrate potassium, Amoxicillin, Lincomycin, Troleandomycin, Dirithromycin", "updated_at": 1767369485}, {"id": 67788, "ingredient1": "Clarithromycin", "ingredient2": "Lactitol", "severity": "Moderate", "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67875/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Schaefer DC, Cheskin LJ \"Constipation in the elderly.\" Am Fam Physician 58 (1998): 907-14[4] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993): 138-45[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998): 517-8", "alternatives_a": "Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Sucralfate, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 67789, "ingredient1": "Clarithromycin", "ingredient2": "Lactobacillus acidophilus", "severity": "Moderate", "effect": "INTERVAL: Coadministration of oral probiotic preparations with oral antibiotics may reduce the efficacy of the probiotic. It has been theorized that concomitant antibiotics may kill the live organisms found in lactobacillus-, bacillus coagulans-, and bifidobacteria-containing oral probiotic preparations. However, the clinical significance of the interaction has not been established.", "source": "DDInter", "management_text": "Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.", "mechanism_text": "Others", "recommendation": "Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67876/", "reference_text": "[1] Clarion Brands, Inc. \"Florajen Probiotics. Available from: URL: https://www.florajen.com/products/florajen-women.\" ([2018]):", "alternatives_a": "Tinidazole, Pantoprazole, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Famotidine, Rifabutin, Cimetidine, Esomeprazole, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67790, "ingredient1": "Clarithromycin", "ingredient2": "Lactulose", "severity": "Moderate", "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67877/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Schaefer DC, Cheskin LJ \"Constipation in the elderly.\" Am Fam Physician 58 (1998): 907-14[4] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993): 138-45[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998): 517-8", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, Linaclotide, More", "alternatives_b": "Tinidazole, Tetracycline, Dexlansoprazole, Bismuth subcitrate potassium, Rifabutin, Esomeprazole, Vonoprazan, Troleandomycin, Dirithromycin", "updated_at": 1767369485}, {"id": 67791, "ingredient1": "Clarithromycin", "ingredient2": "Lansoprazole", "severity": "Moderate", "effect": "Coadministration with clarithromycin may increase the plasma concentrations of lansoprazole. The proposed mechanism is clarithromycin inhibition of intestinal (first-pass) and hepatic metabolism of lansoprazole via CYP450 3A4. Although lansoprazole is primarily metabolized by CYP450 2C19 in the liver, 3A4-mediated metabolism is the predominant pathway in individuals who are 2C19-deficient (approximately 3% to 5% of the Caucasian and 17% to 20% of the Asian population). Additionally, inhibition of P-glycoprotein intestinal efflux transporter by clarithromycin may also contribute to the interaction, resulting in increased bioavailability of lansoprazole.", "source": "DDInter", "management_text": "Although lansoprazole is generally well tolerated, caution may be advised during coadministration with clarithromycin, particularly if higher dosages of one or both drugs are used. Dosage adjustment may be necessary in patients who experience excessive adverse effects of lansoprazole.", "mechanism_text": "Metabolism", "recommendation": "Although lansoprazole is generally well tolerated, caution may be advised during coadministration with clarithromycin, particularly if higher dosages of one or both drugs are used.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67878/", "reference_text": "[1] Miura M, Tada H, Yasui-Furukori N, et al. \"Effect of clarithromycin on the enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes.\" Chirality 17 (2005): 338-344[2] Saito M, Yasui-Furukori N, Uno T, et al. \"Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes.\" Br J Clin Pharmacol 59 (2005): 302-9[3] Ushiama H, Echizen H, Nachi S, Ohnishi A \"Dose-dependent inhibition of CYP3A activity by clarithromycin during Helicobacter pylori eradication therapy assessed by changes in plasma lansoprazole levels and partial cortisol clearance to 6beta-hydroxycortisol.\" Clin Pharmacol Ther 72 (2002): 33-43[4] Cheng KL, Nafziger AN, Peloquin CA, Amsden GW \"Effect of grapefruit juice on clarithromycin pharmacokinetics.\" Antimicrob Agents Chemother 42 (1998): 927-9", "alternatives_a": "Tinidazole, Bismuth subcitrate potassium, Vonoprazan, Clarithromycin", "alternatives_b": "Tinidazole, Dexlansoprazole, Bismuth subcitrate potassium, Rifabutin, Esomeprazole, Vonoprazan, Levofloxacin, Lansoprazole, Lincomycin, Troleandomycin, Dirithromycin", "updated_at": 1767369485}, {"id": 67792, "ingredient1": "Clarithromycin", "ingredient2": "Lapatinib", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of lapatinib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of lapatinib with potent CYP450 3A4 inhibitors should generally be avoided. Some authorities recommend avoiding concomitant use of lapatinib during and for 2 weeks after treatment with itraconazole. If coadministration is required, the manufacturer recommends reducing the lapatinib dosage to 500 mg once a day. However, clinical data are lacking. Following discontinuation of the potent CYP450 3A4 inhibitor, a washout period of approximately one week should be allowed before the lapatinib dosage is adjusted upward to the indicated dosage (i.e., 1250 mg once a day).", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of lapatinib with potent CYP450 3A4 inhibitors should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67879/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Tykerb (lapatinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[4] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[5] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[6] \"Product Information. Tykerb (lapatinib).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Tetracycline, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Amoxicillin, Dirithromycin, Lincomycin, Clindamycin", "alternatives_b": "Alpelisib, Trametinib, Dacomitinib, Tivozanib, Alectinib", "updated_at": 1767369485}, {"id": 67793, "ingredient1": "Clarithromycin", "ingredient2": "Larotrectinib", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of larotrectinib, which is primarily metabolized by the isoenzyme. Increased exposure to larotrectinib may increase the risk of adverse effects such as neurotoxicity (delirium, dysarthria, dizziness, gait disturbance, paresthesia, encephalopathy, memory impairment, tremor) and hepatotoxicity (elevations in liver transaminases).", "source": "DDInter", "management_text": "Concomitant use of larotrectinib with potent CYP450 3A4 inhibitors should generally be avoided. If coadministration is required, the manufacturer recommends reducing the larotrectinib dose by 50%. After the inhibitor has been discontinued for 3 to 5 elimination half-lives, the larotrectinib dose that was taken prior to initiating the inhibitor may be resumed.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of larotrectinib with potent CYP450 3A4 inhibitors should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67880/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Vitrakvi (larotrectinib).\" Bayer Pharmaceutical Inc, West Haven, CT.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[5] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[6] \"Product Information. Vitrakvi (larotrectinib).\" Bayer Pharmaceutical Inc, West Haven, CT.", "alternatives_a": "Tetracycline, Levofloxacin, Rabeprazole, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Nizatidine, Ranitidine, More", "alternatives_b": "Alpelisib, Trametinib, Dacomitinib, Tivozanib, Alectinib", "updated_at": 1767369485}, {"id": 67794, "ingredient1": "Clarithromycin", "ingredient2": "Lefamulin", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 and/or P-gp may significantly increase the plasma concentrations of lefamulin, which is a substrate of both the isoenzyme and efflux transporter. Coadministration of intravenous lefamulin with oral ketoconazole increased mean lefamulin Cmax and AUC by 6% and 31%, respectively. Increased exposure to lefamulin may increase the risk of QT interval prolongation, which has been associated with ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Concomitant use of lefamulin with potent inhibitors of CYP450 3A4 and/or P-gp should generally be avoided.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of lefamulin with potent inhibitors of CYP450 3A4 and/or P-gp should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67881/", "reference_text": "[1] \"Product Information. Xenleta (lefamulin).\" Nabriva Therapeutics US, Inc., King of Prussia, PA.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[3] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[4] \"Product Information. Xenleta (lefamulin).\" Nabriva Therapeutics US, Inc., King of Prussia, PA.", "alternatives_a": "Tetracycline, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Nizatidine, Ranitidine, Vonoprazan, Amoxicillin, Dirithromycin, Lincomycin, Clindamycin", "alternatives_b": "Tinidazole, Bacitracin, Polymyxin B, Oritavancin, Daptomycin, Methenamine, Spectinomycin, Fosfomycin, Tedizolid, Dalbavancin", "updated_at": 1767369485}, {"id": 67795, "ingredient1": "Clarithromycin", "ingredient2": "Leflunomide", "severity": "Major", "effect": "The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.", "source": "DDInter", "management_text": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67882/", "reference_text": "[1] EMEA \"EMEA public statement on leflunomide (ARAVA) - severe and serious hepatic reactions. Available from URL: http://www.eudra.org/emea.html.\" ([1999 Sept 2]):[2] \"Product Information. Arava (leflunomide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Anakinra, More", "alternatives_b": "Tetracycline, Dexlansoprazole, Bismuth subcitrate potassium, Rifabutin, Nizatidine, Esomeprazole, Vonoprazan, Lincomycin, Dirithromycin", "updated_at": 1767369485}, {"id": 67796, "ingredient1": "Clarithromycin", "ingredient2": "Lemborexant", "severity": "Major", "effect": "Coadministration with potent or moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of lemborexant, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of lemborexant with potent or moderate CYP450 3A4 inhibitors should be avoided.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of lemborexant with potent or moderate CYP450 3A4 inhibitors should be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67883/", "reference_text": "[1] \"Product Information. Dayvigo (lemborexant).\" Eisai Inc, Woodcliff Lake, NJ.[2] \"Product Information. Dayvigo (lemborexant).\" Eisai Inc, Woodcliff Lake, NJ.", "alternatives_a": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, More", "alternatives_b": "Methohexital, Methylphenobarbital, Pentobarbital, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, Paraldehyde, Ethchlorvynol, Amobarbital, More", "updated_at": 1767369485}, {"id": 67797, "ingredient1": "Clarithromycin", "ingredient2": "Lenvatinib", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67884/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[16] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, More", "alternatives_b": "Alpelisib, Trametinib, Dacomitinib, Tivozanib, Alectinib", "updated_at": 1767369485}, {"id": 67798, "ingredient1": "Clarithromycin", "ingredient2": "Letermovir", "severity": "Moderate", "effect": "Coadministration with letermovir may increase the plasma concentrations of drugs that are substrates of CYP450 2C8, CYP450 3A4, and/or organic anion transporting polypeptide protein (OATP) 1B1 and 1B3. Letermovir has been shown to be a reversible inhibitor of CYP450 2C8 in vitro, although its effect on CYP450 2C8 substrates has not been evaluated clinically. Letermovir is also a time-dependent inhibitor and inducer of CYP450 3A4 in vitro.", "source": "DDInter", "management_text": "Caution is advised when letermovir is used concurrently with drugs that are substrates of CYP450 2C8, CYP450 3A4, and/or OATP 1B1 and 1B3, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever letermovir is added to or withdrawn from therapy. Moreover, clinicians should be aware that the magnitude of CYP450 3A- and OATP1B1/3-mediated drug interactions with coadministered drugs may be different when letermovir is used with cyclosporine. The combined effect of the two drugs on CYP450 3A4 may be similar to that of a strong CYP450 3A4 inhibitor, hence clinicians should refer to the prescribing information for dosing recommendations of the CYP450 3A4 substrate with a strong CYP450 3A4 inhibitor. Similarly, letermovir and cyclosporine may demonstrate some additive effects on OATP1B1 inhibition, although cyclosporine by itself is already a strong OATP1B1/3 inhibitor.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when letermovir is used concurrently with drugs that are substrates of CYP450 2C8, CYP450 3A4, and/or OATP 1B1 and 1B3, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67885/", "reference_text": "[1] \"Product Information. Prevymis (letermovir).\" Merck & Company Inc, Whitehouse Station, NJ.", "alternatives_a": "Tetracycline, Levofloxacin, Rabeprazole, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Cimetidine, Nizatidine, More", "alternatives_b": "Glecaprevir, Tenofovir alafenamide, Cabotegravir, Lenacapavir, Velpatasvir, Voxilaprevir, Maribavir, Pibrentasvir, Rimantadine, Elvitegravir, Valganciclovir, More", "updated_at": 1767369485}, {"id": 67799, "ingredient1": "Clarithromycin", "ingredient2": "Leuprolide", "severity": "Moderate", "effect": "Long-term androgen deprivation therapy can prolong the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).", "source": "DDInter", "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.", "mechanism_text": "Synergism", "recommendation": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67886/", "reference_text": "[1] \"Product Information. Vantas (histrelin).\" Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc), Lexington, MA.[2] \"Product Information. Zoladex (goserelin).\" Zeneca Pharmaceuticals, Wilmington, DE.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Trelstar (triptorelin)\" Pharmacia and Upjohn, Kalamazoo, MI.[5] \"Product Information. Firmagon (degarelix).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Lupron (leuprolide).\" TAP Pharmaceuticals Inc, Deerfield, IL.[7] \"Product Information. Eligard (leuprolide).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[8] \"Product Information. Plenaxis (abarelix).\" Praecis Pharmaceuticals Inc, Waltham, MA.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67800, "ingredient1": "Clarithromycin", "ingredient2": "Levosalbutamol", "severity": "Moderate", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.", "source": "DDInter", "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67887/", "reference_text": "[1] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990): 575-9[6] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003): 1817-24[8] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998): 145-7[11] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990): 1396-9[16] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.[17] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006): 582-90[19] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[20] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[21] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001): 45-51[26] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986): 619-20", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Rifabutin, Cimetidine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67801, "ingredient1": "Clarithromycin", "ingredient2": "Levamlodipine", "severity": "Moderate", "effect": "Coadministration with CYP450 3A4 inhibitors may increase the plasma concentrations of amlodipine, which is a substrate of the isoenzyme.", "source": "DDInter", "management_text": "Close monitoring of clinical response and tolerance is recommended if amlodipine is prescribed with potent or moderate CYP450 3A4 inhibitors. Dosage reduction may be required for amlodipine. Patients should be advised to seek medical attention if they experience edema or swelling of the lower extremities; sudden, unexplained weight gain; difficulty breathing; chest pain or tightness; or hypotension as indicated by dizziness, fainting, or orthostasis.", "mechanism_text": "Metabolism", "recommendation": "Close monitoring of clinical response and tolerance is recommended if amlodipine is prescribed with potent or moderate CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67888/", "reference_text": "[1] Sasaki M, Maeda A, Fujimura A \"Influence of diltiazem on the pharmacokinetics of amlodipine in elderly hypertensive patients.\" Eur J Clin Pharmacol 57 (2001): 85-6[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Norvasc (amlodipine).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, More", "alternatives_b": "Clevidipine, Nisoldipine, Nicardipine", "updated_at": 1767369485}, {"id": 67802, "ingredient1": "Clarithromycin", "ingredient2": "Levobupivacaine", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 1A2 and/or 3A4 may increase the plasma concentrations of levobupivacaine, which is primarily metabolized by these isoenzymes.", "source": "DDInter", "management_text": "Caution may be advisable if levobupivacaine is administered to patients receiving inhibitors of CYP450 1A2 (e.g., quinolones, deferasirox, mexiletine, propafenone, ticlopidine, zileuton) or CYP450 3A4 (e.g., azole antifungals, macrolide antibiotics, protease inhibitors, kinase inhibitors, aprepitant, conivaptan, cyclosporine, delavirdine, diltiazem, nefazodone, verapamil). Particular caution and dosage adjustment of levobupivacaine may be warranted during concomitant use of both a CYP450 1A2 inhibitor and a CYP450 3A4 inhibitor, or a drug that inhibits both isoenzymes (e.g., fluvoxamine). Patients should be monitored for early signs and symptoms of central nervous system toxicity such as dizziness, drowsiness, lightheadedness, anxiety, restlessness, incoherent speech, tremors, twitching, numbness and tingling of the mouth and lips, metallic taste, tinnitus, and blurred vision, as well as more serious reactions including convulsions, hypotension, arrhythmias, and cardiorespiratory depression.", "mechanism_text": "Metabolism", "recommendation": "Caution may be advisable if levobupivacaine is administered to patients receiving inhibitors of CYP450 1A2 (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67889/", "reference_text": "[1] \"Product Information. Chirocaine (levobupivacaine)\" Organon, West Orange, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Chloroprocaine, Bupivacaine, Tetracaine, Mepivacaine, Procaine, Prilocaine, Articaine, Etidocaine", "alternatives_b": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, More", "updated_at": 1767369485}, {"id": 67803, "ingredient1": "Clarithromycin", "ingredient2": "Levofloxacin", "severity": "Moderate", "effect": "Certain quinolones, including levofloxacin, norfloxacin, and ofloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of the quinolone, recommended dosages and intravenous infusion rates should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67890/", "reference_text": "[1] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[4] Oliphant CM, Green GM \"Quinolones: a comprehensive review.\" Am Fam Physician 65 (2002): 455-64[5] Stahlmann R \"Clinical toxicological aspects of fluoroquinolones.\" Toxicol Lett 127 (2002): 269-77[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Falagas ME, Rafailidis PI, Rosmarakis ES \"Arrhythmias associated with fluoroquinolone therapy.\" Int J Antimicrob Agents 29 (2007): 374-9[8] Samaha FF \"QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin.\" Am J Med 107 (1999): 528-9[9] Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R \"Effects of three fluoroquinolones on QT interval in healthy adults after single doses.\" Clin Pharmacol Ther 73 (2003): 292-303[10] Kahn JB \"Latest industry information on the safety profile of levofloxacin in the US.\" Chemotherapy 47 Suppl 3 (2001): 32-7[11] Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H \"Risk of torsades de pointes with non-cardiac drugs. Prolongation of QT interval is probably a class effect of fluoroquinolones.\" Br Med J 322 (2001): 46-7[12] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[13] Makaryus AN, Byrns K, Makaryus MN, Natarajan U, Singer C, Goldner B \"Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant \"clinical\" event?\" South Med J 99 (2006): 52-6[14] Frothingham R \"Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.\" Pharmacotherapy 21 (2001): 1468-72[15] Nykamp DL, Blackmon CL, Schmidt PE, Roberson AG \"QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine.\" Ann Pharmacother 39 (2005): 543-6[16] Owens RC \"QT Prolongation with Antimicrobial Agents : Understanding the Significance.\" Drugs 64 (2004): 1091-124[17] Thomas M, Maconochie JG, Fletcher E \"The dilemma of the prolonged QT interval in early drug studies.\" Br J Clin Pharmacol 41 (1996): 77-81[18] Kang J, Wang L, Chen XL, Triggle DJ, Rampe D \"Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.\" Mol Pharmacol 59 (2001): 122-6[19] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[20] Owens RC \"Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes.\" Pharmacotherapy 21 (2001): 301-19[21] Katritsis D, Camm AJ \"Quinolones: cardioprotective or cardiotoxic.\" Pacing Clin Electrophysiol 26 (2003): 2317-20[22] Ball P \"Quinolone-induced QT interval prolongation: a not-so-unexpected class effect.\" J Antimicrob Chemother 45 (2000): 557-9[23] Owens RC Jr, Ambrose PG \"Torsades de pointes associated with fluoroquinolones.\" Pharmacotherapy 22 (2002): 663-8; discussion 668-72[24] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[25] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Enoxacin, Nalidixic acid, Cinoxacin, Trovafloxacin, Delafloxacin, Tinidazole, Bismuth subcitrate potassium, Vonoprazan, Clarithromycin, Tinidazole, Cefixime, More", "alternatives_b": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, More", "updated_at": 1767369485}, {"id": 67804, "ingredient1": "Clarithromycin", "ingredient2": "Levacetylmethadol", "severity": "Major", "effect": "Levomethadyl acetate may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. High dosages of levomethadyl acetate alone have been associated with QT interval prolongation and torsade de pointes.", "source": "DDInter", "management_text": "Coadministration of levomethadyl acetate with other drugs that can prolong the QT interval is considered contraindicated.", "mechanism_text": "Synergism", "recommendation": "Coadministration of levomethadyl acetate with other drugs that can prolong the QT interval is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67891/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Orlaam (levomethadyl acetate)\" Roxanne Laboratories Inc, Columbus, OH.[3] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[4] Krantz MJ, Mehler PS \"Synthetic opioids and QT prolongation.\" Arch Intern Med 163 (2003): 1615; author reply 1615[5] Deamer RL, Wilson DR, Clark DS, Prichard JG \"Torsades de pointes associated with high dose levomethadyl acetate (ORLAAM).\" J Addict Dis 20 (2001): 7-14[6] \"Product Information. Orlaam (levomethadyl acetate)\" Roxanne Laboratories Inc, Columbus, OH.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Nizatidine, Esomeprazole, Ranitidine, More", "alternatives_b": "Nalmefene, Diamorphine, Acamprosate", "updated_at": 1767369485}, {"id": 67805, "ingredient1": "Clarithromycin", "ingredient2": "Levomilnacipran", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of levomilnacipran, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The dosage of levomilnacipran should not exceed 80 mg once daily when used with potent CYP450 3A4 inhibitors.", "mechanism_text": "Metabolism", "recommendation": "The dosage of levomilnacipran should not exceed 80 mg once daily when used with potent CYP450 3A4 inhibitors.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67892/", "reference_text": "[1] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[2] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.[3] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[4] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[6] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, More", "alternatives_b": "Phenelzine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Vortioxetine, Milnacipran, Tryptophan, Esketamine", "updated_at": 1767369485}, {"id": 67806, "ingredient1": "Clarithromycin", "ingredient2": "Levonorgestrel", "severity": "Moderate", "effect": "RECOMMENDED: The effectiveness of estrogen-containing oral contraceptives may be impaired by concomitant treatment with antimicrobial agents. Most antimicrobials, with the exception of the rifamycins and possibly griseofulvin, do not induce hepatic enzymes and have not been shown to significantly increase the clearance of oral contraceptive estrogens. Certain macrolide antibiotics (e.g., erythromycin, clarithromycin) may increase the plasma concentrations and the risk of adverse effects of estrogens and progestogens. The mechanism is decreased clearance of the hormones due to inhibition of CYP450 3A4 activity by the macrolide antibiotic. Concomitant administration with erythromycin may increase the estradiol exposure by approximately 50%.", "source": "DDInter", "management_text": "Until further data are available, women using oral contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant antimicrobial therapy. During concomitant therapy with erythromycin or clarithromycin, patients should be observed for increased or altered pharmacologic response to estrogens and progestogens, and dosage(s) adjusted accordingly as necessary.", "mechanism_text": "Metabolism", "recommendation": "Until further data are available, women using oral contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant antimicrobial therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67893/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception. Available from: URL: file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf.\" ([2012, Jan 1]):[4] \"Product Information. Angeliq (drospirenone-estradiol).\" Berlex Laboratories, Wayne, NJ.[5] \"Product Information. Ortho-Est (estropipate).\" Ortho McNeil Pharmaceutical, Raritan, NJ.[6] \"Product Information. Premarin (conjugated estrogens).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[7] \"Product Information. Yasmin (drospirenone-ethinyl estradiol)\" Berlex Laboratories, Richmond, CA.[8] Welling PG, Huang H, Hewitt PF, Lyons LL \"Bioavailability of erythromycin stearate: influence of food and fluid volume.\" J Pharm Sci 67 (1978): 764-6[9] Welling PG \"Influence of food and diet on gastrointestinal drug absorption: a review.\" J Pharmacokinet Biopharm 5 (1977): 291-334[10] Randinitis EJ, Sedman AJ, Welling PG, Kinkel AW \"Effect of a high-fat meal on the bioavailability of a polymer-coated erythromycin particle tablet formulation.\" J Clin Pharmacol 29 (1989): 79-84[11] Coyne TC, Shum S, Chun AH, Jeansonne L, Shirkey HC \"Bioavailability of erythromycin ethylsuccinate in pediatric patients.\" J Clin Pharmacol 18 (1978): 194-202[12] Malmborg AS \"Effect of food on absorption of erythromycin. A study of two derivatives, the stearate and the base.\" J Antimicrob Chemother 5 (1979): 591-9[13] Welling PG, Elliott RL, Pitterle ME, et al \"Plasma levels following single and repeated doses of erythromycin estolate and erythromycin stearate.\" J Pharm Sci 68 (1979): 150-5[14] Kanazawa S, Ohkubo T, Sugawara K \"The effects of grapefruit juice on the pharmacokinetics of erythromycin.\" Eur J Clin Pharmacol 56 (2001): 799-803[15] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[16] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Estetrol", "alternatives_b": "Tinidazole, Levofloxacin, Tetracycline, Dexlansoprazole, Sucralfate, Bismuth subcitrate potassium, Famotidine, Cimetidine, Esomeprazole, Nizatidine, Vonoprazan, More", "updated_at": 1767369485}, {"id": 67807, "ingredient1": "Clarithromycin", "ingredient2": "Linagliptin", "severity": "Moderate", "effect": "Concomitant use of insulin and other antidiabetic agents with clarithromycin may cause significant hypoglycemia. There have been rare reports of hypoglycemia in patients treated with clarithromycin, some of whom were taking oral hypoglycemic agents or insulin. The exact mechanism of interaction has not been established. With certain hypoglycemic drugs such as nateglinide, pioglitazone, repaglinide and rosiglitazone, inhibition of the CYP450 3A4 isoenzyme by clarithromycin may be involved.", "source": "DDInter", "management_text": "Caution is advised if clarithromycin is prescribed to patients receiving antidiabetic agents. Patients should be advised to regularly monitor their blood sugar and counseled on how to recognize and treat hypoglycemia, which may include symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if clarithromycin is prescribed to patients receiving antidiabetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67894/", "reference_text": "[1] Otsuka SH \"Severe hypoglycemia from helicobacter pylori triple-drug therapy and insulin detemir drug interaction.\" Pharmacotherapy 33 (2013): e45-9[2] Niemi M, Neuvonen PJ, Kivisto KT \"The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide.\" Clin Pharmacol Ther 70 (2001): 58-65[3] Schelleman H, Bilker WB, Brensinger CM, Wan F, Hennessy S \"Anti-infectives and the risk of severe hypoglycemia in users of glipizide or glyburide.\" Clin Pharmacol Ther 88 (2010): 214-22[4] Khamaisi M, Leitersdorf E \"Severe hypoglycemia from clarithromycin-repaglinide drug interaction.\" Pharmacotherapy 28 (2008): 682-4[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Leiba A, Leibowitz A, Grossman E \"An unusual case of hypoglycemia in a diabetic patient.\" Ann Emerg Med 44 (2004): 427-8[7] Bussing R, Gende A \"Severe hypoglycemia from clarithromycin-sulfonylurea drug interaction.\" Diabetes Care 25 (2002): 1659-61[8] \"Product Information. Biaxin (clarithromycin).\" Abbott Pharmaceutical, Abbott Park, IL.[9] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[10] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[11] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[12] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[13] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[14] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[15] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[16] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[17] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[18] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[19] Cheng KL, Nafziger AN, Peloquin CA, Amsden GW \"Effect of grapefruit juice on clarithromycin pharmacokinetics.\" Antimicrob Agents Chemother 42 (1998): 927-9", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Cimetidine, Esomeprazole, More", "alternatives_b": "Guar gum", "updated_at": 1767369485}, {"id": 67808, "ingredient1": "Clarithromycin", "ingredient2": "Liraglutide", "severity": "Moderate", "effect": "Concomitant use of insulin and other antidiabetic agents with clarithromycin may cause significant hypoglycemia. There have been rare reports of hypoglycemia in patients treated with clarithromycin, some of whom were taking oral hypoglycemic agents or insulin. The exact mechanism of interaction has not been established. With certain hypoglycemic drugs such as nateglinide, pioglitazone, repaglinide and rosiglitazone, inhibition of the CYP450 3A4 isoenzyme by clarithromycin may be involved.", "source": "DDInter", "management_text": "Caution is advised if clarithromycin is prescribed to patients receiving antidiabetic agents. Patients should be advised to regularly monitor their blood sugar and counseled on how to recognize and treat hypoglycemia, which may include symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if clarithromycin is prescribed to patients receiving antidiabetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67895/", "reference_text": "[1] Otsuka SH \"Severe hypoglycemia from helicobacter pylori triple-drug therapy and insulin detemir drug interaction.\" Pharmacotherapy 33 (2013): e45-9[2] Niemi M, Neuvonen PJ, Kivisto KT \"The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide.\" Clin Pharmacol Ther 70 (2001): 58-65[3] Schelleman H, Bilker WB, Brensinger CM, Wan F, Hennessy S \"Anti-infectives and the risk of severe hypoglycemia in users of glipizide or glyburide.\" Clin Pharmacol Ther 88 (2010): 214-22[4] Khamaisi M, Leitersdorf E \"Severe hypoglycemia from clarithromycin-repaglinide drug interaction.\" Pharmacotherapy 28 (2008): 682-4[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Leiba A, Leibowitz A, Grossman E \"An unusual case of hypoglycemia in a diabetic patient.\" Ann Emerg Med 44 (2004): 427-8[7] Bussing R, Gende A \"Severe hypoglycemia from clarithromycin-sulfonylurea drug interaction.\" Diabetes Care 25 (2002): 1659-61[8] \"Product Information. Biaxin (clarithromycin).\" Abbott Pharmaceutical, Abbott Park, IL.[9] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[10] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[11] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[12] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[13] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[14] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[15] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[16] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[17] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[18] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[19] Cheng KL, Nafziger AN, Peloquin CA, Amsden GW \"Effect of grapefruit juice on clarithromycin pharmacokinetics.\" Antimicrob Agents Chemother 42 (1998): 927-9", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Rifabutin, Cimetidine, More", "alternatives_b": "Guar gum", "updated_at": 1767369485}, {"id": 67809, "ingredient1": "Clarithromycin", "ingredient2": "Lisdexamfetamine", "severity": "Moderate", "effect": "Limited data suggests the lisdexamfetamine may rarely prolong the QT interval of the electrocardiogram in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including ventricular tachycardia, torsade de pointes, and sudden death.", "source": "DDInter", "management_text": "Caution is recommended whenever lisdexamfetamine is used concomitantly with other agents known to cause QT prolongation. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended whenever lisdexamfetamine is used concomitantly with other agents known to cause QT prolongation.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67896/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[6] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[7] Jiao X, Velez S, Ringstad J, Eyma V, Miller D, Bleiberg M \"Myocardial infarction associated with Adderall XR and alcohol use in a young man.\" J Am Board Fam Med 22 (2009): 197-201", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, More", "alternatives_b": "Amphetamine, Pemoline, Metamfetamine, Solriamfetol, Caffeine, Dexmethylphenidate, Dextroamphetamine, Citicoline", "updated_at": 1767369485}, {"id": 67810, "ingredient1": "Clarithromycin", "ingredient2": "Lithium carbonate", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67897/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[16] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Pantoprazole, Rabeprazole, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, Ranitidine, Nizatidine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67811, "ingredient1": "Clarithromycin", "ingredient2": "Lixisenatide", "severity": "Moderate", "effect": "Concomitant use of insulin and other antidiabetic agents with clarithromycin may cause significant hypoglycemia. There have been rare reports of hypoglycemia in patients treated with clarithromycin, some of whom were taking oral hypoglycemic agents or insulin. The exact mechanism of interaction has not been established. With certain hypoglycemic drugs such as nateglinide, pioglitazone, repaglinide and rosiglitazone, inhibition of the CYP450 3A4 isoenzyme by clarithromycin may be involved.", "source": "DDInter", "management_text": "Caution is advised if clarithromycin is prescribed to patients receiving antidiabetic agents. Patients should be advised to regularly monitor their blood sugar and counseled on how to recognize and treat hypoglycemia, which may include symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if clarithromycin is prescribed to patients receiving antidiabetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67898/", "reference_text": "[1] Otsuka SH \"Severe hypoglycemia from helicobacter pylori triple-drug therapy and insulin detemir drug interaction.\" Pharmacotherapy 33 (2013): e45-9[2] Niemi M, Neuvonen PJ, Kivisto KT \"The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide.\" Clin Pharmacol Ther 70 (2001): 58-65[3] Schelleman H, Bilker WB, Brensinger CM, Wan F, Hennessy S \"Anti-infectives and the risk of severe hypoglycemia in users of glipizide or glyburide.\" Clin Pharmacol Ther 88 (2010): 214-22[4] Khamaisi M, Leitersdorf E \"Severe hypoglycemia from clarithromycin-repaglinide drug interaction.\" Pharmacotherapy 28 (2008): 682-4[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Leiba A, Leibowitz A, Grossman E \"An unusual case of hypoglycemia in a diabetic patient.\" Ann Emerg Med 44 (2004): 427-8[7] Bussing R, Gende A \"Severe hypoglycemia from clarithromycin-sulfonylurea drug interaction.\" Diabetes Care 25 (2002): 1659-61[8] \"Product Information. Biaxin (clarithromycin).\" Abbott Pharmaceutical, Abbott Park, IL.[9] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[10] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[11] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[12] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[13] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[14] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[15] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[16] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[17] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[18] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[19] Cheng KL, Nafziger AN, Peloquin CA, Amsden GW \"Effect of grapefruit juice on clarithromycin pharmacokinetics.\" Antimicrob Agents Chemother 42 (1998): 927-9", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Rifabutin, Cimetidine, More", "alternatives_b": "Guar gum", "updated_at": 1767369485}, {"id": 67812, "ingredient1": "Clarithromycin", "ingredient2": "Lofexidine", "severity": "Moderate", "effect": "Lofexidine has been associated with asymptomatic prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Coadministration of lofexidine with other agents with hypotensive effects may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution is recommended if lofexidine is used in combination with other drugs that can prolong the QT interval. Periodic monitoring with on-treatment electrocardiograms and serum electrolytes (magnesium, potassium) should be considered. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if lofexidine is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67899/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Lucemyra (lofexidine).\" US WorldMeds LLC, Louisville , KY.[4] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[7] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, More", "alternatives_b": "Nalmefene, Diamorphine, Acamprosate", "updated_at": 1767369485}, {"id": 67813, "ingredient1": "Clarithromycin", "ingredient2": "Lomefloxacin", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67900/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[16] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Rifamycin, Oxytetracycline, Netilmicin, Polymyxin B, Sulfamethizole, Trifluridine, Sulfisoxazole, Povidone-iodine, Enoxacin, Nalidixic acid, Cinoxacin, More", "alternatives_b": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, More", "updated_at": 1767369485}, {"id": 67814, "ingredient1": "Clarithromycin", "ingredient2": "Lomitapide", "severity": "Major", "effect": "Coadministration with potent and moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of lomitapide, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of lomitapide with potent or moderate inhibitors of CYP450 3A4 is considered contraindicated. Some authorities consider concomitant administration of lomitapide and itraconazole to be contraindicated during and for 2 weeks after treatment with itraconazole.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of lomitapide with potent or moderate inhibitors of CYP450 3A4 is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67901/", "reference_text": "[1] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[2] \"Product Information. Juxtapid (lomitapide).\" Aegerion Pharmaceuticals Inc, Cambridge, MA.[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Juxtapid (lomitapide).\" Aegerion Pharmaceuticals Inc, Cambridge, MA.", "alternatives_a": "Tinidazole, Pantoprazole, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Rifabutin, Nizatidine, More", "alternatives_b": "Gemfibrozil, Fenofibric acid, Pitavastatin, Evinacumab, Evolocumab, Dextrothyroxine, Cholestyramine, Clofibrate, Colestipol, Bempedoic acid, Colesevelam, More", "updated_at": 1767369485}, {"id": 67815, "ingredient1": "Clarithromycin", "ingredient2": "Lonafarnib", "severity": "Major", "effect": "Coadministration with potent or moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of lonafarnib.", "source": "DDInter", "management_text": "Concomitant use of lonafarnib with potent or moderate CYP450 3A4 inhibitors is considered contraindicated.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of lonafarnib with potent or moderate CYP450 3A4 inhibitors is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67902/", "reference_text": "[1] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.[2] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.", "alternatives_a": "Tetracycline, Levofloxacin, Rabeprazole, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Famotidine, Nizatidine, Ranitidine, Amoxicillin, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 67816, "ingredient1": "Clarithromycin", "ingredient2": "Lorlatinib", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of lorlatinib, which has been found to be metabolized primarily by CYP450 3A4 and UGT1A4 in vitro. Increased exposure to lorlatinib may increase the risk of central nervous system adverse effects (e.g., seizures, hallucinations, changes in cognitive function, mood disorders, mental status changes, sleep impairment), hyperlipidemia (hypercholesterolemia and hypertriglyceridemia), PR interval prolongation and atrioventricular (AV) block, and interstitial lung disease/pneumonitis.", "source": "DDInter", "management_text": "Concomitant use of lorlatinib with potent CYP450 3A4 inhibitors should generally be avoided. If coadministration is required, the initial dosage of lorlatinib should be reduced from 100 mg orally once daily to 75 mg orally once daily. In patients who have had a dosage reduction to 75 mg orally once daily due to adverse reactions, the lorlatinib dosage should be further reduced to 50 mg orally once daily upon initiation of a potent CYP450 3A4 inhibitor. After 3 plasma half-lives following discontinuation of the potent CYP450 3A4 inhibitor, the lorlatinib dosage may be increased to that used prior to initiation of the inhibitor.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of lorlatinib with potent CYP450 3A4 inhibitors should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67903/", "reference_text": "[1] \"Product Information. Lorbrena (lorlatinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Lorbrena (lorlatinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.[4] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[5] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tetracycline, Levofloxacin, Rabeprazole, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Nizatidine, Esomeprazole, More", "alternatives_b": "Alpelisib, Trametinib, Dacomitinib, Tivozanib, Alectinib", "updated_at": 1767369485}, {"id": 67817, "ingredient1": "Clarithromycin", "ingredient2": "Loteprednol (ophthalmic)", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme. The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations. Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy. Cushing's syndrome and adrenal insufficiency have been attributed to the interaction.", "source": "DDInter", "management_text": "The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors. When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical \"buffalo\" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.", "mechanism_text": "Metabolism", "recommendation": "The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67904/", "reference_text": "[1] Edsbacker S, Andersson T \"Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease.\" Clin Pharmacokinet 43 (2004): 803-21[2] Finkenbine RD, Frye MD \"Case of psychosis due to prednisone-clarithromycin interaction.\" Gen Hosp Psychiat 20 (1998): 325-6[3] Soldatos G, Sztal-Mazer S, Woolley I, Stockigt J \"Exogenous glucocorticoid excess as a result of ritonavir-fluticasone interaction.\" Intern Med J 35 (2005): 67-8[4] Kandrotas RJ, Slaughter RL, Brass C, Jusko WJ \"Ketoconazole effects on methylprednisolone disposition and their joint suppression of endogenous cortisol.\" Clin Pharmacol Ther 42 (1987): 465-70[5] Raaska K, Niemi M, Neuvonen M, Neuvonen PJ, Kivisto KT \"Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole.\" Clin Pharmacol Ther 72 (2002): 362-369[6] Ulrich B, Frey FJ, Speck RF, Frey BM \"Pharmacokinetics/pharmacodynamics of ketoconazole-prednisolone interaction.\" J Pharmacol Exp Ther 260 (1992): 487-90[7] Zurcher RM, Frey BM, Frey FJ \"Impact of ketoconazole on the metabolism of prednisolone.\" Clin Pharmacol Ther 45 (1989): 366-72[8] Busse KH, Formentini E, Alfaro RM, Kovacs JA, Penzak SR \"Influence of antiretroviral drugs on the pharmacokinetics of prednisolone in HIV-infected individuals.\" J Acquir Immune Defic Syndr 48 (2008): 561-6[9] Yamashita SK, Ludwig EA, Middleton E Jr, Jusko WJ \"Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone.\" Clin Pharmacol Ther 49 (1991): 558-70[10] Hillebrand-Haverkort ME, Prummel MF, ten Veen JH \"Ritonavir-induced Cushing's syndrome in a patient treated with nasal fluticasone.\" AIDS 13 (1999): 1803[11] Kotlyar M, Brewer ER, Golding M, Carson SW \"Nefazodone inhibits methylprednisolone disposition and enhances its adrenal-suppressant effect.\" J Clin Psychopharmacol 23 (2003): 652-6[12] Itkin IH, Menzel ML \"The use of macrolide antibiotic substances in the treatment of asthma.\" J Allergy Clin Immunol 45 (1970): 146-62[13] Skov M, Main KM, Sillesen IB, Muller J, Koch C, Lanng S \"Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide.\" Eur Respir J 20 (2002): 127-33[14] Samaras K, Pett S, Gowers A, McMurchie M, Cooper DA \"Iatrogenic Cushing's syndrome with osteoporosis and secondary adrenal failure in HIV-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: six cases.\" J Clin Endocrinol Metab 90 (2005): 4394-8[15] Garey KW, Rubinstein I, Gotfried MH, Khan IJ, Varma S, Danziger LH \"Long-term clarithromycin decreases prednisone requirements in elderly patients with prednisone-dependent asthma.\" Chest 118 (2000): 1826-7[16] Glynn AM, Slaughter RL, Brass C, et al \"Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretion.\" Clin Pharmacol Ther 39 (1986): 654-9[17] LaForce CF, Szefler SJ, Miller MF, Ebling W, Brenner M \"Inhibition of methylprednisolone elimination in the presence of erythromycin therapy.\" J Allergy Clin Immunol 72 (1983): 34-9[18] Lebrun-Vignes B, Archer VC, Diquest B, et al. \"Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects.\" Br J Clin Pharmacol 51 (2001): 443-50[19] Varis T, Kivisto KT, Neuvonen PJ \"The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone.\" Eur J Clin Pharmacol 56 (2000): 57-60[20] Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN \"Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole.\" Ann Pharmacother 38 (2004): 46-9[21] Gupta SK, Dube MP \"Exogenous Cushing syndrome mimicking human immunodeficiency virus lipodystrophy.\" Clin Infect Dis 35 (2002): E69-71[22] Varis T, Kaukonen KM, Kivisto KT, Neuvonen PJ \"Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole.\" Clin Pharmacol Ther 64 (1998): 363-8[23] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[24] Couturier J, Steele M, Hussey L, Pawliuk G \"Steroid-induced mania in an adolescent: risk factors and management.\" Can J Clin Pharmacol 8 (2001): 109-12[25] Varis T, Backman JT, Kivisto KT, Neuvonen PJ \"Diltiazem and mibefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone.\" Clin Pharmacol Ther 67 (2000): 215-21[26] Bhumbra NA, Sahloff EG, Oehrtman SJ, Horner JM \"Exogenous Cushing syndrome with inhaled fluticasone in a child receiving lopinavir/ritonavir.\" Ann Pharmacother 41 (2007): 1306-9[27] Main KM, Skov M, Sillesen IB, et al. \"Cushing's syndrome due to pharmacological interaction in a cystic fibrosis patient.\" Acta Paediatr 91 (2002): 1008-11[28] Penzak SR, Formentini E, Alfaro RM, Long M, Natarajan V, Kovacs J \"Prednisolone pharmacokinetics in the presence and absence of ritonavir after oral prednisone administration to healthy volunteers.\" J Acquir Immune Defic Syndr 40 (2005): 573-80[29] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[30] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.", "alternatives_a": "Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67818, "ingredient1": "Clarithromycin", "ingredient2": "Lovastatin", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of simvastatin and lovastatin and their active acid metabolites, all of which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Due to the potential for severe interaction, concomitant use of simvastatin or lovastatin with potent CYP450 3A4 inhibitors is considered contraindicated. Fluvastatin, pravastatin, pitavastatin, and rosuvastatin are probably safer alternatives, since they are not metabolized by CYP450 3A4. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark-colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.", "mechanism_text": "Metabolism", "recommendation": "Due to the potential for severe interaction, concomitant use of simvastatin or lovastatin with potent CYP450 3A4 inhibitors is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67905/", "reference_text": "[1] Williams D, Feely J \"Pharmacokinetic-Pharmacodynamic Drug Interactions with HMG-CoA Reductase Inhibitors.\" Clin Pharmacokinet 41 (2002): 343-70[2] Spach DH, Bauwens JE, Clark CD, Burke WG \"Rhabdomyolysis associated with lovastatin and erythromycin use.\" West J Med 154 (1991): 213-5[3] Watkins JL, Atkinson BJ, Pagliaro LC \"Rhabdomyolysis in a prostate cancer patient taking ketoconazole and simvastatin: case report and review of the literature.\" Ann Pharmacother 45 (2011): e9[4] Itakura H, Vaughn D, Haller DG, O'Dwyer PJ \"Rhabdomyolysis from cytochrome p-450 interaction of ketoconazole and simvastatin in prostate cancer.\" J Urol 169 (2003): 613[5] Huynh T, Cordato D, Yang F, et al. \"HMG coA reductase-inhibitor-related myopathy and the influence of drug interactions.\" Intern Med J 32(9-10) (2002): 486-90[6] \"Product Information. Zocor (simvastatin).\" Merck & Co, Inc, West Point, PA.[7] Ayanian JZ, Fuchs CS, Stone RM \"Lovastatin and rhabdomyolysis.\" Ann Intern Med 109 (1988): 682-3[8] Kivisto KT, Kantola T, Neuvonen PJ \"Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin.\" Br J Clin Pharmacol 46 (1998): 49-53[9] Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F \"New insights into the pharmacodynamic and pharmacokinetic properties of statins.\" Pharmacol Ther 84 (1999): 413-28[10] Kantola T, Kivisto KT, Neuvonen PJ \"Effect of itraconazole on cerivastatin pharmacokinetics.\" Eur J Clin Pharmacol 54 (1999): 851-5[11] Corpier CL, Jones PH, Suki WN, et al. \"Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients.\" JAMA 260 (1988): 239-41[12] Kantola T, Kivisto KT, Neuvonen PJ \"Effect of itraconazole on the pharmacokinetics of atorvastatin.\" Clin Pharmacol Ther 64 (1998): 58-65[13] Neuvonen PJ, Backman JT, Niemi M \"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.\" Clin Pharmacokinet 47 (2008): 463-74[14] Jacobson TA \"Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors.\" Am J Cardiol 94 (2004): 1140-6[15] Lees RS, Lees AM \"Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole.\" N Engl J Med 333 (1995): 664-5[16] Sipe BE, Jones RJ, Bokhart GH \"Rhabdomyolysis Causing AV Blockade Due to Possible Atorvastatin, Esomeprazole, and Clarithromycin Interaction.\" Ann Pharmacother 37 (2003): 808-11[17] Chouhan UM, Chakrabarti S, Millward LJ \"Simvastatin interaction with clarithromycin and amiodarone causing myositis.\" Ann Pharmacother 39 (2005): 1760-1[18] Grunden JW, Fisher KA \"Lovastatin-induced rhabdomyolysis possibly associated with clarithromycin and azithromycin.\" Ann Pharmacother 31 (1997): 859-63[19] Horn M \"Coadministration of itraconazole with hypolipidemic agents may induce rhabdomyolysis in healthy individuals.\" Arch Dermatol 132 (1996): 1254[20] Garnett WR \"Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors.\" Am J Health Syst Pharm 52 (1995): 1639-45[21] Paoletti R, Corsini A, Bellosta S \"Pharmacological interactions of statins.\" Atheroscler Suppl 3 (2002): 35-40[22] Stein CA, Goel S, Ghavamian R \"Hepatitis and rhabdomyolysis in a patient with hormone refractory prostate cancer on ketoconazole and concurrent lovastatin therapy.\" Invest New Drugs 25 (2007): 277-8[23] Jacobson RH, Wang P, Glueck CJ \"Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone.\" JAMA 277 (1997): 296[24] Hare CB, Vu MP, Grunfeld C, Lampiris HW \"Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death.\" Clin Infect Dis 35 (2002): E111-2[25] Neuvonen PJ, Kantola T, Kivisto KT \"Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole.\" Clin Pharmacol Ther 63 (1998): 332-41[26] Cheng CH, Miller C, Lowe C, Pearson VE \"Rhabdomyolysis due to probable interaction between simvastatin and ritonavir.\" Am J Health Syst Pharm 59 (2002): 728-30[27] Lee AJ, Maddix DS \"Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin.\" Ann Pharmacother 35 (2001): 26-31[28] East C, Alivizatos PA, Grundy SM, Jones PH, Farmer JA \"Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation.\" N Engl J Med 318 (1988): 47-8[29] Neuvonen PJ, Jalava KM \"Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 60 (1996): 54-61[30] Wong PW, Dillard TA, Kroenke K \"Multiple organ toxicity from addition of erythromycin to long-term lovastatin therapy.\" South Med J 91 (1998): 202-5[31] Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al. \"Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047.\" AIDS 16 (2002): 569-577[32] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[33] \"Product Information. Mevacor (lovastatin).\" Merck & Co, Inc, West Point, PA.[34] Omar MA, Wilson JP \"FDA adverse event reports on statin-associated rhabdomyolysis.\" Ann Pharmacother 36 (2002): 288-95[35] Gruer PJK, Vega JM, Mercuri MF, Dobrinska MR, Tobert JA \"Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin.\" Am J Cardiol 84 (1999): 811-5[36] Gilad R, Lampl Y \"Rhabdomyolysis induced by simvastatin and ketoconazole treatment.\" Clin Neuropharmacol 22 (1999): 295-7[37] Skrabal MZ, Stading JA, Monaghan MS \"Rhabdomyolysis associated with simvastatin-nefazodone therapy.\" South Med J 96 (2003): 1034-5[38] Karnik NS, Maldonado JR \"Antidepressant and statin interactions: a review and case report of simvastatin and nefazodone-induced rhabdomyolysis and transaminitis.\" Psychosomatics 46 (2005): 565-8[39] Thompson M, Samuels S \"Rhabdomyolysis with simvastatin and nefazodone.\" Am J Psychiatry 159 (2002): 1607[40] Piliero PJ \"Interaction between ritonavir and statins.\" Am J Med 112 (2002): 510-1[41] Schmidt GA, Hoehns JD, Purcell JL, Friedman RL, Elhawi Y \"Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir.\" J Am Board Fam Med 20 (2007): 411-6[42] Jody DN \"Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone.\" JAMA 277 (1997): 296-7[43] Richter WO, Jacob BG, Schwandt P \"Interaction between fibre and lovastatin.\" Lancet 338 (1991): 706[44] Neuvonen PJ, Backman JT, Niemi M \"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.\" Clin Pharmacokinet 47 (2008): 463-74[45] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[46] \"Product Information. Mevacor (lovastatin).\" Merck & Co, Inc, West Point, PA.[47] Thompson PD, Clarkson P, Karas RH \"Statin-associated myopathy.\" JAMA 289 (2003): 1681-90[48] \"Product Information. Zocor (simvastatin).\" Merck & Co, Inc, West Point, PA.[49] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[50] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10", "alternatives_a": "Gemfibrozil, Fenofibric acid, Pitavastatin, Evinacumab, Evolocumab, Dextrothyroxine, Cholestyramine, Clofibrate, Colestipol, Bempedoic acid, Colesevelam, More", "alternatives_b": "Levofloxacin, Bismuth subcitrate potassium, Dexlansoprazole, Rifabutin, Dirithromycin", "updated_at": 1767369485}, {"id": 67819, "ingredient1": "Clarithromycin", "ingredient2": "Lumateperone", "severity": "Major", "effect": "Coadministration with strong or moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of lumateperone, which is metabolized by the isoenzyme in vitro.", "source": "DDInter", "management_text": "Coadministration of strong or moderate CYP450 3A4 inhibitors with lumateperone should be avoided.", "mechanism_text": "Metabolism", "recommendation": "Coadministration of strong or moderate CYP450 3A4 inhibitors with lumateperone should be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67906/", "reference_text": "[1] \"Product Information. Caplyta (lumateperone).\" Intra-Cellular Therapies, Inc., New York, NY.[2] \"Product Information. Caplyta (lumateperone).\" Intra-Cellular Therapies, Inc., New York, NY.", "alternatives_a": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, More", "alternatives_b": "Loxapine, Molindone, Thiothixene", "updated_at": 1767369485}, {"id": 67820, "ingredient1": "Clarithromycin", "ingredient2": "Lurasidone", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of lurasidone and its active metabolite, both of which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of lurasidone with potent CYP450 3A4 inhibitors is considered contraindicated. Some authorities consider concomitant administration of lurasidone and itraconazole to be contraindicated during and for 2 weeks after treatment with itraconazole.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of lurasidone with potent CYP450 3A4 inhibitors is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67907/", "reference_text": "[1] \"Product Information. Latuda (lurasidone).\" Sunovion Pharmaceuticals Inc, Marlborough, MA.[2] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Latuda (lurasidone).\" Sunovion Pharmaceuticals Inc, Marlborough, MA.[8] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[9] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[10] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, More", "alternatives_b": "Loxapine, Molindone, Thiothixene", "updated_at": 1767369485}, {"id": 67821, "ingredient1": "Clarithromycin", "ingredient2": "Lurbinectedin", "severity": "Major", "effect": "Coadministration with a strong CYP450 3A4 inhibitor is predicted to increase lurbinectedin systemic exposure, which may increase the incidence and severity of adverse reactions to lurbinectedin, such as myelosuppression and hepatotoxicity.", "source": "DDInter", "management_text": "Concomitant use of lurbinectedin and strong CYP450 3A4 inhibitors should generally be avoided.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of lurbinectedin and strong CYP450 3A4 inhibitors should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67908/", "reference_text": "[1] \"Product Information. Zepzelca (lurbinectedin).\" Jazz Pharmaceuticals, Palo Alto, CA.[2] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.[3] \"Product Information. Zepzelca (lurbinectedin).\" Jazz Pharmaceuticals, Palo Alto, CA.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Nizatidine, More", "alternatives_b": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Mitotane, Niraparib, Porfimer sodium, More", "updated_at": 1767369485}, {"id": 67822, "ingredient1": "Clarithromycin", "ingredient2": "Lusutrombopag", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of lusutrombopag, which is a substrate of both efflux transporter proteins.", "source": "DDInter", "management_text": "Caution is advised if lusutrombopag is prescribed in combination with P-gp and/or BCRP inhibitors. Pharmacologic response to lusutrombopag should be monitored more closely following initiation, discontinuation, or change of dosage of the concomitant P-gp or BCRP inhibitor.", "mechanism_text": "Distribution", "recommendation": "Caution is advised if lusutrombopag is prescribed in combination with P-gp and/or BCRP inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67909/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):", "alternatives_a": "Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, More", "alternatives_b": "Eltrombopag, Romiplostim, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Coagulation Factor IX Human", "updated_at": 1767369485}, {"id": 67823, "ingredient1": "Clarithromycin", "ingredient2": "Macimorelin", "severity": "Major", "effect": "Macimorelin can cause prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of macimorelin with other drugs that can prolong the QT interval should generally be avoided. A sufficient washout period following discontinuation of these drugs is recommended prior to macimorelin administration. Patients treated with any medication that can cause QT prolongation should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of macimorelin with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67910/", "reference_text": "[1] \"Product Information. Macrilen (macimorelin).\" Aeterna Zentaris, Charleston, SC.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[6] \"Product Information. Macrilen (macimorelin).\" Aeterna Zentaris, Charleston, SC.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Famotidine, Cimetidine, Esomeprazole, More", "alternatives_b": "Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, Sorbitol, Magnesium sulfate, Vitamin A, Caffeine, Metyrapone, Edrophonium, More", "updated_at": 1767369485}, {"id": 67824, "ingredient1": "Clarithromycin", "ingredient2": "Macitentan", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of macitentan, which is primarily metabolized by the isoenzyme. Macitentan was well tolerated with or without ketoconazole in the study, and there were no relevant differences in safety parameters between the treatments.", "source": "DDInter", "management_text": "According to the product labeling, concomitant use of macitentan with potent CYP450 3A4 inhibitors such as itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, nefazodone, cobicistat, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics should generally be avoided. Alternative treatment options for pulmonary arterial hypertension are recommended when potent CYP450 3A4 inhibitors are needed as part of HIV treatment.", "mechanism_text": "Metabolism", "recommendation": "According to the product labeling, concomitant use of macitentan with potent CYP450 3A4 inhibitors such as itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, nefazodone, cobicistat, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67911/", "reference_text": "[1] \"Product Information. Opsumit (macitentan).\" Actelion Pharmaceuticals US Inc, South San Francisco, CA.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[3] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, More", "alternatives_b": "Metyrosine", "updated_at": 1767369485}, {"id": 67825, "ingredient1": "Clarithromycin", "ingredient2": "Magnesium citrate", "severity": "Moderate", "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67912/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Schaefer DC, Cheskin LJ \"Constipation in the elderly.\" Am Fam Physician 58 (1998): 907-14[4] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993): 138-45[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998): 517-8", "alternatives_a": "Tinidazole, Pantoprazole, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Rifabutin, Cimetidine, More", "alternatives_b": "Sorbitol, Sulfamethizole, Sodium citrate, Mannitol, Sodium chloride, Magnesium gluconate, Zinc sulfate, Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Sodium chloride, More", "updated_at": 1767369485}, {"id": 67826, "ingredient1": "Clarithromycin", "ingredient2": "Magnesium hydroxide", "severity": "Moderate", "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67913/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Schaefer DC, Cheskin LJ \"Constipation in the elderly.\" Am Fam Physician 58 (1998): 907-14[4] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993): 138-45[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998): 517-8", "alternatives_a": "Tinidazole, Pantoprazole, Dexlansoprazole, Rabeprazole, Bismuth subcitrate potassium, Metronidazole, Rifabutin, Esomeprazole, Vonoprazan, Amoxicillin, Lansoprazole, More", "alternatives_b": "Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Phenyl salicylate, Ammonium chloride, Dimethyl sulfoxide, More", "updated_at": 1767369485}, {"id": 67827, "ingredient1": "Clarithromycin", "ingredient2": "Maprotiline", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67914/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[16] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Phenelzine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Vortioxetine, Milnacipran, Tryptophan, Esketamine", "alternatives_b": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, More", "updated_at": 1767369485}, {"id": 67828, "ingredient1": "Clarithromycin", "ingredient2": "Maraviroc", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of maraviroc, which is primarily metabolized by the isoenzyme. Patients with severe renal impairment or end-stage renal disease (CrCl <30 mL/min) given maraviroc in combination with potent CYP450 3A4 inhibitors may have an increased risk of postural hypotension due to increased maraviroc exposure.", "source": "DDInter", "management_text": "Maraviroc should be administered at a dosage of 150 mg twice daily during coadministration with potent CYP450 3A4 inhibitors, including most protease inhibitors except tipranavir plus ritonavir. This dosage is recommended whether or not a concomitant CYP450 3A4 inducer (e.g., efavirenz, rifampin, carbamazepine, phenobarbital, phenytoin) is given. Patients with moderate hepatic impairment who receive 150 mg with a potent CYP450 3A4 inhibitor should be monitored closely for maraviroc-associated adverse events. Maraviroc is contraindicated for use in combination with potent CYP450 3A4 inhibitors in patients with severe renal impairment or end-stage renal disease (CrCl <30 mL/min).", "mechanism_text": "Metabolism", "recommendation": "Maraviroc should be administered at a dosage of 150 mg twice daily during coadministration with potent CYP450 3A4 inhibitors, including most protease inhibitors except tipranavir plus ritonavir.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67915/", "reference_text": "[1] \"Product Information. Selzentry (maraviroc).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[3] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[4] \"Product Information. Selzentry (maraviroc).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, More", "alternatives_b": "Glecaprevir, Tenofovir alafenamide, Cabotegravir, Lenacapavir, Velpatasvir, Voxilaprevir, Maribavir, Pibrentasvir, Rimantadine, Elvitegravir, Valganciclovir, More", "updated_at": 1767369485}, {"id": 67829, "ingredient1": "Clarithromycin", "ingredient2": "Medroxyprogesterone acetate", "severity": "Moderate", "effect": "RECOMMENDED: The effectiveness of estrogen-containing oral contraceptives may be impaired by concomitant treatment with antimicrobial agents. Most antimicrobials, with the exception of the rifamycins and possibly griseofulvin, do not induce hepatic enzymes and have not been shown to significantly increase the clearance of oral contraceptive estrogens. Certain macrolide antibiotics (e.g., erythromycin, clarithromycin) may increase the plasma concentrations and the risk of adverse effects of estrogens and progestogens. The mechanism is decreased clearance of the hormones due to inhibition of CYP450 3A4 activity by the macrolide antibiotic. Concomitant administration with erythromycin may increase the estradiol exposure by approximately 50%.", "source": "DDInter", "management_text": "Until further data are available, women using oral contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant antimicrobial therapy. During concomitant therapy with erythromycin or clarithromycin, patients should be observed for increased or altered pharmacologic response to estrogens and progestogens, and dosage(s) adjusted accordingly as necessary.", "mechanism_text": "Metabolism", "recommendation": "Until further data are available, women using oral contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant antimicrobial therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67916/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception. Available from: URL: file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf.\" ([2012, Jan 1]):[4] \"Product Information. Angeliq (drospirenone-estradiol).\" Berlex Laboratories, Wayne, NJ.[5] \"Product Information. Ortho-Est (estropipate).\" Ortho McNeil Pharmaceutical, Raritan, NJ.[6] \"Product Information. Premarin (conjugated estrogens).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[7] \"Product Information. Yasmin (drospirenone-ethinyl estradiol)\" Berlex Laboratories, Richmond, CA.[8] Welling PG, Huang H, Hewitt PF, Lyons LL \"Bioavailability of erythromycin stearate: influence of food and fluid volume.\" J Pharm Sci 67 (1978): 764-6[9] Welling PG \"Influence of food and diet on gastrointestinal drug absorption: a review.\" J Pharmacokinet Biopharm 5 (1977): 291-334[10] Randinitis EJ, Sedman AJ, Welling PG, Kinkel AW \"Effect of a high-fat meal on the bioavailability of a polymer-coated erythromycin particle tablet formulation.\" J Clin Pharmacol 29 (1989): 79-84[11] Coyne TC, Shum S, Chun AH, Jeansonne L, Shirkey HC \"Bioavailability of erythromycin ethylsuccinate in pediatric patients.\" J Clin Pharmacol 18 (1978): 194-202[12] Malmborg AS \"Effect of food on absorption of erythromycin. A study of two derivatives, the stearate and the base.\" J Antimicrob Chemother 5 (1979): 591-9[13] Welling PG, Elliott RL, Pitterle ME, et al \"Plasma levels following single and repeated doses of erythromycin estolate and erythromycin stearate.\" J Pharm Sci 68 (1979): 150-5[14] Kanazawa S, Ohkubo T, Sugawara K \"The effects of grapefruit juice on the pharmacokinetics of erythromycin.\" Eur J Clin Pharmacol 56 (2001): 799-803[15] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[16] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Estetrol", "alternatives_b": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, More", "updated_at": 1767369485}, {"id": 67830, "ingredient1": "Clarithromycin", "ingredient2": "Mefloquine", "severity": "Moderate", "effect": "Mefloquine is a myocardial depressant and can cause ECG abnormalities. Theoretically, coadministration with other agents that can affect cardiac conduction (e.g., antiarrhythmic agents, beta blockers, calcium channel blockers, certain antihistamines, tricyclic antidepressants, phenothiazines, some neuroleptics) may result in additive effects and increased risk of ventricular arrhythmias including ventricular tachycardia and torsade de pointes.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended if mefloquine is used in combination with other drugs that can prolong the QT interval or otherwise affect cardiac conduction. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes or other arrhythmia such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended if mefloquine is used in combination with other drugs that can prolong the QT interval or otherwise affect cardiac conduction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67917/", "reference_text": "[1] \"Product Information. Lariam (mefloquine).\" Roche Laboratories, Nutley, NJ.[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Lariam (mefloquine).\" Roche Laboratories, Nutley, NJ.[6] Schmidt LE, Dalhoff K \"Food-drug interactions.\" Drugs 62 (2002): 1481-502[7] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[8] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[9] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[10] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Artesunate, Pyrimethamine, Tafenoquine, Proguanil, Sulfadoxine", "alternatives_b": "Tinidazole, Pantoprazole, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Cimetidine, Esomeprazole, Ranitidine, Nizatidine, More", "updated_at": 1767369485}, {"id": 67831, "ingredient1": "Clarithromycin", "ingredient2": "Megestrol acetate", "severity": "Moderate", "effect": "RECOMMENDED: The effectiveness of estrogen-containing oral contraceptives may be impaired by concomitant treatment with antimicrobial agents. Most antimicrobials, with the exception of the rifamycins and possibly griseofulvin, do not induce hepatic enzymes and have not been shown to significantly increase the clearance of oral contraceptive estrogens. Certain macrolide antibiotics (e.g., erythromycin, clarithromycin) may increase the plasma concentrations and the risk of adverse effects of estrogens and progestogens. The mechanism is decreased clearance of the hormones due to inhibition of CYP450 3A4 activity by the macrolide antibiotic. Concomitant administration with erythromycin may increase the estradiol exposure by approximately 50%.", "source": "DDInter", "management_text": "Until further data are available, women using oral contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant antimicrobial therapy. During concomitant therapy with erythromycin or clarithromycin, patients should be observed for increased or altered pharmacologic response to estrogens and progestogens, and dosage(s) adjusted accordingly as necessary.", "mechanism_text": "Metabolism", "recommendation": "Until further data are available, women using oral contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant antimicrobial therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67918/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception. Available from: URL: file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf.\" ([2012, Jan 1]):[4] \"Product Information. Angeliq (drospirenone-estradiol).\" Berlex Laboratories, Wayne, NJ.[5] \"Product Information. Ortho-Est (estropipate).\" Ortho McNeil Pharmaceutical, Raritan, NJ.[6] \"Product Information. Premarin (conjugated estrogens).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[7] \"Product Information. Yasmin (drospirenone-ethinyl estradiol)\" Berlex Laboratories, Richmond, CA.[8] Welling PG, Huang H, Hewitt PF, Lyons LL \"Bioavailability of erythromycin stearate: influence of food and fluid volume.\" J Pharm Sci 67 (1978): 764-6[9] Welling PG \"Influence of food and diet on gastrointestinal drug absorption: a review.\" J Pharmacokinet Biopharm 5 (1977): 291-334[10] Randinitis EJ, Sedman AJ, Welling PG, Kinkel AW \"Effect of a high-fat meal on the bioavailability of a polymer-coated erythromycin particle tablet formulation.\" J Clin Pharmacol 29 (1989): 79-84[11] Coyne TC, Shum S, Chun AH, Jeansonne L, Shirkey HC \"Bioavailability of erythromycin ethylsuccinate in pediatric patients.\" J Clin Pharmacol 18 (1978): 194-202[12] Malmborg AS \"Effect of food on absorption of erythromycin. A study of two derivatives, the stearate and the base.\" J Antimicrob Chemother 5 (1979): 591-9[13] Welling PG, Elliott RL, Pitterle ME, et al \"Plasma levels following single and repeated doses of erythromycin estolate and erythromycin stearate.\" J Pharm Sci 68 (1979): 150-5[14] Kanazawa S, Ohkubo T, Sugawara K \"The effects of grapefruit juice on the pharmacokinetics of erythromycin.\" Eur J Clin Pharmacol 56 (2001): 799-803[15] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[16] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Estetrol", "alternatives_b": "Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, More", "updated_at": 1767369485}, {"id": 67832, "ingredient1": "Clarithromycin", "ingredient2": "Mephenytoin", "severity": "Moderate", "effect": "Coadministration with phenytoin may reduce the plasma concentrations and antimicrobial efficacy of erythromycin and other macrolide antibiotics. The mechanism is induction of CYP450 3A metabolism by phenytoin. Additionally, plasma concentrations of phenytoin may be increased.", "source": "DDInter", "management_text": "If concomitant use is medically necessary, caution and monitoring for altered efficacy and safety of both medications is recommended.", "mechanism_text": "Metabolism", "recommendation": "If concomitant use is medically necessary, caution and monitoring for altered efficacy and safety of both medications is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67919/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Milne RW, Coulthard K, Nation RL, et al \"Lack of effect of erythromycin on the pharmacokinetics of single oral doses of phenytoin.\" Br J Clin Pharmacol 26 (1988): 330-3[4] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[5] Bachmann K, Schwartz JI, Forney RB Jr, Jauregui L \"Single dose phenytoin clearance during erythromycin treatment.\" Res Commun Chem Pathol Pharmacol 46 (1984): 207-17[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Fleisher D, Sheth N, Kou JH \"Phenytoin interaction with enteral feedings administered through nasogastric tubes.\" JPEN J Parenter Enteral Nutr 14 (1990): 513-6[9] Krueger KA, Garnett WR, Comstock TJ, Fitzsimmons WE, Karnes HT, Pellock JM \"Effect of two administration schedules of an enteral nutrient formula on phenytoin bioavailability.\" Epilepsia 28 (1987): 706-12[10] Haley CJ, Nelson J \"Phenytoin-enteral feeding interaction.\" DICP 23 (1989): 796-8[11] Faraji B, Yu PP \"Serum phenytoin levels of patients on gastrostomy tube feeding.\" J Neurosci Nurs 30 (1998): 55-9[12] Au Yeung SC, Ensom MH \"Phenytoin and enteral feedings: does evidence support an interaction?\" Ann Pharmacother 34 (2000): 896-905[13] Sandor P, Sellers EM, Dumbrell M, Khouw V \"Effect of short- and long-term alcohol use on phenytoin kinetics in chronic alcoholics.\" Clin Pharmacol Ther 30 (1981): 390-7[14] Ozuna J, Friel P \"Effect of enteral tube feeding on serum phenytoin levels.\" J Neurosurg Nurs 16 (1984): 289-91[15] Guidry JR, Eastwood TF, Curry SC \"Phenytoin absorption in volunteers receiving selected enteral feedings.\" West J Med 150 (1989): 659-61[16] Marvel ME, Bertino JS \"Comparative effects of an elemental and a complex enteral feeding formulation on the absorption of phenytoin suspension.\" JPEN J Parenter Enteral Nutr 15 (1991): 316-8[17] \"Product Information. Dilantin (phenytoin).\" Parke-Davis, Morris Plains, NJ.[18] Doak KK, Haas CE, Dunnigan KJ, et al. \"Bioavailability of phenytoin acid and phenytoin sodium with enteral feedings.\" Pharmacotherapy 18 (1998): 637-45[19] Rodman DP, Stevenson TL, Ray TR \"Phenytoin malabsorption after jejunostomy tube delivery.\" Pharmacotherapy 15 (1995): 801-5[20] Sellers EM, Holloway MR \"Drug kinetics and alcohol ingestion.\" Clin Pharmacokinet 3 (1978): 440-52[21] Holtz L, Milton J, Sturek JK \"Compatibility of medications with enteral feedings.\" JPEN J Parenter Enteral Nutr 11 (1987): 183-6", "alternatives_a": "Tiagabine, Brivaracetam, Rufinamide, Methsuximide, Paramethadione, Fenfluramine, Eslicarbazepine, Phensuximide, Methylphenobarbital, Phenacemide, Primidone, More", "alternatives_b": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Cimetidine, More", "updated_at": 1767369485}, {"id": 67833, "ingredient1": "Clarithromycin", "ingredient2": "Mesoridazine", "severity": "Major", "effect": "Mesoridazine can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Mesoridazine overdosage has been associated with ventricular arrhythmias and death. The extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s). In addition, certain agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive parasympatholytic and central nervous system-depressant effects when used in combination with mesoridazine. Excessive parasympatholytic effects may include paralytic ileus, hyperthermia, mydriasis, blurred vision, tachycardia, urinary retention, psychosis, and seizures.", "source": "DDInter", "management_text": "Coadministration of mesoridazine with other drugs that can prolong the QT interval is considered contraindicated.", "mechanism_text": "Synergism", "recommendation": "Coadministration of mesoridazine with other drugs that can prolong the QT interval is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67920/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Serentil (mesoridazine)\" Boehringer-Ingelheim, Ridgefield, CT.[4] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[5] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):", "alternatives_a": "Loxapine, Molindone, Thiothixene", "alternatives_b": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, Ranitidine, More", "updated_at": 1767369485}, {"id": 67834, "ingredient1": "Clarithromycin", "ingredient2": "Orciprenaline", "severity": "Moderate", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.", "source": "DDInter", "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67921/", "reference_text": "[1] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990): 575-9[6] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003): 1817-24[8] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998): 145-7[11] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990): 1396-9[16] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.[17] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006): 582-90[19] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[20] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[21] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001): 45-51[26] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986): 619-20", "alternatives_a": "Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Ipratropium, Beclomethasone dipropionate, Ephedrine", "alternatives_b": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Rifabutin, Cimetidine, More", "updated_at": 1767369485}, {"id": 67835, "ingredient1": "Clarithromycin", "ingredient2": "Methadone", "severity": "Major", "effect": "Methadone may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. High dosages of methadone alone have been associated with QT interval prolongation and torsade de pointes.", "source": "DDInter", "management_text": "Caution is recommended if methadone is used in combination with other drugs that can prolong the QT interval, particularly in the setting of chronic pain management or methadone maintenance for opioid dependency where high dosages may be employed. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. If taking drugs that also cause CNS-depressant or orthostatic effects (e.g., sedating antihistamines, psychotropic drugs like tricyclic antidepressants, phenothiazines, and neuroleptics), patients should be made aware of the possibility of additive effects with methadone and counseled to avoid activities requiring mental alertness until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if methadone is used in combination with other drugs that can prolong the QT interval, particularly in the setting of chronic pain management or methadone maintenance for opioid dependency where high dosages may be employed.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67922/", "reference_text": "[1] Krantz MJ, Mehler PS \"Synthetic opioids and QT prolongation.\" Arch Intern Med 163 (2003): 1615; author reply 1615[2] Mokwe EO, Ositadinma O \"Torsade de pointes due to methadone.\" Ann Intern Med 139 (2003): W64[3] Gil M, Sala M, Anguera I, et al. \"QT prolongation and Torsades de Pointes in patients infected with human immunodeficiency virus and treated with methadone.\" Am J Cardiol 92 (2003): 995-7[4] Krantz MJ, Lewkowiez L, Hays H, et al \"Torsade de pointes associated with very-high-dose methadone.\" Ann Intern Med 137 (2002): 501-4[5] Ehret GB, Desmeules JA, Broers B \"Methadone-associated long QT syndrome: improving pharmacotherapy for dependence on illegal opioids and lessons learned for pharmacology.\" Expert Opin Drug Saf 6 (2007): 289-303[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Sala M, Anguera I, Cervantes M \"Torsade de pointes due to methadone.\" Ann Intern Med 139 (2003): W64[8] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[9] Walker PW, Klein D, Kasza L \"High dose methadone and ventricular arrhythmias: a report of three cases.\" Pain 103 (2003): 321-4[10] Krantz MJ, Kutinsky IB, Robertson AD, Mehler PS \"Dose-related effects of methadone on QT prolongation in a series of patients with torsade de pointes.\" Pharmacotherapy 23 (2003): 802-5[11] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[12] De Bels D, Staroukine M, Devriendt J \"Torsades de pointes due to methadone.\" Ann Intern Med 139 (2003): E156[13] Cerner Multum, Inc. \"Australian Product Information.\" O 0[14] Martell BA, Arnsten JH, Krantz MJ, Gourevitch MN \"Impact of methadone treatment on cardiac repolarization and conduction in opioid users.\" Am J Cardiol 95 (2005): 915-8[15] Beauverie P, Taburet AM, Dessalles MC, Furlan V, Touzeau D \"Therapeutic drug monitoring of methadone in HIV-infected patients receiving protease inhibitors.\" AIDS 12 (1998): 2510-1[16] Geletko SM, Erickson AD \"Decreased methadone effect after ritonavir initiation.\" Pharmacotherapy 20 (2000): 93-4[17] Foster DJ, Somogyi AA, Bochner F \"Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4.\" Br J Clin Pharmacol 47 (1999): 403-12[18] Benmebarek M, Devaud C, Gex-Fabry M, et al. \"Effects of grapefruit juice on the pharmacokinetics of the enantiomers of methadone.\" Clin Pharmacol Ther 76 (2004): 55-63[19] Oda Y, Kharasch ED \"Metabolism of methadone and levo-alpha-acetylmethadol (LAAM) by human intestinal cytochrome P450 3A4 (CYP3A4): potential contribution of intestinal metabolism to presystemic clearance and bioactivation.\" J Pharmacol Exp Ther 298 (2001): 1021-32[20] Iribarne C, Berthou F, Baird S, Dreano Y, Picart D, Bail JP, Beaune P, Menez JF \"Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes.\" Chem Res Toxicol 9 (1996): 365-73[21] \"Product Information. Kaletra (lopinavir-ritonavir)\" Abbott Pharmaceutical, Abbott Park, IL.[22] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Nalmefene, Diamorphine, Acamprosate, Oxymorphone, Tapentadol, Dezocine, Opium, Pentazocine, Nalbuphine, Dihydrocodeine, Naloxone, Codeine", "alternatives_b": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Nizatidine, Esomeprazole, Amoxicillin, Dirithromycin, More", "updated_at": 1767369485}, {"id": 67836, "ingredient1": "Clarithromycin", "ingredient2": "Meticillin", "severity": "Minor", "effect": "Although some in vitro data indicate synergism between macrolide antibiotics and penicillins, other in vitro data indicate antagonism. When these drugs are given together, neither has predictable therapeutic efficacy. Data are available for erythromycin, although theoretically this interaction could occur with any macrolide. Except for monitoring of the effectiveness of antibiotic therapy, no special precautions appear to be necessary.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67923/", "reference_text": "[1] Strom J \"Penicillin and erythromycin singly and in combination in scarlatina therapy and the interference between them.\" Antibiot Chemother 11 (1961): 694-7[2] Cohn JR, Jungkind DL, Baker JS \"In vitro antagonism by erythromycin of the bactericidal action of antimicrobial agents against common respiratory pathogens.\" Antimicrob Agents Chemother 18 (1980): 872-6[3] Penn RL, Ward TT, Steigbigel RT \"Effects of erythromycin in combination with penicillin, ampicillin, or gentamicin on the growth of listeria monocytogenes.\" Antimicrob Agents Chemother 22 (1982): 289-94", "alternatives_a": "Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, More", "alternatives_b": "Tazobactam, Sulbactam", "updated_at": 1767369485}, {"id": 67837, "ingredient1": "Clarithromycin", "ingredient2": "Methotrexate", "severity": "Moderate", "effect": "Coadministration of methotrexate with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Methotrexate, especially at higher doses or with prolonged treatment, has been associated with hepatotoxicity including acute hepatitis, chronic fibrosis, necrosis, cirrhosis, and liver enzyme elevations.", "source": "DDInter", "management_text": "The risk of hepatic injury should be considered when methotrexate is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Baseline and periodic monitoring of hepatic function is recommended, while liver biopsy may be warranted during long-term use of methotrexate. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, pale stools, and jaundice.", "mechanism_text": "Synergism", "recommendation": "The risk of hepatic injury should be considered when methotrexate is used with other potentially hepatotoxic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67924/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Methotrexate (methotrexate).\" Lederle Laboratories, Wayne, NJ.[3] Nesher G, Mates M, Zevin S \"Effect of caffeine consumption on efficacy of methotrexate in rheumatoid arthritis.\" Arthritis Rheum 48 (2003): 571-572", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Anakinra, More", "alternatives_b": "Tinidazole, Bismuth subcitrate potassium, Rifabutin, Vonoprazan, Lincomycin, Dirithromycin", "updated_at": 1767369485}, {"id": 67838, "ingredient1": "Clarithromycin", "ingredient2": "Methotrimeprazine", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67925/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[16] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, Ranitidine, More", "alternatives_b": "Loxapine, Molindone, Thiothixene", "updated_at": 1767369485}, {"id": 67839, "ingredient1": "Clarithromycin", "ingredient2": "Methylergometrine", "severity": "Major", "effect": "Coadministration with certain macrolide antibiotics may significantly increase the plasma concentrations of ergot derivatives. The mechanism is macrolide inhibition of CYP450 3A4, the isoenzyme responsible for the metabolic clearance of ergotamine and related drugs. Macrolides that may significantly inhibit CYP450 3A4 include clarithromycin, erythromycin and troleandomycin, and clinical ergotism has been reported in patients receiving ergotamine or dihydroergotamine with these agents.", "source": "DDInter", "management_text": "Given the potential for ergot toxicity characterized by peripheral vasospasm, ischemia, thrombosis, tachycardia and hypertension, concomitant use of ergot derivatives with clarithromycin, erythromycin, or troleandomycin is considered contraindicated. Although clinical data have not been reported, some manufacturers also consider the combination of cabergoline with macrolides contraindicated or to be avoided on theoretical grounds. Azithromycin may be a safer alternative during therapy with ergot derivatives.", "mechanism_text": "Metabolism", "recommendation": "Given the potential for ergot toxicity characterized by peripheral vasospasm, ischemia, thrombosis, tachycardia and hypertension, concomitant use of ergot derivatives with clarithromycin, erythromycin, or troleandomycin is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67926/", "reference_text": "[1] Matthews NT, Havill JH \"Ergotism with therapeutic doses of ergotamine tartrate.\" N Z Med J 89 (1979): 476-7[2] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[3] Ghali R, De Lean J, Douville Y, Noel HP, Labbe R \"Erythromycin-associated ergotamine intoxication: arteriographic and electrophysiologic analysis of a rare cause of severe ischemia of the lower extremities and associated ischemic neuropathy.\" Ann Vasc Surg 7 (1993): 291-6[4] Srisuma S, Lavonas EJ, Wananukul W \"Ergotism and factitious hypotension associated with interaction of ergotamine with CYP3A4 inhibitors.\" Clin Toxicol (Phila) (2014): 1-4[5] Horowitz RS, Dart RC, Gomez HF \"Clinical ergotism with lingual ischemia induced by clarithromycin-ergotamine interaction.\" Arch Intern Med 156 (1996): 456-8[6] Francis H, Tyndall A, Webb J \"Severe vascular spasm due to erythromycin-ergotamine interaction.\" Clin Rheumatol 3 (1984): 243-6[7] Hayton AC \"Precipitation of acute ergotism by triacetyloleandomycin.\" N Z Med J 69 (1969): 42[8] \"Product Information. Migranal (dihydroergotamine nasal).\" Novartis Pharmaceuticals, East Hanover, NJ.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Cafergot (caffeine-ergotamine).\" Novartis Pharmaceuticals, East Hanover, NJ.[11] Eadie MJ \"Clinically significant drug interactions with agents specific for migraine attacks.\" Cns Drugs 15 (2001): 105-18[12] Leroy F, Asseman P, Pruvost P, Adnet P, Lacroix D, Thery C \"Dihydroergotamine-erythromycin-induced ergotism.\" Ann Intern Med 109 (1988): 249[13] Bird PA, Sturgess AD \"Clinical ergotism with severe bilateral upper limb ischaemia precipitated by an erythromycin - ergotamine drug interaction.\" Aust N Z J Med 30 (2000): 635-6[14] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[15] Ausband SC, Goodman PE \"An unusual case of clarithromycin associated ergotism.\" J Emerg Med 4 (2001): 411-3[16] Nakatsuka A, Nagai M, Yabe H, et al. \"Effect of clarithromycin on the pharmacokinetics of cabergoline in healthy controls and in patients with Parkinson's disease.\" J Pharmacol Sci 100 (2006): 59-64[17] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[18] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[19] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[20] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[21] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[22] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[23] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[24] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[25] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[26] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[27] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[28] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[29] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[30] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[31] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[32] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[33] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[34] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[35] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[36] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[37] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[38] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[39] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[40] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[41] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[42] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[43] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[44] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[45] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[46] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[47] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[48] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8", "alternatives_a": "Dinoprostone", "alternatives_b": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Bismuth subcitrate potassium, Metronidazole, Famotidine, Nizatidine, Esomeprazole, More", "updated_at": 1767369485}, {"id": 67840, "ingredient1": "Clarithromycin", "ingredient2": "Methylprednisolone", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of methylprednisolone. Various CYP450 3A4 inhibitors including clarithromycin, diltiazem, erythromycin, itraconazole, ketoconazole, mibefradil, nefazodone, and troleandomycin have been shown to increase methylprednisolone systemic exposure (AUC) by approximately 100% to 300%, with increased adrenal suppression as evidenced by reduced plasma cortisol levels.", "source": "DDInter", "management_text": "The possibility of increased corticosteroid effects should be considered when methylprednisolone is used with potent CYP450 3A4 inhibitors. Coadministration is not recommended unless the potential benefit to the patient outweighs the risk. If concomitant use is necessary, a 50% reduction in methylprednisolone dosage has been recommended by some investigators. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical \"buffalo\" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if methylprednisolone is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression. Signs and symptoms of adrenal insufficiency include anorexia, hypoglycemia, nausea, vomiting, weight loss, muscle wasting, fatigue, weakness, dizziness, postural hypotension, depression, and adrenal crisis manifested as inability to respond to stress (e.g., illness, infection, surgery, trauma).", "mechanism_text": "Metabolism", "recommendation": "The possibility of increased corticosteroid effects should be considered when methylprednisolone is used with potent CYP450 3A4 inhibitors.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67927/", "reference_text": "[1] Varis T, Backman JT, Kivisto KT, Neuvonen PJ \"Diltiazem and mibefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone.\" Clin Pharmacol Ther 67 (2000): 215-21[2] Varis T, Kaukonen KM, Kivisto KT, Neuvonen PJ \"Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole.\" Clin Pharmacol Ther 64 (1998): 363-8[3] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[4] Kandrotas RJ, Slaughter RL, Brass C, Jusko WJ \"Ketoconazole effects on methylprednisolone disposition and their joint suppression of endogenous cortisol.\" Clin Pharmacol Ther 42 (1987): 465-70[5] Glynn AM, Slaughter RL, Brass C, et al \"Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretion.\" Clin Pharmacol Ther 39 (1986): 654-9[6] Kotlyar M, Brewer ER, Golding M, Carson SW \"Nefazodone inhibits methylprednisolone disposition and enhances its adrenal-suppressant effect.\" J Clin Psychopharmacol 23 (2003): 652-6[7] LaForce CF, Szefler SJ, Miller MF, Ebling W, Brenner M \"Inhibition of methylprednisolone elimination in the presence of erythromycin therapy.\" J Allergy Clin Immunol 72 (1983): 34-9[8] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[9] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[10] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[11] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[12] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[13] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[14] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[15] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[16] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[17] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[18] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[19] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[20] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[21] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[22] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[23] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[24] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[25] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[26] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[27] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[28] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[29] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[30] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[31] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[32] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[33] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[34] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[35] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[36] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[37] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[38] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[39] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[40] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[41] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[42] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Vitamin A, Isotretinoin, Fluorometholone, Azelaic acid, Adapalene, Fluocinolone acetonide, Beclomethasone dipropionate, Fluocinonide, Fluorometholone, Fluocinolone acetonide, Fluorometholone, More", "alternatives_b": "Tinidazole, Dexlansoprazole, Bismuth subcitrate potassium, Esomeprazole, Vonoprazan, Lincomycin, Dirithromycin", "updated_at": 1767369485}, {"id": 67841, "ingredient1": "Clarithromycin", "ingredient2": "Methysergide", "severity": "Major", "effect": "Coadministration with certain macrolide antibiotics may significantly increase the plasma concentrations of ergot derivatives. The mechanism is macrolide inhibition of CYP450 3A4, the isoenzyme responsible for the metabolic clearance of ergotamine and related drugs. Macrolides that may significantly inhibit CYP450 3A4 include clarithromycin, erythromycin and troleandomycin, and clinical ergotism has been reported in patients receiving ergotamine or dihydroergotamine with these agents.", "source": "DDInter", "management_text": "Given the potential for ergot toxicity characterized by peripheral vasospasm, ischemia, thrombosis, tachycardia and hypertension, concomitant use of ergot derivatives with clarithromycin, erythromycin, or troleandomycin is considered contraindicated. Although clinical data have not been reported, some manufacturers also consider the combination of cabergoline with macrolides contraindicated or to be avoided on theoretical grounds. Azithromycin may be a safer alternative during therapy with ergot derivatives.", "mechanism_text": "Metabolism", "recommendation": "Given the potential for ergot toxicity characterized by peripheral vasospasm, ischemia, thrombosis, tachycardia and hypertension, concomitant use of ergot derivatives with clarithromycin, erythromycin, or troleandomycin is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67928/", "reference_text": "[1] Matthews NT, Havill JH \"Ergotism with therapeutic doses of ergotamine tartrate.\" N Z Med J 89 (1979): 476-7[2] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[3] Ghali R, De Lean J, Douville Y, Noel HP, Labbe R \"Erythromycin-associated ergotamine intoxication: arteriographic and electrophysiologic analysis of a rare cause of severe ischemia of the lower extremities and associated ischemic neuropathy.\" Ann Vasc Surg 7 (1993): 291-6[4] Srisuma S, Lavonas EJ, Wananukul W \"Ergotism and factitious hypotension associated with interaction of ergotamine with CYP3A4 inhibitors.\" Clin Toxicol (Phila) (2014): 1-4[5] Horowitz RS, Dart RC, Gomez HF \"Clinical ergotism with lingual ischemia induced by clarithromycin-ergotamine interaction.\" Arch Intern Med 156 (1996): 456-8[6] Francis H, Tyndall A, Webb J \"Severe vascular spasm due to erythromycin-ergotamine interaction.\" Clin Rheumatol 3 (1984): 243-6[7] Hayton AC \"Precipitation of acute ergotism by triacetyloleandomycin.\" N Z Med J 69 (1969): 42[8] \"Product Information. Migranal (dihydroergotamine nasal).\" Novartis Pharmaceuticals, East Hanover, NJ.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Cafergot (caffeine-ergotamine).\" Novartis Pharmaceuticals, East Hanover, NJ.[11] Eadie MJ \"Clinically significant drug interactions with agents specific for migraine attacks.\" Cns Drugs 15 (2001): 105-18[12] Leroy F, Asseman P, Pruvost P, Adnet P, Lacroix D, Thery C \"Dihydroergotamine-erythromycin-induced ergotism.\" Ann Intern Med 109 (1988): 249[13] Bird PA, Sturgess AD \"Clinical ergotism with severe bilateral upper limb ischaemia precipitated by an erythromycin - ergotamine drug interaction.\" Aust N Z J Med 30 (2000): 635-6[14] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[15] Ausband SC, Goodman PE \"An unusual case of clarithromycin associated ergotism.\" J Emerg Med 4 (2001): 411-3[16] Nakatsuka A, Nagai M, Yabe H, et al. \"Effect of clarithromycin on the pharmacokinetics of cabergoline in healthy controls and in patients with Parkinson's disease.\" J Pharmacol Sci 100 (2006): 59-64[17] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[18] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[19] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[20] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[21] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[22] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[23] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[24] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[25] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[26] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[27] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[28] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[29] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[30] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[31] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[32] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[33] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[34] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[35] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[36] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[37] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[38] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[39] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[40] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[41] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[42] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[43] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[44] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[45] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[46] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[47] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[48] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8", "alternatives_a": "Frovatriptan, Eptinezumab, Lasmiditan, Rizatriptan, Galcanezumab, Zolmitriptan, Erenumab, Fremanezumab", "alternatives_b": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Nizatidine, More", "updated_at": 1767369485}, {"id": 67842, "ingredient1": "Clarithromycin", "ingredient2": "Metronidazole", "severity": "Minor", "effect": "Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67929/", "reference_text": "[1] Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F \"QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.\" Pacing Clin Electrophysiol 28 (2005): 472-3[2] Giannini AJ, DeFrance DT \"Metronidazole and alcohol: potential for combinative abuse.\" J Toxicol Clin Toxicol 20 (1983): 509-15[3] \"Product Information. Benznidazole (benznidazole).\" Everett Laboratories Inc, West Orange, NJ.[4] Williams CS, Woodcock KR \"Do ethanol and metronidazole interact to produce a disulfiram-like reaction?.\" Ann Pharmacother 34 (2000): 255-7[5] Krulewitch CJ \"An unexpected adverse drug effect.\" J Midwifery Womens Health 48 (2003): 67-8[6] Alexander I \"Alcohol-antabuse syndrome in patients receiving metronidazole during gynaecological treatment.\" Br J Clin Pract 39 (1985): 292-3[7] \"Product Information. Flagyl (metronidazole).\" Searle, Skokie, IL.[8] Harries DP, Teale KF, Sunderland G \"Metronidazole and alcohol: potential problems.\" Scott Med J 35 (1990): 179-80[9] Visapaa JP, Tillonen JS, Kaihovaara PS, Salaspuro MP \"Lack of disulfiram-like reaction with metronidazole and ethanol.\" Ann Pharmacother 36 (2002): 971-4[10] Edwards DL, Fink PC, Van Dyke PO \"Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole.\" Clin Pharm 5 (1986): 999-1000[11] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[12] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[13] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[14] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Bismuth subcitrate potassium, Vonoprazan, Clarithromycin, Tinidazole, Quinacrine, Secnidazole, Furazolidone, Nitazoxanide, Trimetrexate, Mafenide, More", "alternatives_b": "Tinidazole, Dexlansoprazole, Bismuth subcitrate potassium, Metronidazole, Esomeprazole, Vonoprazan, Lincomycin, Troleandomycin, Dirithromycin", "updated_at": 1767369485}, {"id": 67843, "ingredient1": "Clarithromycin", "ingredient2": "Mezlocillin", "severity": "Minor", "effect": "Although some in vitro data indicate synergism between macrolide antibiotics and penicillins, other in vitro data indicate antagonism. When these drugs are given together, neither has predictable therapeutic efficacy. Data are available for erythromycin, although theoretically this interaction could occur with any macrolide. Except for monitoring of the effectiveness of antibiotic therapy, no special precautions appear to be necessary.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67930/", "reference_text": "[1] Strom J \"Penicillin and erythromycin singly and in combination in scarlatina therapy and the interference between them.\" Antibiot Chemother 11 (1961): 694-7[2] Cohn JR, Jungkind DL, Baker JS \"In vitro antagonism by erythromycin of the bactericidal action of antimicrobial agents against common respiratory pathogens.\" Antimicrob Agents Chemother 18 (1980): 872-6[3] Penn RL, Ward TT, Steigbigel RT \"Effects of erythromycin in combination with penicillin, ampicillin, or gentamicin on the growth of listeria monocytogenes.\" Antimicrob Agents Chemother 22 (1982): 289-94", "alternatives_a": "Tazobactam, Sulbactam", "alternatives_b": "Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, More", "updated_at": 1767369485}, {"id": 67844, "ingredient1": "Clarithromycin", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "The macrolide antibiotics clarithromycin and erythromycin may increase and prolong the CNS effects of certain benzodiazepines. The mechanism is inhibition of CYP450 3A4 hepatic oxidation of the benzodiazepines. The effect appears most pronounced with oral midazolam and triazolam.", "source": "DDInter", "management_text": "The use of oral midazolam or triazolam in combination with clarithromycin or erythromycin should generally be avoided. Some authorities consider the use of oral midazolam with clarithromycin contraindicated. Patients receiving triazolam or IV midazolam in combination with erythromycin or clarithromycin should be monitored for excessive or prolonged sedation. Dose adjustment of the benzodiazepine should be considered. Some authorities suggest a dose reduction of midazolam during long-term IV infusion of up to 50% of the initial dose followed by careful titration. Non-interacting benzodiazepines or antimicrobials may be considered as alternatives.", "mechanism_text": "Metabolism", "recommendation": "The use of oral midazolam or triazolam in combination with clarithromycin or erythromycin should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67931/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Versed (midazolam).\" Roche Laboratories, Nutley, NJ.[3] \"Product Information. Halcion (triazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Welling PG, Huang H, Hewitt PF, Lyons LL \"Bioavailability of erythromycin stearate: influence of food and fluid volume.\" J Pharm Sci 67 (1978): 764-6[6] Welling PG \"Influence of food and diet on gastrointestinal drug absorption: a review.\" J Pharmacokinet Biopharm 5 (1977): 291-334[7] Randinitis EJ, Sedman AJ, Welling PG, Kinkel AW \"Effect of a high-fat meal on the bioavailability of a polymer-coated erythromycin particle tablet formulation.\" J Clin Pharmacol 29 (1989): 79-84[8] Coyne TC, Shum S, Chun AH, Jeansonne L, Shirkey HC \"Bioavailability of erythromycin ethylsuccinate in pediatric patients.\" J Clin Pharmacol 18 (1978): 194-202[9] Malmborg AS \"Effect of food on absorption of erythromycin. A study of two derivatives, the stearate and the base.\" J Antimicrob Chemother 5 (1979): 591-9[10] Welling PG, Elliott RL, Pitterle ME, et al \"Plasma levels following single and repeated doses of erythromycin estolate and erythromycin stearate.\" J Pharm Sci 68 (1979): 150-5[11] Kanazawa S, Ohkubo T, Sugawara K \"The effects of grapefruit juice on the pharmacokinetics of erythromycin.\" Eur J Clin Pharmacol 56 (2001): 799-803[12] Kupferschmidt HHT, Ha HR, Ziegler WH, Meier PJ, Krahenbuhl S \"Interaction between grapefruit juice and midazolam in humans.\" Clin Pharmacol Ther 58 (1995): 20-8[13] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[14] \"Product Information. Valium (diazepam).\" Roche Laboratories, Nutley, NJ.[15] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[16] \"Product Information. Halcion (triazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.[17] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[18] \"Product Information. Xanax (alprazolam).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Methohexital, Methylphenobarbital, Pentobarbital, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, Paraldehyde, Ethchlorvynol, Amobarbital, More", "alternatives_b": "Tinidazole, Levofloxacin, Tetracycline, Dexlansoprazole, Rabeprazole, Misoprostol, Bismuth subcitrate potassium, Nizatidine, Esomeprazole, Vonoprazan, Amoxicillin, More", "updated_at": 1767369485}, {"id": 67845, "ingredient1": "Clarithromycin", "ingredient2": "Midostaurin", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of midostaurin and its active metabolites, which are all substrates of the isoenzyme. The increase in midostaurin concentrations may be particularly pronounced when CYP450 3A4 inhibitors are administered during the first week of midostaurin administration.", "source": "DDInter", "management_text": "Concomitant use of midostaurin with potent CYP450 3A4 inhibitors should generally be avoided. If coadministration is required, patients should be closely monitored for increased adverse reactions (e.g., nausea, vomiting, diarrhea, edema, hyperglycemia, hyperuricemia, QT prolongation, neutropenia, lymphopenia, thrombocytopenia, anemia), especially during the first week of consecutive midostaurin administration in patients with advanced systemic mastocytosis and during the first week of midostaurin administration in each cycle of chemotherapy in patients with acute myeloid leukemia.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of midostaurin with potent CYP450 3A4 inhibitors should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67932/", "reference_text": "[1] Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y \"Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers.\" Cancer Chemother Pharmacol 72 (2013): 1223-34[2] \"Product Information. Rydapt (midostaurin).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Rydapt (midostaurin).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[5] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Nizatidine, Esomeprazole, Ranitidine, More", "alternatives_b": "Alpelisib, Trametinib, Dacomitinib, Tivozanib, Alectinib", "updated_at": 1767369485}, {"id": 67846, "ingredient1": "Clarithromycin", "ingredient2": "Mifepristone", "severity": "Major", "effect": "Mifepristone may prolong the QTc interval in a dose-related manner. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Coadministration with potent inhibitors of CYP450 3A4 such as ceritinib, clarithromycin, ketoconazole, posaconazole, saquinavir, telithromycin, and voriconazole may significantly increase the plasma concentrations of mifepristone, which is primarily metabolized by the isoenzyme. Additionally, these agents may prolong the QT interval, which may potentiate the risk of cardiac arrhythmias when administered with mifepristone.", "source": "DDInter", "management_text": "When mifepristone is used daily to control hyperglycemia secondary to hypercortisolism in patients with endogenous Cushing's syndrome, coadministration with other drugs that can prolong the QT interval should generally be avoided. If concomitant use with ceritinib, clarithromycin, ketoconazole, posaconazole, saquinavir, telithromycin, or voriconazole is required and no alternatives are available, the dosage of mifepristone should be limited to 300 mg/day in accordance with labeling recommendation for use in combination with potent CYP450 3A4 inhibitors. Serum potassium should be assessed prior to starting mifepristone and 1 to 2 weeks following initiation of therapy or an increase in dosage, and periodically as needed. Hypokalemia must be corrected prior to initiation of mifepristone. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hypokalemia such as fatigue, weakness, myalgia, muscle cramps, numbness, tingling, abdominal pain, constipation, palpitation, and irregular heart rhythm. Because mifepristone is eliminated slowly from the body, drug interactions may be observed for a prolonged period following discontinuation (approximately 2 to 3 weeks if mifepristone had been administered chronically to steady state).", "mechanism_text": "Metabolism, Synergism", "recommendation": "When mifepristone is used daily to control hyperglycemia secondary to hypercortisolism in patients with endogenous Cushing's syndrome, coadministration with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67933/", "reference_text": "[1] \"Product Information. Korlym (mifepristone).\" Corcept Therapeutics Incorporated, Menlo Park, CA.[2] \"Product Information. Mifeprex (mifepristone)\" Danco Laboratories, New York, NY.[3] \"Product Information. Korlym (mifepristone).\" Corcept Therapeutics Incorporated, Menlo Park, CA.[4] \"Product Information. Mifeprex (mifepristone)\" Danco Laboratories, New York, NY.[5] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[6] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Prasterone, Danazol, Bazedoxifene", "alternatives_b": "Pantoprazole, Tetracycline, Rabeprazole, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Nizatidine, Esomeprazole, Ranitidine, Amoxicillin, More", "updated_at": 1767369485}, {"id": 67847, "ingredient1": "Clarithromycin", "ingredient2": "Miglitol", "severity": "Moderate", "effect": "Concomitant use of insulin and other antidiabetic agents with clarithromycin may cause significant hypoglycemia. There have been rare reports of hypoglycemia in patients treated with clarithromycin, some of whom were taking oral hypoglycemic agents or insulin. The exact mechanism of interaction has not been established. With certain hypoglycemic drugs such as nateglinide, pioglitazone, repaglinide and rosiglitazone, inhibition of the CYP450 3A4 isoenzyme by clarithromycin may be involved.", "source": "DDInter", "management_text": "Caution is advised if clarithromycin is prescribed to patients receiving antidiabetic agents. Patients should be advised to regularly monitor their blood sugar and counseled on how to recognize and treat hypoglycemia, which may include symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if clarithromycin is prescribed to patients receiving antidiabetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67934/", "reference_text": "[1] Otsuka SH \"Severe hypoglycemia from helicobacter pylori triple-drug therapy and insulin detemir drug interaction.\" Pharmacotherapy 33 (2013): e45-9[2] Niemi M, Neuvonen PJ, Kivisto KT \"The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide.\" Clin Pharmacol Ther 70 (2001): 58-65[3] Schelleman H, Bilker WB, Brensinger CM, Wan F, Hennessy S \"Anti-infectives and the risk of severe hypoglycemia in users of glipizide or glyburide.\" Clin Pharmacol Ther 88 (2010): 214-22[4] Khamaisi M, Leitersdorf E \"Severe hypoglycemia from clarithromycin-repaglinide drug interaction.\" Pharmacotherapy 28 (2008): 682-4[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Leiba A, Leibowitz A, Grossman E \"An unusual case of hypoglycemia in a diabetic patient.\" Ann Emerg Med 44 (2004): 427-8[7] Bussing R, Gende A \"Severe hypoglycemia from clarithromycin-sulfonylurea drug interaction.\" Diabetes Care 25 (2002): 1659-61[8] \"Product Information. Biaxin (clarithromycin).\" Abbott Pharmaceutical, Abbott Park, IL.[9] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[10] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[11] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[12] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[13] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[14] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[15] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[16] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[17] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[18] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[19] Cheng KL, Nafziger AN, Peloquin CA, Amsden GW \"Effect of grapefruit juice on clarithromycin pharmacokinetics.\" Antimicrob Agents Chemother 42 (1998): 927-9", "alternatives_a": "Guar gum", "alternatives_b": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Rifabutin, Cimetidine, More", "updated_at": 1767369485}, {"id": 67848, "ingredient1": "Clarithromycin", "ingredient2": "Mineral oil", "severity": "Moderate", "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67935/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Schaefer DC, Cheskin LJ \"Constipation in the elderly.\" Am Fam Physician 58 (1998): 907-14[4] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993): 138-45[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998): 517-8", "alternatives_a": "Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Sucralfate, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 67849, "ingredient1": "Clarithromycin", "ingredient2": "Mipomersen", "severity": "Major", "effect": "Coadministration of mipomersen with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Mipomersen can cause elevations in serum transaminases and hepatic steatosis.", "source": "DDInter", "management_text": "Caution is advised if mipomersen is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; amiodarone; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; kinase inhibitors; methotrexate; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; tamoxifen; tetracyclines; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; other lipid-lowering medications such as fenofibrate, lomitapide, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Mipomersen has not been studied with other LDL-lowering agents that can also increase hepatic fat, thus concomitant use is not recommended. Patients treated with mipomersen should have serum ALT, AST, alkaline phosphatase, and total bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary. Since alcohol may increase levels of hepatic fat and induce or exacerbate liver injury, the manufacturer recommends that patients taking mipomersen not consume more than one alcoholic drink per day. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if mipomersen is used with other potentially hepatotoxic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67936/", "reference_text": "[1] \"Product Information. Kynamro (mipomersen).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Kynamro (mipomersen).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Tinidazole, Pantoprazole, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Rifabutin, Cimetidine, More", "alternatives_b": "Gemfibrozil, Fenofibric acid, Pitavastatin, Evinacumab, Evolocumab, Dextrothyroxine, Cholestyramine, Clofibrate, Colestipol, Bempedoic acid, Colesevelam, More", "updated_at": 1767369485}, {"id": 67850, "ingredient1": "Clarithromycin", "ingredient2": "Mirabegron", "severity": "Minor", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of mirabegron, which has been shown in vitro to be a substrate of the isoenzyme. However, in vivo results indicate that CYP450 3A4 may play a limited role in the overall elimination. No dosage adjustment is recommended when mirabegron is administered in combination with ketoconazole and probably other CYP450 3A4 inhibitors.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67937/", "reference_text": "[1] \"Product Information. Myrbetriq (mirabegron).\" Astellas Pharma US, Inc, Deerfield, IL.[2] \"Product Information. Myrbetriq (mirabegron).\" Astellas Pharma US, Inc, Deerfield, IL.", "alternatives_a": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, More", "alternatives_b": "Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Phenyl salicylate, Ammonium chloride, Dimethyl sulfoxide", "updated_at": 1767369485}, {"id": 67851, "ingredient1": "Clarithromycin", "ingredient2": "Mirtazapine", "severity": "Moderate", "effect": "Coadministration of mirtazapine with drugs that inhibit one or more of its metabolic pathways may result in increased plasma concentrations of mirtazapine. In vitro data from human liver microsomes indicate that CYP450 2D6 and 1A2 are involved in the formation of the 8-hydroxy metabolite, while CYP450 3A4 is primarily responsible for the formation of the N-desmethyl and N-oxide metabolites.", "source": "DDInter", "management_text": "The possibility of prolonged and/or increased pharmacologic effects of mirtazapine should be considered during coadministration of drugs that inhibit CYP450 1A2, 2D6 and/or 3A4. Therapeutic response to mirtazapine should be monitored more closely following initiation, discontinuation, or dosing change of CYP450 inhibitors, and the mirtazapine dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "The possibility of prolonged and/or increased pharmacologic effects of mirtazapine should be considered during coadministration of drugs that inhibit CYP450 1A2, 2D6 and/or 3A4.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67938/", "reference_text": "[1] Sitsen JM, Maris FA, Timmer CJ \"Concomitant use of mirtazapine and cimetidine: a drug-drug interaction study in healthy male subjects.\" Eur J Clin Pharmacol 56 (2000): 389-94[2] \"Product Information. Remeron (mirtazapine).\" Organon, West Orange, NJ.[3] Stormer E, von Moltke LL, Shader RI, Greenblatt DJ \"Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4\" Drug Metab Dispos 28 (2000): 1168-75[4] Okubo M, Murayama N, Miura J, Chiba Y, Yamazaki H \"Effects of cytochrome P450 2D6 and 3A5 genotypes and possible coadministered medicines on the metabolic clearance of antidepressant mirtazapine in Japanese patients.\" Biochem Pharmacol 93 (2015): 104-9[5] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[6] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[7] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[8] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Phenelzine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Vortioxetine, Milnacipran, Tryptophan, Esketamine", "alternatives_b": "Tinidazole, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Esomeprazole, Vonoprazan, Lincomycin, Dirithromycin", "updated_at": 1767369485}, {"id": 67852, "ingredient1": "Clarithromycin", "ingredient2": "Mitoxantrone", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of mitoxantrone, which is a substrate of the efflux transporter also known as ABCB1 or MDR1. The interaction has been studied with cyclosporine, a potent P-gp inhibitor.", "source": "DDInter", "management_text": "Caution is advised if mitoxantrone is prescribed in combination with a P-gp inhibitor. Patients should be closely monitored for increased adverse effects including cardiotoxicity and myelosuppression.", "mechanism_text": "Others", "recommendation": "Caution is advised if mitoxantrone is prescribed in combination with a P-gp inhibitor.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67939/", "reference_text": "[1] \"Product Information. Novantrone (mitoxantrone).\" Immunex Corporation, Seattle, WA.[2] \"Multum Information Services, Inc. Expert Review Panel\"[3] \"Product Information. Novantrone (mitoxantrone).\" Immunex Corporation, Seattle, WA.[4] \"Multum Information Services, Inc. Expert Review Panel\"[5] \"Product Information. Mavyret (glecaprevir-pibrentasvir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Dactinomycin, Mitomycin, Valrubicin, Plicamycin", "alternatives_b": "Tinidazole, Tetracycline, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, Nizatidine, Vonoprazan, Amoxicillin, More", "updated_at": 1767369485}, {"id": 67853, "ingredient1": "Clarithromycin", "ingredient2": "Modafinil", "severity": "Minor", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of modafinil (the racemate) and armodafinil (the R-enantiomer), which are both partially metabolized by the isoenzyme. Conversely, the plasma levels of some of these inhibitors may decrease, since many of them are also substrates of CYP450 3A4, and modafinil and armodafinil have been found to be modest inducers of CYP450 3A4. The clinical significance of this potential interaction is unknown. Clinical monitoring for altered effects of modafinil and armodafinil as well as the CYP450 3A4 inhibitor may be appropriate following addition or withdrawal of one or the other drug.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67940/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Nuvigil (armodafinil).\" Cephalon Inc, West Chester, PA.[3] \"Product Information. Provigil (modafinil).\" Cephalon, Inc, West Chester, PA.[4] \"Product Information. Provigil (modafinil).\" Cephalon, Inc, West Chester, PA.[5] \"Product Information. Nuvigil (armodafinil).\" Cephalon Inc, West Chester, PA.", "alternatives_a": "Amphetamine, Pemoline, Metamfetamine, Solriamfetol, Caffeine, Dexmethylphenidate, Dextroamphetamine, Citicoline", "alternatives_b": "Tinidazole, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Levofloxacin, Lincomycin, Dirithromycin", "updated_at": 1767369485}, {"id": 67854, "ingredient1": "Clarithromycin", "ingredient2": "Moxifloxacin", "severity": "Major", "effect": "Certain quinolones, including gatifloxacin and moxifloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).", "source": "DDInter", "management_text": "Coadministration of gatifloxacin or moxifloxacin with other drugs that can prolong the QT interval should generally be avoided. Caution and clinical monitoring are recommended if concomitant use is required. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of the quinolone, recommended dosages and intravenous infusion rates should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of gatifloxacin or moxifloxacin with other drugs that can prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67941/", "reference_text": "[1] Siepmann M, Kirch W \"Drug points - Tachycardia associated with moxifloxacin.\" Br Med J 322 (2001): 23[2] Ansari SR, Chopra N \"Gatifloxacin and Prolonged QT Interval.\" Am J Med Sci 327 (2004): 55-6[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R \"Effects of three fluoroquinolones on QT interval in healthy adults after single doses.\" Clin Pharmacol Ther 73 (2003): 292-303[5] Oliphant CM, Green GM \"Quinolones: a comprehensive review.\" Am Fam Physician 65 (2002): 455-64[6] \"Product Information. Tequin (gatifloxacin)\" Bristol-Myers Squibb, Princeton, NJ.[7] Owens RC \"QT Prolongation with Antimicrobial Agents : Understanding the Significance.\" Drugs 64 (2004): 1091-124[8] Owens RC Jr, Ambrose PG \"Torsades de pointes associated with fluoroquinolones.\" Pharmacotherapy 22 (2002): 663-8; discussion 668-72[9] Dale KM, Lertsburapa K, Kluger J, White CM \"Moxifloxacin and torsade de pointes.\" Ann Pharmacother 41 (2007): 336-40[10] Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB \"Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors.\" Clin Infect Dis 34 (2002): 861-3[11] Katritsis D, Camm AJ \"Quinolones: cardioprotective or cardiotoxic.\" Pacing Clin Electrophysiol 26 (2003): 2317-20[12] Ball P \"Quinolone-induced QT interval prolongation: a not-so-unexpected class effect.\" J Antimicrob Chemother 45 (2000): 557-9[13] Iannini PB, Circiumaru I \"Gatifloxacin-induced QTc prolongation and ventricular tachycardia.\" Pharmacotherapy 21 (2001): 361-2[14] Tsikouris JP, Peeters MJ, Cox CD, Meyerrose GE, Seifert CF \"Effects of three fluoroquinolones on QT analysis after standard treatment courses.\" Ann Noninvasive Electrocardiol 11 (2006): 52-6[15] Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C \"Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects.\" Clin Pharmacol Ther 68 (2000): 658-66[16] Owens RC \"Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes.\" Pharmacotherapy 21 (2001): 301-19[17] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[18] Falagas ME, Rafailidis PI, Rosmarakis ES \"Arrhythmias associated with fluoroquinolone therapy.\" Int J Antimicrob Agents 29 (2007): 374-9[19] \"Product Information. Avelox (moxifloxacin)\" Bayer, West Haven, CT.[20] White CM, Grant EM, Quintiliani R \"Moxifloxacin does increase the corrected QT interval.\" Clin Infect Dis 33 (2001): 1441-2[21] Stahlmann R \"Clinical toxicological aspects of fluoroquinolones.\" Toxicol Lett 127 (2002): 269-77[22] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[23] Frothingham R \"Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.\" Pharmacotherapy 21 (2001): 1468-72[24] Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H \"Risk of torsades de pointes with non-cardiac drugs.\" BMJ 322 (2001): 46-7[25] Cerner Multum, Inc. \"Australian Product Information.\" O 0[26] Kang J, Wang L, Chen XL, Triggle DJ, Rampe D \"Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.\" Mol Pharmacol 59 (2001): 122-6[27] \"Product Information. Tequin (gatifloxacin)\" Bristol-Myers Squibb, Princeton, NJ.[28] Wallace AW, Victory JM, Amsden GW \"Lack of bioequivalence of gatifloxacin when coadministered with calcium-fortified orange juice in healthy volunteers.\" J Clin Pharmacol 43 (2003): 92-6", "alternatives_a": "Rifamycin, Oxytetracycline, Netilmicin, Polymyxin B, Sulfamethizole, Trifluridine, Sulfisoxazole, Povidone-iodine, Enoxacin, Nalidixic acid, Cinoxacin, More", "alternatives_b": "Tinidazole, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, Nizatidine, Vonoprazan, Levofloxacin, Troleandomycin, Dirithromycin", "updated_at": 1767369485}, {"id": 67855, "ingredient1": "Clarithromycin", "ingredient2": "Mycophenolate mofetil", "severity": "Moderate", "effect": "Theoretically, drugs that alter the gastrointestinal flora (e.g., antibiotics) may reduce the oral bioavailability of mycophenolic acid products. Some investigators believe that antimicrobials may interfere with the enterohepatic recirculation of mycophenolic acid by decreasing bacterial hydrolytic enzymes in the gastrointestinal tract that are responsible for regenerating mycophenolic acid from its glucuronide metabolite following first-pass metabolism.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.", "mechanism_text": "Absorption", "recommendation": "Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67942/", "reference_text": "[1] \"Product Information. CellCept (mycophenolate mofetil).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Sucralfate, Misoprostol, Bismuth subcitrate potassium, Famotidine, Rifabutin, Cimetidine, Nizatidine, Ranitidine, Telithromycin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67856, "ingredient1": "Clarithromycin", "ingredient2": "Mycophenolic acid", "severity": "Moderate", "effect": "Theoretically, drugs that alter the gastrointestinal flora (e.g., antibiotics) may reduce the oral bioavailability of mycophenolic acid products. Some investigators believe that antimicrobials may interfere with the enterohepatic recirculation of mycophenolic acid by decreasing bacterial hydrolytic enzymes in the gastrointestinal tract that are responsible for regenerating mycophenolic acid from its glucuronide metabolite following first-pass metabolism.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.", "mechanism_text": "Absorption", "recommendation": "Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67943/", "reference_text": "[1] \"Product Information. CellCept (mycophenolate mofetil).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Anakinra, More", "alternatives_b": "Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, Nizatidine, Vonoprazan, Telithromycin", "updated_at": 1767369485}, {"id": 67857, "ingredient1": "Clarithromycin", "ingredient2": "Nadolol", "severity": "Minor", "effect": "Some macrolide antibiotics may alter gastrointestinal flora. Biliary elimination of nadolol may be increased. The clinical implications of this interaction are not known. No special precautions are necessary.", "source": "DDInter", "management_text": "-", "mechanism_text": "Excretion", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67944/", "reference_text": "[1] du Souich P, Caille G, Larochelle P \"Enhancement of nadolol elimination by activated charcoal and antibiotics.\" Clin Pharmacol Ther 33 (1983): 585-90", "alternatives_a": "Labetalol, Nebivolol, Labetalol, Esmolol, Betaxolol, Nebivolol, Penbutolol, Carteolol, Pindolol", "alternatives_b": "Tinidazole, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Nizatidine, Esomeprazole, Vonoprazan, Levofloxacin, Telithromycin, Clindamycin", "updated_at": 1767369485}, {"id": 67858, "ingredient1": "Clarithromycin", "ingredient2": "Nafcillin", "severity": "Minor", "effect": "Although some in vitro data indicate synergism between macrolide antibiotics and penicillins, other in vitro data indicate antagonism. When these drugs are given together, neither has predictable therapeutic efficacy. Data are available for erythromycin, although theoretically this interaction could occur with any macrolide. Except for monitoring of the effectiveness of antibiotic therapy, no special precautions appear to be necessary.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67945/", "reference_text": "[1] Strom J \"Penicillin and erythromycin singly and in combination in scarlatina therapy and the interference between them.\" Antibiot Chemother 11 (1961): 694-7[2] Cohn JR, Jungkind DL, Baker JS \"In vitro antagonism by erythromycin of the bactericidal action of antimicrobial agents against common respiratory pathogens.\" Antimicrob Agents Chemother 18 (1980): 872-6[3] Penn RL, Ward TT, Steigbigel RT \"Effects of erythromycin in combination with penicillin, ampicillin, or gentamicin on the growth of listeria monocytogenes.\" Antimicrob Agents Chemother 22 (1982): 289-94", "alternatives_a": "Tazobactam, Sulbactam", "alternatives_b": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Rifabutin, More", "updated_at": 1767369485}, {"id": 67859, "ingredient1": "Clarithromycin", "ingredient2": "Naldemedine", "severity": "Moderate", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of naldemedine, which is primarily metabolized by CYP450 3A4 to nor-naldemedine and to a minor extent by UGT1A3 to naldemedine 3-G. Both metabolites have demonstrated antagonistic activity for opioid receptors, but with less potency than the parent drug. Increased exposure to naldemedine may precipitate opioid withdrawal symptoms such as hyperhidrosis, lacrimation, rhinorrhea, chills, diarrhea, abdominal pain, anxiety, insomnia, irritability, restlessness, and yawning.", "source": "DDInter", "management_text": "Caution is advised during concomitant use of naldemedine with potent inhibitors of CYP450 3A4. Patients should be closely monitored for potential opioid withdrawal symptoms as well as other adverse effects of naldemedine.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant use of naldemedine with potent inhibitors of CYP450 3A4.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67946/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Symproic (naldemedine).\" Shionogi USA Inc, Florham Park, NJ.[3] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[4] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[5] \"Product Information. Symproic (naldemedine).\" Shionogi USA Inc, Florham Park, NJ.", "alternatives_a": "Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 67860, "ingredient1": "Clarithromycin", "ingredient2": "Naloxegol", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of naloxegol, which is primarily metabolized by the isoenzyme. Increased exposure to naloxegol may precipitate opioid withdrawal symptoms such as hyperhidrosis, lacrimation, rhinorrhea, chills, diarrhea, abdominal pain, anxiety, insomnia, irritability, restlessness, and yawning.", "source": "DDInter", "management_text": "Concomitant use of naloxegol with potent CYP450 3A4 inhibitors such as clarithromycin, telithromycin, itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, idelalisib, nefazodone, cobicistat, delavirdine, and protease inhibitors is considered contraindicated. Some authorities consider concomitant administration of naloxegol and itraconazole to be contraindicated during and for 2 weeks after treatment with itraconazole.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of naloxegol with potent CYP450 3A4 inhibitors such as clarithromycin, telithromycin, itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, idelalisib, nefazodone, cobicistat, delavirdine, and protease inhibitors is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67947/", "reference_text": "[1] \"Product Information. Movantik (naloxegol).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Movantik (naloxegol).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[6] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[7] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 67861, "ingredient1": "Clarithromycin", "ingredient2": "Naltrexone", "severity": "Moderate", "effect": "Coadministration of naltrexone with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Naltrexone, especially in larger than recommended doses (more than 50 mg/day), has been associated with hepatocellular injury, hepatitis, and elevations in liver transaminases and bilirubin. Other potential causative or contributory etiologies identified include preexisting alcoholic liver disease, hepatitis B and/or C infection, and concomitant usage of other hepatotoxic drugs.", "source": "DDInter", "management_text": "The use of naltrexone with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Periodic monitoring of hepatic function is advisable.", "mechanism_text": "Synergism", "recommendation": "The use of naltrexone with other potentially hepatotoxic agents should be avoided whenever possible (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67948/", "reference_text": "[1] \"Product Information. ReVia (naltrexone).\" DuPont Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Oxymorphone, Tapentadol, Dezocine, Opium, Pentazocine, Nalbuphine, Dihydrocodeine, Naloxone, Codeine, Nalmefene, Diamorphine, More", "alternatives_b": "Tinidazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Rifabutin, Cimetidine, More", "updated_at": 1767369485}, {"id": 67862, "ingredient1": "Clarithromycin", "ingredient2": "Nateglinide", "severity": "Moderate", "effect": "Concomitant use of insulin and other antidiabetic agents with clarithromycin may cause significant hypoglycemia. There have been rare reports of hypoglycemia in patients treated with clarithromycin, some of whom were taking oral hypoglycemic agents or insulin. The exact mechanism of interaction has not been established. With certain hypoglycemic drugs such as nateglinide, pioglitazone, repaglinide and rosiglitazone, inhibition of the CYP450 3A4 isoenzyme by clarithromycin may be involved.", "source": "DDInter", "management_text": "Caution is advised if clarithromycin is prescribed to patients receiving antidiabetic agents. Patients should be advised to regularly monitor their blood sugar and counseled on how to recognize and treat hypoglycemia, which may include symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if clarithromycin is prescribed to patients receiving antidiabetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67949/", "reference_text": "[1] Otsuka SH \"Severe hypoglycemia from helicobacter pylori triple-drug therapy and insulin detemir drug interaction.\" Pharmacotherapy 33 (2013): e45-9[2] Niemi M, Neuvonen PJ, Kivisto KT \"The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide.\" Clin Pharmacol Ther 70 (2001): 58-65[3] Schelleman H, Bilker WB, Brensinger CM, Wan F, Hennessy S \"Anti-infectives and the risk of severe hypoglycemia in users of glipizide or glyburide.\" Clin Pharmacol Ther 88 (2010): 214-22[4] Khamaisi M, Leitersdorf E \"Severe hypoglycemia from clarithromycin-repaglinide drug interaction.\" Pharmacotherapy 28 (2008): 682-4[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Leiba A, Leibowitz A, Grossman E \"An unusual case of hypoglycemia in a diabetic patient.\" Ann Emerg Med 44 (2004): 427-8[7] Bussing R, Gende A \"Severe hypoglycemia from clarithromycin-sulfonylurea drug interaction.\" Diabetes Care 25 (2002): 1659-61[8] \"Product Information. Biaxin (clarithromycin).\" Abbott Pharmaceutical, Abbott Park, IL.[9] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[10] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[11] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[12] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[13] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[14] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[15] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[16] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[17] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[18] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[19] Cheng KL, Nafziger AN, Peloquin CA, Amsden GW \"Effect of grapefruit juice on clarithromycin pharmacokinetics.\" Antimicrob Agents Chemother 42 (1998): 927-9", "alternatives_a": "Guar gum", "alternatives_b": "Tinidazole, Tetracycline, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, Nizatidine, Vonoprazan, Amoxicillin, More", "updated_at": 1767369485}, {"id": 67863, "ingredient1": "Clarithromycin", "ingredient2": "Nefazodone", "severity": "Moderate", "effect": "The use of some macrolide antibiotics has been associated with increased blood levels of some selective serotonin reuptake inhibitors (SSRIs), resulting in excessive serotonergic effects or serotonin syndrome. The mechanism is inhibition of the CYP450 3A4 isoenzyme, which metabolizes SSRIs.", "source": "DDInter", "management_text": "In cases where both drugs are necessary, one could consider using a macrolide antibiotic that does not inhibit CYP450 3A4, such as azithromycin or dirithromycin.", "mechanism_text": "Metabolism", "recommendation": "In cases where both drugs are necessary, one could consider using a macrolide antibiotic that does not inhibit CYP450 3A4, such as azithromycin or dirithromycin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67950/", "reference_text": "[1] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[2] Pollak PT, Slayter KL \"Delirium probably induced by clarithromycin in a patient receiving fluoxetine - reply.\" Ann Pharmacother 30 (1996): 1200[3] Timothy P, Sketris IS, Mackenzie SL, Hewlett TJ \"Delirium probably induced by clarithromycin in a patient receiving fluoxetine.\" Ann Pharmacother 29 (1995): 486-8[4] Tracy TS, Cupp MJ \"Delirium probably induced by clarithromycin in a patient receiving fluoxetine - comment.\" Ann Pharmacother 30 (1996): 1199-200[5] Lee DO, Lee CD \"Serotonin syndrome in a child associated with erythromycin and sertraline.\" Pharmacotherapy 19 (1999): 894-6[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Ueda N, Yoshimura R, Umene-Nakano W, et al. \"Grapefruit juice alters plasma sertraline levels after single ingestion of sertraline in healthy volunteers.\" World J Biol Psychiatry 10(4 Pt 3) (2009): 832-5[8] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[9] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9", "alternatives_a": "Phenelzine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Vortioxetine, Milnacipran, Tryptophan, Esketamine", "alternatives_b": "Tinidazole, Levofloxacin, Tetracycline, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Cimetidine, Esomeprazole, Vonoprazan, Amoxicillin, More", "updated_at": 1767369485}, {"id": 67864, "ingredient1": "Clarithromycin", "ingredient2": "Nelfinavir", "severity": "Moderate", "effect": "Coadministration with nelfinavir may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by nelfinavir.", "source": "DDInter", "management_text": "Caution is advised if nelfinavir must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever nelfinavir is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if nelfinavir must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67951/", "reference_text": "[1] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc, La Jolla, CA.", "alternatives_a": "Glecaprevir, Tenofovir alafenamide, Cabotegravir, Lenacapavir, Velpatasvir, Voxilaprevir, Maribavir, Pibrentasvir, Rimantadine, Elvitegravir, Valganciclovir, More", "alternatives_b": "Tinidazole, Levofloxacin, Tetracycline, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Amoxicillin, Lincomycin, Dirithromycin", "updated_at": 1767369485}, {"id": 67865, "ingredient1": "Clarithromycin", "ingredient2": "Neratinib", "severity": "Major", "effect": "Coadministration with potent or moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of neratinib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Given the potential for increased risk of toxicity, concomitant use of neratinib with potent or moderate inhibitors of CYP450 3A4 should generally be avoided.", "mechanism_text": "Metabolism", "recommendation": "Given the potential for increased risk of toxicity, concomitant use of neratinib with potent or moderate inhibitors of CYP450 3A4 should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67952/", "reference_text": "[1] \"Product Information. Nerlynx (neratinib).\" Puma Biotechnology, Inc., Los Angeles, CA.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D \"Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects.\" Br J Clin Pharmacol 71 (2011): 522-7[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Nerlynx (neratinib).\" Puma Biotechnology, Inc., Los Angeles, CA.[6] Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D \"Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects.\" Br J Clin Pharmacol 71 (2011): 522-7[7] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.", "alternatives_a": "Tinidazole, Levofloxacin, Tetracycline, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Vonoprazan, Amoxicillin, Dirithromycin, Lincomycin, More", "alternatives_b": "Alpelisib, Trametinib, Dacomitinib, Tivozanib, Alectinib", "updated_at": 1767369485}, {"id": 67866, "ingredient1": "Clarithromycin", "ingredient2": "Nevirapine", "severity": "Moderate", "effect": "Coadministration with nevirapine may significantly decrease the plasma concentrations of clarithromycin. The mechanism is nevirapine induction of CYP450 3A4, the isoenzyme responsible for the metabolic clearance of clarithromycin.", "source": "DDInter", "management_text": "Clarithromycin should preferably not be used in the treatment and prophylaxis of Mycobacterium avium-intracellulare complex in patients treated with nevirapine. Alternatives such as azithromycin should be considered.", "mechanism_text": "Metabolism", "recommendation": "Clarithromycin should preferably not be used in the treatment and prophylaxis of Mycobacterium avium-intracellulare complex in patients treated with nevirapine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67953/", "reference_text": "[1] Back D, Gibbons S, Khoo S \"Pharmacokinetic drug interactions with nevirapine.\" J Acquir Immune Defic Syndr 34 Suppl 1 (2003): S8-14[2] \"Product Information. Viramune (nevirapine).\" Boehringer-Ingelheim, Ridgefield, CT.[3] Cheng KL, Nafziger AN, Peloquin CA, Amsden GW \"Effect of grapefruit juice on clarithromycin pharmacokinetics.\" Antimicrob Agents Chemother 42 (1998): 927-9", "alternatives_a": "Glecaprevir, Tenofovir alafenamide, Cabotegravir, Lenacapavir, Velpatasvir, Voxilaprevir, Maribavir, Pibrentasvir, Rimantadine, Elvitegravir, Valganciclovir, More", "alternatives_b": "Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Cimetidine, Esomeprazole, Nizatidine, Levofloxacin, Dirithromycin, Lincomycin, Clindamycin", "updated_at": 1767369485}, {"id": 67867, "ingredient1": "Clarithromycin", "ingredient2": "Nilotinib", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of nilotinib, which is primarily metabolized by the isoenzyme. Because nilotinib is associated with concentration-dependent prolongation of the QT interval, increased levels may potentiate the risk of ventricular arrhythmias such as torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Concomitant use of nilotinib with potent CYP450 3A4 inhibitors such as itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, nefazodone, cobicistat, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics should generally be avoided. Some authorities recommend avoiding concomitant use of nilotinib during and for 2 weeks after treatment with itraconazole. Should treatment with a potent inhibitor be required, the manufacturer recommends that nilotinib therapy be withheld temporarily. If concomitant use is unavoidable, a reduction of the nilotinib dosage to 400 mg once daily should be considered. Based on pharmacokinetic studies, this dosage is predicted to adjust the nilotinib systemic exposure (AUC) to the range observed without inhibitors. However, clinical data are lacking. Patients should have frequent ECGs and be monitored for arrhythmias when QT interval is prolonged. A QTc interval exceeding 480 msec will require suspension of nilotinib therapy and immediate action to correct any concomitant risk factors before resuming treatment. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of nilotinib with potent CYP450 3A4 inhibitors such as itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, nefazodone, cobicistat, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67954/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Tasigna (nilotinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[4] \"Product Information. Tasigna (nilotinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[5] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[6] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tetracycline, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Amoxicillin, Dirithromycin, Lincomycin, Clindamycin", "alternatives_b": "Alpelisib, Trametinib, Dacomitinib, Tivozanib, Alectinib", "updated_at": 1767369485}, {"id": 67868, "ingredient1": "Clarithromycin", "ingredient2": "Nilutamide", "severity": "Moderate", "effect": "Long-term androgen deprivation therapy can prolong the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).", "source": "DDInter", "management_text": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.", "mechanism_text": "Synergism", "recommendation": "The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67955/", "reference_text": "[1] \"Product Information. Vantas (histrelin).\" Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc), Lexington, MA.[2] \"Product Information. Zoladex (goserelin).\" Zeneca Pharmaceuticals, Wilmington, DE.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Trelstar (triptorelin)\" Pharmacia and Upjohn, Kalamazoo, MI.[5] \"Product Information. Firmagon (degarelix).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[6] \"Product Information. Lupron (leuprolide).\" TAP Pharmaceuticals Inc, Deerfield, IL.[7] \"Product Information. Eligard (leuprolide).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[8] \"Product Information. Plenaxis (abarelix).\" Praecis Pharmaceuticals Inc, Waltham, MA.", "alternatives_a": "Anastrozole, Aminoglutethimide, Exemestane, Fulvestrant", "alternatives_b": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, More", "updated_at": 1767369485}, {"id": 67869, "ingredient1": "Clarithromycin", "ingredient2": "Nimodipine", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations and blood pressure lowering effect of nimodipine, which is primarily metabolized by CYP450 3A4 in the intestinal mucosa and liver.", "source": "DDInter", "management_text": "The use of nimodipine in combination with potent CYP450 3A4 inhibitors such as itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, nefazodone, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics is considered contraindicated because of a risk of significant hypotension.", "mechanism_text": "Metabolism", "recommendation": "The use of nimodipine in combination with potent CYP450 3A4 inhibitors such as itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, nefazodone, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics is considered contraindicated because of a risk of significant hypotension.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67956/", "reference_text": "[1] \"Product Information. Nimotop (nimodipine).\" Bayer, West Haven, CT.[2] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[3] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[4] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[5] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[6] \"Product Information. Procardia (nifedipine).\" Pfizer US Pharmaceuticals, New York, NY.[7] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[8] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[9] Edgar B, Bailey D, Bergstrand R, Johnsson G, Regardh CG \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics of felodipine--and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[10] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[11] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[12] Fuhr U, Muller-Peltzer H, Kern R, et al. \"Effects of grapefruit juice and smoking on verapamil concentrations in steady state.\" Eur J Clin Pharmacol 58 (2002): 45-53[13] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[14] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[15] \"Product Information. Sular (nisoldipine).\" Zeneca Pharmaceuticals, Wilmington, DE.[16] Ho PC, Ghose K, Saville D, Wanwimolruk S \"Effect of grapefruit juice on pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy volunteers.\" Eur J Clin Pharmacol 56 (2000): 693-8[17] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[18] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[19] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[20] \"Product Information. Plendil (felodipine).\" Merck & Co, Inc, West Point, PA.[21] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[22] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Clevidipine, Nisoldipine, Nicardipine", "alternatives_b": "Tinidazole, Levofloxacin, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Nizatidine, More", "updated_at": 1767369485}, {"id": 67870, "ingredient1": "Clarithromycin", "ingredient2": "Nintedanib", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) and CYP450 3A4 may increase the plasma concentrations of nintedanib, which is a substrate of the efflux transporter and a minor substrate of the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if nintedanib is prescribed in combination with P-gp and CYP450 3A4 inhibitors. Pharmacologic response to nintedanib should be monitored more closely whenever a CYP450 3A4/P-gp inhibitor is added to or withdrawn from therapy, and the nintedanib dosing adjusted or interrupted as necessary in accordance with the product labeling. Patients should be closely monitored for increased adverse effects such as liver enzyme and bilirubin elevations, diarrhea, nausea, vomiting, gastrointestinal perforation, bleeding, and arterial thromboembolic events (e.g., myocardial infarction).", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if nintedanib is prescribed in combination with P-gp and CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67957/", "reference_text": "[1] \"Product Information. Ofev (nintedanib).\" Boehringer Ingelheim, Ridgefield, CT.[2] \"Product Information. Ofev (nintedanib).\" Boehringer Ingelheim, Ridgefield, CT.", "alternatives_a": "Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, Sucralfate, More", "alternatives_b": "Alpelisib, Trametinib, Dacomitinib, Tivozanib, Alectinib", "updated_at": 1767369485}, {"id": 67871, "ingredient1": "Clarithromycin", "ingredient2": "Nitisinone", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of and exposure to, nitisinone. The proposed mechanism is inhibition of CYP450 3A4-mediated metabolism of nitisinone, which has been shown in in vitro studies to be metabolized by this isoenzyme.", "source": "DDInter", "management_text": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inhibitors. Pharmacologic response to nitisinone should be monitored whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the nitisinone dosage adjusted as necessary. Patients should be monitored for the development of adverse effects.", "mechanism_text": "Metabolism", "recommendation": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67958/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[13] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[14] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[15] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[21] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[23] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[25] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[26] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[29] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[30] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[31] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[32] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[33] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[34] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[35] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[36] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[37] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[38] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[39] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[40] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[41] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[42] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[43] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[44] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[45] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[46] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[47] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[48] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[49] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[50] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[51] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[52] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[53] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[54] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[55] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[56] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[57] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[58] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[59] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[60] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[61] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[62] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[63] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[64] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[65] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[66] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[67] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, More", "updated_at": 1767369485}, {"id": 67872, "ingredient1": "Clarithromycin", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Certain quinolones, including levofloxacin, norfloxacin, and ofloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of the quinolone, recommended dosages and intravenous infusion rates should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67959/", "reference_text": "[1] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[4] Oliphant CM, Green GM \"Quinolones: a comprehensive review.\" Am Fam Physician 65 (2002): 455-64[5] Stahlmann R \"Clinical toxicological aspects of fluoroquinolones.\" Toxicol Lett 127 (2002): 269-77[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Falagas ME, Rafailidis PI, Rosmarakis ES \"Arrhythmias associated with fluoroquinolone therapy.\" Int J Antimicrob Agents 29 (2007): 374-9[8] Samaha FF \"QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin.\" Am J Med 107 (1999): 528-9[9] Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R \"Effects of three fluoroquinolones on QT interval in healthy adults after single doses.\" Clin Pharmacol Ther 73 (2003): 292-303[10] Kahn JB \"Latest industry information on the safety profile of levofloxacin in the US.\" Chemotherapy 47 Suppl 3 (2001): 32-7[11] Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H \"Risk of torsades de pointes with non-cardiac drugs. Prolongation of QT interval is probably a class effect of fluoroquinolones.\" Br Med J 322 (2001): 46-7[12] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[13] Makaryus AN, Byrns K, Makaryus MN, Natarajan U, Singer C, Goldner B \"Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant \"clinical\" event?\" South Med J 99 (2006): 52-6[14] Frothingham R \"Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.\" Pharmacotherapy 21 (2001): 1468-72[15] Nykamp DL, Blackmon CL, Schmidt PE, Roberson AG \"QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine.\" Ann Pharmacother 39 (2005): 543-6[16] Owens RC \"QT Prolongation with Antimicrobial Agents : Understanding the Significance.\" Drugs 64 (2004): 1091-124[17] Thomas M, Maconochie JG, Fletcher E \"The dilemma of the prolonged QT interval in early drug studies.\" Br J Clin Pharmacol 41 (1996): 77-81[18] Kang J, Wang L, Chen XL, Triggle DJ, Rampe D \"Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.\" Mol Pharmacol 59 (2001): 122-6[19] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[20] Owens RC \"Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes.\" Pharmacotherapy 21 (2001): 301-19[21] Katritsis D, Camm AJ \"Quinolones: cardioprotective or cardiotoxic.\" Pacing Clin Electrophysiol 26 (2003): 2317-20[22] Ball P \"Quinolone-induced QT interval prolongation: a not-so-unexpected class effect.\" J Antimicrob Chemother 45 (2000): 557-9[23] Owens RC Jr, Ambrose PG \"Torsades de pointes associated with fluoroquinolones.\" Pharmacotherapy 22 (2002): 663-8; discussion 668-72[24] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[25] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Cefixime, Secnidazole, Rifamycin, Oxytetracycline, Netilmicin, Polymyxin B, Sulfamethizole, Trifluridine, Sulfisoxazole, Povidone-iodine, More", "alternatives_b": "Tinidazole, Tetracycline, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, Nizatidine, Vonoprazan, Levofloxacin, More", "updated_at": 1767369485}, {"id": 67873, "ingredient1": "Clarithromycin", "ingredient2": "Norgestrel", "severity": "Moderate", "effect": "RECOMMENDED: The effectiveness of estrogen-containing oral contraceptives may be impaired by concomitant treatment with antimicrobial agents. Most antimicrobials, with the exception of the rifamycins and possibly griseofulvin, do not induce hepatic enzymes and have not been shown to significantly increase the clearance of oral contraceptive estrogens. Certain macrolide antibiotics (e.g., erythromycin, clarithromycin) may increase the plasma concentrations and the risk of adverse effects of estrogens and progestogens. The mechanism is decreased clearance of the hormones due to inhibition of CYP450 3A4 activity by the macrolide antibiotic. Concomitant administration with erythromycin may increase the estradiol exposure by approximately 50%.", "source": "DDInter", "management_text": "Until further data are available, women using oral contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant antimicrobial therapy. During concomitant therapy with erythromycin or clarithromycin, patients should be observed for increased or altered pharmacologic response to estrogens and progestogens, and dosage(s) adjusted accordingly as necessary.", "mechanism_text": "Metabolism", "recommendation": "Until further data are available, women using oral contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant antimicrobial therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67960/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception. Available from: URL: file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf.\" ([2012, Jan 1]):[4] \"Product Information. Angeliq (drospirenone-estradiol).\" Berlex Laboratories, Wayne, NJ.[5] \"Product Information. Ortho-Est (estropipate).\" Ortho McNeil Pharmaceutical, Raritan, NJ.[6] \"Product Information. Premarin (conjugated estrogens).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[7] \"Product Information. Yasmin (drospirenone-ethinyl estradiol)\" Berlex Laboratories, Richmond, CA.[8] Welling PG, Huang H, Hewitt PF, Lyons LL \"Bioavailability of erythromycin stearate: influence of food and fluid volume.\" J Pharm Sci 67 (1978): 764-6[9] Welling PG \"Influence of food and diet on gastrointestinal drug absorption: a review.\" J Pharmacokinet Biopharm 5 (1977): 291-334[10] Randinitis EJ, Sedman AJ, Welling PG, Kinkel AW \"Effect of a high-fat meal on the bioavailability of a polymer-coated erythromycin particle tablet formulation.\" J Clin Pharmacol 29 (1989): 79-84[11] Coyne TC, Shum S, Chun AH, Jeansonne L, Shirkey HC \"Bioavailability of erythromycin ethylsuccinate in pediatric patients.\" J Clin Pharmacol 18 (1978): 194-202[12] Malmborg AS \"Effect of food on absorption of erythromycin. A study of two derivatives, the stearate and the base.\" J Antimicrob Chemother 5 (1979): 591-9[13] Welling PG, Elliott RL, Pitterle ME, et al \"Plasma levels following single and repeated doses of erythromycin estolate and erythromycin stearate.\" J Pharm Sci 68 (1979): 150-5[14] Kanazawa S, Ohkubo T, Sugawara K \"The effects of grapefruit juice on the pharmacokinetics of erythromycin.\" Eur J Clin Pharmacol 56 (2001): 799-803[15] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[16] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, More", "alternatives_b": "Estetrol", "updated_at": 1767369485}, {"id": 67874, "ingredient1": "Clarithromycin", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67961/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[16] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Phenelzine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Vortioxetine, Milnacipran, Tryptophan, Esketamine", "alternatives_b": "Tinidazole, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Esomeprazole, Vonoprazan, Lincomycin, Troleandomycin, Dirithromycin", "updated_at": 1767369485}, {"id": 67875, "ingredient1": "Clarithromycin", "ingredient2": "Ofloxacin", "severity": "Moderate", "effect": "Certain quinolones, including levofloxacin, norfloxacin, and ofloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of the quinolone, recommended dosages and intravenous infusion rates should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Although the risk of a serious interaction is probably low, caution is recommended if levofloxacin, norfloxacin, or ofloxacin is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67962/", "reference_text": "[1] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[4] Oliphant CM, Green GM \"Quinolones: a comprehensive review.\" Am Fam Physician 65 (2002): 455-64[5] Stahlmann R \"Clinical toxicological aspects of fluoroquinolones.\" Toxicol Lett 127 (2002): 269-77[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Falagas ME, Rafailidis PI, Rosmarakis ES \"Arrhythmias associated with fluoroquinolone therapy.\" Int J Antimicrob Agents 29 (2007): 374-9[8] Samaha FF \"QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin.\" Am J Med 107 (1999): 528-9[9] Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R \"Effects of three fluoroquinolones on QT interval in healthy adults after single doses.\" Clin Pharmacol Ther 73 (2003): 292-303[10] Kahn JB \"Latest industry information on the safety profile of levofloxacin in the US.\" Chemotherapy 47 Suppl 3 (2001): 32-7[11] Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H \"Risk of torsades de pointes with non-cardiac drugs. Prolongation of QT interval is probably a class effect of fluoroquinolones.\" Br Med J 322 (2001): 46-7[12] \"Product Information. Floxin (ofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[13] Makaryus AN, Byrns K, Makaryus MN, Natarajan U, Singer C, Goldner B \"Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant \"clinical\" event?\" South Med J 99 (2006): 52-6[14] Frothingham R \"Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.\" Pharmacotherapy 21 (2001): 1468-72[15] Nykamp DL, Blackmon CL, Schmidt PE, Roberson AG \"QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine.\" Ann Pharmacother 39 (2005): 543-6[16] Owens RC \"QT Prolongation with Antimicrobial Agents : Understanding the Significance.\" Drugs 64 (2004): 1091-124[17] Thomas M, Maconochie JG, Fletcher E \"The dilemma of the prolonged QT interval in early drug studies.\" Br J Clin Pharmacol 41 (1996): 77-81[18] Kang J, Wang L, Chen XL, Triggle DJ, Rampe D \"Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.\" Mol Pharmacol 59 (2001): 122-6[19] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[20] Owens RC \"Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes.\" Pharmacotherapy 21 (2001): 301-19[21] Katritsis D, Camm AJ \"Quinolones: cardioprotective or cardiotoxic.\" Pacing Clin Electrophysiol 26 (2003): 2317-20[22] Ball P \"Quinolone-induced QT interval prolongation: a not-so-unexpected class effect.\" J Antimicrob Chemother 45 (2000): 557-9[23] Owens RC Jr, Ambrose PG \"Torsades de pointes associated with fluoroquinolones.\" Pharmacotherapy 22 (2002): 663-8; discussion 668-72[24] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[25] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Enoxacin, Nalidixic acid, Cinoxacin, Trovafloxacin, Delafloxacin, Tinidazole, Cefixime, Secnidazole, Rifamycin, Oxytetracycline, Netilmicin, More", "alternatives_b": "Tinidazole, Dexlansoprazole, Bismuth subcitrate potassium, Rifabutin, Esomeprazole, Vonoprazan, Levofloxacin, Lincomycin, Troleandomycin, Dirithromycin", "updated_at": 1767369485}, {"id": 67876, "ingredient1": "Clarithromycin", "ingredient2": "Olanzapine", "severity": "Moderate", "effect": "It is uncertain whether olanzapine causes clinically significant prolongation of the QT interval.", "source": "DDInter", "management_text": "Some authorities recommend caution when olanzapine is used with drugs that are known to cause QT prolongation.", "mechanism_text": "Synergism", "recommendation": "Some authorities recommend caution when olanzapine is used with drugs that are known to cause QT prolongation.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67963/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company, Indianapolis, IN.[4] \"Product Information. Qbrexza (glycopyrrolate topical).\" Dermira, Inc., Menlo Park, CA.[5] \"Product Information. Anoro Ellipta (umeclidinium-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[6] \"Product Information. Combivent (albuterol-ipratropium).\" Boehringer-Ingelheim, Ridgefield, CT.[7] \"Product Information. Atrovent (ipratropium).\" Boehringer-Ingelheim, Ridgefield, CT.[8] \"Product Information. Yupelri (revefenacin).\" Mylan Specialty, Morgantown, WV.[9] \"Product Information. Tudorza Pressair (aclidinium).\" Forest Pharmaceuticals, St. Louis, MO.[10] \"Product Information. Spiriva (tiotropium).\" Boehringer Ingelheim, Ridgefield, CT.[11] Cole JM, Sheehan AH, Jordan JK \"Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease.\" Ann Pharmacother 46 (2012): 1717-21[12] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[16] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[17] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[19] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Loxapine, Molindone, Thiothixene", "alternatives_b": "Tinidazole, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Esomeprazole, Vonoprazan, Lincomycin, Troleandomycin, Dirithromycin", "updated_at": 1767369485}, {"id": 67877, "ingredient1": "Clarithromycin", "ingredient2": "Olaparib", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of olaparib, which is primarily metabolized by the isoenzyme. Increased exposure to olaparib may increase the risk of adverse effects such as hematologic toxicity, nausea, vomiting, diarrhea, anorexia, dyspepsia, and abdominal pain or discomfort.", "source": "DDInter", "management_text": "Concomitant use of olaparib with potent CYP450 3A4 inhibitors should be avoided whenever possible. Some authorities recommend avoiding concomitant use of olaparib during and for 2 weeks after treatment with itraconazole. If coadministration is required, dose reductions are recommended as follows: the olaparib tablet dosage should be reduced to 100 mg twice a day; the olaparib capsule dosage should be reduced to 150 mg twice a day. Specific dose recommendations for each formulation should be followed as the tablet and capsule formulations are not interchangeable due to differences in bioavailability. Once the CYP450 3A4 inhibitor has been discontinued for 3 to 5 elimination half-lives, the usual olaparib dose should be resumed.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of olaparib with potent CYP450 3A4 inhibitors should be avoided whenever possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67964/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Lynparza (olaparib).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[5] \"Product Information. Lynparza (olaparib).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, More", "alternatives_b": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Mitotane, Niraparib, Porfimer sodium, More", "updated_at": 1767369485}, {"id": 67878, "ingredient1": "Clarithromycin", "ingredient2": "Oliceridine", "severity": "Major", "effect": "Coadministration with moderate or potent inhibitors of CYP450 2D6 and/or 3A4 may increase the plasma concentrations and adverse opioid effects of oliceridine, which is primarily metabolized by both isoenzymes in vitro. In addition, oliceridine concentrations may decrease following discontinuation of a concomitant moderate or potent CYP450 2D6 or 3A4 inhibitor, possibly resulting in decreased opioid efficacy or withdrawal syndrome. The effect of a CYP450 2D6 inhibitor on the pharmacokinetics of oliceridine has not been studied. However, it may be similar to that reported in CYP450 2D6 poor metabolizers, whose plasma clearance of oliceridine is reduced by approximately 50% compared to those who are nonpoor CYP450 2D6 metabolizers.", "source": "DDInter", "management_text": "Caution is recommended if oliceridine is used in combination with moderate or potent inhibitors of CYP450 2D6 or 3A4. If concomitant use is considered necessary, patients may require less frequent dosing of oliceridine and should be closely monitored for respiratory depression, sedation, and QT prolongation. If a moderate or potent CYP450 2D6 or 3A4 inhibitor is discontinued, an increase of the oliceridine dosage may be considered while monitoring for signs of opioid withdrawal until stable drug effects are achieved.", "mechanism_text": "Metabolism", "recommendation": "Caution is recommended if oliceridine is used in combination with moderate or potent inhibitors of CYP450 2D6 or 3A4.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67965/", "reference_text": "[1] \"Product Information. Olinvyk (oliceridine).\" Trevena Inc, Chesterbrook, PA.[2] \"Product Information. Olinvyk (oliceridine).\" Trevena Inc, Chesterbrook, PA.[3] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[4] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[6] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[7] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[8] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[9] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[10] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[11] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[14] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[15] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[16] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[18] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[20] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[21] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[22] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[23] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[24] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[25] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[26] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[27] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[28] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[29] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[30] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[31] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[32] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[33] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[34] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Nizatidine, Esomeprazole, Ranitidine, More", "alternatives_b": "Oxymorphone, Tapentadol, Dezocine, Opium, Pentazocine, Nalbuphine, Dihydrocodeine, Naloxone, Codeine", "updated_at": 1767369485}, {"id": 67879, "ingredient1": "Clarithromycin", "ingredient2": "Olodaterol", "severity": "Moderate", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.", "source": "DDInter", "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67966/", "reference_text": "[1] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990): 575-9[6] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003): 1817-24[8] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998): 145-7[11] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990): 1396-9[16] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.[17] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006): 582-90[19] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[20] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[21] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001): 45-51[26] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986): 619-20", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Rifabutin, Cimetidine, More", "alternatives_b": "Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Ipratropium, Beclomethasone dipropionate", "updated_at": 1767369485}, {"id": 67880, "ingredient1": "Clarithromycin", "ingredient2": "Ondansetron", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67967/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[16] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Scopolamine, Nabilone, Rolapitant, Dronabinol", "alternatives_b": "Tinidazole, Dexlansoprazole, Bismuth subcitrate potassium, Esomeprazole, Vonoprazan, Lincomycin, Troleandomycin, Dirithromycin", "updated_at": 1767369485}, {"id": 67881, "ingredient1": "Clarithromycin", "ingredient2": "Osilodrostat", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of osilodrostat, which is partially metabolized by the isoenzyme. Clinically, high plasma levels of osilodrostat may increase the risk of adverse effects such as hypocortisolism (which may lead to life-threatening adrenal insufficiency), QT prolongation (which may increase the risk of ventricular arrhythmias including torsade de pointes and sudden death), and elevated androgen and 11-deoxycorticosterone levels (the latter of which may activate mineralocorticoid receptors and cause hypokalemia, edema, and hypertension).", "source": "DDInter", "management_text": "The manufacturer recommends reducing the dosage of osilodrostat by one-half during concomitant use of a potent CYP450 3A4 inhibitor. Further dosage adjustments should be based on clinical response and tolerance. Patients should have regular monitoring of 24-hour urine free cortisol and serum or plasma cortisol during treatment, as well as regular evaluations for signs and symptoms of hypocortisolism such as nausea, vomiting, abdominal pain, loss of appetite, fatigue, dizziness, hypotension, abnormal electrolyte levels, and hypoglycemia. Decrease dosing or temporarily discontinue osilodrostat if patients experience symptoms of hypocortisolism or if urine free cortisol levels fall below the target range or there is a rapid decrease in cortisol levels. Stop osilodrostat and administer exogenous glucocorticoid replacement therapy if patients have symptoms of adrenal insufficiency and serum or plasma cortisol levels are below target range. Osilodrostat therapy may be restarted at a lower dosage when symptoms have resolved and cortisol values are within target range. Additionally, an electrocardiogram and serum electrolyte levels should also be obtained prior to initiating osilodrostat therapy and periodically thereafter.", "mechanism_text": "Metabolism", "recommendation": "The manufacturer recommends reducing the dosage of osilodrostat by one-half during concomitant use of a potent CYP450 3A4 inhibitor.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67968/", "reference_text": "[1] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Inc, Lebanon, NJ.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[3] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tetracycline, Sucralfate, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Nizatidine, Ranitidine, Amoxicillin, Lansoprazole, Dirithromycin, Lincomycin, Clindamycin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67882, "ingredient1": "Clarithromycin", "ingredient2": "Osimertinib", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of osimertinib, which has been shown in vitro to be primarily metabolized by the isoenzyme. However, no pharmacokinetic data are available from drug interaction studies. Because osimertinib is associated with concentration-dependent prolongation of the QT interval, increased levels may potentiate the risk of ventricular arrhythmias such as torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Concomitant use of osimertinib with potent CYP450 3A4 inhibitors should generally be avoided. If coadministration is required, close monitoring for adverse effects such as diarrhea, QT prolongation, torsade de pointes arrhythmia, and cardiomyopathy (e.g., cardiac failure, pulmonary edema, ejection fraction decreases) is recommended, and the osimertinib dosage adjusted accordingly or treatment discontinued as necessary.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of osimertinib with potent CYP450 3A4 inhibitors should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67969/", "reference_text": "[1] \"Product Information. Tagrisso (osimertinib).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[3] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Nizatidine, Esomeprazole, Ranitidine, More", "alternatives_b": "Alpelisib, Trametinib, Dacomitinib, Tivozanib, Alectinib", "updated_at": 1767369485}, {"id": 67883, "ingredient1": "Clarithromycin", "ingredient2": "Ospemifene", "severity": "Moderate", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of ospemifene, which is partially metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when ospemifene is used with potent CYP450 3A4 inhibitors. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain, shortness of breath, and pain or swelling in the arms or legs.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when ospemifene is used with potent CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67970/", "reference_text": "[1] \"Product Information. Osphena (ospemifene).\" Shionogi USA Inc, Florham Park, NJ.[2] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.[3] \"Product Information. Osphena (ospemifene).\" Shionogi USA Inc, Florham Park, NJ.", "alternatives_a": "Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, More", "alternatives_b": "Prasterone, Danazol, Bazedoxifene", "updated_at": 1767369485}, {"id": 67884, "ingredient1": "Clarithromycin", "ingredient2": "Oxacillin", "severity": "Minor", "effect": "Although some in vitro data indicate synergism between macrolide antibiotics and penicillins, other in vitro data indicate antagonism. When these drugs are given together, neither has predictable therapeutic efficacy. Data are available for erythromycin, although theoretically this interaction could occur with any macrolide. Except for monitoring of the effectiveness of antibiotic therapy, no special precautions appear to be necessary.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67971/", "reference_text": "[1] Strom J \"Penicillin and erythromycin singly and in combination in scarlatina therapy and the interference between them.\" Antibiot Chemother 11 (1961): 694-7[2] Cohn JR, Jungkind DL, Baker JS \"In vitro antagonism by erythromycin of the bactericidal action of antimicrobial agents against common respiratory pathogens.\" Antimicrob Agents Chemother 18 (1980): 872-6[3] Penn RL, Ward TT, Steigbigel RT \"Effects of erythromycin in combination with penicillin, ampicillin, or gentamicin on the growth of listeria monocytogenes.\" Antimicrob Agents Chemother 22 (1982): 289-94", "alternatives_a": "Tazobactam, Sulbactam", "alternatives_b": "Tinidazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Misoprostol, Bismuth subcitrate potassium, Famotidine, Rifabutin, Cimetidine, Esomeprazole, Nizatidine, More", "updated_at": 1767369485}, {"id": 67885, "ingredient1": "Clarithromycin", "ingredient2": "Oxaliplatin", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67972/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[16] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Mitotane, Niraparib, Porfimer sodium, More", "alternatives_b": "Dexlansoprazole, Bismuth subcitrate potassium, Rifabutin, Nizatidine, Esomeprazole, Vonoprazan, Amoxicillin, Lincomycin, Troleandomycin, Dirithromycin", "updated_at": 1767369485}, {"id": 67886, "ingredient1": "Clarithromycin", "ingredient2": "Oxcarbazepine", "severity": "Moderate", "effect": "Coadministration with oxcarbazepine may decrease the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is accelerated clearance due to induction of CYP450 3A4 activity by oxcarbazepine.", "source": "DDInter", "management_text": "Caution is advised if oxcarbazepine must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever oxcarbazepine is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if oxcarbazepine must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67973/", "reference_text": "[1] Rosche J, Froscher W, Abendroth D, Liebel J \"Possible oxcarbazepine interaction with cyclosporine serum levels: A single case study.\" Clin Neuropharmacol 24 (2001): 113-6[2] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[3] Zaccara G, Gangemi PF, Bendoni L, Menge GP, Schwabe S, Monza GC \"Influence of single and repeated doses of oxcarbazepine on the pharmacokinetic profile of felodipine.\" Ther Drug Monit 15 (1993): 39-42[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[5] \"Product Information. Ambien (zolpidem).\" sanofi-aventis, Bridgewater, NJ.[6] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[7] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[8] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tiagabine, Brivaracetam, Rufinamide, Methsuximide, Paramethadione, Fenfluramine, Eslicarbazepine, Phensuximide, Methylphenobarbital, Phenacemide, Primidone, More", "alternatives_b": "Tinidazole, Levofloxacin, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Nizatidine, Amoxicillin, Dirithromycin, Lincomycin, Clindamycin", "updated_at": 1767369485}, {"id": 67887, "ingredient1": "Clarithromycin", "ingredient2": "Oxtriphylline", "severity": "Moderate", "effect": "Coadministration with certain macrolide antibiotics may increase the serum concentrations of theophylline, which may result in toxicity. The proposed mechanism is macrolide inhibition of CYP450 3A4, the isoenzyme partially responsible for the metabolic clearance of theophylline.", "source": "DDInter", "management_text": "Pharmacologic response and serum theophylline levels should be monitored more closely whenever a macrolide antibiotic is added to or withdrawn from therapy, and the methylxanthine dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response and serum theophylline levels should be monitored more closely whenever a macrolide antibiotic is added to or withdrawn from therapy, and the methylxanthine dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67974/", "reference_text": "[1] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part I).\" Clin Pharmacokinet 20 (1991): 66-80[2] Amsden GW \"Erythromycin, clarithromycin, and azithromycin: are the differences real?\" Clin Ther 18 (1996): 56-72[3] Amsden GW \"Macrolides versus azalides: a drug interaction update.\" Ann Pharmacother 29 (1995): 906-17[4] Principi N, Esposito S \"Comparative tolerability of erythromycin and newer macrolide antibacterials in paediatric: Patients.\" Drug Safety 20 (1999): 25-41[5] Descotes J, Andre P, Evreux JC \"Pharmacokinetic drug interactions with macrolide antibiotics.\" J Antimicrob Chemother 15 (1985): 659-64[6] Rockwood RP, Embardo LS \"Theophylline, ciprofloxacin, erythromycin: a potentially harmful regimen.\" Ann Pharmacother 27 (1993): 651-2[7] von Rosenstiel NA, Adam D \"Macrolide antibacterials. Drug interactions of clinical significance.\" Drug Saf 13 (1995): 105-22[8] Reisz G, Pingleton SK, Melethil S, Ryan PB \"The effect of erythromycin on theophylline pharmacokinetics in chronic bronchitis.\" Am Rev Respir Dis 127 (1983): 581-4[9] Jonkman JH, Upton RA \"Pharmacokinetic drug interactions with theophylline.\" Clin Pharmacokinet 9 (1984): 309-34[10] Ludden TM \"Pharmacokinetic interactions of the macrolide antibiotics.\" Clin Pharmacokinet 10 (1985): 63-79[11] Hildebrandt R, Moller H, Gundert-Remy U \"Influence of theophylline on the renal clearance of erythromycin.\" Int J Clin Pharmacol Ther Toxicol 25 (1987): 601-4[12] May DC, Jarboe CH, Ellenburg DT, et al \"The effects of erythromycin on theophylline elimination in normal males.\" J Clin Pharmacol 22 (1982): 125-30[13] Gillum JG, Israel DS, Scott RB, Climo MW, Polk RE \"Effect of combination therapy with ciprofloxacin and clarithromycin on theophylline pharmacokinetics in healthy volunteers.\" Antimicrob Agents Chemother 40 (1996): 1715-6[14] Richer C, Mathieu M, Bah H, Thuillez C, Duroux P, Giudicelli JF \"Theophylline kinetics and ventilatory flow in bronchial asthma and chronic airflow obstruction: influence of erythromycin.\" Clin Pharmacol Ther 31 (1982): 579-86[15] Pfeifer HJ, Greenblatt DJ, Friedman P \"Effects of three antibiotics on theophylline kinetics.\" Clin Pharmacol Ther 26 (1979): 36-40[16] Prince RA, Wing DS, Weinberger MM, et al \"Effect of erythromycin on theophylline kinetics.\" J Allergy Clin Immunol 68 (1981): 427-31[17] Kozak PP, Cummins LH, Gillman SH \"Administration of erythromycin to patients on theophylline.\" J Allergy Clin Immunol 60 (1977): 149-51[18] Zarowitz BJ, Szefler SJ, Lasezkay GM \"Effect of erythromycin base on theophylline kinetics.\" Clin Pharmacol Ther 29 (1981): 601-5[19] Bachmann K, Nunlee M, Martin M, et al \"Changes in the steady-state pharmacokinetics of theophylline during treatment with dirithromycin.\" J Clin Pharmacol 30 (1990): 1001-5[20] Maddux MS, Leeds NH, Organek HW, Hasegawa GR, Bauman JL \"The effect of erythromycin on theophylline pharmacokinetics at steady state.\" Chest 81 (1982): 563-5[21] Pollak PT, Slayter KL \"Reduced serum theophylline concentrations after discontinuation of azithromycin: evidence for an unusual interaction.\" Pharmacotherapy 17 (1997): 827-9[22] Wiggins J, Arbab O, Ayres JG, Skinner C \"Elevated serum theophylline concentration following cessation of erythromycin treatment.\" Eur J Respir Dis 68 (1986): 298-300[23] Kamada AK, Hill MR, Brenner AM, Szefler SJ \"Effect of low-dose troleandomycin on theophylline clearance: implications for therapeutic drug monitoring.\" Pharmacotherapy 12 (1992): 98-102[24] Parish RA, Haulman NJ, Burns RM \"Interaction of theophylline with erythromycin base in a patient with seizure activity.\" Pediatrics 72 (1983): 828-30[25] Branigan TA, Robbins RA, Cady WJ, et al \"The effects of erythromycin on the absorption and disposition kinetics of theophylline.\" Eur J Clin Pharmacol 21 (1981): 115-20[26] Renton KW, Gray JD, Hung OR \"Depression of theophylline elimination by erythromycin.\" Clin Pharmacol Ther 30 (1981): 422-6[27] Bachmann K, Jauregui L, Sides G, Sullivan TJ \"Steady-state pharmacokinetics of theophylline in COPD patients treated with dirithromycin.\" J Clin Pharmacol 33 (1993): 861-5[28] Peters DH, Friedel HA, McTavish D \"Azithromycin: a review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy.\" Drugs 44 (1992): 750-99[29] Iliopoulou A, Aldhous ME, Johnston A, Turner P \"Pharmacokinetic interaction between theophylline and erythromycin.\" Br J Clin Pharmacol 14 (1982): 495-9[30] Nahata M \"Drug interactions with azithromycin and the macrolides: an overview.\" J Antimicrob Chemother 37 Suppl C (1996): 133-42[31] Tenenbein M \"Theophylline toxicity due to drug interaction.\" J Emerg Med 7 (1989): 249-51[32] Paulsen O, Hoglund P, Nilsson LG, Bengtsson HI \"The interaction of erythromycin with theophylline.\" Eur J Clin Pharmacol 32 (1987): 493-8", "alternatives_a": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Rifabutin, Esomeprazole, More", "alternatives_b": "Omalizumab, Tezepelumab, Benralizumab, Caffeine, Reslizumab, Dyphylline, Mepolizumab, Roflumilast, Bromotheophylline", "updated_at": 1767369485}, {"id": 67888, "ingredient1": "Clarithromycin", "ingredient2": "Oxycodone", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of oxycodone, which is substantially metabolized by the isoenzyme. Increased oxycodone concentrations could conceivably increase or prolong adverse drug effects and may cause potentially fatal respiratory depression. Because oxycodone is also partially metabolized by CYP450 2D6, the magnitude of interaction may be even greater with concomitant use of a CYP450 3A4 and a CYP450 2D6 inhibitor, or concomitant use of a drug that is a dual inhibitor of both isoenzymes.", "source": "DDInter", "management_text": "Extreme caution is advised if oxycodone is prescribed with CYP450 3A4 inhibitors, particularly potent and moderate inhibitors (e.g., azole antifungal agents, protease inhibitors, aprepitant, ciprofloxacin, chloramphenicol, clarithromycin, cobicistat, conivaptan, crizotinib, delavirdine, diltiazem, dronedarone, erythromycin, fusidic acid, idelalisib, imatinib, mibefradil, mifepristone, nefazodone, netupitant, quinupristin-dalfopristin, telithromycin, verapamil) or weak inhibitors that also inhibit CYP450 2D6 (e.g., abiraterone, amiodarone, cimetidine, pazopanib, ranolazine).", "mechanism_text": "Metabolism", "recommendation": "Extreme caution is advised if oxycodone is prescribed with CYP450 3A4 inhibitors, particularly potent and moderate inhibitors (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67975/", "reference_text": "[1] \"Product Information. OxyContin (oxycodone).\" Purdue Frederick Company, Norwalk, CT.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Vizcaychipi MP, Walker S, Palazzo M \"Serotonin syndrome triggered by tramadol.\" Br J Anaesth 99 (2007): 919[5] Das PK, Warkentin DI, Hewko R, Forrest DL \"Serotonin syndrome after concomitant treatment with linezolid and meperidine.\" Clin Infect Dis 46 (2008): 264-5[6] Mittino D, Mula M, Monaco F \"Serotonin syndrome associated with tramadol-sertraline coadministration.\" Clin Neuropharmacol 27 (2004): 150-1[7] Gillman PK \"Possible serotonin syndrome with moclobemide and pethidine.\" Med J Aust 162 (1995): 554[8] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997): 175-7[9] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002): 1647-1648[10] Kesavan S, Sobala GM \"Serotonin syndrome with fluoxetine plus tramadol.\" J R Soc Med 92 (1999): 474-5[11] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994): 593-7[12] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990): 949-50[13] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992): 1061-6[14] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008): 521-5[15] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[16] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007): 199-202[17] Meyer D, Halfin V \"Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review.\" J Clin Psychopharmacol 1 (1981): 319-21[18] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997): 763[19] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth (2005):[20] US Food and Drug Administration (FDA) \"FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes. Available from: URL: https://www.fda.gov/downloads/Drugs/DrugSafety/UCM491302.pdf.\" ([2016, Mar 22]):[21] Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K \"Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology.\" J Clin Psychopharmacol 22 (2002): 440-1[22] Gonzalez-Pinto A, Imaz H, De Heredia JL, Gutierrez M, Mico JA \"Mania and tramadol-fluoxetine combination.\" Am J Psychiatry 158 (2001): 964-5[23] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998): 523-5[24] Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F \"Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance Database.\" J Clin Psychopharmacol (2015):[25] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001): 224-7[26] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997): 181-2[27] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE \"Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil.\" J Clin Anesth 25 (2013): 52-4[28] Shakoor M, Ayub S, Ahad A, Ayub Z \"Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.\" Am J Case Rep 15 (2014): 562-4[29] Lantz MS, Buchalter EN, Giambanco V \"Serotonin syndrome following the administration of tramadol with paroxetine.\" Int J Geriatr Psychiatry 13 (1998): 343-5[30] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003): 1511-1512[31] \"Venlafaxine + tramadol: serotonin syndrome.\" Prescrire Int 13 (2004): 57[32] Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB \"Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected?\" J Am Med Dir Assoc 6 (2005): 265-9[33] Houlihan DJ \"Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine.\" Ann Pharmacother 38 (2004): 411-3[34] Hillman AD, Witenko CJ, Sultan SM, Gala G \"Serotonin syndrome caused by fentanyl and methadone in a burn injury.\" Pharmacotherapy 35 (2015): 112-7[35] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991): 705-13[36] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003): 32-5[37] Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL \"Meperidine-induced serotonin syndrome in a susceptible patient.\" Br J Anaesth (2009):[38] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H \"Serotonin Syndrome Probably Triggered by a Morphine-Phenelzine Interaction.\" Pharmacotherapy (2015):[39] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006): 1589[40] Kitson R, Carr B \"Tramadol and severe serotonin syndrome.\" Anaesthesia 60 (2005): 934-5[41] Zornberg GL, Bodkin JA, Cohen BM \"Severe adverse interaction between pethidine and selegiline.\" Lancet 337 (1991): 246[42] Mahlberg R, Kunz D, Sasse J, Kirchheiner J \"Serotonin syndrome with tramadol and citalopram.\" Am J Psychiatry 161 (2004): 1129[43] Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J \"Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy.\" J Clin Anesth 27 (2015): 247-51[44] Nieminen TH, Hagelberg NM, Saari TI, et al \"Grapefruit juice enhances the exposure to oral oxycodone.\" Basic Clin Pharmacol Toxicol 107 (2010): 782-8", "alternatives_a": "Oxymorphone, Tapentadol, Dezocine, Opium, Pentazocine, Nalbuphine, Dihydrocodeine, Naloxone, Codeine", "alternatives_b": "Tinidazole, Dexlansoprazole, Bismuth subcitrate potassium, Esomeprazole, Vonoprazan, Levofloxacin, Lincomycin, Dirithromycin", "updated_at": 1767369485}, {"id": 67889, "ingredient1": "Clarithromycin", "ingredient2": "Oxytocin", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67976/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[16] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Dinoprostone, Terlipressin, Desmopressin", "alternatives_b": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, Ranitidine, More", "updated_at": 1767369485}, {"id": 67890, "ingredient1": "Clarithromycin", "ingredient2": "Ozanimod", "severity": "Major", "effect": "Due to the risk of bradycardia and atrioventricular (AV) block, the risk of QT prolongation and torsade de pointes arrhythmia may be increased during initiation of ozanimod treatment in patients receiving drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Ozanimod has not been studied in patients receiving drugs that can prolong the QT interval. Because bradycardia and AV block are recognized risk factors for QT prolongation and torsade de pointes arrhythmia, treatment with ozanimod should generally not be initiated in patients who are concurrently treated with QT prolonging drugs with known arrhythmogenic properties.", "mechanism_text": "Synergism", "recommendation": "Ozanimod has not been studied in patients receiving drugs that can prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67977/", "reference_text": "[1] \"Product Information. Zeposia (ozanimod).\" Celgene Corporation, Summit, NJ.[2] \"Product Information. Zeposia (ozanimod).\" Celgene Corporation, Summit, NJ.[3] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[4] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Esomeprazole, Vonoprazan, More", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Anakinra, More", "updated_at": 1767369485}, {"id": 67891, "ingredient1": "Clarithromycin", "ingredient2": "Paclitaxel (protein-bound)", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 2C8 and/or 3A4 may increase the plasma concentrations of paclitaxel, which has been found in vitro to be a substrate of these isoenzymes.", "source": "DDInter", "management_text": "Clinicians should consider the potential for interaction with drugs that inhibit CYP450 2C8 and/or 3A4 and monitor for evidence of dose-related toxicities of paclitaxel during coadministration, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy.", "mechanism_text": "Metabolism", "recommendation": "Clinicians should consider the potential for interaction with drugs that inhibit CYP450 2C8 and/or 3A4 and monitor for evidence of dose-related toxicities of paclitaxel during coadministration, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67978/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Bergmann TK, Filppula AM, Launiainen T, Nielsen F, Backman J, Brosen K \"Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60 year old Caucasian woman with ovarian carcinoma.\" Br J Clin Pharmacol (2015):[3] Bun SS, Ciccolini J, Bun H, Aubert C, Catalin J \"Drug interactions of paclitaxel metabolism in human liver microsomes.\" J Chemother 15 (2003): 266-74[4] Spencer CM, Faulds D \"Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer.\" Drugs 48 (1994): 794-847[5] \"Product Information. Abraxane (paclitaxel protein-bound).\" American Pharmaceutical Partners, Schaumberg, IL.[6] \"Product Information. Taxol (paclitaxel).\" Bristol-Myers Squibb, Princeton, NJ.[7] Jamis-Dow CA, Klecker RW, Katki AG, Collins JM \"Metabolism of Taxol by human liver microsomes and effect of inhibitors (Meeting abstract).\" Proc Annu Meet Am Assoc Cancer Res 34 (1993): a21981993[8] Starr SP, Hammann F, Gotta V, et al. \"Pharmacokinetic interaction between taxanes and amiodarone leading to severe toxicity.\" Br J Clin Pharmacol 450 (2016): 22-27[9] \"Product Information. Taxotere (docetaxel).\" Rhone-Poulenc Rorer, Collegeville, PA.[10] Starr SP, Hammann F, Gotta V, et al. \"Pharmacokinetic interaction between taxanes and amiodarone leading to severe toxicity.\" Br J Clin Pharmacol 450 (2016): 22-27[11] Cerner Multum, Inc. \"Australian Product Information.\" O 0[12] Yong WP, Wang LZ, Tham LS, et al. \"A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancers.\" Cancer Chemother Pharmacol 62 (2008): 243-51[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] Aronson JK, Grahame-Smith DG \"Clinical pharmacology: adverse drug interactions.\" Br Med J 282 (1981): 288-91[15] Valenzuela B, Rebollo J, Perez T, Brugarolas A, Perez-Ruixo JJ \"Effect of grapefruit juice on the pharmacokinetics of docetaxel in cancer patients: a case report.\" Br J Clin Pharmacol (2011):[16] McInnes GT, Brodie MJ \"Drug interactions that matter: a critical reappraisal.\" Drugs 36 (1988): 83-110[17] Engels FK, Mathot RA, Loos WJ, van Schaik RH, Verweij J \"Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel.\" Cancer Biol Ther 5 (2006): 833-9", "alternatives_a": "Pantoprazole, Tetracycline, Rabeprazole, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Famotidine, Nizatidine, Esomeprazole, Ranitidine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67892, "ingredient1": "Clarithromycin", "ingredient2": "Palbociclib", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of palbociclib, which is a substrate of the isoenzyme. The risk of adverse effects such as infections, neutropenia, leukopenia, anemia, thrombocytopenia, anorexia, nausea, vomiting, diarrhea, stomatitis, alopecia, asthenia, peripheral neuropathy, and epistaxis may be increased.", "source": "DDInter", "management_text": "Concomitant use of palbociclib with potent CYP450 3A4 inhibitors should generally be avoided. Alternative agents with no or minimal CYP450 3A4 inhibitory potential are recommended whenever possible. If no alternatives exist, consider reducing the palbociclib dosage to 75 mg once daily. Following discontinuation of the potent CYP450 3A4 inhibitor, the palbociclib dosage should be returned (after 3 to 5 half-lives of the inhibitor) to that used prior to initiation of the inhibitor.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of palbociclib with potent CYP450 3A4 inhibitors should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67979/", "reference_text": "[1] \"Product Information. Ibrance (palbociclib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[3] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[4] \"Product Information. Ibrance (palbociclib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, More", "alternatives_b": "Alpelisib, Trametinib, Dacomitinib, Tivozanib, Alectinib", "updated_at": 1767369485}, {"id": 67893, "ingredient1": "Clarithromycin", "ingredient2": "Paliperidone", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67980/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[16] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, More", "alternatives_b": "Loxapine, Molindone, Thiothixene", "updated_at": 1767369485}, {"id": 67894, "ingredient1": "Clarithromycin", "ingredient2": "Palonosetron", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67981/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[16] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Scopolamine, Nabilone, Rolapitant, Dronabinol", "alternatives_b": "Tinidazole, Tetracycline, Dexlansoprazole, Rabeprazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Nizatidine, Esomeprazole, Vonoprazan, Amoxicillin, More", "updated_at": 1767369485}, {"id": 67895, "ingredient1": "Clarithromycin", "ingredient2": "Panobinostat", "severity": "Major", "effect": "Panobinostat can cause dose-dependent prolongation of the QT interval. Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of panobinostat, which is partially metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of panobinostat with potent CYP450 3A4 inhibitors that can also prolong the QT interval including ceritinib, clarithromycin, ketoconazole, posaconazole, saquinavir, telithromycin, and voriconazole should generally be avoided. If coadministration with these agents is required, the manufacturer recommends reducing the dose of panobinostat to 10 mg for the treatment of multiple myeloma, given in combination with bortezomib and dexamethasone. ECG and serum electrolytes, including potassium, magnesium and calcium, should be monitored before starting panobinostat therapy and periodically during treatment as clinically indicated. In the premarketing trial, ECGs were performed at baseline and prior to initiation of each cycle for the first 8 cycles. Panobinostat should not be started if baseline QTc is greater than 450 msec. Likewise, treatment should be interrupted in patients who develop QTc prolongation of 480 msec or greater until recovery to less than or equal to Grade 1, then resumed at a reduced dose. In case of recurrence, therapy should be withheld until recovery to less than or equal to Grade 1, then resumed at a further reduced dose if necessary. Permanently discontinue panobinostat therapy if Grade 3 or 4 QTc prolongation does not resolve.", "mechanism_text": "Metabolism, Synergism", "recommendation": "Concomitant use of panobinostat with potent CYP450 3A4 inhibitors that can also prolong the QT interval including ceritinib, clarithromycin, ketoconazole, posaconazole, saquinavir, telithromycin, and voriconazole should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67982/", "reference_text": "[1] \"Product Information. Farydak (panobinostat).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Hamberg P, Woo MM, Chen LC, et al. \"Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor.\" Cancer Chemother Pharmacol 68 (2011): 805-13[3] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[4] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Farydak (panobinostat).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Nizatidine, Esomeprazole, Ranitidine, More", "alternatives_b": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Mitotane, Niraparib, Porfimer sodium, More", "updated_at": 1767369485}, {"id": 67896, "ingredient1": "Clarithromycin", "ingredient2": "Papaverine", "severity": "Major", "effect": "Intracoronary administration of papaverine has been associated with QT interval prolongation and torsade de pointes (TdP) arrhythmia. The risk may theoretically increase in patients receiving concomitant medications that can also prolong the QT interval or cause bradycardia. The precise mechanism of papaverine-induced ventricular tachyarrhythmias has not been delineated, but may involve inhibition of potassium currents and prolongation of the action potential duration.", "source": "DDInter", "management_text": "Caution and close monitoring are advised during intracoronary administration of papaverine, particularly in patients receiving concomitant drugs that can prolong the QT interval or cause bradycardia and in patients with other risk factors described above.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring are advised during intracoronary administration of papaverine, particularly in patients receiving concomitant drugs that can prolong the QT interval or cause bradycardia and in patients with other risk factors described above.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67983/", "reference_text": "[1] Vrolix M, Piessens J, De Geest H \"Torsades de pointes after intracoronary papaverine.\" Eur Heart J 12 (1991): 273-6[2] Jain A, Jenkins MG \"Intracoronary electrocardiogram during torsade des pointes secondary to intracoronary papaverine.\" Cathet Cardiovasc Diagn 18 (1989): 255-7[3] Goto M, Sato M, Kitzazawa H, et.al \"Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation.\" Intern Med 53 (2014): 1629-31[4] Talman CL, Winniford MD, Rossen JD, Simonetti I, Kienzle MG, Marcus ML \"Polymorphous ventricular tachycardia: a side effect of intracoronary papaverine.\" J Am Coll Cardiol 15 (1990): 275-8[5] Kern MJ, Deligonul U, Serota H, Gudipati C, Buckingham T \"Ventricular arrhythmia due to intracoronary papaverine: analysis of QT intervals and coronary vasodilatory reserve.\" Cathet Cardiovasc Diagn 19 (1990): 229-36[6] Nakayama M, Tanaka N, Sakoda K, et.al \"Papaverine-induced polymorphic ventricular tachycardia during coronary flow reserve study of patients with moderate coronary artery disease.\" Circ J 79 (2015): 530-6[7] Inoue T, Asahi S, Takayanagi K, Morooka S, Takabatake Y \"QT prolongation and possibility of ventricular arrhythmias after intracoronary papaverine.\" Cardiology 84 (1994): 9-13[8] Nakayama M, Saito A, Kitazawa H, et.al \"Papaverine-induced polymorphic ventricular tachycardia in relation to QTU and giant T-U waves in four cases.\" Intern Med 51 (2012): 351-6", "alternatives_a": "Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Phenyl salicylate, Ammonium chloride, Dimethyl sulfoxide, More", "alternatives_b": "Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Sucralfate, More", "updated_at": 1767369485}, {"id": 67897, "ingredient1": "Clarithromycin", "ingredient2": "Paricalcitol", "severity": "Moderate", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of paricalcitol, which is partially metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when paricalcitol is used with potent CYP450 3A4 inhibitors. Serum calcium and phosphorus levels should be monitored closely. If clinically significant hypercalcemia develops, the paricalcitol dose should be reduced or interrupted and support therapy administered.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when paricalcitol is used with potent CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67984/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Zemplar (paricalcitol).\" Abbott Pharmaceutical, Abbott Park, IL.[3] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[4] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Etelcalcetide, Doxercalciferol, Salmon calcitonin, Calcifediol", "alternatives_b": "Tinidazole, Levofloxacin, Tetracycline, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Cimetidine, Esomeprazole, Nizatidine, Vonoprazan, Amoxicillin, More", "updated_at": 1767369485}, {"id": 67898, "ingredient1": "Clarithromycin", "ingredient2": "Paroxetine", "severity": "Moderate", "effect": "The use of some macrolide antibiotics has been associated with increased blood levels of some selective serotonin reuptake inhibitors (SSRIs), resulting in excessive serotonergic effects or serotonin syndrome. The mechanism is inhibition of the CYP450 3A4 isoenzyme, which metabolizes SSRIs.", "source": "DDInter", "management_text": "In cases where both drugs are necessary, one could consider using a macrolide antibiotic that does not inhibit CYP450 3A4, such as azithromycin or dirithromycin.", "mechanism_text": "Metabolism", "recommendation": "In cases where both drugs are necessary, one could consider using a macrolide antibiotic that does not inhibit CYP450 3A4, such as azithromycin or dirithromycin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67985/", "reference_text": "[1] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[2] Pollak PT, Slayter KL \"Delirium probably induced by clarithromycin in a patient receiving fluoxetine - reply.\" Ann Pharmacother 30 (1996): 1200[3] Timothy P, Sketris IS, Mackenzie SL, Hewlett TJ \"Delirium probably induced by clarithromycin in a patient receiving fluoxetine.\" Ann Pharmacother 29 (1995): 486-8[4] Tracy TS, Cupp MJ \"Delirium probably induced by clarithromycin in a patient receiving fluoxetine - comment.\" Ann Pharmacother 30 (1996): 1199-200[5] Lee DO, Lee CD \"Serotonin syndrome in a child associated with erythromycin and sertraline.\" Pharmacotherapy 19 (1999): 894-6[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Ueda N, Yoshimura R, Umene-Nakano W, et al. \"Grapefruit juice alters plasma sertraline levels after single ingestion of sertraline in healthy volunteers.\" World J Biol Psychiatry 10(4 Pt 3) (2009): 832-5[8] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[9] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9", "alternatives_a": "Phenelzine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Vortioxetine, Milnacipran, Tryptophan, Esketamine", "alternatives_b": "Tinidazole, Dexlansoprazole, Bismuth subcitrate potassium, Rifabutin, Esomeprazole, Vonoprazan, Levofloxacin, Lincomycin, Dirithromycin", "updated_at": 1767369485}, {"id": 67899, "ingredient1": "Clarithromycin", "ingredient2": "Pasireotide", "severity": "Major", "effect": "Pasireotide can cause bradycardia and QT prolongation. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is recommended if pasireotide is used in combination with other drugs that can prolong the QT interval. ECG and serum electrolytes, including potassium, magnesium and calcium, should be monitored before starting pasireotide therapy and periodically during treatment in accordance with the product labeling. Hypokalemia and hypomagnesemia must be corrected prior to pasireotide administration.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if pasireotide is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67986/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Signifor (pasireotide).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[5] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[6] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, More", "alternatives_b": "Nafarelin, Octreotide, Cetrorelix, Ganirelix, Lanreotide, Gonadorelin", "updated_at": 1767369485}, {"id": 67900, "ingredient1": "Clarithromycin", "ingredient2": "Pazopanib", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of pazopanib, which is primarily metabolized by the isoenzyme. Although not studied, the interaction may increase the risk of QT interval prolongation and torsade de pointes arrhythmia as well as severe and fatal hepatotoxicity associated with the use of pazopanib.", "source": "DDInter", "management_text": "Concomitant use of pazopanib with potent CYP450 3A4 inhibitors should generally be avoided. Some authorities recommend avoiding concomitant use of pazopanib during and for 2 weeks after treatment with itraconazole. If coadministration is unavoidable, a reduction of the pazopanib dosage to 400 mg once daily should be considered. Based on pharmacokinetic studies, this dosage is predicted to adjust the pazopanib systemic exposure (AUC) to the range observed without inhibitors. However, clinical data are lacking. Patients should have liver function tests (ALT, AST, bilirubin), electrocardiograms, and serum electrolyte levels performed at baseline and regular intervals as recommended in the product labeling. Further dosage reductions may be needed if adverse effects occur during therapy. Patients should be advised to notify their physician if they experience signs and symptoms of hepatotoxicity such as fever, rash, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, and jaundice. In addition, they should seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, or syncope. Following discontinuation of the potent CYP450 3A4 inhibitor, a washout period of approximately one week should be allowed before the pazopanib dosage is adjusted upward.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of pazopanib with potent CYP450 3A4 inhibitors should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67987/", "reference_text": "[1] \"Product Information. Votrient (pazopanib).\" GlaxoSmithKline, Research Triangle Park, NC.[2] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Votrient (pazopanib).\" GlaxoSmithKline, Research Triangle Park, NC.[5] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[6] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Tetracycline, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Vonoprazan, Amoxicillin, Dirithromycin, Lincomycin, Clindamycin", "alternatives_b": "Alpelisib, Trametinib, Dacomitinib, Tivozanib, Alectinib", "updated_at": 1767369485}, {"id": 67901, "ingredient1": "Clarithromycin", "ingredient2": "Pegaspargase", "severity": "Moderate", "effect": "Concomitant use of asparaginase with other hepatotoxic agents may potentiate the risk of liver injury. Hepatomegaly, acute severe hepatotoxicity, and fatal liver failure have been reported with asparaginase treatment in adults. Also, asparaginase may increase the toxicity of drugs bound to plasma proteins or metabolized by the liver.", "source": "DDInter", "management_text": "The risk of additive hepatotoxicity should be considered when asparaginase is used with other hepatotoxic agents (e.g., alcohol, androgens, antituberculosis agents, azole antifungal agents, ACE inhibitors, macrolide antibiotics, nonsteroidal anti-inflammatory agents, nucleoside reverse transcriptase inhibitors, sulfonamides, thiazolidinediones, and statins). Liver function tests should be monitored at regular intervals during asparaginase treatment with or without other hepatotoxic drugs. Patients should be advised to seek medical attention if they experience potential symptoms of hepatotoxicity such as right upper quadrant pain, increasing abdominal size, fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, dark urine, pale stools, and jaundice.", "mechanism_text": "Synergism", "recommendation": "The risk of additive hepatotoxicity should be considered when asparaginase is used with other hepatotoxic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67988/", "reference_text": "[1] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Bodmer M, Sulz M, Stadlmann S, Droll A, Terracciano L, Krahenbuhl S \"Fatal liver failure in an adult patient with acute lymphoblastic leukemia following treatment with L-asparaginase.\" Digestion 74 (2006): epub[4] Cerner Multum, Inc \"ANVISA Bulrio Eletrnico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[5] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[6] Christ TN, Stock W, Knoebel RW \"Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen.\" J Oncol Pharm Pract 24 (2018): 299-308[7] Lu G, Karur V, Herrington JD, Walker MG \"Successful treatment of pegaspargase-induced acute hepatotoxicity with vitamin B complex and L-carnitine\" Proc (Bayl Univ Med Cent) 29 (2016): 46-7[8] Jenkins R, Perlin E \"Severe hepatotoxicity from Escherichia coli L-asparaginase.\" J Natl Med Assoc 79 (1987): 775-9[9] \"Product Information. Asparlas (calaspargase pegol).\" Servier, Boston, MA.[10] Burke PW, Aldoss I, Lunning MA, et.al \"High-grade PEGylated asparaginase-related hepatotoxicity occurrence in a pediatric-inspired adult acute lymphoblastic leukemia regimen does not necessarily predict recurrent hepatotoxicity in subsequent cycles.\" Blood 122 (2013): 2671[11] \"Product Information. Erwinaze (asparaginase Erwinia chrysanthemi).\" EUSA Pharma, Newtown, PA.[12] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[13] Al-Nawakil C, Willems L, Mauprivez C, et.al \"Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors.\" Leuk Lymphoma 55 (2014): 1670-4", "alternatives_a": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Mitotane, Niraparib, Porfimer sodium, More", "alternatives_b": "Tinidazole, Pantoprazole, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Rifabutin, Cimetidine, More", "updated_at": 1767369485}, {"id": 67902, "ingredient1": "Clarithromycin", "ingredient2": "Peginterferon beta-1a", "severity": "Moderate", "effect": "Coadministration of beta interferons with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Use of beta interferons has been associated with rare cases of liver injury, including autoimmune hepatitis and severe liver damage leading to hepatic failure, some of which required transplantation.", "source": "DDInter", "management_text": "The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; other interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.", "mechanism_text": "Synergism", "recommendation": "The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67989/", "reference_text": "[1] \"Product Information. Plegridy (peginterferon beta-1a).\" Biogen Idec Inc, Cambridge, MA.[2] \"Product Information. Betaseron (interferon beta-1b).\" Berlex, Richmond, CA.[3] \"Product Information. Rebif (interferon beta-1a).\" Serono Laboratories Inc, Norwell, MA.[4] \"Product Information. Avonex (interferon beta-1a).\" Biogen, Cambridge, MA.", "alternatives_a": "Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Sucralfate, More", "alternatives_b": "Interferon alfa-n1, Oprelvekin, Sipuleucel-T, Elapegademase, Peginterferon alfa-2a, Ropeginterferon alfa-2b, Interferon alfacon-1, Sargramostim, Histamine, Aldesleukin, Pegademase, More", "updated_at": 1767369485}, {"id": 67903, "ingredient1": "Clarithromycin", "ingredient2": "Pemigatinib", "severity": "Major", "effect": "Coadministration with potent or moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of pemigatinib, which is primarily metabolized by the isoenzyme in vitro.", "source": "DDInter", "management_text": "Concomitant use of pemigatinib with potent or moderate CYP450 3A4 inhibitors should be avoided. If coadministration is required, a reduction in the dosage of pemigatinib is recommended.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of pemigatinib with potent or moderate CYP450 3A4 inhibitors should be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67990/", "reference_text": "[1] \"Product Information. Pemazyre (pemigatinib).\" Incyte Corporation, Wilmington, DE.[2] \"Product Information. Pemazyre (pemigatinib).\" Incyte Corporation, Wilmington, DE.", "alternatives_a": "Tinidazole, Levofloxacin, Tetracycline, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Nizatidine, Ranitidine, Amoxicillin, More", "alternatives_b": "Alpelisib, Trametinib, Dacomitinib, Tivozanib, Alectinib", "updated_at": 1767369485}, {"id": 67904, "ingredient1": "Clarithromycin", "ingredient2": "Benzylpenicillin", "severity": "Minor", "effect": "Although some in vitro data indicate synergism between macrolide antibiotics and penicillins, other in vitro data indicate antagonism. When these drugs are given together, neither has predictable therapeutic efficacy. Data are available for erythromycin, although theoretically this interaction could occur with any macrolide. Except for monitoring of the effectiveness of antibiotic therapy, no special precautions appear to be necessary.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67991/", "reference_text": "[1] Strom J \"Penicillin and erythromycin singly and in combination in scarlatina therapy and the interference between them.\" Antibiot Chemother 11 (1961): 694-7[2] Cohn JR, Jungkind DL, Baker JS \"In vitro antagonism by erythromycin of the bactericidal action of antimicrobial agents against common respiratory pathogens.\" Antimicrob Agents Chemother 18 (1980): 872-6[3] Penn RL, Ward TT, Steigbigel RT \"Effects of erythromycin in combination with penicillin, ampicillin, or gentamicin on the growth of listeria monocytogenes.\" Antimicrob Agents Chemother 22 (1982): 289-94", "alternatives_a": "Tazobactam, Sulbactam, Rifamycin, Oxytetracycline, Netilmicin, Polymyxin B, Sulfamethizole, Trifluridine, Sulfisoxazole, Povidone-iodine", "alternatives_b": "Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, More", "updated_at": 1767369485}, {"id": 67905, "ingredient1": "Clarithromycin", "ingredient2": "Benzylpenicillin (potassium)", "severity": "Minor", "effect": "Although some in vitro data indicate synergism between macrolide antibiotics and penicillins, other in vitro data indicate antagonism. When these drugs are given together, neither has predictable therapeutic efficacy. Data are available for erythromycin, although theoretically this interaction could occur with any macrolide. Except for monitoring of the effectiveness of antibiotic therapy, no special precautions appear to be necessary.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67992/", "reference_text": "[1] Strom J \"Penicillin and erythromycin singly and in combination in scarlatina therapy and the interference between them.\" Antibiot Chemother 11 (1961): 694-7[2] Cohn JR, Jungkind DL, Baker JS \"In vitro antagonism by erythromycin of the bactericidal action of antimicrobial agents against common respiratory pathogens.\" Antimicrob Agents Chemother 18 (1980): 872-6[3] Penn RL, Ward TT, Steigbigel RT \"Effects of erythromycin in combination with penicillin, ampicillin, or gentamicin on the growth of listeria monocytogenes.\" Antimicrob Agents Chemother 22 (1982): 289-94", "alternatives_a": "Tazobactam, Sulbactam, Rifamycin, Oxytetracycline, Netilmicin, Polymyxin B, Sulfamethizole, Trifluridine, Sulfisoxazole, Povidone-iodine", "alternatives_b": "Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, More", "updated_at": 1767369485}, {"id": 67906, "ingredient1": "Clarithromycin", "ingredient2": "Benzylpenicillin (sodium)", "severity": "Minor", "effect": "Although some in vitro data indicate synergism between macrolide antibiotics and penicillins, other in vitro data indicate antagonism. When these drugs are given together, neither has predictable therapeutic efficacy. Data are available for erythromycin, although theoretically this interaction could occur with any macrolide. Except for monitoring of the effectiveness of antibiotic therapy, no special precautions appear to be necessary.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67993/", "reference_text": "[1] Strom J \"Penicillin and erythromycin singly and in combination in scarlatina therapy and the interference between them.\" Antibiot Chemother 11 (1961): 694-7[2] Cohn JR, Jungkind DL, Baker JS \"In vitro antagonism by erythromycin of the bactericidal action of antimicrobial agents against common respiratory pathogens.\" Antimicrob Agents Chemother 18 (1980): 872-6[3] Penn RL, Ward TT, Steigbigel RT \"Effects of erythromycin in combination with penicillin, ampicillin, or gentamicin on the growth of listeria monocytogenes.\" Antimicrob Agents Chemother 22 (1982): 289-94", "alternatives_a": "Tazobactam, Sulbactam, Rifamycin, Oxytetracycline, Netilmicin, Polymyxin B, Sulfamethizole, Trifluridine, Sulfisoxazole, Povidone-iodine", "alternatives_b": "Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, More", "updated_at": 1767369485}, {"id": 67907, "ingredient1": "Clarithromycin", "ingredient2": "Phenoxymethylpenicillin", "severity": "Minor", "effect": "Although some in vitro data indicate synergism between macrolide antibiotics and penicillins, other in vitro data indicate antagonism. When these drugs are given together, neither has predictable therapeutic efficacy. Data are available for erythromycin, although theoretically this interaction could occur with any macrolide. Except for monitoring of the effectiveness of antibiotic therapy, no special precautions appear to be necessary.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67994/", "reference_text": "[1] Strom J \"Penicillin and erythromycin singly and in combination in scarlatina therapy and the interference between them.\" Antibiot Chemother 11 (1961): 694-7[2] Cohn JR, Jungkind DL, Baker JS \"In vitro antagonism by erythromycin of the bactericidal action of antimicrobial agents against common respiratory pathogens.\" Antimicrob Agents Chemother 18 (1980): 872-6[3] Penn RL, Ward TT, Steigbigel RT \"Effects of erythromycin in combination with penicillin, ampicillin, or gentamicin on the growth of listeria monocytogenes.\" Antimicrob Agents Chemother 22 (1982): 289-94", "alternatives_a": "Tazobactam, Sulbactam", "alternatives_b": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Rifabutin, More", "updated_at": 1767369485}, {"id": 67908, "ingredient1": "Clarithromycin", "ingredient2": "Pentamidine", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67995/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[16] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Miltefosine, Nifurtimox, Benznidazole", "alternatives_b": "Tinidazole, Tetracycline, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Nizatidine, Ranitidine, Vonoprazan, Amoxicillin, More", "updated_at": 1767369485}, {"id": 67909, "ingredient1": "Clarithromycin", "ingredient2": "Perampanel", "severity": "Minor", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of perampanel, which is primarily metabolized by the isoenzyme. In a clinical study, ketoconazole 400 mg daily for 10 days resulted in an increase in perampanel AUC by 20% and half-life by 15%.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67996/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[3] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[4] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[5] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[6] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[7] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[8] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, More", "alternatives_b": "Tiagabine, Brivaracetam, Rufinamide, Methsuximide, Paramethadione, Fenfluramine, Eslicarbazepine, Phensuximide, Methylphenobarbital, Phenacemide, Primidone, More", "updated_at": 1767369485}, {"id": 67910, "ingredient1": "Clarithromycin", "ingredient2": "Perflutren", "severity": "Moderate", "effect": "Perflutren lipid microsphere suspension (Definity) has been reported to cause prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is recommended if perflutren lipid microsphere suspension is used in combination with other drugs that can prolong the QT interval. Please refer to the prescribing information for these drugs for more information. No data are available regarding the effect of perflutren protein-type A microsphere suspension (Optison) on the QT interval of the electrocardiogram.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if perflutren lipid microsphere suspension is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67997/", "reference_text": "[1] \"Product Information. Definity (perflutren).\" Lantheus Medical Imaging Inc, North Billerica, MA.[2] \"Product Information. Optison (perflutren).\" Mallinckrodt Medical Inc, St. Louis, MO.[3] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[4] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Famotidine, Rifabutin, Cimetidine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67911, "ingredient1": "Clarithromycin", "ingredient2": "Perphenazine", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67998/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[16] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Loxapine, Molindone, Thiothixene", "alternatives_b": "Tinidazole, Tetracycline, Dexlansoprazole, Rabeprazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, Nizatidine, Vonoprazan, More", "updated_at": 1767369485}, {"id": 67912, "ingredient1": "Clarithromycin", "ingredient2": "Pexidartinib", "severity": "Major", "effect": "Coadministration of pexidartinib with strong CYP450 3A4 inhibitors and/or uridine diphosphate glucuronosyltransferase (UGT) inhibitors may significantly increase the plasma concentrations and the incidence and severity of adverse effects of pexidartinib, including potentially fatal hepatotoxicity. The proposed mechanism is inhibition of CYP450 3A4 and/or UGT, the primary isoenzymes responsible for the metabolic clearance of pexidartinib.", "source": "DDInter", "management_text": "The use of pexidartinib with strong CYP450 3A4 inhibitors and/or UGT inhibitors should generally be avoided. If concomitant use is required, the dose of pexidartinib should be reduced according to the manufacturer's recommendations. If concomitant use of a strong CYP450 3A4 inhibitor or UGT inhibitor is discontinued, the dose of pexidartinib may be increased, after 3 plasma half-lives of the strong CYP450 3A4 inhibitor or UGT inhibitor, to the dose that was used prior to starting the strong CYP450 3A4 inhibitor or UGT inhibitor.", "mechanism_text": "Metabolism", "recommendation": "The use of pexidartinib with strong CYP450 3A4 inhibitors and/or UGT inhibitors should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/67999/", "reference_text": "[1] \"Product Information. Turalio (pexidartinib).\" Daiichi Sankyo, Inc., Parsippany, NJ.[2] \"Product Information. Turalio (pexidartinib).\" Daiichi Sankyo, Inc., Parsippany, NJ.[3] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[4] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Amoxicillin, Dirithromycin, Lincomycin, Clindamycin", "alternatives_b": "Alpelisib, Trametinib, Dacomitinib, Tivozanib, Alectinib", "updated_at": 1767369485}, {"id": 67913, "ingredient1": "Clarithromycin", "ingredient2": "Phenolphthalein", "severity": "Moderate", "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68000/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Schaefer DC, Cheskin LJ \"Constipation in the elderly.\" Am Fam Physician 58 (1998): 907-14[4] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993): 138-45[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998): 517-8", "alternatives_a": "Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Sucralfate, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 67914, "ingredient1": "Clarithromycin", "ingredient2": "Phenytoin", "severity": "Moderate", "effect": "Coadministration with phenytoin may reduce the plasma concentrations and antimicrobial efficacy of erythromycin and other macrolide antibiotics. The mechanism is induction of CYP450 3A metabolism by phenytoin. Additionally, plasma concentrations of phenytoin may be increased.", "source": "DDInter", "management_text": "If concomitant use is medically necessary, caution and monitoring for altered efficacy and safety of both medications is recommended.", "mechanism_text": "Metabolism", "recommendation": "If concomitant use is medically necessary, caution and monitoring for altered efficacy and safety of both medications is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68001/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Milne RW, Coulthard K, Nation RL, et al \"Lack of effect of erythromycin on the pharmacokinetics of single oral doses of phenytoin.\" Br J Clin Pharmacol 26 (1988): 330-3[4] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[5] Bachmann K, Schwartz JI, Forney RB Jr, Jauregui L \"Single dose phenytoin clearance during erythromycin treatment.\" Res Commun Chem Pathol Pharmacol 46 (1984): 207-17[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Fleisher D, Sheth N, Kou JH \"Phenytoin interaction with enteral feedings administered through nasogastric tubes.\" JPEN J Parenter Enteral Nutr 14 (1990): 513-6[9] Krueger KA, Garnett WR, Comstock TJ, Fitzsimmons WE, Karnes HT, Pellock JM \"Effect of two administration schedules of an enteral nutrient formula on phenytoin bioavailability.\" Epilepsia 28 (1987): 706-12[10] Haley CJ, Nelson J \"Phenytoin-enteral feeding interaction.\" DICP 23 (1989): 796-8[11] Faraji B, Yu PP \"Serum phenytoin levels of patients on gastrostomy tube feeding.\" J Neurosci Nurs 30 (1998): 55-9[12] Au Yeung SC, Ensom MH \"Phenytoin and enteral feedings: does evidence support an interaction?\" Ann Pharmacother 34 (2000): 896-905[13] Sandor P, Sellers EM, Dumbrell M, Khouw V \"Effect of short- and long-term alcohol use on phenytoin kinetics in chronic alcoholics.\" Clin Pharmacol Ther 30 (1981): 390-7[14] Ozuna J, Friel P \"Effect of enteral tube feeding on serum phenytoin levels.\" J Neurosurg Nurs 16 (1984): 289-91[15] Guidry JR, Eastwood TF, Curry SC \"Phenytoin absorption in volunteers receiving selected enteral feedings.\" West J Med 150 (1989): 659-61[16] Marvel ME, Bertino JS \"Comparative effects of an elemental and a complex enteral feeding formulation on the absorption of phenytoin suspension.\" JPEN J Parenter Enteral Nutr 15 (1991): 316-8[17] \"Product Information. Dilantin (phenytoin).\" Parke-Davis, Morris Plains, NJ.[18] Doak KK, Haas CE, Dunnigan KJ, et al. \"Bioavailability of phenytoin acid and phenytoin sodium with enteral feedings.\" Pharmacotherapy 18 (1998): 637-45[19] Rodman DP, Stevenson TL, Ray TR \"Phenytoin malabsorption after jejunostomy tube delivery.\" Pharmacotherapy 15 (1995): 801-5[20] Sellers EM, Holloway MR \"Drug kinetics and alcohol ingestion.\" Clin Pharmacokinet 3 (1978): 440-52[21] Holtz L, Milton J, Sturek JK \"Compatibility of medications with enteral feedings.\" JPEN J Parenter Enteral Nutr 11 (1987): 183-6", "alternatives_a": "Tiagabine, Brivaracetam, Rufinamide, Methsuximide, Paramethadione, Fenfluramine, Eslicarbazepine, Phensuximide, Methylphenobarbital, Phenacemide, Primidone, More", "alternatives_b": "Tetracycline, Dexlansoprazole, Bismuth subcitrate potassium, Nizatidine, Levofloxacin, Lincomycin, Dirithromycin", "updated_at": 1767369485}, {"id": 67915, "ingredient1": "Clarithromycin", "ingredient2": "Pimavanserin", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of pimavanserin, which is primarily metabolized by the isoenzyme. High plasma levels of pimavanserin may increase the risk of QT interval prolongation, which has been associated with ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Pimavanserin dosage should be reduced to 10 mg once a day when used with potent CYP450 3A4 inhibitors.", "mechanism_text": "Metabolism", "recommendation": "Pimavanserin dosage should be reduced to 10 mg once a day when used with potent CYP450 3A4 inhibitors.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68002/", "reference_text": "[1] \"Product Information. Nuplazid (pimavanserin).\" Accelis Pharma, East Windsor, NJ.[2] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Nizatidine, Esomeprazole, Ranitidine, More", "alternatives_b": "Loxapine, Molindone, Thiothixene", "updated_at": 1767369485}, {"id": 67916, "ingredient1": "Clarithromycin", "ingredient2": "Pimecrolimus (topical)", "severity": "Minor", "effect": "Theoretically, coadministration with CYP450 3A inhibitors may increase the plasma concentrations of pimecrolimus, which has been shown in vitro to undergo metabolism by this subfamily of hepatic microsomal enzymes. Although clinically significant drug interactions are not expected due to minimal systemic absorption of topically administered pimecrolimus, the possibility cannot be ruled out.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68003/", "reference_text": "[1] \"Product Information. Elidel (pimecrolimus topical).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67917, "ingredient1": "Clarithromycin", "ingredient2": "Pimozide", "severity": "Major", "effect": "Coadministration with the ketolide, telithromycin, as well as certain macrolide antibiotics may increase the plasma concentrations of pimozide. The mechanism is inhibition of pimozide metabolism via CYP450 3A4. High plasma levels of pimozide have been associated with prolongation of the QT interval on the ECG; ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes; cardiac arrest; and sudden death. Macrolides that may significantly inhibit CYP450 3A4 include clarithromycin, erythromycin, and troleandomycin.", "source": "DDInter", "management_text": "The use of pimozide with telithromycin or macrolide antibiotics is considered contraindicated by the manufacturers, although azithromycin and dirithromycin are generally believed to have little, if any, effect on CYP450 3A4.", "mechanism_text": "Metabolism", "recommendation": "The use of pimozide with telithromycin or macrolide antibiotics is considered contraindicated by the manufacturers, although azithromycin and dirithromycin are generally believed to have little, if any, effect on CYP450 3A4.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68004/", "reference_text": "[1] Krahenbuhl S, Sauter B, Kupferschmidt H, Krause M, Wyss PA, Meier PJ \"Case report: reversible QT prolongation with torsades de pointes in a patient with pimozide intoxication.\" Am J Med Sci 309 (1995): 315-6[2] European Agency for the Evaluation of Medicinal Products. Committee for Proprietary Medicinal Products \"European Public Assessment Report Ketek (telithromycin) (Rev. 2) Available from: URL: http:www.emea.eu.int/humandocs/Humans/EPAR/Ketek/Ketek.htm.\" ([2001]):[3] Desta Z, Soukhova N, Flockhart DA \"In Vitro Inhibition of Pimozide N-Dealkylation by Selective Serotonin Reuptake Inhibitors and Azithromycin.\" J Clin Psychopharmacol 22 (2002): 162-168[4] \"Product Information. Ketek (telithromycin).\" Aventis Pharmaceuticals, Bridgewater, NJ.[5] \"Product Information. Orap Tablets (pimozide).\" Gate Pharmaceuticals, Sellersville, PA.[6] Flockhart DA, Drici MD, Kerbusch T, et al \"Studies on the mechanism of a fatal clarithromycin-pimozide interaction in a patient with tourette syndrome.\" J Clin Psychopharmacol 20 (2000): 317-24[7] Desta Z, Kerbusch T, Flockhart DA \"Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6).\" Clin Pharmacol Ther 65 (1999): 10-20[8] Amsden GW \"Macrolides versus azalides: a drug interaction update.\" Ann Pharmacother 29 (1995): 906-17[9] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[10] \"Product Information. Orap Tablets (pimozide).\" Gate Pharmaceuticals, Sellersville, PA.", "alternatives_a": "Loxapine, Molindone, Thiothixene", "alternatives_b": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Nizatidine, Esomeprazole, More", "updated_at": 1767369485}, {"id": 67918, "ingredient1": "Clarithromycin", "ingredient2": "Piperacillin", "severity": "Minor", "effect": "Although some in vitro data indicate synergism between macrolide antibiotics and penicillins, other in vitro data indicate antagonism. When these drugs are given together, neither has predictable therapeutic efficacy. Data are available for erythromycin, although theoretically this interaction could occur with any macrolide. Except for monitoring of the effectiveness of antibiotic therapy, no special precautions appear to be necessary.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68005/", "reference_text": "[1] Strom J \"Penicillin and erythromycin singly and in combination in scarlatina therapy and the interference between them.\" Antibiot Chemother 11 (1961): 694-7[2] Cohn JR, Jungkind DL, Baker JS \"In vitro antagonism by erythromycin of the bactericidal action of antimicrobial agents against common respiratory pathogens.\" Antimicrob Agents Chemother 18 (1980): 872-6[3] Penn RL, Ward TT, Steigbigel RT \"Effects of erythromycin in combination with penicillin, ampicillin, or gentamicin on the growth of listeria monocytogenes.\" Antimicrob Agents Chemother 22 (1982): 289-94", "alternatives_a": "Tazobactam, Sulbactam", "alternatives_b": "Tinidazole, Levofloxacin, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Esomeprazole, Vonoprazan, Amoxicillin, Telithromycin, Lincomycin", "updated_at": 1767369485}, {"id": 67919, "ingredient1": "Clarithromycin", "ingredient2": "Pirbuterol", "severity": "Moderate", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.", "source": "DDInter", "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68006/", "reference_text": "[1] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990): 575-9[6] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003): 1817-24[8] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998): 145-7[11] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990): 1396-9[16] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.[17] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006): 582-90[19] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[20] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[21] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001): 45-51[26] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986): 619-20", "alternatives_a": "Tinidazole, Tetracycline, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Rifabutin, Cimetidine, Esomeprazole, Vonoprazan, More", "alternatives_b": "Ephedrine, Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Ipratropium, Beclomethasone dipropionate", "updated_at": 1767369485}, {"id": 67920, "ingredient1": "Clarithromycin", "ingredient2": "Pitolisant", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68007/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[16] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Nizatidine, Esomeprazole, Ranitidine, More", "alternatives_b": "Dextromethorphan, Dalfampridine, Sodium oxybate, Riluzole, Inotersen, Amifampridine, Tafamidis", "updated_at": 1767369485}, {"id": 67921, "ingredient1": "Clarithromycin", "ingredient2": "Polatuzumab vedotin", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may increase exposure to unconjugated monomethyl auristatin E (MMAE), the anti-mitotic and cytotoxic component of polatuzumab vedotin. Polatuzumab vedotin is an antibody-drug conjugate (ADC) that releases MMAE via proteolytic cleavage, and MMAE has been shown in vitro to be primarily metabolized by CYP450 3A4.", "source": "DDInter", "management_text": "Caution is advised when polatuzumab vedotin is used concomitantly with potent CYP450 3A4 inhibitors. Patients should be closely monitored for development or exacerbation of toxicities such as peripheral neuropathy, myelosuppression, opportunistic infections, tumor lysis syndrome and hepatotoxicity, and the dosing of polatuzumab vedotin adjusted or withheld as necessary in accordance with the product labeling.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when polatuzumab vedotin is used concomitantly with potent CYP450 3A4 inhibitors.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68008/", "reference_text": "[1] \"Product Information. Polivy (polatuzumab vedotin).\" Genentech, South San Francisco, CA.", "alternatives_a": "Pantoprazole, Levofloxacin, Tetracycline, Rabeprazole, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Famotidine, Nizatidine, Esomeprazole, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 67922, "ingredient1": "Clarithromycin", "ingredient2": "Polyethylene glycol (3350)", "severity": "Moderate", "effect": "Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68009/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Schaefer DC, Cheskin LJ \"Constipation in the elderly.\" Am Fam Physician 58 (1998): 907-14[4] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993): 138-45[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998): 517-8", "alternatives_a": "Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Sucralfate, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67923, "ingredient1": "Clarithromycin", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68010/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[3] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[4] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996): 347[5] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.[11] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.", "alternatives_a": "Tinidazole, Pantoprazole, Dexlansoprazole, Rabeprazole, Bismuth subcitrate potassium, Metronidazole, Rifabutin, Esomeprazole, Vonoprazan, Amoxicillin, Lansoprazole, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67924, "ingredient1": "Clarithromycin", "ingredient2": "Pomalidomide", "severity": "Moderate", "effect": "Coadministration with potent inhibitors of CYP450 1A2, CYP450 3A4, and P-glycoprotein may increase the plasma concentrations of pomalidomide, which has been shown to be primarily metabolized by these isoenzymes and also a substrate of the efflux transporter. Pomalidomide exposure is increased when given with a strong CYP450 1A2 inhibitor (e.g., fluvoxamine) in the presence of a strong CYP450 3A4 and P-gp inhibitor (e.g., ketoconazole). Coadministration with ketoconazole alone did not have a clinically significant effect on exposure to pomalidomide.", "source": "DDInter", "management_text": "The use of pomalidomide with potent inhibitors of CYP450 1A2 (e.g., ciprofloxacin, fluvoxamine, tiabendazole) in the presence of strong CYP450 3A4 and P-gp inhibitors should generally be avoided. If coadministration is considered clinically necessary, the pomalidomide dose should be reduced by 50%. Dose reduction may also be required if pomalidomide is given with a strong inhibitor of CYP450 1A2 in the absence of a coadministered CYP450 3A4 and P-gp inhibitor. Patients should be monitored for occurrence of pomalidomide-related side effects, including nausea, diarrhea, and neutropenia.", "mechanism_text": "Metabolism", "recommendation": "The use of pomalidomide with potent inhibitors of CYP450 1A2 (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68011/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Pomalyst (pomalidomide).\" QLT Phototherapeutics Inc, Vancouver, AZ.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[5] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[6] \"Product Information. Pomalyst (pomalidomide).\" QLT Phototherapeutics Inc, Vancouver, AZ.", "alternatives_a": "Pantoprazole, Levofloxacin, Tetracycline, Rabeprazole, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Famotidine, Cimetidine, Esomeprazole, More", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Anakinra, More", "updated_at": 1767369485}, {"id": 67925, "ingredient1": "Clarithromycin", "ingredient2": "Ponatinib", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of ponatinib, which is a substrate of the isoenzyme.", "source": "DDInter", "management_text": "Caution is recommended if concomitant use is required, and the recommended starting dosage of ponatinib should be reduced to 30 mg once daily. Patients may be at increased risk for adverse effects such as thromboembolism, ischemia, congestive heart failure, hypertension, hepatotoxicity, pancreatitis, myelosuppression, hemorrhage, and fluid retention.", "mechanism_text": "Metabolism", "recommendation": "Caution is recommended if concomitant use is required, and the recommended starting dosage of ponatinib should be reduced to 30 mg once daily.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68012/", "reference_text": "[1] \"Product Information. Iclusig (ponatinib).\" Ariad Pharmaceuticals Inc, Cambridge, MA.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[3] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[4] \"Product Information. Iclusig (ponatinib).\" Ariad Pharmaceuticals Inc, Cambridge, MA.", "alternatives_a": "Tetracycline, Levofloxacin, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Vonoprazan, Amoxicillin, Dirithromycin, Lincomycin, Azithromycin, Clindamycin", "alternatives_b": "Alpelisib, Trametinib, Dacomitinib, Tivozanib, Alectinib", "updated_at": 1767369485}, {"id": 67926, "ingredient1": "Clarithromycin", "ingredient2": "Posaconazole", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68013/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[16] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Tinidazole, Tetracycline, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Vonoprazan, Amoxicillin, Lincomycin, Troleandomycin, Dirithromycin", "alternatives_b": "Flucytosine, Anidulafungin, Micafungin, Oteseconazole", "updated_at": 1767369485}, {"id": 67927, "ingredient1": "Clarithromycin", "ingredient2": "Pralsetinib", "severity": "Major", "effect": "Coadministration with a combined P-glycoprotein (P-gp) and potent CYP450 3A inhibitor may significantly increase the plasma concentrations of pralsetinib, which is primarily metabolized by the CYP450 3A isoenzyme. In vitro studies have shown pralsetinib is a time-dependent inhibitor of CYP450 3A4/5 isoenzymes and a P-gp inhibitor at clinically relevant concentrations.", "source": "DDInter", "management_text": "Concomitant use of pralsetinib with a combined P-gp and potent CYP450 3A inhibitor should be avoided when possible. Following discontinuation of the combined P-gp and potent CYP450 3A inhibitor, and after an appropriate washout period (3 to 5 elimination half-lives), the pralsetinib dose taken prior to initiating the combined P-gp and potent CYP450 3A4 inhibitor may be resumed.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of pralsetinib with a combined P-gp and potent CYP450 3A inhibitor should be avoided when possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68014/", "reference_text": "[1] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation, Cambridge, MA.[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation, Cambridge, MA.[3] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.", "alternatives_a": "Tetracycline, Sucralfate, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Nizatidine, Ranitidine, Amoxicillin, Dirithromycin, Lincomycin, Clindamycin", "alternatives_b": "Alpelisib, Trametinib, Dacomitinib, Tivozanib, Alectinib", "updated_at": 1767369485}, {"id": 67928, "ingredient1": "Clarithromycin", "ingredient2": "Pramlintide", "severity": "Moderate", "effect": "Concomitant use of insulin and other antidiabetic agents with clarithromycin may cause significant hypoglycemia. There have been rare reports of hypoglycemia in patients treated with clarithromycin, some of whom were taking oral hypoglycemic agents or insulin. The exact mechanism of interaction has not been established. With certain hypoglycemic drugs such as nateglinide, pioglitazone, repaglinide and rosiglitazone, inhibition of the CYP450 3A4 isoenzyme by clarithromycin may be involved.", "source": "DDInter", "management_text": "Caution is advised if clarithromycin is prescribed to patients receiving antidiabetic agents. Patients should be advised to regularly monitor their blood sugar and counseled on how to recognize and treat hypoglycemia, which may include symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if clarithromycin is prescribed to patients receiving antidiabetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68015/", "reference_text": "[1] Otsuka SH \"Severe hypoglycemia from helicobacter pylori triple-drug therapy and insulin detemir drug interaction.\" Pharmacotherapy 33 (2013): e45-9[2] Niemi M, Neuvonen PJ, Kivisto KT \"The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide.\" Clin Pharmacol Ther 70 (2001): 58-65[3] Schelleman H, Bilker WB, Brensinger CM, Wan F, Hennessy S \"Anti-infectives and the risk of severe hypoglycemia in users of glipizide or glyburide.\" Clin Pharmacol Ther 88 (2010): 214-22[4] Khamaisi M, Leitersdorf E \"Severe hypoglycemia from clarithromycin-repaglinide drug interaction.\" Pharmacotherapy 28 (2008): 682-4[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Leiba A, Leibowitz A, Grossman E \"An unusual case of hypoglycemia in a diabetic patient.\" Ann Emerg Med 44 (2004): 427-8[7] Bussing R, Gende A \"Severe hypoglycemia from clarithromycin-sulfonylurea drug interaction.\" Diabetes Care 25 (2002): 1659-61[8] \"Product Information. Biaxin (clarithromycin).\" Abbott Pharmaceutical, Abbott Park, IL.[9] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[10] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[11] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[12] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[13] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[14] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[15] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[16] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[17] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[18] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[19] Cheng KL, Nafziger AN, Peloquin CA, Amsden GW \"Effect of grapefruit juice on clarithromycin pharmacokinetics.\" Antimicrob Agents Chemother 42 (1998): 927-9", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Rifabutin, Cimetidine, More", "alternatives_b": "Guar gum", "updated_at": 1767369485}, {"id": 67929, "ingredient1": "Clarithromycin", "ingredient2": "Pravastatin", "severity": "Moderate", "effect": "Coadministration with clarithromycin or erythromycin may increase the plasma concentrations of pravastatin and the risk of myopathy and rhabdomyolysis. The proposed mechanism is inhibition of the hepatic uptake of pravastatin via organic anion transporting polypeptide 1B1 and 1B3.", "source": "DDInter", "management_text": "The benefits of using pravastatin in combination with clarithromycin or erythromycin should be carefully weighed against the potentially increased risk of myopathy including rhabdomyolysis. A lower dosage of pravastatin should be considered if concomitant use is required. The product labeling for pravastatin recommends that dosage not exceed 40 mg daily when used in combination with clarithromycin. No dosage recommendations are available for use with erythromycin. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.", "mechanism_text": "Metabolism", "recommendation": "The benefits of using pravastatin in combination with clarithromycin or erythromycin should be carefully weighed against the potentially increased risk of myopathy including rhabdomyolysis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68016/", "reference_text": "[1] Seithel A, Eberl S, Singer K, et al. \"The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3.\" Drug Metab Dispos 35 (2007): 779-86[2] Jacobson TA \"Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors.\" Am J Cardiol 94 (2004): 1140-6[3] \"Product Information. Pravachol (pravastatin).\" Bristol-Myers Squibb, Princeton, NJ.[4] Welling PG, Huang H, Hewitt PF, Lyons LL \"Bioavailability of erythromycin stearate: influence of food and fluid volume.\" J Pharm Sci 67 (1978): 764-6[5] Welling PG \"Influence of food and diet on gastrointestinal drug absorption: a review.\" J Pharmacokinet Biopharm 5 (1977): 291-334[6] Randinitis EJ, Sedman AJ, Welling PG, Kinkel AW \"Effect of a high-fat meal on the bioavailability of a polymer-coated erythromycin particle tablet formulation.\" J Clin Pharmacol 29 (1989): 79-84[7] Coyne TC, Shum S, Chun AH, Jeansonne L, Shirkey HC \"Bioavailability of erythromycin ethylsuccinate in pediatric patients.\" J Clin Pharmacol 18 (1978): 194-202[8] Malmborg AS \"Effect of food on absorption of erythromycin. A study of two derivatives, the stearate and the base.\" J Antimicrob Chemother 5 (1979): 591-9[9] Welling PG, Elliott RL, Pitterle ME, et al \"Plasma levels following single and repeated doses of erythromycin estolate and erythromycin stearate.\" J Pharm Sci 68 (1979): 150-5[10] Kanazawa S, Ohkubo T, Sugawara K \"The effects of grapefruit juice on the pharmacokinetics of erythromycin.\" Eur J Clin Pharmacol 56 (2001): 799-803", "alternatives_a": "Gemfibrozil, Fenofibric acid, Pitavastatin, Evinacumab, Evolocumab, Dextrothyroxine, Cholestyramine, Clofibrate, Colestipol, Bempedoic acid, Colesevelam, More", "alternatives_b": "Dexlansoprazole, Bismuth subcitrate potassium, Rifabutin, Esomeprazole, Vonoprazan, Levofloxacin, Lincomycin, Troleandomycin, Dirithromycin", "updated_at": 1767369485}, {"id": 67930, "ingredient1": "Clarithromycin", "ingredient2": "Prednisolone", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme. The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations. Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy. Cushing's syndrome and adrenal insufficiency have been attributed to the interaction.", "source": "DDInter", "management_text": "The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors. When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical \"buffalo\" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.", "mechanism_text": "Metabolism", "recommendation": "The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68017/", "reference_text": "[1] Edsbacker S, Andersson T \"Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease.\" Clin Pharmacokinet 43 (2004): 803-21[2] Finkenbine RD, Frye MD \"Case of psychosis due to prednisone-clarithromycin interaction.\" Gen Hosp Psychiat 20 (1998): 325-6[3] Soldatos G, Sztal-Mazer S, Woolley I, Stockigt J \"Exogenous glucocorticoid excess as a result of ritonavir-fluticasone interaction.\" Intern Med J 35 (2005): 67-8[4] Kandrotas RJ, Slaughter RL, Brass C, Jusko WJ \"Ketoconazole effects on methylprednisolone disposition and their joint suppression of endogenous cortisol.\" Clin Pharmacol Ther 42 (1987): 465-70[5] Raaska K, Niemi M, Neuvonen M, Neuvonen PJ, Kivisto KT \"Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole.\" Clin Pharmacol Ther 72 (2002): 362-369[6] Ulrich B, Frey FJ, Speck RF, Frey BM \"Pharmacokinetics/pharmacodynamics of ketoconazole-prednisolone interaction.\" J Pharmacol Exp Ther 260 (1992): 487-90[7] Zurcher RM, Frey BM, Frey FJ \"Impact of ketoconazole on the metabolism of prednisolone.\" Clin Pharmacol Ther 45 (1989): 366-72[8] Busse KH, Formentini E, Alfaro RM, Kovacs JA, Penzak SR \"Influence of antiretroviral drugs on the pharmacokinetics of prednisolone in HIV-infected individuals.\" J Acquir Immune Defic Syndr 48 (2008): 561-6[9] Yamashita SK, Ludwig EA, Middleton E Jr, Jusko WJ \"Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone.\" Clin Pharmacol Ther 49 (1991): 558-70[10] Hillebrand-Haverkort ME, Prummel MF, ten Veen JH \"Ritonavir-induced Cushing's syndrome in a patient treated with nasal fluticasone.\" AIDS 13 (1999): 1803[11] Kotlyar M, Brewer ER, Golding M, Carson SW \"Nefazodone inhibits methylprednisolone disposition and enhances its adrenal-suppressant effect.\" J Clin Psychopharmacol 23 (2003): 652-6[12] Itkin IH, Menzel ML \"The use of macrolide antibiotic substances in the treatment of asthma.\" J Allergy Clin Immunol 45 (1970): 146-62[13] Skov M, Main KM, Sillesen IB, Muller J, Koch C, Lanng S \"Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide.\" Eur Respir J 20 (2002): 127-33[14] Samaras K, Pett S, Gowers A, McMurchie M, Cooper DA \"Iatrogenic Cushing's syndrome with osteoporosis and secondary adrenal failure in HIV-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: six cases.\" J Clin Endocrinol Metab 90 (2005): 4394-8[15] Garey KW, Rubinstein I, Gotfried MH, Khan IJ, Varma S, Danziger LH \"Long-term clarithromycin decreases prednisone requirements in elderly patients with prednisone-dependent asthma.\" Chest 118 (2000): 1826-7[16] Glynn AM, Slaughter RL, Brass C, et al \"Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretion.\" Clin Pharmacol Ther 39 (1986): 654-9[17] LaForce CF, Szefler SJ, Miller MF, Ebling W, Brenner M \"Inhibition of methylprednisolone elimination in the presence of erythromycin therapy.\" J Allergy Clin Immunol 72 (1983): 34-9[18] Lebrun-Vignes B, Archer VC, Diquest B, et al. \"Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects.\" Br J Clin Pharmacol 51 (2001): 443-50[19] Varis T, Kivisto KT, Neuvonen PJ \"The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone.\" Eur J Clin Pharmacol 56 (2000): 57-60[20] Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN \"Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole.\" Ann Pharmacother 38 (2004): 46-9[21] Gupta SK, Dube MP \"Exogenous Cushing syndrome mimicking human immunodeficiency virus lipodystrophy.\" Clin Infect Dis 35 (2002): E69-71[22] Varis T, Kaukonen KM, Kivisto KT, Neuvonen PJ \"Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole.\" Clin Pharmacol Ther 64 (1998): 363-8[23] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[24] Couturier J, Steele M, Hussey L, Pawliuk G \"Steroid-induced mania in an adolescent: risk factors and management.\" Can J Clin Pharmacol 8 (2001): 109-12[25] Varis T, Backman JT, Kivisto KT, Neuvonen PJ \"Diltiazem and mibefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone.\" Clin Pharmacol Ther 67 (2000): 215-21[26] Bhumbra NA, Sahloff EG, Oehrtman SJ, Horner JM \"Exogenous Cushing syndrome with inhaled fluticasone in a child receiving lopinavir/ritonavir.\" Ann Pharmacother 41 (2007): 1306-9[27] Main KM, Skov M, Sillesen IB, et al. \"Cushing's syndrome due to pharmacological interaction in a cystic fibrosis patient.\" Acta Paediatr 91 (2002): 1008-11[28] Penzak SR, Formentini E, Alfaro RM, Long M, Natarajan V, Kovacs J \"Prednisolone pharmacokinetics in the presence and absence of ritonavir after oral prednisone administration to healthy volunteers.\" J Acquir Immune Defic Syndr 40 (2005): 573-80[29] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[30] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.", "alternatives_a": "Mometasone furoate, Amcinonide, Fluocinolone acetonide, Hydrocortisone butyrate, Fluocinonide, Fluorometholone, Beclomethasone dipropionate, Fluocinolone acetonide, Fluorometholone, Mometasone furoate, Fluorometholone, More", "alternatives_b": "Tinidazole, Dexlansoprazole, Bismuth subcitrate potassium, Esomeprazole, Vonoprazan, Lincomycin, Dirithromycin", "updated_at": 1767369485}, {"id": 67931, "ingredient1": "Clarithromycin", "ingredient2": "Prednisolone (ophthalmic)", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme. The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations. Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy. Cushing's syndrome and adrenal insufficiency have been attributed to the interaction.", "source": "DDInter", "management_text": "The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors. When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical \"buffalo\" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.", "mechanism_text": "Metabolism", "recommendation": "The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68018/", "reference_text": "[1] Edsbacker S, Andersson T \"Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease.\" Clin Pharmacokinet 43 (2004): 803-21[2] Finkenbine RD, Frye MD \"Case of psychosis due to prednisone-clarithromycin interaction.\" Gen Hosp Psychiat 20 (1998): 325-6[3] Soldatos G, Sztal-Mazer S, Woolley I, Stockigt J \"Exogenous glucocorticoid excess as a result of ritonavir-fluticasone interaction.\" Intern Med J 35 (2005): 67-8[4] Kandrotas RJ, Slaughter RL, Brass C, Jusko WJ \"Ketoconazole effects on methylprednisolone disposition and their joint suppression of endogenous cortisol.\" Clin Pharmacol Ther 42 (1987): 465-70[5] Raaska K, Niemi M, Neuvonen M, Neuvonen PJ, Kivisto KT \"Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole.\" Clin Pharmacol Ther 72 (2002): 362-369[6] Ulrich B, Frey FJ, Speck RF, Frey BM \"Pharmacokinetics/pharmacodynamics of ketoconazole-prednisolone interaction.\" J Pharmacol Exp Ther 260 (1992): 487-90[7] Zurcher RM, Frey BM, Frey FJ \"Impact of ketoconazole on the metabolism of prednisolone.\" Clin Pharmacol Ther 45 (1989): 366-72[8] Busse KH, Formentini E, Alfaro RM, Kovacs JA, Penzak SR \"Influence of antiretroviral drugs on the pharmacokinetics of prednisolone in HIV-infected individuals.\" J Acquir Immune Defic Syndr 48 (2008): 561-6[9] Yamashita SK, Ludwig EA, Middleton E Jr, Jusko WJ \"Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone.\" Clin Pharmacol Ther 49 (1991): 558-70[10] Hillebrand-Haverkort ME, Prummel MF, ten Veen JH \"Ritonavir-induced Cushing's syndrome in a patient treated with nasal fluticasone.\" AIDS 13 (1999): 1803[11] Kotlyar M, Brewer ER, Golding M, Carson SW \"Nefazodone inhibits methylprednisolone disposition and enhances its adrenal-suppressant effect.\" J Clin Psychopharmacol 23 (2003): 652-6[12] Itkin IH, Menzel ML \"The use of macrolide antibiotic substances in the treatment of asthma.\" J Allergy Clin Immunol 45 (1970): 146-62[13] Skov M, Main KM, Sillesen IB, Muller J, Koch C, Lanng S \"Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide.\" Eur Respir J 20 (2002): 127-33[14] Samaras K, Pett S, Gowers A, McMurchie M, Cooper DA \"Iatrogenic Cushing's syndrome with osteoporosis and secondary adrenal failure in HIV-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: six cases.\" J Clin Endocrinol Metab 90 (2005): 4394-8[15] Garey KW, Rubinstein I, Gotfried MH, Khan IJ, Varma S, Danziger LH \"Long-term clarithromycin decreases prednisone requirements in elderly patients with prednisone-dependent asthma.\" Chest 118 (2000): 1826-7[16] Glynn AM, Slaughter RL, Brass C, et al \"Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretion.\" Clin Pharmacol Ther 39 (1986): 654-9[17] LaForce CF, Szefler SJ, Miller MF, Ebling W, Brenner M \"Inhibition of methylprednisolone elimination in the presence of erythromycin therapy.\" J Allergy Clin Immunol 72 (1983): 34-9[18] Lebrun-Vignes B, Archer VC, Diquest B, et al. \"Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects.\" Br J Clin Pharmacol 51 (2001): 443-50[19] Varis T, Kivisto KT, Neuvonen PJ \"The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone.\" Eur J Clin Pharmacol 56 (2000): 57-60[20] Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN \"Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole.\" Ann Pharmacother 38 (2004): 46-9[21] Gupta SK, Dube MP \"Exogenous Cushing syndrome mimicking human immunodeficiency virus lipodystrophy.\" Clin Infect Dis 35 (2002): E69-71[22] Varis T, Kaukonen KM, Kivisto KT, Neuvonen PJ \"Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole.\" Clin Pharmacol Ther 64 (1998): 363-8[23] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[24] Couturier J, Steele M, Hussey L, Pawliuk G \"Steroid-induced mania in an adolescent: risk factors and management.\" Can J Clin Pharmacol 8 (2001): 109-12[25] Varis T, Backman JT, Kivisto KT, Neuvonen PJ \"Diltiazem and mibefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone.\" Clin Pharmacol Ther 67 (2000): 215-21[26] Bhumbra NA, Sahloff EG, Oehrtman SJ, Horner JM \"Exogenous Cushing syndrome with inhaled fluticasone in a child receiving lopinavir/ritonavir.\" Ann Pharmacother 41 (2007): 1306-9[27] Main KM, Skov M, Sillesen IB, et al. \"Cushing's syndrome due to pharmacological interaction in a cystic fibrosis patient.\" Acta Paediatr 91 (2002): 1008-11[28] Penzak SR, Formentini E, Alfaro RM, Long M, Natarajan V, Kovacs J \"Prednisolone pharmacokinetics in the presence and absence of ritonavir after oral prednisone administration to healthy volunteers.\" J Acquir Immune Defic Syndr 40 (2005): 573-80[29] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[30] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.", "alternatives_a": "Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67932, "ingredient1": "Clarithromycin", "ingredient2": "Prednisone", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme. The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations. Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy. Cushing's syndrome and adrenal insufficiency have been attributed to the interaction.", "source": "DDInter", "management_text": "The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors. When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical \"buffalo\" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.", "mechanism_text": "Metabolism", "recommendation": "The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68019/", "reference_text": "[1] Edsbacker S, Andersson T \"Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease.\" Clin Pharmacokinet 43 (2004): 803-21[2] Finkenbine RD, Frye MD \"Case of psychosis due to prednisone-clarithromycin interaction.\" Gen Hosp Psychiat 20 (1998): 325-6[3] Soldatos G, Sztal-Mazer S, Woolley I, Stockigt J \"Exogenous glucocorticoid excess as a result of ritonavir-fluticasone interaction.\" Intern Med J 35 (2005): 67-8[4] Kandrotas RJ, Slaughter RL, Brass C, Jusko WJ \"Ketoconazole effects on methylprednisolone disposition and their joint suppression of endogenous cortisol.\" Clin Pharmacol Ther 42 (1987): 465-70[5] Raaska K, Niemi M, Neuvonen M, Neuvonen PJ, Kivisto KT \"Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole.\" Clin Pharmacol Ther 72 (2002): 362-369[6] Ulrich B, Frey FJ, Speck RF, Frey BM \"Pharmacokinetics/pharmacodynamics of ketoconazole-prednisolone interaction.\" J Pharmacol Exp Ther 260 (1992): 487-90[7] Zurcher RM, Frey BM, Frey FJ \"Impact of ketoconazole on the metabolism of prednisolone.\" Clin Pharmacol Ther 45 (1989): 366-72[8] Busse KH, Formentini E, Alfaro RM, Kovacs JA, Penzak SR \"Influence of antiretroviral drugs on the pharmacokinetics of prednisolone in HIV-infected individuals.\" J Acquir Immune Defic Syndr 48 (2008): 561-6[9] Yamashita SK, Ludwig EA, Middleton E Jr, Jusko WJ \"Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone.\" Clin Pharmacol Ther 49 (1991): 558-70[10] Hillebrand-Haverkort ME, Prummel MF, ten Veen JH \"Ritonavir-induced Cushing's syndrome in a patient treated with nasal fluticasone.\" AIDS 13 (1999): 1803[11] Kotlyar M, Brewer ER, Golding M, Carson SW \"Nefazodone inhibits methylprednisolone disposition and enhances its adrenal-suppressant effect.\" J Clin Psychopharmacol 23 (2003): 652-6[12] Itkin IH, Menzel ML \"The use of macrolide antibiotic substances in the treatment of asthma.\" J Allergy Clin Immunol 45 (1970): 146-62[13] Skov M, Main KM, Sillesen IB, Muller J, Koch C, Lanng S \"Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide.\" Eur Respir J 20 (2002): 127-33[14] Samaras K, Pett S, Gowers A, McMurchie M, Cooper DA \"Iatrogenic Cushing's syndrome with osteoporosis and secondary adrenal failure in HIV-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: six cases.\" J Clin Endocrinol Metab 90 (2005): 4394-8[15] Garey KW, Rubinstein I, Gotfried MH, Khan IJ, Varma S, Danziger LH \"Long-term clarithromycin decreases prednisone requirements in elderly patients with prednisone-dependent asthma.\" Chest 118 (2000): 1826-7[16] Glynn AM, Slaughter RL, Brass C, et al \"Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretion.\" Clin Pharmacol Ther 39 (1986): 654-9[17] LaForce CF, Szefler SJ, Miller MF, Ebling W, Brenner M \"Inhibition of methylprednisolone elimination in the presence of erythromycin therapy.\" J Allergy Clin Immunol 72 (1983): 34-9[18] Lebrun-Vignes B, Archer VC, Diquest B, et al. \"Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects.\" Br J Clin Pharmacol 51 (2001): 443-50[19] Varis T, Kivisto KT, Neuvonen PJ \"The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone.\" Eur J Clin Pharmacol 56 (2000): 57-60[20] Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN \"Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole.\" Ann Pharmacother 38 (2004): 46-9[21] Gupta SK, Dube MP \"Exogenous Cushing syndrome mimicking human immunodeficiency virus lipodystrophy.\" Clin Infect Dis 35 (2002): E69-71[22] Varis T, Kaukonen KM, Kivisto KT, Neuvonen PJ \"Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole.\" Clin Pharmacol Ther 64 (1998): 363-8[23] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[24] Couturier J, Steele M, Hussey L, Pawliuk G \"Steroid-induced mania in an adolescent: risk factors and management.\" Can J Clin Pharmacol 8 (2001): 109-12[25] Varis T, Backman JT, Kivisto KT, Neuvonen PJ \"Diltiazem and mibefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone.\" Clin Pharmacol Ther 67 (2000): 215-21[26] Bhumbra NA, Sahloff EG, Oehrtman SJ, Horner JM \"Exogenous Cushing syndrome with inhaled fluticasone in a child receiving lopinavir/ritonavir.\" Ann Pharmacother 41 (2007): 1306-9[27] Main KM, Skov M, Sillesen IB, et al. \"Cushing's syndrome due to pharmacological interaction in a cystic fibrosis patient.\" Acta Paediatr 91 (2002): 1008-11[28] Penzak SR, Formentini E, Alfaro RM, Long M, Natarajan V, Kovacs J \"Prednisolone pharmacokinetics in the presence and absence of ritonavir after oral prednisone administration to healthy volunteers.\" J Acquir Immune Defic Syndr 40 (2005): 573-80[29] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[30] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.", "alternatives_a": "Beclomethasone dipropionate, Olsalazine", "alternatives_b": "Tinidazole, Dexlansoprazole, Bismuth subcitrate potassium, Esomeprazole, Vonoprazan, Lincomycin, Dirithromycin", "updated_at": 1767369485}, {"id": 67933, "ingredient1": "Clarithromycin", "ingredient2": "Primaquine", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68020/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[16] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Artesunate, Pyrimethamine, Tafenoquine, Proguanil, Sulfadoxine", "alternatives_b": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, More", "updated_at": 1767369485}, {"id": 67934, "ingredient1": "Clarithromycin", "ingredient2": "Probucol", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68021/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[16] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, More", "alternatives_b": "Gemfibrozil, Fenofibric acid, Pitavastatin, Evinacumab, Evolocumab, Dextrothyroxine, Cholestyramine, Clofibrate, Colestipol, Bempedoic acid, Colesevelam, More", "updated_at": 1767369485}, {"id": 67935, "ingredient1": "Clarithromycin", "ingredient2": "Procainamide", "severity": "Major", "effect": "Class IA (e.g., disopyramide, quinidine, procainamide) and class III (e.g., amiodarone, dofetilide, sotalol) antiarrhythmic agents can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks. Caution and clinical monitoring are recommended if concomitant use is required. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68022/", "reference_text": "[1] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[2] Yamreudeewong W, DeBisschop M, Martin L, Lower D \"Potentially Significant Drug Interactions of Class III Antiarrhythmic Drugs.\" Drug Saf 26 (2003): 421-38[3] \"Product Information. Norpace (disopyramide).\" Searle, Skokie, IL.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Betapace (sotalol).\" Berlex, Richmond, CA.[6] \"Product Information. Procan SR (procainamide).\" Parke-Davis, Morris Plains, NJ.[7] Maxa JL, Hebeler RF, Adeeko MA \"Torsades de pointes following concurrent amiodarone and levofloxacin therapy.\" Proc (Bayl Univ Med Cent) 19 (2006): 345-6[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] \"Product Information. Cordarone (amiodarone).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[10] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[11] \"Product Information. Vascor (bepridil).\" McNeil Pharmaceutical, Raritan, NJ.[12] \"Product Information. Quiniglute (quinidine).\" Berlex, Richmond, CA.[13] Trujillo TC, Nolan PE \"Antiarrhythmic agents - Drug interactions of clinical significance.\" Drug Safety 23 (2000): 509-32[14] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[15] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[16] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[17] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[18] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[19] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[20] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[21] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[22] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[25] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[26] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[27] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[28] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[29] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[30] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[31] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[32] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[33] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[34] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[35] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[36] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[37] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[38] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[39] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[40] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[41] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[42] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[43] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[44] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[45] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8", "alternatives_a": "Tocainide, Moricizine, Bretylium", "alternatives_b": "Tinidazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Nizatidine, Esomeprazole, Vonoprazan, More", "updated_at": 1767369485}, {"id": 67936, "ingredient1": "Clarithromycin", "ingredient2": "Prochlorperazine", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68023/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[16] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Loxapine, Molindone, Thiothixene", "alternatives_b": "Tinidazole, Dexlansoprazole, Bismuth subcitrate potassium, Rifabutin, Esomeprazole, Vonoprazan, Lincomycin, Troleandomycin, Dirithromycin", "updated_at": 1767369485}, {"id": 67937, "ingredient1": "Clarithromycin", "ingredient2": "Progesterone", "severity": "Moderate", "effect": "RECOMMENDED: The effectiveness of estrogen-containing oral contraceptives may be impaired by concomitant treatment with antimicrobial agents. Most antimicrobials, with the exception of the rifamycins and possibly griseofulvin, do not induce hepatic enzymes and have not been shown to significantly increase the clearance of oral contraceptive estrogens. Certain macrolide antibiotics (e.g., erythromycin, clarithromycin) may increase the plasma concentrations and the risk of adverse effects of estrogens and progestogens. The mechanism is decreased clearance of the hormones due to inhibition of CYP450 3A4 activity by the macrolide antibiotic. Concomitant administration with erythromycin may increase the estradiol exposure by approximately 50%.", "source": "DDInter", "management_text": "Until further data are available, women using oral contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant antimicrobial therapy. During concomitant therapy with erythromycin or clarithromycin, patients should be observed for increased or altered pharmacologic response to estrogens and progestogens, and dosage(s) adjusted accordingly as necessary.", "mechanism_text": "Metabolism", "recommendation": "Until further data are available, women using oral contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant antimicrobial therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68024/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception. Available from: URL: file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf.\" ([2012, Jan 1]):[4] \"Product Information. Angeliq (drospirenone-estradiol).\" Berlex Laboratories, Wayne, NJ.[5] \"Product Information. Ortho-Est (estropipate).\" Ortho McNeil Pharmaceutical, Raritan, NJ.[6] \"Product Information. Premarin (conjugated estrogens).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[7] \"Product Information. Yasmin (drospirenone-ethinyl estradiol)\" Berlex Laboratories, Richmond, CA.[8] Welling PG, Huang H, Hewitt PF, Lyons LL \"Bioavailability of erythromycin stearate: influence of food and fluid volume.\" J Pharm Sci 67 (1978): 764-6[9] Welling PG \"Influence of food and diet on gastrointestinal drug absorption: a review.\" J Pharmacokinet Biopharm 5 (1977): 291-334[10] Randinitis EJ, Sedman AJ, Welling PG, Kinkel AW \"Effect of a high-fat meal on the bioavailability of a polymer-coated erythromycin particle tablet formulation.\" J Clin Pharmacol 29 (1989): 79-84[11] Coyne TC, Shum S, Chun AH, Jeansonne L, Shirkey HC \"Bioavailability of erythromycin ethylsuccinate in pediatric patients.\" J Clin Pharmacol 18 (1978): 194-202[12] Malmborg AS \"Effect of food on absorption of erythromycin. A study of two derivatives, the stearate and the base.\" J Antimicrob Chemother 5 (1979): 591-9[13] Welling PG, Elliott RL, Pitterle ME, et al \"Plasma levels following single and repeated doses of erythromycin estolate and erythromycin stearate.\" J Pharm Sci 68 (1979): 150-5[14] Kanazawa S, Ohkubo T, Sugawara K \"The effects of grapefruit juice on the pharmacokinetics of erythromycin.\" Eur J Clin Pharmacol 56 (2001): 799-803[15] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[16] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Tinidazole, Levofloxacin, Tetracycline, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Nizatidine, Esomeprazole, Vonoprazan, Amoxicillin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67938, "ingredient1": "Clarithromycin", "ingredient2": "Progesterone (topical)", "severity": "Moderate", "effect": "RECOMMENDED: The effectiveness of estrogen-containing oral contraceptives may be impaired by concomitant treatment with antimicrobial agents. Most antimicrobials, with the exception of the rifamycins and possibly griseofulvin, do not induce hepatic enzymes and have not been shown to significantly increase the clearance of oral contraceptive estrogens. Certain macrolide antibiotics (e.g., erythromycin, clarithromycin) may increase the plasma concentrations and the risk of adverse effects of estrogens and progestogens. The mechanism is decreased clearance of the hormones due to inhibition of CYP450 3A4 activity by the macrolide antibiotic. Concomitant administration with erythromycin may increase the estradiol exposure by approximately 50%.", "source": "DDInter", "management_text": "Until further data are available, women using oral contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant antimicrobial therapy. During concomitant therapy with erythromycin or clarithromycin, patients should be observed for increased or altered pharmacologic response to estrogens and progestogens, and dosage(s) adjusted accordingly as necessary.", "mechanism_text": "Metabolism", "recommendation": "Until further data are available, women using oral contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant antimicrobial therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68025/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception. Available from: URL: file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf.\" ([2012, Jan 1]):[4] \"Product Information. Angeliq (drospirenone-estradiol).\" Berlex Laboratories, Wayne, NJ.[5] \"Product Information. Ortho-Est (estropipate).\" Ortho McNeil Pharmaceutical, Raritan, NJ.[6] \"Product Information. Premarin (conjugated estrogens).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[7] \"Product Information. Yasmin (drospirenone-ethinyl estradiol)\" Berlex Laboratories, Richmond, CA.[8] Welling PG, Huang H, Hewitt PF, Lyons LL \"Bioavailability of erythromycin stearate: influence of food and fluid volume.\" J Pharm Sci 67 (1978): 764-6[9] Welling PG \"Influence of food and diet on gastrointestinal drug absorption: a review.\" J Pharmacokinet Biopharm 5 (1977): 291-334[10] Randinitis EJ, Sedman AJ, Welling PG, Kinkel AW \"Effect of a high-fat meal on the bioavailability of a polymer-coated erythromycin particle tablet formulation.\" J Clin Pharmacol 29 (1989): 79-84[11] Coyne TC, Shum S, Chun AH, Jeansonne L, Shirkey HC \"Bioavailability of erythromycin ethylsuccinate in pediatric patients.\" J Clin Pharmacol 18 (1978): 194-202[12] Malmborg AS \"Effect of food on absorption of erythromycin. A study of two derivatives, the stearate and the base.\" J Antimicrob Chemother 5 (1979): 591-9[13] Welling PG, Elliott RL, Pitterle ME, et al \"Plasma levels following single and repeated doses of erythromycin estolate and erythromycin stearate.\" J Pharm Sci 68 (1979): 150-5[14] Kanazawa S, Ohkubo T, Sugawara K \"The effects of grapefruit juice on the pharmacokinetics of erythromycin.\" Eur J Clin Pharmacol 56 (2001): 799-803[15] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[16] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67939, "ingredient1": "Clarithromycin", "ingredient2": "Promazine", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68026/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[16] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Loxapine, Molindone, Thiothixene", "alternatives_b": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, Ranitidine, More", "updated_at": 1767369485}, {"id": 67940, "ingredient1": "Clarithromycin", "ingredient2": "Promethazine", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68027/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[16] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Mepyramine, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Dexbrompheniramine, Clemastine, Doxylamine, Meclizine, Cyclizine, More", "alternatives_b": "Tinidazole, Dexlansoprazole, Bismuth subcitrate potassium, Rifabutin, Esomeprazole, Vonoprazan, Lincomycin, Troleandomycin, Dirithromycin", "updated_at": 1767369485}, {"id": 67941, "ingredient1": "Clarithromycin", "ingredient2": "Propafenone", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68028/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[16] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Tocainide, Moricizine, Bretylium", "alternatives_b": "Tinidazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Nizatidine, Esomeprazole, Vonoprazan, More", "updated_at": 1767369485}, {"id": 67942, "ingredient1": "Dextropropoxyphene", "ingredient2": "Clarithromycin", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68029/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[16] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Oxymorphone, Tapentadol, Dezocine, Opium, Pentazocine, Nalbuphine, Dihydrocodeine, Naloxone, Codeine", "alternatives_b": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Nizatidine, Esomeprazole, More", "updated_at": 1767369485}, {"id": 67943, "ingredient1": "Clarithromycin", "ingredient2": "Protriptyline", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68030/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[16] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Phenelzine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Vortioxetine, Milnacipran, Tryptophan, Esketamine", "alternatives_b": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Nizatidine, Esomeprazole, More", "updated_at": 1767369485}, {"id": 67944, "ingredient1": "Clarithromycin", "ingredient2": "Quazepam", "severity": "Moderate", "effect": "Macrolide antibiotics may increase and prolong the CNS effects of certain benzodiazepines. The mechanism is inhibition of CYP450 3A4 hepatic oxidation of the benzodiazepines.", "source": "DDInter", "management_text": "Patients receiving this combination should be monitored for excessive or prolonged sedation. Non-interacting benzodiazepines or antimicrobials may be considered as alternatives.", "mechanism_text": "Metabolism", "recommendation": "Patients receiving this combination should be monitored for excessive or prolonged sedation.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68031/", "reference_text": "[1] Warot D, Bergougnan L, Lamiable D, et al \"Troleandomycin-triazolam interaction in healthy volunteers: pharmacokinetic and psychometric evaluation.\" Eur J Clin Pharmacol 32 (1987): 389-93[2] Yeates RA, Laufen H, Zimmermann T, Schumacher T \"Pharmacokinetic and pharmacodynamic interaction study between midazolam and the macrolide antibiotics, erythromycin clarithromycin, and the azalide azithromycin.\" Int J Clin Pharmacol Ther 35 (1997): 577-9[3] Mattila MJ, Idanpaanheikkila JJ, Tornwall M, Vanakoski J \"Oral single doses of erythromycin and roxithromycin may increase the effects of midazolam on human performance.\" Pharmacol Toxicol 73 (1993): 180-5[4] Zimmermann T, Yeates RA, Laufen H, Scharpf F, Leitold M, Wildfeuer A \"Influence of the antibiotics erythromycin and azithromycin on the pharmacokinetics and pharmacodynamics of midazolam.\" Arzneimittelforschung 46 (1996): 213-7[5] Yasui N, Otani K, Kaneko S, et al \"A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: in vivo evidence for the involvement of CYP3a4 in alprazolam metabolism.\" Clin Pharmacol Ther 59 (1996): 514-9[6] Yeates RA, Laufen H, Zimmermann T \"Interaction between midazolam and clarithromycin: comparison with azithromycin.\" Int J Clin Pharmacol Ther 34 (1996): 400-5[7] Gorski JC, Jones DR, HaehnerDaniels BD, Hamman MA, OMara EM, Hall SD \"The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin.\" Clin Pharmacol Ther 64 (1998): 133-43[8] Phillips JP, Antal EJ, Smith RB \"A pharmacokinetic drug interaction between erythromycin and triazolam.\" J Clin Psychopharmacol 6 (1986): 297-9[9] Wrighton SA, Ring BJ \"Inhibition of human CYP3A catalyzed 1'-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine.\" Pharm Res 11 (1994): 921-4[10] Kanamitsu S, Ito K, Green CE, Tyson CA, Shimada N, Sugiyama Y \"Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4.\" Pharmaceut Res 17 (2000): 419-26[11] Ito K, Ogihara K, Kanamitsu SI, Itoh T \"Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes.\" Drug Metab Dispos 31 (2003): 945-954[12] Amsden GW \"Macrolides versus azalides: a drug interaction update.\" Ann Pharmacother 29 (1995): 906-17[13] Luurila H, Olkkola KT, Neuvonen PJ \"Interaction between erythromycin and the benzodiazepines diazepam and flunitrazepam.\" Pharmacol Toxicol 78 (1996): 117-22[14] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[15] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[16] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[17] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Tinidazole, Levofloxacin, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Bismuth subcitrate potassium, Metronidazole, Nizatidine, Esomeprazole, Vonoprazan, More", "alternatives_b": "Methohexital, Methylphenobarbital, Pentobarbital, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, Paraldehyde, Ethchlorvynol, Amobarbital, More", "updated_at": 1767369485}, {"id": 67945, "ingredient1": "Clarithromycin", "ingredient2": "Quetiapine", "severity": "Major", "effect": "There is some concern that quetiapine may have additive cardiovascular effects in combination with other drugs that are known to prolong the QT interval of the electrocardiogram, including saquinavir, azole antifungal agents, and macrolide or ketolide antibiotics. Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of quetiapine, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of quetiapine with potent CYP450 3A4 inhibitors that can also prolong the QT interval should generally be avoided. Caution and clinical monitoring are recommended if coadministration is required. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. In addition, the dosage of quetiapine should be reduced due to CYP450 3A4 inhibition. The product labeling recommends a reduction to one-sixth of the original dosage. Following discontinuation of the CYP450 3A4 inhibitor, the dosage of quetiapine should be increased by 6-fold.", "mechanism_text": "Metabolism, Synergism", "recommendation": "Concomitant use of quetiapine with potent CYP450 3A4 inhibitors that can also prolong the QT interval should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68032/", "reference_text": "[1] Urichuk L, Prior TI, Dursun S, Baker G \"Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions.\" Curr Drug Metab 9 (2008): 410-8[2] Schulz-Du Bois C, Schulz-Du Bois AC, Bewig B, et al. \"Major increase of quetiapine steady-state plasma concentration following co-administration of clarithromycin: confirmation of the pharmacokinetic interaction potential of quetiapine.\" Pharmacopsychiatry 41 (2008): 258-9[3] Grimm SW, Richtand NM, Winter HR, Stams KR, Reele SB \"Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics.\" Br J Clin Pharmacol 61 (2006): 58-69[4] Spina E, Scordo MG, D'Arrigo C \"Metabolic drug interactions with new psychotropic agents.\" Fundam Clin Pharmacol 17 (2003): 517-38[5] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[6] Hantson P, Di Fazio V, Wallemacq P \"Toxicokinetic interaction between quetiapine and antiretroviral therapy following quetiapine overdose.\" Drug Metab Lett 4 (2010): 7-8[7] Spina E, de Leon J \"Metabolic drug interactions with newer antipsychotics: a comparative review.\" Basic Clin Pharmacol Toxicol 100 (2007): 4-22[8] DeVane CL, Nemeroff CB \"Clinical pharmacokinetics of quetiapine - An atypical antipsychotic.\" Clin Pharmacokinet 40 (2001): 509-22[9] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[10] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Dexlansoprazole, Bismuth subcitrate potassium, Esomeprazole, Vonoprazan, Lincomycin, Dirithromycin", "alternatives_b": "Loxapine, Molindone, Thiothixene", "updated_at": 1767369485}, {"id": 67946, "ingredient1": "Clarithromycin", "ingredient2": "Quinestrol", "severity": "Moderate", "effect": "RECOMMENDED: The effectiveness of estrogen-containing oral contraceptives may be impaired by concomitant treatment with antimicrobial agents. Most antimicrobials, with the exception of the rifamycins and possibly griseofulvin, do not induce hepatic enzymes and have not been shown to significantly increase the clearance of oral contraceptive estrogens. Certain macrolide antibiotics (e.g., erythromycin, clarithromycin) may increase the plasma concentrations and the risk of adverse effects of estrogens and progestogens. The mechanism is decreased clearance of the hormones due to inhibition of CYP450 3A4 activity by the macrolide antibiotic. Concomitant administration with erythromycin may increase the estradiol exposure by approximately 50%.", "source": "DDInter", "management_text": "Until further data are available, women using oral contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant antimicrobial therapy. During concomitant therapy with erythromycin or clarithromycin, patients should be observed for increased or altered pharmacologic response to estrogens and progestogens, and dosage(s) adjusted accordingly as necessary.", "mechanism_text": "Metabolism", "recommendation": "Until further data are available, women using oral contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant antimicrobial therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68033/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception. Available from: URL: file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf.\" ([2012, Jan 1]):[4] \"Product Information. Angeliq (drospirenone-estradiol).\" Berlex Laboratories, Wayne, NJ.[5] \"Product Information. Ortho-Est (estropipate).\" Ortho McNeil Pharmaceutical, Raritan, NJ.[6] \"Product Information. Premarin (conjugated estrogens).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[7] \"Product Information. Yasmin (drospirenone-ethinyl estradiol)\" Berlex Laboratories, Richmond, CA.[8] Welling PG, Huang H, Hewitt PF, Lyons LL \"Bioavailability of erythromycin stearate: influence of food and fluid volume.\" J Pharm Sci 67 (1978): 764-6[9] Welling PG \"Influence of food and diet on gastrointestinal drug absorption: a review.\" J Pharmacokinet Biopharm 5 (1977): 291-334[10] Randinitis EJ, Sedman AJ, Welling PG, Kinkel AW \"Effect of a high-fat meal on the bioavailability of a polymer-coated erythromycin particle tablet formulation.\" J Clin Pharmacol 29 (1989): 79-84[11] Coyne TC, Shum S, Chun AH, Jeansonne L, Shirkey HC \"Bioavailability of erythromycin ethylsuccinate in pediatric patients.\" J Clin Pharmacol 18 (1978): 194-202[12] Malmborg AS \"Effect of food on absorption of erythromycin. A study of two derivatives, the stearate and the base.\" J Antimicrob Chemother 5 (1979): 591-9[13] Welling PG, Elliott RL, Pitterle ME, et al \"Plasma levels following single and repeated doses of erythromycin estolate and erythromycin stearate.\" J Pharm Sci 68 (1979): 150-5[14] Kanazawa S, Ohkubo T, Sugawara K \"The effects of grapefruit juice on the pharmacokinetics of erythromycin.\" Eur J Clin Pharmacol 56 (2001): 799-803[15] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[16] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67947, "ingredient1": "Clarithromycin", "ingredient2": "Quinidine", "severity": "Major", "effect": "Coadministration of quinidine with some macrolide antibiotics (e.g., clarithromycin, erythromycin, troleandomycin) may increase the risk of ventricular arrhythmias including torsade de pointes and sudden death due to additive effects on the QT interval. In addition, the clearance of quinidine may be reduced.", "source": "DDInter", "management_text": "The use of quinidine in combination with macrolide antibiotics should be avoided. Patients treated with these agents should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.", "mechanism_text": "Metabolism, Synergism", "recommendation": "The use of quinidine in combination with macrolide antibiotics should be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68034/", "reference_text": "[1] \"Product Information. ERYC (erythromycin).\" Parke-Davis, Morris Plains, NJ.[2] Lin JC, Quasny HA \"QT prolongation and development of torsades de pointes with the concomitant administration of oral erythromycin base and quinidine.\" Pharmacotherapy 17 (1997): 626-30[3] Damkier P, Hansen LL, Brosen K \"Effect of fluvoxamine on the pharmacokinetics of quinidine.\" Eur J Clin Pharmacol 55 (1999): 451-6[4] Spinler SA, Cheng JWM, Kindwall KE, Charland SL \"Possible inhibition of hepatic metabolism of quinidine by erythromycin.\" Clin Pharmacol Ther 57 (1995): 89-94[5] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[6] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Tocainide, Moricizine, Bretylium", "alternatives_b": "Tinidazole, Tetracycline, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Esomeprazole, Vonoprazan, Lincomycin, Dirithromycin", "updated_at": 1767369485}, {"id": 67948, "ingredient1": "Clarithromycin", "ingredient2": "Quinine", "severity": "Major", "effect": "Coadministration with ketolide and macrolide antibiotics that inhibit CYP450 3A4 may significantly increase the plasma concentrations of quinine, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The use of quinine in combination with ketolide and macrolide antibiotics that inhibit CYP450 3A4 should generally be avoided. Azithromycin may be a safer alternative during therapy with quinine.", "mechanism_text": "Metabolism", "recommendation": "The use of quinine in combination with ketolide and macrolide antibiotics that inhibit CYP450 3A4 should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68035/", "reference_text": "[1] Wanwimolruk S, Paine MF, Pusek SN, Watkins PB \"Is quinine a suitable probe to assess the hepatic drug-metabolizing enzyme CYP3A4?\" Br J Clin Pharmacol 54 (2002): 643-51[2] Mirghani RA, Ericsson O, Tybring G, Gustafsson LL, Bertilsson L \"Quinine 3-hydroxylation as a biomarker reaction for the activity of CYP3A4 in man.\" Eur J Clin Pharmacol 59 (2003): 23-8[3] Mirghani RA, Hellgren U, Westerberg PA, Ericsson O, Bertilsson L, Gustafsson LL \"The roles of cytochrome P450 3A4 and 1A2 in the 3-hydroxylation of quinine in vivo.\" Clin Pharmacol Ther 66 (1999): 454-60[4] \"Product Information. Qualaquin (quinine).\" AR Scientific Inc, Philadelphia, PA.[5] Zhang H, Coville PF, Walker RJ, Miners JO, Birkett DJ, Wanwimolruk S \"Evidence for involvement of human CYP3A in the 3-hydroxylation of quinine.\" Br J Clin Pharmacol 43 (1997): 245-52[6] Zhao XJ, Ishizaki T \"A further interaction study of quinine with clinically important drugs by human liver microsomes: determinations of inhibition constant (K-i) and type of inhibition.\" Eur J Drug Metab Pharm 24 (1999): 272-8[7] Mirghani RA, Yasar U, Zheng T, et al \"Enzyme kinetics for the formation of 3-hydroxyquinine and three new metabolites of quinine in vitro; 3-hydroxylation by CYP3A4 is indeed the major metabolic pathway.\" Drug Metab Dispos 30 (2002): 1368-71[8] Mirghani RA, Hellgren U, Bertilsson L, Gustafsson LL, Ericsson O \"Metabolism and elimination of quinine in healthy volunteers.\" Eur J Clin Pharmacol (2003):[9] Zhao XJ, Ishizaki T \"Metabolic interactions of selected antimalarial and non-antimalarial drugs with the major pathway (3-hydroxylation) of quinine in human liver microsomes.\" Br J Clin Pharmacol 44 (1997): 505-11[10] \"Product Information. Qualaquin (quinine).\" AR Scientific Inc, Philadelphia, PA.[11] Ho PC, Chalcroft SC, Coville PF, Wanwimolruk S \"Grapefruit juice has no effect on quinine pharmacokinetics.\" Eur J Clin Pharmacol 55 (1999): 393-8[12] Zhang H, Coville PF, Walker RJ, Miners JO, Birkett DJ, Wanwimolruk S \"Evidence for involvement of human CYP3A in the 3-hydroxylation of quinine.\" Br J Clin Pharmacol 43 (1997): 245-52[13] Hermans K, Stockman D, Van den Branden F \"Grapefruit and tonic: a deadly combination in a patient with the long QT syndrome.\" Am J Med 114 (2003): 511-2[14] Mirghani RA, Yasar U, Zheng T, et al \"Enzyme kinetics for the formation of 3-hydroxyquinine and three new metabolites of quinine in vitro; 3-hydroxylation by CYP3A4 is indeed the major metabolic pathway.\" Drug Metab Dispos 30 (2002): 1368-71", "alternatives_a": "Risdiplam, Collagenase clostridium histolyticum, Onasemnogene abeparvovec, Hyaluronic acid, Artesunate, Pyrimethamine, Tafenoquine, Proguanil, Sulfadoxine", "alternatives_b": "Tinidazole, Pantoprazole, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Nizatidine, Esomeprazole, Ranitidine, Vonoprazan, More", "updated_at": 1767369485}, {"id": 67949, "ingredient1": "Clarithromycin", "ingredient2": "Ramelteon", "severity": "Moderate", "effect": "Coadministration with potent inhibitors of CYP450 3A4 and/or 2C9 may increase the plasma concentrations and pharmacologic effects of ramelteon, which is partially metabolized by these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised if ramelteon is prescribed in combination with potent inhibitors of CYP450 3A4 (e.g., itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, delavirdine, nefazodone, protease inhibitors, ketolide and certain macrolide antibiotics) and/or CYP450 2C9 (e.g., fluconazole, gemfibrozil, imatinib, miconazole). A reduction in the ramelteon dosage may be necessary in patients who experience excessive sedation.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if ramelteon is prescribed in combination with potent inhibitors of CYP450 3A4 (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68036/", "reference_text": "[1] \"Product Information. Rozerem (ramelteon).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[3] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[4] \"Product Information. Rozerem (ramelteon).\" Takeda Pharmaceuticals America, Lincolnshire, IL.", "alternatives_a": "Methohexital, Methylphenobarbital, Pentobarbital, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, Paraldehyde, Ethchlorvynol, Amobarbital, More", "alternatives_b": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Nizatidine, More", "updated_at": 1767369485}, {"id": 67950, "ingredient1": "Clarithromycin", "ingredient2": "Ranolazine", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ranolazine, which is primarily metabolized by the isoenzyme. Because ranolazine prolongs QT interval in a dose-dependent manner, high plasma levels of ranolazine may increase the risk of ventricular arrhythmias such as ventricular tachycardia, ventricular fibrillation, and torsade de pointes.", "source": "DDInter", "management_text": "Concomitant use of ranolazine with potent CYP450 3A4 inhibitors is considered contraindicated. Some authorities consider concomitant administration of ranolazine and itraconazole to be contraindicated during and for 2 weeks after treatment with itraconazole.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of ranolazine with potent CYP450 3A4 inhibitors is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68037/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[4] \"Product Information. Ranexa (ranolazine).\" Calmoseptine Inc, Huntington Beach, CA.[5] \"Product Information. Ranexa (ranolazine).\" Calmoseptine Inc, Huntington Beach, CA.[6] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[7] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Regadenoson, Alprostadil, Ubidecarenone", "alternatives_b": "Tinidazole, Tetracycline, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Nizatidine, Esomeprazole, Vonoprazan, Amoxicillin, Dirithromycin, More", "updated_at": 1767369485}, {"id": 67951, "ingredient1": "Clarithromycin", "ingredient2": "Regorafenib", "severity": "Moderate", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of regorafenib and decrease the plasma concentrations of its active metabolites.", "source": "DDInter", "management_text": "Concomitant use of regorafenib with potent CYP450 3A4 inhibitors should generally be avoided. Some authorities recommend avoiding concomitant use of regorafenib during and for 2 weeks after treatment with itraconazole.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of regorafenib with potent CYP450 3A4 inhibitors should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68038/", "reference_text": "[1] \"Product Information. Stivarga (regorafenib).\" Bayer Pharmaceutical Inc, West Haven, CT.[2] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[5] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[6] \"Product Information. Stivarga (regorafenib).\" Bayer Pharmaceutical Inc, West Haven, CT.", "alternatives_a": "Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, More", "alternatives_b": "Alpelisib, Trametinib, Dacomitinib, Tivozanib, Alectinib", "updated_at": 1767369485}, {"id": 67952, "ingredient1": "Clarithromycin", "ingredient2": "Relugolix", "severity": "Major", "effect": "Coadministration with inhibitors of the P-glycoprotein (P-gp) efflux transporter may increase the plasma concentrations of relugolix, particularly when the inhibitors are given orally. Relugolix is a substrate for intestinal P-gp. In vitro, it is metabolized primarily by CYP450 3A and, to a lesser extent, by CYP450 2C8. When relugolix was coadministered with erythromycin, a combined P-gp and moderate CYP450 3A inhibitor, relugolix peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 6.2-fold. Increased exposure to relugolix may increase the risk and/or severity of adverse effects such as hot flushes; weight gain; decreased sex drive; erectile function difficulties; QT interval prolongation; musculoskeletal pain; constipation; diarrhea; increases in glucose, triglyceride, and liver transaminase levels; and decreased hemoglobin. Long-term androgen deprivation therapy, including relugolix, can prolong the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Concomitant use of relugolix with orally administered P-gp inhibitors should be avoided when possible. In addition, the benefits of androgen deprivation therapy such as relugolix should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval, many of which are also P-gp inhibitors (e.g., amiodarone, azithromycin, bepridil, cabozantinib, clarithromycin, crizotinib, dronedarone, elagolix, erythromycin, ketoconazole, lapatinib, mifepristone, nilotinib, osimertinib, propafenone, quinidine, quinine, ranolazine, tacrolimus, telithromycin, valbenazine, vemurafenib). If coadministration is required, the manufacturer recommends taking relugolix first and separating the dosing by at least 6 hours. Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered. Alternatively, treatment with relugolix may be interrupted for up to two weeks if a short course of treatment with a P-gp inhibitor is necessary.", "mechanism_text": "Synergism, Absorption", "recommendation": "Concomitant use of relugolix with orally administered P-gp inhibitors should be avoided when possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68039/", "reference_text": "[1] \"Product Information. Orgovyx (relugolix).\" Myovant Sciences, Inc., Brisbane, CA.[2] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[3] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[4] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[5] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Cimetidine, Esomeprazole, Ranitidine, More", "alternatives_b": "Nafarelin, Octreotide, Cetrorelix, Ganirelix, Lanreotide, Gonadorelin, Anastrozole, Aminoglutethimide, Exemestane, Fulvestrant", "updated_at": 1767369485}, {"id": 67953, "ingredient1": "Clarithromycin", "ingredient2": "Remdesivir", "severity": "Moderate", "effect": "Concomitant use of remdesivir with other agents that are known to induce hepatotoxicity may theoretically increase the risk of liver injury. Data from investigational use and clinical studies suggest that remdesivir may be associated with hepatotoxic effects.", "source": "DDInter", "management_text": "Until more information is available, concomitant use of remdesivir with known hepatotoxic drugs should be avoided when possible. Liver function should be evaluated prior to starting remdesivir and monitored during treatment as clinically appropriate. Remdesivir should not be initiated in patients with ALT greater than or equal to 5 times the upper limit of normal (ULN) at baseline. Likewise, remdesivir should be discontinued immediately if ALT increases to 5 times ULN or greater during treatment (may be restarted when ALT falls below 5 times ULN), or if ALT elevation is accompanied by signs or symptoms of liver inflammation or increasing conjugated bilirubin, alkaline phosphatase, or INR.", "mechanism_text": "Synergism", "recommendation": "Until more information is available, concomitant use of remdesivir with known hepatotoxic drugs should be avoided when possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68040/", "reference_text": "[1] Gilead Sciences, Inc \"About Remdesivir. Available from: URL: https://www.gilead.com/purpose/advancing-global-health/covid-19/about-remdesivir.\" ([2020]):[2] US Food and Drug Administration \"Fact sheet for health care providers emergency use authorization (EUA) of remdesivir (GS-5734TM) Available from: URL: https://www.fda.gov/media/137566/download.\" ([2020, May 1]]):[3] European Medicines Agency \"Summary on compassionate use. Remdesivir Gilead. Available from: URL: https://www.ema.europa.eu/en/documents/other/summary-compassionate-use-remdesivir-gilead_en.pdf.\" ([2020 Apr 03]):[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Tinidazole, Pantoprazole, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Rifabutin, Cimetidine, More", "alternatives_b": "Glecaprevir, Tenofovir alafenamide, Cabotegravir, Lenacapavir, Velpatasvir, Voxilaprevir, Maribavir, Pibrentasvir, Rimantadine, Elvitegravir, Valganciclovir, More", "updated_at": 1767369485}, {"id": 67954, "ingredient1": "Clarithromycin", "ingredient2": "Repaglinide", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of repaglinide, which is partially metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Because the antidiabetic effect of repaglinide is dose- and concentration-dependent, pharmacologic response to repaglinide should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy. Patients should be advised to regularly monitor their blood sugar and counseled on how to recognize and treat hypoglycemia, which may include symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, and palpitations.", "mechanism_text": "Metabolism", "recommendation": "Because the antidiabetic effect of repaglinide is dose- and concentration-dependent, pharmacologic response to repaglinide should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68041/", "reference_text": "[1] Khamaisi M, Leitersdorf E \"Severe hypoglycemia from clarithromycin-repaglinide drug interaction.\" Pharmacotherapy 28 (2008): 682-4[2] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[3] Hatorp V, Hansen KT, Thomsen MS \"Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide.\" J Clin Pharmacol 43 (2003): 649-60[4] Niemi M, Backman JT, Neuvonen M, Neuvonen PJ \"Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide.\" Diabetologia 46 (2003): 347-51[5] Niemi M, Neuvonen PJ, Kivisto KT \"The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide.\" Clin Pharmacol Ther 70 (2001): 58-65[6] Bidstrup TB, Bjornsdottir I, Sidelmann UG, Thomsen MS, Hansen KT \"CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide.\" Br J Clin Pharmacol 56 (2003): 305-14[7] Tornio A, Niemi M, Neuvonen M, et al. \"The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo.\" Clin Pharmacol Ther 84 (2008): 403-11[8] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[9] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[10] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[11] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[12] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[13] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[14] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[15] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[16] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[17] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[18] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[19] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[20] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[21] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[22] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[23] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[24] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[25] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[26] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[27] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[28] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[29] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[30] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[31] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[32] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[33] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[34] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[35] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[36] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[37] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[38] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[39] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8", "alternatives_a": "Guar gum", "alternatives_b": "Tinidazole, Tetracycline, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Esomeprazole, Lincomycin, Dirithromycin", "updated_at": 1767369485}, {"id": 67955, "ingredient1": "Clarithromycin", "ingredient2": "Retapamulin (topical)", "severity": "Minor", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of retapamulin, which is primarily metabolized by the isoenzyme. However, dosage adjustments are not necessary due to the low systemic exposure to retapamulin following topical application.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68042/", "reference_text": "[1] \"Product Information. Altabax (retapamulin topical).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67956, "ingredient1": "Clarithromycin", "ingredient2": "Ribociclib", "severity": "Major", "effect": "Ribociclib can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In general, the risk of an individual agent or a combination of agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances (e.g., hypokalemia, hypomagnesemia). In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s). Coadministration with potent CYP450 3A4 inhibitors may increase the plasma concentrations and the risk of adverse effects of ribociclib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Coadministration of ribociclib with other drugs that can prolong the QT interval and are CYP450 3A4 inhibitors should generally be avoided. Since the magnitude of QT prolongation may increase with increasing plasma concentrations of ribociclib, caution and close clinical monitoring are recommended if concomitant use with these drugs is unavoidable. Alternative agents with no or minimal CYP450 3A4 inhibitory potential are recommended whenever possible. If no alternatives exist, the dose of ribociclib should be reduced to 400 mg once daily. Following discontinuation of the potent CYP450 3A4 inhibitor, the ribociclib dosage should be returned (after at least 5 half-lives of the inhibitor) to that used prior to initiation of the inhibitor. In addition, ECGs should be assessed prior to initiation of treatment, during treatment when clinically necessary, and more frequently if QTcF prolongation occurs at any time during treatment. Ribociclib should be permanently discontinued if the QTcF interval prolongation is either greater than 500 msec or there is a greater than 60 msec change from baseline and associated with any of the following: Torsades de Pointes, polymorphic ventricular tachycardia, unexplained syncope, or signs/symptoms of serious arrhythmia.", "mechanism_text": "Metabolism, Synergism", "recommendation": "Coadministration of ribociclib with other drugs that can prolong the QT interval and are CYP450 3A4 inhibitors should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68043/", "reference_text": "[1] \"Product Information. Kisqali (ribociclib).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[3] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[4] \"Product Information. Kisqali (ribociclib).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Pantoprazole, Tetracycline, Rabeprazole, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Nizatidine, Esomeprazole, Ranitidine, Vonoprazan, More", "alternatives_b": "Alpelisib, Trametinib, Dacomitinib, Tivozanib, Alectinib", "updated_at": 1767369485}, {"id": 67957, "ingredient1": "Clarithromycin", "ingredient2": "Rifabutin", "severity": "Moderate", "effect": "The coadministration of clarithromycin and rifabutin at normally recommended dosages has been reported to have resulted in significantly altered pharmacokinetics for both drugs. This bidirectional interaction is consistent with rifabutin's cumulative inducing effect over time on the CYP450 enzymatic pathway as well as clarithromycin's immediate inhibiting effect on the pathway. Other macrolide antibiotics may interact in a similar manner with rifamycins.", "source": "DDInter", "management_text": "Some experts recommend that this combination be avoided since it may result in decreased efficacy of the macrolide and increased rifamycin toxicity (e.g, neutropenia, uveitis).", "mechanism_text": "Metabolism", "recommendation": "Some experts recommend that this combination be avoided since it may result in decreased efficacy of the macrolide and increased rifamycin toxicity (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68044/", "reference_text": "[1] Wallace RJ, Brown BA, Griffith DE, Girard W, Tanaka K \"Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for Mycobacterium avium -M.intracellulare infection.\" J Infect Dis 171 (1995): 747-50[2] Griffith DE, Brown BA, Girard WM, Wallace RJ Jr \"Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease.\" Clin Infect Dis 21 (1995): 594-8[3] Apseloff G, Foulds G, LaBoy-Goral L, Willavize S, Vincent J \"Comparison of azithromycin and clarithromycin in their interactions with rifabutin in healthy volunteers.\" J Clin Pharmacol 38 (1998): 830-5[4] von Rosenstiel NA, Adam D \"Macrolide antibacterials. Drug interactions of clinical significance.\" Drug Saf 13 (1995): 105-22[5] Hafner R, Bethel J, Power M, et al. \"Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.\" Antimicrob Agents Chemother 42 (1998): 631-9[6] Benson CA, Williams PL, Cohn DL, Becker S, Hojczyk P, Nevin T, Korvick JA, Heifets L, Child CC, Lederman MM, Reichman RC, \"Clarithromycin or rifabutin alone or in combination for primary prophylaxis of Mycobacterium avium complex disease in patients with AIDS: A randomized, double-blind, placebo-controlled trial.\" J Infec Dis 181 (2000): 1289-97[7] Jordan MK, Polis MA, Kelly G, Narang PK, Masur H, Piscitelli SC \"Effects of fluconazole and clarithromycin on rifabutin and 25-O-desacetylrifabutin pharmacokinetics.\" Antimicrob Agents Chemother 44 (2000): 2170-72[8] Benson CA, Williams PL, Currier JS, et al. \"A Prospective, Randomized Trial Examining the Efficacy and Safety of Clarithromycin in Combination with Ethambutol, Rifabutin, or Both for the Treatment of Disseminated Mycobacterium avium Complex Disease in Persons with Acquired Immunodeficiency Syndrome\" Clin Infect Dis 37 (2003): 1234-43", "alternatives_a": "Capreomycin, Rifamycin, Cycloserine, Pyridoxine, Ethionamide, Pretomanid, Aminosalicylic acid, Tinidazole, Bismuth subcitrate potassium, Vonoprazan, Clarithromycin", "alternatives_b": "Pantoprazole, Levofloxacin, Tetracycline, Rabeprazole, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Famotidine, Rifabutin, Cimetidine, More", "updated_at": 1767369485}, {"id": 67958, "ingredient1": "Clarithromycin", "ingredient2": "Rifampicin", "severity": "Moderate", "effect": "The coadministration of clarithromycin and rifabutin at normally recommended dosages has been reported to have resulted in significantly altered pharmacokinetics for both drugs. This bidirectional interaction is consistent with rifabutin's cumulative inducing effect over time on the CYP450 enzymatic pathway as well as clarithromycin's immediate inhibiting effect on the pathway. Other macrolide antibiotics may interact in a similar manner with rifamycins.", "source": "DDInter", "management_text": "Some experts recommend that this combination be avoided since it may result in decreased efficacy of the macrolide and increased rifamycin toxicity (e.g, neutropenia, uveitis).", "mechanism_text": "Metabolism", "recommendation": "Some experts recommend that this combination be avoided since it may result in decreased efficacy of the macrolide and increased rifamycin toxicity (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68045/", "reference_text": "[1] Wallace RJ, Brown BA, Griffith DE, Girard W, Tanaka K \"Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for Mycobacterium avium -M.intracellulare infection.\" J Infect Dis 171 (1995): 747-50[2] Griffith DE, Brown BA, Girard WM, Wallace RJ Jr \"Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease.\" Clin Infect Dis 21 (1995): 594-8[3] Apseloff G, Foulds G, LaBoy-Goral L, Willavize S, Vincent J \"Comparison of azithromycin and clarithromycin in their interactions with rifabutin in healthy volunteers.\" J Clin Pharmacol 38 (1998): 830-5[4] von Rosenstiel NA, Adam D \"Macrolide antibacterials. Drug interactions of clinical significance.\" Drug Saf 13 (1995): 105-22[5] Hafner R, Bethel J, Power M, et al. \"Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.\" Antimicrob Agents Chemother 42 (1998): 631-9[6] Benson CA, Williams PL, Cohn DL, Becker S, Hojczyk P, Nevin T, Korvick JA, Heifets L, Child CC, Lederman MM, Reichman RC, \"Clarithromycin or rifabutin alone or in combination for primary prophylaxis of Mycobacterium avium complex disease in patients with AIDS: A randomized, double-blind, placebo-controlled trial.\" J Infec Dis 181 (2000): 1289-97[7] Jordan MK, Polis MA, Kelly G, Narang PK, Masur H, Piscitelli SC \"Effects of fluconazole and clarithromycin on rifabutin and 25-O-desacetylrifabutin pharmacokinetics.\" Antimicrob Agents Chemother 44 (2000): 2170-72[8] Benson CA, Williams PL, Currier JS, et al. \"A Prospective, Randomized Trial Examining the Efficacy and Safety of Clarithromycin in Combination with Ethambutol, Rifabutin, or Both for the Treatment of Disseminated Mycobacterium avium Complex Disease in Persons with Acquired Immunodeficiency Syndrome\" Clin Infect Dis 37 (2003): 1234-43", "alternatives_a": "Capreomycin, Rifamycin, Cycloserine, Pyridoxine, Ethionamide, Pretomanid, Aminosalicylic acid", "alternatives_b": "Tetracycline, Levofloxacin, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Nizatidine, Amoxicillin, Lincomycin, Dirithromycin", "updated_at": 1767369485}, {"id": 67959, "ingredient1": "Clarithromycin", "ingredient2": "Rifapentine", "severity": "Moderate", "effect": "Coadministration with rifapentine may decrease the plasma concentrations of drugs that are substrates of the CYP450 2C8, 2C9, and/or 3A4 isoenzymes. The mechanism is accelerated clearance due to induction of these isoenzymes by rifapentine. Enzyme activities may be induced within 4 days of the first dose and return to normal 14 days after discontinuation of rifapentine.", "source": "DDInter", "management_text": "The possibility of a diminished therapeutic response to drugs that are known substrates of CYP450 2C8, 2C9, and/or 3A4 should be considered during coadministration with rifapentine. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs, particularly those with a narrow therapeutic range, whenever rifapentine is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "The possibility of a diminished therapeutic response to drugs that are known substrates of CYP450 2C8, 2C9, and/or 3A4 should be considered during coadministration with rifapentine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68046/", "reference_text": "[1] Thijssen HH, Flin ois JP, Beaune PH \"Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes.\" Drug Metab Dispos 28 (2000): 1284-90[2] \"Product Information. Priftin (rifapentine).\" Hoechst Marion-Roussel Inc, Kansas City, MO.", "alternatives_a": "Capreomycin, Rifamycin, Cycloserine, Pyridoxine, Ethionamide, Pretomanid, Aminosalicylic acid", "alternatives_b": "Pantoprazole, Levofloxacin, Tetracycline, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Famotidine, Cimetidine, Esomeprazole, Ranitidine, More", "updated_at": 1767369485}, {"id": 67960, "ingredient1": "Clarithromycin", "ingredient2": "Rilpivirine", "severity": "Moderate", "effect": "Coadministration with macrolide antibiotics that are inhibitors of CYP450 3A4 may increase the blood concentrations of rilpivirine, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if rilpivirine is used with macrolide antibiotics that are inhibitors of CYP450 3A4. Alternative antibiotics that do not interfere with rilpivirine metabolism, such as azithromycin, should be considered whenever possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if rilpivirine is used with macrolide antibiotics that are inhibitors of CYP450 3A4.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68047/", "reference_text": "[1] \"Product Information. Edurant (rilpivirine).\" Tibotec Pharmaceuticals, Titusville, NJ.[2] \"Product Information. Edurant (rilpivirine).\" Tibotec Pharmaceuticals, Titusville, NJ.[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Viread (tenofovir).\" Gilead Sciences, Foster City, CA.", "alternatives_a": "Tinidazole, Tetracycline, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Amoxicillin, Dirithromycin, Lincomycin, Clindamycin", "alternatives_b": "Glecaprevir, Tenofovir alafenamide, Cabotegravir, Lenacapavir, Velpatasvir, Voxilaprevir, Maribavir, Pibrentasvir, Rimantadine, Elvitegravir, Valganciclovir, More", "updated_at": 1767369485}, {"id": 67961, "ingredient1": "Clarithromycin", "ingredient2": "Rimegepant", "severity": "Moderate", "effect": "Coadministration with strong inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of rimegepant, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Coadministration of rimegepant with strong inhibitors of CYP450 3A4 should be avoided.", "mechanism_text": "Metabolism", "recommendation": "Coadministration of rimegepant with strong inhibitors of CYP450 3A4 should be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68048/", "reference_text": "[1] \"Product Information. Nurtec ODT (rimegepant).\" Biohaven Pharmaceuticals, New Haven, CT.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[3] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[4] \"Product Information. Nurtec ODT (rimegepant).\" Biohaven Pharmaceuticals, New Haven, CT.", "alternatives_a": "Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, More", "alternatives_b": "Frovatriptan, Eptinezumab, Lasmiditan, Rizatriptan, Galcanezumab, Zolmitriptan, Erenumab, Fremanezumab", "updated_at": 1767369485}, {"id": 67962, "ingredient1": "Clarithromycin", "ingredient2": "Riociguat", "severity": "Moderate", "effect": "Coadministration with potent inhibitors of CYP450 3A4 or moderate to potent inhibitors of P-glycoprotein (P-gp) or breast cancer resistant protein (BCRP) may increase the plasma concentrations of riociguat, which is partially metabolized by CYP450 3A and also a substrate of the P-gp and BCRP efflux transporters. Increased levels of riociguat may increase the risk for hypotension.", "source": "DDInter", "management_text": "Caution is advised when riociguat is prescribed with potent CYP450 3A4 inhibitors or moderate to potent P-gp or BCRP inhibitors. Patients should be monitored for signs and symptoms of hypotension, and the dosage of riociguat adjusted if necessary.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when riociguat is prescribed with potent CYP450 3A4 inhibitors or moderate to potent P-gp or BCRP inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68049/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Adempas (riociguat).\" Bayer Pharmaceutical Inc, West Haven, CT.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Adempas (riociguat).\" Bayer Pharmaceutical Inc, West Haven, CT.", "alternatives_a": "Tinidazole, Levofloxacin, Tetracycline, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Cimetidine, Nizatidine, Ranitidine, More", "alternatives_b": "Metyrosine", "updated_at": 1767369485}, {"id": 67963, "ingredient1": "Clarithromycin", "ingredient2": "Ripretinib", "severity": "Major", "effect": "Coadministration of strong CYP450 3A4 inhibitors with ripretinib may increase the plasma concentrations and the risk of adverse effects (e.g., palmar-plantar erythrodysesthesia, hypertension, cardiac dysfunction, arthralgia/myalgia) of ripretinib and its active metabolite (DP-5439). The proposed mechanism is inhibition of CYP450 3A4, the isoenzyme responsible for the metabolic clearance of ripretinib and DP-5439.", "source": "DDInter", "management_text": "Caution is recommended when ripretinib is used concomitantly with a strong CYP450 3A4 inhibitor. Clinical and laboratory monitoring should be considered whenever a strong CYP450 3A4 inhibitor is added to or withdrawn from therapy with ripretinib, and the dosage adjusted as necessary. Patients should be monitored for development of adverse effects.", "mechanism_text": "Metabolism", "recommendation": "Caution is recommended when ripretinib is used concomitantly with a strong CYP450 3A4 inhibitor.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68050/", "reference_text": "[1] \"Product Information. Qinlock (ripretinib).\" Deciphera Pharmaceuticals, Waltham, MA.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[4] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[5] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[6] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[9] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[10] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[11] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[12] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[13] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[14] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[15] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[16] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[17] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[18] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[19] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[20] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[21] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[22] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[23] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[24] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[25] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[26] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[27] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[28] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[29] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[30] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[31] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[32] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[33] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[34] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[35] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[36] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, More", "alternatives_b": "Alpelisib, Trametinib, Dacomitinib, Tivozanib, Alectinib", "updated_at": 1767369485}, {"id": 67964, "ingredient1": "Clarithromycin", "ingredient2": "Risperidone", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68051/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[16] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Loxapine, Molindone, Thiothixene", "alternatives_b": "Tinidazole, Dexlansoprazole, Bismuth subcitrate potassium, Rifabutin, Esomeprazole, Vonoprazan, Lincomycin, Troleandomycin, Dirithromycin", "updated_at": 1767369485}, {"id": 67965, "ingredient1": "Clarithromycin", "ingredient2": "Ritodrine", "severity": "Moderate", "effect": "Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.", "source": "DDInter", "management_text": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68052/", "reference_text": "[1] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL \"The mechanism of salbutamol-induced hypokalaemia.\" Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA \"Metabolic and cardiovascular effects of carbuterol and metaproterenol.\" J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N \"Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics.\" Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK \"Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses.\" Am Rev Respir Dis 141 (1990): 575-9[6] \"Hypokalaemia due to salbutamol overdosage.\" Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C \"Cardiovascular Safety of Salmeterol in COPD.\" Chest 123 (2003): 1817-24[8] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R \"A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol.\" N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC \"Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler.\" Pediatr Emerg Care 14 (1998): 145-7[11] \"Product Information. Brovana (arformoterol).\" Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO \"Extrapulmonary effects of terbutaline during prolonged administration.\" Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE \"The effect of oral salbutamol on serum potassium and blood sugar.\" Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD \"Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease.\" Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990): 1396-9[16] \"Product Information. Xopenex (levalbuterol).\" Sepracor, Marlborough, MA.[17] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG \"Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation.\" Clin Ther 28 (2006): 582-90[19] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[20] \"Product Information. Proventil (albuterol).\" Schering Laboratories, Kenilworth, NJ.[21] \"Product Information. Foradil (formoterol)\" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ \"Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment.\" Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L \"Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome.\" J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A \"Hypokalemia induced by inhaled bronchodilators.\" Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001): 45-51[26] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL \"Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences.\" Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K \"Serum potassium levels during and after terbutaline.\" Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K \"Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects.\" Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L \"Hypokalemia from usual salbutamol dosage .\" Chest 89 (1986): 619-20", "alternatives_a": "Bremelanotide", "alternatives_b": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Rifabutin, Cimetidine, More", "updated_at": 1767369485}, {"id": 67966, "ingredient1": "Clarithromycin", "ingredient2": "Ritonavir", "severity": "Moderate", "effect": "Coadministration with ritonavir may increase the plasma concentrations of clarithromycin. The mechanism is ritonavir inhibition of CYP450 3A4, the isoenzyme responsible for the metabolic conversion of clarithromycin to 14-hydroxyclarithromycin.", "source": "DDInter", "management_text": "No dosage adjustment of clarithromycin or ritonavir is required during coadministration in patients with normal renal function. However, clarithromycin dosage should be reduced by 50% in patients with moderate renal impairment (CrCl 30 to 60 mL/min) and 75% in patients with more severe renal impairment (CrCl below 30 mL/min).", "mechanism_text": "Metabolism", "recommendation": "No dosage adjustment of clarithromycin or ritonavir is required during coadministration in patients with normal renal function.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68053/", "reference_text": "[1] Ouellet D, Hsu A, Granneman GR, et al. \"Assessment of the pharmacokinetic interaction between ritonavir and clarithromycin.\" Clin Pharmacol Ther 59 (1996): 143[2] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[3] Ouellet D, Hsu A, Granneman GR, Carlson G, Cavanaugh J, Guenther H, Leonard JM \"Pharmacokinetic interaction between ritonavir and clarithromycin.\" Clin Pharmacol Ther 64 (1998): 355-62[4] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical, Abbott Park, IL.[5] Cheng KL, Nafziger AN, Peloquin CA, Amsden GW \"Effect of grapefruit juice on clarithromycin pharmacokinetics.\" Antimicrob Agents Chemother 42 (1998): 927-9", "alternatives_a": "Glecaprevir, Tenofovir alafenamide, Cabotegravir, Lenacapavir, Velpatasvir, Voxilaprevir, Maribavir, Pibrentasvir, Rimantadine, Elvitegravir, Valganciclovir, More", "alternatives_b": "Tetracycline, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Nizatidine, Esomeprazole, Vonoprazan, Levofloxacin, Telithromycin, Lincomycin, Dirithromycin", "updated_at": 1767369485}, {"id": 67967, "ingredient1": "Clarithromycin", "ingredient2": "Rivaroxaban", "severity": "Moderate", "effect": "Coadministration with weak or moderate dual inhibitors of CYP450 3A4 and P-glycoprotein (P-gp) may increase the plasma concentrations of rivaroxaban, which is a substrate of both the isoenzyme and efflux transporter.", "source": "DDInter", "management_text": "In patients with CrCl of 15 to less than 80 mL/min, the use of rivaroxaban with weak or moderate dual inhibitors of CYP450 3A4 and P-gp should only be considered if the potential benefits justify the increased risk of bleeding complications. Patients should be routinely evaluated for signs and symptoms suggesting blood loss such as a drop in hemoglobin and/or hematocrit, hypotension, or fetal distress (in pregnant women). Renal function should also be assessed periodically, and treatment with rivaroxaban discontinued if acute renal failure develops. Due to the lack of clinical data, rivaroxaban is not recommended in patients with CrCl below 30 mL/min when used for the prophylaxis of deep vein thrombosis and in patients with CrCl below 15 mL/min when used for reducing the risk of stroke and systemic embolism in nonvalvular atrial fibrillation.", "mechanism_text": "Metabolism", "recommendation": "In patients with CrCl of 15 to less than 80 mL/min, the use of rivaroxaban with weak or moderate dual inhibitors of CYP450 3A4 and P-gp should only be considered if the potential benefits justify the increased risk of bleeding complications.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68054/", "reference_text": "[1] \"Product Information. Xarelto (rivaroxaban).\" Bayer Inc, Toronto, IA.[2] Hooks MA \"Tacrolimus, a new immunosuppressant--a review of the literature.\" Ann Pharmacother 28 (1994): 501-11[3] \"Product Information. Prograf (tacrolimus).\" Fujisawa, Deerfield, IL.", "alternatives_a": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, More", "alternatives_b": "Iloprost, Lepirudin, Urokinase, Cangrelor, Caplacizumab, Argatroban, Prasugrel, Desirudin, Eptifibatide, Streptokinase, Tinzaparin, More", "updated_at": 1767369485}, {"id": 67968, "ingredient1": "Clarithromycin", "ingredient2": "Rivastigmine", "severity": "Moderate", "effect": "Acetylcholinesterase inhibitors may have vagotonic effects on the sinoatrial and atrioventricular nodes, which occasionally manifest as bradycardia or heart block (<2%). Because bradycardia is a risk factor for torsade de pointes, a theoretical risk exists when combined with agents that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when acetylcholinesterase inhibitors are used with drugs that can prolong the QT interval. Patients should be monitored for bradycardia, atrioventricular block and syncope, and advised to seek medical attention if they experience dizziness, lightheadedness, fainting, shortness of breath, or slow or irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when acetylcholinesterase inhibitors are used with drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68055/", "reference_text": "[1] \"Product Information. Razadyne (galantamine).\" Johnson and Johnson Medical Inc, Arlington, TX.[2] \"Product Information. Exelon (rivastigmine)\" Novartis Pharmaceuticals, East Hanover, NJ.[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Aricept (donepezil).\" Pfizer US Pharmaceuticals, New York, NY.[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"", "alternatives_a": "Memantine, Ginkgo biloba, Aducanumab", "alternatives_b": "Tinidazole, Tetracycline, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Nizatidine, Esomeprazole, Vonoprazan, Amoxicillin, More", "updated_at": 1767369485}, {"id": 67969, "ingredient1": "Clarithromycin", "ingredient2": "Romidepsin", "severity": "Moderate", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of romidepsin, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when romidepsin is used with potent CYP450 3A4 inhibitors. Patients should have complete blood cell counts, electrocardiograms, and serum electrolyte levels performed at baseline and regular intervals as recommended in the product labeling. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when romidepsin is used with potent CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68056/", "reference_text": "[1] \"Product Information. Istodax (romidepsin).\" Gloucester Pharmaceuticals, Cambridge, MA.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[3] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Cimetidine, Esomeprazole, Ranitidine, More", "alternatives_b": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Mitotane, Niraparib, Porfimer sodium, More", "updated_at": 1767369485}, {"id": 67970, "ingredient1": "Clarithromycin", "ingredient2": "Ropivacaine", "severity": "Minor", "effect": "Coadministration with inhibitors of CYP450 3A4 may modestly increase the plasma concentrations of ropivacaine. Although ropivacaine is primarily metabolized by CYP450 1A2, it has been shown to undergo some metabolism via CYP450 3A4.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68057/", "reference_text": "[1] Jokinen MJ, Ahonen J, Neuvonen PJ, Olkkola KT \"The effect of erythromycin, fluvoxamine, and their combination on the pharmacokinetics of ropivacaine.\" Anesth Analg 91 (2000): 1207-12[2] Ekstrom G, Gunnarsson UB \"Ropivacaine, a new amide-type local anesthetic agent, is metabolized by cytochromes P450 1A and 3A in human liver microsomes.\" Drug Metab Dispos 24 (1996): 955-61[3] Arlander E, Ekstrom G, Alm C, Carrillo JA, Bielenstein M, Bottiger Y, Bertilsson L, Gustafsson LL \"Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: An interaction study with fluvoxamine and ketoconazole as in vivo inhibitors.\" Clin Pharmacol Ther 64 (1998): 484-91[4] McClure JH \"Ropivacaine.\" Br J Anaesth 76 (1996): 300-7[5] \"Product Information. Naropin (ropivacaine).\" Astra USA, Westborough, MA.[6] Halldin MM, Bredberg E, Angelin B, Arvidsson T, Askemark Y, Elofsson S, Widman M \"Metabolism and excretion of ropivacaine in humans.\" Drug Metab Dispos 24 (1996): 962-8[7] Oda Y, Furuichi K, Tanaka K, Hiroi T, Imaoka S, Asada A, Fujimori M, Funae Y \"Metabolism of a new local anesthetic, ropivacaine, by human hepatic cytochrome P450.\" Anesthesiology 82 (1995): 214-20", "alternatives_a": "Chloroprocaine, Bupivacaine, Tetracaine, Mepivacaine, Procaine, Prilocaine, Articaine, Etidocaine", "alternatives_b": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, More", "updated_at": 1767369485}, {"id": 67971, "ingredient1": "Clarithromycin", "ingredient2": "Rosiglitazone", "severity": "Moderate", "effect": "Concomitant use of insulin and other antidiabetic agents with clarithromycin may cause significant hypoglycemia. There have been rare reports of hypoglycemia in patients treated with clarithromycin, some of whom were taking oral hypoglycemic agents or insulin. The exact mechanism of interaction has not been established. With certain hypoglycemic drugs such as nateglinide, pioglitazone, repaglinide and rosiglitazone, inhibition of the CYP450 3A4 isoenzyme by clarithromycin may be involved.", "source": "DDInter", "management_text": "Caution is advised if clarithromycin is prescribed to patients receiving antidiabetic agents. Patients should be advised to regularly monitor their blood sugar and counseled on how to recognize and treat hypoglycemia, which may include symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if clarithromycin is prescribed to patients receiving antidiabetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68058/", "reference_text": "[1] Otsuka SH \"Severe hypoglycemia from helicobacter pylori triple-drug therapy and insulin detemir drug interaction.\" Pharmacotherapy 33 (2013): e45-9[2] Niemi M, Neuvonen PJ, Kivisto KT \"The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide.\" Clin Pharmacol Ther 70 (2001): 58-65[3] Schelleman H, Bilker WB, Brensinger CM, Wan F, Hennessy S \"Anti-infectives and the risk of severe hypoglycemia in users of glipizide or glyburide.\" Clin Pharmacol Ther 88 (2010): 214-22[4] Khamaisi M, Leitersdorf E \"Severe hypoglycemia from clarithromycin-repaglinide drug interaction.\" Pharmacotherapy 28 (2008): 682-4[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Leiba A, Leibowitz A, Grossman E \"An unusual case of hypoglycemia in a diabetic patient.\" Ann Emerg Med 44 (2004): 427-8[7] Bussing R, Gende A \"Severe hypoglycemia from clarithromycin-sulfonylurea drug interaction.\" Diabetes Care 25 (2002): 1659-61[8] \"Product Information. Biaxin (clarithromycin).\" Abbott Pharmaceutical, Abbott Park, IL.[9] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[10] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[11] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[12] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[13] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[14] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[15] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[16] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[17] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[18] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[19] Cheng KL, Nafziger AN, Peloquin CA, Amsden GW \"Effect of grapefruit juice on clarithromycin pharmacokinetics.\" Antimicrob Agents Chemother 42 (1998): 927-9", "alternatives_a": "Guar gum", "alternatives_b": "Tinidazole, Dexlansoprazole, Bismuth subcitrate potassium, Esomeprazole, Vonoprazan, Lincomycin, Troleandomycin, Dirithromycin", "updated_at": 1767369485}, {"id": 67972, "ingredient1": "Clarithromycin", "ingredient2": "Rucaparib", "severity": "Moderate", "effect": "Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.", "source": "DDInter", "management_text": "Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical monitoring are recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68059/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ \"Psychotropic drugs, cardiac arrhythmia, and sudden death.\" J Clin Psychopharmacol 23 (2003): 58-77[3] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Glassman AH, Bigger JT Jr \"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.\" Am J Psychiatry 158 (2001): 1774-82[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Honig PK, Wortham DC, Zamani K, et al \"Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences.\" JAMA 269 (1993): 1513-8[9] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[10] Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P \"Torsades de pointes after terfenadine-itraconazole interaction.\" BMJ 306 (1993): 186[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Mathews DR, McNutt B, Okerholm R, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 266 (1991): 2375-6[13] Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL \"Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram.\" Clin Pharmacol Ther 59 (1996): 383-8[14] Zechnich AD, Haxby DG \"Drug interactions associated with terfenadine and related nonsedating antihistamines.\" West J Med 164 (1996): 68-9[15] Hsieh MH, Chen SA, Chiang CE, et al. \"Drug-induced torsades de pointes in one patient with congenital long QT syndrome.\" Int J Cardiol 54 (1996): 85-8[16] Woosley RL \"Cardiac actions of antihistamines.\" Annu Rev Pharmacol Toxicol 36 (1996): 233-52[17] Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP \"Torsades-de-pointes induced by erythromycin and terfenadine.\" Am J Emerg Med 12 (1994): 636-8[18] Zimmermann M, Duruz H, Guinand O, et al \"Torsades de Pointes after treatment with terfenadine and ketoconazole.\" Eur Heart J 13 (1992): 1002-3[19] Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG \"Grapefruit juice terfenadine single-dose interaction: Magnitude, mechanism, and relevance.\" Clin Pharmacol Ther 61 (1997): 401-9[20] Honig PK, Wortham DC, Lazarev A, Cantilena LR \"Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine.\" J Clin Pharmacol 36 (1996): 345-51[21] Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr \"Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.\" Clin Pharmacol Ther 52 (1992): 231-8[22] Monahan BP, Ferguson CL, Killeavy ES, et al \"Torsades de pointes occurring in association with terfenadine use.\" JAMA 264 (1990): 2788-90[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Cortese LM, Bjornson DC \"Potential interaction between terfenadine and macrolide antibiotics.\" Clin Pharm 11 (1992): 675", "alternatives_a": "Pantoprazole, Tetracycline, Rabeprazole, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Cimetidine, Esomeprazole, Ranitidine, Nizatidine, More", "alternatives_b": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Mitotane, Niraparib, Porfimer sodium, More", "updated_at": 1767369485}, {"id": 67973, "ingredient1": "Clarithromycin", "ingredient2": "Ruxolitinib", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ruxolitinib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Indication specific dose modifications should be made when ruxolitinib is coadministered with strong CYP450 3A4 inhibitors. The recommended starting dose for patients with Polycythemia vera (PV) coadministered potent CYP450 3A4 inhibitors is ruxolitinib 5 mg twice a day. For patients with MF or PV who are stabilized on ruxolitinib 10 mg twice a day or greater and starting a potent CYP450 3A4 inhibitor, the ruxolitinib dose should be reduced by 50% (rounded up to the closest available tablet strength). For patients with MF or PV stabilized on a dose of 5 mg twice a day and starting fluconazole (at a dose of 200 mg per day or less), the ruxolitinib dose should be reduced to 5 mg once a day. For patients with MF or PV stabilized on ruxolitinib 5 mg once a day, concomitant use of strong CYP450 3A4 inhibitors should be avoided or ruxolitinib therapy interrupted for the duration of strong CYP450 3A4 inhibitor use. For patients with for acute graft versus host disease (GVHD) coadministered strong CYP450 3A4 inhibitors, the ruxolitinib dose should be reduced to 5 mg once a day with concomitant ketoconazole use; however, no dose adjustments are necessary with other potent CYP450 3A4 inhibitors.", "mechanism_text": "Metabolism", "recommendation": "Indication specific dose modifications should be made when ruxolitinib is coadministered with strong CYP450 3A4 inhibitors.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68060/", "reference_text": "[1] \"Product Information. Jakafi (ruxolitinib).\" Incyte Corporation, Wilmington, DE.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[3] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[4] \"Product Information. Jakafi (ruxolitinib).\" Incyte Corporation, Wilmington, DE.", "alternatives_a": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, More", "alternatives_b": "Alpelisib, Trametinib, Dacomitinib, Tivozanib, Alectinib", "updated_at": 1767369485}, {"id": 67974, "ingredient1": "Clarithromycin", "ingredient2": "Salmeterol", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the systemic levels and pharmacologic effects of salmeterol, which is primarily metabolized by the isoenzyme. Because salmeterol prolongs the QT interval in a dose-dependent manner, high systemic levels of salmeterol may increase the risk of ventricular arrhythmias such as ventricular tachycardia, ventricular fibrillation, and torsade de pointes.", "source": "DDInter", "management_text": "Concomitant use of salmeterol with potent CYP450 3A4 inhibitors is not recommended. Some authorities recommend avoiding concomitant use of salmeterol during and for 2 weeks after treatment with itraconazole.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of salmeterol with potent CYP450 3A4 inhibitors is not recommended.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68061/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[4] \"Product Information. Severent (salmeterol).\" Glaxo Wellcome, Research Triangle Park, NC.[5] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[6] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Ipratropium, Beclomethasone dipropionate", "alternatives_b": "Tinidazole, Tetracycline, Dexlansoprazole, Bismuth subcitrate potassium, Rifabutin, Esomeprazole, Vonoprazan, Dirithromycin", "updated_at": 1767369485}, {"id": 67975, "ingredient1": "Clarithromycin", "ingredient2": "Saquinavir", "severity": "Major", "effect": "Saquinavir in combination with ritonavir may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of ritonavir-boosted saquinavir with other drugs that can prolong the QT interval is considered contraindicated.", "mechanism_text": "Synergism", "recommendation": "Coadministration of ritonavir-boosted saquinavir with other drugs that can prolong the QT interval is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68062/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Invirase (saquinavir).\" Roche Laboratories, Nutley, NJ.[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] FDA. U.S. Food and Drug Administration \"FDA drug safety communication: Ongoing safety review of Invirase (saquinavir) and possible association with abnormal heart rhythms. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm201221.h\" ([2010 Feb 23]):[5] Biondi L \"Health Canada endorsed important safety information on Invirase (saquinavir mesylate). Available from: URL: http://hc-sc.gc.ca/dhp-mps/alt_formats/pdf/medeff/advisories-avis/prof/2010/invirase_hpc-cps-eng.pdf.\" ([2010 Apr 14]):[6] Anson BD, Weaver JG, Ackerman MJ, et al. \"Blockade of HERG channels by HIV protease inhibitors.\" Lancet 365 (2005): 682-686[7] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[10] Cerner Multum, Inc. \"Australian Product Information.\" O 0[11] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[12] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[13] Kupferschmidt HHT, Fattinger KE, Ha HR, Follath F, Krahenbuhl S \"Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man.\" Br J Clin Pharmacol 45 (1998): 355-9[14] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[15] \"Product Information. Invirase (saquinavir).\" Roche Laboratories, Nutley, NJ.", "alternatives_a": "Tinidazole, Tetracycline, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Cimetidine, Nizatidine, Vonoprazan, Amoxicillin, Lincomycin, Dirithromycin", "alternatives_b": "Glecaprevir, Tenofovir alafenamide, Cabotegravir, Lenacapavir, Velpatasvir, Voxilaprevir, Maribavir, Pibrentasvir, Rimantadine, Elvitegravir, Valganciclovir, More", "updated_at": 1767369485}, {"id": 67976, "ingredient1": "Clarithromycin", "ingredient2": "Saxagliptin", "severity": "Moderate", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly alter the plasma concentrations of saxagliptin and its pharmacologically active metabolite, both of which are substrates of the isoenzyme.", "source": "DDInter", "management_text": "Some authorities advise against using saxagliptin in combination with potent CYP450 3A4 inhibitors. Other authorities recommend that the dosage of saxagliptin should be limited to 2.5 mg once daily when used with potent CYP450 3A4 inhibitors such as itraconazole, ketoconazole, voriconazole, nefazodone, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics.", "mechanism_text": "Metabolism", "recommendation": "Some authorities advise against using saxagliptin in combination with potent CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68063/", "reference_text": "[1] \"Product Information. Onglyza (saxagliptin).\" Bristol-Myers Squibb, Princeton, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[4] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[5] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[6] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[7] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[12] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Nizatidine, Esomeprazole, More", "alternatives_b": "Guar gum", "updated_at": 1767369485}, {"id": 67977, "ingredient1": "Clarithromycin", "ingredient2": "Selpercatinib", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of selpercatinib, which is primarily metabolized by the isoenzyme. Increased exposure to selpercatinib may increase the risk of serious adverse effects such as QT interval prolongation, liver transaminase and bilirubin elevations, hypertension, hemorrhage, edema, and hypersensitivity reactions (e.g., fever, rash, arthralgias/myalgias with concurrent decreased platelets or transaminitis).", "source": "DDInter", "management_text": "Concomitant use of selpercatinib with potent CYP450 3A4 inhibitors should generally be avoided. If coadministration is required, the manufacturer recommends decreasing the dosage of selpercatinib. Patients receiving selpercatinib 120 mg twice daily should have the dosage reduced to 40 mg twice daily, and those receiving 160 mg twice daily should have the dosage reduced to 80 mg twice daily. Close monitoring for adverse effects is advisable, including more frequent ECGs and laboratory monitoring of liver enzymes, bilirubin, electrolytes, glucose, and blood counts. Selpercatinib treatment should be discontinued, interrupted, or dosage reduced in patients with serious or life-threatening toxicities in accordance with the product labeling. After the inhibitor has been discontinued for 3 to 5 elimination half-lives, the selpercatinib dosage that was taken prior to initiating the inhibitor may be resumed.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of selpercatinib with potent CYP450 3A4 inhibitors should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68064/", "reference_text": "[1] \"Product Information. Retevmo (selpercatinib).\" Lilly, Eli and Company, Indianapolis, IN.[2] \"Product Information. Retevmo (selpercatinib).\" Lilly, Eli and Company, Indianapolis, IN.[3] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[4] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tetracycline, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Amoxicillin, Dirithromycin, Lincomycin, Clindamycin", "alternatives_b": "Alpelisib, Trametinib, Dacomitinib, Tivozanib, Alectinib", "updated_at": 1767369485}, {"id": 67978, "ingredient1": "Clarithromycin", "ingredient2": "Selumetinib", "severity": "Major", "effect": "Coadministration with potent or moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of selumetinib, which is primarily metabolized by CYP450 3A4 and to a lesser extent by CYP450 2C19, 1A2, 2C9, 2E1, and 3A5. Selumetinib also undergoes glucuronidation by UGT1A1 and UGT1A3. When coadministered with itraconazole, a potent CYP450 3A4 inhibitor, selumetinib peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 19% and 49%, respectively.", "source": "DDInter", "management_text": "Concomitant use of selumetinib with potent or moderate CYP450 3A4 inhibitors should generally be avoided. If coadministration is required, a reduction in the dosage of selumetinib is recommended.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of selumetinib with potent or moderate CYP450 3A4 inhibitors should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68065/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] \"Multum Information Services, Inc. Expert Review Panel\"[3] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals, Palo Alto, CA.", "alternatives_a": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, More", "alternatives_b": "Alpelisib, Trametinib, Dacomitinib, Tivozanib, Alectinib", "updated_at": 1767369485}, {"id": 67979, "ingredient1": "Clarithromycin", "ingredient2": "Semaglutide", "severity": "Moderate", "effect": "Concomitant use of insulin and other antidiabetic agents with clarithromycin may cause significant hypoglycemia. There have been rare reports of hypoglycemia in patients treated with clarithromycin, some of whom were taking oral hypoglycemic agents or insulin. The exact mechanism of interaction has not been established. With certain hypoglycemic drugs such as nateglinide, pioglitazone, repaglinide and rosiglitazone, inhibition of the CYP450 3A4 isoenzyme by clarithromycin may be involved.", "source": "DDInter", "management_text": "Caution is advised if clarithromycin is prescribed to patients receiving antidiabetic agents. Patients should be advised to regularly monitor their blood sugar and counseled on how to recognize and treat hypoglycemia, which may include symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if clarithromycin is prescribed to patients receiving antidiabetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68066/", "reference_text": "[1] Otsuka SH \"Severe hypoglycemia from helicobacter pylori triple-drug therapy and insulin detemir drug interaction.\" Pharmacotherapy 33 (2013): e45-9[2] Niemi M, Neuvonen PJ, Kivisto KT \"The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide.\" Clin Pharmacol Ther 70 (2001): 58-65[3] Schelleman H, Bilker WB, Brensinger CM, Wan F, Hennessy S \"Anti-infectives and the risk of severe hypoglycemia in users of glipizide or glyburide.\" Clin Pharmacol Ther 88 (2010): 214-22[4] Khamaisi M, Leitersdorf E \"Severe hypoglycemia from clarithromycin-repaglinide drug interaction.\" Pharmacotherapy 28 (2008): 682-4[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Leiba A, Leibowitz A, Grossman E \"An unusual case of hypoglycemia in a diabetic patient.\" Ann Emerg Med 44 (2004): 427-8[7] Bussing R, Gende A \"Severe hypoglycemia from clarithromycin-sulfonylurea drug interaction.\" Diabetes Care 25 (2002): 1659-61[8] \"Product Information. Biaxin (clarithromycin).\" Abbott Pharmaceutical, Abbott Park, IL.[9] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[10] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[11] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[12] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[13] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[14] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[15] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[16] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[17] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[18] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[19] Cheng KL, Nafziger AN, Peloquin CA, Amsden GW \"Effect of grapefruit juice on clarithromycin pharmacokinetics.\" Antimicrob Agents Chemother 42 (1998): 927-9", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Rifabutin, Cimetidine, More", "alternatives_b": "Guar gum", "updated_at": 1767369485}, {"id": 67980, "ingredient1": "Clarithromycin", "ingredient2": "Sertraline", "severity": "Moderate", "effect": "The use of some macrolide antibiotics has been associated with increased blood levels of some selective serotonin reuptake inhibitors (SSRIs), resulting in excessive serotonergic effects or serotonin syndrome. The mechanism is inhibition of the CYP450 3A4 isoenzyme, which metabolizes SSRIs.", "source": "DDInter", "management_text": "In cases where both drugs are necessary, one could consider using a macrolide antibiotic that does not inhibit CYP450 3A4, such as azithromycin or dirithromycin.", "mechanism_text": "Metabolism", "recommendation": "In cases where both drugs are necessary, one could consider using a macrolide antibiotic that does not inhibit CYP450 3A4, such as azithromycin or dirithromycin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68067/", "reference_text": "[1] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996): 520-6[2] Pollak PT, Slayter KL \"Delirium probably induced by clarithromycin in a patient receiving fluoxetine - reply.\" Ann Pharmacother 30 (1996): 1200[3] Timothy P, Sketris IS, Mackenzie SL, Hewlett TJ \"Delirium probably induced by clarithromycin in a patient receiving fluoxetine.\" Ann Pharmacother 29 (1995): 486-8[4] Tracy TS, Cupp MJ \"Delirium probably induced by clarithromycin in a patient receiving fluoxetine - comment.\" Ann Pharmacother 30 (1996): 1199-200[5] Lee DO, Lee CD \"Serotonin syndrome in a child associated with erythromycin and sertraline.\" Pharmacotherapy 19 (1999): 894-6[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Ueda N, Yoshimura R, Umene-Nakano W, et al. \"Grapefruit juice alters plasma sertraline levels after single ingestion of sertraline in healthy volunteers.\" World J Biol Psychiatry 10(4 Pt 3) (2009): 832-5[8] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[9] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9", "alternatives_a": "Phenelzine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Vortioxetine, Milnacipran, Tryptophan, Esketamine", "alternatives_b": "Tinidazole, Dexlansoprazole, Bismuth subcitrate potassium, Rifabutin, Esomeprazole, Vonoprazan, Lincomycin, Dirithromycin", "updated_at": 1767369485}, {"id": 67981, "ingredient1": "Clarithromycin", "ingredient2": "Sevoflurane", "severity": "Moderate", "effect": "Sevoflurane may cause prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is recommended if sevoflurane is used in combination with other drugs that can prolong the QT interval. The patient's cardiovascular status and serum electrolytes should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if sevoflurane is used in combination with other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68068/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Ultane (sevoflurane).\" Abbott Pharmaceutical, Abbott Park, IL.[4] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[5] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[6] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, Nizatidine, More", "alternatives_b": "Thiopental, Remifentanil, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Enflurane, Esketamine, Etomidate, Ketamine", "updated_at": 1767369485}, {"id": 67982, "ingredient1": "Clarithromycin", "ingredient2": "Sibutramine", "severity": "Minor", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of sibutramine and its active metabolites, which are metabolized by the isoenzyme. Inhibitors such as ketoconazole, cimetidine, and erythromycin have caused moderate increases in the peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) of the active metabolites.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68069/", "reference_text": "[1] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[2] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[3] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[4] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Dexfenfluramine, Ephedrine, Fenfluramine, Lorcaserin, Diethylpropion, Mazindol", "alternatives_b": "Tinidazole, Levofloxacin, Tetracycline, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Rifabutin, Nizatidine, Esomeprazole, More", "updated_at": 1767369485}, {"id": 67983, "ingredient1": "Clarithromycin", "ingredient2": "Sildenafil", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of sildenafil, which is primarily metabolized by the isoenzyme. The possibility of prolonged and/or increased pharmacologic effects of sildenafil should be considered.", "source": "DDInter", "management_text": "Caution is advised if sildenafil is coadministered with potent CYP450 3A4 inhibitors. Dosage adjustments may be appropriate for sildenafil whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy based on efficacy and side effects. For the treatment of erectile dysfunction, an initial sildenafil dosage of 25 mg should be considered in patients treated concomitantly with potent CYP450 3A4 inhibitors. Patients should be advised to promptly notify their physician if they experience pain or tightness in the chest or jaw, irregular heartbeat, nausea, shortness of breath, visual disturbances, syncope, or prolonged erection (greater than 4 hours). For the treatment of pulmonary arterial hypertension, a dosage adjustment for sildenafil should be considered during coadministration with some CYP450 3A4 inhibitors such as erythromycin, saquinavir, clarithromycin, telithromycin, and nefazodone. However, use with very potent CYP450 3A4 inhibitors such as ritonavir, ketoconazole, or itraconazole is not recommended. Some authorities consider the use of very potent CYP450 3A4 inhibitors with sildenafil to be contraindicated in patients with pulmonary arterial hypertension.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if sildenafil is coadministered with potent CYP450 3A4 inhibitors.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68070/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Muirhead GJ, Wulff MB, Fielding A, Kleinermans D, Buss N \"Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir.\" Br J Clin Pharmacol 50 (2000): 99-107[3] Merry C, Barry MG, Ryan M, Tjia JF, Hennessy M, Eagling VA, Mulcahy F, Back DJ \"Interaction of sildenafil and indinavir when co-administered to HIV-positive patients.\" AIDS 13 (1999): f101-7[4] \"Product Information. Viagra (sildenafil).\" Pfizer US Pharmaceuticals, New York, NY.[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Hyland R, Roe GH, Jones BC, Smith DA \"Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil.\" Br J Clin Pharmaacol 51 (2001): 239-48[7] Warrington JS, Shader RI, vonMoltke LL, Greenblatt DJ \"In vitro biotransformation of sildenafil (Viagra): Identification of human cytochromes and potential drug interactions.\" Drug Metab Disposition 28 (2000): 392-7[8] Hall MCS, Ahmad S \"Interaction between sildenafil and HIV-1 combination therapy.\" Lancet 353 (1999): 2071-2[9] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[10] \"Product Information. Revatio (sildenafil).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.[11] Nandwani R, Gourlay Y \"Possible interaction between sildenafil and HIV combination therapy.\" Lancet 353 (1999): 840[12] Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. \"Effects of grapefruit juice on the pharmacokinetics of sildenafil.\" Clin Pharmacol Ther 71 (2002): 21-29[13] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[14] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Lactic acid, Methazolamide, Trichlormethiazide, Probenecid, Tioconazole, Brinzolamide, Furazolidone, More", "alternatives_b": "Tinidazole, Dexlansoprazole, Bismuth subcitrate potassium, Esomeprazole, Vonoprazan, Levofloxacin, Lincomycin, Dirithromycin", "updated_at": 1767369485}, {"id": 67984, "ingredient1": "Clarithromycin", "ingredient2": "Silodosin", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of silodosin, which is primarily metabolized by the isoenzyme. Severe hypotension and priapism may occur.", "source": "DDInter", "management_text": "Concomitant use of silodosin with potent CYP450 3A4 inhibitors is considered contraindicated. Some authorities recommend avoiding concomitant use of silodosin during and for 2 weeks after treatment with itraconazole.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of silodosin with potent CYP450 3A4 inhibitors is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68071/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Rapaflo (silodosin).\" Watson Pharmaceuticals, Corona, CA.[3] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[4] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[5] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[6] \"Product Information. Rapaflo (silodosin).\" Watson Pharmaceuticals, Corona, CA.", "alternatives_a": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Sucralfate, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 67985, "ingredient1": "Clarithromycin", "ingredient2": "Simeprevir", "severity": "Major", "effect": "Coadministration with potent and some moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of simeprevir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The use of simeprevir in combination with potent and some moderate CYP450 3A4 inhibitors such as azole antifungal agents, conivaptan, nefazodone, cobicistat, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics should generally be avoided. Some authorities recommend avoiding concomitant use of simeprevir during and for 2 weeks after treatment with itraconazole.", "mechanism_text": "Metabolism", "recommendation": "The use of simeprevir in combination with potent and some moderate CYP450 3A4 inhibitors such as azole antifungal agents, conivaptan, nefazodone, cobicistat, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68072/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[3] \"Product Information. Olysio (simeprevir).\" Janssen Pharmaceuticals, Titusville, NJ.[4] \"Product Information. Olysio (simeprevir).\" Janssen Pharmaceuticals, Titusville, NJ.[5] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[6] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[8] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[9] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[10] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[11] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[12] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[13] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[14] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[15] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[16] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[17] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[18] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[19] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[20] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[21] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[22] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[23] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[24] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[25] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[26] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[27] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[28] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[29] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[30] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[31] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[32] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[33] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[34] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[35] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[36] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, More", "alternatives_b": "Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Lactic acid, Methazolamide, Trichlormethiazide, Probenecid, Tioconazole, Brinzolamide, Furazolidone, More", "updated_at": 1767369485}, {"id": 67986, "ingredient1": "Clarithromycin", "ingredient2": "Simvastatin", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of simvastatin and lovastatin and their active acid metabolites, all of which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Due to the potential for severe interaction, concomitant use of simvastatin or lovastatin with potent CYP450 3A4 inhibitors is considered contraindicated. Fluvastatin, pravastatin, pitavastatin, and rosuvastatin are probably safer alternatives, since they are not metabolized by CYP450 3A4. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark-colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.", "mechanism_text": "Metabolism", "recommendation": "Due to the potential for severe interaction, concomitant use of simvastatin or lovastatin with potent CYP450 3A4 inhibitors is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68073/", "reference_text": "[1] Williams D, Feely J \"Pharmacokinetic-Pharmacodynamic Drug Interactions with HMG-CoA Reductase Inhibitors.\" Clin Pharmacokinet 41 (2002): 343-70[2] Spach DH, Bauwens JE, Clark CD, Burke WG \"Rhabdomyolysis associated with lovastatin and erythromycin use.\" West J Med 154 (1991): 213-5[3] Watkins JL, Atkinson BJ, Pagliaro LC \"Rhabdomyolysis in a prostate cancer patient taking ketoconazole and simvastatin: case report and review of the literature.\" Ann Pharmacother 45 (2011): e9[4] Itakura H, Vaughn D, Haller DG, O'Dwyer PJ \"Rhabdomyolysis from cytochrome p-450 interaction of ketoconazole and simvastatin in prostate cancer.\" J Urol 169 (2003): 613[5] Huynh T, Cordato D, Yang F, et al. \"HMG coA reductase-inhibitor-related myopathy and the influence of drug interactions.\" Intern Med J 32(9-10) (2002): 486-90[6] \"Product Information. Zocor (simvastatin).\" Merck & Co, Inc, West Point, PA.[7] Ayanian JZ, Fuchs CS, Stone RM \"Lovastatin and rhabdomyolysis.\" Ann Intern Med 109 (1988): 682-3[8] Kivisto KT, Kantola T, Neuvonen PJ \"Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin.\" Br J Clin Pharmacol 46 (1998): 49-53[9] Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F \"New insights into the pharmacodynamic and pharmacokinetic properties of statins.\" Pharmacol Ther 84 (1999): 413-28[10] Kantola T, Kivisto KT, Neuvonen PJ \"Effect of itraconazole on cerivastatin pharmacokinetics.\" Eur J Clin Pharmacol 54 (1999): 851-5[11] Corpier CL, Jones PH, Suki WN, et al. \"Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients.\" JAMA 260 (1988): 239-41[12] Kantola T, Kivisto KT, Neuvonen PJ \"Effect of itraconazole on the pharmacokinetics of atorvastatin.\" Clin Pharmacol Ther 64 (1998): 58-65[13] Neuvonen PJ, Backman JT, Niemi M \"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.\" Clin Pharmacokinet 47 (2008): 463-74[14] Jacobson TA \"Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors.\" Am J Cardiol 94 (2004): 1140-6[15] Lees RS, Lees AM \"Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole.\" N Engl J Med 333 (1995): 664-5[16] Sipe BE, Jones RJ, Bokhart GH \"Rhabdomyolysis Causing AV Blockade Due to Possible Atorvastatin, Esomeprazole, and Clarithromycin Interaction.\" Ann Pharmacother 37 (2003): 808-11[17] Chouhan UM, Chakrabarti S, Millward LJ \"Simvastatin interaction with clarithromycin and amiodarone causing myositis.\" Ann Pharmacother 39 (2005): 1760-1[18] Grunden JW, Fisher KA \"Lovastatin-induced rhabdomyolysis possibly associated with clarithromycin and azithromycin.\" Ann Pharmacother 31 (1997): 859-63[19] Horn M \"Coadministration of itraconazole with hypolipidemic agents may induce rhabdomyolysis in healthy individuals.\" Arch Dermatol 132 (1996): 1254[20] Garnett WR \"Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors.\" Am J Health Syst Pharm 52 (1995): 1639-45[21] Paoletti R, Corsini A, Bellosta S \"Pharmacological interactions of statins.\" Atheroscler Suppl 3 (2002): 35-40[22] Stein CA, Goel S, Ghavamian R \"Hepatitis and rhabdomyolysis in a patient with hormone refractory prostate cancer on ketoconazole and concurrent lovastatin therapy.\" Invest New Drugs 25 (2007): 277-8[23] Jacobson RH, Wang P, Glueck CJ \"Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone.\" JAMA 277 (1997): 296[24] Hare CB, Vu MP, Grunfeld C, Lampiris HW \"Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death.\" Clin Infect Dis 35 (2002): E111-2[25] Neuvonen PJ, Kantola T, Kivisto KT \"Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole.\" Clin Pharmacol Ther 63 (1998): 332-41[26] Cheng CH, Miller C, Lowe C, Pearson VE \"Rhabdomyolysis due to probable interaction between simvastatin and ritonavir.\" Am J Health Syst Pharm 59 (2002): 728-30[27] Lee AJ, Maddix DS \"Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin.\" Ann Pharmacother 35 (2001): 26-31[28] East C, Alivizatos PA, Grundy SM, Jones PH, Farmer JA \"Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation.\" N Engl J Med 318 (1988): 47-8[29] Neuvonen PJ, Jalava KM \"Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 60 (1996): 54-61[30] Wong PW, Dillard TA, Kroenke K \"Multiple organ toxicity from addition of erythromycin to long-term lovastatin therapy.\" South Med J 91 (1998): 202-5[31] Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al. \"Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047.\" AIDS 16 (2002): 569-577[32] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[33] \"Product Information. Mevacor (lovastatin).\" Merck & Co, Inc, West Point, PA.[34] Omar MA, Wilson JP \"FDA adverse event reports on statin-associated rhabdomyolysis.\" Ann Pharmacother 36 (2002): 288-95[35] Gruer PJK, Vega JM, Mercuri MF, Dobrinska MR, Tobert JA \"Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin.\" Am J Cardiol 84 (1999): 811-5[36] Gilad R, Lampl Y \"Rhabdomyolysis induced by simvastatin and ketoconazole treatment.\" Clin Neuropharmacol 22 (1999): 295-7[37] Skrabal MZ, Stading JA, Monaghan MS \"Rhabdomyolysis associated with simvastatin-nefazodone therapy.\" South Med J 96 (2003): 1034-5[38] Karnik NS, Maldonado JR \"Antidepressant and statin interactions: a review and case report of simvastatin and nefazodone-induced rhabdomyolysis and transaminitis.\" Psychosomatics 46 (2005): 565-8[39] Thompson M, Samuels S \"Rhabdomyolysis with simvastatin and nefazodone.\" Am J Psychiatry 159 (2002): 1607[40] Piliero PJ \"Interaction between ritonavir and statins.\" Am J Med 112 (2002): 510-1[41] Schmidt GA, Hoehns JD, Purcell JL, Friedman RL, Elhawi Y \"Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir.\" J Am Board Fam Med 20 (2007): 411-6[42] Jody DN \"Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone.\" JAMA 277 (1997): 296-7[43] Richter WO, Jacob BG, Schwandt P \"Interaction between fibre and lovastatin.\" Lancet 338 (1991): 706[44] Neuvonen PJ, Backman JT, Niemi M \"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.\" Clin Pharmacokinet 47 (2008): 463-74[45] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[46] \"Product Information. Mevacor (lovastatin).\" Merck & Co, Inc, West Point, PA.[47] Thompson PD, Clarkson P, Karas RH \"Statin-associated myopathy.\" JAMA 289 (2003): 1681-90[48] \"Product Information. Zocor (simvastatin).\" Merck & Co, Inc, West Point, PA.[49] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[50] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10", "alternatives_a": "Guar gum, Gemfibrozil, Fenofibric acid, Pitavastatin, Evinacumab, Evolocumab, Dextrothyroxine, Cholestyramine, Clofibrate, Colestipol, Bempedoic acid, More", "alternatives_b": "Levofloxacin, Bismuth subcitrate potassium, Dexlansoprazole, Rifabutin, Dirithromycin", "updated_at": 1767369485}, {"id": 67987, "ingredient1": "Clarithromycin", "ingredient2": "Siponimod", "severity": "Major", "effect": "Due to its significant bradycardic effects, the risk of QT prolongation and torsade de pointes arrhythmia may be increased during initiation of siponimod treatment in patients receiving drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Siponimod has not been studied in patients receiving drugs that can prolong the QT interval. Because bradycardia and AV block are recognized risk factors for QT prolongation and torsade de pointes arrhythmia, treatment with siponimod should generally not be initiated in patients who are concurrently treated with QT prolonging drugs with known arrhythmogenic properties.", "mechanism_text": "Synergism", "recommendation": "Siponimod has not been studied in patients receiving drugs that can prolong the QT interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68074/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Mayzent (siponimod).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[4] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[6] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Esomeprazole, Vonoprazan, Amoxicillin, More", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Anakinra, More", "updated_at": 1767369485}, {"id": 67988, "ingredient1": "Clarithromycin", "ingredient2": "Sirolimus", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 and/or P-glycoprotein (P-gp) may significantly increase the plasma concentrations of sirolimus following oral administration. Sirolimus is a substrate of both CYP450 3A4 isoenzyme and P-gp efflux transporter, thus their inhibition in the intestine can enhance the absorption of sirolimus.", "source": "DDInter", "management_text": "Concomitant use of sirolimus with potent CYP450 3A4 and/or P-gp inhibitors should generally be avoided. The manufacturers of posaconazole and voriconazole consider coadministration with sirolimus to be contraindicated. Some authorities recommend avoiding concomitant use of sirolimus during and for 2 weeks after treatment with itraconazole.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of sirolimus with potent CYP450 3A4 and/or P-gp inhibitors should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68075/", "reference_text": "[1] \"Product Information. Noxafil (posaconazole).\" Schering-Plough Corporation, Kenilworth, NJ.[2] Dodds-Ashley E \"Management of drug and food interactions with azole antifungal agents in transplant recipients.\" Pharmacotherapy 30 (2010): 842-54[3] \"Product Information. Rapamune (sirolimus)\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[4] Claesson K, Brattstrom C, Burke JT \"Sirolimus and erythromycin interaction: two cases.\" Transplant Proc 33 (2001): 2136[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Floren LC, Christians U, Zimmerman JJ, et al \"Sirolimus oral bioavailability increases ten-fold with concomitant ketoconazole.\" Clin Pharmacol Ther 65 (1999): 159[7] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[8] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[9] \"Product Information. Victrelis (boceprevir).\" Schering-Plough Corporation, Kenilworth, NJ.[10] \"Product Information. Rapamune (sirolimus)\" Wyeth-Ayerst Laboratories, Philadelphia, PA.", "alternatives_a": "Alteplase, Ascorbic acid, Vitamin A, Potassium Iodide, Nandrolone, Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, More", "alternatives_b": "Tinidazole, Levofloxacin, Tetracycline, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Esomeprazole, Amoxicillin, Lincomycin, Azithromycin, Dirithromycin", "updated_at": 1767369485}, {"id": 67989, "ingredient1": "Clarithromycin", "ingredient2": "Sitagliptin", "severity": "Moderate", "effect": "Concomitant use of insulin and other antidiabetic agents with clarithromycin may cause significant hypoglycemia. There have been rare reports of hypoglycemia in patients treated with clarithromycin, some of whom were taking oral hypoglycemic agents or insulin. The exact mechanism of interaction has not been established. With certain hypoglycemic drugs such as nateglinide, pioglitazone, repaglinide and rosiglitazone, inhibition of the CYP450 3A4 isoenzyme by clarithromycin may be involved.", "source": "DDInter", "management_text": "Caution is advised if clarithromycin is prescribed to patients receiving antidiabetic agents. Patients should be advised to regularly monitor their blood sugar and counseled on how to recognize and treat hypoglycemia, which may include symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if clarithromycin is prescribed to patients receiving antidiabetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68076/", "reference_text": "[1] Otsuka SH \"Severe hypoglycemia from helicobacter pylori triple-drug therapy and insulin detemir drug interaction.\" Pharmacotherapy 33 (2013): e45-9[2] Niemi M, Neuvonen PJ, Kivisto KT \"The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide.\" Clin Pharmacol Ther 70 (2001): 58-65[3] Schelleman H, Bilker WB, Brensinger CM, Wan F, Hennessy S \"Anti-infectives and the risk of severe hypoglycemia in users of glipizide or glyburide.\" Clin Pharmacol Ther 88 (2010): 214-22[4] Khamaisi M, Leitersdorf E \"Severe hypoglycemia from clarithromycin-repaglinide drug interaction.\" Pharmacotherapy 28 (2008): 682-4[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Leiba A, Leibowitz A, Grossman E \"An unusual case of hypoglycemia in a diabetic patient.\" Ann Emerg Med 44 (2004): 427-8[7] Bussing R, Gende A \"Severe hypoglycemia from clarithromycin-sulfonylurea drug interaction.\" Diabetes Care 25 (2002): 1659-61[8] \"Product Information. Biaxin (clarithromycin).\" Abbott Pharmaceutical, Abbott Park, IL.[9] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[10] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[11] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[12] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[13] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[14] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[15] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[16] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[17] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[18] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[19] Cheng KL, Nafziger AN, Peloquin CA, Amsden GW \"Effect of grapefruit juice on clarithromycin pharmacokinetics.\" Antimicrob Agents Chemother 42 (1998): 927-9", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Rifabutin, Cimetidine, More", "alternatives_b": "Guar gum", "updated_at": 1767369485}, {"id": 67990, "ingredient1": "Clarithromycin", "ingredient2": "Solifenacin", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of solifenacin, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "The dosage of solifenacin should not exceed 5 mg/day when used with potent CYP450 3A4 inhibitors. Close clinical and laboratory monitoring is advised whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy. Patients should be advised to contact their physician if they experience undue adverse effects of solifenacin such as severe abdominal pain or constipation for 3 or more days. Patients should seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope. Concomitant use of solifenacin with potent CYP450 3A4 inhibitors, such as itraconazole, is considered contraindicated by some authorities in patients with severe renal impairment or moderate to severe hepatic impairment during and for 2 weeks after treatment with these drugs.", "mechanism_text": "Metabolism", "recommendation": "The dosage of solifenacin should not exceed 5 mg/day when used with potent CYP450 3A4 inhibitors.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68077/", "reference_text": "[1] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[2] \"Product Information. Sporonox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[3] \"Product Information. VESIcare (solifenacin).\" GlaxoSmithKline, Research Triangle Park, NC.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[7] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Nizatidine, Esomeprazole, Ranitidine, More", "alternatives_b": "Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Phenyl salicylate, Ammonium chloride, Dimethyl sulfoxide", "updated_at": 1767369485}, {"id": 67991, "ingredient1": "Clarithromycin", "ingredient2": "Somapacitan", "severity": "Moderate", "effect": "Coadministration with human growth hormone may decrease the plasma concentrations of drugs that are metabolized by CYP450 3A4.", "source": "DDInter", "management_text": "Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever human growth hormone is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68078/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Zorbtive (somatropin).\" Serono Laboratories Inc, Rockland, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Humatrope (somatropin).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Tetracycline, Levofloxacin, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Cimetidine, Nizatidine, Ranitidine, More", "alternatives_b": "Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant", "updated_at": 1767369485}, {"id": 67992, "ingredient1": "Clarithromycin", "ingredient2": "Somatrem", "severity": "Moderate", "effect": "Coadministration with human growth hormone may decrease the plasma concentrations of drugs that are metabolized by CYP450 3A4.", "source": "DDInter", "management_text": "Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever human growth hormone is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68079/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Zorbtive (somatropin).\" Serono Laboratories Inc, Rockland, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Humatrope (somatropin).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Tetracycline, Levofloxacin, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Cimetidine, Nizatidine, Ranitidine, More", "alternatives_b": "Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant", "updated_at": 1767369485}, {"id": 67993, "ingredient1": "Clarithromycin", "ingredient2": "Somatotropin", "severity": "Moderate", "effect": "Coadministration with human growth hormone may decrease the plasma concentrations of drugs that are metabolized by CYP450 3A4.", "source": "DDInter", "management_text": "Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever human growth hormone is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68080/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Zorbtive (somatropin).\" Serono Laboratories Inc, Rockland, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Humatrope (somatropin).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant", "alternatives_b": "Tetracycline, Levofloxacin, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Cimetidine, Nizatidine, Ranitidine, More", "updated_at": 1767369485}, {"id": 67994, "ingredient1": "Clarithromycin", "ingredient2": "Sonidegib", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of sonidegib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Concomitant use of sonidegib with potent CYP450 3A4 inhibitors should generally be avoided.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of sonidegib with potent CYP450 3A4 inhibitors should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68081/", "reference_text": "[1] \"Product Information. Odomzo (sonidegib).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[3] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[4] \"Product Information. Odomzo (sonidegib).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Tinidazole, Levofloxacin, Tetracycline, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Amoxicillin, Dirithromycin, Lincomycin, Azithromycin, Clindamycin", "alternatives_b": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Mitotane, Niraparib, Porfimer sodium, More", "updated_at": 1767369485}, {"id": 67995, "ingredient1": "Clarithromycin", "ingredient2": "Sorafenib", "severity": "Moderate", "effect": "Sorafenib has the potential to prolong QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is recommended if sorafenib is used in combination with cumulative high-dose anthracycline therapy or other drugs that can prolong the QT interval. ECG and serum electrolytes, including potassium, magnesium and calcium, should be monitored before starting sorafenib therapy and periodically during treatment. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if sorafenib is used in combination with cumulative high-dose anthracycline therapy or other drugs that can prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68082/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] \"Product Information. Nexavar (sorafenib).\" Bayer Pharmaceutical Inc, West Haven, CT.[5] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[6] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.[7] \"Product Information. Nexavar (sorafenib).\" Bayer Pharmaceutical Inc, West Haven, CT.", "alternatives_a": "Alpelisib, Trametinib, Dacomitinib, Tivozanib, Alectinib", "alternatives_b": "Tinidazole, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Cimetidine, Esomeprazole, Nizatidine, Vonoprazan, Amoxicillin, Dirithromycin, Lincomycin, More", "updated_at": 1767369485}, {"id": 67996, "ingredient1": "Clarithromycin", "ingredient2": "Sotalol", "severity": "Major", "effect": "Class IA (e.g., disopyramide, quinidine, procainamide) and class III (e.g., amiodarone, dofetilide, sotalol) antiarrhythmic agents can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks. Caution and clinical monitoring are recommended if concomitant use is required. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68083/", "reference_text": "[1] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[2] Yamreudeewong W, DeBisschop M, Martin L, Lower D \"Potentially Significant Drug Interactions of Class III Antiarrhythmic Drugs.\" Drug Saf 26 (2003): 421-38[3] \"Product Information. Norpace (disopyramide).\" Searle, Skokie, IL.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Betapace (sotalol).\" Berlex, Richmond, CA.[6] \"Product Information. Procan SR (procainamide).\" Parke-Davis, Morris Plains, NJ.[7] Maxa JL, Hebeler RF, Adeeko MA \"Torsades de pointes following concurrent amiodarone and levofloxacin therapy.\" Proc (Bayl Univ Med Cent) 19 (2006): 345-6[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] \"Product Information. Cordarone (amiodarone).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[10] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):[11] \"Product Information. Vascor (bepridil).\" McNeil Pharmaceutical, Raritan, NJ.[12] \"Product Information. Quiniglute (quinidine).\" Berlex, Richmond, CA.[13] Trujillo TC, Nolan PE \"Antiarrhythmic agents - Drug interactions of clinical significance.\" Drug Safety 23 (2000): 509-32[14] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[15] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[16] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[17] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[18] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[19] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[20] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[21] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[22] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[23] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[24] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[25] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[26] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[27] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[28] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[29] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[30] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[31] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[32] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[33] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[34] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[35] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[36] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[37] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[38] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[39] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[40] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[41] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[42] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[43] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[44] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[45] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8", "alternatives_a": "Labetalol, Esmolol, Betaxolol, Nebivolol, Penbutolol, Carteolol, Pindolol, Labetalol, Nebivolol, Nebivolol", "alternatives_b": "Tinidazole, Tetracycline, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Nizatidine, Esomeprazole, Vonoprazan, Amoxicillin, Dirithromycin, More", "updated_at": 1767369485}, {"id": 67997, "ingredient1": "Clarithromycin", "ingredient2": "Sparfloxacin", "severity": "Major", "effect": "Sparfloxacin may cause dose-related prolongation of the QT interval in some patients. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Coadministration of sparfloxacin with other drugs that can prolong the QT interval is considered contraindicated.", "mechanism_text": "Synergism", "recommendation": "Coadministration of sparfloxacin with other drugs that can prolong the QT interval is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68084/", "reference_text": "[1] Thomas M, Maconochie JG, Fletcher E \"The dilemma of the prolonged QT interval in early drug studies.\" Br J Clin Pharmacol 41 (1996): 77-81[2] Jaillon P, Morganroth J, Brumpt I, Talbot G \"Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group.\" J Antimicrob Chemother 37(suppl a) (1996): 161-7[3] Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B \"Torsades de pointe probably related to sparfloxacin.\" Eur J Clin Microbiol Infect Dis 15 (1996): 350-1[4] Lipsky BA, Dorr MB, Magner DJ, Talbot GH \"Safety profile of sparfloxacin, a new fluoroquinolone antibiotic.\" Clin Ther 21 (1999): 148-59[5] Owens RC Jr, Ambrose PG \"Torsades de pointes associated with fluoroquinolones.\" Pharmacotherapy 22 (2002): 663-8; discussion 668-72[6] Owens RC \"QT Prolongation with Antimicrobial Agents : Understanding the Significance.\" Drugs 64 (2004): 1091-124[7] Zix JA, GeerdesFenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H \"Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate.\" Antimicrob Agents Chemother 41 (1997): 1668-72[8] Oliphant CM, Green GM \"Quinolones: a comprehensive review.\" Am Fam Physician 65 (2002): 455-64[9] \"Product Information. Zagam (sparfloxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[10] Falagas ME, Rafailidis PI, Rosmarakis ES \"Arrhythmias associated with fluoroquinolone therapy.\" Int J Antimicrob Agents 29 (2007): 374-9[11] Iannini PB \"Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.\" Expert Opin Drug Saf 1 (2002): 121-8[12] Katritsis D, Camm AJ \"Quinolones: cardioprotective or cardiotoxic.\" Pacing Clin Electrophysiol 26 (2003): 2317-20[13] Ball P \"Quinolone-induced QT interval prolongation: a not-so-unexpected class effect.\" J Antimicrob Chemother 45 (2000): 557-9[14] Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H \"Risk of torsades de pointes with non-cardiac drugs.\" BMJ 322 (2001): 46-7[15] Kang J, Wang L, Chen XL, Triggle DJ, Rampe D \"Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.\" Mol Pharmacol 59 (2001): 122-6[16] Demolis JL, Charransol A, Funck-Brentano C, Jaillon P \"Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers.\" Br J Clin Pharmacol 41 (1996): 499-503[17] Cerner Multum, Inc. \"Australian Product Information.\" O 0[18] Owens RC \"Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes.\" Pharmacotherapy 21 (2001): 301-19[19] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[20] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[21] Stahlmann R \"Clinical toxicological aspects of fluoroquinolones.\" Toxicol Lett 127 (2002): 269-77", "alternatives_a": "Enoxacin, Nalidixic acid, Cinoxacin, Trovafloxacin, Delafloxacin", "alternatives_b": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, More", "updated_at": 1767369485}, {"id": 67998, "ingredient1": "Clarithromycin", "ingredient2": "St. John's Wort", "severity": "Moderate", "effect": "Coadministration with St. John's wort (Hypericum perforatum) may reduce the plasma concentrations and antimicrobial efficacy of clarithromycin. The mechanism is induction of CYP450 3A metabolism by St. John's wort. Clinical data have not been reported.", "source": "DDInter", "management_text": "If concomitant use is medically necessary, it is recommended to monitor for altered efficacy and safety of clarithromycin.", "mechanism_text": "Metabolism", "recommendation": "If concomitant use is medically necessary, it is recommended to monitor for altered efficacy and safety of clarithromycin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68085/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Biaxin (clarithromycin).\" Abbott Pharmaceutical, Abbott Park, IL.[4] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[5] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8[6] Cheng KL, Nafziger AN, Peloquin CA, Amsden GW \"Effect of grapefruit juice on clarithromycin pharmacokinetics.\" Antimicrob Agents Chemother 42 (1998): 927-9", "alternatives_a": "Tinidazole, Levofloxacin, Tetracycline, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Rifabutin, Cimetidine, Nizatidine, More", "alternatives_b": "Phenelzine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Vortioxetine, Milnacipran, Tryptophan, Esketamine", "updated_at": 1767369485}, {"id": 67999, "ingredient1": "Clarithromycin", "ingredient2": "Stiripentol", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 1A2 and/or 3A4 may increase the plasma concentrations of stiripentol, which has been shown in vitro to undergo phase I metabolism via these pathways. Conversely, many of these inhibitors are also substrates of CYP450 1A2 and/or 3A4, and coadministration with stiripentol may alter their plasma concentrations as well. Stiripentol is both an inhibitor and inducer of CYP450 1A2 and 3A4 in vitro.", "source": "DDInter", "management_text": "Caution is advised when stiripentol is used with inhibitors of CYP450 1A2 and/or 3A4 that are also substrates of these enzymatic pathways. Patients should be monitored for potentially increased adverse effects of stiripentol such as anorexia, nausea, vomiting, weight loss, somnolence, dizziness, confusion, difficulty concentrating, ataxia, hypotonia, tremor, hyperkinesia, dysarthria, suicidal ideation/behavior, neutropenia, and thrombocytopenia. In addition, clinical and laboratory monitoring may be appropriate for concomitant drugs whenever stiripentol is added to or withdrawn from therapy. Dosage adjustments or alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when stiripentol is used with inhibitors of CYP450 1A2 and/or 3A4 that are also substrates of these enzymatic pathways.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68086/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Diacomit (stiripentol).\" Biocodex Inc, Creswell, OR.[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[5] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[6] \"Product Information. Diacomit (stiripentol).\" Biocodex Inc, Creswell, OR.", "alternatives_a": "Pantoprazole, Levofloxacin, Tetracycline, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Nizatidine, Ranitidine, More", "alternatives_b": "Tiagabine, Brivaracetam, Rufinamide, Methsuximide, Paramethadione, Fenfluramine, Eslicarbazepine, Phensuximide, Methylphenobarbital, Phenacemide, Primidone, More", "updated_at": 1767369485}, {"id": 68000, "ingredient1": "Clarithromycin", "ingredient2": "Sufentanil", "severity": "Moderate", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of sufentanil, which is primarily metabolized by the isoenzyme. Increased sufentanil concentrations may enhance or prolong pharmacologic effects and potentiate the risk of central nervous system and respiratory depression.", "source": "DDInter", "management_text": "Patients receiving sufentanil with potent CYP450 3A4 inhibitors should be carefully monitored for excessive central nervous system and respiratory depression, and dosage adjustments made accordingly if necessary.", "mechanism_text": "Metabolism", "recommendation": "Patients receiving sufentanil with potent CYP450 3A4 inhibitors should be carefully monitored for excessive central nervous system and respiratory depression, and dosage adjustments made accordingly if necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/68087/", "reference_text": "[1] Bartkowski RR, Goldberg ME, Huffnagle S, Epstein RH \"Sufentanil disposition. Is it affected by erythromycin administration?\" Anesthesiology 78 (1993): 260-5[2] \"Product Information. Sufenta (sufentanil).\" Janssen Pharmaceutica, Titusville, NJ.[3] Tateishi T, Krivoruk Y, Ueng YF, Wood AJ, Guengerich FP, Wood M \"Identification of human cytochrome P-450 3A4 as the enzyme responsible for fentanyl and sufentanil N-dealkylation.\" Anesth Analg 82 (1996): 167-72[4] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[5] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Thiopental, Remifentanil, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Enflurane, Esketamine, Etomidate, Ketamine", "alternatives_b": "Tinidazole, Levofloxacin, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Famotidine, Rifabutin, Nizatidine, More", "updated_at": 1767369485}]